Document

0001125376-18-000028.txt : 20180208 0001125376-18-000028.hdr.sgml : 20180208 20180208163640 ACCESSION NUMBER: 0001125376-18-000028 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 127 CONFORMED PERIOD OF REPORT: 20171231 FILED AS OF DATE: 20180208 DATE AS OF CHANGE: 20180208 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ENSIGN GROUP, INC CENTRAL INDEX KEY: 0001125376 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-SKILLED NURSING CARE FACILITIES [8051] IRS NUMBER: 330861263 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33757 FILM NUMBER: 18586211 BUSINESS ADDRESS: STREET 1: 27101 PUERTA REAL, SUITE 450 CITY: MISSION VIEJO STATE: CA ZIP: 92691 BUSINESS PHONE: (949) 487-9500 MAIL ADDRESS: STREET 1: 27101 PUERTA REAL, SUITE 450 CITY: MISSION VIEJO STATE: CA ZIP: 92691 FORMER COMPANY: FORMER CONFORMED NAME: ENSIGN GROUP INC DATE OF NAME CHANGE: 20000930 10-K 1 ensg1231201710k.htm 10-K Document

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_____________________________

FORM 10-K



x	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

For the fiscal year ended December 31, 2017.



o	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

For the transition period from to .

Commission file number: 001-33757

__________________________

THE ENSIGN GROUP, INC.

(Exact Name of Registrant as Specified in Its Charter)



Delaware	33-0861263
(State or Other Jurisdiction of	(I.R.S. Employer
Incorporation or Organization)	Identification No.)

27101 Puerta Real, Suite 450

Mission Viejo, CA 92691

(Address of Principal Executive Offices and Zip Code)

(949) 487-9500

(Registrant’s Telephone Number, Including Area Code)

_____________________________



Title of Each Class		Name of Each Exchange on Which Registered
Common Stock, par value $0.001 per share		NASDAQ Global Select Market

Securities registered pursuant to Section 12(g) of the Act:

None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. x Yes o No

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. o Yes x No

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. x Yes o No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). x Yes o No

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of the registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):



Large accelerated filer x	Accelerated filer o	Non-accelerated filer o (Do not check if a smaller reporting company)	Smaller reporting company o	Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by a check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). o Yes x No

The aggregate market value of the registrant's common stock held by non-affiliates of the registrant, computed by reference to the closing price as of the last business day of the registrant's most recently completed second fiscal quarter, June 30, 2017, was approximately $780,000,000. Shares of Common Stock held by each executive officer, director and each person owning more than 10% of the outstanding Common Stock of the registrant have been excluded in that such persons may be deemed to be affiliates of the registrant. This determination of affiliate status is not necessarily a conclusive determination for other purposes.

As of February 5, 2018, 51,484,963 shares of the registrant’s common stock were outstanding.

DOCUMENTS INCORPORATED BY REFERENCE:

Part III of this Form 10-K incorporates information by reference from the Registrant's definitive proxy statement for the Registrant's 2017 Annual Meeting of Stockholders to be filed within 120 days after the close of the fiscal year covered by this annual report.

THE ENSIGN GROUP, INC.

INDEX TO ANNUAL REPORT ON FORM 10-K

FOR THE FISCAL YEAR ENDED DECEMBER 31, 2017

TABLE OF CONTENTS



PART I.
Item 1.	Business	1
Item 1A.	Risk Factors	24
Item 1B.	Unresolved Staff Comments	60
Item 2.	Properties	60
Item 3.	Legal Proceedings	61
Item 4.	Mine Safety Disclosures	63

PART II.
Item 5.	Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	63
Item 6.	Selected Financial Data	65
Item 7.	Management's Discussion and Analysis of Financial Condition and Results of Operations	71
Item 7A.	Quantitative and Qualitative Disclosures About Market Risk	99
Item 8.	Financial Statements and Supplementary Data	100
Item 9.	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	101
Item 9A.	Controls and Procedures	101
Item 9B.	Other Information	103

PART III.
Item 10.	Directors, Executive Officers and Corporate Governance	103
Item 11.	Executive Compensation	103
Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	103
Item 13.	Certain Relationships and Related Transactions and Director Independence	103
Item 14.	Principal Accountant Fees and Services	103

PART IV.
Item 15.	Exhibits, Financial Statements and Schedules	103
Item 16.	Form 10-K Summary	111

Signatures		112
EX-10.87
EX-10.88
EX-21.1
EX-23.1
EX-31.1
EX-31.2
EX-32.1
EX-32.2
EX-101

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Annual Report on Form 10-K contains forward-looking statements, which include, but are not limited to our expected future financial position, results of operations, cash flows, financing plans, business strategy, budgets, capital expenditures, competitive positions, growth opportunities and plans and objectives of management. Forward-looking statements can often be identified by words such as “anticipates,” “expects,” “intends,” “plans,” “predicts,” “believes,” “seeks,” “estimates,” “may,” “will,” “should,” “would,” “could,” “potential,” “continue,” “ongoing,” similar expressions, and variations or negatives of these words. These statements are subject to the safe harbors created under the Securities Act of 1933 (Security Act) and the Securities Exchange Act of 1934 (Exchange Act). These statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various factors, some of which are listed under the section “Risk Factors” in Part I, Item 1A of this Annual Report on Form 10-K. Accordingly, you should not rely upon forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this Annual Report, and are based on our current expectations, estimates and projections about our industry and business, management's beliefs, and certain assumptions made by us, all of which are subject to change. We undertake no obligation to revise or update publicly any forward-looking statement for any reason, except as otherwise required by law.

As used in this Annual Report on Form 10-K, the words, "Ensign," Company," “we,” “our” and “us” refer to The Ensign Group, Inc. and its consolidated subsidiaries. All of our operating subsidiaries, the Service Center (defined below) and our wholly-owned captive insurance subsidiary (the Captive) are operated by separate, wholly-owned, independent subsidiaries that have their own management, employees and assets. References herein to the consolidated “Company” and “its” assets and activities, as well as the use of the terms “we,” “us,” “our” and similar terms in this Annual Report is not meant to imply, nor should it be construed as meaning, that The Ensign Group, Inc. has direct operating assets, employees or revenue, or that any of the subsidiaries are operated by The Ensign Group.

The Ensign Group, Inc. is a holding company with no direct operating assets, employees or revenues. In addition, certain of our wholly-owned independent subsidiaries, collectively referred to as the Service Center, provide centralized accounting, payroll, human resources, information technology, legal, risk management and other centralized services to the other operating subsidiaries through contractual relationships with such subsidiaries. In addition, our wholly-owned captive insurance subsidiary, which we refer to as the Captive, provides some claims-made coverage to our operating subsidiaries for general and professional liability, as well as for certain workers' compensation insurance liabilities.

We were incorporated in 1999 in Delaware. The Service Center address is 27101 Puerta Real, Suite 450, Mission Viejo, CA 92691, and our telephone number is (949) 487-9500. Our corporate website is located at www.ensigngroup.net. The information contained in, or that can be accessed through, our website does not constitute a part of this Annual Report.

Ensign^TM is our United States trademark. All other trademarks and trade names appearing in this annual report are the property of their respective owners.

PART I.

Item 1. Business

Company Overview

We are a provider of health care services across the post-acute care continuum, as well as other ancillary businesses located in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, Oklahoma, Oregon, South Carolina, Texas, Utah, Washington and Wisconsin. Our operating subsidiaries, each of which strives to be the service of choice in the community it serves, provide a broad spectrum of skilled nursing, assisted and independent living, home health and hospice and other ancillary services. As of December 31, 2017, we offered skilled nursing, assisted and independent living and rehabilitative care services through 230 skilled nursing and assisted and independent living facilities across 13 states. Of the 230 facilities, we owned 63 and operated an additional 167 facilities under long-term lease arrangements, and had options to purchase 11 of those 167 facilities. Our home health and hospice business provides home health, hospice and home care services from 46 agencies across eleven states.

Our organizational structure is centered upon local leadership. We believe our organizational structure, which empowers leaders and staff at the local level, is unique within the healthcare services industry. Each of our leaders are highly dedicated individuals who are responsible for key operational decisions at their operations. Leaders and staff are trained and motivated to pursue superior clinical outcomes, high patient and family satisfaction, operating efficiencies and financial performance at their operations.

We encourage and empower our leaders and staff to make their operation the “operation of choice” in the community it serves. This means that our leaders and staff are generally authorized to discern and address the unique needs and priorities of healthcare professionals, customers and other stakeholders in the local community or market, and then work to create a superior service offering for, and reputation in, that particular community or market. We believe that our localized approach encourages prospective customers and referral sources to choose or recommend the operation. In addition, our leaders are enabled and motivated to share real-time operating data and otherwise benchmark clinical and operational performance against their peers in order to improve clinical care, enhance patient satisfaction and augment operational efficiencies, promoting the sharing of best practices.

We view healthcare services primarily as a local business, influenced by personal relationships and community reputation. We believe our success is largely dependent upon our ability to build strong relationships with key stakeholders from the local healthcare community, based upon a solid foundation of reliably superior care. Accordingly, our brand strategy is focused on encouraging the leaders and staff of each operation to focus on clinical excellence, and promote their operation independently within their local community.

Much of our historical growth can be attributed to our expertise in acquiring real estate or leasing both under-performing and performing post-acute care operations and transforming them into market leaders in clinical quality, staff competency, employee loyalty and financial performance. We have also invested in new business lines that are complementary to our existing businesses, such as ancillary services. We plan to continue to grow our revenue and earnings by:

•continuing to grow our talent base and develop future leaders;

•increasing the overall percentage or “mix” of higher-acuity patients;

•focusing on organic growth and internal operating efficiencies;

•continuing to acquire additional operations in existing and new markets;

•expanding and renovating our existing operations, and

•strategically investing in and integrating other post-acute care healthcare businesses.

Company History

Our company was formed in 1999 with the goal of establishing a new level of quality care within the skilled nursing industry. The name “Ensign” is synonymous with a “flag” or a “standard,” and refers to our goal of setting the standard by which all others in our industry are measured. We believe that through our efforts and leadership, we can foster a new level of patient care and professional competence at our operating subsidiaries, and set a new industry standard for quality skilled nursing and rehabilitative care services.

We organize our operating subsidiaries into portfolio companies, which we believe has enabled us to maintain a local, field-driven organizational structure, attract additional qualified leadership talent, and to identify, acquire, and improve operations at a generally faster rate. Each of our portfolio companies has its own president. These presidents, who are experienced and proven leaders that are generally taken from the ranks of operational CEOs, serve as leadership resources within their own portfolio companies, and have the primary responsibility for recruiting qualified talent, finding potential acquisition targets, and identifying other internal and external growth opportunities. We believe this organizational structure has improved the quality of our recruiting and will continue to facilitate successful acquisitions.

We have three reportable segments: (1) transitional and skilled services, which includes the operation of skilled nursing facilities; (2) assisted and independent living services, which includes the operation of assisted and independent living facilities; and (3) home health and hospice services, which includes our home health, home care and hospice businesses. Our Chief Executive Officer, who is our chief operating decision maker, or CODM, reviews financial information at the operating segment level. We also report an “all other” category that includes revenue from our mobile diagnostics and other ancillary operations. Our mobile diagnostics and other ancillary operations businesses are neither significant individually nor in aggregate and therefore do not constitute a reportable segment. Our reporting segments are business units that offer different services and that are managed separately to provide greater visibility into those operations. For more information about our operating segments, as well as financial information, see Part II Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations and Note 7, Business Segments of the Notes to Consolidated Financial Statements.

Segments

Transitional and Skilled Services

As of December 31, 2017, our skilled nursing companies provided skilled nursing care at 181 operations, with 18,870 operational beds, in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin. Through our skilled nursing operations, we provide short stay patients and long stay patients with a full range of medical, nursing, rehabilitative, pharmacy and routine services, including daily dietary, social and recreational services. We generate our revenue from Medicaid, private pay, managed care and Medicare payors. During the year ended December 31, 2017, approximately 45.7% and 27.0% of our transitional and skilled services revenue was derived from Medicaid and Medicare programs, respectively.

Assisted and Independent Living Services

We provide assisted and independent living services at 70 operations, of which 21 are located on the same site location as our skilled nursing care operations. As of December 31, 2017, we had 5,011 assisted and independent living units. Our assisted living companies located in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, Texas, Utah, Washington and Wisconsin, provide residential accommodations, activities, meals, security, housekeeping and assistance in the activities of daily living to seniors who are independent or who require some support, but not the level of nursing care provided in a skilled nursing operation. Our independent living units are non-licensed independent living apartments in which residents are independent and require no support with the activities of daily living. We generate revenue at these units primarily from private pay sources, with a portion earned from Medicaid or other state-specific programs. During the year ended December 31, 2017, approximately 77.7% of our assisted and independent living revenue was derived from private pay sources.

Home Health and Hospice Services

Home Health

As of December 31, 2017, we provided home health care services in Arizona, California, Colorado, Idaho, Iowa, Oklahoma, Oregon, Texas, Utah and Washington. Our home health care services generally consist of providing some combination of nursing, speech, occupational and physical therapists, medical social workers and certified home health aide services. Home health care is often a cost-effective solution for patients, and can also increase their quality of life and allow them to receive quality medical care in the comfort and convenience of a familiar setting. We derive the majority of our home health revenue from Medicare and managed care organizations. During the year ended December 31, 2017, approximately 50.1% of our home health revenue was derived from Medicare.

Hospice

As of December 31, 2017, we provided hospice care services in Arizona, California, Colorado, Idaho, Iowa, Nevada, Oklahoma, Oregon, Texas, Utah and Washington. Hospice services focus on the physical, spiritual and psychosocial needs of terminally ill individuals and their families, and consists primarily of palliative and clinical care, education and counseling. We derive the majority of our hospice revenue from Medicare reimbursement. During the year ended December 31, 2017, approximately 88.6% of our hospice revenue was derived from Medicare.

Other

As of December 31, 2017, we held a majority membership interest of ancillary operations located in Arizona, California, Colorado, Idaho, Texas, Utah and Washington. We have invested in and are exploring new business lines that are complementary to our existing transitional and skilled services; assisted and independent living services and home health and hospice businesses. These new business lines consist of mobile ancillary services, including digital x-ray, ultrasound, electrocardiograms, sub-acute services and patient transportation to people in their homes or at long-term care facilities. To date these businesses are not meaningful contributors to our operating results.

Growth

We have an established track record of successful acquisitions. Much of our historical growth can be attributed to our expertise in acquiring real estate or leasing both under-performing and performing post-acute care operations and transforming them into market leaders in clinical quality, staff competency, employee loyalty and financial performance. With each acquisition, we apply our core operating expertise to improve these operations, both clinically and financially. In years where pricing has been high, we have focused on the integration and improvement of our existing operating subsidiaries while limiting our acquisitions to strategically situated properties.

Over the last several years, our acquisition activity accelerated, allowing us to add 128 facilities between January 1, 2012 and December 31, 2017. From January 1, 2008 through December 31, 2017, we acquired 169 facilities, which added 12,434 operational skilled nursing beds and 4,433 assisted and independent living units to our operating subsidiaries. The following table summarizes our growth through December 31, 2017:



	December 31,
	2007	2008	2009	2010	2011	2012	2013		2014	2015		2016	2017
Cumulative number of skilled nursing, assisted and independent living operations	61	63	77	82	102	108	119	(1)	136	186	(2)	210	230
Cumulative number of operational skilled nursing beds	6,436	6,635	8,250	8,548	9,787	10,215	10,949		12,379	14,925		17,724	18,870
Cumulative number of assisted living and independent living units	578	578	578	791	1,509	1,677	1,968	(1)	2,285	4,298	(2)	4,450	5,011
Number of home health, hospice and home care agencies	—	—	1	3	7	10	16		25	32		39	46

(1) Included in 2013 operational units are operational units of the three independent living facilities we transferred to CareTrust REIT, Inc. (CareTrust) as part of the spin-off transaction (the Spin-Off). Prior to the Spin-Off, the Company separated the healthcare operations from the independent living operations at two locations, resulting in two separate facilities and transferred the two separate facilities and one stand-alone independent facility to CareTrust.

(2) Included in 2010-2015 operational beds and number of operations are operational beds and operation of facilities we discontinued in 2016 and 2017. In the current and prior year, the number of operations and operational beds do not include the closed facilities.

New Market CEO and New Ventures Programs. In order to broaden our reach into new markets, and in an effort to provide existing leaders in our company with the entrepreneurial opportunity and challenge of entering a new market and starting a new business, we established our New Market CEO program in 2006. Supported by our Service Center and other resources, a New Market CEO evaluates a target market, develops a comprehensive business plan, and relocates to the target market to find talent and connect with other providers, regulators and the healthcare community in that market, with the goal of ultimately acquiring businesses and establishing an operating platform for future growth. In addition, this program includes other lines of business that are closely related to the skilled nursing industry. For example, we entered into home health and hospice as part of this program. The New Ventures program encourages our local leaders to evaluate service offerings with the goal of establishing an operating platform in new markets and new businesses. We believe that this program will not only continue to drive growth, but will also provide a valuable training ground for our next generation of leaders, who will have experienced the challenges of growing and operating a new business.

Acquisition History

The following table sets forth the location of our facilities and the number of operational beds and units located at our facilities as of December 31, 2017:



	TX	CA	AZ	WI	UT	CO	WA	ID	NE	KS	IA	SC	NV	Total
Number of facilities
Skilled nursing operations	43	39	23	2	16	9	9	6	4	—	4	4	1	160
Assisted and independent living services	4	6	6	19	1	5	1	3	1	—	—	—	3	49
Campuses(1)	4	3	1	—	1	1	—	1	2	6	2	—	—	21
Number of operational beds/units
Operational skilled nursing beds	5,634	4,163	3,180	138	1,763	766	841	544	413	542	368	426	92	18,870
Assisted and independent living units	387	735	1,250	758	106	618	98	274	301	142	31	—	311	5,011

(1) Campus represents a facility that offers both skilled nursing and assisted and/or independently living services.

As of December 31, 2017, we provided home health and hospice services through our 46 agencies in Arizona, California, Colorado, Idaho, Iowa, Nevada, Oklahoma, Oregon, Texas, Utah and Washington.

During the year ended December 31, 2017, we continued to expand our operations through a combination of long-term leases and purchases, with the addition of eight stand-alone skilled nursing operations, nine stand-alone assisted and independent living operations, one campus operation, three home health agencies, three hospice agencies and one home care agency. We did not acquire any material assets or assume any liabilities other than the tenant's post-assumption rights and obligations under the long-term leases. We have also invested in ancillary services that are complementary to our existing transitional and skilled services, assisted and independent living services, and home health and hospice businesses. The aggregate purchase price for these acquisitions for the year ended December 31, 2017 was $89.7 million. The addition of these operations added 905 operational skilled nursing beds and 594 assisted living units operated by our operating subsidiaries. We entered into a separate operations transfer agreement with the prior operator as part of each transaction.

Our operating subsidiaries also opened four newly constructed stand-alone skilled nursing operations under long-term lease agreements, which added 455 operational skilled nursing beds.

Subsequent to December 31, 2017, we acquired two stand-alone assisted and independent living operations for an aggregate purchase price of $4.3 million. The addition of these operations added 74 assisted living units operated by our Company's operating subsidiaries.

For further discussion of our acquisitions, see Note 8, Acquisitions in the Notes to Consolidated Financial Statements.

Quality of Care Measures

Skilled Nursing

In December 2008, the Centers for Medicare and Medicaid Services (CMS) introduced the Five-Star Quality Rating System to help consumers, their families and caregivers compare nursing homes more easily. The Five-Star Quality Rating System gives each skilled nursing operation a rating of between one and five stars in various categories. In cases of acquisitions, the previous operator's clinical ratings are included in our overall Five-Star Quality Rating. The prior operator's results will impact our rating until we have sufficient clinical measurements subsequent to the acquisition date. Generally we acquire facilities with a 1 or 2-Star rating at the time we acquire them, which impacts our overall Five-Star Quality rating as a percentage of all our skilled nursing operations. We believe compliance and quality outcomes are precursors to outstanding financial performance.

Our star ratings starting in 2015 were impacted by changes in the CMS Five Star Quality Rating System requirements that were established on February 20, 2015. These changes include the use of antipsychotics in calculating the star ratings, modified calculations for staffing levels and reflect higher standards for nursing homes to achieve a high rating on the quality measure dimension. In 2016, CMS added six new quality measures to the Nursing Home Five-Star Quality Ratings, including the rate of hospitalization, emergency room use, community discharge, improvements in function, independently worsened and anxiety or

hypnotic medication among nursing home residents. Since the revised standards for performance are more difficult to achieve, many nursing homes experienced a lower quality measure rating based on new measurement standards rather than a change in the quality of care. In 2017, CMS issued a temporary freeze of the Health Inspection Five Star Ratings beginning in 2018 that will last approximately 12 months. The health inspection star rating for recertification surveys and complaints conducted on or after November 28, 2017 will be frozen. This freeze could impact have a negative impact on our star rating in 2018. Because of these changes, we believe that it is not appropriate to compare our 2017, 2016 and 2015 star ratings with those that appeared in earlier years. In addition, our percentage of 4 and 5-Star Quality Rated skilled nursing facilities is also impacted by the number of newly acquired facilities. As mentioned above, generally we acquire facilities with a 1 or 2-Star rating.

The table below summarizes the improvements we have made in these quality measures since 2012:



	As of December 31,
	2012		2013		2014		2015		2016		2017
Cumulative number of skilled nursing facilities(1)	98		106		121		146		170		181
4 and 5-Star Quality Rated skilled nursing facilities	45		60		77		72		86		100
Percentage of 4 and 5-Star Quality Rated skilled nursing facilities	45.9	%	56.6	%	63.6	%	49.3	%	50.6	%	55.2	%

(1) Cumulative number includes only skilled nursing facilities as of the end of the respective period as star rating reports are only applicable to skilled nursing facilities.

Home Health

On July 17, 2015, CMS announced Home Health Star Ratings for home health agencies (HHAs). All Medicare-certified HHAs are potentially eligible to receive a Quality of Patient Care Star Rating. The Star Ratings include assessments of quality of patient care based on Medicare claims data and patient experience of care. Currently, HHAs must have at least 20 complete episodes of data for each measure and have reported data for five of the nine measures used in the calculation to have a Quality of Patient Care Star Rating computed. On December 14, 2017, CMS announced the influenza vaccination measure would be removed from consideration in the Quality of Patient Care Star Rating beginning with the April 2018 Home Health Compare refresh, reducing the number of quality measures used from nine to eight. As of December 31, 2017, we had 15 agencies, or 65.2%, with a 4 or 5-Star rating and our average rating was 3.89, as compared to the industry average of 3.67.

Industry Trends

The post-acute care industry has evolved to meet the growing demand for post-acute and custodial healthcare services generated by an aging population, increasing life expectancies and the trend toward shifting of patient care to lower cost settings. The industry has evolved in recent years, which we believe has led to a number of favorable improvements in the industry, as described below:

•

Shift of Patient Care to Lower Cost Alternatives. The growth of the senior population in the United States continues to increase healthcare costs, often faster than the available funding from government-sponsored healthcare programs. In response, federal and state governments have adopted cost-containment measures that encourage the treatment of patients in more cost-effective settings such as skilled nursing facilities, for which the staffing requirements and associated costs are often significantly lower than acute care hospitals, and other post-acute care settings. As a result, skilled nursing facilities are generally serving a larger population of higher-acuity patients than in the past.

•

Significant Acquisition and Consolidation Opportunities. The skilled nursing industry is large and highly fragmented, characterized predominantly by numerous local and regional providers. Due to the increasing demands from hospitals and insurance carriers to implement sophisticated and expensive reporting systems, we believe this fragmentation provides significant acquisition and consolidation opportunities for us.


•	Improving Supply and Demand Balance. The number of skilled nursing facilities has declined modestly over the past several years. We expect that the supply and demand balance in the skilled nursing industry will continue to improve due to the shift of patient care to lower cost settings, an aging population and increasing life expectancies.

•

Increased Demand Driven by Aging Populations and Increased Life Expectancy. As life expectancy continues to increase in the United States and seniors account for a higher percentage of the total U.S. population, we believe the overall demand for skilled nursing services will increase. At present, the primary market demographic for skilled nursing services is primarily individuals age 75 and older. According to the 2010 U.S. Census, there were over 40 million people in the United States in 2010 that are over 65 years old. The 2010 U.S. Census estimates this group is one of the fastest growing segments of the United States population and is expected to more than double between 2000 and 2030.


•	Accountable Care Organizations and Reimbursement Reforms. A significant goal of federal health care reform is to transform the delivery of health care by changing reimbursement for health care services to hold providers accountable

for the cost and quality of care provided. Medicare and many commercial third party payors are implementing Accountable Care Organization (ACO) models in which groups of providers share in the benefit and risk of providing care to an assigned group of individuals. Other reimbursement methodology reforms include value-based purchasing, in which a portion of provider reimbursement is redistributed based on relative performance on designated economic, clinical quality, and patient satisfaction metrics. In addition, CMS is implementing demonstration and mandatory programs to bundle acute care and post-acute care reimbursement to hold providers accountable for costs across a broader continuum of care. These reimbursement methodologies and similar programs are likely to continue and expand, both in public and commercial health plans. On April 26, 2015, CMS announced its goal to have 30% of Medicare payments for quality and value through alternative payment models such as ACOs or bundled payments by 2016 and up to 50% by the end of 2018. In March 2016, CMS announced that its 30% target for 2016 was reached in January 2016. On December 1, 2017, CMS finalized changes to the Comprehensive Care for Joint Replacement (CJR) Model, as well as the cancellation of care coordination through mandatory Episode Payments and Cardiac Rehabilitation Incentive Payment Model, and rescinded the regulations governing these models. Through the final rule, CMS canceled the Episode Payment Models, which were scheduled to begin on January 1, 2018 and implemented certain revisions to CJR, including giving certain hospitals a one-time option to choose whether to continue participation. The changes in the final rule allow the agency to engage providers in future voluntary efforts, including additional voluntary episode-based payment models, but removes the mandatory episode payment models.

We believe the post-acute industry has been and will continue to be impacted by several other trends. The use of long-term care insurance is increasing among seniors as a means of planning for the costs of skilled nursing services. In addition, as a result of increased mobility in society, reduction of average family size, and the increased number of two-wage earner couples, more seniors are looking for alternatives outside the family for their care.

Effects of Changing Prices

Medicare reimbursement rates and procedures are subject to change from time to time, which could materially impact our revenue. Medicare reimburses our skilled nursing operations under a PPS for certain inpatient covered services. Under the PPS, facilities are paid a predetermined amount per patient, per day, based on the anticipated costs of treating patients. The amount to be paid is determined by classifying each patient into a resource utilization group (RUG) category that is based upon each patient’s acuity level. As of October 1, 2010, the RUG categories were expanded from 53 to 66 with the introduction of minimum data set (MDS) 3.0. Should future changes in skilled nursing facility payments reduce rates or increase the standards for reaching certain reimbursement levels, our Medicare revenues could be reduced and/or our costs to provide those services could increase, with a corresponding adverse impact on our financial condition or results of operations.

Our Medicare reimbursement rates and procedures for our home health and hospice operations are based on the severity of the patient’s condition, his or her service needs and other factors relating to the cost of providing services and supplies. Our home health rates and services are bundled into 60-day episodes of care. Payments can be adjusted for: (a) an outlier payment if our patient’s care was unusually costly (capped at 10% of total reimbursement per provider number); (b) a low utilization payment adjustment (LUPA) if the number of visits during the episode was fewer than five; (c) a partial payment if our patient transferred to another provider or we received a patient from another provider before completing the episode; (d) a payment adjustment based upon the level of therapy services required (with various incremental adjustments made for additional visits, and larger payment increases associated with the sixth, fourteenth and twentieth visit thresholds); (e) a payment adjustment if we are unable to perform periodic therapy assessments; (f) the number of episodes of care provided to a patient, regardless of whether the same home health provider provided care for the entire series of episodes; (g) changes in the base episode payments established by the Medicare program; (h) adjustments to the base episode payments for case mix and geographic wages; and (i) recoveries of overpayments.

Various healthcare reform provisions became law upon enactment of the Patient Protection and Affordable Care Act and the Healthcare Education and Reconciliation Act (collectively, the ACA). The reforms contained in the ACA have affected our operating subsidiaries in some manner and are directed in large part at increased quality and cost reductions. Several of the reforms are very significant and could ultimately change the nature of our services, the methods of payment for our services and the underlying regulatory environment. These reforms include the possible modifications to the conditions of qualification for payment, bundling of payments to cover both acute and post-acute care and the imposition of enrollment limitations on new providers. The recent presidential and congressional elections in the United States could result in significant changes in, and uncertainty with respect to, legislation, regulation, implementation of Medicare and/or Medicaid, and government policy that could significantly impact our business and the health care industry. We continually monitor these developments in an effort to respond to the changing regulatory environment impacting our business.

On October 4, 2016, CMS released a final rule that reforms the requirements for long-term care (LTC) facilities, specifically skilled nursing facilities (SNFs) and nursing facilities (NFs), to participate in the Medicare and Medicaid programs. The regulations have not been updated since 1991 and have been revised to improve quality of life, care and services in LTC facilities, optimize

resident safety, reflect current professional standards and improve the logical flow of the regulations. The regulations became effective November 28, 2016 and are being implemented in three phases. The first phase was effective November 28, 2016, the second phase was effective November 28, 2017 and the third phase becomes effective November 28, 2019.

A few highlights from the new regulation include the following:


•	investigate and report all allegations of abusive conduct, and refrain from employing individuals who have had a disciplinary action taken against their professional license by a state licensure body as a result of a finding of abuse, neglect, mistreatment of residents or misappropriation of their property;


•	document a transfer or discharge in the medical record and exchange certain information to a receiving provider or facility when a resident is transferred;


•	develop and implement a baseline care plan for each resident within 48 hours of their admission that includes instructions to provide effective and person-centered care that meets professional standards of quality care;


•	develop and implement a discharge planning process that prepares residents to be active partners in post-discharge care;


•	provide the necessary care and services to attain or maintain the highest practicable physical, mental and psychosocial well-being;


•	add a competency requirement for determining the sufficiency of nursing staff;


•	require that a pharmacist reviews a resident’s medical chart during each monthly drug regiment review;


•	refrain from charging a Medicare resident for loss or damage of dentures;


•	provide each resident with a nourishing, palatable and well-balanced diet;


•	conduct, document and annually review a facility-wide assessment to determine what resources are necessary to care for its residents;


•	refrain from entering into a binding arbitration agreement until after a dispute arises between the parties;


•	develop, implement and maintain an effective comprehensive, data-driven quality assurance and performance improvement program;


•	develop an Infection Prevention and Control Program; and


•	require their operating organization have in effect a compliance and ethics program.

CMS estimates that the average cost per facility for compliance with the new rule to be approximately $62,900 in the first year and approximately $55,000 in subsequent years. However, these amounts vary per organization. In addition to the monetary costs, these regulations may create compliance issues, as state regulators and surveyors interpret requirements that are less explicit. On June 8, 2017, CMS issued a proposed rule that would remove the provisions prohibiting binding pre-dispute arbitration agreements, but would retain other provisions that protect the interests of LTC residents.

On June 9, 2017, CMS issued revised requirements for emergency preparedness for Medicare and Medicaid participating providers, including long-term care facilities, hospices, and home health agencies. The revised requirements update the conditions of participation for such providers. Specifically, outpatient facilities, such as home health agencies, are required to ensure that patients with limited mobility are addressed within the emergency plan; home health agencies are also required to develop and implement emergency preparedness policies and procedures that are reviewed and updated at least annually and each patient must have an individual plan; hospice-operated inpatient care facilities are required to provide subsistence needs for hospice employees and patients and a means to shelter in place patients and employees who remain in the hospice; all hospices and home health agencies must implement procedures to follow up with on duty staff and patients to determine services that are needed in the event that there is an interruption in services during or due to an emergency; hospices must train their employees in emergency preparedness policies and long-term care facilities are required to share emergency preparedness plans and policies with family members and resident representatives.

On September 16, 2016, CMS issued its final rule concerning emergency preparedness requirements for Medicare and Medicaid participating providers, specifically skilled nursing facilities (SNFs), nursing facilities (NFs), and intermediate care facilities for individuals with intellectual disabilities (ICF/IIDs). The rule is designed to ensure providers and suppliers have comprehensive and integrated emergency policies and procedures in place, in particular during natural and man-made disasters. Under the rule, facilities are required to 1) document risk assessment and emergency planning; 2) develop and implement policies and procedures based on that risk assessment; 3) develop and maintain an emergency preparedness communication plan in compliance with both federal and state law; and 4) develop and maintain an emergency preparedness training and testing program. The regulations outlined in the final rule must be implemented by November 15, 2017.

On July 29, 2016, CMS issued its final rule laying out the performance standards relating to preventable hospital readmissions from skilled nursing facilities. The final rule includes the SNF 30-day All Cause Readmission Measure which assesses the risk-standardized rate of all-cause, all condition, unplanned inpatient hospital readmissions for Medicare fee-for-service SNF patients within 30 days of discharge from admission to an inpatient prospective payment system hospital, CAH or psychiatric hospital. The final rule includes the SNF 30-Day Potentially Preventable Readmission Measure as the SNF all condition risk adjusted potentially preventable hospital readmission measure. This measure assesses the facility-level risk-standardized rate of unplanned, potentially preventable hospital readmissions for SNF patients within 30 days of discharge from a prior admission to an IPPS hospital, CAH, or psychiatric hospital. Hospital readmissions include readmissions to a short-stay acute-care hospital or CAH, with a diagnosis considered to be unplanned and potentially preventable. This measure is claims-based, requiring no additional data collection or submission burden for SNFs.

On December 20, 2016, the Centers for Medicare & Medicaid Services (CMS) issued the final rule for a new Cardiac Rehabilitation Incentive (CR) model, which includes mandatory bundled payment programs for an acute myocardial infarction (AMI) episode of care or a coronary artery bypass graft (CABG) episode of care, and modifications to the existing Comprehensive Care for Joint Replacement (CJR) model to include surgical hip/femur fracture treatment episodes. The new mandatory cardiac programs mirror the Bundled Payments for Care Improvement (BPCI) and Comprehensive Care for Joint Replacement (CJR) models in that actual episode payments will be retrospectively compared against a target price. Similar to CJR, participating hospitals will be at risk for Medicare Part A and B payments in the inpatient admission and 90 days post-discharge. BPCI episodes would continue to take precedence over episodes in the CJR program and in the new cardiac bundled payment program. The cardiac model will be mandatory in 98 randomly selected geographic areas and the hip/femur procedure model will be mandatory in the same 67 geographic areas that were selected for CJR. CMS is also providing “Cardiac Rehabilitation Incentive Payments”, which can be used by hospitals to facilitate cardiac rehabilitation plans and adherence. The incentive will be provided to hospitals in 45 of the 98 geographic areas included in the mandatory bundled payment program and 45 geographic areas outside of the program. On May 19, 2017, CMS issued a final rule which delayed the effective date until May 20, 2017 and the start date was scheduled for January 1, 2018, and the final rule will continue for five performance years.

On August 15, 2017, CMS proposed changes to the Comprehensive Care for Joint Replacement (CJR) Model, which included the cancellation of care coordination through mandatory Episode Payments and Cardiac Rehabilitation Incentive Payment Model. On December 1, 2017, CMS issued a final rule which officially canceled the Episode Payment Models and Cardiac Rehabilitation Incentive Payment Model, rescinding the regulations governing these models. Additionally, the final rule implemented certain revisions to the CJR program, including making participation voluntary for approximately half of the geographic areas, along with other technical refinements. These regulation changes are effective January 1, 2018.

On January 9, 2018, CMS launched a new voluntary bundled payment called Bundled Payments for Care Improvement Advanced (BCPI Advanced). The Model Performance Period for BCPI Advanced commences on October 1, 2018 and runs through December 31, 2023. Under this bundled payment model, participants can earn additional payment if all expenditures for a beneficiary’s episode of care are under a spending target that factors in quality. BPCI Advanced Participants may receive payments for performance on 32 different clinical episodes, such as major joint replacement of the lower extremity (inpatient) and percutaneous coronary intervention (inpatient or outpatient). Participants bear financial risk, have payments under the model tied to quality performance, and are required to use Certified Electronic Health Record Technology. An episode model such as BPCI Advanced supports healthcare providers who invest in practice innovation and care redesign to improve quality and reduce expenditures.

Of note, BPCI Advanced will qualify as the first Advanced Alternative Payment Model (Advanced APM) under the Quality Payment Program. In 2015, Congress passed the Medicare Access and Chip Reauthorization Act or MACRA. MACRA requires CMS to implement a program called the Quality Payment Program or QPP, which changes the way physicians are paid who participate in Medicare. QPP creates two tracks for physician payment - the Merit-Based Incentive Payment System or MIPS track and the Advanced APM track. Under MIPS, providers have to report a range of performance metrics and their payment amount is adjusted based on their performance. Under Advanced APMs, providers take on financial risk to earn the Advanced APM incentive payment that they are participating in.

Skilled Nursing

CMS Payment Rules. In 2017, CMS proposed an alternative case-mix classification system for fiscal year 2018, named Resident Classification System, Version I (RCS-I). RCS-I would case-mix adjust for the following major cost categories: Physical therapy (PT), occupational therapy (OT), speech-language pathology (SLP) services, nursing services and non-therapy ancillaries (NTAs). Thus, where RUG-IV consists of two case-mix adjusted components (therapy and nursing), RCS-I would create four (PT/OT, SLP, nursing, and NTA) for a more resident-centered case-mix adjustment. RCS-I would also maintain the existing non-case-mix component to cover utilization of SNF resources that do not vary according to resident characteristics. For two of the case-mix-adjusted components, PT/OT and NTA, RCS-I includes variable per-diem payment adjustments that modify payment based on changes in utilization of these services over the course of a stay. The proposed model will compensate SNFs accurately based on the complexity of the particular beneficiaries they serve and the resources necessary in caring for those beneficiaries and addresses concerns about current incentives for SNFs to delivery therapy to beneficiaries based on financial considerations, rather than the most effective course of treatment for beneficiaries. The proposed RCS-I classification model could improve the SNF PPS by basing payments predominantly on clinical characteristics rather than service provision, thereby enhancing payment accuracy and strengthening incentives for appropriate care. The proposed rule is expected to reduce payments associated with residents in the highest therapy RUG (RU) and increase payments associated with residents who receive extensive services or have high NTA costs. The proposed rule also simplifies the MDS structure and reduces labor needs. Additionally, it is estimated that RCS-I would result in higher payments associated with the following resident types: dual enrollment in Medicare and Medicaid, end-stage renal disease (ESRD), having a longer qualifying inpatient stay, diabetes, wound infections, and use of IV medication.

On July 31, 2017, CMS issued its final rule outlining fiscal year 2018 Medicare payment rates for skilled nursing facilities. Under the final rule, the market basket index is revised and rebased by updating the base year from 2010 to 2014 and adding a new cost category for Installation, Maintenance, and Repair Services. The rule also includes revisions to the SNF Quality Reporting Program, including measure and standardized patient assessment data policies, as well as policies related to public display. In addition, it finalized policies for the Skilled Nursing Facility Value-Based Purchasing Program that will affect Medicare payment to SNFs beginning in fiscal year 2019 and clarification of the requirements regarding the composition of professionals for the survey team. The final rule uses a market basket percentage of 1% to update the federal rates, but if a SNF fails to submit quality reporting program requirements there will be a 2% reduction to the market basket update for the fiscal year involved. Thus, the increase in the proposed federal rates may increase the amount of our reimbursements for SNF services so long as we meet the reporting requirements.

On July 29, 2016, CMS issued its final rule outlining fiscal year 2017 Medicare payment rates and quality programs for skilled nursing facilities. The policies in the finalized rule continue to shift Medicare payments from volume to value. The aggregate payments to skilled nursing facilities increased by a net 2.4% for fiscal year 2017. This estimate increase reflected a 2.7% market basket increase, reduced by a 0.3% multi-factor productivity (MFP) adjustment required by the Patient Protection and Affordable Care Act (ACA). This final rule also further defines the skilled nursing facilities Quality Reporting Program and clarifies the Value-Based Purchasing Program to establish performance standards, baseline and performance periods, performance scoring methodology and feedback reports.

The Value-Based Purchasing Program rewards skilled nursing facilities with incentive payments for the quality of care they give to people with Medicare. The final rule specifies the skilled nursing facility 30-day potentially preventable readmission measure, which assesses the facility-level risk standardized rate of unplanned, potentially preventable hospital readmissions for skilled nursing facility patients within 30 days of discharge from a prior admission to a hospital paid under the Inpatient Prospective Payment System, a critical access hospital, or a psychiatric hospital. There is also finalized additional policies related to the Value-Based Purchasing Program including: establishing performance standards; establishing baseline and performance periods; adopting a performance scoring methodology; and providing confidential feedback reports to the skilled nursing facilities. This SNF Value-Based Purchasing Program will start in fiscal year 2019.

On July 30, 2015, CMS issued its final rule outlining fiscal year 2016 Medicare payment rates for skilled nursing facilities. The aggregate payments to skilled nursing facilities increased by 1.2% for fiscal year 2016. This increase reflected a 2.3% market basket increase, reduced by a 0.6% point forecast error adjustment and further reduced by 0.5% MFP adjustment required by the Patient Protection and Affordable Care Act (ACA). This final rule also identified a new skilled nursing facility value-based purchasing program and all-cause all-condition hospital readmission measure.

Should future changes in PPS include further reduced rates or increased standards for reaching certain reimbursement levels, our Medicare revenues derived from our affiliated skilled nursing facilities (including rehabilitation therapy services provided at our affiliated skilled nursing facilities) could be reduced, with a corresponding adverse impact on our financial condition or results of operations.

Home Health

On November 1, 2017, CMS issued a final rule that became effective on January 1, 2018 and updated the calendar year 2018 Medicare payment rates and the wage index for home health agencies serving Medicare beneficiaries. The rule also finalized proposals for the Home Health Value-Based Purchasing (HHVBP) Model and the Home Health Quality Reporting Program (HH QRP). Under the final rule. Medicare payments will be reduced by 0.4%. This decrease reflects the effects of a 1.0% home health payment update percentage; a -0.97% adjustment to the national, standardized 60-day episode payment rate to account for nominal case-mix growth for an impact of -0.9%; and the sunset of the rural add-on provision.

On January 13, 2017, CMS issued a final rule that modernized the Home Health Conditions of Participation (CoPs). This rule is a continuation of CMS's effort to improve quality of care while streamlining provider requirements to reduce unnecessary procedural requirements. The rule makes significant revisions to the conditions currently in place, including (1) adding new conditions of participation related to quality assurance and performance improvement programs (QAPI) and infection control; and (2) expanding or revising requirements related to patient rights, comprehensive evaluations, coordination and care planning, home health aide training and supervision, and discharge and transfer summary and time frames. The new CoPs became effective on January 13, 2018.

On October 31, 2016, CMS issued final payment changes to the Medicare HH PPS for calendar year 2017. Under this rule, Medicare payments were reduced by 0.7%. This decrease reflects a negative 0.97% adjustment to the national, standardized 60-day episode payment rate to account for nominal case-mix growth from 2012 through 2014; a 2.3% reduction in payments due to the final year of the four-year phase-in of the rebasing adjustments to the national, standardized 60-day episode payment rate, the national per-visit payment rates and the non-routine medical supplies (NRS) conversion factor; and the effects of the revised fixed-dollar loss (FDL) ratio used in determining outlier payments; partially offset by the home health payment update percentage of 2.5%.

On November 5, 2015, CMS issued final payment changes to the Medicare HH PPS for calendar year 2016. Under this rule, Medicare payments were reduced by 1.4%. This decrease reflects a 1.9% home health payment update percentage; a 0.9% decrease in payments due to the 0.97% payment reduction to the national, standardized 60-day episode payment rate to account for nominal case-mix growth from 2012 through 2014; and a 2.4% decrease in payments due to the third year of the four-year phase-in of the rebasing adjustments to the national, standardized 60-day episode payment rate, the national per-visit payment rates, and the non-routine medical supplies (NRS) conversion factor. Along with the payment update, CMS is revising the ICD-10-CM translation list and adding certain initial encounter codes to the HH PPS Grouper based upon revised ICD-10-CM coding guidance.

Pursuant to the rule, CMS also implemented a Home Health Value-Based Purchasing model effective for calendar year 2016, in which all Medicare-certified home health agencies (HHAs) in selected states are required to participate. The model applied a payment reduction or increase to current Medicare-certified HHA payments, depending on quality performance, for all agencies delivering services within nine randomly-selected states. Payment adjustments are applied on an annual basis, beginning at 3.0% in the first payment adjustment year, 5.0% in the second payment adjustment year, 6.0% in the third payment adjustment year and 8.0% in the final two payment adjustment years. The implementation of a home health value-based model resulted in a 1.4% decrease in Medicare payments to home health agencies across the industry.

Lastly, CMS implemented a standardized cross-setting measure for calendar year 2016. The CoPs require home health agencies to submit OASIS assessments, within 30 days of completing the assessment of the beneficiary, as a condition of payment and also for quality measurement purposes. Commencing on April 3, 2017, if the OASIS assessment is not found in the quality system upon receipt of a final claim for an HH episode and the receipt date of the claim is more than 30 days after the assessment completion date, Medicare systems will deny the HH claim. Home health agencies that do not submit quality measure data to CMS incur a 2.0% reduction in their annual home health payment update percentage. Under the rule, all home health agencies are required to timely submit both Start of Care (initial assessment) or Resumption of Care OASIS assessment and a Transfer or Discharge OASIS assessment for a minimum of 70.0% of all patients with episodes of care occurring during the annual reporting period starting July 1, 2015 and ending June 30, 2016, 80% of all patients with episodes occurring during the reporting period starting July 1, 2016 and ending June 30, 2017, and 90% for all episodes beginning on or after July 1, 2017.

Hospice

amount for fiscal year 2018 is increased by 1.0% , which is equal to the 2017 cap amount updated by the fiscal year 2018 hospice payment update percentage of 1.0%. In addition, this rule discusses changes to the Hospice Quality Reporting Program (HQRP), including changes to the Consumer Assessment of Healthcare Providers and Systems (CAHPS) hospice survey measures and plans for sharing HQRP data in fiscal year 2017.

On July 29, 2016, CMS issued its final rule outlining fiscal year 2017 Medicare payment rates, wage index and cap amount for hospices serving Medicare beneficiaries. Under the final rule, there was a net 2.1% increase in hospice payments effective October 1, 2016. The hospice payment increase was the net result of 2.7% inpatient hospital market basket update, reduced by a 0.3% productivity adjustment and by a 0.3% adjustment set by the ACA. The hospice cap amount for fiscal year 2017 increased by 2.1%, which is equal to the 2016 cap amount updated by the fiscal year 2017 hospice payment update percentage of 2.1%. In addition, this rule changes the HQRP requirements, including care surveys and two new quality measures that assess hospice staff visits to patients and caregivers in the last three and seven days of life and the percentage of hospice patients who received care processes consistent with guidelines.

On July 31, 2015, CMS issued its final rule outlining fiscal year 2016 Medicare payment rates and the wage index for hospices serving Medicare beneficiaries. Under the final rule, there was a net 1.1% increase in payments effective October 1, 2015. The hospice payment increase was the net result of a hospice payment update to the hospice per diem rates of 2.1% (a “hospital market basket” increase of 2.4% minus 0.3% for reductions required by law) and 1.2% decrease in payments to hospices due to updated wage data and the phase-out of its wage index budget neutrality adjustment factor (BNAF), offset by the newly announced Core Based Statistical Areas (CBSA) delineation impact of 0.2%. The rule also created two different payment rates for routine home care (RHC) that resulted in a higher base payment rate for the first 60 days of hospice care and a reduced base payment rate for 61 or more days of hospice care and a Service Intensity Add-On (SIA) Payment for fiscal year 2016 and beyond in conjunction with the proposed RHC rates.

Medicare Part B Therapy Cap. Some of our rehabilitation therapy revenue is paid by the Medicare Part B program under a fee schedule. Congress has established annual caps that limit the amounts that can be paid (including deductible and coinsurance amounts) for rehabilitation therapy services rendered to any Medicare beneficiary under Medicare Part B. The Deficit Reduction Act of 2005 (DRA) added Sec. 1833(g)(5) of the Social Security Act and directed CMS to develop a process that allows exceptions for Medicare beneficiaries to therapy caps when continued therapy is deemed medically necessary.

Annual limitations on beneficiary incurred expenses for outpatient therapy services under Medicare Part B are commonly referred to as “therapy caps.” All beneficiaries began a new cap year on January 1, 2017 since the therapy caps are determined on a calendar year basis. For physical therapy (PT) and speech-language pathology services (SLP) combined, the limit on incurred expenses was $1,980 in 2017 compared to $1,960 in 2016. For occupational therapy (OT) services, the limit was $1,980 for 2017 compared to $1,960 in 2016. Deductible and coinsurance amounts paid by the beneficiary for therapy services count toward the amount applied to the limit.

An “exceptions process” to the therapy caps exists; however, manual policies relevant to the exceptions process apply only when exceptions to the therapy caps are in effect. The therapy exception process, which under previous legislation was due to expire, was extended and the expected SGR of 21% to the Physician Fee Screen for outpatient therapy services was repealed through the MACRA. Under the legislation, the therapy cap exception extends through December 31, 2017. The application of the therapy caps, and related provisions, to outpatient hospitals is also extended until January 1, 2018.

The Medicare Access to Rehabilitation Services Act of 2017 (S. 253/H.R. 807), which repeals the therapy cap has been introduced to Congress. Congress has not yet addressed a permanent fix of the therapy cap nor has final legislation been put in place to extend the exceptions process beyond 2017 for Medicare beneficiaries to receive medically necessary therapy above the cap. Therefore, there is a hard cap of $2010 for PT/SLP services and $2010 for OT services in effect since January 1, 2018.

A manual medical review process, as part of the therapy exceptions process, applies to therapy claims when a beneficiary’s incurred expenses exceed a threshold amount of $3,700 annually. Specifically, combined PT and SLP services that exceed $3,700 are subject to manual medical review, as well as OT services that exceed $3,700. A beneficiary’s incurred expenses apply towards the manual medical review thresholds in the same manner as it applies to the therapy caps. Manual medical review was in effect through a post-payment review system until March 31, 2015. On February 9, 2016, MACRA modified the requirement for manual medical review for services over the $3,700 therapy thresholds to eliminate the requirement for manual medical review of all claims exceeding the thresholds and instead allows a targeted review process.

Medicare Coverage Settlement Agreement. A proposed federal class action settlement was filed in federal district court on October 16, 2012 that would end the Medicare coverage standard for skilled nursing, home health and outpatient therapy services that a beneficiary's condition must be expected to improve. The settlement was approved on January 24, 2013, which tasked CMS

with revising its Medicare Benefit Manual and numerous other policies, guidelines and instructions to ensure that Medicare coverage is available for skilled maintenance services in the home health, skilled nursing and outpatient settings. CMS was also required to develop and implement a nationwide education campaign for all who make Medicare determinations to ensure that beneficiaries with chronic conditions are not denied coverage for critical services because their underlying conditions will not improve, after which the members of the class were given the opportunity for re-review of their claims. The major provisions of this settlement agreement have been implemented by CMS, which could favorably impact Medicare coverage reimbursement for our services. However, health care providers may be subject to liability in the event they fail to appropriately adapt to the newly clarified reimbursement rules and consequently overbill state Medicaid programs in connection with services rendered to dual-eligible Medicare patients (i.e., by not maximizing Medicare coverage before billing Medicaid).

Historically, adjustments to reimbursement under Medicare have had a significant effect on our revenue. For a discussion of historic adjustments and recent changes to the Medicare program and related reimbursement rates, see Part II, Item 1A Risk Factors under the headings Risks Related to Our Business and Industry - “Our revenue could be impacted by federal and state changes to reimbursement and other aspects of Medicaid and Medicare,” “Our future revenue, financial condition and results of operations could be impacted by continued cost containment pressures on Medicaid spending,” “We may not be fully reimbursed for all services for which each facility bills through consolidated billing, which could adversely affect our revenue, financial condition and results of operations” and “Reforms to the U.S. healthcare system will impose new requirements upon us and may lower our reimbursements.” The federal government and state governments continue to focus on efforts to curb spending on healthcare programs such as Medicare and Medicaid. We are not able to predict the outcome of the legislative process. We also cannot predict the extent to which proposals will be adopted or, if adopted and implemented, what effect, if any, such proposals and existing new legislation will have on us. Efforts to impose reduced allowances, greater discounts and more stringent cost controls by government and other payors are expected to continue and could adversely affect our business, financial condition and results of operations.

Payor Sources

We derive revenue primarily from the Medicaid and Medicare programs, private pay patients and managed care payors. Medicaid typically covers patients that require standard room and board services, and provides reimbursement rates that are generally lower than rates earned from other sources. We monitor our quality mix, which is the percentage of non-Medicaid revenue from each of our facilities, to measure the level received from each payor across each of our business units. We intend to continue to focus on enhancing our care offerings to accommodate more high acuity patients.

Medicaid. Medicaid is a state-administered program financed by state funds and matching federal funds. Medicaid programs are administered by the states and their political subdivisions, and often go by state-specific names, such as Medi-Cal in California and the Arizona Healthcare Cost Containment System in Arizona. Medicaid programs generally provide health benefits for qualifying individuals, and may supplement Medicare benefits for financially needy persons aged 65 and older. Medicaid reimbursement formulas are established by each state with the approval of the federal government in accordance with federal guidelines. Seniors who enter skilled nursing facilities as private pay clients can become eligible for Medicaid once they have substantially depleted their assets. Medicaid is the largest source of funding for nursing home facilities.

Medicaid reimburses home health and hospice providers, physicians, and certain other health care providers for care provided to certain low income patients. Reimbursement varies from state to state and is based upon a number of different systems, including cost-based, prospective payment and negotiated rate systems. Rates are subject to statutory and regulatory changes and interpretations and rulings by individual state agencies.

Medicare. Medicare is a federal program that provides healthcare benefits to individuals who are 65 years of age or older or are disabled. To achieve and maintain Medicare certification, a skilled nursing facility must sign a Medicare provider agreement and meet the CMS “Conditions of Participation” on an ongoing basis, as determined in periodic facility inspections or “surveys” conducted primarily by the state licensing agency in the state where the facility is located. Medicare pays for inpatient skilled nursing facility services under the prospective payment system. The prospective payment for each beneficiary is based upon the medical condition of and care needed by the beneficiary. Medicare skilled nursing facility coverage is limited to 100 days per episode of illness for those beneficiaries who require daily care following discharge from an acute care hospital.

The Medicare home health benefit is available both for patients who need care following discharge from a hospital and patients who suffer from chronic conditions that require ongoing but intermittent care. As a condition of participation under Medicare, beneficiaries must be homebound (meaning that the beneficiary is unable to leave his/her home without a considerable and taxing effort), require intermittent skilled nursing, physical therapy or speech therapy services, and receive treatment under a plan of care established and periodically reviewed by a physician. Medicare rates are based on the severity of the patient’s

condition, his or her service needs and other factors relating to the cost of providing services and supplies, bundled into 60-day episodes of care. There is no limit to the number of episodes a patient may receive as long as he or she remains Medicare eligible.

The Medicare hospice benefit is also available to Medicare-eligible patients with terminal illnesses, certified by a physician, where life expectancy is six months or less. Medicare rates are based on standard prospective rates for delivering care over a base 90-day or 60-day period (90-day episodes of care for the first two episodes and 60-day episodes of care for any subsequent episodes). Payments are based on daily rates for each day a beneficiary is enrolled in the hospice benefit. Rates are set based on specific levels of care, are adjusted by a wage index to reflect health care labor costs across the country and are established annually through Federal legislation. Medicare payments are subject to two fixed annual caps, which are assessed on a provider number basis. The annual caps per patient, known as hospice caps, are calculated and published by the Medicare fiscal intermediary on an annual basis and cover the twelve month period from November 1 through October 31. The caps can be subject to annual and retroactive adjustments, which can cause providers to owe money back to Medicare if such caps are exceeded.

Managed Care and Private Insurance. Managed care patients consist of individuals who are insured by certain third-party entities, or who are Medicare beneficiaries who have assigned their Medicare benefits to a senior managed care organization plan. Another type of insurance, long-term care insurance, is also becoming more widely available to consumers, but is not expected to contribute significantly to industry revenues in the near term.

Private and Other Payors. Private and other payors consist primarily of individuals, family members or other third parties who directly pay for the services we provide.

Billing and Reimbursement. Our revenue from government payors, including Medicare and state Medicaid agencies, is subject to retroactive adjustments in the form of claimed overpayments and underpayments based on rate adjustments, audits or asserted billing and reimbursement errors. We believe billing and reimbursement errors, disagreements, overpayments and underpayments are common in our industry, and we are regularly engaged with government payors and their contractors in reviews, audits and appeals of our claims for reimbursement due to the subjectivity inherent in the processes related to patient diagnosis and care, recordkeeping, claims processing and other aspects of the patient service and reimbursement processes, and the errors or disagreements those subjectivities can produce.

We take seriously our responsibility to act appropriately under applicable laws and regulations, including Medicare and Medicaid billing and reimbursement laws and regulations. Accordingly, we employ accounting, reimbursement and compliance specialists who train, mentor and assist our clerical, clinical and rehabilitation staffs in the preparation of claims and supporting documentation, regularly monitor billing and reimbursement practices within our operating subsidiaries, and assist with the appeal of overpayment and recoupment claims generated by governmental, Medicare contractors and other auditors and reviewers. In addition, due to the potentially serious consequences that could arise from any impropriety in our billing and reimbursement processes, we investigate allegations of impropriety or irregularity relative thereto, and sometimes do so with the aid of outside auditors (other than our independent registered public accounting firm), attorneys and other professionals.

Whether information about our billing and reimbursement processes is obtained from external sources or activities such as Medicare and Medicaid audits or probe reviews, internal investigations, or our regular day-to-day monitoring and training activities, we collect and utilize such information to improve our billing and reimbursement functions and the various processes related thereto. While, like other operators in our industry, we experience billing and reimbursement errors, disagreements and other effects of the inherent subjectivities in reimbursement processes on a regular basis, we believe that we are in substantial compliance with applicable Medicare and Medicaid reimbursement requirements. We continually strive to improve the efficiency and accuracy of all of our operational and business functions, including our billing and reimbursement processes.

The following table sets forth our total revenue by payor source generated by each of our reportable segments and our "All Other" category and as a percentage of total revenue for the periods indicated (dollars in thousands):



	Year Ended December 31, 2017
	Transitional and Skilled Services		Assisted and Independent Living Services		Home Health and Hospice Services				All Other
	Transitional and Skilled Services		Assisted and Independent Living Services		Home Health Services		Hospice Services		All Other			Total Revenue		Revenue %
Medicaid	$	603,104	$	30,469	$	4,398	$	6,832	$	—		$	644,803	34.9	%
Medicare	417,870		—		36,592		61,422		—			515,884		27.9
Medicaid-skilled	102,875		—		—		—		—			102,875		5.6
Subtotal	1,123,849		30,469		40,990		68,254		—			1,263,562		68.4
Managed care	281,563		—		21,058		765		—			303,386		16.4
Private and other	139,798		106,177		10,997		339		25,058		(1)	282,369		15.2
Total revenue	$	1,545,210	$	136,646	$	73,045	$	69,358	$	25,058		$	1,849,317	100.0	%
(1) Private and other payors in our "All Other" category includes revenue from all payors generated in our other ancillary operations.



	Year Ended December 31, 2016
	Transitional and Skilled Services		Assisted and Independent Living Services		Home Health and Hospice Services				All Other
	Transitional and Skilled Services		Assisted and Independent Living Services		Home Health Services		Hospice Services		All Other			Total Revenue		Revenue %
Medicaid	$	521,063	$	26,397	$	4,131	$	6,367	$	—		$	557,958	33.7	%
Medicare	396,519		—		32,376		48,124		—			477,019		28.8
Medicaid-skilled	87,517		—		—		—		—			87,517		5.3
Subtotal	1,005,099		26,397		36,507		54,491		—			1,122,494		67.8
Managed care	247,844		—		16,913		751		—			265,508		16.0
Private and other	121,860		97,239		6,906		245		40,612		(1)	266,862		16.2
Total revenue	$	1,374,803	$	123,636	$	60,326	$	55,487	$	40,612		$	1,654,864	100.0	%
(1) Private and other payors in our "All Other" category includes revenue from all payors generated in our urgent care centers and other ancillary operations.



	Year Ended December 31, 2015
	Transitional and Skilled Services		Assisted and Independent Living Services		Home Health and Hospice Services				All Other
	Transitional and Skilled Services		Assisted and Independent Living Services		Home Health Services		Hospice Services		All Other			Total Revenue		Revenue %
Medicaid	$	430,368	$	19,642	$	3,598	$	5,348	$	—		$	458,956	34.2	%
Medicare	332,429		—		26,828		36,246		—			395,503		29.5
Medicaid-skilled	71,905		—		—		—		—			71,905		5.4
Subtotal	834,702		19,642		30,426		41,594		—			926,364		69.1
Managed care	194,743		—		11,391		636		—			206,770		15.4
Private and other	96,943		68,487		6,138		171		36,953		(1)	208,692		15.5
Total revenue	$	1,126,388	$	88,129	$	47,955	$	42,401	$	36,953		$	1,341,826	100.0	%
(1) Private and other payors in our "All Other" category includes revenue from all payors generated in our urgent care centers and other ancillary operations.

Payor Sources as a Percentage of Skilled Nursing Services. We use both our skilled mix and quality mix as measures of the quality of reimbursements we receive at our skilled nursing operations over various periods. The following table sets forth our percentage of skilled nursing patient days by payor source:



	Year Ended December 31,
	2017		2016		2015
Percentage of Skilled Nursing Days:
Medicare	13.4	%	14.4	%	14.6	%
Managed care	12.2		12.0		11.4
Other skilled	4.7		4.5		4.4
Skilled mix	30.3		30.9		30.4
Private and other payors	12.5		12.5		12.1
Quality mix	42.8		43.4		42.5
Medicaid	57.2		56.6		57.5
Total skilled nursing	100.0	%	100.0	%	100.0	%

Reimbursement for Specific Services

Reimbursement for Skilled Nursing Services. Skilled nursing facility revenue is primarily derived from Medicaid, Medicare, managed care and private payors. Our skilled nursing operations provide Medicaid-covered services to eligible individuals consisting of nursing care, room and board and social services. In addition, states may, at their option, cover other services such as physical, occupational and speech therapies.

Reimbursement for Rehabilitation Therapy Services. Rehabilitation therapy revenue is primarily received from private pay, managed care and Medicare for services provided at skilled nursing operations and assisted living operations. The payments are based on negotiated patient per diem rates or a negotiated fee schedule based on the type of service rendered.

Reimbursement for Assisted Living Services. Assisted living facility revenue is primarily derived from private pay patients at rates we establish based upon the services we provide and market conditions in the area of operation. In addition, Medicaid or other state-specific programs in some states where we operate supplement payments for board and care services provided in assisted living facilities.

Reimbursement for Hospice Services. Hospice revenues are primarily derived from Medicare. We receive one of four predetermined rate categories based on the level of care we furnish to the beneficiary. This payment is designed to include all of the services needed to manage the beneficiary's care. These rates are subject to annual adjustments based on inflation and geographic wage considerations. In its 2016 Final Rule, CMS established a two-tiered payment system for routine home care services. Effective January 1, 2016, hospices are reimbursed at a higher rate for routine home care services provided from days 1 through 60 of a hospice episode of care and a lower rate for all subsequent days of service. CMS also provided for a Service Intensity Add-On, which increases payments for certain routine home care services provided by registered nurses and social workers to hospice patients during the final seven days of life.

We are subject to two limitations on Medicare payments for hospice services. First, we are subject to an inpatient cap. This cap limits the number of days that can be reimbursed at an inpatient care rate (both respite and general) to 20% of the total number of days of hospice care (both inpatient and in the home) that we provide to Medicare beneficiaries. Payments for days in excess of this limit are paid at the routine home care rate, and we must reimburse the government for any amounts received in excess of that rate.

Second, hospices are subject to an aggregate payment cap. This cap amount is calculated annually by multiplying the number of beneficiaries electing hospice care during the year by a statutory amount that is indexed for inflation. For cap years ended on or after October 31, 2012, and all subsequent cap years, the hospice aggregate cap is calculated using the proportional method. Under the proportional method, the hospice shall include in its number of Medicare beneficiaries only that fraction which represents the portion of a patient's total days of care in all hospices and all years that were spent in that hospice in that cap year, using the best data available at the time of the calculation. The whole and fractional shares of Medicare beneficiaries' time in a given cap year are then summed to compute the total number of Medicare beneficiaries served by that hospice in that cap year. The hospice's total Medicare beneficiaries in a given cap year is multiplied by the Medicare per beneficiary cap amount, resulting in that hospice's aggregate cap, which is the allowable amount of total Medicare payments that hospice can receive for that cap year. If a hospice exceeds its aggregate cap, then the hospice must repay the excess back to Medicare. The Medicare cap amount is reduced proportionately for patients who transferred in and out of our hospice services.

Traditionally, the hospice inpatient and aggregate caps covered revenue received and services provided from November 1 to October 31. The 2017 cap year was an 11 month transition year with cap amounts calculated for the 11 month period from November 1, 2016 to September 30, 2017. Beginning October 1, 2017, CMS has changed the hospice inpatient and aggregate cap year to coincide with the fiscal year (October 1 to September 30).

Reimbursement for Home Health Services. We derive substantially all of the revenue from our home health business from Medicare and managed care sources. Our home health care services generally consist of providing some combination of the services of registered nurses, speech, occupational and physical therapists, medical social workers and certified home health aides. Home health care is often a cost-effective solution for patients, and can also increase their quality of life and allow them to receive quality medical care in the comfort and convenience of a familiar setting.

Competition

The post-acute care industry is highly competitive, and we expect that the industry will become increasingly competitive in the future. The industry is highly fragmented and characterized by numerous local and regional providers, in addition to large national providers that have achieved geographic diversity and economies of scale. Our operating subsidiaries also compete with inpatient rehabilitation facilities and long-term acute care hospitals. Competitiveness may vary significantly from location to location, depending upon factors such as the number of competing facilities, availability of services, expertise of staff, and the physical appearance and amenities of each location. We believe that the primary competitive factors in the post-acute care industry are:


•	ability to attract and to retain qualified management and caregivers;


•	reputation and achievements of quality healthcare outcomes;


•	attractiveness and location of facilities;


•	the expertise and commitment of the facility management team and employees; and


•	community value, including amenities and ancillary services.

We seek to compete effectively in each market by establishing a reputation within the local community as the “operation of choice.” This means that the operation leaders are generally free to discern and address the unique needs and priorities of healthcare professionals, customers and other stakeholders in the local community or market, and then create a superior service offering and reputation for that particular community or market that is calculated to encourage prospective customers and referral sources to choose or recommend the operation.

Increased competition could limit our ability to attract and retain patients, maintain or increase rates or to expand our business. Some of our competitors have greater financial and other resources than we have, may have greater brand recognition and may be more established in their respective communities than we are. Competing companies may also offer newer facilities or different programs or services than we offer, and may therefore attract individuals who are currently patients of our facilities, potential patients of our facilities, or who are otherwise receiving our healthcare services. Other competitors may have lower expenses or other competitive advantages than us and, therefore, provide services at lower prices than we offer.

There are few barriers to entry in the home health and hospice business in jurisdictions that do not require certificates of need or permits of approval. Our primary competition in these jurisdictions comes from local privately and publicly-owned and hospital-owned health care providers. We compete based on the availability of personnel, the quality of services, expertise of visiting staff, and, in certain instances, on the price of our services. In addition, we compete with a number of non-profit organizations that finance acquisitions and capital expenditures on a tax-exempt basis and charity-funded programs that may have strong ties to their local medical communities and receive charitable contributions that are unavailable to us.

Our other services, such as assisted living facilities and other ancillary services, also compete with local, regional, and national companies. The primary competitive factors in these businesses are similar to those for our skilled nursing facilities and include reputation, cost of services, quality of clinical services, responsiveness to patient/resident needs, location and the ability to provide support in other areas such as third-party reimbursement, information management and patient recordkeeping.

Our Competitive Strengths

We believe that we are well positioned to benefit from the ongoing changes within our industry. We believe that our ability to acquire, integrate and improve our facilities is a direct result of the following key competitive strengths:

Experienced and Dedicated Employees. We believe that our operating subsidiaries' employees are among the best in their respective industry. We believe each of our operating subsidiaries is led by an experienced and caring leadership team, including dedicated front-line care staff, who participates daily in the clinical and operational improvement of their individual operations. We have been successful in attracting, training, incentivizing and retaining a core group of outstanding business and clinical leaders to lead our operating subsidiaries. These leaders operate as separate local businesses. With broad local control, these talented leaders and their care staffs are able to quickly meet the needs of their patients and residents, employees and local communities, without waiting for permission to act or being bound to a “one-size-fits-all” corporate strategy.

Unique Incentive Programs. We believe that our employee compensation programs are unique within the industry. Employee stock options and performance bonuses, based on achieving target clinical quality, cultural, compliance and financial benchmarks, represent a significant component of total compensation for our operational leaders. We believe that these compensation programs assist us in encouraging our leaders and key employees to act with a shared ownership mentality. Furthermore, our leaders are motivated to help local operations within a defined “cluster” and "market," which is a group of geographically-proximate operations that share clinical best practices, real-time financial data and other resources and information.

Staff and Leadership Development. We have a company-wide commitment to ongoing education, training and professional development. Accordingly, our operational leaders participate in regular training. Most participate in training sessions at Ensign University, our in-house educational system. Other training opportunities are generally offered on a monthly basis. Training and educational topics include leadership development, our values, updates on Medicaid and Medicare billing requirements, updates on new regulations or legislation, emerging healthcare service alternatives and other relevant clinical, business and industry specific coursework. Additionally, we encourage and provide ongoing education classes for our clinical staff to maintain licensing and increase the breadth of their knowledge and expertise. We believe that our commitment to, and substantial investment in, ongoing education will further strengthen the quality of our operational leaders and staff, and the quality of the care they provide to our patients and residents.

Innovative Service Center Approach. We do not maintain a corporate headquarters; rather, we operate a Service Center to support the efforts of each operation. Our Service Center is a dedicated service organization that acts as a resource and provides centralized information technology, human resources, accounting, payroll, legal, risk management, educational and other centralized services, so that local leaders can focus on delivering top-quality care and efficient business operations. Our Service Center approach allows individual operations to function with the strength, synergies and economies of scale found in larger organizations, but without what we believe are the disadvantages of a top-down management structure or corporate hierarchy. We believe our Service Center approach is unique within the industry, and allows us to preserve the “one-facility-at-a-time” focus and culture that has contributed to our success.

Proven Track Record of Successful Acquisitions. We have established a disciplined acquisition strategy that is focused on selectively acquiring operations within our target markets. Our acquisition strategy is highly operations driven. Prospective leaders are included in the decision making process and compensated as these acquired operations reach pre-established clinical quality and financial benchmarks, helping to ensure that we only undertake acquisitions that key leaders believe can become clinically sound and contribute to our financial performance.

As of December 31, 2017, we have expanded to 230 facilities with 18,870 operational skilled nursing beds and 5,011 assisted and independent units, through both long-term leases and purchases. We believe our experience in acquiring these facilities and our demonstrated success in significantly improving their operations enables us to consider a broad range of acquisition targets. In addition, we believe we have developed expertise in transitioning newly-acquired facilities to our unique organizational culture and operating systems, which enables us to acquire facilities with limited disruption to patients, residents and facility operating staff, while significantly improving quality of care. We have also constructed new facilities to target demand, which exists for high-end healthcare facilities when we determine that market conditions justify the cost of new construction in some of our markets.

Reputation for Quality Care. We believe that we have achieved a reputation for high-quality and cost-effective care and services to our patients and residents within the communities we serve. We believe that our achievement of quality outcomes enhances our reputation for quality, that when coupled with the integrated services that we offer, allows us to attract patients that require more intensive and medically complex care and generally result in higher reimbursement rates than lower acuity patients.

Community Focused Approach. We view our services primarily as a local, community-based business. Our local leadership-centered management culture enables each operation's nursing and support staff and leaders to meet the unique needs of their

patients and local communities. We believe that our commitment to this “one-operation-at-a-time” philosophy helps to ensure that each operation, its patients, their family members and the community will receive the individualized attention they need. By serving our patients, their families, the community and our fellow healthcare professionals, we strive to make each individual facility the operation of choice in its local community.

We further believe that when choosing a healthcare provider, consumers usually choose a person or people they know and trust, rather than a corporation or business. Therefore, rather than pursuing a traditional organization-wide branding strategy, we actively seek to develop the facility brand at the local level, serving and marketing one-on-one to caregivers, our patients, their families, the community and our fellow healthcare professionals in the local market.

Investment in Information Technology. We utilize information technology that enables our facility leaders to access, and to share with their peers, both clinical and financial performance data in real time. Armed with relevant and current information, our operation leaders and their management teams are able to share best practices and the latest information, adjust to challenges and opportunities on a timely basis, improve quality of care, mitigate risk and improve both clinical outcomes and financial performance. We have also invested in specialized healthcare technology systems to assist our nursing and support staff. We have installed automated software and touch-screen interface systems in each facility to enable our clinical staff to more efficiently monitor and deliver patient care and record patient information. We believe these systems have improved the quality of our medical and billing records, while improving the productivity of our staff.

Our Growth Strategy

We believe that the following strategies are primarily responsible for our growth to date, and will continue to drive the growth of our business:

Grow Talent Base and Develop Future Leaders. Our primary growth strategy is to expand our talent base and develop future leaders. A key component of our organizational culture is our belief that strong local leadership is a primary key to the success of each operation. While we believe that significant acquisition opportunities exist, we have generally followed a disciplined approach to growth that permits us to acquire an operation only when we believe, among other things, that we will have qualified leadership for that operation. To develop these leaders, we have a rigorous “CEO-in-Training Program” that attracts proven business leaders from various industries and backgrounds, and provides them the knowledge and hands-on training they need to successfully lead one of our operating subsidiaries. We generally have between five and 30 prospective administrators progressing through the various stages of this training program, which is generally much more rigorous, hands-on and intensive than the minimum 1,000 hours of training mandated by the licensing requirements of most states where we do business. Once administrators are licensed and assigned to an operation, they continue to learn and develop in our facility Chief Executive Officer Program, which facilitates the continued development of these talented business leaders into outstanding facility CEOs, through regular peer review, our Ensign University and on-the-job training.

In addition, our Chief Operating Officer Program recruits and trains highly-qualified Directors of Nursing to lead the clinical programs in our skilled nursing facilities. Working together with their facility CEO and/or administrator, other key facility leaders and front-line staff, these experienced nurses manage delivery of care and other clinical personnel and programs to optimize both clinical outcomes and employee and patient satisfaction.

Increase Mix of High Acuity Patients. Many skilled nursing facilities are serving an increasingly larger population of patients who require a high level of skilled nursing and rehabilitative care, whom we refer to as high acuity patients, as a result of government and other payors seeking lower-cost alternatives to traditional acute-care hospitals. We generally receive higher reimbursement rates for providing care for these medically complex patients. In addition, many of these patients require therapy and other rehabilitative services, which we are able to provide as part of our integrated service offerings. Where therapy services are medically necessary and prescribed by a patient's physician or other appropriate healthcare professional, we generally receive additional revenue in connection with the provision of those services. By making these integrated services available to such patients, and maintaining established clinical standards in the delivery of those services, we are able to increase our overall revenues. We believe that we can continue to attract high acuity patients and therapy patients to our facilities by maintaining and enhancing our reputation for quality care and continuing our community focused approach.

Focus on Organic Growth and Internal Operating Efficiencies. We plan to continue to grow organically by focusing on increasing patient occupancy within our existing facilities. Although some of the facilities we have acquired were in good physical and operating condition, the majority have been clinically and financially troubled, with some facilities having had occupancy rates as low as 30% at the time of acquisition. Additionally, we believe that incremental operating margins on the last 20% of our beds are significantly higher than on the first 80%, offering opportunities to improve financial performance within our existing

facilities. Our overall occupancy is impacted significantly by the number of facilities acquired and the operational occupancy on the acquisition date. Therefore, consolidated occupancy will vary significantly based on these factors. Our average occupancy rates for our skilled nursing facilities for the years ended December 31, 2017, 2016 and 2015 were 75.4%, 75.4% and 77.6%, respectively. Our average occupancy rates for our assisted and independent living facilities for the years ended December 31, 2017, 2016 and 2015 were 76.4%, 76.0%, and 75.3%, respectively.

We also believe we can generate organic growth by improving operating efficiencies and the quality of care at the patient level. By focusing on staff development, clinical systems and the efficient delivery of quality patient care, we believe we are able to deliver higher quality care at lower costs than many of our competitors.

We also have achieved incremental occupancy and revenue growth by creating or expanding outpatient therapy programs in existing facilities. Physical, occupational and speech therapy services account for a significant portion of revenue in most of our skilled nursing facilities. By expanding therapy programs to provide outpatient services in many markets, we are able to increase revenue while spreading the fixed costs of maintaining these programs over a larger patient base. Outpatient therapy has also proven to be an effective marketing tool, raising the visibility of our facilities in their local communities and enhancing the reputation of our facilities with short-stay rehabilitation patients.

Add New Facilities and Expand Existing Facilities. A key element of our growth strategy includes the acquisition of new and existing facilities from third parties and the expansion and upgrade of current facilities. In the near term, we plan to take advantage of the fragmented skilled nursing industry by acquiring operations within select geographic markets and may consider the construction of new facilities. In addition, we have targeted facilities that we believed were performing and operations that were underperforming, and where we believed we could improve service delivery, occupancy rates and cash flow. With experienced leaders in place at the community level, and demonstrated success in significantly improving operating conditions at acquired facilities, we believe that we are well positioned for continued growth. While the integration of underperforming facilities generally has a negative short-term effect on overall operating margins, these facilities are typically accretive to earnings within 12 to 18 months following their acquisition. For the 147 facilities that we acquired from 2001 through 2017, the aggregate EBITDAR (See Part II, Item 6 - Selected Financial Data) as a percentage of revenue improved from 12.0% during the first full three months of operations to 13.4% during the thirteenth through fifteenth months of operations.

Strategically Invest In and Integrate Other Post-Acute Care Healthcare Businesses. Another important element to our growth strategy includes acquiring new and existing home health, hospice and other post-acute care healthcare businesses. Since 2010, we have steadily expanded our home health and hospice businesses through the acquisition of smaller third-party providers. Our strategy is to provide a more seamless experience to manage the transition of care throughout the post-acute continuum. Our objective is to simultaneously improve patient outcomes and reduce costs to payers, ACOs and hospital systems. We believe that the same principles that have guided our skilled nursing and assisted living operations are transferable to these businesses, including reliance on experienced local leaders at the community level to focus on integrating these operations into the continuum of care services we provide. Between 2009 and February 2018, we have acquired 22 hospice agencies, 24 home health and home care agencies, and we are well positioned for continued growth in these and other healthcare businesses.

Labor

The operation of our skilled nursing and assisted and independent living facilities, home health and hospice operations requires a large number of highly skilled healthcare professionals and support staff. At December 31, 2017, we had approximately 21,301 full-time equivalent employees who were employed by our Service Center and our operating subsidiaries. For the year ended December 31, 2017, approximately 60.0% of our total expenses were payroll related. Periodically, market forces, which vary by region, require that we increase wages in excess of general inflation or in excess of increases in reimbursement rates we receive. We believe that we staff appropriately, focusing primarily on the acuity level and day-to-day needs of our patients and residents. In most of the states where we operate, our skilled nursing facilities are subject to state mandated minimum staffing ratios, so our ability to reduce costs by decreasing staff, notwithstanding decreases in acuity or need, is limited and subject to government audits and penalties in some states. We seek to manage our labor costs by improving staff retention, improving operating efficiencies, maintaining competitive wage rates and benefits and reducing reliance on overtime compensation and temporary nursing agency services.

The healthcare industry as a whole has been experiencing shortages of qualified professional clinical staff. We believe that our ability to attract and retain qualified professional clinical staff stems from our ability to offer attractive wage and benefits packages, a high level of employee training, an empowered culture that provides incentives for individual efforts and a quality work environment.

Government Regulation

The types of laws and statutes affecting the regulatory landscape of the skilled nursing industry continue to expand. In addition to this changing regulatory environment, federal, state and local officials are increasingly focusing their efforts on the enforcement of these laws. In order to operate our businesses we must comply with federal, state and local laws relating to licensure, delivery and adequacy of medical care, distribution of pharmaceuticals, equipment, personnel, operating policies, fire prevention, rate-setting, billing and reimbursement, building codes and environmental protection. Additionally, we must also adhere to anti-kickback statues, physician referral laws, and safety and health standards set by the Occupational Safety and Health Administration (OSHA). Changes in the law or new interpretations of existing laws may have an adverse impact on our methods and costs of doing business.

Our operating subsidiaries are also subject to various regulations and licensing requirements promulgated by state and local health and social service agencies and other regulatory authorities. Requirements vary from state to state and these requirements can affect, among other things, personnel education and training, patient and personnel records, services, staffing levels, monitoring of patient wellness, patient furnishings, housekeeping services, dietary requirements, emergency plans and procedures, certification and licensing of staff prior to beginning employment, and patient rights. These laws and regulations could limit our ability to expand into new markets and to expand our services and facilities in existing markets.

State Regulations. On March 24, 2011, the governor of California signed Assembly Bill 97 (AB 97), the budget trailer bill on health, into law. AB 97 outlines significant cuts to state health and human services programs. Specifically, the law reduced provider payments by 10% for physicians, pharmacies, clinics, medical transportation, certain hospitals, home health, and nursing facilities. AB X1 19 Long Term Care was subsequently approved by the governor on June 28, 2011. Federal approval was obtained on October 27, 2011. AB X1 19 limited the 10% payment reduction to skilled-nursing providers to 14 months for the services provided on June 1, 2011 through July 31, 2012. The 10% reduction in provider payments was repaid by December 31, 2012.

Federal Health Care Reform. On April 16, 2015, the President signed MACRA into law. This law included a number of provisions, including (1) replacement of the Sustainable Growth Rate (SGR) formula used by Medicare to pay physicians with new systems for establishing annual payment rate updates for physicians' services, (2) an extension of the outpatient therapy cap exception process until December 31, 2017; and (3) payment updates for post-acute providers at 1% after other adjustments required by the ACA for 2018. In addition, it increased premiums for Part B and Part D of Medicare for beneficiaries with income above certain levels and made numerous other changes to Medicare and Medicaid.

On February 20, 2015, CMS updated the Five Star Quality Rating System for nursing homes to include the use of antipsychotics in calculating the star ratings, include modified calculations for staffing levels and the establishment of more exacting standards for nursing homes to achieve a high rating on the quality measure dimension. Since the standards for performance are more difficult to achieve, the number of our 4 and 5 star facilities could be reduced.

On October 30, 2015, CMS released a final rule addressing, among other things, implementation of certain provisions of MACRA, including the implementation of the new Merit-Based Incentive Payment System (MIPS) that streamlines multiple quality programs and Alternative Payment Models (APMs) that give bonus payments for participation in eligible APMs. The current Value-Based Payment Modifier program is set to expire in 2018, with the first MIPS adjustments to begin in 2019. The October 30, 2015 final rule added measures where gaps exist in the current Physician Quality Reporting System (PQRS), which is used by CMS to track the quality of care provided to Medicare beneficiaries. The final rule also excludes services furnished in SNFs from the definition of primary care services for purposes of the Shared Savings Program. The final rule could impact our revenue in the future.

On February 2, 2016, CMS issued its final rule concerning face-to-face requirements for Medicaid home health services. Under the rule, the Medicaid home health service definition was revised to be consistent with applicable sections of the ACA and MACRA. The rule also requires that for the initial ordering of home health services, the physician must document the occurrence of a face-to-face encounter related to the primary reason the beneficiary requires home health services occurred no more than 90 days before or 30 days after the start of services. The final rule also requires that for the initial ordering of certain medical equipment, the physician or authorized non-physician provider (NPP) must document a face-to-face encounter that is related to the primary reason the beneficiary requires medical equipment which occur no more than six months prior to the start of services.

On April 27, 2016, CMS added six new quality measures to its consumer-based Nursing Home Compare website. These quality measures include the rate of rehospitalization, emergency room use, community discharge, improvements in function, independent worsening of ability to move, and use antianxiety or hypnotic medication among nursing home residents. Beginning in July 2016, CMS incorporated all of these measures, except for the antianxiety/hypnotic medication measure, into the calculation of the Nursing Home Five-Star Quality Ratings.

On January 13, 2017, CMS issued a Final Rule revising the conditions of participation for home health agencies serving Medicare beneficiaries. The rule makes significant revisions to the conditions currently in place, including (1) adding new conditions of participation related to quality assurance and performance improvement programs; and (2) expanding or revising requirements related to patient rights, comprehensive evaluations, coordination and care planning, home health aide training and supervision, and discharge and transfer summary and time frames. Without any contrary action by the new administration, the new conditions were scheduled to be effective January 13, 2018.

The Improving Medicare Post-Acute Care Transformation Act of 2014 (the IMPACT Act), which was signed into law on October 6, 2014, requires the submission of standardized assessment data for quality improvement, payment and discharge planning purposes across the spectrum of post-acute care providers (PACs), including skilled nursing facilities and home health agencies. The IMPACT Act will require PACs to begin reporting: (1) standardized patient assessment data at admission and discharge by October 1, 2018 for post-acute care providers, including skilled nursing facilities, and by January 1, 2019 for home health agencies; (2) new quality measures, including functional status, skin integrity, medication reconciliation, incidence of major falls, and patient preference regarding treatment and discharge at various intervals between October 1, 2016 and January 1, 2019; and (3) resource use measures, including Medicare spending per beneficiary, discharge to community, and hospitalization rates of potentially preventable readmissions by October 1, 2016 for post-acute care providers, including skilled nursing facilities and by January 1, 2017 for home health agencies. Failure to report such data when required would subject a facility to a 2% reduction in market basket prices then in effect.

The IMPACT Act further requires HHS and the Medicare Payment Advisory Commission (MedPAC), a commission chartered by Congress to advise it on Medicare payment issues, to study alternative PAC payment models, including payment based upon individual patient characteristics and not care setting, with corresponding Congressional reports required based on such analysis. The IMPACT Act also included provisions impacting Medicare-certified hospices, including: (1) increasing survey frequency for Medicare-certified hospices to once every 36 months; (2) imposing a medical review process for facilities with a high percentage of stays in excess of 180 days; and (3) updating the annual aggregate Medicare payment cap.

On April 1, 2014, the President signed into law the Protecting Access to Medicare Act of 2014, which averted a 24% cut in Medicare payments to physicians and other Part B providers until March 31, 2015. In addition, this law maintains the 0.5% update for such services through December 31, 2014 and provides a 0.0% update to the 2015 Medicare Physician Fee Schedule (MPFS) through March 31, 2015. Among other things, this law provides the framework for implementation of a value-based purchasing program for skilled nursing facilities. Under this legislation HHS is required to develop by October 1, 2016 measures and performance standards regarding preventable hospital readmissions from skilled nursing facilities. Beginning October 1, 2018, HHS will withhold 2% of Medicare payments to all skilled nursing facilities and distribute this pool of payment to skilled nursing facilities as incentive payments for preventing readmissions to hospitals.

On January 2, 2013, the President signed the American Taxpayer Relief Act of 2012 into law. This statute created a Commission on Long Term Care, the goal of which is to develop a plan for the establishment, implementation, and financing of a comprehensive, coordinated, and high-quality system that ensures the availability of long-term care services and support for individuals in need of such services and supports. Any implementation of recommendations from this commission may have an impact on coverage and payment for our services.

On February 22, 2012, the President signed into law H.R. 3630, which among other things, delayed a cut in physician and Part B services. In establishing the funding for the law, payments to nursing facilities for patients' unpaid Medicare A co-insurance was reduced. The Deficit Reduction Act of 2005 had previously limited reimbursement of bad debt to 70% on privately responsibile co-insurance. However, under H.R. 3630, this reimbursement will be reduced to 65%.

Further, prior to the introduction of H.R. 3630, we were reimbursed for 100% of bad debt related to dual-eligible Medicare patients' co-insurance. H.R. 3630 will phase down the dual-eligible reimbursement over three years. Effective October 1, 2012, Medicare dual-eligible co-insurance reimbursement decreased from 100% to 88%, with further rate reductions to 77% and 65% as of October 1, 2013 and 2014, respectively. Any reductions in Medicare or Medicaid reimbursement could materially adversely affect our profitability.

On August 2, 2011, the President signed into law the Budget Control Act of 2011 (Budget Control Act), which raised the debt ceiling and put into effect a series of actions for deficit reduction. The Budget Control Act created a Congressional Joint Select Committee on Deficit Reduction (the Committee) that was tasked with proposing additional deficit reduction of at least $1.5 trillion over ten years. As the Committee was unable to achieve its targeted savings, this regulation triggered automatic reductions in discretionary and mandatory spending, or budget sequestration, starting in 2013, including reductions of not more than 2% to payments to Medicare providers. The Budget Control Act also requires Congress to vote on an amendment to the Constitution that would require a balanced budget.

On March 23, 2010, President Obama signed the ACA or the Affordable Care Act into law, which contained several sweeping changes to America’s health insurance system. Among other reforms contained in ACA, many Medicare providers received reductions in their market basket updates. But ACA made no reduction to the market basket update for skilled nursing facilities in fiscal years 2010 or 2011. However, under ACA, the skilled nursing facility market basket update became subject to a full productivity adjustment beginning in fiscal year 2012. In addition, ACA enacted several reforms with respect to skilled nursing facilities and hospice organizations, including payment measures to realize significant savings of federal and state funds by deterring and prosecuting fraud and abuse in both the Medicare and Medicaid programs.

Some key provisions of ACA include (i) enhanced civil monetary penalties, (ii) substantial and onerous transparency requirements for Medicare-participating nursing facilities, (iii) face-to-face encounter requirements applicable to home health agencies and hospices, (iv) expanded authority to suspend payment if a provider is investigated for allegations or issues of fraud, (v) a requirement that overpayments for services provided to Medicare and Medicaid beneficiaries be reported to the applicable payor within sixty days of identification of the overpayment or the date of the corresponding cost report, (vi) implementation of a value-based purchasing program for Medicare payments to skilled nursing facilities, (vii) implementation of a value-based purchasing program for home health services, (viii) implementation of a voluntary bundled payments pilot program (i.e., Bundled Payments for Care Improvement), and (ix) the creation of Accountable Care Organizations (ACOs).

On June 28, 2012, the United States Supreme Court ruled that the enactment of ACA did not violate the Constitution of the United States. On June 25, 2015, the United States Supreme Court ruled that the tax credits described in Section 36B of ACA are available to individuals who purchase health insurance on an exchange created by the federal government. These rulings, taken together, permit the implementation of most of the provisions of ACA to proceed in substantially the same form contemplated after ACA’s enactment. The provisions of ACA discussed above are only examples of federal health reform provisions that we believe may have a material impact on the long-term care industry and on our business. However, the foregoing discussion is not intended to constitute, nor does it constitute, an exhaustive review and discussion of ACA. It is possible that these and other provisions of ACA may be interpreted, clarified, or applied to our affiliated facilities or operating subsidiaries in a way that could have a material adverse impact on the results of operations.

Regulations Regarding Our Facilities. Governmental agencies and other authorities periodically inspect our facilities to assess our compliance with various standards, rules and regulations. The robust regulatory and enforcement environment continues to impact healthcare providers, especially in connection with responses to any alleged noncompliance identified in periodic surveys and other inspections by governmental authorities. Unannounced surveys or inspections generally occur at least annually, and may also follow a government agency's receipt of a complaint about a facility. We must pass these inspections to maintain our licensure under state law, to obtain or maintain certification under the Medicare and Medicaid programs, to continue participation in the Veterans Administration (VA) program at some facilities, and to comply with our provider contracts with managed care clients at many facilities. From time to time, we, like others in the healthcare industry, may receive notices from federal and state regulatory agencies alleging that we failed to substantially comply with applicable standards, rules or regulations. These notices may require us to take corrective action, may impose civil monetary penalties for noncompliance, and may threaten or impose other operating restrictions on skilled nursing facilities such as admission holds, provisional skilled nursing license or increased staffing requirements. If our facilities fail to comply with these directives or otherwise fail to comply substantially with licensure and certification laws, rules and regulations, we could lose our certification as a Medicare or Medicaid provider, or lose our state licenses to operate the facilities.

Regulations Protecting Against Fraud. Various complex federal and state laws exist which govern a wide array of referrals, relationships and arrangements, and prohibit fraud by healthcare providers. Governmental agencies are devoting increasing attention and resources to such anti-fraud efforts. The Health Insurance Portability and Accountability Act of 1996 (HIPAA), and the Balanced Budget Act of 1997 (BBA) expanded the penalties for healthcare fraud. Additionally, in connection with our involvement with federal healthcare reimbursement programs, the government or those acting on its behalf may bring an action under the False Claims Act (FCA), alleging that a healthcare provider has defrauded the government. These claimants may seek treble damages for false claims and payment of additional civil monetary penalties. The FCA allows a private individual with knowledge of fraud to bring a claim on behalf of the federal government and earn a percentage of the federal government's recovery. Due to these “whistleblower” incentives, suits have become more frequent. Many states also have a false claim prohibition that mirrors or tracks the federal FCA.

as it is knowingly improper. In addition, FERA extended protections against retaliation for whistleblowers, including protections not only for employees, but also contractors and agents. Thus, there is no need for an employment relationship in order to qualify for protection against retaliation for whistleblowing.

On January 2, 2013 the President signed the American Taxpayer Relief Act of 2012 into law. This statute lengthened the retrospective time period for which CMS can recover overpayments from health care providers, from three to five years following the year in which payment was made.

Regulations Regarding Financial Arrangements. We are also subject to federal and state laws that regulate financial arrangement by healthcare providers, such as the federal and state anti-kickback laws, the Stark laws, and various state referral laws. The federal anti-kickback laws and similar state laws make it unlawful for any person to pay, receive, offer, or solicit any benefit, directly or indirectly, for the referral or recommendation for products or services which are eligible for payment under federal healthcare programs, including Medicare and Medicaid. For the purposes of the anti-kickback law, a “federal healthcare program” includes Medicare and Medicaid programs and any other plan or program that provides health benefits which are funded directly, in whole or in part, by the United States government.

The arrangements prohibited under these anti-kickback laws can involve nursing homes, hospitals, physicians and other healthcare providers, plans, suppliers and non-healthcare providers. These laws have been interpreted very broadly to include a number of practices and relationships between healthcare providers and sources of patient referral. The scope of prohibited payments is very broad, including anything of value, whether offered directly or indirectly, in cash or in kind. Federal “safe harbor” regulations describe certain arrangements that will not be deemed to constitute violations of the anti-kickback law. Arrangements that do not comply with all of the strict requirements of a safe harbor are not necessarily illegal, but, due to the broad language of the statute, failure to comply with a safe harbor may increase the potential that a government agency or whistleblower will seek to investigate or challenge the arrangement. The safe harbors are narrow and do not cover a wide range of economic relationships.

Violations of the federal anti-kickback laws can result in criminal penalties of up to $25,000 and five years imprisonment. Violations of the anti-kickback laws can also result in civil monetary penalties of up to $50,000 and an assessment of up to three times the total amount of remuneration offered, paid, solicited, or received. Violation of the anti-kickback laws may also result in an individual's or organization's exclusion from future participation in Medicare, Medicaid and other state and federal healthcare programs. Exclusion of us or any of our key employees from the Medicare or Medicaid program could have a material adverse impact on our operations and financial condition.

In addition to these regulations, we may face adverse consequences if we violate the federal Stark laws related to certain Medicare physician referrals. The Stark laws prohibit a physician from referring Medicare patients for certain designated health services where the physician has an ownership interest in or compensation arrangement with the provider of the services, with limited exceptions. Also, any services furnished pursuant to a prohibited referral are not eligible for payment by the Medicare programs, and the provider is prohibited from billing any third party for such services. The Stark laws provide for the imposition of a civil monetary penalty of $15,000 per prohibited claim, and up to $100,000 for knowingly entering into certain prohibited cross-referral schemes, and potential exclusion from Medicare for any person who presents or causes to be presented a bill or claim the person knows or should know is submitted in violation of the Stark laws. Such designated health services include physical therapy services; occupational therapy services; radiology services, including CT, MRI and ultrasound; durable medical equipment and services; radiation therapy services and supplies; parenteral and enteral nutrients, equipment and supplies; prosthetics, orthotics and prosthetic devices and supplies; home health services; outpatient prescription drugs; inpatient and outpatient hospital services; clinical laboratory services; and diagnostic and therapeutic nuclear medical services.

Regulations Regarding Patient Record Confidentiality. We are also subject to laws and regulations enacted to protect the confidentiality of patient health information. For example, HHS has issued rules pursuant to HIPAA, which relate to the privacy of certain patient information. These rules govern our use and disclosure of protected health information. We have established policies and procedures to comply with HIPAA privacy and security requirements at our affiliated facilities and operating subsidiaries. We maintain a company-wide HIPAA compliance plan, which we believe complies with the HIPAA privacy and security regulations. The HIPAA privacy regulations and security regulations have and will continue to impose significant costs on our facilities in order to comply with these standards. There are numerous other laws and legislative and regulatory initiatives at the federal and state levels addressing privacy and security concerns. Our operations are also subject to any federal or state privacy-related laws that are more restrictive than the privacy regulations issued under HIPAA. These laws vary and could impose additional penalties for privacy and security breaches.

Antitrust Laws. We are also subject to federal and state antitrust laws. Enforcement of the antitrust laws against healthcare providers is common, and antitrust liability may arise in a wide variety of circumstances, including third party contracting, physician

relations, joint venture, merger, affiliation and acquisition activities. In some respects, the application of federal and state antitrust laws to healthcare is still evolving, and enforcement activity by federal and state agencies appears to be increasing. At various times, healthcare providers and insurance and managed care organizations may be subject to an investigation by a governmental agency charged with the enforcement of antitrust laws, or may be subject to administrative or judicial action by a federal or state agency or a private party. Violators of the antitrust laws could be subject to criminal and civil enforcement by federal and state agencies, as well as by private litigants.

Environmental Matters

Our business is subject to a variety of federal, state and local environmental laws and regulations. As a healthcare provider, we face regulatory requirements in areas of air and water quality control, medical and low-level radioactive waste management and disposal, asbestos management, response to mold and lead-based paint in our facilities and employee safety.

As an owner or operator of our facilities, we also may be required to investigate and remediate hazardous substances that are located on and/or under the property, including any such substances that may have migrated off, or may have been discharged or transported from the property. Part of our operations involves the handling, use, storage, transportation, disposal and discharge of medical, biological, infectious, toxic, flammable and other hazardous materials, wastes, pollutants or contaminants. In addition, we are sometimes unable to determine with certainty whether prior uses of our facilities and properties or surrounding properties may have produced continuing environmental contamination or noncompliance, particularly where the timing or cost of making such determinations is not deemed cost-effective. These activities, as well as the possible presence of such materials in, on and under our properties, may result in damage to individuals, property or the environment; may interrupt operations or increase costs; may result in legal liability, damages, injunctions or fines; may result in investigations, administrative proceedings, penalties or other governmental agency actions; and may not be covered by insurance.

We believe that we are in material compliance with applicable environmental and occupational health and safety requirements. However, we cannot assure you that we will not encounter liabilities with respect to these regulations in the future, and such liabilities may result in material adverse consequences to our operations or financial condition.

Available Information

We are subject to the reporting requirements under the Exchange Act. Consequently, we are required to file reports and information with the Securities and Exchange Commission (SEC), including reports on the following forms: annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act. These reports and other information concerning our company may be accessed through the SEC's website at http://www.sec.gov.

You may also find on our website at http://www.ensigngroup.net, electronic copies of our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act. Such filings are placed on our website as soon as reasonably possible after they are filed with the SEC. All such filings are available free of charge. Information contained in our website is not deemed to be a part of this Annual Report.

Item 1A. Risk Factors

Set forth below are certain risk factors that could harm our business, results of operations and financial condition. You should carefully read the following risk factors, together with the financial statements, related notes and other information contained in this Annual Report on Form 10-K. This Annual Report on Form 10-K contains forward-looking statements that contain risks and uncertainties. Please refer to the section entitled "Cautionary Note Regarding Forward-Looking Statements" on page 1 of this Annual Report on Form 10-K in connection with your consideration of the risk factors and other important factors that may affect future results described below.

Risks Related to Our Business and Industry

Our revenue could be impacted by federal and state changes to reimbursement and other aspects of Medicaid and Medicare.

We derived 40.5% and 39.0% of our revenue from the Medicaid program for the years ended December 31, 2017 and 2016, respectively. We derived 27.9% and 28.8% of our revenue from the Medicare program for the years ended December 31, 2017 and 2016, respectively. If reimbursement rates under these programs are reduced or fail to increase as quickly as our costs, or if

Table of Contents

there are changes in the way these programs pay for services, our business and results of operations would be adversely affected. The services for which we are currently reimbursed by Medicaid and Medicare may not continue to be reimbursed at adequate levels or at all. Further limits on the scope of services being reimbursed, delays or reductions in reimbursement or changes in other aspects of reimbursement could impact our revenue. For example, in the past, the enactment of the Deficit Reduction Act of 2005 (DRA), the Medicaid Voluntary Contribution and Provider-Specific Tax Amendments of 1991 and the Balanced Budget Act of 1997 (BBA) caused changes in government reimbursement systems, which, in some cases, made obtaining reimbursements more difficult and costly and lowered or restricted reimbursement rates for some of our patients.

The Medicaid and Medicare programs are subject to statutory and regulatory changes affecting base rates or basis of payment, retroactive rate adjustments, annual caps that limit the amount that can be paid (including deductible and coinsurance amounts) for rehabilitation therapy services rendered to Medicare beneficiaries, administrative or executive orders and government funding restrictions, all of which may materially adversely affect the rates and frequency at which these programs reimburse us for our services. For example, the Medicaid Integrity Contractor (MIC) program is increasing the scrutiny placed on Medicaid payments, and could result in recoupments of alleged overpayments in an effort to rein in Medicaid spending. Recent budget proposals and legislation at both the federal and state levels have called for cuts in reimbursement for health care providers participating in the Medicare and Medicaid programs. Enactment and implementation of measures to reduce or delay reimbursement could result in substantial reductions in our revenue and profitability. Payors may disallow our requests for reimbursement based on determinations that certain costs are not reimbursable or reasonable because either adequate or additional documentation was not provided or because certain services were not covered or considered reasonably necessary. Additionally, revenue from these payors can be retroactively adjusted after a new examination during the claims settlement process or as a result of post-payment audits. New legislation and regulatory proposals could impose further limitations on government payments to healthcare providers.

In addition, on October 1, 2010, the next generation of the Minimum Data Set (MDS) 3.0 was implemented, creating significant changes in the methodology for calculating the resource utilization group (RUG) category under Medicare Part A, most notably eliminating Section T. Because therapy does not necessarily begin upon admission, MDS 2.0 and the RUGS-III system included a provision to capture therapy services that are scheduled to occur but have not yet been provided in order to calculate a RUG level that better reflects the level of care the recipient would actually receive. This is eliminated with MDS 3.0, which creates a new category of assessment called the Medicare Short Stay Assessment. This assessment provides for calculation of a rehabilitation RUG for patients discharged on or before day eight who received less than five days of therapy.

On November 16, 2015, the Centers for Medicare & Medicaid Services (CMS) issued the final rule for a new mandatory Comprehensive Care for Joint Replacement (CJR) model focusing on coordinated, patient-centered care. Under this model, the hospital in which the hip or knee replacement takes place is accountable for the costs and quality of care from the time of the surgery through 90 days after, or an “episode” of care. Depending on the hospital’s quality and cost performance during the episode, the hospital either earns a financial reward or is required to repay Medicare for a portion of the costs. This payment is intended to give hospitals an incentive to work with physicians, home health agencies and nursing facilities to make sure beneficiaries receive the coordinated care they need with the goal of reducing avoidable hospitalizations and complications. This model initially covers 67 geographic areas throughout the country and most hospitals in those regions are required to participate. Following the implementation of the CJR program on April 1, 2016, our Medicare revenues derived from our affiliated skilled nursing facilities and other post-acute services related to lower extremity joint replacement hospital discharges could be increased or decreased in those geographic areas identified by CMS for mandatory participation in the bundled payment program.

On August 15, 2017, CMS proposed changes to the Comprehensive Care for Joint Replacement Model, which included the cancellation of care coordination through mandatory Episode Payments and Cardiac Rehabilitation Incentive Payment Model.

Table of Contents

On December 1, 2017, CMS issued a final rule which officially canceled the Episode Payment Models and Cardiac Rehabilitation Incentive Payment Model, rescinding the regulations governing these models. Additionally, the final rule implemented certain revisions to the CJR program, including making participation voluntary for approximately half of the geographic areas, along with other technical refinements. These regulation changes are effective January 1, 2018.

On October 1, 2015, International Classification of Diseases (ICD) 10 was implemented as the new medical coding system. Some of the main points include: Claims with antibiotic removal devices (ARDs) on or after October 1, 2015 must contain a valid ICD-10 code. CMS will reject MDS assessments if a Section I diagnosis code version does not apply for the ARD entered. Flexibility is being provided to physician providers with coding, but this flexibility will not be passed on to facility-based providers, including skilled nursing facilities that are providing Part B services.

Various healthcare reform provisions became law upon enactment of the Patient Protection and Affordable Care Act and the Healthcare Education and Reconciliation Act (collectively, the ACA). The reforms contained in the ACA have affected our operating subsidiaries in some manner and are directed in large part at increased quality and cost reductions. Several of the reforms are very significant and could ultimately change the nature of our services, the methods of payment for our services and the underlying regulatory environment. These reforms include the possible modifications to the conditions of qualification for payment, bundling of payments to cover both acute and post-acute care and the imposition of enrollment limitations on new providers. As discussed below under the heading “Our business may be materially impacted if certain aspects of the Affordable Care Act are amended, repealed, or successfully challenged”, any further amendments or revisions to the ACA or its implementing regulations could materially impact our business.

Skilled Nursing

In 2017, CMS proposed an alternative case-mix classification system for fiscal year 2018, named Resident Classification System, Version I (RCS-I). RCS-I, would case-mix adjust for the following major cost categories: Physical therapy (PT), occupational therapy (OT), speech-language pathology (SLP) services, nursing services and non-therapy ancillaries (NTAs). Thus, where RUG-IV consists of two case-mix adjusted components (therapy and nursing), RCS-I would create four (PT/OT, SLP, nursing, and NTA) for a more resident-centered case-mix adjustment. RCS-I would also maintain the existing non-case-mix component to cover utilization of SNF resources that do not vary according to resident characteristics. For two of the case-mix-adjusted components, PT/OT and NTA, RCS-I includes variable per-diem payment adjustments that modify payment based on changes in utilization of these services over the course of a stay. The proposed model will compensate SNFs accurately based on the complexity of the particular beneficiaries they serve and the resources necessary in caring for those beneficiaries and addresses concerns about current incentives for SNFs to delivery therapy to beneficiaries based on financial considerations, rather than the most effective course of treatment for beneficiaries. The proposed RCS-I classification model could improve the SNF PPS by basing payments predominantly on clinical characteristics rather than service provision, thereby enhancing payment accuracy and strengthening incentives for appropriate care. The proposed rule is expected to reduce payments associated with residents in the highest therapy RUG (RU) and increase payments associated with residents who receive extensive services or have high NTA costs. The proposed rule also simplifies the MDS structure and reduces labor needs. Additionally, it is estimated that RCS-I would result in higher payments associated with the following resident types: dual enrollment in Medicare and Medicaid, end-stage renal disease (ESRD), having a longer qualifying inpatient stay, diabetes, wound infections, and use of IV medication.

Table of Contents

On July 31, 2017, CMS issued its final rule outlining fiscal year 2018 Medicare payment rates for skilled nursing facilities. Under the final rule, the market basket index is revised and rebased by updating the base year from 2010 to 2014 and adding a new cost category for Installation, Maintenance, and Repair Services. The rule also includes revisions to the SNF Quality Reporting Program, including measure and standardized patient assessment data policies, as well as policies related to public display. In addition, it finalized policies for the Skilled Nursing Facility Value-Based Purchasing Program that will affect Medicare payment to SNFs beginning in fiscal year 2019 and clarification of the requirements regarding the composition of professionals for the survey team. The final rule uses a market basket percentage of 1% to update the federal rates, but if a SNF fails to submit quality reporting program requirements there will be a 2% reduction to the market basket update. Thus, the increase in the federal rates may increase the amount of our reimbursements for SNF services so long as we meet the reporting requirements.

On July 29, 2016, CMS issued its final rule outlining fiscal year 2017 Medicare payment rates and quality programs for skilled nursing facilities. The policies in the finalized rule continue to shift Medicare payments from volume to value. The aggregate payments to skilled nursing facilities increased by a net 2.4% for fiscal year 2017. This increase reflected a 2.7% market basket increase, reduced by a 0.3% multi-factor productivity (MFP) adjustment required by ACA. This final rule also further defines the skilled nursing facilities Quality Reporting Program and clarifies the Value-Based Purchasing Program to establish performance standards, baseline and performance periods, performance scoring methodology and feedback reports.

The Value-Based Purchasing Program final rule specifies the skilled nursing facility 30-day potentially preventable readmission measure, which assesses the facility-level risk standardized rate of unplanned, potentially preventable hospital readmissions for skilled nursing facility patients within 30 days of discharge from a prior admission to a hospital paid under the Inpatient Prospective Payment System, a critical access hospital, or a psychiatric hospital. There is also finalized additional policies related to the Value-Based Purchasing Program including: establishing performance standards; establishing baseline and performance periods; adopting a performance scoring methodology; and providing confidential feedback reports to the skilled nursing facilities. This SNF Value-Based Purchasing Program will start in fiscal year 2019.

On July 30, 2015, CMS published its final rule outlining fiscal year 2016 Medicare payment rates for skilled nursing facilities. The aggregate payments to skilled nursing facilities increased by 1.2% for fiscal year 2016. This increase reflected a 2.3% market basket increase, reduced by a 0.6% point forecast error adjustment and further reduced by 0.5% MFP adjustment required by the Patient Protection and Affordable Care Act (ACA). This final rule also identified a new skilled nursing facility value-based purchasing program and all-cause all-condition hospital readmission measure.

Home Health

On November 5, 2015, CMS issued a final rule updating the Medicare HH PPS rates and wage index for calendar year 2016. In the final rule, CMS implemented the third year of the four year phase-in of rebasing adjustments to the HH PPS payment rates

Table of Contents

as required by ACA. In addition, CMS decreased the national, standardized 60-day episode payment amount by 0.97% in each year for calendar years 2016, 2017 and 2018.

Pursuant to the rule, CMS also implemented a Home Health Value-Based Purchasing model effective for calendar year 2016, in which all Medicare-certified HHAs in selected states are required to participate. The model applied a payment reduction or increase to current Medicare-certified HHA payments, depending on quality performance, for all agencies delivering services within nine randomly-selected states. Payment adjustments are applied on an annual basis, beginning at 3.0% in the first payment adjustment year, 5.0% in the second payment adjustment year, 6.0% in the third payment adjustment year and 8.0% in the final two payment adjustment years. The implementation of a home health value-based model resulted in a 1.4% decrease in Medicare payments to home health agencies across the industry.

Lastly, CMS implemented a standardized cross-setting measure for calendar year 2016. The CoPs require home health agencies to submit OASIS assessments as a condition of payment and also for quality measurement purposes. Home health agencies that do not submit quality measure data to CMS incur a 2.0% reduction in their annual home health payment update percentage. Under the rule, all home health agencies are required to timely submit both Start of Care (initial assessment) or Resumption of Care OASIS assessment and a Transfer or Discharge OASIS assessment for a minimum of 70.0% of all patients with episodes of care occurring during the annual reporting period starting July 1, 2015 and ending June 30, 2016, 80% of all patients with episodes occurring during the reporting period starting July 1, 2016 and ending June 30, 2017, and 90% for all episodes beginning on or after July 1, 2017.

Hospice

On August 1, 2017, CMS issued its final rule outlining the fiscal year 2018 Medicare payment rates, wage index and cap amount for hospices serving Medicare beneficiaries. The final rule uses a net market basket percentage increase of 1.0% to update the federal rates, as mandated by section 411(d) of the MACRA. Although, if a hospice fails to comply with quality reporting program requirements, there will be a net 2.0% reduction to the market basket update for the fiscal year involved. The hospice cap amount for fiscal year 2018 is increased by 1.0%, which is equal to the 2017 cap amount updated by the fiscal year 2018 hospice payment update percentage of 1.0%. In addition, this rule discusses changes to the Hospice Quality Reporting Program (HQRP), including changes to the Consumer Assessment of Healthcare Providers and Systems (CAHPS) hospice survey measures and plans for sharing HQRP data in fiscal year 2017.

On July 29, 2016, CMS issued its final rule outlining fiscal year 2017 Medicare payment rates, wage index and cap amount for hospices serving Medicare beneficiaries. Under the final rule, there was a net 2.1% increase in the hospices' payments effective October 1, 2016. The hospice payment increase was the net result of 2.7% inpatient hospital market basket update, reduced by a 0.3% productivity adjustment and by a 0.3% adjustment set by the ACA. The hospice cap amount for fiscal year 2017 increased by 2.1%, which is equal to the 2016 cap amount updated by the fiscal year 2017 hospice payment update percentage of 2.1%. In addition, this rule changes the hospice quality reporting program requirements, including care surveys and two new quality measures that will assess hospice staff visits to patients and caregivers in the last three and seven days of life and the percentage of hospice patients who received care processes consistent with guidelines.

On July 31, 2015, CMS issued its final rule outlining fiscal year 2016 Medicare payment rates and the wage index for hospices serving Medicare beneficiaries. Under the final rule, there was a net 1.1% increase in payments effective October 1, 2015. The hospice payment increase was the net result of a hospice payment update to the hospice per diem rates of 2.1% (a “hospital market basket” increase of 2.4% minus 0.3% for reductions required by law) and a 1.2% decrease in payments to hospices due to updated wage data and the phase-out of its wage index budget neutrality adjustment factor (BNAF), offset by the newly announced Core Based Statistical Areas (CBSA) delineation impact of 0.2%. The rule also created two different payment rates for routine home care (RHC) that resulted in a higher base payment rate for the first 60 days of hospice care and a reduced base payment rate for 61 or more days of hospice care and a Service Intensity Add-On (SIA) Payment for fiscal year 2016 and beyond in conjunction with the proposed RHC rates.

On April 1, 2014, the President signed into law the Protecting Access to Medicare Act of 2014, which averted a 24% cut in Medicare payments to physicians and other Part B providers until March 31, 2015. In addition, this law maintained the 0.5% update for such services through December 31, 2014 and provides a 0.0% update to the 2015 Medicare Physician Fee Schedule (MPFS) through March 31, 2015. Among other things, this law provides the framework for implementation of a value-based purchasing program for skilled nursing facilities. Under this legislation HHS is required to develop by October 1, 2016 measures and performance standards regarding preventable hospital readmissions from skilled nursing facilities. Beginning October 1, 2018, HHS will withhold 2% of Medicare payments to all skilled nursing facilities and distribute this pool of payment to skilled nursing facilities as incentive payments for preventing readmissions to hospitals.

Table of Contents

On April 16, 2015, the President signed MACRA into law. This bill includes a number of provisions, including replacement of the Sustainable Growth Rate (SGR) formula used by Medicare to pay physicians with new systems for establishing annual payment rate updates for physicians' services. In addition, it increases premiums for Part B and Part D of Medicare for beneficiaries with income above certain levels and makes numerous other changes to Medicare and Medicaid.

On October 30, 2015, CMS released a final rule (with comment period) addressing, among other things, implementation of certain provisions of MACRA, including the implementation of the new Merit-Based Incentive Payment System (MIPS). The current Value-Based Payment Modifier program is set to expire in 2018, with MIPS to begin in 2019. The October 30, 2015 final rule added measures where gaps exist in the current Physician Quality Reporting System (PQRS), which is used by CMS to track the quality of care provided to Medicare beneficiaries. The final rule also excludes services furnished in SNFs from the definition of primary care services for purposes of the Shared Savings Program. The final rule could impact our revenue in the future.

The Improving Medicare Post-Acute Care Transformation Act of 2014 (the IMPACT Act), which was signed into law on October 6, 2014, requires the submission of standardized assessment data for quality improvement, payment and discharge planning purposes across the spectrum of post-acute care providers (PACs), including skilled nursing facilities and home health agencies. The IMPACT Act will require PACs to begin reporting: (1) standardized patient assessment data at admission and discharge by October 1, 2018 for post-acute care providers, including skilled nursing facilities by January 1, 2019 for home health agencies; (2) new quality measures, including functional status, skin integrity, medication reconciliation, incidence of major falls, and patient preference regarding treatment and discharge at various intervals between October 1, 2016 and January 1, 2019; and (3) resource use measures, including Medicare spending per beneficiary, discharge to community, and hospitalization rates of potentially preventable readmissions by October 1, 2016 for post-acute care providers, including skilled nursing facilities and by January 1, 2017 for home health agencies. Failure to report such data when required would subject a facility to a two percent reduction in market basket prices then in effect.

On January 2, 2013 the President signed the American Taxpayer Relief Act of 2012 into law. This statute delayed significant cuts in Medicare rates for physician services until December 31, 2013. The statute also created a Commission on Long-Term Care, the goal of which was to develop a plan for the establishment, implementation, and financing of a comprehensive, coordinated, and high-quality system that ensures the availability of long-term care services and supports for individuals in need of such services and supports.

On February 22, 2012, the President signed into law H.R. 3630, which among other things, delayed a cut in physician and Part B services. In establishing the funding for the law, payments to nursing facilities for patients' unpaid Medicare A co-insurance was reduced. The Deficit Reduction Act of 2005 had previously limited reimbursement of bad debt to 70% on privately responsibility co-insurance. However, under H.R. 3630, this reimbursement will be reduced to 65%.

Further, prior to the introduction of H.R. 3630, we were reimbursed for 100% of bad debt related to dual-eligible Medicare patients' co-insurance. H.R. 3630 will phase down the dual-eligible reimbursement over three years. Effective October 1, 2012, Medicare dual-eligible co-insurance reimbursement decreased from 100% to 88%, with further reductions to 77% and 65% as of October 1, 2013 and 2014, respectively. Any reductions in Medicare or Medicaid reimbursement could materially adversely affect our profitability.

Our future revenue, financial condition and results of operations could be impacted by continued cost containment pressures on Medicaid spending.

Medicaid, which is largely administered by the states, is a significant payor for our skilled nursing services. Rapidly increasing Medicaid spending, combined with slow state revenue growth, has led many states to institute measures aimed at controlling spending growth. For example, in February 2009, the California legislature approved a new budget to help relieve a $42 billion budget deficit. The budget package was signed after months of negotiation, during which time California's governor declared a fiscal state of emergency in California. The new budget implemented spending cuts in several areas, including Medi-Cal spending. Further, California initially had extended its cost-based Medi-Cal long-term care reimbursement system enacted through Assembly Bill 1629 (A.B.1629) through the 2009-2010 and 2010-2011 rate years with a growth rate of up to five percent for both years. However, due to California's severe budget crisis, in July 2009, the State passed a budget-balancing proposal that eliminated this five percent growth cap by amending the current statute to provide that, for the 2009-2010 and 2010-2011 rate years, the weighted

Table of Contents

average Medi-Cal reimbursement rate paid to long-term care facilities shall not exceed the weighted average Medi-Cal reimbursement rate for the 2008-2009 rate year. In addition, the budget proposal increased the amounts that California nursing facilities will pay to Medi-Cal in quality assurance fees for the 2009-2010 and 2010-2011 rate years by including Medicare revenue in the calculation of the quality assurance fee that nursing facilities pay under A.B. 1629. Although overall reimbursement from Medi-Cal remained stable, individual facility rates varied.

California's Governor signed the budget trailer into law in October 2010. Despite its enactment, these changes in reimbursement to long-term care facilities were to be implemented retroactively to the beginning of the calendar quarter in which California submitted its request for federal approval of CMS. California’s Governor released a 2014-2015 budget that includes $1.2 billion in additional Medi-Cal funding. This proposal, however, would not eliminate retroactive rate cuts for hospital-based skilled nursing facilities.

Because state legislatures control the amount of state funding for Medicaid programs, cuts or delays in approval of such funding by legislatures could reduce the amount of, or cause a delay in, payment from Medicaid to skilled nursing facilities. Since a significant portion of our revenue is generated from our skilled nursing operating subsidiaries in California, these budget reductions, if approved, could adversely affect our net patient service revenue and profitability. We expect continuing cost containment pressures on Medicaid outlays for skilled nursing facilities, and any such decline could adversely affect our financial condition and results of operations.

To generate funds to pay for the increasing costs of the Medicaid program, many states utilize financial arrangements such as provider taxes. Under provider tax arrangements, states collect taxes or fees from healthcare providers and then return the revenue to these providers as Medicaid expenditures. Congress, however, has placed restrictions on states' use of provider tax and donation programs as a source of state matching funds. Under the Medicaid Voluntary Contribution and Provider-Specific Tax Amendments of 1991, the federal medical assistance percentage available to a state was reduced by the total amount of healthcare related taxes that the state imposed, unless certain requirements are met. The federal medical assistance percentage is not reduced if the state taxes are broad-based and not applied specifically to Medicaid reimbursed services. In addition, the healthcare providers receiving Medicaid reimbursement must be at risk for the amount of tax assessed and must not be guaranteed to receive reimbursement through the applicable state Medicaid program for the tax assessed. Lower Medicaid reimbursement rates would adversely affect our revenue, financial condition and results of operations.

We may not be fully reimbursed for all services for which each facility bills through consolidated billing, which could adversely affect our revenue, financial condition and results of operations.

Skilled nursing facilities are required to perform consolidated billing for certain items and services furnished to patients and residents. The consolidated billing requirement essentially confers on the skilled nursing facility itself the Medicare billing responsibility for the entire package of care that its patients receive in these situations. The BBA also affected skilled nursing facility payments by requiring that post-hospitalization skilled nursing services be “bundled” into the hospital's Diagnostic Related Group (DRG) payment in certain circumstances. Where this rule applies, the hospital and the skilled nursing facility must, in effect, divide the payment which otherwise would have been paid to the hospital alone for the patient's treatment, and no additional funds are paid by Medicare for skilled nursing care of the patient. At present, this provision applies to a limited number of DRGs, but already is apparently having a negative effect on skilled nursing facility utilization and payments, either because hospitals are finding it difficult to place patients in skilled nursing facilities which will not be paid as before or because hospitals are reluctant to discharge the patients to skilled nursing facilities and lose part of their payment. This bundling requirement could be extended to more DRGs in the future, which would accentuate the negative impact on skilled nursing facility utilization and payments. We may not be fully reimbursed for all services for which each facility bills through consolidated billing, which could adversely affect our revenue, financial condition and results of operations.

Reforms to the U.S. healthcare system will impose new requirements upon us and may lower our reimbursements.

ACA and the Health Care and Education Reconciliation Act of 2010 (the Reconciliation Act) include sweeping changes to how health care is paid for and furnished in the United States. As discussed below under the heading “-Our business may be materially impacted if certain aspects of the Affordable Care Act are amended, repealed, or successfully challenged”, any further amendments or revisions to ACA or its implementing regulations could materially impact our business. The recent presidential and congressional elections in the United States could result in significant changes in, and uncertainty with respect to, legislation, regulation, implementation of Medicare and/or Medicaid, and government policy that could significantly impact our business and the health care industry. We continually monitor these developments in an effort to respond to the changing regulatory environment impacting our business.

Table of Contents

ACA, as modified by the Reconciliation Act, is projected to expand access to Medicaid for approximately 11 to 13 million additional people each year between 2015-2024. It also reduces the projected growth of Medicare by $106 billion by 2020 by tying payments to providers more closely to quality outcomes. It also imposes new obligations on skilled nursing facilities, requiring them to disclose information regarding ownership, expenditures and certain other information. This information is disclosed on a website for comparison by members of the public.

To address potential fraud and abuse in federal health care programs, including Medicare and Medicaid, ACA includes provider screening and enhanced oversight periods for new providers and suppliers, as well as enhanced penalties for submitting false claims. It also provides funding for enhanced anti-fraud activities. The new law imposes enrollment moratoria in elevated risk areas by requiring providers and suppliers to establish compliance programs. ACA also provides the federal government with expanded authority to suspend payment if a provider is investigated for allegations or issues of fraud. Section 6402 of the ACA provides that Medicare and Medicaid payments may be suspended pending a “credible investigation of fraud,” unless the Secretary of HHS determines that good cause exists not to suspend payments. To the extent the Secretary applies this suspension of payments provision to one of our affiliated facilities for allegations of fraud, such a suspension could adversely affect our results of operations.

Under ACA, HHS will establish, test and evaluate alternative payment methodologies for Medicare services through a five-year, national, voluntary pilot program starting in 2013. This program will provide incentives for providers to coordinate patient care across the continuum and to be jointly accountable for an entire episode of care centered around a hospitalization. HHS will develop qualifying provider payment methods that may include bundled payments and bids from entities for episodes of care. The bundled payment will cover the costs of acute care inpatient services; physicians’ services delivered in and outside of an acute care hospital; outpatient hospital services including emergency department services; post-acute care services, including home health services, skilled nursing services; inpatient rehabilitation services; and inpatient hospital services. The payment methodology will include payment for services, such as care coordination, medication reconciliation, discharge planning and transitional care services, and other patient-centered activities. Payments for items and services cannot result in spending more than would otherwise be expended for such entities if the pilot program was not implemented. As with Medicare’s shared savings program discussed above, payment arrangements among providers on the backside of the bundled payment must take into account significant hurdles under the Anti-Kickback Statue, the Stark Law and the Civil Monetary Penalties Law.

ACA attempts to improve the health care delivery system through incentives to enhance quality, improve beneficiary outcomes and increase value of care. One of these key delivery system reforms is the encouragement of Accountable Care Organizations (ACOs). ACOs will facilitate coordination and cooperation among providers to improve the quality of care for Medicare beneficiaries and reduce unnecessary costs. Participating ACOs that meet specified quality performance standards will be eligible to receive a share of any savings if the actual per capita expenditures of their assigned Medicare beneficiaries are a sufficient percentage below their specified benchmark amount. Quality performance standards will include measures in such categories as clinical processes and outcomes of care, patient experience and utilization of services.

We routinely receive Requests for Information (RFIs) from active referral and managed care networks asking for quality, rating, performance and other information about our SNFs operating in the geographic areas that they are being serviced. The RFIs are used to evaluate which SNFs should be included in each network of preferred providers. For those SNFs included in the network, the ACO and its associated providers may then recommend the SNF as a “preferred provider” to patients in need of skilled care. In the past, after responding to such RFIs, our SNFs have in some instances been rewarded with inclusion in a network of preferred providers, and in other instances have not been included. While referrals to a SNF in a preferred provider network will always be subject to a patient’s freedom of choice, as well as the patient’s physician’s medical judgment as to which facility will best serve the patient’s needs, the inclusion as a preferred provider in a network will likely result in an increase in overall admissions to that SNF. On the other hand, the failure to be included could result in some volume of patient admissions being shifted to other facilities that have been designated instead as preferred providers. As a result, to the extent that one of our SNF is not included in a preferred provider network, our revenues and results of operations could be adversely affected.

In addition, ACA required HHS to develop a plan to implement a value-based purchasing program for Medicare payments to skilled nursing facilities. HHS delivered a report to Congress outlining its plans for implementing this value-based purchasing program. The value-based purchasing program would provide payment incentives for Medicare-participating skilled nursing facilities to improve the quality of care provided to Medicare beneficiaries. Among the most relevant factors in HHS' plans to implement value-based purchasing for skilled nursing facilities is the current Nursing Home Value-Based Purchasing Demonstration Project, which concluded in 2012. HHS provided Congress with an outline of plans to implement a value-based purchasing program, and any permanent value-based purchasing program for skilled nursing facilities will be implemented after that evaluation.

Table of Contents

have not been updated since 1991 and have been revised to improve quality of life, care and services in LTC facilities, optimize resident safety, reflect current professional standards and improve the logical flow of the regulations. The regulations are effective November 28, 2016 and will be implemented in three phases. The first phase was effective November 28, 2016, the second phase was effective November 28, 2017 and the third phase becomes effective November 28, 2019.

A few highlights from the new regulation include the following:


•	investigate and report all allegations of abusive conduct, and refrain from employing individuals who have had a disciplinary action taken against their professional license by a state licensure body as a result of a finding of abuse, neglect, mistreatment of residents or misappropriation of their property;


•	document a transfer or discharge in the medical record and exchange certain information to a receiving provider or facility when a resident is transferred;


•	develop and implement a baseline care plan for each resident within 48 hours of their admission that includes instructions to provide effective and person-centered care that meets professional standards of quality care;


•	develop and implement a discharge planning process that prepares residents to be active partners in post-discharge care;


•	provide the necessary care and services to attain or maintain the highest practicable physical, mental and psychosocial well-being;


•	add a competency requirement for determining the sufficiency of nursing staff;


•	require that a pharmacist reviews a resident’s medical chart during each monthly drug regiment review;


•	refrain from charging a Medicare resident for loss or damage of dentures;


•	provide each resident with a nourishing, palatable and well-balanced diet;


•	conduct, document and annually review a facility-wide assessment to determine what resources are necessary to care for its residents;


•	refrain from entering into a binding arbitration agreement until after a dispute arises between the parties;


•	develop, implement and maintain an effective comprehensive, data-driven quality assurance and performance improvement program;


•	develop an Infection Prevention and Control Program; and


•	require their operating organization have in effect a compliance and ethics program.

Table of Contents

In addition, the proposed rule states, beginning in 2019, the achievement performance standard for skilled nursing facilities for quality measures specified under the SNF Value Based Purchasing Program (SNF VBP) will be the 25^th percentile of national SNF performance on the quality measure during the applicable baseline period. This will affect the value based incentive payments paid to skilled nursing facilities.

On February 2, 2016, CMS issued its final rule concerning face-to-face requirements for Medicaid home health services. Under the rule, the Medicaid home health service definition was revised consistent with applicable sections of the ACA and H.R. 2 Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). The rule also requires that for the initial ordering of home health services, the physician must document that a face-to-face encounter that is related to the primary reason the beneficiary requires home health services occurred no more than 90 days before or 30 days after the start of services. The final rule also requires that for the initial ordering of certain medical equipment, the physician or authorized non-physician provider (NPP) must document that a face-to-face encounter that is related to the primary reason the beneficiary requires medical equipment occurred no more than 6 months prior to the start of services.

On April 27, 2016, CMS added six new quality measures to its consumer-based Nursing Home Compare website. These quality measures include the rate of rehospitalization, emergency room use, community discharge, improvements in function, independently worsened and antianxiety or hypnotic medication among nursing home residents. Beginning in July 2016, CMS incorporates all of these measures, except for the antianxiety/hypnotic medication measure, into the calculation of the Nursing Home Five-Star Quality Ratings.

On July 6, 2015, CMS announced a proposal to launch Home Health Value-Based Purchasing model to test whether incentives for better care can improve outcomes in the delivery of home health services. The model would apply a payment reduction or increase to current Medicare-certified home health agency payments, depending on quality performance, for all agencies delivering services within nine randomly-selected states. Payment adjustments would be applied on an annual basis, beginning at 5.0% in each of the first two payment adjustment years, 6.0% in the third payment adjustment year and 8.0% in the final two payment adjustment years.

On June 28, 2012, the United States Supreme Court ruled that the enactment of ACA did not violate the Constitution of the United States. This ruling permits the implementation of most of the provisions of ACA to proceed. The provisions of ACA discussed above are only examples of federal health reform provisions that we believe may have a material impact on the long-term care industry and on our business. However, the foregoing discussion is not intended to constitute, nor does it constitute, an exhaustive review and discussion of ACA. It is possible that these and other provisions of ACA may be interpreted, clarified, or applied to our affiliated facilities or operating subsidiaries in a way that could have a material adverse impact on the results of operations.

On April 1, 2014, the President signed into law the Protecting Access to Medicare Act of 2014 which, among other things, provides the framework for implementation of a value-based purchasing program for skilled nursing facilities. Under this legislation HHS is required to develop by October 1, 2016 measures and performance standards regarding preventable hospital readmissions from skilled nursing facilities. Beginning October 1, 2018, HHS will withhold 2% of Medicare payments to all skilled nursing

Table of Contents

facilities and distribute this pool of payment to skilled nursing facilities as incentive payments for preventing readmissions to hospitals.

We cannot predict what effect these changes will have on our business, including the demand for our services or the amount of reimbursement available for those services. However, it is possible these new laws may lower reimbursement and adversely affect our business.

The Affordable Care Act and its implementation could impact our business.

In addition, the Affordable Care Act could result in sweeping changes to the existing U.S. system for the delivery and financing of health care. The details for implementation of many of the requirements under the Affordable Care Act will depend on the promulgation of regulations by a number of federal government agencies, including the HHS. It is impossible to predict the outcome of these changes, what many of the final requirements of the Health Reform Law will be, and the net effect of those requirements on us. As such, we cannot predict the impact of the Affordable Care Act on our business, operations or financial performance.

A significant goal of Federal health care reform is to transform the delivery of health care by changing reimbursement for health care services to hold providers accountable for the cost and quality of care provided. Medicare and many commercial third party payors are implementing Accountable Care Organization models in which groups of providers share in the benefit and risk of providing care to an assigned group of individuals at lower cost. Other reimbursement methodology reforms include value-based purchasing, in which a portion of provider reimbursement is redistributed based on relative performance on designated economic, clinical quality, and patient satisfaction metrics. In addition, CMS is implementing programs to bundle acute care and post-acute care reimbursement to hold providers accountable for costs across a broader continuum of care. These reimbursement methodologies and similar programs are likely to continue and expand, both in public and commercial health plans. Providers who respond successfully to these trends and are able to deliver quality care at lower cost are likely to benefit financially.

The Affordable Care Act and the programs implemented by the law may reduce reimbursements for our services and may impact the demand for the Company’s products. In addition, various healthcare programs and regulations may be ultimately implemented at the federal or state level. Failure to respond successfully to these trends could negatively impact our business, results of operations and/or financial condition. As discussed below under the heading “Our business may be materially impacted if certain aspects of the Affordable Care Act are amended, repealed, or successfully challenged”, any further amendments or revisions to ACA or its implementing regulations could materially impact our business.

Our business may be materially impacted if certain aspects of the Affordable Care Act are amended, repealed, or successfully challenged.

A number of lawsuits have been filed challenging various aspects of ACA and related regulations. In addition, the efficacy of ACA is the subject of much debate among members of Congress and the public. The recent presidential and congressional elections in the United States could result in significant changes in, and uncertainty with respect to, legislation, regulation, implementation of Medicare and/or Medicaid, and government policy that could significantly impact our business and the health care industry. In the event that legal challenges are successful or ACA is repealed or materially amended, particularly any elements of ACA that are beneficial to our business or that cause changes in the health insurance industry, including reimbursement and coverage by private, Medicare or Medicaid payers, our business, operating results and financial condition could be harmed. While it is not possible to predict whether and when any such changes will occur, specific proposals discussed during and after the election, including a repeal or material amendment of ACA, could harm our business, operating results and financial condition. In addition, even if ACA is not amended or repealed, the President and the executive branch of the federal government, as well as CMS and HHS have a significant impact on the implementation of the provisions of ACA, and the new administration could make changes impacting the implementation and enforcement of ACA, which could harm our business, operating results and financial condition. If we are slow or unable to adapt to any such changes, our business, operating results and financial condition could be adversely affected.

Increased competition for, or a shortage of, nurses and other skilled personnel could increase our staffing and labor costs and subject us to monetary fines.

Our success depends upon our ability to retain and attract nurses, Certified Nurse Assistants (CNAs) and therapists. Our success also depends upon our ability to retain and attract skilled management personnel who are responsible for the day-to-day operations of each of our affiliated facilities. Each facility has a facility leader responsible for the overall day-to-day operations of the facility, including quality of care, social services and financial performance. Depending upon the size of the facility, each facility leader is supported by facility staff that is directly responsible for day-to-day care of the patients and marketing and

Table of Contents

community outreach programs. Other key positions supporting each facility may include individuals responsible for physical, occupational and speech therapy, food service and maintenance. We compete with various healthcare service providers, including other skilled nursing providers, in retaining and attracting qualified and skilled personnel.

We operate one or more affiliated skilled nursing facilities in the states of Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin. With the exception of Utah, which follows federal regulations, each of these states has established minimum staffing requirements for facilities operating in that state. Failure to comply with these requirements can, among other things, jeopardize a facility's compliance with the conditions of participation under relevant state and federal healthcare programs. In addition, if a facility is determined to be out of compliance with these requirements, it may be subject to a notice of deficiency, a citation, or a significant fine or litigation risk. Deficiencies (depending on the level) may also result in the suspension of patient admissions and/or the termination of Medicaid participation, or the suspension, revocation or nonrenewal of the skilled nursing facility's license. If the federal or state governments were to issue regulations which materially change the way compliance with the minimum staffing standard is calculated or enforced, our labor costs could increase and the current shortage of healthcare workers could impact us more significantly.

Increased competition for, or a shortage of, nurses or other trained personnel, or general inflationary pressures may require that we enhance our pay and benefits packages to compete effectively for such personnel. We may not be able to offset such added costs by increasing the rates we charge to the patients of our operating subsidiaries. Turnover rates and the magnitude of the shortage of nurses or other trained personnel vary substantially from facility to facility. An increase in costs associated with, or a shortage of, skilled nurses, could negatively impact our business. In addition, if we fail to attract and retain qualified and skilled personnel, our ability to conduct our business operations effectively would be harmed.

We are subject to various government reviews, audits and investigations that could adversely affect our business, including an obligation to refund amounts previously paid to us, potential criminal charges, the imposition of fines, and/or the loss of our right to participate in Medicare and Medicaid programs.

As a result of our participation in the Medicaid and Medicare programs, we are subject to various governmental reviews, audits and investigations to verify our compliance with these programs and applicable laws and regulations. We are also subject to audits under various government programs, including Recovery Audit Contractors (RAC), Zone Program Integrity Contractors (ZPIC), Program Safeguard Contractors (PSC) and Medicaid Integrity Contributors (MIC) programs, in which third party firms engaged by CMS conduct extensive reviews of claims data and medical and other records to identify potential improper payments under the Medicare programs. Private pay sources also reserve the right to conduct audits. We believe that billing and reimbursement errors and disagreements are common in our industry. We are regularly engaged in reviews, audits and appeals of our claims for reimbursement due to the subjectivities inherent in the process related to patient diagnosis and care, record keeping, claims processing and other aspects of the patient service and reimbursement processes, and the errors and disagreements those subjectivities can produce. An adverse review, audit or investigation could result in:


•	an obligation to refund amounts previously paid to us pursuant to the Medicare or Medicaid programs or from private payors, in amounts that could be material to our business;


•	state or federal agencies imposing fines, penalties and other sanctions on us;


•	loss of our right to participate in the Medicare or Medicaid programs or one or more private payor networks;


•	an increase in private litigation against us; and


•	damage to our reputation in various markets.

In 2004, our Medicare fiscal intermediaries began to conduct selected reviews of claims previously submitted by and paid to some of our affiliated facilities. While we have always been subject to post-payment audits and reviews, more intensive “probe reviews” appear to be a permanent procedure with our fiscal intermediaries. All findings of overpayment from CMS contractors are eligible for appeal through the CMS defined continuum. With the exception of rare findings of overpayment related to objective errors in Medicare payment methodology or claims processing, the Organization utilizes all defenses at its disposal to demonstrate that the services provided meet all clinical and regulatory requirements for reimbursement.

If the government or court were to conclude that such errors and deficiencies constituted criminal violations, or were to conclude that such errors and deficiencies resulted in the submission of false claims to federal healthcare programs, or if it were to discover other problems in addition to the ones identified by the probe reviews that rose to actionable levels, we and certain of our officers might face potential criminal charges and/or civil claims, administrative sanctions and penalties for amounts that

Table of Contents

could be material to our business, results of operations and financial condition. In addition, we and/or some of the key personnel of our operating subsidiaries could be temporarily or permanently excluded from future participation in state and federal healthcare reimbursement programs such as Medicaid and Medicare. In any event, it is likely that a governmental investigation alone, regardless of its outcome, would divert material time, resources and attention from our management team and our staff, and could have a materially detrimental impact on our results of operations during and after any such investigation or proceedings.

In cases where claim and documentation review by any CMS contractor results in repeated poor performance, a facility can be subjected to protracted oversight. This oversight may include repeat education and re-probe, extended pre-payment review, referral to recovery audit or integrity contractors, or extrapolation of an error rate to other reimbursement outside of specifically reviewed claims. Sustained failure to demonstrate improvement towards meeting all claim filing and documentation requirements could ultimately lead to Medicare decertification. As of December 31, 2017, we had seven operating subsidiaries that had probes scheduled or in process, both pre- and post-payment.

Public and government calls for increased survey and enforcement efforts toward long-term care facilities could result in increased scrutiny by state and federal survey agencies. In addition, potential sanctions and remedies based upon alleged regulatory deficiencies could negatively affect our financial condition and results of operations.

CMS has undertaken several initiatives to increase or intensify Medicaid and Medicare survey and enforcement activities, including federal oversight of state actions. CMS is taking steps to focus more survey and enforcement efforts on facilities with findings of substandard care or repeat violations of Medicaid and Medicare standards, and to identify multi-facility providers with patterns of noncompliance. In addition, HHS has adopted a rule that requires CMS to charge user fees to healthcare facilities cited during regular certification, recertification or substantiated complaint surveys for deficiencies, which require a revisit to assure that corrections have been made. CMS is also increasing its oversight of state survey agencies and requiring state agencies to use enforcement sanctions and remedies more promptly when substandard care or repeat violations are identified, to investigate complaints more promptly, and to survey facilities more consistently.

The intensified and evolving enforcement environment impacts providers like us because of the increase in the scope or number of inspections or surveys by governmental authorities and the severity of consequent citations for alleged failure to comply with regulatory requirements. We also divert personnel resources to respond to federal and state investigations and other enforcement actions. The diversion of these resources, including our management team, clinical and compliance staff, and others take away from the time and energy that these individuals could otherwise spend on routine operations. As noted, from time to time in the ordinary course of business, we receive deficiency reports from state and federal regulatory bodies resulting from such inspections or surveys. The focus of these deficiency reports tends to vary from year to year. Although most inspection deficiencies are resolved through an agreed-upon plan of corrective action, the reviewing agency typically has the authority to take further action against a licensed or certified facility, which could result in the imposition of fines, imposition of a provisional or conditional license, suspension or revocation of a license, suspension or denial of payment for new admissions, loss of certification as a provider under state or federal healthcare programs, or imposition of other sanctions, including criminal penalties. In the past, we have experienced inspection deficiencies that have resulted in the imposition of a provisional license and could experience these results in the future. We currently have no affiliated facilities operating under provisional licenses which were the result of inspection deficiencies.

Furthermore, in some states, citations in one facility impact other facilities in the state. Revocation of a license at a given facility could therefore impair our ability to obtain new licenses or to renew existing licenses at other facilities, which may also trigger defaults or cross-defaults under our leases and our credit arrangements, or adversely affect our ability to operate or obtain financing in the future. If state or federal regulators were to determine, formally or otherwise, that one facility's regulatory history ought to impact another of our existing or prospective facilities, this could also increase costs, result in increased scrutiny by state and federal survey agencies, and even impact our expansion plans. Therefore, our failure to comply with applicable legal and regulatory requirements in any single facility could negatively impact our financial condition and results of operations as a whole.

When a facility is found to be deficient under state licensing and Medicaid and Medicare standards, sanctions may be threatened or imposed such as denial of payment for new Medicaid and Medicare admissions, civil monetary penalties, focused state and federal oversight and even loss of eligibility for Medicaid and Medicare participation or state licensure. Sanctions such as denial of payment for new admissions often are scheduled to go into effect before surveyors return to verify compliance. Generally, if the surveyors confirm that the facility is in compliance upon their return, the sanctions never take effect. However, if they determine that the facility is not in compliance, the denial of payment goes into effect retroactive to the date given in the original notice. This possibility sometimes leaves affected operators, including us, with the difficult task of deciding whether to continue accepting patients after the potential denial of payment date, thus risking the retroactive denial of revenue associated with those patients' care if the operators are later found to be out of compliance, or simply refusing admissions from the potential denial of payment date until the facility is actually found to be in compliance. In the past, some of our affiliated facilities have

Table of Contents

been in denial of payment status due to findings of continued regulatory deficiencies, resulting in an actual loss of the revenue associated with the Medicare and Medicaid patients admitted after the denial of payment date. Additional sanctions could ensue and, if imposed, these sanctions, entailing various remedies up to and including decertification, would further negatively affect our financial condition and results of operations. In 2016, we elected to voluntarily close one operating subsidiary as a result of multiple regulatory deficiencies in order to avoid continued strain on our staff and other resources and to avoid restrictions on our ability to acquire new facilities or expand or operate existing facilities. In addition, from time to time, we have opted to voluntarily stop accepting new patients pending completion of a new state survey, in order to avoid possible denial of payment for new admissions during the deficiency cure period, or simply to avoid straining staff and other resources while retraining staff, upgrading operating systems or making other operational improvements. If we elect to voluntary close any operations in the future or to opt to stop accepting new patients pending completion of a state or federal survey, it could negatively impact our financial condition and results of operation.

Facilities with otherwise acceptable regulatory histories generally are given an opportunity to correct deficiencies and continue their participation in the Medicare and Medicaid programs by a certain date, usually within nine months, although where denial of payment remedies are asserted, such interim remedies go into effect much sooner. Facilities with deficiencies that immediately jeopardize patient health and safety and those that are classified as poor performing facilities, however, are not generally given an opportunity to correct their deficiencies prior to the imposition of remedies and other enforcement actions. Moreover, facilities with poor regulatory histories continue to be classified by CMS as poor performing facilities notwithstanding any intervening change in ownership, unless the new owner obtains a new Medicare provider agreement instead of assuming the facility's existing agreement. However, new owners (including us, historically) nearly always assume the existing Medicare provider agreement due to the difficulty and time delays generally associated with obtaining new Medicare certifications, especially in previously-certified locations with sub-par operating histories. Accordingly, facilities that have poor regulatory histories before we acquire them and that develop new deficiencies after we acquire them are more likely to have sanctions imposed upon them by CMS or state regulators. In addition, CMS has increased its focus on facilities with a history of serious quality of care problems through the special focus facility initiative. A facility's administrators and owners are notified when it is identified as a special focus facility. This information is also provided to the general public. The special focus facility designation is based in part on the facility's compliance history typically dating before our acquisition of the facility. Local state survey agencies recommend to CMS that facilities be placed on special focus status. A special focus facility receives heightened scrutiny and more frequent regulatory surveys. Failure to improve the quality of care can result in fines and termination from participation in Medicare and Medicaid. A facility “graduates” from the program once it demonstrates significant improvements in quality of care that are continued over time.

We have received notices of potential sanctions and remedies based upon alleged regulatory deficiencies from time to time, and such sanctions have been imposed on some of our affiliated facilities. We have had several affiliated facilities placed on special focus facility status, due largely or entirely to their respective regulatory histories prior to our acquisition of the operating subsidiaries, and have successfully graduated five operating subsidiaries from the program to date. We currently have one facility placed on special focus facility status. Other operating subsidiaries may be identified for such status in the future.

Annual caps that limit the amounts that can be paid for outpatient therapy services rendered to any Medicare beneficiary may reduce our future revenue and profitability or cause us to incur losses.

Some of our rehabilitation therapy revenue is paid by the Medicare Part B program under a fee schedule. Congress has established annual caps that limit the amounts that can be paid (including deductible and coinsurance amounts) for rehabilitation therapy services rendered to any Medicare beneficiary under Medicare Part B. The BBA requires a combined cap for physical therapy and speech-language pathology and a separate cap for occupational therapy.

The DRA directs CMS to create a process to allow exceptions to therapy caps for certain medically necessary services provided on or after January 1, 2006 for patients with certain conditions or multiple complexities whose therapy services are reimbursed under Medicare Part B. A significant portion of the patients in our affiliated skilled nursing facilities and patients served by our rehabilitation therapy programs whose therapy is reimbursed under Medicare Part B have qualified for the exceptions to these reimbursement caps. DRA added Section 1833(g)(5) of the Social Security Act and directed them to develop a process that allows exceptions for Medicare beneficiaries to therapy caps when continued therapy is deemed medically necessary.

The therapy cap exception has been reauthorized in a number of subsequent laws, including the Protecting Access to Medicare Act of 2014. All beneficiaries began a new cap year on January 1, 2017 since the therapy caps are determined on a calendar year basis. For physical therapy (PT) and speech-language pathology services (SLP) combined, the limit on incurred expenses is $1,980 in 2017 compared to $1,960 in 2016. For occupational therapy (OT) services, the limit is $1,980 in 2017 compared to $1,960 in 2016. Deductible and coinsurance amounts paid by the beneficiary for therapy services count toward the amount applied to the limit.

Table of Contents

The Multiple Procedure Payment Reduction (MPPR) continues at a 50% reduction applied to therapy procedure codes by reducing payments for practice expense of the second and subsequent procedure codes when services provided under subsequent codes are provided on the same day. The implementation of MPPR includes 1) facilities that provide Medicare Part B speech-language pathology, occupational therapy, and physical therapy services and bill under the same provider number; and 2) providers in private practice, including speech-language pathologists, who perform and bill for multiple services in a single day.

The application of annual caps, or the discontinuation of exceptions to the annual caps, could have an adverse effect on our rehabilitation therapy revenue. Most recently, the therapy cap exception was extended through December 31, 2017 pursuant to MACRA.

Our hospice operating subsidiaries are subject to annual Medicare caps calculated by Medicare. If such caps were to be exceeded by any of our hospice providers, our business and consolidated financial condition, results of operations and cash flows could be materially adversely affected.

With respect to our hospice operating subsidiaries, overall payments made by Medicare to each provider number are subject to an inpatient cap amount and an overall payment cap, which are calculated and published by the Medicare fiscal intermediary on an annual basis covering the period from October 1 through September 30. If payments received by any one of our hospice provider numbers exceeds either of these caps, we are required to reimburse Medicare for payments received in excess of the caps, which could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows. During the year ended December 31, 2017 we recorded $0.8 million of hospice cap expense.

We are subject to extensive and complex federal and state government laws and regulations which could change at any time and increase our cost of doing business and subject us to enforcement actions.

We, along with other companies in the healthcare industry, are required to comply with extensive and complex laws and regulations at the federal, state and local government levels relating to, among other things:


•	facility and professional licensure, certificates of need, permits and other government approvals;


•	adequacy and quality of healthcare services;


•	qualifications of healthcare and support personnel;


•	quality of medical equipment;


•	confidentiality, maintenance and security issues associated with medical records and claims processing;


•	relationships with physicians and other referral sources and recipients;


•	constraints on protective contractual provisions with patients and third-party payors;


•	operating policies and procedures;


•	certification of additional facilities by the Medicare program; and


•	payment for services.

The laws and regulations governing our operations, along with the terms of participation in various government programs, regulate how we do business, the services we offer, and our interactions with patients and other healthcare providers. These laws and regulations are subject to frequent change. We believe that such regulations may increase in the future and we cannot predict the ultimate content, timing or impact on us of any healthcare reform legislation. Changes in existing laws or regulations, or the enactment of new laws or regulations, could negatively impact our business. If we fail to comply with these applicable laws and regulations, we could suffer civil or criminal penalties and other detrimental consequences, including denial of reimbursement, imposition of fines, temporary suspension of admission of new patients, suspension or decertification from the Medicaid and Medicare programs, restrictions on our ability to acquire new facilities or expand or operate existing facilities, the loss of our licenses to operate and the loss of our ability to participate in federal and state reimbursement programs.

We are subject to federal and state laws, such as the federal False Claims Act, state false claims acts, the illegal remuneration provisions of the Social Security Act, the federal anti-kickback laws, state anti-kickback laws, and the federal “Stark” laws, that govern financial and other arrangements among healthcare providers, their owners, vendors and referral sources, and that are intended to prevent healthcare fraud and abuse. Among other things, these laws prohibit kickbacks, bribes and rebates, as well as other direct and indirect payments or fee-splitting arrangements that are designed to induce the referral of patients to a particular

Table of Contents

provider for medical products or services payable by any federal healthcare program, and prohibit presenting a false or misleading claim for payment under a federal or state program. They also prohibit some physician self-referrals. Possible sanctions for violation of any of these restrictions or prohibitions include loss of eligibility to participate in federal and state reimbursement programs and civil and criminal penalties. Changes in these laws could increase our cost of doing business. If we fail to comply, even inadvertently, with any of these requirements, we could be required to alter our operations, refund payments to the government, enter into a corporate integrity agreement, deferred prosecution or similar agreements with state or federal government agencies, and become subject to significant civil and criminal penalties. For example, in April 2013, we announced that we reached a tentative settlement with the Department of Justice (DOJ) regarding their investigation related to claims submitted to the Medicare program for rehabilitation services provided at skilled nursing facilities in Southern California. As part of the settlement, we entered into a Corporate Integrity Agreement with the Office of Inspector General-HHS. Failure to comply with the terms of the Corporate Integrity Agreement could result in substantial civil or criminal penalties and being excluded from government health care programs, which could adversely affect our financial condition and results of operations.

In May 2009, Congress passed the Fraud Enforcement and Recovery Act (FERA) of 2009 which made significant changes to the federal False Claims Act (FCA), expanding the types of activities subject to prosecution and whistleblower liability. Following changes by FERA, health care providers face significant penalties for known retention of government overpayments, even if no false claim was involved. Health care providers can now be liable for knowingly and improperly avoiding or decreasing an obligation to pay money or property to the government. This includes the retention of any government overpayment. The government can argue, therefore, that a FCA violation can occur without any affirmative fraudulent action or statement, as long as it is knowingly improper. The ACA supplements FERA by imposing an affirmative obligation on health care providers to return an overpayment to CMS within 60 days of “identification” or the date any corresponding cost report is due, whichever is later. On August 3, 2015, the U.S. District Court for the Southern District of New York held that the 60 day clock following “identification” of an overpayment begins to run when a provider is put on notice of a potential overpayment, rather than the moment when an overpayment is conclusively ascertained. On February 12, 2016, CMS published a final rule with respect to Medicare Parts A and B clarifying that providers have an obligation to proactively exercise “reasonable diligence,” and that the 60 day clock begins to run after the reasonable diligence period has concluded, which may take at most 6 months from the from receipt of credible information, absent extraordinary circumstances. Retention of any overpayment beyond this period may result in FCA liability. In addition, FERA extended protections against retaliation for whistleblowers, including protections not only for employees, but also contractors and agents. Thus, there is no need for an employment relationship in order to qualify for protection against retaliation for whistleblowing.

We are also required to comply with state and federal laws governing the transmission, privacy and security of health information. The Health Insurance Portability and Accountability Act of 1996 (HIPAA) requires us to comply with certain standards for the use of individually identifiable health information within our company, and the disclosure and electronic transmission of such information to third parties, such as payors, business associates and patients. These include standards for common electronic healthcare transactions and information, such as claim submission, plan eligibility determination, payment information submission and the use of electronic signatures; unique identifiers for providers, employers and health plans; and the security and privacy of individually identifiable health information. In addition, some states have enacted comparable or, in some cases, more stringent privacy and security laws. If we fail to comply with these state and federal laws, we could be subject to criminal penalties and civil sanctions and be forced to modify our policies and procedures.

On January 25, 2013, HHS promulgated new HIPAA privacy, security, and enforcement regulations, which increase significantly the penalties and enforcement practices of the Department regarding HIPAA violations. In addition, any breach of individually identifiable health information can result in obligations under HIPAA and state laws to notify patients, federal and state agencies, and in some cases media outlets, regarding the breach incident. Breach incidents and violations of HIPAA or state privacy and security laws could subject us to significant penalties, and could have a significant impact on our business. The new HIPAA regulations are effective as of March 26, 2013, and compliance was required by September 23, 2013.

Our failure to obtain or renew required regulatory approvals or licenses or to comply with applicable regulatory requirements, the suspension or revocation of our licenses or our disqualification from participation in federal and state reimbursement programs, or the imposition of other harsh enforcement sanctions could increase our cost of doing business and expose us to potential sanctions. Furthermore, if we were to lose licenses or certifications for any of our affiliated facilities as a result of regulatory action or otherwise, we could be deemed to be in default under some of our agreements, including agreements governing outstanding indebtedness and lease obligations.

Increased civil and criminal enforcement efforts of government agencies against skilled nursing facilities could harm our business, and could preclude us from participating in federal healthcare programs.

Table of Contents

Both federal and state government agencies have heightened and coordinated civil and criminal enforcement efforts as part of numerous ongoing investigations of healthcare companies and, in particular, skilled nursing facilities. The focus of these investigations includes, among other things:


•	cost reporting and billing practices;


•	quality of care;


•	financial relationships with referral sources; and


•	medical necessity of services provided.

If any of our affiliated facilities is decertified or loses its licenses, our revenue, financial condition or results of operations would be adversely affected. In addition, the report of such issues at any of our affiliated facilities could harm our reputation for quality care and lead to a reduction in the patient referrals of our operating subsidiaries and ultimately a reduction in occupancy at these facilities. Also, responding to enforcement efforts would divert material time, resources and attention from our management team and our staff, and could have a materially detrimental impact on our results of operations during and after any such investigation or proceedings, regardless of whether we prevail on the underlying claim.

Federal law provides that practitioners, providers and related persons may not participate in most federal healthcare programs, including the Medicaid and Medicare programs, if the individual or entity has been convicted of a criminal offense related to the delivery of a product or service under these programs or if the individual or entity has been convicted under state or federal law of a criminal offense relating to neglect or abuse of patients in connection with the delivery of a healthcare product or service. Other individuals or entities may be, but are not required to be, excluded from such programs under certain circumstances, including, but not limited to, the following:


•	medical necessity of services provided;


•	conviction related to fraud;


•	conviction relating to obstruction of an investigation;


•	conviction relating to a controlled substance;


•	licensure revocation or suspension;


•	exclusion or suspension from state or other federal healthcare programs;


•	filing claims for excessive charges or unnecessary services or failure to furnish medically necessary services;


•	ownership or control of an entity by an individual who has been excluded from the Medicaid or Medicare programs, against whom a civil monetary penalty related to the Medicaid or Medicare programs has been assessed or who has been convicted of a criminal offense under federal healthcare programs; and


•	the transfer of ownership or control interest in an entity to an immediate family or household member in anticipation of, or following, a conviction, assessment or exclusion from the Medicare or Medicaid programs.

The OIG, among other priorities, is responsible for identifying and eliminating fraud, abuse and waste in certain federal healthcare programs. The OIG has implemented a nationwide program of audits, inspections and investigations and from time to time issues “fraud alerts” to segments of the healthcare industry on particular practices that are vulnerable to abuse. The fraud alerts inform healthcare providers of potentially abusive practices or transactions that are subject to criminal activity and reportable to the OIG. An increasing level of resources has been devoted to the investigation of allegations of fraud and abuse in the Medicaid and Medicare programs, and federal and state regulatory authorities are taking an increasingly strict view of the requirements imposed on healthcare providers by the Social Security Act and Medicaid and Medicare programs. Although we have created a corporate compliance program that we believe is consistent with the OIG guidelines, the OIG may modify its guidelines or interpret its guidelines in a manner inconsistent with our interpretation or the OIG may ultimately determine that our corporate compliance program is insufficient.

Table of Contents

In some circumstances, if one facility is convicted of abusive or fraudulent behavior, then other facilities under common control or ownership may be decertified from participating in Medicaid or Medicare programs. Federal regulations prohibit any corporation or facility from participating in federal contracts if it or its principals have been barred, suspended or declared ineligible from participating in federal contracts. In addition, some state regulations provide that all facilities under common control or ownership licensed within a state may be de-licensed if one or more of the facilities are de-licensed. If any of our operating subsidiaries were decertified or excluded from participating in Medicaid or Medicare programs, our revenue would be adversely affected.

The Office of the Inspector General or other regulatory authorities may choose to more closely scrutinize billing practices in areas where we operate or propose to expand, which could result in an increase in regulatory monitoring and oversight, decreased reimbursement rates, or otherwise adversely affect our business, financial condition and results of operations.

In March 2016, the OIG released a report entitled “Hospices Inappropriately Billed Medicare Over $250 Million for General Inpatient Care.” The report analyzed the results of a medical record review of 2012 hospice general inpatient care stays to estimate the percentage of such stays that were billed inappropriately, and found that hospices billed one-third of general inpatient stays inappropriately, costing Medicare $268 million in 2012. Consequently, the OIG recommended, and CMS concurred with such recommendations, that CMS (1) increase its oversight of hospice general inpatient stay claims and review Part D payments for drugs for hospice beneficiaries; (2) ensure that a physician is involved in the decision to use general inpatient care; (3) conduct prepayment reviews for lengthy general inpatient care stays; (4) increase surveyor efforts to ensure that hospices meet care planning requirements; (5) establish additional enforcement remedies for poor hospice performance; and (6) follow up on inappropriate general inpatient care stays.

In September 2015, the OIG released a report entitled “The Medicare Payment System for Skilled Nursing Facilities Needs to Be Reevaluated.” Among other things, the report used Medicare cost reports to compare Medicare payments to skilled nursing facilities’ costs for therapy over a ten year period, and found that Medicare payments for therapy greatly exceeded skilled nursing facilities’ costs for therapy. The OIG recommended, and CMS concurred with such recommendations, that CMS evaluate the extent to which Medicare payment rates for therapy should be reduced, change the method for paying for therapy, adjust Medicare payments to eliminate any increases that are unrelated to beneficiary characteristics, and strengthen oversight of Skilled Nursing Facility billing.

In January 2015, the OIG released a report entitled “Medicare Hospices Have Financial Incentives to Provide Care in Assisted Living Facilities.” The report analyzed all Medicare hospices claims from 2007 through 2012, and raised concerns about the financial incentives created by the current payment system and the potential for hospices-especially for-profit hospices-to target beneficiaries in assisted living facilities because they may offer the hospices the greatest financial gain. Accordingly, the report recommended that CMS reform payments to reduce the incentive for hospices to target beneficiaries with certain diagnoses and those likely to have long stays, target certain hospices for review, develop and adopt claims-based measures of quality, make hospice data publicly available for the beneficiaries, and provide additional information to hospices to educate them about how they compare to their peers. CMS concurred with all five recommendations.

In August 2012, the OIG released a report entitled “Inappropriate and Questionable Billing for Medicare Home Health Agencies.” The report analyzed data from home health, inpatient hospital, and skilled nursing facilities claims from 2010 to identify inappropriate home health payments. The report found that in 2010, Medicare made overpayments largely in connection with three specific errors: overlapping with claims for inpatient hospital stays, overlapping with claims for skilled nursing facility stays, or billing for services on dates after beneficiaries’ deaths. The report also concluded that home health agencies with questionable billing were located mostly in Texas, Florida, California, and Michigan. The report recommended that CMS implement claims processing edits or improve existing edits to prevent inappropriate payments for the three specific errors referenced above, increase monitoring of billing for home health services, enforce and consider lowering the ten percent cap on the total outlier payments a home health agency may receive annually, consider imposing a temporary moratorium on new home health agency enrollments in Florida and Texas, and take appropriate action regarding the inappropriate payments identified and home health agencies with questionable billing. CMS concurred with all five recommendations. Moratoria were subsequently put in place, and effective January 29, 2016, extended on July 29, 2016, again on January 9, 2017 and again on July 28, 2017. A moratoria on new home health agencies and home health agency sub-units were extended in various counties in Florida, Michigan, Texas, Illinois, Pennsylvania and New Jersey. Additionally, following recommendations made by the OIG in an April 2014 report entitled “Limited Compliance with Medicare’s Home Health Face-to-Face Documentation Requirements,” CMS committed to implement a plan for oversight of home health agencies through Supplemental Medical Review Contractor audits of every home health agency in the country.

In December 2010, the OIG released a report entitled “Questionable Billing by Skilled Nursing Facilities.” The report examined the billing practices of skilled nursing facilities based on Medicare Part A claims from 2006 to 2008 and found, among

Table of Contents

other things, that for-profit skilled nursing facilities were more likely to bill for higher paying therapy RUGs, particularly in the ultra high therapy categories, than government and not-for-profit operators. It also found that for-profit skilled nursing facilities showed a higher incidence of patients using RUGs with higher activities of daily living (ADL) scores, and had a “long” average length of stay among Part A beneficiaries, compared to their government and not-for-profit counterparts. The OIG recommended that CMS vigilantly monitor overall payments to skilled nursing facilities, adjust RUG rates annually, change the method for determining how much therapy is needed to ensure appropriate payments and conduct additional reviews for skilled nursing operators that exceed certain thresholds for higher paying therapy RUGs. CMS concurred with and agreed to take action on three of the four recommendations, declining only to change the methodology for assessing a patient's therapy needs. The OIG issued a separate memorandum to CMS listing 384 specific facilities that the OIG had identified as being in the top one percent for use of ultra high therapy, RUGs with high ADL scores, or “long” average lengths of stay, and CMS agreed to forward the list to the appropriate fiscal intermediaries or other contractors for follow up. Although we believe our therapy assessment and billing practices are consistent with applicable law and CMS requirements, we cannot predict the extent to which the OIG's recommendations to CMS will be implemented and, what effect, if any, such proposals would have on us. Two of our affiliated facilities have been listed on the report. Our business model, like those of some other for-profit operators, is based in part on seeking out higher-acuity patients whom we believe are generally more profitable, and over time our overall patient mix has consistently shifted to higher-acuity and higher-RUGs patients in most facilities we operate. We also use specialized care-delivery software that assists our caregivers in more accurately capturing and recording ADL services in order to, among other things, increase reimbursement to levels appropriate for the care actually delivered. These efforts may place us under greater scrutiny with the OIG, CMS, our fiscal intermediaries, recovery audit contractors and others, as well as other government agencies, unions, advocacy groups and others who seek to pursue their own mandates and agendas. In its fiscal year 2014 work plan, OIG specifically stated that it will continue to study and report on questionable Part A and Part B billing practices amongst skilled nursing facilities.

In addition, in its 2017 Work Plan, the OIG indicated that it will review compliance with various aspects which impact reimbursement to skilled nursing (SNF), home health, or hospice providers, including the documentation in support of the claims paid by Medicare. According to the 2017 Work Plan, prior OIG reviews found that SNFs are billing for higher levels of therapy than were provided or were reasonable or necessary and also that Medicare payments were not compliant with the requirement of a 3-day inpatient hospital stay within 30 days of a SNF admission. The OIG’s 2017 Work Plan provides that the OIG will review documentation at selected SNFs to determine if it meets the requirements for each particular RUG, compliance with SNF prospective payment system requirements related to a 3-day qualifying inpatient hospital stay, and other billing documentation related to Medicare payments for hospice and home health services to ensure they were made in accordance with Medicare requirements.

Efforts by officials and others to make or advocate for any increase in regulatory monitoring and oversight, adversely change RUG rates, reduce payment rates, revise methodologies for assessing and treating patients, conduct more frequent or intense reviews of our treatment and billing practices, or implement moratoria in areas where we operate or propose to expand, could reduce our reimbursement, increase our costs of doing business and otherwise adversely affect our business, financial condition and results of operations.

State efforts to regulate or deregulate the healthcare services industry or the construction or expansion of healthcare facilities could impair our ability to expand our operations, or could result in increased competition.

Some states require healthcare providers, including skilled nursing facilities, to obtain prior approval, known as a certificate of need, for:


•	the purchase, construction or expansion of healthcare facilities;


•	capital expenditures exceeding a prescribed amount; or


•	changes in services or bed capacity.

In addition, other states that do not require certificates of need have effectively barred the expansion of existing facilities and the development of new ones by placing partial or complete moratoria on the number of new Medicaid beds they will certify in certain areas or in the entire state. Other states have established such stringent development standards and approval procedures for constructing new healthcare facilities that the construction of new facilities, or the expansion or renovation of existing facilities, may become cost-prohibitive or extremely time-consuming. In addition, some states the acquisition of a facility being operated by a non-profit organization requires the approval of the state Attorney General.

Our ability to acquire or construct new facilities or expand or provide new services at existing facilities would be adversely affected if we are unable to obtain the necessary approvals, if there are changes in the standards applicable to those approvals, or if we experience delays and increased expenses associated with obtaining those approvals. We may not be able to obtain licensure,

Table of Contents

certificate of need approval, Medicaid certification, Attorney General approval or other necessary approvals for future expansion projects. Conversely, the elimination or reduction of state regulations that limit the construction, expansion or renovation of new or existing facilities could result in increased competition to us or result in overbuilding of facilities in some of our markets. If overbuilding in the skilled nursing industry in the markets in which we operate were to occur, it could reduce the occupancy rates of existing facilities and, in some cases, might reduce the private rates that we charge for our services.

Changes in federal and state employment-related laws and regulations could increase our cost of doing business.

Our operating subsidiaries are subject to a variety of federal and state employment-related laws and regulations, including, but not limited to, the U.S. Fair Labor Standards Act which governs such matters as minimum wages, overtime and other working conditions, the Americans with Disabilities Act (ADA) and similar state laws that provide civil rights protections to individuals with disabilities in the context of employment, public accommodations and other areas, the National Labor Relations Act, regulations of the Equal Employment Opportunity Commission (EEOC), regulations of the Office of Civil Rights, regulations of state Attorneys General, family leave mandates and a variety of similar laws enacted by the federal and state governments that govern these and other employment law matters. Because labor represents such a large portion of our operating costs, changes in federal and state employment-related laws and regulations could increase our cost of doing business.

The compliance costs associated with these laws and evolving regulations could be substantial. For example, all of our affiliated facilities are required to comply with the ADA. The ADA has separate compliance requirements for “public accommodations” and “commercial properties,” but generally requires that buildings be made accessible to people with disabilities. Compliance with ADA requirements could require removal of access barriers and non-compliance could result in imposition of government fines or an award of damages to private litigants. Further legislation may impose additional burdens or restrictions with respect to access by disabled persons. In addition, federal proposals to introduce a system of mandated health insurance and flexible work time and other similar initiatives could, if implemented, adversely affect our operations. We also may be subject to employee-related claims such as wrongful discharge, discrimination or violation of equal employment law. While we are insured for these types of claims, we could experience damages that are not covered by our insurance policies or that exceed our insurance limits, and we may be required to pay such damages directly, which would negatively impact our cash flow from operations.

Compliance with federal and state fair housing, fire, safety and other regulations may require us to make unanticipated expenditures, which could be costly to us.

We must comply with the federal Fair Housing Act and similar state laws, which prohibit us from discriminating against individuals if it would cause such individuals to face barriers in gaining residency in any of our affiliated facilities. Additionally, the Fair Housing Act and other similar state laws require that we advertise our services in such a way that we promote diversity and not limit it. We may be required, among other things, to change our marketing techniques to comply with these requirements.

In addition, we are required to operate our affiliated facilities in compliance with applicable fire and safety regulations, building codes and other land use regulations and food licensing or certification requirements as they may be adopted by governmental agencies and bodies from time to time. Like other healthcare facilities, our affiliated skilled nursing facilities are subject to periodic surveys or inspections by governmental authorities to assess and assure compliance with regulatory requirements. Surveys occur on a regular (often annual or biannual) schedule, and special surveys may result from a specific complaint filed by a patient, a family member or one of our competitors. We may be required to make substantial capital expenditures to comply with these requirements.

We depend largely upon reimbursement from third-party payors, and our revenue, financial condition and results of operations could be negatively impacted by any changes in the acuity mix of patients in our affiliated facilities as well as payor mix and payment methodologies.

Our revenue is affected by the percentage of the patients of our operating subsidiaries who require a high level of skilled nursing and rehabilitative care, whom we refer to as high acuity patients, and by our mix of payment sources. Changes in the acuity level of patients we attract, as well as our payor mix among Medicaid, Medicare, private payors and managed care companies, significantly affect our profitability because we generally receive higher reimbursement rates for high acuity patients and because the payors reimburse us at different rates. For the year ended December 31, 2017, 68.4% of our revenue was provided by government payors that reimburse us at predetermined rates, respectively. If our labor or other operating costs increase, we will be unable to recover such increased costs from government payors. Accordingly, if we fail to maintain our proportion of high acuity patients or if there is any significant increase in the percentage of the patients of our operating subsidiaries for whom we receive Medicaid reimbursement, our results of operations may be adversely affected.

Table of Contents

Initiatives undertaken by major insurers and managed care companies to contain healthcare costs may adversely affect our business. Among other initiatives, these payors attempt to control healthcare costs by contracting with healthcare providers to obtain services on a discounted basis. We believe that this trend will continue and may limit reimbursements for healthcare services. If insurers or managed care companies from whom we receive substantial payments were to reduce the amounts they pay for services, we may lose patients if we choose not to renew our contracts with these insurers at lower rates.

Compliance with state and federal employment, immigration, licensing and other laws could increase our cost of doing business.

We have hired personnel, including skilled nurses and therapists, from outside the United States. If immigration laws are changed, or if new and more restrictive government regulations proposed by the Department of Homeland Security are enacted, our access to qualified and skilled personnel may be limited.

We operate in at least one state that requires us to verify employment eligibility using procedures and standards that exceed those required under federal Form I-9 and the statutes and regulations related thereto. Proposed federal regulations would extend similar requirements to all of the states in which our affiliated facilities operate. To the extent that such proposed regulations or similar measures become effective, and we are required by state or federal authorities to verify work authorization or legal residence for current and prospective employees beyond existing Form I-9 requirements and other statutes and regulations currently in effect, it may make it more difficult for us to recruit, hire and/or retain qualified employees, may increase our risk of non-compliance with state and federal employment, immigration, licensing and other laws and regulations and could increase our cost of doing business.

We are subject to litigation that could result in significant legal costs and large settlement amounts or damage awards.

The skilled nursing business involves a significant risk of liability given the age and health of the patients and residents of our operating subsidiaries and the services we provide. We and others in our industry are subject to a large and increasing number of claims and lawsuits, including professional liability claims, alleging that our services have resulted in personal injury, elder abuse, wrongful death or other related claims. The defense of these lawsuits has in the past, and may in the future, result in significant legal costs, regardless of the outcome, and can result in large settlement amounts or damage awards. Plaintiffs tend to sue every healthcare provider who may have been involved in the patient's care and, accordingly, we respond to multiple lawsuits and claims every year.

In addition, plaintiffs' attorneys have become increasingly more aggressive in their pursuit of claims against healthcare providers, including skilled nursing providers and other long-term care companies, and have employed a wide variety of advertising and publicity strategies. Among other things, these strategies include establishing their own Internet websites, paying for premium advertising space on other websites, paying Internet search engines to optimize their plaintiff solicitation advertising so that it appears in advantageous positions on Internet search results, including results from searches for our company and affiliated facilities, using newspaper, magazine and television ads targeted at customers of the healthcare industry generally, as well as at customers of specific providers, including us. From time to time, law firms claiming to specialize in long-term care litigation have named us, our affiliated facilities and other specific healthcare providers and facilities in their advertising and solicitation materials. These advertising and solicitation activities could result in more claims and litigation, which could increase our liability exposure and legal expenses, divert the time and attention of the personnel of our operating subsidiaries from day-to-day business operations, and materially and adversely affect our financial condition and results of operations. Furthermore, to the extent the frequency and/or severity of losses from such claims and suits increases, our liability insurance premiums could increase and/or available insurance coverage levels could decline, which could materially and adversely affect our financial condition and results of operations.

Healthcare litigation (including class action litigation) is common and is filed based upon a wide variety of claims and theories, and we are routinely subjected to varying types of claims. One particular type of suit arises from alleged violations of state-established minimum staffing requirements for skilled nursing facilities. Failure to meet these requirements can, among other things, jeopardize a facility's compliance with conditions of participation under certain state and federal healthcare programs; it may also subject the facility to a notice of deficiency, a citation, civil monetary penalty, or litigation. These class-action “staffing” suits have the potential to result in large jury verdicts and settlements, and have become more prevalent in the wake of a previous substantial jury award against one of our competitors. We expect the plaintiff's bar to continue to be aggressive in their pursuit of these staffing and similar claims.

Table of Contents

claimed failures to permit or properly compensate for meal and rest periods, or failure to pay for time worked. If there were a significant increase in the number of these claims or an increase in amounts owing should plaintiffs be successful in their prosecution of these claims, this could have a material adverse effect to our business, financial condition, results of operations and cash flows. In addition, we contract with a variety of landlords, lenders, vendors, suppliers, consultants and other individuals and businesses. These contracts typically contain covenants and default provisions. If the other party to one or more of our contracts were to allege that we have violated the contract terms, we could be subject to civil liabilities which could have a material adverse effect on our financial condition and results of operations.

Were litigation to be instituted against one or more of our subsidiaries, a successful plaintiff might attempt to hold us or another subsidiary liable for the alleged wrongdoing of the subsidiary principally targeted by the litigation. If a court in such litigation decided to disregard the corporate form, the resulting judgment could increase our liability and adversely affect our financial condition and results of operations.

On February 26, 2009, Congress reintroduced the Fairness in Nursing Home Arbitration Act of 2009. After failing to be enacted into law in the 110th Congress in 2008, the Fairness in Nursing Home Arbitration Act of 2009 was introduced in the 111th Congress and referred to the House and Senate judiciary committees in March 2009. The 111th Congress did not pass the bill and therefore has been cleared from the present agenda. This bill was reintroduced in the 112th Congress as the Fairness in Nursing Home Arbitration Act of 2012, and was referred to the House Judiciary committee. If enacted, this bill would require, among other things, that agreements to arbitrate nursing home disputes be made after the dispute has arisen rather than before prospective patients move in, to prevent nursing home operators and prospective patients from mutually entering into a pre-admission pre-dispute arbitration agreement. We use arbitration agreements, which have generally been favored by the courts, to streamline the dispute resolution process and reduce our exposure to legal fees and excessive jury awards. If we are not able to secure pre-admission arbitration agreements, our litigation exposure and costs of defense in patient liability actions could increase, our liability insurance premiums could increase, and our business may be adversely affected.

The U.S. Department of Justice has conducted an investigation into the billing and reimbursement processes of some of our operating subsidiaries, which could adversely affect our operations and financial condition.

In October 2013, we entered into the Settlement Agreement with the DOJ pertaining to an investigation of certain of our operating subsidiaries. Pursuant to the Settlement Agreement, we made a single lump-sum remittance to the government in the amount of $48.0 million in October 2013. We have denied engaging in any illegal conduct, and have agreed to the settlement amount without any admission of wrongdoing in order to resolve the allegations and to avoid the uncertainty and expense of protracted litigation.

In connection with the settlement and effective as of October 1, 2013, we entered into a five-year corporate integrity agreement (the CIA) with the Office of Inspector General-HHS. The CIA acknowledges the existence of our current compliance program, which is in accord with the Office of the Inspector General (OIG)’s guidance related to an effective compliance program, and requires that we continue during the term of the CIA to maintain said compliance program designed to promote compliance with the statutes, regulations, and written directives of Medicare, Medicaid, and all other Federal health care programs. We are also required to notify the Office of Inspector General-HHS in writing, of, among other things: (i) any ongoing government investigation or legal proceeding involving an allegation that we have committed a crime or has engaged in fraudulent activities; (ii) any other matter that a reasonable person would consider a probable violation of applicable criminal, civil, or administrative laws related to compliance with federal healthcare programs; and (iii) any change in location, sale, closing, purchase, or establishment of a new business unit or location related to items or services that may be reimbursed by Federal health care programs. We are also required to retain an Independent Review Organization (IRO) to review certain clinical documentation annually for the term of the CIA.

Our participation in federal healthcare programs is not currently affected by the Settlement Agreement or the CIA. In the event of an uncured material breach of the CIA, we could be excluded from participation in federal healthcare programs and/or subject to prosecution.

If any additional litigation were to proceed in the future, and we are subjected to, alleged to be liable for, or agree to a settlement of, claims or obligations under federal Medicare statutes, the federal False Claims Act, or similar state and federal statutes and related regulations, our business, financial condition and results of operations and cash flows could be materially and adversely affected and our stock price could be adversely impacted. Among other things, any settlement or litigation could involve the payment of substantial sums to settle any alleged civil violations, and may also include our assumption of specific procedural and financial obligations going forward under a corporate integrity agreement and/or other arrangement with the government.

Table of Contents

We conduct regular internal investigations into the care delivery, recordkeeping and billing processes of our operating subsidiaries. These reviews sometimes detect instances of noncompliance which we attempt to correct, which can decrease our revenue.

As an operator of healthcare facilities, we have a program to help us comply with various requirements of federal and private healthcare programs. Our compliance program includes, among other things, (1) policies and procedures modeled after applicable laws, regulations, government manuals and industry practices and customs that govern the clinical, reimbursement and operational aspects of our subsidiaries, (2) training about our compliance process for all of the employees of our operating subsidiaries, our directors and officers, and training about Medicare and Medicaid laws, fraud and abuse prevention, clinical standards and practices, and claim submission and reimbursement policies and procedures for appropriate employees, and (3) internal controls that monitor, for example, the accuracy of claims, reimbursement submissions, cost reports and source documents, provision of patient care, services, and supplies as required by applicable standards and laws, accuracy of clinical assessment and treatment documentation, and implementation of judicial and regulatory requirements (i.e., background checks, licensing and training).

From time to time our systems and controls highlight potential compliance issues, which we investigate as they arise. Historically, we have, and would continue to do so in the future, initiated internal inquiries into possible recordkeeping and related irregularities at our affiliated skilled nursing facilities, which were detected by our internal compliance team in the course of its ongoing reviews.

Through these internal inquiries, we have identified potential deficiencies in the assessment of and recordkeeping for small subsets of patients. We have also identified and, at the conclusion of such investigations, assisted in implementing, targeted improvements in the assessment and recordkeeping practices to make them consistent with the existing standards and policies applicable to our affiliated skilled nursing facilities in these areas. We continue to monitor the measures implemented for effectiveness, and perform follow-up reviews to ensure compliance. Consistent with healthcare industry accounting practices, we record any charge for refunded payments against revenue in the period in which the claim adjustment becomes known.

If additional reviews result in identification and quantification of additional amounts to be refunded, we would accrue additional liabilities for claim costs and interest, and repay any amounts due in normal course. Furthermore, failure to refund overpayments within required time frames (as described in greater detail above) could result in Federal False Claims Act (FCA) liability. If future investigations ultimately result in findings of significant billing and reimbursement noncompliance which could require us to record significant additional provisions or remit payments, our business, financial condition and results of operations could be materially and adversely affected and our stock price could decline.

We may be unable to complete future facility or business acquisitions at attractive prices or at all, which may adversely affect our revenue; we may also elect to dispose of underperforming or non-strategic operating subsidiaries, which would also decrease our revenue.

To date, our revenue growth has been significantly impacted by our acquisition of new facilities and businesses. Subject to general market conditions and the availability of essential resources and leadership within our company, we continue to seek both single-and multi-facility acquisition and business acquisition opportunities that are consistent with our geographic, financial and operating objectives.

We face competition for the acquisition of facilities and businesses and expect this competition to increase. Based upon factors such as our ability to identify suitable acquisition candidates, the purchase price of the facilities, prevailing market conditions, the availability of leadership to manage new facilities and our own willingness to take on new operations, the rate at which we have historically acquired facilities has fluctuated significantly. In the future, we anticipate the rate at which we may acquire facilities will continue to fluctuate, which may affect our revenue.

We have also historically acquired a few facilities, either because they were included in larger, indivisible groups of facilities or under other circumstances, which were or have proven to be non-strategic or less desirable, and we may consider disposing of such facilities or exchanging them for facilities which are more desirable. To the extent we dispose of such a facility without simultaneously acquiring a facility in exchange, our revenues might decrease.

We may not be able to successfully integrate acquired facilities and businesses into our operations, and we may not achieve the benefits we expect from any of our facility acquisitions.

We may not be able to successfully or efficiently integrate new acquisitions with our existing operating subsidiaries, culture and systems. The process of integrating acquisitions into our existing operations may result in unforeseen operating difficulties, divert management's attention from existing operations, or require an unexpected commitment of staff and financial resources,

Table of Contents

and may ultimately be unsuccessful. Existing operations available for acquisition frequently serve or target different markets than those that we currently serve. We also may determine that renovations of acquired facilities and changes in staff and operating management personnel are necessary to successfully integrate those acquisitions into our existing operations. We may not be able to recover the costs incurred to reposition or renovate newly operating subsidiaries. The financial benefits we expect to realize from many of our acquisitions are largely dependent upon our ability to improve clinical performance, overcome regulatory deficiencies, rehabilitate or improve the reputation of the operations in the community, increase and maintain occupancy, control costs, and in some cases change the patient acuity mix. If we are unable to accomplish any of these objectives at the operating subsidiaries we acquire, we will not realize the anticipated benefits and we may experience lower than anticipated profits, or even losses.

During the year ended December 31, 2017, we expanded our operations with the addition of twelve stand-alone skilled nursing operations, nine stand-alone assisted and independent living operations, one campus operation, three home health agencies, three hospice agencies and one home care agency with a total of 1,360 operational skilled nursing beds and 594 assisted living units. During the year ended December 31, 2016, we added to our operations 18 stand-alone skilled nursing operations, seven post-acute care campuses, two home health agencies and five hospice agencies with a total of 2,799 operational skilled nursing beds and 152 assisted living units. This growth has placed and will continue to place significant demands on our current management resources. Our ability to manage our growth effectively and to successfully integrate new acquisitions into our existing business will require us to continue to expand our operational, financial and management information systems and to continue to retain, attract, train, motivate and manage key employees, including facility-level leaders and our local directors of nursing. We may not be successful in attracting qualified individuals necessary for future acquisitions to be successful, and our management team may expend significant time and energy working to attract qualified personnel to manage facilities we may acquire in the future. Also, the newly acquired facilities may require us to spend significant time improving services that have historically been substandard, and if we are unable to improve such facilities quickly enough, we may be subject to litigation and/or loss of licensure or certification. If we are not able to successfully overcome these and other integration challenges, we may not achieve the benefits we expect from any of our facility acquisitions, and our business may suffer.

In undertaking acquisitions, we may be adversely impacted by costs, liabilities and regulatory issues that may adversely affect our operations.

In undertaking acquisitions, we also may be adversely impacted by unforeseen liabilities attributable to the prior providers who operated those facilities, against whom we may have little or no recourse. Many facilities we have historically acquired were underperforming financially and had clinical and regulatory issues prior to and at the time of acquisition. Even where we have improved operating subsidiaries and patient care at affiliated facilities that we have acquired, we still may face post-acquisition regulatory issues related to pre-acquisition events. These may include, without limitation, payment recoupment related to our predecessors' prior noncompliance, the imposition of fines, penalties, operational restrictions or special regulatory status. Further, we may incur post-acquisition compliance risk due to the difficulty or impossibility of immediately or quickly bringing non-compliant facilities into full compliance. Diligence materials pertaining to acquisition targets, especially the underperforming facilities that often represent the greatest opportunity for return, are often inadequate, inaccurate or impossible to obtain, sometimes requiring us to make acquisition decisions with incomplete information. Despite our due diligence procedures, facilities that we have acquired or may acquire in the future may generate unexpectedly low returns, may cause us to incur substantial losses, may require unexpected levels of management time, expenditures or other resources, or may otherwise not meet a risk profile that our investors find acceptable. For example, in July of 2006 we acquired a facility that had a history of intermittent noncompliance. Although the affiliated facility had already been surveyed once by the local state survey agency after being acquired by us, and that survey would have met the heightened requirements of the special focus facility program, based upon the facility's compliance history prior to our acquisition, in January 2008, state officials nevertheless recommended to CMS that the facility be placed on special focus facility status. In addition, in October of 2006, we acquired a facility which had a history of intermittent non-compliance. This affiliated facility was surveyed by the local state survey agency during the third quarter of 2008 and passed the heightened survey requirements of the special focus facility program. Both affiliated facilities have successfully graduated from the Centers for Medicare and Medicaid Services' Special Focus program. We've had other affiliated facilities that have successfully graduated from the program. Other affiliated facilities may be identified for special focus status in the future.

In addition, we might encounter unanticipated difficulties and expenditures relating to any of the acquired facilities, including contingent liabilities. For example, when we acquire a facility, we generally assume the facility's existing Medicare provider number for purposes of billing Medicare for services. If CMS later determined that the prior owner of the facility had received overpayments from Medicare for the period of time during which it operated the facility, or had incurred fines in connection with the operation of the facility, CMS could hold us liable for repayment of the overpayments or fines. If the prior operator is defunct or otherwise unable to reimburse us, we may be unable to recover these funds. We may be unable to improve every facility that we acquire. In addition, operation of these facilities may divert management time and attention from other operations and priorities,

Table of Contents

negatively impact cash flows, result in adverse or unanticipated accounting charges, or otherwise damage other areas of our company if they are not timely and adequately improved.

We also incur regulatory risk in acquiring certain facilities due to the licensing, certification and other regulatory requirements affecting our right to operate the acquired facilities. For example, in order to acquire facilities on a predictable schedule, or to acquire declining operations quickly to prevent further pre-acquisition declines, we frequently acquire such facilities prior to receiving license approval or provider certification. We operate such facilities as the interim manager for the outgoing licensee, assuming financial responsibility, among other obligations for the facility. To the extent that we may be unable or delayed in obtaining a license, we may need to operate the facility under a management agreement from the prior operator. Any inability in obtaining consent from the prior operator of a target acquisition to utilizing its license in this manner could impact our ability to acquire additional facilities. If we were subsequently denied licensure or certification for any reason, we might not realize the expected benefits of the acquisition and would likely incur unanticipated costs and other challenges which could cause our business to suffer.

Termination of our patient admission agreements and the resulting vacancies in our affiliated facilities could cause revenue at our affiliated facilities to decline.

Most state regulations governing skilled nursing and assisted living facilities require written patient admission agreements with each patient. Several of these regulations also require that each patient have the right to terminate the patient agreement for any reason and without prior notice. Consistent with these regulations, all of our skilled nursing patient agreements allow patients to terminate their agreements without notice, and all of our assisted living resident agreements allow patients to terminate their agreements upon thirty days' notice. Patients and residents terminate their agreements from time to time for a variety of reasons, causing some fluctuations in our overall occupancy as patients and residents are admitted and discharged in normal course. If an unusual number of patients or residents elected to terminate their agreements within a short time, occupancy levels at our affiliated facilities could decline. As a result, beds may be unoccupied for a period of time, which would have a negative impact on our revenue, financial condition and results of operations.

We face significant competition from other healthcare providers and may not be successful in attracting patients and residents to our affiliated facilities.

The post-acute care industry is highly competitive, and we expect that our industry may become increasingly competitive in the future. Our affiliated skilled nursing facilities compete primarily on a local and regional basis with many long-term care providers, from national and regional multi-facility providers that have substantially greater financial resources to small providers who operate a single nursing facility. We also compete with other skilled nursing and assisted living facilities, and with inpatient rehabilitation facilities, long-term acute care hospitals, home healthcare and other similar services and care alternatives. Increased competition could limit our ability to attract and retain patients, attract and retain skilled personnel, maintain or increase private pay and managed care rates or expand our business.

We may not be successful in attracting patients to our operating subsidiaries, particularly Medicare, managed care, and private pay patients who generally come to us at higher reimbursement rates. Some of our competitors have greater financial and other resources than us, may have greater brand recognition and may be more established in their respective communities than we are. Competing companies may also offer newer facilities or different programs or services than we do and may thereby attract current or potential patients. Other competitors may have lower expenses or other competitive advantages, and, therefore, present significant price competition for managed care and private pay patients. In addition, some of our competitors operate on a not-for-profit basis or as charitable organizations and have the ability to finance capital expenditures on a tax-exempt basis or through the receipt of charitable contributions, neither of which are available to us.

If we do not achieve and maintain competitive quality of care ratings from CMS and private organizations engaged in similar monitoring activities, or if the frequency of CMS surveys and enforcement sanctions increases, our business may be negatively affected.

CMS, as well as certain private organizations engaged in similar monitoring activities, provides comparative data available to the public on its web site, rating every skilled nursing facility operating in each state based upon quality-of-care indicators. These quality-of-care indicators include such measures as percentages of patients with infections, bedsores and unplanned weight loss. In addition, CMS has undertaken an initiative to increase Medicaid and Medicare survey and enforcement activities, to focus more survey and enforcement efforts on facilities with findings of substandard care or repeat violations of Medicaid and Medicare standards, and to require state agencies to use enforcement sanctions and remedies more promptly when substandard care or repeat violations are identified. We have found a correlation between negative Medicaid and Medicare surveys and the incidence of

Table of Contents

professional liability litigation. From time to time, we experience a higher than normal number of negative survey findings in some of our affiliated facilities.

In December 2008, CMS introduced the Five-Star Quality Rating System to help consumers, their families and caregivers compare nursing homes more easily. The Five-Star Quality Rating System gives each nursing home a rating of between one and five stars in various categories. In cases of acquisitions, the previous operator's clinical ratings are included in our overall Five-Star Quality Rating. The prior operator's results will impact our rating until we have sufficient clinical measurements subsequent to the acquisition date. If we are unable to achieve quality of care ratings that are comparable or superior to those of our competitors, our ability to attract and retain patients could be adversely affected.

On February 20, 2015, CMS modified the Five Star Quality Rating System for nursing homes to include the use of antipsychotics in calculating the star ratings, modified calculations for staffing levels and reflect higher standards for nursing homes to achieve a high rating on the quality measure dimension. On August 10, 2016, CMS modified the Five Star Quality Rating System for nursing homes to include five of the six new quality measures added April 27, 2016 to its consumer-based Nursing Home Compare website as part of an initiative to broaden the quality of information available on that site. They include the rate of rehospitalization, emergency room use, community discharge, improvements in function, and independently worsened ability to move. In 2017, CMS issued a temporary freeze of the Health Inspection Five Star Ratings beginning in 2018 that will last approximately 12 months. The health inspection star rating for recertification surveys and complaints conducted on or after November 28, 2017 will be frozen. The freeze of the Health Inspection Five Star Ratings and the increase in the standards for performance on quality measures could reduce the number of our 4 and 5 star facilities.

In July 17, 2015, CMS announced Home Health Star Ratings for home health agencies. All Medicare-certified HHAs are potentially eligible to receive a Quality of Patient Care Star Rating. The Star Ratings include assessments of quality of patient care based on Medicare claims data and patient experience of care. The Star Rating may impact patient choice of home health agencies and reimbursement from home health agencies, as a higher Star rating indicates better patient care than a lower Star rating. A low Star rating may decrease the number of patients for Medicare reimbursement. On December 14, 2017, CMS announced that the influenza vaccination measure would be removed from consideration in the Quality of Patient Care Star Rating beginning with the April 2018 Home Health Compare refresh, reducing the number of quality measures used from nine to eight.

In addition, CMS announced proposals to adopt new standards that home health agencies must comply with in order to participate in the Medicare program, including the strengthening of patient rights and communication requirements that focus on patient well-being.

If we are unable to obtain insurance, or if insurance becomes more costly for us to obtain, our business may be adversely affected.

It may become more difficult and costly for us to obtain coverage for resident care liabilities and other risks, including property and casualty insurance. For example, the following circumstances may adversely affect our ability to obtain insurance at favorable rates:


•	we experience higher-than-expected professional liability, property and casualty, or other types of claims or losses;


•	we receive survey deficiencies or citations of higher-than-normal scope or severity;


•	we acquire especially troubled operations or facilities that present unattractive risks to current or prospective insurers;


•	insurers tighten underwriting standards applicable to us or our industry; or


•	insurers or reinsurers are unable or unwilling to insure us or the industry at historical premiums and coverage levels.

If any of these potential circumstances were to occur, our insurance carriers may require us to significantly increase our self-insured retention levels or pay substantially higher premiums for the same or reduced coverage for insurance, including workers compensation, property and casualty, automobile, employment practices liability, directors and officers liability, employee healthcare and general and professional liability coverages.

In some states, the law prohibits or limits insurance coverage for the risk of punitive damages arising from professional liability and general liability claims or litigation. Coverage for punitive damages is also excluded under some insurance policies. As a result, we may be liable for punitive damage awards in these states that either are not covered or are in excess of our insurance

Table of Contents

policy limits. Claims against us, regardless of their merit or eventual outcome, also could inhibit our ability to attract patients or expand our business, and could require our management to devote time to matters unrelated to the day-to-day operation of our business.

With few exceptions, workers' compensation and employee health insurance costs have also increased markedly in recent years. To partially offset these increases, we have increased the amounts of our self-insured retention (SIR) and deductibles in connection with general and professional liability claims. We also have implemented a self-insurance program for workers compensation in all states, except Washington and Texas, and elected non-subscriber status for workers' compensation in Texas. In Washington, the insurance coverage is financed through premiums paid by the employers and employees. If we are unable to obtain insurance, or if insurance becomes more costly for us to obtain, or if the coverage levels we can economically obtain decline, our business may be adversely affected.

Our self-insurance programs may expose us to significant and unexpected costs and losses.

We have maintained general and professional liability insurance since 2002 and workers' compensation insurance since 2005 through a wholly-owned subsidiary insurance company, Standardbearer Insurance Company, Ltd. (Standardbearer), to insure our self-insurance reimbursements (SIR) and deductibles as part of a continually evolving overall risk management strategy. We establish the insurance loss reserves based on an estimation process that uses information obtained from both company-specific and industry data. The estimation process requires us to continuously monitor and evaluate the life cycle of the claims. Using data obtained from this monitoring and our assumptions about emerging trends, we, along with an independent actuary, develop information about the size of ultimate claims based on our historical experience and other available industry information. The most significant assumptions used in the estimation process include determining the trend in costs, the expected cost of claims incurred but not reported and the expected costs to settle or pay damages with respect to unpaid claims. It is possible, however, that the actual liabilities may exceed our estimates of loss. We may also experience an unexpectedly large number of successful claims or claims that result in costs or liability significantly in excess of our projections. For these and other reasons, our self-insurance reserves could prove to be inadequate, resulting in liabilities in excess of our available insurance and self-insurance. If a successful claim is made against us and it is not covered by our insurance or exceeds the insurance policy limits, our business may be negatively and materially impacted.

Further, because our SIR under our general and professional liability and workers compensation programs applies on a per claim basis, there is no limit to the maximum number of claims or the total amount for which we could incur liability in any policy period.

In May 2006, we began self-insuring our employee health benefits. With respect to our health benefits self-insurance, our reserves and premiums are computed based on a mix of company specific and general industry data that is not specific to our own company. Even with a combination of limited company-specific loss data and general industry data, our loss reserves are based on actuarial estimates that may not correlate to actual loss experience in the future. Therefore, our reserves may prove to be insufficient and we may be exposed to significant and unexpected losses.

The geographic concentration of our affiliated facilities could leave us vulnerable to an economic downturn, regulatory changes or acts of nature in those areas.

Our affiliated facilities located in Arizona, California, and Texas account for the majority of our total revenue. As a result of this concentration, the conditions of local economies, changes in governmental rules, regulations and reimbursement rates or criteria, changes in demographics, state funding, acts of nature and other factors that may result in a decrease in demand and/or reimbursement for skilled nursing services in these states could have a disproportionately adverse effect on our revenue, costs and results of operations. Moreover, since 20.9% of our affiliated facilities are located in California, we are particularly susceptible to revenue loss, cost increase or damage caused by natural disasters such as fires, earthquakes or mudslides.

In addition, our affiliated facilities in Iowa, Nebraska, Kansas, South Carolina, Washington and Texas are more susceptible to revenue loss, cost increases or damage caused by natural disasters including hurricanes, tornadoes and flooding. These acts of nature may cause disruption to us, the employees of our operating subsidiaries and our affiliated facilities, which could have an adverse impact on the patients of our operating subsidiaries and our business. In order to provide care for the patients of our operating subsidiaries, we are dependent on consistent and reliable delivery of food, pharmaceuticals, utilities and other goods to our affiliated facilities, and the availability of employees to provide services at our affiliated facilities. If the delivery of goods or the ability of employees to reach our affiliated facilities were interrupted in any material respect due to a natural disaster or other reasons, it would have a significant impact on our affiliated facilities and our business. Furthermore, the impact, or impending threat, of a natural disaster may require that we evacuate one or more facilities, which would be costly and would involve risks, including potentially fatal risks, for the patients. The impact of disasters and similar events is inherently uncertain. Such events

Table of Contents

could harm the patients and employees of our operating subsidiaries, severely damage or destroy one or more of our affiliated facilities, harm our business, reputation and financial performance, or otherwise cause our business to suffer in ways that we currently cannot predict.

The actions of a national labor union that has pursued a negative publicity campaign criticizing our business in the past may adversely affect our revenue and our profitability.

We continue to maintain our right to inform the employees of our operating subsidiaries about our views of the potential impact of unionization upon the workplace generally and upon individual employees. With one exception, to our knowledge the staffs at our affiliated facilities that have been approached to unionize have uniformly rejected union organizing efforts. If employees decide to unionize, our cost of doing business could increase, and we could experience contract delays, difficulty in adapting to a changing regulatory and economic environment, cultural conflicts between unionized and non-unionized employees, strikes and work stoppages, and we may conclude that affected facilities or operations would be uneconomical to continue operating.

The unwillingness on the part of both our management and staff to accede to union demands for “neutrality” and other concessions has resulted in a negative labor campaign by at least one labor union, the Service Employees International Union. From 2002 to 2007, this union, and individuals and organizations allied with or sympathetic to this union actively prosecuted a negative retaliatory publicity action, also known as a “corporate campaign,” against us and filed, promoted or participated in multiple legal actions against us. The union's campaign asserted, among other allegations, poor treatment of patients, inferior clinical services provided by the employees of our operating subsidiaries, poor treatment of the employees of our operating subsidiaries, and health code violations by our operating subsidiaries. In addition, the union has publicly mischaracterized actions taken by the DHS against us and our affiliated facilities. In numerous cases, the union's allegations created the false impression that violations and other events that occurred at facilities prior to our acquisition of those facilities were caused by us. Since a large component of our business involves acquiring underperforming and distressed facilities, and improving the quality of operations at these facilities, we may have been associated with the past poor performance of these facilities. To the extent this union or another elects to directly or indirectly prosecute a corporate campaign against us or any of our affiliated facilities, our business could be negatively affected.

The Service Employees International Union has issued in the past, and may again issue in the future, public statements alleging that we or other for-profit skilled nursing operators have engaged in unfair, questionable or illegal practices in various areas, including staffing, patient care, patient evaluation and treatment, billing and other areas and activities related to the industry and our operating subsidiaries. We continue to anticipate similar criticisms, charges and other negative publicity from such sources on a regular basis, particularly in the current political environment and following the December 2010 OIG report entitled “Questionable Billing by Skilled Nursing Facilities," described above in " The Office of the Inspector General or other organizations may choose to more closely scrutinize the billing practices of for-profit skilled nursing facilities, which could result in an increase in regulatory monitoring and oversight, decreased reimbursement rates, or otherwise adversely affect our business, financial condition and results of operations." Two of our affiliated facilities have been listed on the report. Such reports provide unions and their allies with additional opportunities to make negative statements about, and to encourage regulators to seek investigatory and enforcement actions against, the industry in general and non-union operators like us specifically. Although we believe that our operations and business practices substantially conform to applicable laws and regulations, we cannot predict the extent to which we might be subject to adverse publicity or calls for increased regulatory scrutiny from union and union ally sources, or what effect, if any, such negative publicity would have on us, but to the extent they are successful, our revenue may be reduced, our costs may be increased and our profitability and business could be adversely affected.

This union has also in the past attempted to pressure hospitals, doctors, insurers and other healthcare providers and professionals to cease doing business with or referring patients to us. If this union or another union is successful in convincing the patients of our operating subsidiaries, their families or our referral sources to reduce or cease doing business with us, our revenue may be reduced and our profitability could be adversely affected. Additionally, if we are unable to attract and retain qualified staff due to negative public relations efforts by this or other union organizations, our quality of service and our revenue and profits could decline. Our strategy for responding to union allegations involves clear public disclosure of the union's identity, activities and agenda, and rebuttals to its negative campaign.

Our ability to respond to unions, however, may be limited by some state laws, which purport to make it illegal for any recipient of state funds to promote or deter union organizing. For example, such a state law passed by the California Legislature was successfully challenged on the grounds that it was preempted by the National Labor Relations Act, only to have the challenge overturned by the Ninth Circuit in 2006 before being ultimately upheld by the United States Supreme Court in 2008. In addition, proposed legislation making it more difficult for employees and their supervisors to educate co-workers and oppose unionization, such as the proposed Employee Free Choice Act which would allow organizing on a single “card check” and without a secret ballot and similar changes to federal law, regulation and labor practice being advocated by unions and considered by Congress

Table of Contents

and the National Labor Relations Board, could make it more difficult to maintain union-free workplaces in our affiliated facilities. Further, the expedited election rules adopted by the National Labor Relations Board took effect on April 14, 2015 and make it far easier for unions to organize employees. These and similar laws have the potential to facilitate unionization procedures or hinder employer responses thereto, which may hinder our ability to oppose unionization efforts and negatively affect our business.

Because we lease substantially all of our affiliated facilities, we could experience risks associated with leased property, including risks relating to lease termination, lease extensions and special charges, which could adversely affect our business, financial position or results of operations.

As of December 31, 2017, we leased 167 of our 230 affiliated facilities. Most of our leases are triple-net leases, which means that, in addition to rent, we are required to pay for the costs related to the property (including property taxes, insurance, and maintenance and repair costs). We are responsible for paying these costs notwithstanding the fact that some of the benefits associated with paying these costs accrue to the landlords as owners of the associated facilities.

Each lease provides that the landlord may terminate the lease for a number of reasons, including, subject to applicable cure periods, the default in any payment of rent, taxes or other payment obligations or the breach of any other covenant or agreement in the lease. Termination of a lease could result in a default under our debt agreements and could adversely affect our business, financial position or results of operations. There can be no assurance that we will be able to comply with all of our obligations under the leases in the future.

In 2017, we voluntarily discontinued operations at one of our skilled nursing facilities after determining that the facility could not competitively operate in the marketplace without substantial investment renovating the building. After careful consideration, we determined that the costs to renovate the facility would outweigh the future returns from the operation. As part of the arrangement, we remain obligated for lease payments and other obligation under the lease agreement. We have in the past and may need to do so in the future continued to be obligated for lease payments and other obligations under the leases even if we decided to withdraw from those locations. We could incur special charges relating to the closing of such facilities including lease termination costs, impairment charges and other special charges that would reduce our net income and could adversely affect our business, financial condition and results of operations.

Failure to generate sufficient cash flow to cover required payments or meet operating covenants under our long-term debt, mortgages and long-term operating leases could result in defaults under such agreements and cross-defaults under other debt, mortgage or operating lease arrangements, which could harm our operating subsidiaries and cause us to lose facilities or experience foreclosures.

We maintain a revolving credit facility with a lending consortium. As of December 31, 2017, our operating subsidiaries had $190.6 million outstanding under our credit facility. On February 5, 2016, we amended our existing revolving credit facility to increase our aggregate principal amount available to $250.0 million. On July 19, 2016, we entered into the Second Amended Credit Facility to increase the aggregate principal amount up to $450.0 million comprised of a $300.0 million revolving credit facility and a $150.0 million term loan. In December 2017, seventeen of our subsidiaries entered into mortgage loans in the aggregate amount of $112.0 million under Department of Housing and Urban Development (HUD) insured loans. The terms of the mortgage loans range from 30- or 35-years. We also had other outstanding indebtedness of approximately $13.4 million as of December 31, 2017 under other HUD-insured loans and promissory note issued in connection with various acquisitions with maturity dates ranging from 2027 through 2052. Because these mortgage loans are insured with HUD, our borrower subsidiaries under these loans are subject to HUD oversight and periodic inspections.

In addition, we had $1.8 billion of future operating lease obligations as of December 31, 2017. We intend to continue financing our operating subsidiaries through mortgage financing, long-term operating leases and other types of financing, including borrowings under our lines of credit and future credit facilities we may obtain.

We may not generate sufficient cash flow from operations to cover required interest, principal and lease payments. In addition, our outstanding credit facilities and mortgage loans contain restrictive covenants and require us to maintain or satisfy specified coverage tests on a consolidated basis and on a facility or facilities basis. These restrictions and operating covenants include, among other things, requirements with respect to occupancy, debt service coverage, project yield, net leverage ratios, minimum interest coverage ratios and minimum asset coverage ratios. These restrictions may interfere with our ability to obtain additional advances under existing credit facilities or to obtain new financing or to engage in other business activities, which may inhibit our ability to grow our business and increase revenue.

From time to time, the financial performance of one or more of our mortgaged facilities may not comply with the required operating covenants under the terms of the mortgage. Any non-payment, noncompliance or other default under our financing

Table of Contents

arrangements could, subject to cure provisions, cause the lender to foreclose upon the facility or facilities securing such indebtedness or, in the case of a lease, cause the lessor to terminate the lease, each with a consequent loss of revenue and asset value to us or a loss of property. Furthermore, in many cases, indebtedness is secured by both a mortgage on one or more facilities, and a guaranty by us. In the event of a default under one of these scenarios, the lender could avoid judicial procedures required to foreclose on real property by declaring all amounts outstanding under the guaranty immediately due and payable, and requiring us to fulfill our obligations to make such payments. If any of these scenarios were to occur, our financial condition would be adversely affected. For tax purposes, a foreclosure on any of our properties would be treated as a sale of the property for a price equal to the outstanding balance of the debt secured by the mortgage. If the outstanding balance of the debt secured by the mortgage exceeds our tax basis in the property, we would recognize taxable income on foreclosure, but would not receive any cash proceeds, which would negatively impact our earnings and cash position. Further, because our mortgages and operating leases generally contain cross-default and cross-collateralization provisions, a default by us related to one facility could affect a significant number of other facilities and their corresponding financing arrangements and operating leases.

Because our term loans, promissory notes, bonds, mortgages and lease obligations are fixed expenses and secured by specific assets, and because our revolving loan obligations are secured by virtually all of our assets, if reimbursement rates, patient acuity mix or occupancy levels decline, or if for any reason we are unable to meet our loan or lease obligations, we may not be able to cover our costs and some or all of our assets may become at risk. Our ability to make payments of principal and interest on our indebtedness and to make lease payments on our operating leases depends upon our future performance, which will be subject to general economic conditions, industry cycles and financial, business and other factors affecting our operating subsidiaries, many of which are beyond our control. If we are unable to generate sufficient cash flow from operations in the future to service our debt or to make lease payments on our operating leases, we may be required, among other things, to seek additional financing in the debt or equity markets, refinance or restructure all or a portion of our indebtedness, sell selected assets, reduce or delay planned capital expenditures or delay or abandon desirable acquisitions. Such measures might not be sufficient to enable us to service our debt or to make lease payments on our operating leases. The failure to make required payments on our debt or operating leases or the delay or abandonment of our planned growth strategy could result in an adverse effect on our future ability to generate revenue and sustain profitability. In addition, any such financing, refinancing or sale of assets might not be available on terms that are economically favorable to us, or at all.

As we expand our presence in the assisted living, home health or hospice industries, we would become subject to risks in a market in which we have limited experience.

The majority of our affiliated facilities have historically been skilled nursing facilities. As we expand our presence in the assisted living, home health and hospice services or other relevant healthcare service, our existing overall business model will continue to change and expose our company to risks in a market in which we have limited experience. Although assisted living operating subsidiaries generally have lower costs and higher margins than skilled nursing, they typically generate lower overall revenue than skilled nursing operating subsidiaries. In addition, assisted living revenue is derived primarily from private payors as opposed to government reimbursement. In most states, skilled nursing, assisted living, home health and hospice care are regulated by different agencies, and we have less experience with the agencies that regulate assisted living, home health and hospice care. In general, we believe that assisted living is a more competitive industry than skilled nursing. As we expand our presence in the assisted living, home health and hospice services, and other ancillary services we expect that we will have to adjust certain elements of our existing business model, which could have an adverse effect on our business.

If our referral sources fail to view us as an attractive skilled nursing provider, or if our referral sources otherwise refer fewer patients, our patient base may decrease.

We rely significantly on appropriate referrals from physicians, hospitals and other healthcare providers in the communities in which we deliver our services to attract appropriate residents and patients to our affiliated facilities. Our referral sources are not obligated to refer business to us and may refer business to other healthcare providers. We believe many of our referral sources refer business to us as a result of the quality of our patient care and our efforts to establish and build a relationship with our referral sources. If we lose, or fail to maintain, existing relationships with our referral resources, fail to develop new relationships, or if we are perceived by our referral sources as not providing high quality patient care, our occupancy rate and the quality of our patient mix could suffer. In addition, if any of our referral sources have a reduction in patients whom they can refer due to a decrease in their business, our occupancy rate and the quality of our patient mix could suffer.

Our systems are subject to security breaches and other cybersecurity incidents.

Our business is dependent on the proper functioning and availability of our computer systems and networks. While we have taken steps to protect the safety and security of our information systems and the patient health information and other data maintained within those systems, we cannot assure you that our safety and security measures and disaster recovery plan will prevent damage,

Table of Contents

interruption or breach of our information systems and operations. Because the techniques used to obtain unauthorized access, disable or degrade service, or sabotage systems change frequently and may be difficult to detect, we may be unable to anticipate these techniques or implement adequate preventive measures. In addition, hardware, software or applications we develop or procure from third parties may contain defects in design or manufacture or other problems that could unexpectedly compromise the security of our information systems. Unauthorized parties may attempt to gain access to our systems or facilities, or those of third parties with whom we do business, through fraud or other forms of deceiving our employees or contractors.

On occasion, we have acquired additional information systems through our business acquisitions. We have upgraded and expanded our information system capabilities and have committed significant resources to maintain, protect, enhance existing systems and develop new systems to keep pace with continuing changes in technology, evolving industry and regulatory standards, and changing customer preferences.

We license certain third party software to support our operations and information systems. Our inability, or the inability of third party software providers, to continue to maintain and upgrade our information systems and software could disrupt or reduce the efficiency of our operations. In addition, costs and potential problems and interruptions associated with the implementation of new or upgraded systems and technology or with maintenance or adequate support of existing systems also could disrupt or reduce the efficiency of our operations.

A cyber security attack or other incident that bypasses our information systems security could cause a security breach which may lead to a material disruption to our information systems infrastructure or business and may involve a significant loss of business or patient health information. If a cyber security attack or other unauthorized attempt to access our systems or facilities were to be successful, it could result in the theft, destructions, loss, misappropriation or release of confidential information or intellectual property, and could cause operational or business delays that may materially impact our ability to provide various healthcare services. Any successful cyber security attack or other unauthorized attempt to access our systems or facilities also could result in negative publicity which could damage our reputation or brand with our patients, referral sources, payors or other third parties and could subject us to substantial penalties under HIPAA and other federal and state privacy laws, in addition to private litigation with those affected.

Failure to maintain the security and functionality of our information systems and related software, or a failure to defend a cyber security attack or other attempt to gain unauthorized access to our systems, facilities or patient health information could expose us to a number of adverse consequences, the vast majority of which are not insurable, including but not limited to disruptions in our operations, regulatory and other civil and criminal penalties, fines, investigations and enforcement actions (including, but not limited to, those arising from the SEC, Federal Trade Commission, the OIG or state attorneys general), fines, private litigation with those affected by the data breach, loss of customers, disputes with payors and increased operating expense, which either individually or in the aggregate could have a material adverse effect on our business, financial position, results of operations and liquidity.

We may need additional capital to fund our operating subsidiaries and finance our growth, and we may not be able to obtain it on terms acceptable to us, or at all, which may limit our ability to grow.

Our ability to maintain and enhance our operating subsidiaries and equipment in a suitable condition to meet regulatory standards, operate efficiently and remain competitive in our markets requires us to commit substantial resources to continued investment in our affiliated facilities and equipment. We are sometimes more aggressive than our competitors in capital spending to address issues that arise in connection with aging and obsolete facilities and equipment. In addition, continued expansion of our business through the acquisition of existing facilities, expansion of our existing facilities and construction of new facilities may require additional capital, particularly if we were to accelerate our acquisition and expansion plans. Financing may not be available to us or may be available to us only on terms that are not favorable. In addition, some of our outstanding indebtedness and long-term leases restrict, among other things, our ability to incur additional debt. If we are unable to raise additional funds or obtain additional funds on terms acceptable to us, we may have to delay or abandon some or all of our growth strategies. Further, if additional funds are raised through the issuance of additional equity securities, the percentage ownership of our stockholders would be diluted. Any newly issued equity securities may have rights, preferences or privileges senior to those of our common stock.

The condition of the financial markets, including volatility and deterioration in the capital and credit markets, could limit the availability of debt and equity financing sources to fund the capital and liquidity requirements of our business, as well as negatively impact or impair the value of our current portfolio of cash, cash equivalents and investments, including U.S. Treasury securities and U.S.-backed investments.

Table of Contents

Financial markets experienced significant disruptions from 2008 through 2010. These disruptions impacted liquidity in the debt markets, making financing terms for borrowers less attractive and, in certain cases, significantly reducing the availability of certain types of debt financing. As a result of these market conditions, the cost and availability of credit has been and may continue to be adversely affected by illiquid credit markets and wider credit spreads. Concern about the stability of the markets has led many lenders and institutional investors to reduce, and in some cases, cease to provide credit to borrowers.

Further, our cash, cash equivalents and investments are held in a variety of interest-bearing instruments, including U.S. treasury securities. As a result of the uncertain domestic and global political, credit and financial market conditions, investments in these types of financial instruments pose risks arising from liquidity and credit concerns. Given that future deterioration in the U.S. and global credit and financial markets is a possibility, no assurance can be made that losses or significant deterioration in the fair value of our cash, cash equivalents, or investments will not occur. Uncertainty surrounding the trading market for U.S. government securities or impairment of the U.S. government's ability to satisfy its obligations under such treasury securities could impact the liquidity or valuation of our current portfolio of cash, cash equivalents, and investments, a substantial portion of which were invested in U.S. treasury securities. Further, unless and until the current U.S. and global political, credit and financial market crisis has been sufficiently resolved, it may be difficult for us to liquidate our investments prior to their maturity without incurring a loss, which would have a material adverse effect on our consolidated financial position, results of operations or cash flows.

Though we anticipate that the cash amounts generated internally, together with amounts available under the revolving credit facility portion of the Credit Facility, will be sufficient to implement our business plan for the foreseeable future, we may need additional capital if a substantial acquisition or other growth opportunity becomes available or if unexpected events occur or opportunities arise. We cannot assure you that additional capital will be available or available on terms favorable to us. If capital is not available, we may not be able to fund internal or external business expansion or respond to competitive pressures or other market conditions.

Delays in reimbursement may cause liquidity problems.

If we experience problems with our billing information systems or if issues arise with Medicare, Medicaid or other payors, we may encounter delays in our payment cycle. From time to time, we have experienced such delays as a result of government payors instituting planned reimbursement delays for budget balancing purposes or as a result of prepayment reviews. For example, in January 2009, the State of California announced expected cash shortages in February which impacted payments to Medi-Cal providers from late March through April. Medi-Cal had also delayed the release of the reimbursement rates which were announced in January 2010. These rate increases were put in place on a retrospective basis, effective August 1, 2009.

Further, on March 24, 2011, the governor of California signed Assembly Bill 97 (AB 97), the budget trailer bill on health, into law. AB 97 outlines significant cuts to state health and human services programs. Specifically, the law reduced provider payments by 10% for physicians, pharmacies, clinics, medical transportation, certain hospitals, home health, and nursing facilities. AB X1 19 Long-Term Care was subsequently approved by the governor on June 28, 2011. Federal approval was obtained on October 27, 2011. AB X1 19 limited the 10% payment reduction to skilled-nursing providers to 14 months for the services provided on June 1, 2011 through July 31, 2012. The 10% reduction in provider payments was repaid by December 31, 2012. There can be no assurance that similar delays or reductions in our payment cycle of provider payments will not lead to material adverse consequences in the future.

Compliance with the regulations of the Department of Housing and Urban Development may require us to make unanticipated expenditures which could increase our costs.

Nineteen of our affiliated facilities are currently subject to regulatory agreements with HUD that give the Commissioner of HUD broad authority to require us to be replaced as the operator of those facilities in the event that the Commissioner determines there are operational deficiencies at such facilities under HUD regulations. In 2006, one of our HUD-insured mortgaged facilities did not pass its HUD inspection. Following an unsuccessful appeal of the decision, we requested a re-inspection. The re-inspection occurred in the fourth quarter of 2009 and the facility passed its HUD re-inspection. Compliance with HUD's requirements can often be difficult because these requirements are not always consistent with the requirements of other federal and state agencies. Appealing a failed inspection can be costly and time-consuming and, if we do not successfully remediate the failed inspection, we could be precluded from obtaining HUD financing in the future or we may encounter limitations or prohibitions on our operation of HUD-insured facilities.

Failure to comply with existing environmental laws could result in increased expenditures, litigation and potential loss to our business and in our asset value.

Table of Contents

Our operating subsidiaries are subject to regulations under various federal, state and local environmental laws, primarily those relating to the handling, storage, transportation, treatment and disposal of medical waste; the identification and warning of the presence of asbestos-containing materials in buildings, as well as the encapsulation or removal of such materials; and the presence of other substances in the indoor environment.

Our affiliated facilities generate infectious or other hazardous medical waste due to the illness or physical condition of the patients. Each of our affiliated facilities has an agreement with a waste management company for the proper disposal of all infectious medical waste, but the use of a waste management company does not immunize us from alleged violations of such laws for operating subsidiaries for which we are responsible even if carried out by a third party, nor does it immunize us from third-party claims for the cost to cleanup disposal sites at which such wastes have been disposed.

Some of the affiliated facilities we lease, own or may acquire may have asbestos-containing materials. Federal regulations require building owners and those exercising control over a building's management to identify and warn their employees and other employers operating in the building of potential hazards posed by workplace exposure to installed asbestos-containing materials and potential asbestos-containing materials in their buildings. Significant fines can be assessed for violation of these regulations. Building owners and those exercising control over a building's management may be subject to an increased risk of personal injury lawsuits. Federal, state and local laws and regulations also govern the removal, encapsulation, disturbance, handling and disposal of asbestos-containing materials and potential asbestos-containing materials when such materials are in poor condition or in the event of construction, remodeling, renovation or demolition of a building. Such laws may impose liability for improper handling or a release into the environment of asbestos containing materials and potential asbestos-containing materials and may provide for fines to, and for third parties to seek recovery from, owners or operators of real properties for personal injury or improper work exposure associated with asbestos-containing materials and potential asbestos-containing materials. The presence of asbestos-containing materials, or the failure to properly dispose of or remediate such materials, also may adversely affect our ability to attract and retain patients and staff, to borrow when using such property as collateral or to make improvements to such property.

The presence of mold, lead-based paint, underground storage tanks, contaminants in drinking water, radon and/or other substances at any of the affiliated facilities we lease, own or may acquire may lead to the incurrence of costs for remediation, mitigation or the implementation of an operations and maintenance plan and may result in third party litigation for personal injury or property damage. Furthermore, in some circumstances, areas affected by mold may be unusable for periods of time for repairs, and even after successful remediation, the known prior presence of extensive mold could adversely affect the ability of a facility to retain or attract patients and staff and could adversely affect a facility's market value and ultimately could lead to the temporary or permanent closure of the facility.

If we fail to comply with applicable environmental laws, we would face increased expenditures in terms of fines and remediation of the underlying problems, potential litigation relating to exposure to such materials, and a potential decrease in value to our business and in the value of our underlying assets.

In addition, because environmental laws vary from state to state, expansion of our operating subsidiaries to states where we do not currently operate may subject us to additional restrictions in the manner in which we operate our affiliated facilities.

If we fail to safeguard the monies held in our patient trust funds, we will be required to reimburse such monies, and we may be subject to citations, fines and penalties.

Each of our affiliated facilities is required by federal law to maintain a patient trust fund to safeguard certain assets of their residents and patients. If any money held in a patient trust fund is misappropriated, we are required to reimburse the patient trust fund for the amount of money that was misappropriated. If any monies held in our patient trust funds are misappropriated in the future and are unrecoverable, we will be required to reimburse such monies, and we may be subject to citations, fines and penalties pursuant to federal and state laws.

We are a holding company with no operations and rely upon our multiple independent operating subsidiaries to provide us with the funds necessary to meet our financial obligations. Liabilities of any one or more of our subsidiaries could be imposed upon us or our other subsidiaries.

We are a holding company with no direct operating assets, employees or revenues. Each of our affiliated facilities is operated through a separate, wholly-owned, independent subsidiary, which has its own management, employees and assets. Our principal assets are the equity interests we directly or indirectly hold in our multiple operating and real estate holding subsidiaries. As a result, we are dependent upon distributions from our subsidiaries to generate the funds necessary to meet our financial obligations and pay dividends. Our subsidiaries are legally distinct from us and have no obligation to make funds available to us. The ability of our subsidiaries to make distributions to us will depend substantially on their respective operating results and will be subject

Table of Contents

to restrictions under, among other things, the laws of their jurisdiction of organization, which may limit the amount of funds available for distribution to investors or shareholders, agreements of those subsidiaries, the terms of our financing arrangements and the terms of any future financing arrangements of our subsidiaries.

Changes in federal and state income tax laws and regulations could adversely affect our provision for income taxes and estimated income tax liabilities.

We are subject to both state and federal income taxes. Our effective tax rate could be adversely affected by changes in the mix of earnings in states with different statutory tax rates, changes in the valuation of deferred tax assets and liabilities, changes in tax laws and regulations, changes in our interpretations of tax laws, including pending tax law changes. In addition, in certain cases more than one state in which we operate has indicated an intent to attempt to tax the same assets and activities, which could result in double taxation if successful. Unanticipated changes in our tax rates or exposure to additional income tax liabilities could affect our profitability.

The Tax Cuts and Jobs Act of 2017 (the Tax Cut) was approved by Congress and signed into law in December 2017. This legislation makes significant changes to the U.S. Internal Revenue Code. Such changes include a reduction in the corporate tax rate and limitations on certain corporate deductions and credits, among other changes. Certain of these changes could have a negative impact on our business. Moreover, further legislative and regulatory changes may be more likely in the current political environment, particularly to the extent that Congress and the U.S. presidency are controlled by the same political party and significant reform of the tax code has been described publicly as a legislative priority. Significant further changes to the tax code could have an impact on our business, financial condition and results of operations.

We are subject to the continuous examination of our income tax returns by the Internal Revenue Service and other local, state and foreign tax authorities. We regularly assess the likelihood of outcomes resulting from these examinations to determine the adequacy of our estimated income tax liabilities. The outcomes from these continuous examinations could adversely affect our provision for income taxes and estimated income tax liabilities.

If the Spin-Off were to fail to qualify as a tax-free transaction for U.S. federal income tax purposes, we could be subject to significant tax liabilities and, in certain circumstances, we could be required to indemnify CareTrust for material taxes pursuant to indemnification obligations under the Tax Matters Agreement that we entered into with CareTrust.

We received a private letter ruling from the Internal Revenue Services (IRS), which provides substantially to the effect that, on the basis of certain facts presented and representations and assumptions set forth in the request submitted to the IRS, the Spin-Off will qualify as tax-free under Sections 368(a)(1)(D) and 355 of the Internal Revenue Code (the IRS Ruling). The IRS Ruling does not address certain requirements for tax-free treatment of the Spin-Off under Section 355 of the Code, and we received tax opinions from our tax advisor and counsel, substantially to the effect that, with respect to such requirements on which the IRS will not rule, such requirements have been satisfied. The IRS Ruling, and the tax opinions that we received from our tax advisor and counsel, rely on, among other things, certain facts, representations, assumptions and undertakings, including those relating to the past and future conduct of our and CareTrust’s businesses, and the IRS Ruling and the tax opinions would not be valid if such facts, representations, assumptions and undertakings were incorrect in any material respect. Notwithstanding the IRS Ruling and the tax opinions, the IRS could determine the Spin-Off should be treated as a taxable transaction for U.S. federal income tax purposes if it determines any of the facts, representations, assumptions or undertakings that were included in the request for the IRS Ruling are false or have been violated or if it disagrees with the conclusions in the opinions that are not covered by the IRS Ruling.

If the Spin-Off ultimately is determined to be taxable, we would recognize taxable gain in an amount equal to the excess, if any, of the fair market value of the shares of CareTrust common stock held by us on the distribution date over our tax basis in such shares. Such taxable gain and resulting tax liability would be substantial.

In addition, under the terms of the Tax Matters Agreement that we entered into with CareTrust in connection with the Spin-Off, we generally are responsible for any taxes imposed on CareTrust that arise from the failure of the Spin-Off to qualify as tax-free for U.S. federal income tax purposes, within the meaning of Sections 368(a)(1)(D) and 355 of the Code, to the extent such failure to qualify is attributable to certain actions, events or transactions relating to our stock, assets or business, or a breach of the relevant representations or any covenants made by us in the Tax Matters Agreement, the materials submitted to the IRS in connection with the request for the IRS Ruling or the representation letter provided in connection with the tax opinion relating to the Spin-Off. Our indemnification obligations to CareTrust and its subsidiaries, officers and directors are not limited by any maximum amount. If we are required to indemnify CareTrust under the circumstance set forth in the Tax Matters Agreement, we may be subject to substantial tax liabilities.

Table of Contents

In connection with the Spin-Off, CareTrust will indemnify us and we will indemnify CareTrust for certain liabilities. There can be no assurance that the indemnities from CareTrust will be sufficient to insure us against the full amount of such liabilities, or that CareTrust’s ability to satisfy its indemnification obligation will not be impaired in the future.

Pursuant to the Separation and Distribution Agreement that we entered into with CareTrust in connection with the Spin-Off, the Tax Matters Agreement and other agreements we entered into in connection with the Spin-Off, CareTrust agreed to indemnify us for certain liabilities, and we agreed to indemnify CareTrust for certain liabilities. However, third parties might seek to hold us responsible for liabilities that CareTrust agreed to retain under these agreements, and there can be no assurance that CareTrust will be able to fully satisfy its indemnification obligations under these agreements. Moreover, even if we ultimately succeed in recovering from CareTrust any amounts for which we are held liable to a third party, we may be temporarily required to bear these losses while seeking recovery from CareTrust. In addition, indemnities that we may be required to provide to CareTrust could be significant and could adversely affect our business.

Risks Related to Ownership of our Common Stock

We may not be able to pay or maintain dividends and the failure to do so would adversely affect our stock price.

Our ability to pay and maintain cash dividends is based on many factors, including our ability to make and finance acquisitions, our ability to negotiate favorable lease and other contractual terms, anticipated operating cost levels, the level of demand for our beds, the rates we charge and actual results that may vary substantially from estimates. Some of the factors are beyond our control and a change in any such factor could affect our ability to pay or maintain dividends. In addition, the revolving credit facility portion of the Credit Facility restricts our ability to pay dividends to stockholders if we receive notice that we are in default under this agreement. The failure to pay or maintain dividends could adversely affect our stock price.

The market price and trading volume of our common stock may be volatile, which could result in rapid and substantial losses for our stockholders.

The market price of our common stock may be highly volatile and could be subject to wide fluctuations. In addition, the trading volume in our common stock may fluctuate and cause significant price variations to occur. We cannot assure you that the market price of our common stock will not fluctuate or decline significantly in the future. On some occasions in the past, when the market price of a stock has been volatile, holders of that stock have instituted securities class action litigation against the company that issued the stock. If any of our stockholders brought a lawsuit against us due to volatility in the market price of our common stock, we could incur substantial costs defending or settling the lawsuit. Such a lawsuit could also divert the time and attention of our management from our business.

Future offerings of debt or equity securities by us may adversely affect the market price of our common stock.

In February 2015, we completed a common stock offering, issuing approximately 5.5 million shares at approximately $20.50 per share and used a portion of the net proceeds of the offering to pay off outstanding amounts under our credit facility.

In the future, we may attempt to increase our capital resources by offering debt or additional equity securities, including commercial paper, medium-term notes, senior or subordinated notes, preferred shares or shares of our common stock. Upon liquidation, holders of our debt securities and preferred shares, and lenders with respect to other borrowings, would receive a distribution of our available assets prior to any distribution to the holders of our common stock. Additional equity offerings may dilute the economic and voting rights of our existing stockholders or reduce the market price of our common stock, or both. Because our decision to issue securities in any future offering will depend on market conditions and other factors beyond our control, we cannot predict or estimate the amount, timing or nature of our future offerings. Thus, holders of our common stock bear the risk of our future offerings reducing the market price of our common stock and diluting their shareholdings in us. We also intend to continue to actively pursue acquisitions of facilities and may issue shares of stock in connection with these acquisitions.

Any shares issued in connection with our acquisitions, the exercise of outstanding stock options or otherwise would dilute the holdings of the investors who purchase our shares.

Failure to maintain effective internal controls in accordance with Section 404 of the Sarbanes-Oxley Act could result in a restatement of our financial statements, cause investors to lose confidence in our financial statements and our company and have a material adverse effect on our business and stock price.

Table of Contents

We produce our consolidated financial statements in accordance with the requirements of GAAP. Effective internal controls are necessary for us to provide reliable financial reports to help mitigate the risk of fraud and to operate successfully as a publicly traded company. As a public company, we are required to document and test our internal control procedures in order to satisfy the requirements of Section 404 of the Sarbanes-Oxley Act of 2002, or Section 404, which requires annual management assessments of the effectiveness of our internal controls over financial reporting.

Testing and maintaining internal controls can divert our management's attention from other matters that are important to our business. We may not be able to conclude on an ongoing basis that we have effective internal controls over financial reporting in accordance with Section 404 or our independent registered public accounting firm may not be able or willing to issue an unqualified report if we conclude that our internal controls over financial reporting are not effective. If either we are unable to conclude that we have effective internal controls over financial reporting or our independent registered public accounting firm is unable to provide us with an unqualified report as required by Section 404, investors could lose confidence in our reported financial information and our company, which could result in a decline in the market price of our common stock, and cause us to fail to meet our reporting obligations in the future, which in turn could impact our ability to raise additional financing if needed in the future.

Our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law contain provisions that could discourage transactions resulting in a change in control, which may negatively affect the market price of our common stock.

Our amended and restated certificate of incorporation and our amended and restated bylaws contain provisions that may enable our Board of Directors to resist a change in control. These provisions may discourage, delay or prevent a change in the ownership of our company or a change in our management, even if doing so might be beneficial to our stockholders. In addition, these provisions could limit the price that investors would be willing to pay in the future for shares of our common stock. Such provisions set forth in our amended and restated certificate of incorporation or our amended and restated bylaws include:


•	our Board of Directors is authorized, without prior stockholder approval, to create and issue preferred stock, commonly referred to as “blank check” preferred stock, with rights senior to those of common stock;


•	advance notice requirements for stockholders to nominate individuals to serve on our Board of Directors or to submit proposals that can be acted upon at stockholder meetings;


•	our Board of Directors is classified so not all members of our board are elected at one time, which may make it more difficult for a person who acquires control of a majority of our outstanding voting stock to replace our directors;


•	stockholder action by written consent is limited;


•	special meetings of the stockholders are permitted to be called only by the chairman of our Board of Directors, our chief executive officer or by a majority of our Board of Directors;


•	stockholders are not permitted to cumulate their votes for the election of directors;


•	newly created directorships resulting from an increase in the authorized number of directors or vacancies on our Board of Directors are filled only by majority vote of the remaining directors;


•	our Board of Directors is expressly authorized to make, alter or repeal our bylaws; and


•	stockholders are permitted to amend our bylaws only upon receiving the affirmative vote of at least a majority of our outstanding common stock.

We are also subject to the anti-takeover provisions of Section 203 of the General Corporation Law of the State of Delaware. Under these provisions, if anyone becomes an “interested stockholder,” we may not enter into a “business combination” with that person for three years without special approval, which could discourage a third party from making a takeover offer and could delay or prevent a change of control. For purposes of Section 203, “interested stockholder” means, generally, someone owning more than 15% or more of our outstanding voting stock or an affiliate of ours that owned 15% or more of our outstanding voting stock during the past three years, subject to certain exceptions as described in Section 203.

These and other provisions in our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law could discourage acquisition proposals and make it more difficult or expensive for stockholders or potential acquirers

Table of Contents

to obtain control of our Board of Directors or initiate actions that are opposed by our then-current Board of Directors, including delaying or impeding a merger, tender offer or proxy contest involving us. Any delay or prevention of a change of control transaction or changes in our Board of Directors could cause the market price of our common stock to decline.

Item 1B. Unresolved Staff Comments

None.

Item 2. Properties

Service Center. We currently lease 29,829 square feet of office space in Mission Viejo, California for our Service Center pursuant to a lease that expires in August 2019. We have two options to extend our lease term at this location for an additional five-year term for each option. In 2015, we expanded our information technology department and entered into a lease of an office space of 4,972 square feet in Rancho Santa Margarita, California. The lease expires in July 31, 2019. We have two options to extend our lease term at this location for an additional five-year term for each option.

Facilities. As of December 31, 2017, we operated 230 affiliated facilities in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin, with the operational capacity to serve approximately 23,881 patients. As of December 31, 2017, we owned 63 of its 230 affiliated facilities and leased an additional 167 facilities through long-term lease arrangements, and had options to purchase 11 of those 167 facilities. We currently do not manage any facilities for third parties, except on a short-term basis pending receipt of new operating licenses by our operating subsidiaries.

The following table provides summary information regarding the number of operational beds at our skilled nursing and assisted and independent living facilities at December 31, 2017:



	TX	CA	AZ	WI	UT	CO	WA	ID	NE	KS	IA	SC	NV	Total
Number of operational beds/units
Operational skilled nursing bed	5,634	4,163	3,180	138	1,763	766	841	544	413	542	368	426	92	18,870
Assisted and independent living units	387	735	1,250	758	106	618	98	274	301	142	31	—	311	5,011
Leased without a Purchase Agreement	4,978	4,043	3,845	—	1,248	570	735	453	367	188	399	—	403	17,229
Purchase Agreement or Leased with a Purchase Option	353	318	—	—	130	125	—	—	—	325	—	—	—	1,251
Owned	690	537	585	896	491	689	204	365	347	171	—	426	—	5,401

Home health and hospice agencies. As of December 31, 2016, we had 46 home health, hospice and home care agencies in Arizona, California, Colorado, Idaho, Iowa, Nevada, Oklahoma, Oregon, Texas, Utah and Washington.

The following table provides summary information regarding the locations of our home health, home care and hospice agencies at December 31, 2017:

Table of Contents



State	Home Health and Home Care Services	Hospice Services
Arizona	2	4
California⁽¹⁾	5	3
Colorado	1	1
Idaho⁽¹⁾	3	3
Iowa	1	1
Nevada	—	1
Oklahoma⁽¹⁾	2	1
Oregon	1	1
Texas	2	3
Utah⁽¹⁾	3	3
Washington⁽¹⁾	4	1
Total	24	22


(1)	Including a home health and a hospice agency that are located in the same location

Item 3. Legal Proceedings

Regulatory Matters — Laws and regulations governing Medicare and Medicaid programs are complex and subject to

interpretation. Compliance with such laws and regulations can be subject to future governmental review and interpretation and failure to comply can result in significant regulatory action including fines, penalties, and exclusion from certain governmental programs. Included in these laws and regulations is the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), which requires healthcare providers (among other things) to safeguard and keep confidential protected health information. In late December 2016, we learned of a potential issue at one of our independent operating entities in Arizona which involved the limited and inadvertent disclosure of certain confidential information. The issue has been fully investigated, addressed and disclosed as required under HIPAA. We believe that we are presently in compliance in all material respects with all applicable laws and regulations.

Cost-Containment Measures — Both government and private pay sources have instituted cost-containment measures designed to limit payments made to providers of healthcare services, and there can be no assurance that future measures designed to limit payments made to providers will not adversely affect us.

Indemnities — From time to time, we enter into certain types of contracts that contingently require us to indemnify parties against third-party claims. These contracts primarily include (i) certain real estate leases, under which we may be required to indemnify property owners or prior facility operators for post-transfer environmental or other liabilities and other claims arising from our use of the applicable premises, (ii) operations transfer agreements, in which we agree to indemnify past operators of facilities we acquire against certain liabilities arising from the transfer of the operation and/or the operation thereof after the transfer, (iii) certain lending agreements, under which we may be required to indemnify the lender against various claims and liabilities, and (iv) certain agreements with our officers, directors and employees, under which we may be required to indemnify such persons for liabilities arising out of their employment relationships. The terms of such obligations vary by contract and, in most instances, a specific or maximum dollar amount is not explicitly stated therein. Generally, amounts under these contracts cannot be reasonably estimated until a specific claim is asserted. Consequently, because no claims have been asserted, no liabilities have been recorded for these obligations on our balance sheets for any of the periods presented.

Litigation — We are party to various legal actions and administrative proceedings and are subject to various claims arising in the ordinary course of business, including claims that services provided to patients have resulted in injury or death and claims related to employment and commercial matters. Although we intend to vigorously defend ourselves in response to these claims, there can be no assurance that the outcomes of these matters will not have a material adverse effect on our results of operations and financial condition. In certain states in which we have or have had operations, insurance coverage for the risk of punitive damages arising from general and professional liability litigation may not be available due to state law public policy prohibitions. There can be no assurance that we will not be liable for punitive damages awarded in litigation arising in states for which punitive damage insurance coverage is not available.

The skilled nursing and post-acute care industry is extremely regulated. As such, in the ordinary course of business, we are continuously subject to state and federal regulatory scrutiny, supervision and control. Such regulatory scrutiny often includes

Table of Contents

inquiries, investigations, examinations, audits, site visits and surveys, some of which are non-routine. In addition to being subject to direct regulatory oversight of state and federal regulatory agencies, the skilled nursing and post-acute care industry is also subject to regulatory requirements, which could subject us to civil, administrative or criminal fines, penalties or restitutionary relief, and reimbursement authorities could also seek the suspension or exclusion of the provider or individual from participation in their program. We believe that there has been, and will continue to be, an increase in governmental investigations of long-term care providers, particularly in the area of Medicare/Medicaid false claims, as well as an increase in enforcement actions resulting from these investigations. Adverse determinations in legal proceedings or governmental investigations, whether currently asserted or arising in the future, could have a material adverse effect on our financial position, results of operations and cash flows.

In addition to the potential lawsuits and claims described above, we are also subject to potential lawsuits under the Federal False Claims Act and comparable state laws alleging submission of fraudulent claims for services to any healthcare program (such as Medicare) or payor. A violation may provide the basis for exclusion from federally-funded healthcare programs. Such exclusions could have a correlative negative impact on our financial performance. Some states, including California, Arizona and Texas, have enacted similar whistleblower and false claims laws and regulations. In addition, the Deficit Reduction Act of 2005 created incentives for states to enact anti-fraud legislation modeled on the Federal False Claims Act. As such, we could face increased scrutiny, potential liability and legal expenses and costs based on claims under state false claims acts in markets in which it does business.

In May 2009, Congress passed the Fraud Enforcement and Recovery Act (FERA) of 2009 which made significant changes to the Federal False Claims Act (FCA), expanding the types of activities subject to prosecution and whistleblower liability. Following changes by FERA, health care providers face significant penalties for the knowing retention of government overpayments, even if no false claim was involved. Health care providers can now be liable for knowingly and improperly avoiding or decreasing an obligation to pay money or property to the government. This includes the retention of any government overpayment. The government can argue, therefore, that a FCA violation can occur without any affirmative fraudulent action or statement, as long as it is knowingly improper. In addition, FERA extended protections against retaliation for whistleblowers, including protections not only for employees, but also contractors and agents. Thus, there is generally no need for an employment relationship in order to qualify for protection against retaliation for whistleblowing.

Healthcare litigation (including class action litigation) is common and is filed based upon a wide variety of claims and theories, and we are routinely subjected to varying types of claims. One particular type of suit arises from alleged violations of minimum staffing requirements for skilled nursing facilities in those states which have enacted such requirements. Failure to meet these requirements can, among other things, jeopardize a facility's compliance with conditions of participation under certain state and federal healthcare programs; it may also subject the facility to a notice of deficiency, a citation, a civil money penalty, or litigation. These class-action “staffing” suits have the potential to result in large jury verdicts and settlements. We expect the plaintiffs' bar to continue to be aggressive in their pursuit of these staffing and similar claims.

Since 2011, we have been involved in a class action litigation claim alleging violations of state and federal wage and hour laws. In January 2017, we participated in an initial mediation session with plaintiffs' counsel.

In March 2017, we were invited to engage in further mediation discussions to determine whether settlement in advance of a decision on class certification was possible. In April 2017, we reached an agreement in principle to settle the subject class action litigation, without any admission of liability and subject to approval by the California Superior Court. Based upon the change in case status, we recorded an accrual for estimated probable losses of $11.0 million, exclusive of legal fees, in the first quarter of 2017. In December 2017, we settled this class action lawsuit and the settlement was approved by the Court. We funded the settlement in December 2017 in the amount of $11.0 million, and it will be distributed to the class members in Q1 of 2018.

A class action staffing suit was previously filed against us and certain of our California affiliated facilities, alleging, among other things, violations of certain Health and Safety Code provisions and a violation of the Consumer Legal Remedies Act. In 2007, we settled this class action suit, and the settlement was approved by the affected class and the Court. A second such class action staffing suit was filed in Los Angeles in 2010 and was resolved in a settlement and Court approval in 2012. Neither of the referenced lawsuits or settlements had a material ongoing adverse effect on our business, financial condition or results of operations.

Other claims and suits, including class actions, continue to be filed against us and other companies in the industry. For example, we have been subjected to, and are currently involved in, class action litigation alleging violations of state and federal wage and hour law. If there were a significant increase in the number of these claims or an increase in amounts owing should plaintiffs be successful in their prosecution of these claims, this could materially adversely affect our business, financial condition, results of operations and cash flows.

Table of Contents

We have in the past been subject to class action litigation involving claims of violations of various regulatory requirements. While we have been able to settle these claims without a material ongoing adverse effect on our business, future claims could be brought that may materially affect our business, financial condition and results of operations. Other claims and suits continue to be filed against us and other companies in the industry. By way of recent example, we defended a general/premise liability claim in San Luis Obispo, California, on behalf of an affiliated facility, involving an injury to a non-employee/contractor. Further, another one of the affiliated independent operating entities was sued on allegations of professional negligence, which claim was recently settled. We do not expect that there will be any material ongoing adverse effect on our business, financial condition or results of operations in connection with the resolution of these matters.

Medicare Revenue Recoupments — We are subject to reviews relating to Medicare services, billings and potential overpayments resulting from RAC, ZPIC, PSC and MIC. As of December 31, 2017, seven of our operating subsidiaries had probes scheduled and in process, both pre- and post-payment. We anticipate that these probe reviews will increase in frequency in the future. If a facility fails a probe review and subsequent re-probes, the facility could then be subject to extended pre-pay review or extrapolation of the identified error rate to all billing in the same time period. None of our operating subsidiaries are currently on extended prepayment review, although that may occur in the future.

U.S. Government Inquiry — In late 2006, we learned that we might be the subject of an on-going criminal and civil investigation by the DOJ. This was confirmed in March 2007. The investigation was prompted by a whistleblower complaint and related primarily to claims submitted to the Medicare program for rehabilitation services provided at certain skilled nursing facilities in Southern California. We resolved and settled the matter for $48.0 million in 2013. In October 2013, we executed a final settlement agreement with the Government and remitted full payment of $48.0 million. In addition, we executed a corporate integrity agreement with the Office of Inspector General HHS as part of the resolution.

See additional description of our contingencies in Notes 15, Debt, 17, Leases and 19, Commitments and Contingencies in

Notes to Consolidated Financial Statements.

Item 4. Mine Safety Disclosures

None.

PART II.

Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Market Information

Our common stock has been traded under the symbol “ENSG” on the NASDAQ Global Select Market since our initial public offering on November 8, 2007. Prior to that time, there was no public market for our common stock. The following table shows the high and low sale prices for the common stock as reported by the NASDAQ Global Select Market for the periods indicated:



	High		Low
Fiscal 2016
First Quarter	$	23.20	$	17.60
Second Quarter	$	23.86	$	19.13
Third Quarter	$	22.10	$	17.87
Fourth Quarter	$	23.18	$	17.60
Fiscal 2017
First Quarter	$	22.66	$	16.76
Second Quarter	$	22.24	$	16.51
Third Quarter	$	23.35	$	18.75
Fourth Quarter	$	24.78	$	20.81

Table of Contents

During fiscal 2017, we declared aggregate cash dividends of $0.1725 per share of common stock, for a total of approximately $8.9 million. As of February 5, 2018, there were approximately 240 holders of record of our common stock.

Notwithstanding anything to the contrary set forth in any of our filings under the Securities Act or the Exchange Act that might incorporate future filings, including this Annual Report on Form 10-K, in whole or in part, the Stock Performance Graph and supporting data which follows shall not be deemed to be incorporated by reference into any such filings except to the extent that we specifically incorporate any such information into any such future filings.

The graph below shows the cumulative total stockholder return of an investment of $100 (and the reinvestment of any dividends thereafter) on December 31, 2012 in (i) our common stock, (ii) the Skilled Nursing Facilities Peer Group 1 and (iii) the NASDAQ Market Index. Our stock price performance shown in the graph below is not indicative of future stock price performance.

COMPARISON OF 60 MONTH CUMULATIVE TOTAL RETURN*

Among Ensign Group, the NASDAQ Composite Index

and a Peer Group

*$100 invested on 12/31/12 in stock in index, including reinvestment of dividends.

Fiscal year ending December 31.



	December 31,
	2012		2013		2014		2015		2016		2017
The Ensign Group, Inc.	$	100.00	$	164.13	$	287.36	$	294.92	$	291.62	$	293.84
NASDAQ Market Index	$	100.00	$	140.12	$	160.78	$	171.97	$	187.22	$	242.71
Peer Group	$	100.00	$	124.32	$	178.08	$	160.68	$	178.50	$	132.03

The current composition of the Skilled Nursing Facilities Peer Group 1, SIC Code 8051 is as follows:

Diversicare Healthcare Services, Five Star Quality Care, Inc., National Healthcare Corporation, Genesis Healthcare, Inc., Regional Health Properties, and The Ensign Group, Inc.

Dividend Policy

The following table summarizes common stock dividends declared to shareholders during the two most recent fiscal years:

Table of Contents



	Dividend per Share		Aggregate Dividend Declared
			(in thousands)
2016
First Quarter	$	0.0400	$	2,026
Second Quarter	$	0.0400	$	2,034
Third Quarter	$	0.0400	$	2,042
Fourth Quarter	$	0.0425	$	2,180
2017
First Quarter	$	0.0425	$	2,171
Second Quarter	$	0.0425	$	2,178
Third Quarter	$	0.0425	$	2,189
Fourth Quarter	$	0.0450	$	2,329

We do not have a formal dividend policy but we currently intend to continue to pay regular quarterly dividends to the holders of our common stock. From 2002 to 2017, we paid aggregate annual dividends equal to approximately 5% to 18% of our net income, after adjusting for the class action lawsuit of $11.0 million in December 31, 2017 and charge related to the U.S. Government inquiry settlement of $33.0 million and $15.0 million in fiscal years ended December 31, 2013 and 2012, respectively. However, future dividends will continue to be at the discretion of our board of directors, and we may or may not continue to pay dividends at such rate. We expect that the payment of dividends will depend on many factors, including our results of operations, financial condition and capital requirements, earnings, general business conditions, legal restrictions on the payment of dividends and other factors the Board of Directors deems relevant.

The Credit Facility restricts our subsidiaries' and our ability to pay dividends to stockholders in excess of 20% of consolidated net income, or at all if we receive notice that we are in default under the facility. In addition, we are a holding company with no direct operating assets, employees or revenues. As a result, we are dependent upon distributions from our independent operating subsidiaries to generate the funds necessary to meet our financial obligations and pay dividends. It is possible that in certain quarters, we may pay dividends that exceed our net income for such period as calculated in accordance with GAAP.

Issuer Repurchases of Equity Securities

Stock Repurchase Programs.On February 8, 2017, we announced that our Board of Directors authorized a stock repurchase program, under which we may repurchase up to $30.0 million of our common stock under the program for a period of 12 months. Under this program, we are authorized to repurchase our issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. The stock repurchase program expired on February 8, 2018. During the year ended December 31, 2017, we repurchased approximately 0.4 million shares of our common stock for a total of $7.3 million.

On November 4, 2015 and February 9, 2016, we announced that our Board of Directors authorized two stock repurchase programs, under which we may repurchase up to $15.0 million of our common stock under each program for a period of 12 months. During the first quarter of 2016, we repurchased 1.5 million shares of our common stock for a total of $30.0 million and the repurchase programs expired upon the repurchase of the full authorized amount under the plans.

Item 6. Selected Financial Data

All share and per share amounts presented reflect a two-for-one stock split effected in December 2015.The financial data set forth below should be read in connection with Part II, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations and with our consolidated financial statements and related notes thereto:

Table of Contents



	Year Ended December 31,
	2017			2016			2015			2014			2013
	(In thousands, except per share data)
Revenue	$	1,849,317		$	1,654,864		$	1,341,826		$	1,027,406		$	904,556
Expense:
Cost of services	1,497,703			1,341,814			1,067,694			822,669			725,989
Charge related to U.S. Government inquiry	—			—			—			—			33,000
Charge related to class action lawsuit	11,000			—			—			—			—
(Gain)/losses related to divestitures ⁽²⁾	2,321			(11,225		)	—			—			—
Rent - cost of services	131,919			124,581			88,776			48,488			13,613
General and administrative expense	80,617			69,165			64,163			56,895			40,103
Depreciation and amortization	44,472			38,682			28,111			26,430			33,909
Total expenses	1,768,032			1,563,017			1,248,744			954,482			846,614
Income from operations	81,285			91,847			93,082			72,924			57,942
Other income (expense):
Interest expense	(13,616		)	(7,136		)	(2,828		)	(12,976		)	(12,787		)
Interest income	1,609			1,107			845			594			506
Other expense, net	(12,007		)	(6,029		)	(1,983		)	(12,382		)	(12,281		)
Income before provision for income taxes	69,278			85,818			91,099			60,542			45,661
Provision for income taxes	28,445			32,975			35,182			26,801			20,003
Income from continuing operations	40,833			52,843			55,917			33,741			25,658
Loss from discontinued operations	—			—			—			—			(1,804		)
Net income	$	40,833		$	52,843		$	55,917		$	33,741		$	23,854
Less: net income (loss) attributable to noncontrolling interests	358			2,853			485			(2,209		)	(186		)
Net income attributable to The Ensign Group, Inc.	$	40,475		$	49,990		$	55,432		$	35,950		$	24,040
Amounts attributable to The Ensign Group, Inc.:
Income from continuing operations attributable to The Ensign Group, Inc.	$	40,475		$	49,990		$	55,432		$	35,950		$	25,844
Loss from discontinued operations, net of income tax	—			—			—			—			(1,804		)
Net income attributable to The Ensign Group, Inc.	$	40,475		$	49,990		$	55,432		$	35,950		$	24,040
Net income per share^:
Basic:
Income from continuing operations attributable to The Ensign Group, Inc.	$	0.79		$	0.99		$	1.10		$	0.80		$	0.59
Loss from discontinued operations ⁽¹⁾	—			—			—			—			(0.04		)
Net income attributable to The Ensign Group, Inc.	$	0.79		$	0.99		$	1.10		$	0.80		$	0.55
Diluted:
Income from continuing operations attributable to The Ensign Group, Inc.	$	0.77		$	0.96		$	1.06		$	0.78		$	0.58
Loss from discontinued operations ⁽¹⁾	—			—			—			—			(0.04		)
Net income attributable to The Ensign Group, Inc.	$	0.77		$	0.96		$	1.06		$	0.78		$	0.54
Weighted average common shares outstanding
Basic	50,932			50,555			50,316			44,682			43,800
Diluted	52,829			52,133			52,210			46,190			44,728
⁽¹⁾ On March 25, 2013, we agreed to terms to sell DRX, a national urgent care franchise system for approximately $8,000, adjusted for certain assets and liabilities. The asset sale was effective on April 15, 2013. The sale resulted in a pre-tax loss of $2,837 for the year ended December 31, 2013. The assets acquired at the initial purchase of DRX, including noncontrolling interest, were recorded at fair value. The initial fair value was greater than total cash paid to acquire all interests in DRX and the subsequent sale price. The sale of DRX has been accounted for as discontinued operations.
⁽²⁾ In 2016, we completed the sale of seventeen urgent care centers for an aggregate sale price of $41,492. As a result of the sale, we recognized a pretax gain of $19,160, which is included in operating income. The sale transactions did not meet the criteria of a discontinued operation as they do not represent a strategic shift that has or will have a major effect on our operations and financial results.

Table of Contents



	December 31,
	2017		2016		2015		2014		2013
	(In thousands, except per share data)
Consolidated Balance Sheet Data:
Cash and cash equivalents	$	42,337	$	57,706	$	41,569	$	50,408	$	65,755
Working capital	142,255		121,934		115,104		83,209		98,540
Total assets	1,102,433		1,001,025		747,759		493,916		716,315
Long-term debt, less current maturities	302,990		275,486		99,051		68,279		251,895
Equity	500,059		460,495		426,985		257,803		357,257
Cash dividends declared per common share	$	0.1725	$	0.1625	$	0.1525	$	0.1425	$	0.1325



	Year Ended December 31,
	2017		2016		2015
	(In thousands)
Non-GAAP Financial Measures:
Performance Metrics
EBITDA	$	125,399	$	127,676	$	120,708
Adjusted EBITDA	169,276		150,098		135,248
Valuation Metric
Adjusted EBITDAR	284,700		262,194		221,278

______________________

The following discussion includes references to EBITDA, Adjusted EBITDA and Adjusted EBITDAR which are non-GAAP financial measures (collectively, Non-GAAP Financial Measures). Regulation G, Conditions for Use of Non-GAAP Financial Measures, and other provisions of the Exchange Act define and prescribe the conditions for use of certain non-GAAP financial information. These non-GAAP financial measures are used in addition to and in conjunction with results presented in accordance with GAAP. These non-GAAP financial measures should not be relied upon to the exclusion of GAAP financial measures. These non-GAAP financial measures reflect an additional way of viewing aspects of our operations that, when viewed with our GAAP results and the accompanying reconciliations to corresponding GAAP financial measures, provide a more complete understanding of factors and trends affecting our business.

We believe the presentation of Non-GAAP Financial Measures are useful to investors and other external users of our financial statements regarding our results of operations because:

•

they are widely used by investors and analysts in our industry as a supplemental measure to evaluate the overall performance of companies in our industry without regard to items such as interest expense, net and depreciation and amortization, which can vary substantially from company to company depending on the book value of assets, capital structure and the method by which assets were acquired; and


•	they help investors evaluate and compare the results of our operations from period to period by removing the impact of our capital structure and asset base from our operating results.

We use Non-GAAP Financial Measures:


•	as measurements of our operating performance to assist us in comparing our operating performance on a consistent basis;


•	to allocate resources to enhance the financial performance of our business;


•	to assess the value of a potential acquisition;


•	to assess the value of a transformed operation's performance;


•	to evaluate the effectiveness of our operational strategies; and


•	to compare our operating performance to that of our competitors.

Table of Contents

We typically use Non-GAAP Financial Measures to compare the operating performance of each operation. These measures are useful in this regard because they do not include such costs as net interest expense, income taxes, depreciation and amortization expense, which may vary from period-to-period depending upon various factors, including the method used to finance operations, the amount of debt that we have incurred, whether an operation is owned or leased, the date of acquisition of a facility or business, and the tax law of the state in which a business unit operates.

We also establish compensation programs and bonuses for our leaders that are partially based upon the achievement of Adjusted EBITDAR targets.

Despite the importance of these measures in analyzing our underlying business, designing incentive compensation and for our goal setting, Non-GAAP Financial Measures have no standardized meaning defined by GAAP. Therefore, our Non-GAAP Financial Measures have limitations as analytical tools, and they should not be considered in isolation, or as a substitute for analysis of our results as reported in accordance with GAAP. Some of these limitations are:


•	they do not reflect our current or future cash requirements for capital expenditures or contractual commitments;


•	they do not reflect changes in, or cash requirements for, our working capital needs;


•	they do not reflect the net interest expense, or the cash requirements necessary to service interest or principal payments, on our debt;


•	they do not reflect rent expenses, which are necessary to operate our leased operations, in the case of Adjusted EBITDAR;


•	they do not reflect any income tax payments we may be required to make;


•	although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and do not reflect any cash requirements for such replacements; and


•	other companies in our industry may calculate these measures differently than we do, which may limit their usefulness as comparative measures.

We compensate for these limitations by using them only to supplement net income on a basis prepared in accordance with GAAP in order to provide a more complete understanding of the factors and trends affecting our business.

Management strongly encourages investors to review our consolidated financial statements in their entirety and to not rely on any single financial measure. Because these Non-GAAP Financial Measures are not standardized, it may not be possible to compare these financial measures with other companies’ Non-GAAP Financial Measures having the same or similar names. These Non-GAAP Financial Measures should not be considered a substitute for, nor superior to, financial results and measures determined or calculated in accordance with GAAP. We strongly urge you to review the reconciliation of income from operations to the Non-GAAP Financial Measures in the table below, along with our consolidated financial statements and related notes included elsewhere in this document.

We use the following Non-GAAP Financial Measures that we believe are useful to investors as key valuation and operating performance measures:

EBITDA

We believe EBITDA is useful to investors in evaluating our operating performance because it helps investors evaluate and compare the results of our operations from period to period by removing the impact of our asset base (depreciation and amortization expense) from our operating results.

We calculate EBITDA as net income from continuing operations, adjusted for net losses attributable to noncontrolling interest, before (a) interest expense, net, (b) provision for income taxes, and (c) depreciation and amortization.

Adjusted EBITDA

We adjust EBITDA when evaluating our performance because we believe that the exclusion of certain additional items described below provides useful supplemental information to investors regarding our ongoing operating performance, in the case

Table of Contents

of Adjusted EBITDA. We believe that the presentation of Adjusted EBITDA, when combined with EBITDA and GAAP net income (loss) attributable to The Ensign Group, Inc., is beneficial to an investor’s complete understanding of our operating performance.

Adjusted EBITDA is EBITDA adjusted for non-core business items, which for the reported periods includes, to the extent applicable:


•	legal costs and charges related to the settlement of class action lawsuits, insurance claims and the U.S. Government inquiry;


•	share-based compensation expense;


•	results related to closed operations and operations not at full capacity, including continued obligations and closing expenses;


•	results at facilities currently being constructed and other start-up operations;


•	bonus accrual as a result of the Tax Cut and Jobs Act (the Tax Act);


•	losses related to Hurricane Harvey and California fires on impacted operations;


•	operating results and gain on sale of urgent care centers (including the portion related to non-controlling interest);


•	charges related to the Spin-Off;


•	transaction-related costs;


•	professional fees costs fees including costs incurred to recognize income tax credits, tax reform impacts, adoption of the new revenue recognition standard and new systems implementation;


•	break-up fee received in connection with a public auction; and


•	impairment of goodwill.

Adjusted EBITDAR

We use Adjusted EBITDAR as one measure in determining the value of prospective acquisitions. It is also a commonly used measure by our management, research analysts and investors, to compare the enterprise value of different companies in the healthcare industry, without regard to differences in capital structures and leasing arrangements. Adjusted EBITDAR is a financial valuation measure that is not specified in GAAP. This measure is not displayed as a performance measure as it excludes rent expense, which is a normal and recurring operating expense.

The adjustments made and previously described in the computation of Adjusted EBITDA are also made when computing Adjusted EBITDAR. We calculate Adjusted EBITDAR by excluding rent-cost of services from Adjusted EBITDA.

The table below reconciles net income to EBITDA, Adjusted EBITDA and Adjusted EBITDAR for the periods presented:

Table of Contents



	Year Ended December 31,
	2017			2016			2015			2014			2013
	(In thousands)
Consolidated statements of income data:
Net income	$	40,833		$	52,843		$	55,917		$	33,741		$	23,854
Less: net income attributable to noncontrolling interests	358			2,853			485			(2,209		)	(186		)
Loss from discontinued operations	—			—			—			—			1,804
Interest expense, net	12,007			6,029			1,983			12,382			12,281
Provision for income taxes	28,445			32,975			35,182			26,801			20,003
Depreciation and amortization	44,472			38,682			28,111			26,430			33,909
EBITDA	$	125,399		$	127,676		$	120,708		$	101,563		$	92,037

Legal costs and charges related to the U.S. Government inquiry, class action lawsuits and settlement of insurance claims(a)	11,177			4,924			—			—			35,622
Share-based compensation expense(b)	9,695			9,101			6,677			—			—
Results related to closed operations and operations not at full capacity, including continued obligations and closing expenses(c)	4,632			8,705			—			—			—
(Earnings)/losses related to facilities currently being constructed and other start-up operations(d)	(3,261		)	3,850			3,054			—			1,256
Bonus accrual as a result of the Tax Act(e)	3,100			—			—			—			—
Losses related to Hurricane Harvey and California fires on impacted operations (f)	1,242			—			—			—			—
Operating results and gain on sale of urgent care centers(g)	—			(18,893		)	(1,132		)	(389		)	1,844
Spin-Off charges including results at three independent living facilities transferred to CareTrust(h)	—			—			—			8,904			4,050
Transaction-related costs(i)	717			1,102			1,397			672			288
Costs incurred related to new systems implementation and professional service fee(j)	80			1,148			2,817			138			145
Breakup fee, net of costs, received in connection with a public auction(k)	—			—			(1,019		)	—			—
Impairment of goodwill(l)	—			—			—			—			490
Rent related to items(c),(d),(f),(g) and (h) above	16,495			12,485			2,746			1,941			1,009
Adjusted EBITDA	$	169,276		$	150,098		$	135,248		$	112,829		$	136,741
Rent—cost of services	131,919			124,581			88,776			48,488			13,613
Less: rent related to items(c),(d),(f),(g) and (h) above	(16,495		)	(12,485		)	(2,746		)	(1,941		)	(1,009		)
Adjusted EBITDAR	$	284,700		$	262,194		$	221,278		$	159,376		$	149,345

______________________


(a)	Legal costs and charges incurred in connection with the settlement of the class action lawsuits, insurance claims in 2016 and investigation into the billing and reimbursement processes of some of our operating subsidiaries conducted by the DOJ in 2013.

(b) Share-based compensation expense incurred during the years ended December 31, 2017, 2016 and 2015. Adjusted EBITDA and EBITDAR for the years ended December 31, 2014 and 2013 did not include a non-GAAP adjustment related to share-based compensation expense of $5.2 million and $4.4 million, respectively. If adjusted for share-based compensation expense, Adjusted EBITDA for the years ended December 31, 2014 and 2013 would have been $118.0 million and $141.1 million, respectively, and Adjusted EBITDAR for the years ended December 31, 2014 and 2013 would have been $164.6 million and $153.7 million , respectively.

(c)

Represent results at closed operations and operations not at full capacity during the years ended December 31, 2017 and 2016, including the fair value of continued obligation under the lease agreement and related closing expenses of $4.0 million and $7.9 million for the years ended December 31, 2017 and 2016, respectively. Included in the year ended December 31, 2017 and 2016 results is the loss recovery of $1.3 million of certain losses related to a closed facility in prior year.


(d)	Represents results related to facilities currently being constructed and other start-up operations. This amount excludes rent, depreciation and interest expense.

(e) Bonus accrual as a result of the Tax Act.


(f)	Losses related to Hurricane Harvey and California fires on impacted operations.


(g)	Operating results and gain on sale of urgent care centers. This amount excludes rent, depreciation, interest expense and the net loss attributable to the variable interest entity associated with our urgent care business.


(h)	Spin-Off charges including results at three independent living facilities transferred to CareTrust in connection with the Spin-Off transaction. The Company completed the Spin-Off in 2014. In addition, the results during year ended December 31, 2013 did not include rent expense from CareTrust subsequent to the Spin-Off.

Table of Contents


(i)	Costs incurred to acquire operations which are not capitalizable.

(j) Costs incurred related to new systems implementation and professional fees associated with income tax credits, tax reform impacts and adoption of the new revenue recognition standard; and expenses incurred in connection with the stock-split effected in December 2015.


(k)	Break-up fee, net of costs, received in connection with a public auction in which we were the priority bidder.

(l) Impairment charges to goodwill for a skilled nursing facility in Utah during the year ended December 31, 2013.

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion should be read in conjunction with the consolidated financial statements and accompanying notes, which appear elsewhere in this Annual Report. This discussion contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those discussed below and elsewhere in this Annual Report. See Part I. Item 1A. Risk Factors and Cautionary Note Regarding Forward-Looking Statements.

Overview

We are a provider of health care services across the post-acute care continuum, as well as other ancillary businesses located in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, Oklahoma, Oregon, South Carolina, Texas, Utah, Washington and Wisconsin. Our operating subsidiaries, each of which strives to be the service of choice in the community it serves, provide a broad spectrum of skilled nursing, assisted living, home health and hospice and other ancillary services. As of December 31, 2017, we offered skilled nursing, assisted living and rehabilitative care services through 230 skilled nursing and assisted living facilities across 13 states. Of the 230 facilities, we owned 63 and operated an additional 167 facilities under long-term lease arrangements, and had options to purchase 11 of those 167 facilities. Our home health and hospice business provides home health, hospice and home care services from 46 agencies across eleven states.

The following table summarizes our affiliated facilities and operational skilled nursing, assisted living and independent living beds by ownership status as of December 31, 2017:



	Owned		Leased (with a Purchase Option)		Leased (without a Purchase Option)		Total
Number of facilities	63		11		156		230
Percentage of total	27.4	%	4.8	%	67.8	%	100.0	%
Operational skilled nursing beds	3,443		1,067		14,360		18,870
Percentage of total	18.2	%	5.7	%	76.1	%	100.0	%
Assisted and independent living units	1,958		184		2,869		5,011
Percentage of total	39.1	%	3.7	%	57.2	%	100.0	%

Recent Activities

Stock Repurchase Program - On February 8, 2017, we announced that our Board of Directors authorized a stock repurchase program, under which we may repurchase up to $30.0 million of our common stock under the program for a period of 12 months. During the year ended December 31, 2017, we repurchased 0.4 million shares of our common stock for a total of $7.3 million.

Sale and Lease Transaction - In March 2017, we entered into definitive agreements to sell the properties of two skilled nursing facilities and one assisted living community. Upon closing the transaction, we leased the properties under a triple-net master lease with an initial 20-year term, with three 5-year optional extensions, at CPI-based annual escalators. The transaction closed in the second quarter of 2017. We received $38.0 million in proceeds. We recognized a gain on the transaction of $13.2 million, which is deferred, and amortized over the life of the lease.

Lease Terminations - During the first quarter of 2017, we terminated our lease obligations on four transitional care facilities that are currently under development and one newly constructed stand-alone skilled nursing operation. We recorded $1.2 million in lease termination costs and long-lived asset impairment.

Class action lawsuit - In the first quarter of 2017, we recorded an estimated liability of $11.0 million related to the pending settlement of a class action lawsuit. We funded the settlement in the amount of $11.0 million in December 2017, and the settlement will be distributed to the class members in Q1 of 2018.

Closure of facility - In March 2017, we voluntarily discontinued operations at one of our skilled nursing facilities after determining that the facility cannot competitively operate in the marketplace without substantial investment renovating the building.

Table of Contents

After careful consideration, we determined that the costs to renovate the facility could outweigh the future returns from the operation. As part of this closure, we entered into an agreement with our landlord allowing for the closure of the property as well as other provisions to allow our landlord to transfer the property and the licenses free and clear of the applicable master lease. We recorded a continued obligation liability under the lease and related closing expenses of $2.8 million, including the present value of rental payments of approximately $2.7 million, which was recognized in the first quarter of 2017. Residents of the affected facility were transferred to local skilled nursing facilities.

In the second quarter of 2017, we recovered $1.3 million of certain losses that were recorded in 2016 related to the closure of an operation. The loss recovery was recorded as a gain in that period.

HUD Mortgage Loans - In December 2017, seventeen of our subsidiaries entered into mortgage loans in the amount of $112.0 million. The mortgage loans are insured with HUD, which subjects these subsidiaries to HUD oversight and periodic inspections.

The Tax Act - On December 22, 2017, President Trump signed into law H.R. 1, “An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018” (the Tax Act). The Tax Act provides for significant changes in the U.S. Internal Revenue Code of 1986, as amended. The Tax Act contains provisions with separate effective dates but is generally effective for taxable years beginning after December 31, 2017.

The Tax Act had the following effects on our income tax expense for the year ended December 31, 2017:

•Under Financial Accounting Standards Board Accounting Standards Codification (ASC) Topic 740, Income Taxes (ASC 740), we are required to revalue any deferred tax assets or liabilities in the period of enactment of change in tax rates. The Tax Act lowers the corporate income tax rate from 35% to 21%. We have estimated the impact of the revaluation of our deferred tax assets and liabilities, which resulted in a decrease to our net deferred income tax asset by $3.9 million and is reflected as an increase in our income tax expense in our results for the year ended December 31, 2017.

•The Tax Act is generally effective for tax years beginning on January 1, 2018. As such, the reduction in the corporate income tax rate from 35% to 21% will be effective for the fiscal year ended December 31, 2018.

The Securities and Exchange Commission issued Staff Accounting Bulletin No. 118 (“SAB 118”) on December 23, 2017. SAB 118 provides a one-year measurement period from a registrant’s reporting period that includes the U.S. Tax Act’s enactment date to allow the registrant sufficient time to obtain, prepare and analyze information to complete the accounting required under ASC 740.

The ultimate impact of the Tax Act on our reported results may differ from the estimates provided herein, possibly materially, due to, among other things, changes in interpretations and assumptions we have made, guidance that may be issued, and other actions we may take as a result of the Tax Act different from that presently contemplated.

Key Performance Indicators

We manage the fiscal aspects of our business by monitoring key performance indicators that affect our financial performance. These indicators and their definitions include the following:

Transitional and Skilled Services

•

Routine revenue. Routine revenue is generated by the contracted daily rate charged for all contractually inclusive skilled nursing services. The inclusion of therapy and other ancillary treatments varies by payor source and by contract. Services provided outside of the routine contractual agreement are recorded separately as ancillary revenue, including Medicare Part B therapy services, and are not included in the routine revenue definition.

•

Skilled revenue. The amount of routine revenue generated from patients in the skilled nursing facilities who are receiving higher levels of care under Medicare, managed care, Medicaid, or other skilled reimbursement programs. The other skilled patients that are included in this population represent very high acuity patients who are receiving high levels of nursing and ancillary services which are reimbursed by payors other than Medicare or managed care. Skilled revenue excludes any revenue generated from our assisted living services.

•

Skilled mix. The amount of our skilled revenue as a percentage of our total routine revenue. Skilled mix (in days) represents the number of days our Medicare, managed care, or other skilled patients are receiving services at the skilled nursing facilities divided by the total number of days patients (less days from assisted living services) from all payor sources are receiving services at the skilled nursing facilities for any given period (less days from assisted living services).

Table of Contents

•

Quality mix. The amount of routine non-Medicaid revenue as a percentage of our total routine revenue. Quality mix (in days) represents the number of days our non-Medicaid patients are receiving services at the skilled nursing facilities divided by the total number of days patients from all payor sources are receiving services at the skilled nursing facilities for any given period (less days from assisted living services).


•	Average daily rates. The routine revenue by payor source for a period at the skilled nursing facilities divided by actual patient days for that revenue source for that given period.


•	Occupancy percentage (operational beds). The total number of patients occupying a bed in a skilled nursing facility as a percentage of the beds in a facility which are available for occupancy during the measurement period.


•	Number of facilities and operational beds. The total number of skilled nursing facilities that we own or operate and the total number of operational beds associated with these facilities.

Skilled and Quality Mix. Like most skilled nursing providers, we measure both patient days and revenue by payor. Medicare, managed care and other skilled patients, whom we refer to as high acuity patients, typically require a higher level of skilled nursing and rehabilitative care. Accordingly, Medicare and managed care reimbursement rates are typically higher than from other payors. In most states, Medicaid reimbursement rates are generally the lowest of all payor types. Changes in the payor mix can significantly affect our revenue and profitability.

The following table summarizes our overall skilled mix and quality mix from our skilled nursing services for the periods indicated as a percentage of our total routine revenue (less revenue from assisted living services) and as a percentage of total patient days (less days from assisted living services):



	Year Ended December 31,
	2017		2016		2015
Skilled Mix:
Days	30.3	%	30.9	%	30.4	%
Revenue	51.1	%	52.5	%	52.6	%
Quality Mix:
Days	42.8	%	43.4	%	42.5	%
Revenue	59.7	%	61.0	%	60.8	%

Occupancy. We define occupancy derived from our transitional and skilled services as the ratio of actual patient days (one patient day equals one patient occupying one bed for one day) during any measurement period to the number of beds in facilities which are available for occupancy during the measurement period. The number of licensed beds in a skilled nursing facility that are actually operational and available for occupancy may be less than the total official licensed bed capacity. This sometimes occurs due to the permanent dedication of bed space to alternative purposes, such as enhanced therapy treatment space or other desirable uses calculated to improve service offerings and/or operational efficiencies in a facility. In some cases, three- and four-bed wards have been reduced to two-bed rooms for resident comfort, and larger wards have been reduced to conform to changes in Medicare requirements. These beds are seldom expected to be placed back into service. We believe that reporting occupancy based on operational beds is consistent with industry practices and provides a more useful measure of actual occupancy performance from period to period.

The following table summarizes our overall occupancy statistics for the periods indicated:



	Year Ended December 31,
	2017		2016		2015
Occupancy for transitional and skilled services:
Operational beds at end of period	18,870		17,724		14,925
Available patient days	6,699,025		6,125,902		4,991,886
Actual patient days	5,050,140		4,620,735		3,873,409
Occupancy percentage (based on operational beds)	75.4	%	75.4	%	77.6	%

Assisted and Independent Living Services

Table of Contents

• Occupancy. We define occupancy derived from our assisted and independent living services as the ratio of actual number of days our units are occupied during any measurement period to the number of units in facilities which are available for occupancy during the measurement period.

• Average monthly revenue per unit. The revenue for a period at an assisted and independent living facility divided by actual occupied units for that revenue source for that given period.



	Year Ended December 31,
	2017			2016			2015
Occupancy for assisted and independent living services:
Occupancy percentage (units)	76.4		%	76.0		%	75.3		%
Average monthly revenue per unit	$	2,800		$	2,746		$	2,644

Home Health and Hospice


•	Average Medicare revenue per completed episode. The average amount of revenue for each completed 60-day episode generated from patients who are receiving care under Medicare reimbursement programs.


•	Average daily census. The average number of patients who are receiving hospice care as a percentage of total number of patient days.

The following table summarizes our overall home health and hospice statistics for the periods indicated:



	Year Ended December 31,
	2017		2016		2015
Home health services:
Average Medicare Revenue per Completed Episode	$	3,028	$	2,986	$	2,929
Hospice services:
Average Daily Census	1,102		905		679

Segments

We also report an “all other” category that includes revenue from our mobile diagnostics and other ancillary operations. Our mobile diagnostics and other ancillary operations businesses are neither significant individually nor in aggregate and therefore do not constitute a reportable segment. Our reporting segments are business units that offer different services and that are managed separately to provide greater visibility into those operations.

Revenue Sources

Transitional and Skilled Services

Within our skilled nursing operations, we generate our revenue from Medicaid, private pay, managed care and Medicare payors. We believe that our skilled mix, which we define as the number of days our Medicare, managed care and other skilled patients are receiving services at our skilled nursing operations divided by the total number of days patients are receiving services at our skilled nursing operations, from all payor sources (less days from assisted living and independent living services) for any given period, is an important indicator of our success in attracting high-acuity patients because it represents the percentage of our patients who are reimbursed by Medicare, managed care and other skilled payors, for whom we receive higher reimbursement rates.

We are participating in supplemental payment programs in various states that provides supplemental Medicaid payments for skilled nursing facilities that are licensed to non-state government-owned entities such as county hospital districts. Several of our operating subsidiaries entered into transactions with several such hospital districts providing for the transfer of the licenses for

Table of Contents

those skilled nursing facilities to the hospital districts. Each affected operating subsidiary agreement between the hospital district and our subsidiary is terminable by either party to fully restore the prior license status.

Assisted and Independent Living Services.

Within our assisted and independent living operations, we generate revenue primarily from private pay sources, with a portion earned from Medicaid or other state-specific programs.

Home Health and Hospice Services

Home Health. We provided home health care in Arizona, California, Colorado, Idaho, Iowa, Oklahoma, Oregon, Texas, Utah and Washington as of December 31, 2017. We derive the majority of our revenue from our home health business from Medicare and managed care. The payment is adjusted for differences between estimated and actual payment amounts, an inability to obtain appropriate billing documentation or authorizations acceptable to the payor and other reasons unrelated to credit risk. The home health prospective payment system (PPS) provides home health agencies with payments for each 60-day episode of care for each beneficiary. If a beneficiary is still eligible for care after the end of the first episode, a second episode can begin. There are no limits to the number of episodes a beneficiary who remains eligible for the home health benefit can receive. While payment for each episode is adjusted to reflect the beneficiary’s health condition and needs, a special outlier provision exists to ensure appropriate payment for those beneficiaries that have the most expensive care needs. The payment under the Medicare program is also adjusted for certain variables including, but not limited to: (a) a low utilization payment adjustment if the number of visits was fewer than five; (b) a partial payment if the patient transferred to another provider or the Company received a patient from another provider before completing the episode; (c) a payment adjustment based upon the level of therapy services required; (d) the number of episodes of care provided to a patient, regardless of whether the same home health provider provided care for the entire series of episodes; (e) changes in the base episode payments established by the Medicare program; (f) adjustments to the base episode payments for case mix and geographic wages; and (g) recoveries of overpayments.

Hospice. As of December 31, 2017, we provided hospice care in Arizona, California, Colorado, Idaho, Iowa, Nevada, Oklahoma, Oregon, Texas, Utah and Washington. We derive the majority of the revenue from our hospice business from Medicare reimbursement. The estimated payment rates are daily rates for each of the levels of care we deliver. The payment is adjusted for an inability to obtain appropriate billing documentation or authorizations acceptable to the payor and other reasons unrelated to credit risk. Additionally, as Medicare hospice revenue is subject to an inpatient cap limit and an overall payment cap, we monitor our provider numbers and estimate amounts due back to Medicare if a cap has been exceeded.

Beginning January 1, 2016, the Centers for Medicare & Medicaid Services (CMS) provided for two separate payment rates for routine care: payments for the first 60 days of care and care beyond 60 days. In addition to the two routine rates, Medicare is also reimbursing for a service intensity add-on (SIA). The SIA is based on visits made in the last seven days of life by a registered nurse (RN) or medical social worker (MSW) for patients in a routine level of care.

Other

As of December 31, 2017, we held majority membership interests in our other ancillary operations. Payment for these services varies and is based upon the service provided. The payment is adjusted for an inability to obtain appropriate billing documentation or authorizations acceptable to the payor and other reasons unrelated to credit risk. We have historically operated urgent care clinics in Colorado and Washington. Our urgent care centers provided daily access to healthcare for minor injuries and illnesses, including x-ray and lab services, all from convenient neighborhood locations with no appointments. In 2016, we completed the sale of all our urgent care centers.

Primary Components of Expense

Cost of Services (exclusive of rent and depreciation and amortization shown separately). Our cost of services represents the costs of operating our operating subsidiaries, which primarily consists of payroll and related benefits, supplies, purchased services, and ancillary expenses such as the cost of pharmacy and therapy services provided to patients. Cost of services also includes the cost of general and professional liability insurance and other general cost of services with respect to our operations.

Facility Rent - Cost of Services. Rent - cost of services consists solely of base minimum rent amounts payable under lease agreements to third-party owners of the operating subsidiaries that we operate but do not own and does not include taxes, insurance, impounds, capital reserves or other charges payable under the applicable lease agreements.

Table of Contents

General and Administrative Expense. General and administrative expense consists primarily of payroll and related benefits and travel expenses for our Service Center personnel, including training and other operational support. General and administrative expense also includes professional fees (including accounting and legal fees), costs relating to our information systems, stock-based compensation and rent for our Service Center offices.

Depreciation and Amortization. Property and equipment are recorded at their original historical cost. Depreciation is computed using the straight-line method over the estimated useful lives of the depreciable assets. The following is a summary of the depreciable lives of our depreciable assets:



Buildings and improvements	Minimum of three years to a maximum of 57 years, generally 45 years
Leasehold improvements	Shorter of the lease term or estimated useful life, generally 5 to 15 years
Furniture and equipment	3 to 10 years

Critical Accounting Policies

Our discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which have been prepared in accordance with U.S. Generally Accepted Accounting Principles (GAAP). The preparation of these financial statements and related disclosures requires us to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. On an ongoing basis we review our judgments and estimates, including but not limited to those related to doubtful accounts, income taxes, stock compensation, intangible assets and loss contingencies. We base our estimates and judgments upon our historical experience, knowledge of current conditions and our belief of what could occur in the future considering available information, including assumptions that we believe to be reasonable under the circumstances. By their nature, these estimates and judgments are subject to an inherent degree of uncertainty, and actual results could differ materially from the amounts reported. The following summarizes our critical accounting policies, defined as those policies that we believe: (a) are the most important to the portrayal of our financial condition and results of operations; and (b) require management's most subjective or complex judgments, often as a result of the need to make estimates about the effects of matters that are inherently uncertain.

Revenue Recognition

We recognize revenue when the following four conditions have been met: (i) there is persuasive evidence that an arrangement exists; (ii) delivery has occurred or service has been rendered; (iii) the price is fixed or determinable; and (iv) collection is reasonably assured. Our revenue is derived primarily from providing healthcare services to patients and is recognized on the date services are provided at amounts billable to the individual. For reimbursement arrangements with third-party payors, including Medicaid, Medicare and private insurers, revenue is recorded based on contractually agreed-upon amounts on a per patient basis.

Revenue from the Medicare and Medicaid programs accounted for 68.4%, 67.8%and 69.1% of our consolidated total revenue for the years ended December 31, 2017, 2016 and 2015, respectively. We record revenue from these governmental and managed care programs as services are performed at their expected net realizable amounts under these programs. Our revenue from governmental and managed care programs is subject to audit and retroactive adjustment by governmental and third-party agencies. Consistent with healthcare industry accounting practices, any changes to these governmental revenue estimates are recorded in the period the change or adjustment becomes known based on final settlement. We recorded adjustments to revenue which were not material to our consolidated revenue for the years ended December 31, 2017, 2016 and 2015.

Our service specific revenue recognition policies are as follows:

Skilled Nursing Revenue

Our revenue is derived primarily from providing long-term healthcare services to patients and is recognized on the date services are provided at amounts billable to individual patients. For patients under reimbursement arrangements with third-party payors, including Medicaid, Medicare and private insurers, revenue is recorded based on contractually agreed-upon amounts, rates on a per patient, daily basis, or as services are performed.

Assisted and Independent Living Revenue

Our revenue is recorded when services are rendered on the date services are provided at amounts billable to individual residents and consists of fees for basic housing and assisted living care. Residency agreements are generally for a term of 30 days, with resident fees billed monthly in advance. For patients under reimbursement arrangements with Medicaid, revenue is recorded

Table of Contents

based on contractually agreed-upon amounts or rate on a per resident, daily basis or as services are provided. Revenue for certain ancillary charges is recognized as services are provided, and such fees are billed monthly in arrears.

Home Health Revenue

Medicare Revenue

Net service revenue is recorded under the Medicare prospective payment system based on a 60-day episode payment rate that is subject to adjustment based on certain variables including, but not limited to: (a) an outlier payment if patient care was unusually costly; (b) a low utilization payment adjustment if the number of visits was fewer than five; (c) a partial payment if the patient transferred to another provider or we received a patient from another provider before completing the episode; (d) a payment adjustment based upon the level of therapy services required; (e) the number of episodes of care provided to a patient, regardless of whether the same home health provider provided care for the entire series of episodes; (f) changes in the base episode payments established by the Medicare program; (g) adjustments to the base episode payments for case mix and geographic wages; and (h) recoveries of overpayments.

We make adjustments to Medicare revenue on completed episodes to reflect differences between estimated and actual payment amounts, an inability to obtain appropriate billing documentation or authorizations acceptable to the payor and other reasons unrelated to credit risk. Therefore, we believe reported net service revenue and patient accounts receivable will be the net amounts to be realized from Medicare for services rendered.

In addition to revenue recognized on completed episodes, we also recognize a portion of revenue associated with episodes in progress. Episodes in progress are 60-day episodes of care that begin during the reporting period, but were not completed as of the end of the period. As such, we estimate revenue and recognize it on a daily basis. The primary factors underlying this estimate are the number of episodes in progress at the end of the reporting period, expected Medicare revenue per episode and our estimate of the average percentage complete based on visits performed.

Non-Medicare Revenue

Episodic Based Revenue - We recognize revenue in a similar manner as we recognize Medicare revenue for episodic-based rates that are paid by other insurance carriers, including Medicare Advantage programs; however, these rates can vary based upon the negotiated terms.

Non-episodic Based Revenue - Revenue is recorded on an accrual basis based upon the date of service at amounts equal to its established or estimated per-visit rates, as applicable.

Hospice Revenue

Revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are daily rates for each of the levels of care we deliver. We make adjustments to revenue for an inability to obtain appropriate billing documentation or authorizations acceptable to the payor and other reasons unrelated to credit risk. Additionally, as Medicare hospice revenue is subject to an inpatient cap limit and an overall payment cap, we monitor our provider numbers and estimate amounts due back to Medicare if a cap has been exceeded. We record these adjustments as a reduction to revenue and increases to other accrued liabilities.

Accounts Receivable and Allowance for Doubtful Accounts

Accounts receivable consist primarily of amounts due from Medicare and Medicaid programs, other government programs, managed care health plans and private payor sources. Estimated provisions for doubtful accounts are recorded to the extent it is probable that a portion or all of a particular account will not be collected.

In evaluating the collectability of accounts receivable, we consider a number of factors, including the age of the accounts, changes in collection patterns, the composition of patient accounts by payor type and the status of ongoing disputes with third-party payors. On an annual basis, the historical collection percentages are reviewed by payor and by state and are updated to reflect recent collection experience. In order to determine the appropriate reserve rate percentages which ultimately establish the allowance, we analyze historical cash collection patterns by payor and by state. The percentages applied to the aged receivable balances are based on our historical experience and time limits, if any, for managed care, Medicare, Medicaid and other payors. We periodically refine our estimates of the allowance for doubtful accounts based on experience with the estimation process and changes in circumstances.

Self-Insurance

Table of Contents

We are partially self-insured for general and professional liability up to a base amount per claim (the self-insured retention) with an aggregate, one-time deductible above this limit. Losses beyond these amounts are insured through third-party policies with coverage limits per claim, per location and on an aggregate basis for the Company. Starting on January 1, 2017, the combined self-insured retention was $0.5 million per claim, subject to an additional one-time deductible of $0.8 million for California affiliated operations and a separate, one-time, deductible of $1.0 million for non-California operations. For all affiliated operations, except those located in Colorado, the third-party coverage above these limits was $1.0 million per claim, $3.0 million per operation, with a $5.0 million blanket aggregate limit and an additional state-specific aggregate where required by state law. In Colorado, the third-party coverage above these limits was $1.0 million per claim and $3.0 million per operation, which is independent of the aforementioned blanket aggregate limits that apply outside of Colorado.

The self-insured retention and deductible limits for general and professional liability and workers' compensation for all states (except Texas and Washington for workers' compensation) are self-insured through the Captive, the related assets and liabilities of which are included in the accompanying consolidated balance sheets. The Captive is subject to certain statutory requirements as an insurance provider. These requirements include, but are not limited to, maintaining statutory capital.

Our policy is to accrue amounts equal to the actuarially estimated costs to settle open claims of insureds, as well as an estimate of the cost of insured claims that have been incurred but not reported. We develop information about the size of the ultimate claims based on historical experience, current industry information and actuarial analysis, and evaluates the estimates for claim loss exposure on a quarterly basis.

Our operating subsidiaries are self-insured for workers’ compensation in California. To protect itself against loss exposure in California with this policy, we have purchased individual specific excess insurance coverage that insures individual claims that exceed $0.5 million per occurrence. In Texas, the operating subsidiaries have elected non-subscriber status for workers’ compensation claims and, effective February 1, 2011, we have purchased individual stop-loss coverage that insures individual claims that exceed $0.8 million per occurrence. As of July 1, 2014, our operating subsidiaries in all other states, with the exception of Washington, are under a loss sensitive plan that insures individual claims that exceed $0.4 million per occurrence. In Washington, the operating subsidiaries' coverage is financed through premiums paid by the employers and employees. The claims and pay benefits are managed through a state insurance pool. Outside of California, Texas and Washington, we have purchased insurance coverage that insures individual claims that exceed $0.4 million per accident. In all states except Washington, we accrue amounts equal to the estimated costs to settle open claims, as well as an estimate of the cost of claims that have been incurred but not reported. We use actuarial valuations to estimate the liability based on historical experience and industry information.

We self-fund medical (including prescription drugs) and dental healthcare benefits to the majority of our employees. We are fully liable for all financial and legal aspects of these benefit plans. To protect our company against loss exposure with this policy, we have purchased individual stop-loss insurance coverage that insures individual claims that exceed $0.3 million for each covered person with an additional one-time aggregate individual stop loss deductible of $0.1 million. Beginning 2016, our policy does not include the additional one-time aggregate individual stop loss deductible of $0.1 million.

We believe that adequate provision has been made in the Financial Statements for liabilities that may arise out of patient care, workers’ compensation, healthcare benefits and related services provided to date. The amount of our reserves was determined based on an estimation process that uses information obtained from both company-specific and industry data. This estimation process requires us to continuously monitor and evaluate the life cycle of the claims. Using data obtained from this monitoring and our assumptions about emerging trends, we, with the assistance of an independent actuary, develop information about the size of ultimate claims based on our historical experience and other available industry information. The most significant assumptions used in the estimation process include determining the trend in costs, the expected cost of claims incurred but not reported and the expected costs to settle or pay damage awards with respect to unpaid claims. The self-insured liabilities are based upon estimates, and while we believe that the estimates of loss are reasonable, the ultimate liability may be in excess of or less than the recorded amounts. Due to the inherent volatility of actuarially determined loss estimates, it is reasonably possible that we could experience changes in estimated losses that could be material to net income. If our actual liability exceeds its estimates of loss, our future earnings, cash flows and financial condition would be adversely affected.

Leases and Leasehold Improvements

At the inception of each lease, we perform an evaluation to determine whether the lease should be classified as an operating or capital lease. We record rent expense for operating leases that contain scheduled rent increases on a straight-line basis over the term of the lease. The lease term used for straight-line rent expense is calculated from the date we are given control of the leased premises through the end of the lease term. The lease term used for this evaluation also provides the basis for establishing depreciable lives for buildings subject to lease and leasehold improvements, as well as the period over which we record straight-line rent expense.

Table of Contents

Business Combinations

Our acquisition strategy is to purchase or lease operating subsidiaries that are complementary to our current affiliated facilities, accretive to our business or otherwise advance our strategy. The results of all of our operating subsidiaries are included in the accompanying Financial Statements subsequent to the date of acquisition. Acquisitions are typically paid for in cash and are accounted for using the acquisition method of accounting. We account for business combinations using the purchase method of accounting and, accordingly, the assets and liabilities of the acquired entities are recorded at their estimated fair values at the acquisition date. Goodwill represents the excess of the purchase price over the fair value of net assets, including the amount assigned to identifiable intangible assets. Given the time it takes to obtain pertinent information to finalize the acquired company’s balance sheet, the initial fair value might not be finalized at the time of the reported period. Accordingly, it is not uncommon for the initial estimates to be subsequently revised.

In accounting for business combinations, we are required to record the assets and liabilities of the acquired business at fair value. In developing estimates of fair values for long-lived assets, we utilize a variety of factors including market data, cash flows, growth rates, and replacement costs. Determining the fair value for specifically identified intangible assets involves significant judgment, estimates and projections related to the valuation to be applied to intangible assets such as favorable leases, customer relationships, Medicare licenses, and trade names. The subjective nature of management’s assumptions increases the risk associated with estimates surrounding the projected performance of the acquired entity. Additionally, as we amortize finite-lived acquired intangible assets over time, the purchase accounting allocation directly impacts the amortization expense recorded on the financial statements.

Income Taxes

Deferred tax assets and liabilities are established for temporary differences between the financial reporting basis and the tax basis of our assets and liabilities at tax rates in effect when such temporary differences are expected to reverse. We generally expect to fully utilize our deferred tax assets; however, when necessary, we record a valuation allowance to reduce our net deferred tax assets to the amount that is more likely than not to be realized.

In determining the need for a valuation allowance or the need for and magnitude of liabilities for uncertain tax positions, we make certain estimates and assumptions. These estimates and assumptions are based on, among other things, knowledge of operations, markets, historical trends and likely future changes and, when appropriate, the opinions of advisors with knowledge and expertise in certain fields. Due to certain risks associated with our estimates and assumptions, actual results could differ.

The Tax Act increased our income tax expense by $3.9 million for the year ended December 31, 2017. The Tax Act will decrease the corporate income tax rate from 35.0% to 21.0% beginning on January 1, 2018. We expect meaningful benefits from this reduction to continue from its enactment in future periods.

Recent Accounting Pronouncements

Except for rules and interpretive releases of the SEC under authority of federal securities laws and a limited number of grandfathered standards, the Financial Accounting Standards Board (FASB) ASC is the sole source of authoritative GAAP literature recognized by the FASB and applicable to us. We have reviewed the FASB issued Accounting Standards Update (ASU) accounting pronouncements and interpretations thereof that have effectiveness dates during the periods reported and in future periods. For any new pronouncements announced, we consider whether the new pronouncements could alter previous generally accepted accounting principles and determine whether any new or modified principles will have a material impact on our reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of our financial management and certain standards are under consideration.

Recent Accounting Standards Adopted by the Company

In March 2016, the FASB issued a new standard to simplify several aspects the accounting for employee share-based payment transactions, which includes the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The new standard was effective for us in the first quarter of fiscal year 2017. Under the previous guidance, excess tax benefits and deficiencies from share-based compensation arrangements were recorded in equity when the awards vested or were settled. The new guidance requires prospective recognition of excess tax benefits and deficiencies in the income statement, resulting in the recognition of excess tax benefits of income tax expense, rather than in paid-in-capital, net of tax, of $3.4 million, for the year ended December 31, 2017.

Table of Contents

In addition, under the new guidance, excess income tax benefits from share-based compensation arrangements are classified as cash flow from operations, rather than as cash flow from financing activities. We have elected to apply the cash flow classification guidance prospectively, resulting in an increase to operating cash flow for the year ended December 31, 2017, and the prior year period has not been adjusted.

We have also elected to continue to estimate the expected forfeitures rather than electing to account for forfeitures as they occur. Finally, the adoption of the guidance requires excess tax benefits and deficiencies to be prospectively excluded from assumed future proceeds in the calculation of diluted shares, resulting in an increase in diluted weighted average shares outstanding.

Accounting Standards Recently Issued But Not Yet Adopted by the Company

In May 2017, the FASB issued amended authoritative guidance to provide guidance on types of changes to the terms or conditions of share-based payments awards to which an entity would be required to apply modification accounting under ASC 718. This guidance is effective for annual and interim periods beginning after December 15, 2017, which will be our fiscal year 2018, with early adoption permitted in certain cases. The adoption of this standard is not expected to have a material impact on our consolidated financial statements.

In January 2017, the FASB issued amended authoritative guidance to clarify the definition of a business and reduce diversity in practice related to the evaluation of whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The new provisions provide the requirements needed for an integrated set of assets and activities (the set) to be a business and also establish a practical way to determine when a set is not a business. The ASU provides a screen to determine when an integrated set of assets and activities is not a business. The more robust framework helps entities to narrow the definition of outputs created by the set and align it with how outputs are described in the new revenue standard. This guidance is effective for annual and interim periods beginning after December 15, 2017, which will be our fiscal year 2018, with early adoption permitted in certain cases. The new guidance is required to be applied on a prospective basis. The effect of the implementation will depend upon the nature of our future acquisitions.

In January 2017, the FASB issued amended authoritative guidance to simplify and reduce the cost and complexity of the goodwill impairment test. The new provisions eliminate step 2 from the goodwill impairment test and shifts the concept of impairment from a measure of loss when comparing the implied fair value of goodwill to its carrying amount to comparing the fair value of a reporting unit with its carrying amount. The Board also eliminated the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment or step 2 of the goodwill impairment test. The new guidance does not amend the optional qualitative assessment of goodwill impairment. This guidance is effective for annual periods beginning after December 15, 2019, which will be our fiscal year 2020, with early adoption permitted. The adoption of this standard is not expected to have a material impact on our consolidated financial statements.

In October 2016, the FASB issued amended authoritative guidance to require companies to recognize the income tax consequences of an intra-entity transfer of an asset, other than inventory, when the transfer occurs. The amendments will be effective for our fiscal year beginning January 1, 2018. The new guidance is required to be applied on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. The adoption of this standard is not expected to have a material impact on our consolidated financial statements based on our historical activity. Furthermore, the actual impact of implementation will largely depend on future intra-entity asset transfers, if any.

In August 2016, the FASB issued amended authoritative guidance to reduce the diversity in practice related to the presentation and classification of certain cash receipts and cash payments in the statement of cash flows. The new provisions target cash flow issues related to (i) debt prepayment or debt extinguishment costs, (ii) settlement of debt instruments with coupon rates that are insignificant relative to effective interest rates, (iii) contingent consideration payments made after a business combination, (iv) proceeds from settlement of insurance claims, (v) proceeds from the settlement of corporate-owned life insurance and bank-owned life insurance policies, (vi) distributions received from equity method investees, (vii) beneficial interests in securitization transactions and (viii) separately identifiable cash flows and application of the predominance principle. This guidance will be effective for fiscal years beginning after December 15, 2017, which will be our fiscal year 2018, with early adoption permitted. The adoption of this standard is not expected to have a material impact on our consolidated financial statements.

Table of Contents

(term of 12 months or less), a lessee is permitted to make an accounting election not to recognize lease assets and lease liabilities, which would generally result in lease expense being recognized on a straight-line basis over the lease term. This guidance applies to all entities and is effective for annual periods beginning after December 15, 2018, which will be our fiscal year 2019, with early adoption permitted. We are currently evaluating the impact this guidance will have on our consolidated financial statements but expect this adoption will result in a significant increase in the assets and liabilities on our consolidated balance sheets.

In January 2016, the FASB issued amended authoritative guidance which makes targeted improvements for financial instruments. The new provisions impact certain aspects of recognition, measurement, presentation and disclosure requirements of financial instruments. Specifically, the guidance will (1) require equity investments to be measured at fair value with changes in fair value recognized in net income, (2) simplify the impairment assessment of equity investments without readily determinable fair values, (3) eliminate the requirement to disclose the method and assumptions used to estimate fair value for financial instruments measured at amortized cost, and (4) require separate presentation of financial assets and financial liabilities by measurement category. The guidance is effective for annual and interim periods beginning after December 15, 2017, which will be our fiscal year 2018. Early adoption is not permitted. The adoption of this standard is not expected to have a material impact on our consolidated financial statements.

In March 2016, the FASB issued its standard to amend the principal-versus-agent implementation guidance and illustrations in the Board’s new revenue standard, which includes accounting implication related to (1) determining the appropriate unit of account under the revenue standard’s principal-versus-agent guidance and (2) applying the indicators of whether an entity is a principal or an agent in accordance with the revenue standard’s control principle. The guidance will be effective for fiscal years beginning after December 15, 2017, which will be our fiscal year 2018. The guidance has the same effective date as the new revenue standard and we are required to adopt the guidance by using the same transition method we would use to adopt the new revenue standard. Our evaluation of the adoption method and impact to the consolidated financial statements is performed concurrently with the new revenue standard below.

In May 2014, the FASB and International Accounting Standards Board issued their final standard on revenue from contracts with customers that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers. The new standard supersedes most current revenue recognition guidance, including industry-specific guidance, and may be applied retrospectively to each period presented (full retrospective method) or retrospectively with the cumulative effect recognized in beginning retained earnings as of the date of adoption (modified retrospective method). In July 2015, the FASB formally deferred for one year the effective date of the new revenue standard and decided to permit entities to early adopt the standard. In December 2016, the FASB made certain technical corrections to further clarify the core revenue recognition principles, primarily in response to feedback from several sources, including the FASB/IASB Transition Resource Group. The guidance will be effective for fiscal years beginning after December 15, 2017, which will be our fiscal year 2018. We initiated an adoption plan in fiscal year 2015, beginning with preliminary evaluation of the standard, and subsequently performed additional analysis of revenue streams and transactions under the new standard. In particular, we performed analysis into the application of the portfolio approach as a practical expedient to group patient contracts with similar characteristics, such that revenue for a given portfolio would not be materially different than if it were evaluated on a contract-by-contract basis. The adoption plan has been completed and the impact to the consolidated financial statements for periods subsequent to adoption is not material. As part of the impact assessment, we evaluated any variable consideration, potential constraints on the estimate of variable consideration, and significant financing components, in particular as it related to third party settlements. We anticipate that for periods subsequent to adoption, the majority of what is currently classified as bad debt expense under operating expenses will be treated as an implicit price concession factored into net revenue, consistent with the intent of the standard. The new standard also requires enhanced disclosures related to the disaggregation of revenue, information about contract balances, and other disclosures about contracts with customers, including revenue recognition policies to identify performance obligations and significant judgments in measurement and recognition. We adopted the new revenue standard as of January 1, 2018 using the modified retrospective method and the adoption did not have a material impact.

Table of Contents

Results of Operations

The following table sets forth details of our revenue, expenses and earnings as a percentage of total revenue for the periods indicated:



	Year Ended December 31,
	2017		2016		2015
Revenue	100.0	%	100.0	%	100.0	%
Expense:
Cost of services	81.0		81.1		79.6
Charge related to class action lawsuit (Note 19)	0.6		—		—
(Gains)/losses related to divestitures (Note 7 and 17)	0.1		(0.7	)	—
Rent—cost of services (Note 17)	7.1		7.5		6.6
General and administrative expense	4.4		4.2		4.8
Depreciation and amortization	2.4		2.3		2.1
Total expenses	95.6		94.4		93.1
Income from operations	4.4		5.6		6.9
Other income (expense):
Interest expense	(0.7	)	(0.4	)	(0.2	)
Interest income	0.1		0.1		0.1
Other expense, net	(0.6	)	(0.3	)	(0.1	)
Income before provision for income taxes	3.8		5.3		6.8
Provision for income taxes	1.5		2.0		2.6
Net income	2.3		3.3		4.2
Less: net income attributable to noncontrolling interests	0.1		0.2		—
Net income attributable to The Ensign Group, Inc.	2.2	%	3.1	%	4.2	%

Year Ended December 31, 2017 Compared to the Year Ended December 31, 2016

Revenue



	Year Ended December 31,
	2017				2016
	Revenue Dollars		Revenue Percentage		Revenue Dollars		Revenue Percentage
	(Dollars in thousands)
Transitional and skilled services	$	1,545,210	83.6	%	$	1,374,803	83.1	%
Assisted and independent living services	136,646		7.4		123,636		7.5
Home health and hospice services:
Home health	73,045		3.9		60,326		3.6
Hospice	69,358		3.8		55,487		3.4
Total home health and hospice services	142,403		7.7		115,813		7.0
All other (1)	25,058		1.3		40,612		2.4
Total revenue	$	1,849,317	100.0	%	$	1,654,864	100.0	%

(1) Includes revenue from services generated in our other ancillary services for the year ended December 31, 2017 and 2016 and urgent care centers for the year ended December 31, 2016.

Our consolidated revenue increased $194.5 million, or 11.8% in fiscal year 2017. Our transitional and skilled services revenue increased by $170.4 million, or 12.4%, mainly attributable to the increase in patient days, revenue per patient day and the impact of acquisitions. Our assisted and independent living services increased by $13.0 million, or 10.5%, mainly due to the increase in average monthly revenue per unit and occupancy compared to the prior year period, coupled with the impact of

Table of Contents

acquisitions. Our home health and hospice services revenue increased by $26.6 million, or 23.0%, mainly due to an increase in volume in existing agencies combined with new acquisitions. Revenue from operations acquired on or subsequent to January 1, 2016 increased our consolidated revenue by $156.4 million in 2017 when comparing to 2016. Consolidated revenue for the year ended December 31, 2016 included $24.8 million of revenue related to urgent care centers that we sold in the third and fourth quarter of 2016.

Transitional and Skilled Services

The following table presents the transitional and skilled services revenue and key performance metrics by category in fiscal 2017 and 2016:



	Year Ended December 31,
	2017			2016
	(Dollars in thousands)						Change		% Change
Total Facility Results:
Transitional and skilled revenue	$	1,545,210		$	1,374,803		$	170,407	12.4	%
Number of facilities at period end	160			149			11		7.4	%
Number of campuses at period end*	21			21			—		—	%
Actual patient days	5,050,140			4,620,735			429,405		9.3	%
Occupancy percentage — Operational beds	75.4		%	75.4		%			—	%
Skilled mix by nursing days	30.3		%	30.9		%			(0.6	)%
Skilled mix by nursing revenue	51.1		%	52.5		%			(1.4	)%



	Year Ended December 31,
	2017			2016
	(Dollars in thousands)						Change			% Change
Same Facility Results(1):
Transitional and skilled revenue	$	975,203		$	942,854		$	32,349		3.4	%
Number of facilities at period end	93			93			—			—	%
Number of campuses at period end*	11			11			—			—	%
Actual patient days	3,083,292			3,099,764			(16,472		)	(0.5	)%
Occupancy percentage — Operational beds	78.4		%	78.1		%				0.3	%
Skilled mix by nursing days	30.0		%	29.8		%				0.2	%
Skilled mix by nursing revenue	50.8		%	51.3		%				(0.5	)%



	Year Ended December 31,
	2017			2016
	(Dollars in thousands)						Change		% Change
Transitioning Facility Results(2):
Transitional and skilled revenue	$	310,545		$	292,360		$	18,185	6.2	%
Number of facilities at period end	37			37			—		—	%
Number of campuses at period end*	3			3			—		—	%
Actual patient days	988,246			963,760			24,486		2.5	%
Occupancy percentage — Operational beds	74.2		%	71.4		%			2.8	%
Skilled mix by nursing days	35.5		%	36.5		%			(1.0	)%
Skilled mix by nursing revenue	54.3		%	56.8		%			(2.5	)%

Table of Contents



	Year Ended December 31,
	2017			2016
	(Dollars in thousands)						Change		% Change
Recently Acquired Facility Results(3):
Transitional and skilled revenue	$	257,594		$	134,828		$	122,766	NM
Number of facilities at period end	30			18			12		NM
Number of campuses at period end*	7			6			1		NM
Actual patient days	973,027			536,495			436,532		NM
Occupancy percentage — Operational beds	68.5		%	71.4		%			NM
Skilled mix by nursing days	25.8		%	27.5		%			NM
Skilled mix by nursing revenue	48.0		%	52.4		%			NM



	Year Ended December 31,
	2017			2016
	(Dollars in thousands)						Change			% Change
Facility Closed Results(4):
Skilled nursing revenue	$	1,868		$	4,761		$	(2,893	)	NM
Actual patient days	5,575			20,716			(15,141		)	NM
Occupancy percentage — Operational beds	34.3		%	37.5		%				NM
Skilled mix by nursing days	46.7		%	20.1		%				NM
Skilled mix by nursing revenue	71.5		%	42.0		%				NM

__________________

* Campus represents a facility that offers both skilled nursing, assisted and/or independent living services. Revenue and expenses related to skilled nursing, assisted and independent living services have been allocated and recorded in the respective reportable segment.


(1)	Same Facility results represent all facilities purchased prior to January 1, 2014.


(2)	Transitioning Facility results represents all facilities purchased from January 1, 2014 to December 31, 2015.


(3)	Recently Acquired Facility (Acquisitions) results represent all facilities purchased on or subsequent to January 1, 2016.


(4)	Facility Closed results represents closed operations during 2017 and 2016, which were excluded from Recently Acquired results for the years ended December 31, 2017 and 2016, for comparison purposes.

Transitional and skilled services revenue increased $170.4 million, or 12.4% in fiscal year 2017. Of the $170.4 million increase, Medicare and managed care revenue increased $55.1 million, or 8.5%, Medicaid custodial revenue increased $82.0 million, or 15.7%, private and other revenue increased $17.9 million, or 14.7%, and Medicaid skilled revenue increased $15.4 million, or 17.5%.

Transitional and skilled services revenue generated by Same Facilities increased $32.3 million, or 3.4%, on a comparable basis. The following is a description of notable comparable revenue changes:


•	Our Medicaid revenue, including Medicaid skilled revenue, increased by $32.1 million, or 7.4%, mainly driven by an increase in Medicaid days. We also experienced an increase in Medicaid revenue per patient day as a result of our participation in the quality improvement programs and the supplemental programs in various states.


•	Our managed care revenue increased by $13.1 million, or 8.4%, due to an increase in managed care days and an increase in managed care revenue per patient day.


•	Our Medicare revenue decreased by $10.6 million, or 4.0%, primarily due to a decrease in Medicare days, partially offset by an increase in Medicare revenue per patient day.

•

In addition, our Same Facilities patient days decreased compared to fiscal 2016 due to evacuations and subsequent structural work damaged by Hurricane Harvey and California fires. All evacuation orders were lifted and our operations re-opened in the fourth quarter of 2017. We also currently have one operation undergoing structural renovations and is expected to re-open in the second quarter of 2018.

Transitional and skilled services revenue generated by Transitioning Facilities increased $18.2 million, or 6.2%. This is due to increases in total patient days and revenue per patient day of 2.5% and 3.6%, respectively.

Transitional and skilled services revenue generated by Recently Acquired Facilities increased by approximately $122.8 million mainly due to thirty-seven operations we acquired between January 1, 2016 and December 31, 2017 in seven states.

Table of Contents

Historically, we have generally experienced lower occupancy rates, lower skilled mix and quality mix at Recently Acquired Facilities and therefore, we anticipate generally lower overall occupancy during years of growth for our turnaround acquisitions. In the future, if we acquire additional turnaround operations into our overall portfolio, we expect this trend to continue. Accordingly, we anticipate our overall occupancy will vary from period to period based upon the maturity of the facilities within our portfolio.

The following table reflects the change in the skilled nursing average daily revenue rates by payor source, excluding services that are not covered by the daily rate:



	Year Ended December 31,
	Same Facility				Transitioning				Acquisitions				Total
	2017		2016		2017		2016		2017		2016		2017		2016
Skilled Nursing Average Daily Revenue Rates:
Medicare	$	601.53	$	583.21	$	548.09	$	528.65	$	506.27	$	486.45	$	569.77	$	556.89
Managed care	445.73		428.13		445.45		438.21		414.34		401.22		440.55		428.53
Other skilled	483.23		468.59		369.82		369.59		449.89		—		451.16		441.86
Total skilled revenue	518.82		505.95		470.65		462.84		468.89		457.58		499.51		490.18
Medicaid	217.22		205.82		215.49		201.24		172.02		154.73		208.24		198.92
Private and other payors	212.72		197.11		233.26		208.11		191.16		167.15		209.72		197.87
Total skilled nursing revenue	$	307.47	$	294.12	$	307.77	$	297.20	$	252.02	$	240.27	$	296.84	$	288.93

Our Medicare daily rates at Same Facilities and Transitioning Facilities increased by 3.1% and 3.7%, respectively. The increase is attributable to the mandated 1.0% market basket percentage that became effective in October 2017, which was preceded by a 2.4% net market basket increase that went into effect in October 2016, compared to a net market basket increase of 1.2%, which went into effect in October 2015. In addition, the increase in Medicare daily rates was the result of continuous shift towards higher acuity patients.

Our average Medicaid rates increased 4.7% primarily due to our participation in supplemental Medicaid payment programs and quality improvement programs in various states.

Payor Sources as a Percentage of Skilled Nursing Services. We use both our skilled mix and quality mix as measures of the quality of reimbursements we receive at our affiliated skilled nursing facilities over various periods. The following tables set forth our percentage of skilled nursing patient revenue and days by payor source:



	Year Ended December 31,
	Same Facility				Transitioning				Acquisitions				Total
	2017		2016		2017		2016		2017		2016		2017		2016
Percentage of Skilled Nursing Revenue:
Medicare	25.1	%	27.2	%	24.3	%	25.5	%	30.5	%	36.8	%	25.8	%	27.8	%
Managed care	17.2		16.4		22.0		24.1		16.9		15.6		18.1		17.9
Other skilled	8.5		7.7		8.0		7.2		0.6		—		7.2		6.8
Skilled mix	50.8		51.3		54.3		56.8		48.0		52.4		51.1		52.5
Private and other payors	8.0		8.5		7.0		6.2		13.4		12.7		8.6		8.5
Quality mix	58.8		59.8		61.3		63.0		61.4		65.1		59.7		61.0
Medicaid	41.2		40.2		38.7		37.0		38.6		34.9		40.3		39.0
Total skilled nursing	100.0	%	100.0	%	100.0	%	100.0	%	100.0	%	100.0	%	100.0	%	100.0	%

Table of Contents



	Year Ended December 31,
	Same Facility				Transitioning				Acquisitions				Total
	2017		2016		2017		2016		2017		2016		2017		2016
Percentage of Skilled Nursing Days:
Medicare	12.8	%	13.7	%	13.6	%	14.3	%	15.2	%	18.2	%	13.4	%	14.4	%
Managed care	11.8		11.3		15.2		16.3		10.3		9.3		12.2		12.0
Other skilled	5.4		4.8		6.7		5.9		0.3		—		4.7		4.5
Skilled mix	30.0		29.8		35.5		36.5		25.8		27.5		30.3		30.9
Private and other payors	11.9		12.6		9.3		8.9		17.7		18.4		12.5		12.5
Quality mix	41.9		42.4		44.8		45.4		43.5		45.9		42.8		43.4
Medicaid	58.1		57.6		55.2		54.6		56.5		54.1		57.2		56.6
Total skilled nursing	100.0	%	100.0	%	100.0	%	100.0	%	100.0	%	100.0	%	100.0	%	100.0	%

Assisted and Independent Living Services



	Year Ended December 31,
	2017			2016
	(Dollars in thousands)						Change		% Change
Revenue	$	136,646		$	123,636		$	13,010	10.5	%
Number of facilities at period end	49			40			9		22.5	%
Number of campuses at period end	21			21			—		—	%
Occupancy percentage (units)	76.4		%	76.0		%			0.4	%
Average monthly revenue per unit	$	2,800		$	2,746		$	54	2.0	%

Assisted and independent living revenue of $136.6 million increased 10.5% on a comparable basis primarily due to an increase in average monthly revenue per unit of 2.0% and occupancy of 0.4%, coupled with revenue generated from the addition of sixteen assisted and independent living operations in five states between January 1, 2016 and December 31, 2017.

Home Health and Hospice Services



	Year Ended December 31,
	2017		2016		Change		% Change
	(Dollars in thousands)
Home health and hospice revenue
Home health services	$	73,045	$	60,326	$	12,719	21.1	%
Hospice services	69,358		55,487		13,871		25.0
Total home health and hospice revenue	$	142,403	$	115,813	$	26,590	23.0	%
Home health services:
Average Medicare Revenue per Completed Episode	$	3,028	$	2,986	$	42	1.4	%
Hospice services:
Average Daily Census	1,102		905		197		21.8	%

Home health and hospice revenue increased $26.6 million, or 23.0%. Of the $26.6 million increase, Medicare and managed care revenue increased $21.7 million, or 22.1%. The increase in revenue is primarily due to the increase in volume and average daily census in existing agencies, coupled with the addition of eleven home health and hospice operations in eight states between January 1, 2016 and December 31, 2017.

Cost of Services

The following table sets forth total cost of services by each of our reportable segments and our "All Other" category for the periods indicated (dollars in thousands):

Table of Contents



	Cost of Services
	Transitional and Skilled Services		Assisted and Independent Living Services		Home Health and Hospice		All Other		Total
Year Ended December 31, 2017	$	1,267,169	$	89,626	$	119,765	$	21,143	$	1,497,703
Year Ended December 31, 2016	$	1,130,691	$	78,872	$	96,753	$	35,498	$	1,341,814

Consolidated cost of services increased $155.9 million, or 11.6% compared to fiscal 2016.

Transitional and Skilled Services



	Year Ended December 31,								%
	2017			2016			Change		Change
	(Dollars in thousands)
Cost of service dollars	$	1,267,169		$	1,130,691		$	136,478	12.1	%
Revenue percentage	82.0		%	82.2		%			(0.2	)%

Cost of services related to our transitional and skilled services segment increased $136.5 million, or 12.1%, due primarily to additional costs at Recently Acquired Facilities of $99.1 million and organic operational growth. Cost of services as a percentage of revenue decreased to 82.0%, mainly due to the decrease in bad debt expense and ancillary costs, offset by an increase in wage and health insurance costs.

Assisted and Independent Living Services



	Year Ended December 31,								%
	2017			2016			Change		Change
	(Dollars in thousands)
Cost of service dollars	$	89,626		$	78,872		$	10,754	13.6	%
Revenue percentage	65.6		%	63.8		%			1.8	%

Cost of services related to our assisted and independent living services segment increased $10.8 million, or 13.6%, primarily due to recently acquired operations and organic operational growth. Cost of services as a percentage of total revenue increased by 1.8% as a result of the increase in wage and health insurance costs.

Home Health and Hospice Services



	Year Ended December 31,								%
	2017			2016			Change		Change
	(Dollars in thousands)
Cost of service dollars	$	119,765		$	96,753		$	23,012	23.8	%
Revenue percentage	84.1		%	83.5		%			0.6	%

Cost of services related to our home health and hospice services segment increased $23.0 million, or 23.8% due to newly acquired operations and organic operational growth. Cost of services as a percentage of total revenue increased by 0.6% primarily due to costs related to health insurance costs, contract therapy and bad debt expenses.

Charge related to class action lawsuit. We recorded a liability of $11.0 million in fiscal 2017 related to the settlement of a class action lawsuit. Similar charges did not occur for 2016.

(Gains)/losses related to operational closures. We recorded a loss of $4.0 million related to the closure of operations and lease terminations in fiscal 2017. This amount is offset by the recovery of $1.3 million of certain losses that were recorded related to the closure of an operation in 2016. In fiscal 2016, we recorded $7.9 million of losses related to the closure of operations and a gain on the sale of three urgent care centers of $19.2 million.

Rent — Cost of Services. Our rent — cost of services as a percentage of total revenue decreased by 0.4% to 7.1% in fiscal 2017 primarily due to the acquisition of real estate of fifteen assisted living operations in the fourth quarter of 2016 that were

Table of Contents

previously operated under long-term leases, partially offset by the additional rent expense as a result of the sale-leaseback transaction and new leases for newly opened and acquired operations.

General and Administrative Expense. Our general and administrative expense rate increased by 0.2% to 4.4%, mainly due to the additional bonus accrual related to the Tax Cut. Without the bonus accrual, general and administration expense as a percentage of revenue would have been 4.2%, which is consistent with prior year.

Depreciation and Amortization. Depreciation and amortization expense increased $5.8 million, or 15.0%, to $44.5 million. This increase was primarily related to the additional depreciation and amortization incurred as a result of our newly acquired operations. Of the depreciation and amortization at Recently Acquired Facilities for the year ended December 31, 2017, $0.7 million represented amortization expense of patient base intangible assets which are amortized over four to eight months. Depreciation and amortization expense increased as a percentage of revenue by 0.1% to 2.4%.

Other Expense, net. Other expense, net increased $6.0 million to $12.0 million. Other expense as a percentage of revenue increased by 0.3% to 0.6% due to interest expense incurred related to additional borrowings under our credit facility.

Provision for Income Taxes. Our effective tax rate was 41.1% for the year ended December 31, 2017 compared to 38.4% for the same period in 2016. The higher effective tax rate reflects the impact of the Tax Act from our revaluation of our net deferred tax assets of $3.9 million and increases in certain non-taxable and non-deductible items, offset by a tax benefit from share-based payment awards recorded in income tax expense resulting from our adoption of ASU 2016-09, Improvements to Employee Share-Based Payment Accounting: Topic 710, effective January 1, 2017. See Note 2 and Note 14 in the Notes to the Consolidated Financial Statements for further discussion.

Year Ended December 31, 2016 Compared to the Year Ended December 31, 2015

Revenue



	Year Ended December 31,
	2016				2015
	Revenue Dollars		Revenue Percentage		Revenue Dollars		Revenue Percentage
	(Dollars in thousands)
Transitional and skilled services	$	1,374,803	83.1	%	$	1,126,388	83.9	%
Assisted and independent living services	123,636		7.5		88,129		6.6
Home health and hospice services:
Home health	60,326		3.6		47,955		3.6
Hospice	55,487		3.4		42,401		3.2
Total home health and hospice services	115,813		7.0		90,356		6.8
All other (1)	40,612		2.4		36,953		2.7
Total revenue	$	1,654,864	100.0	%	$	1,341,826	100.0	%

(1) Includes revenue from services generated in our other ancillary services and our urgent care centers for the years ended December 31, 2016 and 2015.

Our consolidated revenue increased $313.0 million, or 23.3%. Our transitional and skilled services revenue increased by $248.4 million, or 22.1%, mainly attributable to the increase in patient days, revenue per patient day and the impacts of acquisitions. Our assisted and independent living services increased by $35.5 million, or 40.3%, mainly due to the increase in occupancy and average monthly revenue per unit compared to the prior year period. Our home health and hospice services revenue increased by $25.5 million, or 28.2%, mainly due to an increase in volume and average daily census in existing agencies combined with acquisitions. Revenue from acquisitions increased consolidated revenue by $271.4 million in 2016 when comparing to 2015.

Transitional and Skilled Services

Table of Contents

The following table presents the transitional and skilled services revenue and key performance metrics by category in fiscal 2016 and 2015:



	Year Ended December 31,
	2016			2015
	(Dollars in thousands)						Change		% Change
Total Facility Results:
Transitional and skilled revenue	$	1,374,803		$	1,126,388		$	248,415	22.1	%
Number of facilities at period end	149			131			18		13.7	%
Number of campuses at period end*	21			15			6		40.0	%
Actual patient days	4,620,735			3,873,409			747,326		19.3	%
Occupancy percentage — Operational beds	75.4		%	77.6		%			(2.2	)%
Skilled mix by nursing days	30.9		%	30.4		%			0.5	%
Skilled mix by nursing revenue	52.5		%	52.6		%			(0.1	)%



	Year Ended December 31,
	2016			2015
	(Dollars in thousands)						Change			% Change
Same Facility Results(1):
Transitional and skilled revenue	$	898,385		$	871,450		$	26,935		3.1	%
Number of facilities at period end	85			85			—			—	%
Number of campuses at period end*	12			12			—			—	%
Actual patient days	2,930,232			2,964,185			(33,953		)	(1.1	)%
Occupancy percentage — Operational beds	78.4		%	79.9		%				(1.5	)%
Skilled mix by nursing days	30.1		%	30.2		%				(0.1	)%
Skilled mix by nursing revenue	51.3		%	52.5		%				(1.2	)%



	Year Ended December 31,
	2016			2015
	(Dollars in thousands)						Change		% Change
Transitioning Facility Results(2):
Transitional and skilled revenue	$	173,559		$	164,128		$	9,431	5.7	%
Number of facilities at period end	23			23			—		—	%
Actual patient days	578,178			569,801			8,377		1.5	%
Occupancy percentage — Operational beds	72.9		%	71.8		%			1.1	%
Skilled mix by nursing days	33.4		%	32.2		%			1.2	%
Skilled mix by nursing revenue	55.4		%	54.7		%			0.7	%



	Year Ended December 31,
	2016			2015
	(Dollars in thousands)						Change		% Change
Recently Acquired Facility Results(3):
Transitional and skilled revenue	$	302,237		$	83,693		$	218,544	NM
Number of facilities at period end	41			22			19		NM
Number of campuses at period end*	9			3			6		NM
Actual patient days	1,109,081			303,686			805,395		NM
Occupancy percentage — Operational beds	69.7		%	69.1		%			NM
Skilled mix by nursing days	31.7		%	30.9		%			NM
Skilled mix by nursing revenue	54.4		%	51.3		%			NM

Table of Contents



	Year Ended December 31,
	2016			2015
	(Dollars in thousands)						Change			% Change
Facility Closed Results(4):
Skilled nursing revenue	$	622		$	7,117		$	(6,495	)	NM
Actual patient days	3,244			35,737			(32,493		)	NM
Occupancy percentage — Operational beds	70.7		%	71.5		%				NM
Skilled mix by nursing days	9.6		%	12.7		%				NM
Skilled mix by nursing revenue	14.9		%	26.9		%				NM

__________________


(1)	Same Facility results represent all facilities purchased prior to January 1, 2013.


(2)	Transitioning Facility results represents all facilities purchased from January 1, 2013 to December 31, 2014.


(3)	Recently Acquired Facility (Acquisitions) results represent all facilities purchased on or subsequent to January 1, 2015.


(4)	Facility Closed represents the result of one facility closed during the first quarter of 2016. These results were excluded from Same Facility results for the year ended December 31, 2015 for comparison purposes.

Transitional and skilled services revenue increased $248.4 million, or 22.1%. Of the $248.4 million increase, Medicare and managed care revenue increased $117.2 million, or 22.2%, Medicaid custodial revenue increased $90.7 million, or 21.1%, private and other revenue increased $24.9 million, or 25.7%, and Medicaid skilled revenue increased $15.6 million, or 21.7%.

Transitional and skilled services revenue generated by Same Facilities increased $26.9 million, or 3.1%, on a comparable basis. The following is a description of notable comparable revenue changes:

•

Our Medicaid revenue, including Medicaid skilled revenue, increased by $24.5 million, or 6.2%, which was driven by a 6.6% increase in Medicaid revenue per patient day driven by our participation in quality improvement and the supplemental programs, coupled with the add-on to the reimbursement rate in California. These increases in revenue per patient day are partially offset by a 0.7% decrease in Medicaid days.


•	Our managed care revenue increased by $8.2 million, or 5.9%, as a result of a 4.7% increase in managed care days as well as a 1.2% increase in managed care revenue per patient day.


•	Our Medicare revenue decreased by $11.6 million, or 4.4%, primarily due to a 9.8% decrease in Medicare days, partially offset by a 3.8% increase in Medicare revenue per patient day.

Transitional and skilled services revenue generated by Transitioning Facilities increased $9.4 million, or 5.7%. This is due to increases in total patient days of 1.5%, consisting of a 7.6% increase in managed care days, a 2.0% increase in Medicaid days and a 1.7% increase in Medicare days from the prior year. Revenue per patient day increased by 4.1%, consisting of a 2.0% increase in Medicare, a 5.5% increase in Medicaid and a 1.7% increase in managed care revenue per patient day.

Transitional and skilled services revenue generated by Recently Acquired Facilities increased by approximately $218.5 million. Between January 1, 2015 and December 31, 2016, we have acquired 50 facilities in eight states.

Historically, we have generally experienced lower occupancy rates, lower skilled mix and quality mix at Recently Acquired Facilities and therefore, we anticipate generally lower overall occupancy during years of growth for our turnaround acquisitions. In the future, if we acquire additional turnaround operations into our overall portfolio, we expect this trend to continue. Accordingly, we anticipate our overall occupancy will vary from quarter to quarter based upon the maturity of the facilities within our portfolio. In 2016, our metrics for Recently Acquired Facilities include strategic acquisitions that have higher occupancy rates, higher skilled mix days and skilled mix revenue.

The following table reflects the change in the skilled nursing average daily revenue rates by payor source, excluding services that are not covered by the daily rate:

Table of Contents



	Year Ended December 31,
	Same Facility				Transitioning				Acquisitions				Total
	2016		2015		2016		2015		2016		2015		2016		2015
Skilled Nursing Average Daily Revenue Rates:
Medicare	$	586.51	$	565.20	$	566.32	$	555.33	$	491.49	$	475.51	$	556.89	$	555.50
Managed care	424.70		419.83		468.01		460.21		409.95		414.14		428.53		427.16
Other skilled	469.31		456.62		351.10		330.83		386.66		431.42		441.86		436.41
Total skilled revenue	506.09		497.24		486.30		478.11		452.55		449.07		490.18		490.07
Medicaid	208.41		195.44		195.57		185.31		174.45		188.54		198.92		193.04
Private and other payors	204.33		190.12		198.11		199.83		182.50		198.94		197.87		192.04
Total skilled nursing revenue	$	297.83	$	285.92	$	292.88	$	281.25	$	263.74	$	270.38	$	288.93	$	283.31

Medicare daily rates at Same Facilities and Transitioning Facilities increased by 3.8%. The increase was attributable to a 2.4% net market basket increase, which went into effect in October 2016, compared to a net market basket increase of 1.2%, which went into effect in October 2015. In addition, the increase in Medicare daily rates was impacted by the continuous shift towards higher acuity patients.

The average Medicaid rates increased 3.0% primarily due to increases in rates in various states, supplemental Medicaid payments received from the supplemental payment programs in various states, the quality improvement program and the add-on to the reimbursement rate in California.



	Year Ended December 31,
	Same Facility				Transitioning				Acquisitions				Total
	2016		2015		2016		2015		2016		2015		2016		2015
Percentage of Skilled Nursing Revenue:
Medicare	27.2	%	29.6	%	23.4	%	23.9	%	32.2	%	29.1	%	27.8	%	28.6	%
Managed care	16.1		15.7		26.1		25.6		18.5		16.5		17.9		17.2
Other skilled	8.0		7.2		5.9		5.2		3.7		5.7		6.8		6.8
Skilled mix	51.3		52.5		55.4		54.7		54.4		51.3		52.5		52.6
Private and other payors	8.3		8.0		7.2		8.3		9.7		9.8		8.5		8.2
Quality mix	59.6		60.5		62.6		63.0		64.1		61.1		61.0		60.8
Medicaid	40.4		39.5		37.4		37.0		35.9		38.9		39.0		39.2
Total skilled nursing	100.0	%	100.0	%	100.0	%	100.0	%	100.0	%	100.0	%	100.0	%	100.0	%

Table of Contents



	Year Ended December 31,
	Same Facility				Transitioning				Acquisitions				Total
	2016		2015		2016		2015		2016		2015		2016		2015
Percentage of Skilled Nursing Days:
Medicare	13.7	%	14.9	%	12.1	%	12.1	%	17.3	%	16.6	%	14.4	%	14.6	%
Managed care	11.3		10.7		16.3		15.6		11.9		10.7		12.0		11.4
Other skilled	5.1		4.6		5.0		4.5		2.5		3.6		4.5		4.4
Skilled mix	30.1		30.2		33.4		32.2		31.7		30.9		30.9		30.4
Private and other payors	12.3		12.0		10.6		11.7		14.0		13.3		12.5		12.1
Quality mix	42.4		42.2		44.0		43.9		45.7		44.2		43.4		42.5
Medicaid	57.6		57.8		56.0		56.1		54.3		55.8		56.6		57.5
Total skilled nursing	100.0	%	100.0	%	100.0	%	100.0	%	100.0	%	100.0	%	100.0	%	100.0	%

Assisted and Independent Living Services



	Year Ended December 31,
	2016			2015
	(Dollars in thousands)						Change		% Change
Revenue	$	123,636		$	88,129		$	35,507	40.3	%
Number of facilities at period end	40			40			—		—	%
Number of campuses at period end	21			15			6		40.0	%
Occupancy percentage (units)	76.0		%	75.3		%			0.7	%
Average monthly revenue per unit	$	2,746		$	2,644		$	102	3.9	%

Assisted and independent living revenue increased $35.5 million, or 40.3%. The increase in revenue is primarily due to the increase in average monthly revenue per unit of 3.9% and occupancy of 0.7%, coupled with the addition of 14 assisted and independent living operations in four states between January 1, 2015 and December 31, 2016.

Home Health and Hospice Services



	Year Ended December 31,
	2016		2015		Change		% Change
	(Dollars in thousands)
Home health and hospice revenue
Home health services	$	60,326	$	47,955	$	12,371	25.8	%
Hospice services	55,487		42,401		13,086		30.9
Total home health and hospice revenue	$	115,813	$	90,356	$	25,457	28.2	%
Home health services:
Average Medicare Revenue per Completed Episode	$	2,986	$	2,929	$	57	1.9	%
Hospice services:
Average Daily Census	905		679		226		33.3	%

Home health and hospice revenue increased $25.5 million, or 28.2%. Of the $25.5 million increase, Medicare and managed care revenue increased $23.1 million, or 30.7%. The increase in revenue is primarily due to the increase in volume, average daily census and average Medicare revenue per completed episode in existing agencies, coupled with the addition of eight home health, hospice and home care operations in seven states between January 1, 2015 and December 31, 2016.

Cost of Services

The following table sets forth our total cost of services by each of our reportable segments and our "All Other" category for the periods indicated (dollars in thousands):

Table of Contents



	Cost of Services
	Transitional and Skilled Services		Assisted and Independent Living Services		Home Health and Hospice		All Other		Total
Year Ended December 31, 2016	$	1,130,691	$	78,872	$	96,753	$	35,498	$	1,341,814
Year Ended December 31, 2015	$	902,352	$	57,396	$	74,557	$	33,389	$	1,067,694

Consolidated cost of services increased $274.1 million, or 25.7%, compared to fiscal year 2015 primarily due to acquisitions.

Transitional and Skilled Services



	Year Ended December 31,								%
	2016			2015			Change		Change
	(Dollars in thousands)
Cost of service dollars	$	1,130,691		$	902,352		$	228,339	25.3	%
Revenue percentage	82.2		%	80.1		%			2.1	%

Cost of services related to our transitional and skilled services segment increased $228.3 million, or 25.3%, due to additional costs at Recently Acquired Facilities of $188.8 million and organic operational growth. Cost of service as a percentage of revenue increased to 82.2%. The main components of the increase are start-up costs related to newly constructed post-acute care campuses, additional costs related to our new labor management system roll-out and increases in health, general and professional liability costs of $21.0 million from the change in claims experience. In addition, our provision for doubtful accounts increased by $8.0 million. Same Facilities cost of services increased due to an increase in health, general and professional liability costs of $12.5 million, partially offset by the decrease in worker compensation costs of $2.2 million.

Assisted and Independent Living Services



	Year Ended December 31,								%
	2016			2015			Change		Change
	(Dollars in thousands)
Cost of service dollars	$	78,872		$	57,396		$	21,476	37.4	%
Revenue percentage	63.8		%	65.1		%			(1.3	)%

Cost of services related to our assisted and independent living services segment increased $21.5 million, or 37.4%, primarily due to organic operational growth. The largest component of cost of services is labor expenses. Cost of services as a percentage of total revenue decreased by 1.3% as a result of reduction in labor costs.

Home Health and Hospice Services



	Year Ended December 31,								%
	2016			2015			Change		Change
	(Dollars in thousands)
Cost of service dollars	$	96,753		$	74,557		$	22,196	29.8	%
Revenue percentage	83.5		%	82.5		%			1.0	%

Cost of services related to our home health and hospice services segment increased $22.2 million, or 29.8% due to additional costs at agencies acquired during 2016 of $12.4 million and organic operational growth. Cost of services as a percentage of total revenue increased by 1.0% primarily due to costs related to start-up and transitioning operations. We have generally experienced higher costs due to the addition of resources at our newly acquired and start-up agencies.

Gain related to divestitures. We recorded a gain of $19.2 million relate to the sale of our urgent care centers in 2016. The gain is partially offset by the charges of $7.9 million related to the closure of one facility in February 2016. The charges represent the present value of rental payments of $6.5 million related to our continued obligation liability under the lease and related closing expenses. Similar charges and gains did not occur in 2015.

Table of Contents

Rent — Cost of Services. Rent — cost of services increased $35.8 million, or 40.3%, to $124.6 million. Rent - cost of service as a percentage of total revenue increased by 0.9% to 7.5%. The additional increase in rent was primarily due to new leases for newly opened and acquired operations.

General and Administrative Expense. General and administrative expense increased by $5.0 million, or 7.8%, to $69.2 million. The increase was primarily due to our operational growth during 2016, coupled with an increase in expenses incurred to acquire new operations and additional share-based compensation expense related to the new management subsidiary equity plan that was implemented in the second quarter of 2016, offset by a reduction in incentives. In addition, general and administrative expense as a percentage of revenue decreased as a percentage of revenue by 0.6% to 4.2%.

Depreciation and Amortization. Depreciation and amortization expense increased $10.6 million, or 37.6%, to $38.7 million. Depreciation and amortization expense increased as a percentage of total revenue by 0.2% to 2.3%. This increase was primarily related to the additional depreciation and amortization incurred as a result of our newly acquired operations of $6.2 million. Of the increase at Recently Acquired Facilities, $1.6 million represented amortization expense of patient base intangible assets which are amortized over four to eight months.

Other Expense, net. Other expense, net increased $4.0 million to $6.0 million. Other expense as a percentage of revenue increased by 0.2% to 0.3%. The increase is due to interest expense incurred related to additional borrowings under the credit facility.

Provision for Income Taxes. The provision for income taxes is based upon our annual reported income for each respective accounting period and includes the effect of certain non-taxable and non-deductible items. Our effective tax rate was 38.4% for the year ended December 31, 2016 compared to 38.6% for the same period in 2015. The effective tax rate was consistent with the prior year.

Liquidity and Capital Resources

Our primary sources of liquidity have historically been derived from our cash flows from operations and long-term debt secured by our real property and our revolving credit facilities.

Historically, we have financed the majority of our acquisitions primarily by financing our operating subsidiaries through mortgages, our revolving credit facility, and cash generated from operations. Cash paid for business acquisitions was $89.6 million, $64.3 million and $110.8 million for the years ended December 31, 2017, 2016 and 2015, respectively. Total capital expenditures for property and equipment were $57.2 million, $65.7 million and $60.0 million for the years ended December 31, 2017, 2016 and 2015, respectively. We currently have approximately $60.0 million budgeted for renovation projects for 2018. We believe our current cash balances, our cash flow from operations and the amounts available under our credit facility will be sufficient to cover our operating needs for at least the next 12 months.

We may, in the future, seek to raise additional capital to fund growth, capital renovations, operations and other business activities, but such additional capital may not be available on acceptable terms, on a timely basis, or at all.

Our cash and cash equivalents as of December 31, 2017 consisted of bank term deposits, money market funds and U.S. Treasury bill related investments. In addition, as of December 31, 2017, we held debt security investments of approximately $41.8 million, which were split between AA, A and BBB+ rated securities. Our market risk exposure is interest income sensitivity, which is affected by changes in the general level of U.S. interest rates. The primary objective of our investment activities is to preserve principal while at the same time maximizing the income we receive from our investments without significantly increasing risk. Due to the low risk profile of our investment portfolio, an immediate 10% change in interest rates would not have a material effect on the fair market value of our portfolio. Accordingly, we would not expect our operating results or cash flows to be affected to any significant degree by the effect of a sudden change in market interest rates on our securities portfolio.

The following table presents selected data from our consolidated statement of cash flows for the periods presented:

Table of Contents



	Year Ended December 31,
	2017			2016			2015
	(In thousands)
Net cash provided by operating activities	$	72,952		$	73,888		$	33,369
Net cash used in investing activities	(106,593		)	(210,636		)	(168,538		)
Net cash provided by financing activities	18,272			152,885			126,330
Net (decrease)/increase in cash and cash equivalents	(15,369		)	16,137			(8,839		)
Cash and cash equivalents at beginning of period	57,706			41,569			50,408
Cash and cash equivalents at end of period	$	42,337		$	57,706		$	41,569

Year Ended December 31, 2017 Compared to Year Ended December 31, 2016

Our net cash provided by operating activities for the year ended December 31, 2017 decreased by $0.9 million. The decrease was primarily due to the settlement of class action lawsuit of $11 million and timing of payments of other operating assets and liabilities such as prepaid income taxes and prepayment expenses to take advantage of the Tax Act, offset by various payments and collections. Operating activities for the year ended December 31, 2016 include the gain on sale of urgent care centers of $19.2 million. Similar gains did not occur in 2017.

Our net cash used in investing activities for the year ended December 31, 2017 decreased by $104.0 million. In fiscal 2016, we acquired the real estate of fifteen assisted living operations of $120.2 million. We also decreased our spending in capital expenditures by $8.5 million in fiscal 2017, coupled with cash proceeds we received from the sale-leaseback transaction of $38.0 million. These are partially offset by the increase business acquisitions of $25.3 million.

Our net cash provided by financing activities decreased by $134.6 million. This decrease was primarily due to the decrease in net long-term debt proceeds of $152.6 million during the year ended December 31, 2017 compared to December 31, 2016. This reduction is offset by a decrease in repurchases of common stock of $22.7 million when comparing the year ended December 31, 2017 to the year ended December 31, 2016.

Year Ended December 31, 2016 Compared to Year Ended December 31, 2015

Our net cash provided by operating activities for the year ended December 31, 2016 increased by $40.5 million. The increase was primarily due to the timing in accounts receivable collections and payments of the other operating assets and liabilities such as accounts payable and other accrued expenses. Operating activities for the year ended December 31, 2016 include the gain on sale of urgent care centers of $19.2 million. Similar gains did not occur in 2015.

Our net cash used in investing activities for the year ended December 31, 2016 increased by $42.1 million. The increase was primarily the result of the increase in purchases of business and asset acquisitions of $73.6 million, partially offset by the cash received from the sale of the urgent care centers of $40.7 million. In addition, capital expenditures increased by $5.7 million. The increase in capital expenditures in 2016 resulted from our continued investments in connection with constructing new facilities in existing and new markets and our continued investment in expanding and renovating our existing operations.

Our net cash provided by financing activities increased by $26.6 million. This increase was primarily due to the receipt of $510.0 million in borrowing proceeds from our amendment of the credit facilities during the year ended December 31, 2016, partially offset by an increase in long-term debt repayments of $345.1 million and by the repurchases of common stock of $30.0 million.

Principal Debt Obligations and Capital Expenditures

Total long-term debt obligations, net of debt discount, outstanding as of the end of each fiscal year were as follows:



	December 31,
	2013		2014		2015		2016		2017
	(In thousands)
Credit facilities and term loans	$	193,189	$	65,000	$	85,000	$	270,125	$	190,625
Mortgage loan and promissory notes	66,117		3,390		14,671		14,032		125,394
Total	$	259,306	$	68,390	$	99,671	$	284,157	$	316,019

Table of Contents

The following table represents our cumulative growth from 2010 to the present:



	December 31,
	2010	2011	2012	2013	2014	2015	2016	2017
Cumulative number of skilled nursing, assisted and independent living facilities	82	102	108	119	136	186	210	230
Cumulative number of home health, home care and hospice agencies	3	7	10	16	25	32	39	46

Credit Facility with a Lending Consortium Arranged by SunTrust

We maintain a credit facility with a lending consortium arranged by SunTrust (as amended to date, the Credit Facility). We originally entered into the Credit Facility in an aggregate principal amount of $150.0 million in May 2014. Under the Credit Facility, we could seek to obtain incremental revolving or term loans in an aggregate amount not to exceed $75.0 million. Loans made under the Credit Facility are not subject to interim amortization. We are not required to repay any loans under the Credit Facility prior to maturity, other than to the extent the outstanding borrowings exceed the aggregate commitments under the Credit Facility.

On February 5, 2016, we amended our existing revolving credit facility to increase our aggregate principal amount available to $250.0 million (the Amended Credit Facility). Under the Amended Credit Facility, we may seek to obtain incremental revolving or term loans in an aggregate amount not to exceed $150.0 million. The interest rates applicable to loans under the Amended Credit Facility are, at our option, equal to either a base rate plus a margin ranging from 0.75% to 1.75% per annum or LIBOR plus a margin ranging from 1.75% to 2.75% per annum, based on the Consolidated Total Net Debt to Consolidated EBITDA ratio (as defined in the agreement). In addition, we will pay a commitment fee on the unused portion of the commitments under the Amended Credit Facility that will range from 0.3% to 0.5% per annum, depending on the Consolidated Total Net Debt to Consolidated EBITDA ratio of the Company and our subsidiaries. We are permitted to prepay all or any portion of the loans under the Amended Credit Facility prior to maturity without premium or penalty, subject to reimbursement of any LIBOR breakage costs of the lenders.

On July 19, 2016, we entered into the second amendment to the credit facility (Second Amended Credit Facility), which amended the existing credit agreement to increase the aggregate principal amount up to $450.0 million. The Second Amended Credit Facility comprised of a $300.0 million revolving credit facility and a $150.0 million term loan. Borrowings under the term loan portion of the Second Amended Credit Facility will mature on February 5, 2021 and amortize in equal quarterly installments, in an aggregate annual amount equal to 5.0% per annum of the original principal amount. The interest rates and commitment fee applicable to the Second Amended Credit Facility are similar to the Amended Credit Facility discussed below. Except as set forth in the Second Amended Credit Facility, all other terms and conditions of the Amended Credit Facility remained in full force and effect as described below.

The Credit Facility is guaranteed, jointly and severally, by certain of our wholly owned subsidiaries, and is secured by a pledge of stock of our material operating subsidiaries as well as a first lien on substantially all of our personal property. The Credit Facility contains customary covenants that, among other things, restrict, subject to certain exceptions, the ability of the Company and our operating subsidiaries to grant liens on their assets, incur indebtedness, sell assets, make investments, engage in acquisitions, mergers or consolidations, amend certain material agreements and pay certain dividends and other restricted payments. Under the Credit Facility, we must comply with financial maintenance covenants to be tested quarterly, consisting of a maximum Consolidated Total Net Debt to Consolidated EBITDA ratio (which shall be increased to 3.50:1.00 for the first fiscal quarter and the immediate following three fiscal quarters), and a minimum interest/rent coverage ratio (which cannot be below 1.50:1.00). The majority of lenders can require that we and our operating subsidiaries mortgage certain of our real property assets to secure the credit facility if an event of default occurs, the Consolidated Total Net Debt to Consolidated EBITDA ratio is above 2.75:1.00 for two consecutive fiscal quarters, or our liquidity is equal or less than 10% of the Aggregate Revolving Commitment Amount (as defined in the agreement) for ten consecutive business days, provided that such mortgages will no longer be required if the event of default is cured, the Consolidated Total Net Debt to Consolidated EBITDA ratio is below 2.75:1.00 for two consecutive fiscal quarters, or our liquidity is above 10% of the Aggregate Revolving Commitment Amount (as defined in the agreement) or ninety consecutive days, as applicable. As of December 31, 2017, our operating subsidiaries had $190.6 million outstanding under the Credit Facility. The outstanding balance on the on the term loan was $140.6 million, of which $7.5 million is classified as short-term and the remaining $133.1 million is classified as long-term. The outstanding balance on the revolving Credit Facility was $50.0 million, which is classified as long-term. We were in compliance with all loan covenants as of December 31, 2017.

Table of Contents

As of February 2, 2018, there was approximately $195.6 million outstanding under the Credit Facility.

Mortgage Loans and Promissory Note

During the fourth quarter of 2017, seventeen of our subsidiaries entered into mortgage loans in the aggregate amount of $112.0 million. The mortgage loans are insured with Department of Housing and Urban Development (HUD), which subjects these subsidiaries to HUD oversight and periodic inspections. The mortgage loans and note bear fixed interest rates of 3.3% per annum. Amounts borrowed under the mortgage loans may be prepaid, subject to prepayment fees of the principal balance on the date of prepayment. During the first three years, the prepayment fee is 10% and is reduced by 3% in the fourth year of the loan, and reduced by 1.0% per year for years five through ten of the loan. There is no prepayment penalty after year ten. The term of the mortgage loans are 30 to 35-years. The borrowings were arranged by Lancaster Pollard Mortgage Company, LLC, and insured by HUD. Loan proceeds were used to pay down previously drawn amounts on our revolving line of credit. In addition to refinancing existing borrowings, the proceeds of the HUD-insured debt helped used to fund acquisitions, to renovate and upgrade existing and future facilities, to cover working capital needs and for other business purposes.

In addition to the HUD mortgage loans above, we have outstanding indebtedness under mortgage loans insured with HUD and promissory note issued in connection with various acquisitions. These mortgage loans and note bear fixed interest rates between 2.6% and 5.3% per annum. Amounts borrowed under the mortgage loans may be prepaid starting after the second anniversary of the notes subject to prepayment fees of the principal balance on the date of prepayment. These prepayment fees are reduced by 1.0% per year for years three through eleven of the loan. There is no prepayment penalty after year eleven. The terms of the mortgage loans and note are between 12 and 33 years. The mortgage loans and note are secured by the real property comprising the facilities and the rents, issues and profits thereof, as well as all personal property used in the operation of the facilities.

As of December 31, 2017, our operating subsidiaries had $125.4 million outstanding under the mortgage loans and note, of which $2.4 million is classified as short-term and the remaining $123.0 million is classified as long-term.

Contractual Obligations, Commitments and Contingencies

The following table sets forth our principal contractual obligations and commitments as of December 31, 2017, including the future periods in which payments are expected:



	2018		2019		2020		2021		2022		Thereafter		Total
					(In thousands)
Operating lease obligations	$	135,841	$	135,395	$	135,149	$	134,942	$	133,446	$	1,080,348	$	1,755,121
Long-term debt obligations	$	9,939	$	10,106	$	10,203	$	170,926	$	2,904	$	111,941	$	316,019
Interest payments on long-term debt	$	9,397	$	9,159	$	8,783	$	4,328	$	3,837	$	59,982	$	95,486
Total	$	155,177	$	154,660	$	154,135	$	310,196	$	140,187	$	1,252,271	$	2,166,626

Not included in the table above are our actuarially determined self-insured general and professional malpractice liability, workers' compensation and medical (including prescription drugs) and dental healthcare obligations which are broken out between current and long-term liabilities in our financial statements included in this Annual Report.

We lease from CareTrust REIT, Inc. (CareTrust) real property associated with 92 affiliated skilled nursing, assisted living and independent living facilities used in our operations under the Master Leases as a result of the tax free spin-off (Spin-Off). The Master Leases consist of multiple leases, each with its own pool of properties, that have varying maturities and diversity in property geography. Under each master lease, our individual subsidiaries that operate those properties are the tenants and CareTrust's individual subsidiaries that own the properties subject to the Master Leases are the landlords. The rent structure under the Master Leases includes a fixed component, subject to annual escalation equal to the lesser of the percentage change in the Consumer Price Index (but not less than zero) or 2.5%.

We do not have the ability to terminate the obligations under a Master Lease prior to its expiration without CareTrust’s consent. If a Master Lease is terminated prior to its expiration other than with CareTrust’s consent, we may be liable for damages and incur charges such as continued payment of rent through the end of the lease term and as well as maintenance and repair costs for the leased property.

The Master Leases arrangement is commonly known as a triple-net lease. Accordingly, in addition to rent, we are required to pay the following: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income

Table of Contents

of the lessor), (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties, (3) all insurance required in connection with the leased properties and the business conducted on the leased properties, (4) all facility maintenance and repair costs and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. Total rent expense under the Master Leases was approximately $57.2 million, $56.3 million and $56.0 million for the years ended December 31, 2017, 2016 and 2015, respectively.

At our option, the Master Leases may be extended for two or three five-year renewal terms beyond the initial term, on the same terms and conditions. If we elect to renew the term of a Master Lease, the renewal will be effective as to all, but not less than all, of the leased property then subject to the Master Lease.

Among other things, under the Master Leases, we must maintain compliance with specified financial covenants measured on a quarterly basis, including a portfolio coverage ratio and a minimum rent coverage ratio. The Master Leases also include certain reporting, legal and authorization requirements. As of December 31, 2017, we were in compliance with the Master Leases' covenants.

We also lease certain affiliated facilities and our administrative offices under non-cancelable operating leases, most of which have initial lease terms ranging from five to 20 years. We have entered into multiple lease agreements with various landlords to operate newly constructed state-of-the-art, full-service healthcare resorts upon completion of construction. The term of each lease is 15 years with two five-year renewal options and is subject to annual escalation equal to the percentage change in the Consumer Price Index with a stated cap percentage. In addition, we lease certain of our equipment under non-cancelable operating leases with initial terms ranging from three to five years. Most of these leases contain renewal options, certain of which involve rent increases. Total rent expense, inclusive of straight-line rent adjustments and rent associated with the Master Leases noted above, was $132.9 million, $125.2 million and $89.3 million for the years ended December 31, 2017, 2016 and 2015, respectively.

Twenty-five of our affiliated facilities, excluding the facilities that are operated under the Master Leases from CareTrust, are operated under six separate master lease arrangements. Under these master leases, a breach at a single facility could subject one or more of the other affiliated facilities covered by the same master lease to the same default risk. Failure to comply with Medicare and Medicaid provider requirements is a default under several of our leases, master lease agreements and debt financing instruments. In addition, other potential defaults related to an individual facility may cause a default of an entire master lease portfolio and could trigger cross-default provisions in our outstanding debt arrangements and other leases. With an indivisible lease, it is difficult to restructure the composition of the portfolio or economic terms of the lease without the consent of the landlord.

In March 2017, we voluntarily discontinued operations at one of our skilled nursing facilities after determining that the facility could not competitively operate in the marketplace without substantial investment renovating the building. After careful consideration, we determined that the costs to renovate the facility could outweigh the future returns from the operation. As part of this closure, we entered into an agreement with our landlord allowing for the closure of the property as well as other provisions to allow our landlord to transfer the property and the licenses free and clear of the applicable master lease. This arrangement does not impact the rent expense paid in 2017, or expected to be paid in future periods, and has no material impact on our lease coverage ratios under the Master Leases. We recorded a continued obligation liability under the lease and related closing expenses of $2.8 million, including the present value of rental payments of approximately $2.7 million. Residents of the affected facility were transferred to local skilled nursing facilities.

During the first quarter of 2016, we voluntarily discontinued operations in one of our skilled nursing facilities in order to preserve the overall ability to serve the residents in surrounding counties after careful consideration and some clinical survey challenges. As part of this closure, we entered into an agreement with our landlord allowing for the closure of the property as well as other provisions to allow our landlord to transfer the property and the licenses free and clear of the applicable master lease. This arrangement does not impact the rental payments and has no material impact on our lease coverage ratios under the Master Leases. We recorded a continued obligation liability under the lease and related closing expenses of $7.9 million, including the present value of rental payments of approximately $6.5 million, which was recognized in 2016. During fiscal 2017, we recovered $1.3 million of certain losses that were recorded in 2016 related to the closure of the operation. The loss recovery was recorded as a gain in the second quarter of 2017.

In March 2017, we entered into definitive agreements to sell the properties of two skilled nursing facilities and one assisted living community. The transaction closed in the second quarter of 2017. Upon closing the transaction, we leased the properties under a triple-net master lease with an initial 20-year term, with three 5-year optional extensions, at CPI-based annual escalators. We received $38.0 million in proceeds. The carrying value for the sale was $24.8 million. Under applicable accounting guidance, the master lease was classified as an operating lease. We recognized a deferred gain on the transaction of $13.2 million in the second quarter of 2017 that is amortized over the life of the lease.

Table of Contents

During the first quarter of 2017, we terminated our lease obligations on four transitional care facilities that are currently under development and one newly constructed stand-alone skilled nursing operation. We recorded $1.2 million in lease termination costs and long-lived asset impairment.

Class Action Lawsuit

In March 2017, we were invited to engage in further mediation discussions to determine whether settlement in advance of a determination on class certification was possible. In April 2017, we reached an agreement in principle to settle the subject class action litigation, without any admission of liability and subject to approval by the California Superior Court. Based upon the recent change in case status, we recorded an accrual for estimated probable losses of $11.0 million in the first quarter of 2017. In December 2017, we settled this class action lawsuit and the settlement was approved by the Court. We made a lump-sum payment in the amount of $11.0 million in December 2017.

U.S. Government Inquiry

In late 2006, we learned that we might be the subject of an on-going criminal and civil investigation by the DOJ. This was confirmed in March 2007. The investigation was prompted by a whistleblower complaint and related primarily to claims submitted to the Medicare program for rehabilitation services provided at skilled nursing facilities in Southern California. We resolved and settled the matter for $48.0 million in 2013. In October 2013, we and the government executed a final settlement agreement in accordance with the April 2013 agreement and we remitted full payment of $48.0 million. In addition, we executed a five-year corporate integrity agreement with the Office of Inspector General HHS as part of the resolution.

See additional description of our contingencies in Notes 15, Debt, 17, Leases and 19, Commitments and Contingencies in Notes to Consolidated Financial Statements.

Inflation

We have historically derived a substantial portion of our revenue from the Medicare program. We also derive revenue from state Medicaid and similar reimbursement programs. Payments under these programs generally provide for reimbursement levels that are adjusted for inflation annually based upon the state’s fiscal year for the Medicaid programs and in each October for the Medicare program. These adjustments may not continue in the future, and even if received, such adjustments may not reflect the actual increase in our costs for providing healthcare services.

Labor and supply expenses make up a substantial portion of our cost of services. Those expenses can be subject to increase in periods of rising inflation and when labor shortages occur in the marketplace. To date, we have generally been able to implement cost control measures or obtain increases in reimbursement sufficient to offset increases in these expenses. We may not be successful in offsetting future cost increases.

Off-Balance Sheet Arrangements

During the year ended December 31, 2017, we increased the letters of credit by $4.0 million. As of December 31, 2017, we had approximately $6.3 million on our credit facility of borrowing capacity pledged as collateral to secure outstanding letters of credit.

Item 7A. Quantitative and Qualitative Disclosures about Market Risk

Interest Rate Risk. We are exposed to risks associated with market changes in interest rates. Our credit facility exposes us to variability in interest payments due to changes in LIBOR interest rates. We manage our exposure to this market risk by monitoring available financing alternatives. Our mortgages and promissory notes require principal and interest payments through maturity pursuant to amortization schedules.

Our mortgages generally contain provisions that allow us to make repayments earlier than the stated maturity date. In some cases, we are not allowed to make early repayment prior to a cutoff date. Where prepayment is permitted, we are generally allowed to make prepayments only at a premium which is often designed to preserve a stated yield to the note holder. These prepayment rights may afford us opportunities to mitigate the risk of refinancing our debts at maturity at higher rates by refinancing prior to maturity.

Table of Contents

On July 19, 2016, we entered into the Second Amended Credit Facility with a lending consortium arranged by SunTrust to make available a credit facility consisting of a $300.0 million revolving line of credit and a $150.0 million term loan component. Borrowings under the term loan portion of the credit facility mature on February 5, 2021 and amortize in equal quarterly installments, in an aggregate annual amount equal to 5.0% per annum of the original principal amount. The interest rates, at our option, are equal to either a base rate plus a premium or LIBOR plus a premium. In addition, we are subject to pay a commitment fee on the unused portion of the commitments under the credit facility discussed in Item 7 of this Annual Report under the heading “Liquidity and Capital Resources.” Our exposure to fluctuations in interest rates may increase or decrease in the future with increases or decreases in the outstanding amount under the credit facility. As of December 31, 2017, our operating subsidiaries had $190.6 million outstanding under the credit facility. The outstanding balance on the on the term loan was $140.6 million, of which $7.5 million is classified as short-term and the remaining $133.1 million is classified as long-term. The outstanding balance on the revolving credit facility was $50.0 million, which is classified as long-term.

Our cash and cash equivalents as of December 31, 2017 consisted of bank term deposits, money market funds and U.S. Treasury bill related investments. In addition, as of December 31, 2017, we held debt security investments of approximately $41.8 million, which were split between AA, A, and BBB+ rated securities. Our market risk exposure is interest income sensitivity, which is affected by changes in the general level of U.S. interest rates. The primary objective of our investment activities is to preserve principal while at the same time maximizing the income we receive from our investments without significantly increasing risk. Due to the low risk profile of our investment portfolio, an immediate 10% change in interest rates would not have a material effect on the fair market value of our portfolio. Accordingly, we would not expect our operating results or cash flows to be affected to any significant degree by the effect of a sudden change in market interest rates on our securities portfolio.

The above only incorporates those exposures that exist as of December 31, 2017 and does not consider those exposures or positions which could arise after that date. If we diversify our investment portfolio into securities and other investment alternatives, we may face increased risk and exposures as a result of interest risk and the securities markets in general.

Item 8. Financial Statements and Supplementary Data

Quarterly Financial Data (Unaudited)

The following table presents our unaudited quarterly consolidated results of operations for each of the eight quarters in the two-year period ended December 31, 2017. The unaudited quarterly consolidated information has been derived from our unaudited quarterly financial statements on Forms 10-Q, which were prepared on the same basis as our audited consolidated financial statements. You should read the following table presenting our quarterly consolidated results of operations in conjunction with our audited consolidated financial statements and the related notes included elsewhere in this Annual Report on Form 10-K. The operating results for any quarter are not necessarily indicative of the operating results for any future period.



	Dec. 31,		Sept. 30,		June 30,		Mar. 31,		Dec. 31,		Sept. 30,		June 30,		Mar. 31,
	2017		2017		2017		2017		2016		2016		2016		2016
	(In thousands, except per share data)
Revenue	$	487,705	$	471,594	$	448,279	$	441,739	$	433,048	$	428,065	$	410,517	$	383,234
Cost of services	393,727		381,544		366,946		355,486		355,997		348,971		330,538		306,308
Total expenses	461,562		446,035		426,248		434,187		397,365		408,025		390,708		366,919
Income from operations	26,143		25,559		22,031		7,552		35,683		20,040		19,809		16,315
Net income	$	11,222	$	14,275	$	12,380	$	2,956	$	21,006	$	11,184	$	11,363	$	9,290
Income attributable to noncontrolling interests	16		63		163		116		2,669		29		37		118
Net income attributable to The Ensign Group, Inc.	$	11,206	$	14,212	$	12,217	$	2,840	$	18,337	$	11,155	$	11,326	$	9,172
Net income per share attributable to The Ensign Group, Inc.
Basic	$	0.22	$	0.28	$	0.24	$	0.06	$	0.36	$	0.22	$	0.23	$	0.18
Diluted	$	0.21	$	0.27	$	0.23	$	0.05	$	0.35	$	0.21	$	0.22	$	0.18
Weighted average common shares outstanding:
Basic	51,250		50,911		50,705		50,767		50,724		50,541		50,274		50,679
Diluted	53,176		52,828		52,548		52,633		52,231		52,045		51,931		52,334

(

100

Table of Contents

The additional information required by this Item 8 is incorporated herein by reference to the financial statements set forth in Item 15 of this report, Exhibits, Financial Statements and Schedules.

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosures

None.

Item 9A. Controls and Procedures

(a) Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures

The Company maintains disclosure controls and procedures that are designed to ensure that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms. In designing and evaluating our disclosure controls and procedures, our management recognized that any system of controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, as ours are designed to do, and management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

In connection with the preparation of this Annual Report on Form 10-K our management evaluated, with the participation of our Chief Executive Officer and our Chief Financial Officer, the effectiveness of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) promulgated under the Exchange Act, and to ensure that information required to be disclosed is accumulated and communicated to our management, including our principal executive and financial officers, as appropriate to allow timely decisions regarding required disclosure. Based on this evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of the end of the period covered by this Annual Report on Form 10-K.

(b) Management's Report on Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rule 13a-15(f) promulgated under the Exchange Act. Internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our internal control over financial reporting using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control - Integrated Framework (2013). Based on our evaluation, our management concluded that our internal control over financial reporting was effective as of the end of the period covered by this Annual Report on Form 10-K.

Our independent registered public accounting firm, Deloitte & Touche LLP, has audited the consolidated financial statements included in this Annual Report on Form 10-K and, as part of their audit, has issued an audit report, included herein, on the effectiveness of our internal control over financial reporting. Their report is set forth below.

There were no changes in our internal control over financial reporting, as defined in Rule 13a-15(f) promulgated under the Exchange Act, that occurred during the fourth quarter of fiscal 2017 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

(d) Report of Independent Registered Accounting Firm

To the shareholders and the Board of Directors of

The Ensign Group, Inc.

Mission Viejo, California

101

Table of Contents

Opinion on Internal Control over Financial Reporting

We have audited the internal control over financial reporting of The Ensign Group, Inc. and subsidiaries (the “Company”) as of December 31, 2017, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2017, based on criteria established in Internal Control - Integrated Framework (2013) issued by COSO.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial statements as of and for the year ended December 31, 2017, of the Company and our report dated February 8, 2018, expressed an unqualified opinion on those financial statements.

Basis for Opinion

The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management’s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

Definition and Limitations of Internal Control over Financial Reporting

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ DELOITTE & TOUCHE LLP

Costa Mesa, California February 8, 2018

102

Table of Contents

Item 9B. Other Information

None.

PART III.

Item 10. Directors, Executive Officers and Corporate Governance

The information required by this Item is hereby incorporated by reference to our definitive proxy statement for the 2018 Annual Meeting of Stockholders.

We have adopted a code of ethics and business conduct that applies to all employees, including employees of our subsidiaries, as well as each member of our Board of Directors. The code of ethics and business conduct is available at our website at www.ensigngroup.net under the Investor Relations section. We intend to satisfy any disclosure requirement under Item 5.05 of Form 8-K regarding an amendment to, or waiver from, a provision of the code of ethics by posting such information on our website, at the address specified above.

Item 11. Executive Compensation

The information required by this Item is hereby incorporated by reference to our definitive proxy statement for the 2018 Annual Meeting of Stockholders.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

The information required by this Item is hereby incorporated by reference to our definitive proxy statement for the 2018 Annual Meeting of Stockholders.

Item 13. Certain Relationships and Related Transactions, and Director Independence

The information required by this Item is hereby incorporated by reference to our definitive proxy statement for the 2018 Annual Meeting of Stockholders.

Item 14. Principal Accountant Fees and Services

The information required by this Item is hereby incorporated by reference to our definitive proxy statement for the 2018 Annual Meeting of Stockholders.

PART IV.

Item 15. Exhibits, Financial Statements and Schedules

The following documents are filed as a part of this report:

(a) (1) Financial Statements:

The Financial Statements described in Part II. Item 8 and beginning on page 113 are filed as part of this report.

(a) (2) Financial Statement Schedule:

Schedule II: Valuation and Qualifying Accounts, immediately following the financial statements included in this Annual Report.

(a) (3) Exhibits: The following exhibits are filed with this Report or incorporated by reference:

103

Table of Contents



Exhibit				File	Exhibit	Filing	Filed
No.		Exhibit Description*	Form	No.	No.	Date	Herewith
2.1		Separation and Distribution Agreement, dated as of May 23, 2014, by and between The Ensign Group, Inc. and CareTrust REIT, Inc.	8-K	001-33757	2.1	6/5/2014
3.1		Fifth Amended and Restated Certificate of Incorporation of The Ensign Group, Inc., filed with the Delaware Secretary of State on November 15, 2007	10-Q	001-33757	3.1	12/21/2007
3.2		Amendment to the Amended and Restated Bylaws, dated August 5, 2014	8-K	001-33757	3.2	8/8/2014
3.3		Amended and Restated Bylaws of The Ensign Group, Inc.	10-Q	001-33757	3.2	12/21/2007
3.4		Certificate of Designation, Preferences and Rights of Series A Junior Participating Preferred Stock, as filed with the Secretary of State of the State of Delaware on November 7, 2013	8-K	001-33757	3.1	11/7/2013
3.5		Certificate of Elimination of Series A Junior Participating Preferred Stock	8-K	001-33757	3.1	6/5/2014
4.1		Specimen common stock certificate	S-1	333-142897	4.1	10/5/2007
10.1	+	The Ensign Group, Inc. 2001 Stock Option, Deferred Stock and Restricted Stock Plan, form of Stock Option Grant Notice for Executive Officers and Directors, stock option agreement and form of restricted stock agreement for Executive Officers and Directors	S-1	333-142897	10.1	7/26/2007
10.2	+	The Ensign Group, Inc. 2005 Stock Incentive Plan, form of Nonqualified Stock Option Award for Executive Officers and Directors, and form of restricted stock agreement for Executive Officers and Directors	S-1	333-142897	10.2	7/26/2007
10.3	+	The Ensign Group, Inc. 2007 Omnibus Incentive Plan	S-1	333-142897	10.3	10/5/2007
10.4	+	Amendment to The Ensign Group, Inc. 2007 Omnibus Incentive Plan	8-K	001-33757	99.2	7/28/2009
10.5	+	Form of 2007 Omnibus Incentive Plan Notice of Grant of Stock Options; and form of Non-Incentive Stock Option Award Terms and Conditions	S-1	333-142797	10.4	10/5/2007
10.6	+	Form of 2007 Omnibus Incentive Plan Restricted Stock Agreement	S-1	333-142897	10.5	10/5/2007
10.7	+	Form of Indemnification Agreement entered into between The Ensign Group, Inc. and its directors, officers and certain key employees	S-1	333-142897	10.6	10/5/2007
10.8		Fourth Amended and Restated Loan Agreement, dated as of November 10, 2009, by and among certain subsidiaries of The Ensign Group, Inc. as Borrowers, and General Electric Capital Corporation as Agent and Lender	8-K	001-33757	10.1	11/17/2009
10.9		Consolidated, Amended and Restated Promissory Note, dated as of December 29, 2006, in the original principal amount of $64,692,111.67, by certain subsidiaries of The Ensign Group, Inc. in favor of General Electric Capital Corporation	S-1	333-142897	10.8	7/26/2007
10.10		Third Amended and Restated Guaranty of Payment and Performance, dated as of December 29, 2006, by The Ensign Group, Inc. as Guarantor and General Electric Capital Corporation as Agent and Lender, under which Guarantor guarantees the payment and performance of the obligations of certain of Guarantor's subsidiaries under the Third Amended and Restated Loan Agreement	S-1	333-142897	10.9	7/26/2007

104

Table of Contents



Exhibit			File	Exhibit	Filing	Filed
No.	Exhibit Description*	Form	No.	No.	Date	Herewith
10.11	Form of Amended and Restated Deed of Trust, Assignment of Rents, Security Agreement and Fixture Financing Statement, dated as of June 30, 2006 (filed against Desert Terrace Nursing Center, Desert Sky Nursing Home, Highland Manor Health and Rehabilitation Center and North Mountain Medical and Rehabilitation Center), by and among Terrace Holdings AZ LLC, Sky Holdings AZ LLC, Ensign Highland LLC and Valley Health Holdings LLC as Grantors, Chicago Title Insurance Company as Trustee, and General Electric Capital Corporation as Beneficiary and Schedule of Material Differences therein	S-1	333-142897	10.10	7/26/2007
10.12	Deed of Trust, Assignment of Rents, Security Agreement and Fixture Financing Statement, dated as of June 30, 2006 (filed against Park Manor), by and among Plaza Health Holdings LLC as Grantor, Chicago Title Insurance Company as Trustee, and General Electric Capital Corporation as Beneficiary	S-1	333-142897	10.11	7/26/2007
10.13	Deed of Trust, Assignment of Rents, Security Agreement and Fixture Financing Statement, dated as of June 30, 2006 (filed against Catalina Care and Rehabilitation Center), by and among Rillito Holdings LLC as Grantor, Chicago Title Insurance Company as Trustee, and General Electric Capital Corporation as Beneficiary	S-1	333-142897	10.12	7/26/2007
10.14	Deed of Trust, Assignment of Rents, Security Agreement and Fixture Financing Statement, dated as of October 16, 2006 (filed against Park View Gardens at Montgomery), by and among Mountainview Communitycare LLC as Grantor, Chicago Title Insurance Company as Trustee, and General Electric Capital Corporation as Beneficiary	S-1	333-142897	10.13	7/26/2007
10.15	Deed of Trust, Assignment of Rents, Security Agreement and Fixture Financing Statement, dated as of October 16, 2006 (filed against Sabino Canyon Rehabilitation and Care Center), by and among Meadowbrook Health Associates LLC as Grantor, Chicago Title Insurance Company as Trustee and General Electric Capital Corporation as Beneficiary	S-1	333-142897	10.14	7/26/2007
10.16	Form of Deed of Trust, Assignment of Rents, Security Agreement and Fixture Financing Statement, dated as of December 29, 2006 (filed against Upland Care and Rehabilitation Center and Camarillo Care Center), by and among Cedar Avenue Holdings LLC and Granada Investments LLC as Grantors, Chicago Title Insurance Company as Trustee and General Electric Capital Corporation as Beneficiary and Schedule of Material Differences therein	S-1	333-142897	10.15	7/26/2007
10.17	Form of First Amendment to (Amended and Restated) Deed of Trust, Assignment of Rents, Security Agreement and Fixture Financing Statement, dated as of December 29, 2006 (filed against Desert Terrace Nursing Center, Desert Sky Nursing Home, Highland Manor Health and Rehabilitation Center, North Mountain Medical and Rehabilitation Center, Catalina Care and Rehabilitation Center, Park Manor, Park View Gardens at Montgomery, Sabino Canyon Rehabilitation and Care Center), by and among Terrace Holdings AZ LLC, Sky Holdings AZ LLC, Ensign Highland LLC, Valley Health Holdings LLC, Rillito Holdings LLC, Plaza Health Holdings LLC, Mountainview Communitycare LLC and Meadowbrook Health Associates LLC as Grantors, Chicago Title Insurance Company as Trustee, and General Electric Capital Corporation as Beneficiary and Schedule of Material Differences therein	S-1	333-142897	10.16	7/26/2007
10.18	Amended and Restated Loan and Security Agreement, dated as of March 25, 2004, by and among The Ensign Group, Inc. and certain of its subsidiaries as Borrower, and General Electric Capital Corporation as Agent and Lender	S-1	333-142897	10.19	5/14/2007

105

Table of Contents



Exhibit			File	Exhibit	Filing	Filed
No.	Exhibit Description*	Form	No.	No.	Date	Herewith
10.19	Amendment No. 1, dated as of December 3, 2004, to the Amended and Restated Loan and Security Agreement, by and among The Ensign Group, Inc. and certain of its subsidiaries as Borrower, and General Electric Capital Corporation as Lender	S-1	333-142897	10.20	5/14/2007
10.20	Second Amended and Restated Revolving Credit Note, dated as of December 3, 2004, in the original principal amount of $20,000,000, by The Ensign Group, Inc. and certain of its subsidiaries in favor of General Electric Capital Corporation	S-1	333-142897	10.19	7/26/2007
10.21	Amendment No. 2, dated as of March 25, 2007, to the Amended and Restated Loan and Security Agreement, by and among The Ensign Group, Inc. and certain of its subsidiaries as Borrower, and General Electric Capital Corporation as Lender	S-1	333-142897	10.22	5/14/2007
10.22	Amendment No. 3, dated as of June 22, 2007, to the Amended and Restated Loan and Security Agreement, by and among The Ensign Group, Inc. and certain of its subsidiaries as Borrower and General Electric Capital Corporation as Lender	S-1	333-142897	10.21	7/26/2007
10.23	Amendment No. 4, dated as of August 1, 2007, to the Amended and Restated Loan and Security Agreement, by and among The Ensign Group, Inc. and certain of its subsidiaries as Borrowers and General Electric Capital Corporation as Lender	S-1	333-142897	10.42	8/17/2007
10.24	Amendment No. 5, dated September 13, 2007, to the Amended and Restated Loan and Security Agreement, by and among The Ensign Group, Inc. and certain of its subsidiaries as Borrowers and General Electric Capital Corporation as Lender	S-1	333-142897	10.43	10/5/2007
10.25	Revolving Credit Note, dated as of September 13, 2007, in the original principal amount of $5,000,000 by The Ensign Group, Inc. and certain of its subsidiaries in favor of General Electric Capital Corporation	S-1	333-142897	10.44	10/5/2007
10.26	Commitment Letter, dated October 3, 2007, from General Electric Capital Corporation to The Ensign Group, Inc., setting forth the general terms and conditions of the proposed amendment to the revolving credit facility, which will increase the available credit thereunder to $50.0 million	S-1	333-142897	10.46	10/5/2007
10.27	Amendment No. 6, dated November 19, 2007, to the Amended and Restated Loan and Security Agreement, by and among The Ensign Group, Inc. and certain of its subsidiaries as Borrowers and General Electric Capital Corporation as Lender	8-K	001-33757	10.1	11/21/2007
10.28	Amendment No. 7, dated December 21, 2007, to the Amended and Restated Loan and Security Agreement, by and among The Ensign Group, Inc. and certain of its subsidiaries as Borrowers and General Electric Capital Corporation as Lender	8-K	001-33757	10.1	12/27/2007
10.29	Amendment No. 1 and Joinder Agreement to Second Amended and Restated Loan and Security Agreement, by certain subsidiaries of The Ensign Group, Inc. as Borrower and General Electric Capital Corporation as Lender	8-K	001-33757	10.1	2/9/2009
10.30	Second Amended and Restated Revolving Credit Note, dated February 4, 2009, by certain subsidiaries of The Ensign Group, Inc. as Borrowers for the benefit of General Electric Capital Corporation as Lender	8-K	001-33757	10.2	2/9/2009
10.31	Amended and Restated Revolving Credit Note, dated February 21, 2008, by certain subsidiaries of The Ensign Group, Inc. as Borrowers for the benefit of General Electric Capital Corporation as Lender	8-K	001-33757	10.2	2/27/2008
10.32	Ensign Guaranty, dated February 21, 2008, between The Ensign Group, Inc. as Guarantor and General Electric Capital Corporation as Lender	8-K	001-33757	10.3	2/27/2008

106

Table of Contents



Exhibit			File	Exhibit	Filing	Filed
No.	Exhibit Description*	Form	No.	No.	Date	Herewith
10.33	Holding Company Guaranty, dated February 21, 2008, by and among The Ensign Group, Inc. and certain of its subsidiaries as Guarantors and General Electric Capital Corporation as Lender	8-K	001-33757	10.4	2/27/2008
10.34	Pacific Care Center Loan Agreement, dated as of August 6, 1998, by and between G&L Hoquiam, LLC as Borrower and GMAC Commercial Mortgage Corporation as Lender (later assumed by Cherry Health Holdings, Inc. as Borrower and Wells Fargo Bank, N.A. as Lender)	S-1	333-142897	10.23	5/14/2007
10.35	Deed of Trust and Security Agreement, dated as of August 6, 1998, by and among G&L Hoquiam, LLC as Grantor, Ticor Title Insurance Company as Trustee and GMAC Commercial Mortgage Corporation as Beneficiary	S-1	333-142897	10.24	7/26/2007
10.36	Promissory Note, dated as of August 6, 1998, in the original principal amount of $2,475,000, by G&L Hoquiam, LLC in favor of GMAC Commercial Mortgage Corporation	S-1	333-142897	10.25	7/26/2007
10.37	Loan Assumption Agreement, by and among G&L Hoquiam, LLC as Prior Owner; G&L Realty Partnership, L.P. as Prior Guarantor; Cherry Health Holdings, Inc. as Borrower; and Wells Fargo Bank, N.A., the Trustee for GMAC Commercial Mortgage Securities, Inc., as Lender	S-1	333-142897	10.26	5/14/2007
10.38	Exceptions to Nonrecourse Guaranty, dated as of October 2006, by The Ensign Group, Inc. as Guarantor and Wells Fargo Bank, N.A. as Trustee for GMAC Commercial Mortgage Securities, Inc., under which Guarantor guarantees full and prompt payment of all amounts due and owing by Cherry Health Holdings, Inc. under the Promissory Note	S-1	333-142897	10.22	7/26/2007
10.39	Deed of Trust with Assignment of Rents, dated as of January 30, 2001, by and among Ensign Southland LLC as Trustor, Brian E. Callahan as Trustee and Continental Wingate Associates, Inc. as Beneficiary	S-1	333-142897	10.27	7/26/2007
10.40	Deed of Trust Note, dated as of January 30, 2001, in the original principal amount of $7,455,100, by Ensign Southland, LLC in favor of Continental Wingate Associates, Inc.	S-1	333-142897	10.28	5/14/2007
10.41	Security Agreement, dated as of January 30, 2001, by and between Ensign Southland, LLC and Continental Wingate Associates, Inc.	S-1	333-142897	10.29	5/14/2007
10.42	Master Lease Agreement, dated July 3, 2003, between Adipiscor LLC as Lessee and LTC Partners VI, L.P., Coronado Corporation and Park Villa Corporation collectively as Lessor	S-1	333-142897	10.30	5/14/2007
10.43	Lease Guaranty, dated July 3, 2003, between The Ensign Group, Inc. as Guarantor and LTC Partners VI, L.P., Coronado Corporation and Park Villa Corporation collectively as Lessor, under which Guarantor guarantees the payment and performance of Adipiscor LLC's obligations under the Master Lease Agreement	S-1	333-142897	10.31	5/14/2007
10.44	Master Lease Agreement, dated September 30, 2003, between Permunitum LLC as Lessee, Vista Woods Health Associates LLC, City Heights Health Associates LLC, and Claremont Foothills Health Associates LLC as Sublessees, and OHI Asset (CA), LLC as Lessor	S-1	333-142897	10.32	5/14/2007
10.45	Lease Guaranty, dated September 30, 2003, between The Ensign Group, Inc. as Guarantor and OHI Asset (CA), LLC as Lessor, under which Guarantor guarantees the payment and performance of Permunitum LLC's obligations under the Master Lease Agreement	S-1	333-142897	10.33	5/14/2007

107

Table of Contents



Exhibit			File	Exhibit	Filing	Filed
No.	Exhibit Description*	Form	No.	No.	Date	Herewith
10.46	Lease Guaranty, dated September 30, 2003, between Vista Woods Health Associates LLC, City Heights Health Associates LLC and Claremont Foothills Health Associates LLC as Guarantors and OHI Asset (CA), LLC as Lessor, under which Guarantors guarantee the payment and performance of Permunitum LLC's obligations under the Master Lease Agreement	S-1	333-142897	10.34	5/14/2007
10.47	Master Lease Agreement, dated January 31, 2003, between Moenium Holdings LLC as Lessee and Healthcare Property Investors, Inc., d/b/a in the State of Arizona as HC Properties, Inc., and Healthcare Investors III collectively as Lessor	S-1	333-142897	10.35	5/14/2007
10.48	Lease Guaranty, between The Ensign Group, Inc. as Guarantor and Healthcare Property Investors, Inc. as Owner, under which Guarantor guarantees the payment and performance of Moenium Holdings LLC's obligations under the Master Lease Agreement	S-1	333-142897	10.36	5/14/2007
10.49	First Amendment to Master Lease Agreement, dated May 27, 2003, between Moenium Holdings LLC as Lessee and Healthcare Property Investors, Inc., d/b/a in the State of Arizona as HC Properties, Inc., and Healthcare Investors III collectively as Lessor	S-1	333-142897	10.37	5/14/2007
10.50	Second Amendment to Master Lease Agreement, dated October 31. 2004, between Moenium Holdings LLC as Lessee and Healthcare Property Investors, Inc., d/b/a in the State of Arizona as HC Properties, Inc., and Healthcare Investors III collectively as Lessor	S-1	333-142897	10.38	5/14/2007
10.51	Lease Agreement, by and between Mission Ridge Associates LLC as Landlord and Ensign Facility Services, Inc. as Tenant; and Guaranty of Lease, dated August 2, 2003, by The Ensign Group, Inc. as Guarantor in favor of Landlord, under which Guarantor guarantees Tenant's obligations under the Lease Agreement	S-1	333-142897	10.39	5/14/2007
10.52	First Amendment to Lease Agreement dated January 15, 2004, by and between Mission Ridge Associates LLC as Landlord and Ensign Facility Services, Inc. as Tenant	S-1	333-142897	10.40	5/14/2007
10.53	Second Amendment to Lease Agreement dated December 13, 2007, by and between Mission Ridge Associates LLC as Landlord and Ensign Facility Services, Inc. as Tenant; and Reaffirmation of Guaranty of Lease, dated December 13, 2007, by The Ensign Group, Inc. as Guarantor in favor of Landlord, under which Guarantor reaffirms its guaranty of Tenants obligations under the Lease Agreement	10-K	001-33757	10.52	3/6/2008
10.54	Third Amendment to Lease Agreement dated February 21, 2008, by and between Mission Ridge Associates LLC as Landlord and Ensign Facility Services, Inc. as Tenant	10-K	001-33757	10.54	2/17/2010
10.55	Fourth Amendment to Lease Agreement dated July 15, 2009, by and between Mission Ridge Associates LLC as Landlord and Ensign Facility Services, Inc. as Tenant	10-K	001-33757	10.55	2/17/2010
10.56	Form of Independent Consulting and Centralized Services Agreement between Ensign Facility Services, Inc. and certain of its subsidiaries	S-1	333-142897	10.41	5/14/2007
10.57	Form of Health Insurance Benefit Agreement pursuant to which certain subsidiaries of The Ensign Group, Inc. participate in the Medicare program	S-1	333-142897	10.48	10/19/2007
10.58	Form of Medi-Cal Provider Agreement pursuant to which certain subsidiaries of The Ensign Group, Inc. participate in the California Medicaid program	S-1	333-142897	10.49	10/19/2007
10.59	Form of Provider Participation Agreement pursuant to which certain subsidiaries of The Ensign Group, Inc. participate in the Arizona Medicaid program	S-1	333-142897	10.50	10/19/2007

108

Table of Contents



Exhibit			File	Exhibit	Filing	Filed
No.	Exhibit Description*	Form	No.	No.	Date	Herewith
10.60	Form of Contract to Provide Nursing Facility Services under the Texas Medical Assistance Program pursuant to which certain subsidiaries of The Ensign Group, Inc. participate in the Texas Medicaid program	S-1	333-142897	10.51	10/19/2007
10.61	Form of Client Service Contract pursuant to which certain subsidiaries of The Ensign Group, Inc. participate in the Washington Medicaid program	S-1	333-142897	10.52	10/19/2007
10.62	Form of Provider Agreement for Medicaid and UMAP pursuant to which certain subsidiaries of The Ensign Group, Inc. participate in the Utah Medicaid program	S-1	333-142897	10.53	10/19/2007
10.63	Form of Medicaid Provider Agreement pursuant to which a subsidiary of The Ensign Group, Inc. participates in the Idaho Medicaid program	S-1	333-142897	10.54	10/19/2007
10.64	Six Project Promissory Note dated as of November 10, 2009, in the original principal amount of $40,000,000, by certain subsidiaries of the Ensign Group, Inc. in favor of General Electric Capital Corporation	8-K	001-33757	10.2	11/17/2009
10.65	Note, dated December 31, 2010 by certain subsidiaries of the Company.	8-K	001-33757	10.1	1/6/2011
10.66	Revolving Credit and Term Loan Agreement, dated as of July 15, 2011, among the Ensign Group, Inc. and the several banks and other financial institutions and lenders from time to time party thereto (the "Lenders") and SunTrust Bank, in its capacity as administrative agent for the Lenders, as issuing bank and as swingline lender.	8-K	001-33757	10.1	7/19/2011
10.67	Commercial Deeds of Trust, Security Agreements, Assignment of Leases and Rents and Future Filing, dated as of February 17, 2012, made by certain subsidiaries of the Company for the benefit of RBS Asset Finance, Inc. 8-K.	8-K	001-33757	10.1	2/22/2012
10.68	First Amendment to Revolving Credit and Term Loan Agreement, dated as of October 27, 2011, among The Ensign Group, Inc. and the several banks and other financial institutions and lenders from time to time party thereto (the "Lenders") and SunTrust Bank, in its capacity as administrative agent for the Lenders, as issuing bank and as swingline lender.	10-K	001-33757	10.70	2/13/2013
10.69	Second Amendment to Revolving Credit and Term Loan Agreement, dated as of April 30, 2012, among The Ensign Group, Inc. and the several banks and other financial institutions and lenders from time to time party thereto (the "Lenders") and SunTrust Bank, in its capacity as administrative agent for the Lenders, as issuing bank and as swingline lender.	10-K	001-33757	10.71	2/13/2013
10.70	Third Amendment to Revolving Credit and Term Loan Agreement, dated as of February 1, 2013, among The Ensign Group, Inc. and the several banks and other financial institutions and lenders from time to time party thereto (the "Lenders") and SunTrust Bank, in its capacity as administrative agent for the Lenders, as issuing bank and as swingline lender.	8-K	001-33757	10.1	2/6/2013
10.71	Fourth Amendment to Revolving Credit and Term Loan Agreement, dated as of April 16, 2013, among the Ensign Group, Inc. and the several banks and other financial institutions and lenders from time to time party thereto(the "Lenders") and SunTrust Bank, in its capacity as administrative agent fort he Lenders, as issuing bank and as swingline lender.	8-K	001-33757	10.1	4/22/2013

109

Table of Contents



Exhibit			File	Exhibit	Filing	Filed
No.	Exhibit Description*	Form	No.	No.	Date	Herewith
10.72	Corporate Integrity Agreement between the Office of Inspector General of the Department of Health and Human Services and The Ensign Group, Inc. dated October 1, 2013.	10-K	001-33757	10.74	2/13/2014
10.73	Settlement agreement dated October 1, 2013, entered into among the United States of America, acting through the United States Department of Justice and on behalf of the Office of Inspector General ("OIG-HHS") of the Department of Health and Human Services ("HHS") (collectively the "United States") and the Company.	8-K	001-33757	10.75	5/8/2014
10.74	Form of Master Lease by and among certain subsidiaries of The Ensign Group, Inc. and certain subsidiaries of CareTrust REIT, Inc.	8-K	001-33757	10.1	6/5/2014
10.75	Form of Guaranty of Master Lease by The Ensign Group, Inc. in favor of certain subsidiaries of CareTrust REIT, Inc., as landlords under the Master Leases	8-K	001-33757	10.2	6/5/2014
10.76	Opportunities Agreement, dated as of May 30, 2014, by and between The Ensign Group, Inc. and CareTrust REIT, Inc.	8-K	001-33757	10.3	6/5/2014
10.77	Transition Services Agreement, dated as of May 30, 2014, by and between The Ensign Group, Inc. and CareTrust REIT, Inc.	8-K	001-33757	10.4	6/5/2014
10.78	Tax Matters Agreement, dated as of May 30, 2014, by and between The Ensign Group, Inc. and CareTrust REIT, Inc.	8-K	001-33757	10.5	6/5/2014
10.79	Employee Matters Agreement, dated as of May 30, 2014, by and between The Ensign Group, Inc. and CareTrust REIT, Inc.	8-K	001-33757	10.6	6/5/2014
10.80	Contribution Agreement, dated as of May 30, 2014, by and among CTR Partnership L.P., CareTrust GP, LLC, CareTrust REIT, Inc. and The Ensign Group, Inc.	8-K	001-33757	10.7	6/5/2014
10.81	Credit Agreement, dated as of May 30, 2014, by and among The Ensign Group, Inc., SunTrust Bank, as administrative agent, and the lenders party thereto	8-K	001-33757	10.8	6/5/2014
10.82	Amended and Restated Credit Agreement as of February 5, 2016, by and among The Ensign Group, Inc., SunTrust Bank, as administrative agent, and the lenders party thereto	8-K	001-33757	10.1	2/8/2016
10.83	Second Amended Credit Agreement as of July 19, 2016, by and among The Ensign Group, Inc., SunTrust Bank, as administrative agent, and the lenders party thereto	8-K	001-33757	10.1	7/25/2016
10.84	Cornerstone Healthcare, Inc. 2016 Omnibus Incentive	10-Q	001-33757	10.2	8/1/2016
10.85	Cornerstone Healthcare, Inc. Stockholders Agreement	10-Q	001-33757	10.3	8/1/2016
10.86	The Ensign Group, Inc. 2017 Omnibus Incentive Plan	DEF 14A	001-33757	A	4/13/2017
10.87	Form of 2017 Omnibus Incentive Plan Notice of Grant of Stock Options; and form of Non-Incentive Stock Option Award Terms and Conditions					X
10.88	Form of 2017 Omnibus Incentive Plan Restricted Stock Agreement					X
10.89	Form of U.S. Department of Housing and Urban Development Healthcare Facility Note and schedule of individual subsidiary loans, by and among The Ensign Group, Inc.'s subsidiaries listed therein and U.S. Department of Housing and Urban Development	8-K	001-33757	10.1	1/3/2018
10.90	Form of U.S. Department of Housing and Urban Development Security Instrument/Mortgage/Deed of Trust	8-K	001-33757	10.2	1/3/2018

110

Table of Contents

Exhibit

File

Exhibit

Filing

Filed

No.

Exhibit Description*

Form

No.

Date

Herewith

21.1

Subsidiaries of The Ensign Group, Inc., as amended

23.1

Consent of Deloitte & Touche LLP

31.1

Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2

Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1

Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2

Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101

Interactive data file (furnished electronically herewith pursuant to Rule 406T of Regulations S-T)

Indicates management contract or compensatory plan.

Documents not filed herewith are incorporated by reference to the prior filings identified in the table above.

Item 16. Form 10-K Summary

Not applicable

111

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.



	THE ENSIGN GROUP, INC.

February 8, 2018	BY:	/s/ SUZANNE D. SNAPPER
		Suzanne D. Snapper
		Chief Financial Officer (Principal Financial Officer and Duly Authorized Officer)

Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.



Signature	Title	Date

/s/ CHRISTOPHER R. CHRISTENSEN	Chief Executive Officer, President and Director (principal executive officer)	February 8, 2018
Christopher R. Christensen

/s/ SUZANNE D. SNAPPER	Chief Financial Officer (principal financial and accounting officer)	February 8, 2018
Suzanne D. Snapper

/s/ ROY E. CHRISTENSEN	Chairman of the Board	February 8, 2018
Roy E. Christensen

/s/ MALENE S. DAVIS	Director	February 8, 2018
Malene S. Davis

/s/ JOHN G. NACKEL	Director	February 8, 2018
John G. Nackel

/s/ DAREN J. SHAW	Director	February 8, 2018
Daren J. Shaw

/s/ LEE A. DANIELS	Director	February 8, 2018
Lee A. Daniels

/s/ BARRY M. SMITH	Director	February 8, 2018
Barry M. Smith

112

Table of Contents

THE ENSIGN GROUP, INC.

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

AND FINANCIAL STATEMENT SCHEDULES



Report of Independent Registered Public Accounting Firm	114
Consolidated Financial Statements:
Consolidated Balance Sheets as of December 31, 2017 and 2016	115
Consolidated Statements of Income for the Years Ended December 31, 2017, 2016 and 2015	116
Consolidated Statements of Stockholders' Equity for the Years Ended December 31, 2017, 2016 and 2015	117
Consolidated Statements of Cash Flows for the Years Ended December 31, 2017, 2016 and 2015	118
Notes to Consolidated Financial Statements	120

113

Table of Contents

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the shareholders and the Board of Directors of

The Ensign Group, Inc.

Mission Viejo, California

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of The Ensign Group, Inc. and subsidiaries (the "Company") as of December 31, 2017 and 2016, the related consolidated statements of income, stockholders' equity, and cash flows, for each of the three years in the period ended December 31, 2017, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2017 and 2016, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2017, in conformity with accounting principles generally accepted in the United States of America.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2017, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February 8, 2018, expressed an unqualified opinion on the Company's internal control over financial reporting.

Basis for Opinion

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

/s/ DELOITTE & TOUCHE LLP

Costa Mesa, California

February 8, 2018

We have served as the Company's auditor since 1999.

114

THE ENSIGN GROUP, INC.

CONSOLIDATED BALANCE SHEETS



	December 31,
	2017			2016
	(In thousands, except par values)
Assets
Current assets:
Cash and cash equivalents	$	42,337		$	57,706
Accounts receivable—less allowance for doubtful accounts of $43,961 and $39,791 at December 31, 2017 and 2016, respectively	265,068			244,433
Investments—current	13,092			11,550
Prepaid income taxes	19,447			302
Prepaid expenses and other current assets	28,132			19,871
Total current assets	368,076			333,862
Property and equipment, net	537,084			484,498
Insurance subsidiary deposits and investments	28,685			23,634
Escrow deposits	228			1,582
Deferred tax assets	12,745			23,073
Restricted and other assets	16,501			12,614
Intangible assets, net	32,803			35,076
Goodwill	81,062			67,100
Other indefinite-lived intangibles	25,249			19,586
Total assets	$	1,102,433		$	1,001,025
Liabilities and equity
Current liabilities:
Accounts payable	$	39,043		$	38,991
Accrued wages and related liabilities	90,508			84,686
Accrued self-insurance liabilities—current	22,516			21,359
Other accrued liabilities	63,815			58,763
Current maturities of long-term debt	9,939			8,129
Total current liabilities	225,821			211,928
Long-term debt—less current maturities	302,990			275,486
Accrued self-insurance liabilities—less current portion	50,220			43,992
Deferred rent and other long-term liabilities	11,268			9,124
Deferred gain related to sale-leaseback (Note 17)	12,075			—
Total liabilities	602,374			540,530

Commitments and contingencies (Notes 15, 17 and 19)
Equity:
Ensign Group, Inc. stockholders' equity:
Common stock; $0.001 par value; 75,000 shares authorized; 53,675 and 51,360 shares issued and outstanding at December 31, 2017, respectively, and 52,787 and 50,838 shares issued and outstanding at December 31, 2016, respectively (Note 3)	53			52
Additional paid-in capital (Note 3)	266,058			252,493
Retained earnings	264,691			235,021
Common stock in treasury, at cost, 1,932 and 1,520 shares at December 31, 2017 and 2016, respectively (Note 3)	(38,405		)	(31,117		)
Total Ensign Group, Inc. stockholders' equity	492,397			456,449
Non-controlling interest	7,662			4,046
Total equity	500,059			460,495
Total liabilities and equity	$	1,102,433		$	1,001,025

See accompanying notes to consolidated financial statements.

115

Table of Contents

THE ENSIGN GROUP, INC.

CONSOLIDATED STATEMENTS OF INCOME



	Year Ended December 31,
	2017			2016			2015
	(In thousands, except per share data)
Revenue	$	1,849,317		$	1,654,864		$	1,341,826
Expense:
Cost of services	1,497,703			1,341,814			1,067,694
Charge related to class action lawsuit (Note 19)	11,000			—			—
(Gains)/losses related to divestitures (Note 7 and 17)	2,321			(11,225		)	—
Rent—cost of services (Note 17)	131,919			124,581			88,776
General and administrative expense	80,617			69,165			64,163
Depreciation and amortization	44,472			38,682			28,111
Total expenses	1,768,032			1,563,017			1,248,744
Income from operations	81,285			91,847			93,082
Other income (expense):
Interest expense	(13,616		)	(7,136		)	(2,828		)
Interest income	1,609			1,107			845
Other expense, net	(12,007		)	(6,029		)	(1,983		)
Income before provision for income taxes	69,278			85,818			91,099
Provision for income taxes	28,445			32,975			35,182
Net income	40,833			52,843			55,917
Less: net income attributable to noncontrolling interests	358			2,853			485
Net income attributable to The Ensign Group, Inc.	$	40,475		$	49,990		$	55,432
Net income per share attributable to The Ensign Group, Inc.:
Basic	$	0.79		$	0.99		$	1.10
Diluted	$	0.77		$	0.96		$	1.06
Weighted average common shares outstanding:
Basic	50,932			50,555			50,316
Diluted	52,829			52,133			52,210

Dividends per share	$	0.1725		$	0.1625		$	0.1525

See accompanying notes to consolidated financial statements.

116

Table of Contents

THE ENSIGN GROUP, INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY



	Common Stock				Additional Paid-In Capital			Retained Earnings			Treasury Stock					Non-Controlling Interest
	Shares		Amount		Additional Paid-In Capital			Retained Earnings			Shares		Amount			Non-Controlling Interest			Total
	(In thousands)
Balance - January 1, 2015	22,591		$	22	$	114,293		$	145,846		150		$	(1,310	)	$	(1,048	)	$	257,803
Issuance of common stock to employees and directors resulting from the exercise of stock options and grant of stock awards	255		—		2,443			—			(27	)	87			—			2,530
Issuance of restricted stock to employees	105		—		1,892			—			—		—			—			1,892
Issuance of common stock through public offering, net of issuance costs	2,734		3		106,117			—			—		—			—			106,120
Dividends declared	—		—					(7,858		)	—		—			—			(7,858		)
Employee stock award compensation	—		—		6,677			—			—		—			—			6,677
Excess tax benefit from share-based compensation	—		—		3,680			—			—		—			—			3,680
Stock issued to effect stock split	25,685		26		(26		)	—			—		—			—			—
Noncontrolling interest assumed related to acquisition	—		—		—			—			—		—			224			224
Net income attributable to noncontrolling interest	—		—		—			—			—		—			485			485
Net income attributable to the Ensign Group, Inc.	—		—		—			55,432			—		—			—			55,432
Balance - December 31, 2015	51,370		$	51	$	235,076		$	193,420		123		$	(1,223	)	$	(339	)	$	426,985
Issuance of common stock to employees and directors resulting from the exercise of stock options and grant of stock awards	668		1		4,045			—			(55	)	106			—			4,152
Issuance of restricted stock to employees	252		—		2,517			—			—		—			—			2,517
Repurchase of common stock (Note 3)	(1,452	)									1,452		(30,000		)	—			(30,000		)
Dividends declared	—		—		—			(8,282		)	—		—			—			(8,282		)
Employee stock award compensation	—		—		7,776			—			—		—			—			7,776
Excess tax benefit from share-based compensation	—		—		3,079			—			—		—			—			3,079
Noncontrolling interest attributable to subsidiary equity plan (Note 16)	—		—		—			(107		)	—		—			1,432			1,325
Noncontrolling interest assumed related to acquisition	—		—		—			—			—		—			100			100
Net income attributable to noncontrolling interest	—		—		—			—			—		—			2,853			2,853
Net income attributable to the Ensign Group, Inc.	—		—		—			49,990			—		—			—			49,990
Balance - December 31, 2016	50,838		$	52	$	252,493		$	235,021		1,520		$	(31,117	)	$	4,046		$	460,495
Issuance of common stock to employees and directors resulting from the exercise of stock options and grant of stock awards	807		1		5,127			—			—		—			—			5,128
Issuance of restricted stock to employees	127		—		146			—			—		—			—			146
Repurchase of common stock (Note 3)	(412	)	—		—			—			412		(7,288		)	—			(7,288		)
Dividends declared	—		—		—			(8,867		)	—		—			—			(8,867		)
Employee stock award compensation	—		—		8,331			—			—		—			—			8,331
Acquisition of noncontrolling interest, net of tax	—		—		(39		)	—			—		—			(44		)	(83		)
Noncontrolling interest attributable to subsidiary equity plan (Note 16)	—		—		—			(1,938		)	—		—			3,302			1,364
Net income attributable to noncontrolling interest	—		—		—			—			—		—			358			358
Net income attributable to the Ensign Group, Inc.	—		—		—			40,475			—		—			—			40,475
Balance - December 31, 2017	51,360		$	53	$	266,058		$	264,691		1,932		$	(38,405	)	$	7,662		$	500,059

See accompanying notes to consolidated financial statements.

117

Table of Contents

THE ENSIGN GROUP, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)



	Year Ended December 31,
	2017			2016			2015
Cash flows from operating activities:
Net income	$	40,833		$	52,843		$	55,917
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	44,472			38,682			28,111
Amortization of deferred financing fees	1,039			825			591
Amortization of deferred gain on sale-leaseback	(421		)	—			—
Impairment of long-lived assets	111			137			—
Write-off of deferred financing fees	—			321			—
Deferred income taxes	10,329			(2,208		)	1,251
Provision for doubtful accounts	31,023			28,512			19,802
Share-based compensation	9,695			9,101			6,677
Excess tax benefit from share-based compensation (Note 2)	—			(3,079		)	(3,680		)
Insurance proceeds received for damage to property	477			—			—
Gain on disposition of intangibles, property and equipment	278			164			205
Gain on sale of urgent care centers	—			(19,160		)	—
Change in operating assets and liabilities
Accounts receivable	(52,301		)	(63,617		)	(100,324		)
Prepaid income taxes	(19,145		)	7,839			(5,149		)
Prepaid expenses and other assets	(9,380		)	(1,465		)	(10,340		)
Insurance subsidiary deposits and investments	(6,592		)	(467		)	(10,785		)
Liabilities related to operational closures (Note 7 and 17)	2,210			7,205			—
Accounts payable	3,329			577			1,780
Accrued wages and related liabilities	5,822			(4,978		)	22,178
Income taxes payable	(1,182		)	987			—
Other accrued liabilities	5,777			12,588			21,403
Accrued self-insurance liabilities	6,095			8,125			5,418
Deferred rent liability	483			956			314
Net cash provided by operating activities	72,952			73,888			33,369
Cash flows from investing activities:
Purchase of property and equipment	(57,166		)	(65,699		)	(60,018		)
Cash payments for business acquisitions	(89,565		)	(64,310		)	(110,802		)
Cash payments for asset acquisitions	(195		)	(120,935		)	(17,750		)
Escrow deposits	(228		)	(1,582		)	(400		)
Escrow deposits used to fund business acquisitions	1,582			400			16,153
Use of restricted cash	—			—			5,082
Cash received from sale of urgent care centers and franchising businesses, net of note receivable	—			40,734			2,000
Cash proceeds from sale-leaseback	38,000			—			—
Cash proceeds from the sale of fixed assets and insurance proceeds	3,215			391			10
Restricted and other assets	(2,236		)	365			(2,813		)
Net cash used in investing activities	(106,593		)	(210,636		)	(168,538		)
Cash flows from financing activities:
Proceeds from revolving credit facility and other debt (Note 15)	1,022,015			844,000			334,000
Payments on revolving credit facility and other debt (Note 15)	(990,154		)	(659,514		)	(314,417		)
Proceeds from common stock offering (Note 3)	—			—			112,078
Issuance costs in connection with common stock offering (Note 3)	—			—			(5,961		)
Issuance of treasury stock upon exercise of options	—			106			87
Issuance of common stock upon exercise of options	5,274			6,563			4,337
Repurchase of shares of common stock (Note 3)	(7,288		)	(30,000		)	—
Dividends paid	(8,717		)	(8,173		)	(7,494		)
Excess tax benefit from share-based compensation (Note 2)	—			3,181			3,700
Purchase of non-controlling interest	(83		)	—			—
Payments of deferred financing costs	(2,775		)	(3,278		)	—
Net cash provided by financing activities	18,272			152,885			126,330
Net (decrease)/increase in cash and cash equivalents	(15,369		)	16,137			(8,839		)
Cash and cash equivalents beginning of period	57,706			41,569			50,408
Cash and cash equivalents end of period	$	42,337		$	57,706		$	41,569

See accompanying notes to consolidated financial statements.

118

Table of Contents

THE ENSIGN GROUP, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS - (Continued)



	Year Ended December 31,
	2017		2016		2015
Supplemental disclosures of cash flow information:
Cash paid during the period for:
Interest	$	13,284	$	6,428	$	2,773
Income taxes	$	38,382	$	23,163	$	35,490
Non-cash financing and investing activity:
Accrued capital expenditures	$	3,550	$	6,828	$	4,171
Note receivable from sale of urgent care centers and franchising business	$	—	$	700	$	—
Favorable lease included in the fair value of assets acquisitions	$	—	$	7,190	$	—
Refundable deposits assumed as part of business acquisition	$	—	$	—	$	3,488
Debt assumed as part of asset acquisition	$	—	$	—	$	11,699

See accompanying notes to consolidated financial statements.

119

Table of Contents

THE ENSIGN GROUP, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Dollars and shares in thousands, except per share data)

1. DESCRIPTION OF BUSINESS

The Company - The Ensign Group, Inc. (collectively, Ensign or the Company), is a holding company with no direct operating assets, employees or revenue. The Company, through its operating subsidiaries, is a provider of health care services across the post-acute care continuum, as well as other ancillary businesses. As of December 31, 2017, the Company operated 230 facilities, 46 home health, hospice and home care agencies and other ancillary operations located in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, Oklahoma, Oregon, South Carolina, Texas, Utah, Washington and Wisconsin. The Company's operating subsidiaries, each of which strives to be the operation of choice in the community it serves, provide a broad spectrum of skilled nursing, assisted living, home health, home care, hospice and other ancillary services. The Company's operating subsidiaries have a collective capacity of approximately 18,900 operational skilled nursing beds and 5,000 assisted living and independent living units. As of December 31, 2017, the Company owned 63 of its 230 affiliated facilities and leased an additional 167 facilities through long-term lease arrangements and had options to purchase 11 of those 167 facilities. As of December 31, 2016, the Company owned 50 of its 210 affiliated facilities and leased an additional 160 facilities through long-term lease arrangements, and had options to purchase nine of those 160 facilities.

Certain of the Company’s wholly-owned independent subsidiaries, collectively referred to as the Service Center, provide certain accounting, payroll, human resources, information technology, legal, risk management and other centralized services to the other operating subsidiaries through contractual relationships with such subsidiaries. The Company also has a wholly-owned captive insurance subsidiary (the Captive) that provides some claims-made coverage to the Company’s operating subsidiaries for general and professional liability, as well as coverage for certain workers’ compensation insurance liabilities.

Each of the Company's affiliated operations are operated by separate, wholly-owned, independent subsidiaries that have their own management, employees and assets. References herein to the consolidated “Company” and “its” assets and activities in this Annual Report is not meant to imply, nor should it be construed as meaning, that The Ensign Group, Inc. has direct operating assets, employees or revenue, or that any of the subsidiaries, are operated by The Ensign Group, Inc.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation — The accompanying consolidated financial statements (Financial Statements) have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The Company is the sole member or shareholder of various consolidated limited liability companies and corporations established to operate various acquired skilled nursing and assisted living operations, home health, hospice and home care operations, and related ancillary services. All intercompany transactions and balances have been eliminated in consolidation. The consolidated financial statements include the accounts of all entities controlled by the Company through its ownership of a majority voting interest. The Company presents noncontrolling interest within the equity section of its consolidated balance sheets. The Company presents the amount of consolidated net income that is attributable to The Ensign Group, Inc. and the noncontrolling interest in its consolidated statements of income.

The consolidated financial statements include the accounts of all entities controlled by the Company through its ownership of a majority voting interest and the accounts of any variable interest entities (VIEs) where the Company is subject to a majority of the risk of loss from the VIE's activities, or entitled to receive a majority of the entity's residual returns, or both. The Company assesses the requirements related to the consolidation of VIEs, including a qualitative assessment of power and economics that considers which entity has the power to direct the activities that "most significantly impact" the VIE's economic performance and has the obligation to absorb losses of, or the right to receive benefits that could be potentially significant to, the VIE. The Company's relationship with variable interest entities was not material during the year ended December 31, 2017.

In 2016, the Company completed the sale of its urgent care centers for an aggregate purchase price of $41,492. The sale transactions do not meet the criteria of discontinued operations as they do not represent a strategic shift that has, or will have, a major effect on the Company’s operations and financial results.

Estimates and Assumptions — The preparation of Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Financial Statements and the reported amounts of revenue and expenses during the reporting periods. The most significant estimates in the Company’s Financial Statements relate to revenue, allowance for doubtful accounts, intangible

120

Table of Contents

THE ENSIGN GROUP, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

assets and goodwill, impairment of long-lived assets, general and professional liability, workers' compensation and healthcare claims included in accrued self-insurance liabilities, and income taxes. Actual results could differ from those estimates.

Fair Value of Financial Instruments —The Company’s financial instruments consist principally of cash and cash equivalents, debt security investments, accounts receivable, insurance subsidiary deposits, accounts payable and borrowings. The Company believes all of the financial instruments’ recorded values approximate fair values because of their nature or respective short durations.

Revenue Recognition — The Company recognizes revenue when the following four conditions have been met: (i) there is persuasive evidence that an arrangement exists; (ii) delivery has occurred or service has been rendered; (iii) the price is fixed or determinable; and (iv) collection is reasonably assured. The Company's revenue is derived primarily from providing healthcare services to patients and is recognized on the date services are provided at amounts billable to the individual. For reimbursement arrangements with third-party payors, including Medicaid, Medicare and private insurers, revenue is recorded based on contractually agreed-upon amounts on a per patient basis.

Revenue from the Medicare and Medicaid programs accounted for 68.4%, 67.8% and 69.1% of the Company's revenue for the years ended December 31, 2017, 2016 and 2015, respectively. The Company records revenue from these governmental and managed care programs as services are performed at their expected net realizable amounts under these programs. The Company’s revenue from governmental and managed care programs is subject to audit and retroactive adjustment by governmental and third-party agencies. Consistent with healthcare industry accounting practices, any changes to these governmental revenue estimates are recorded in the period the change or adjustment becomes known based on final settlement. The Company recorded adjustments to revenue which were not material to the Company's consolidated revenue or Financial Statements for the years ended December 31, 2017, 2016 and 2015.

The Company’s service specific revenue recognition policies are as follows:

Skilled Nursing Revenue

The Company’s revenue is derived primarily from providing long-term healthcare services to patients and is recognized on the date services are provided at amounts billable to individual patients. For patients under reimbursement arrangements with third-party payors, including Medicaid, Medicare and private insurers, revenue is recorded based on contractually agreed-upon amounts or rate on a per patient, daily basis or as services are performed.

Assisted and Independent Living Revenue

The Company's revenue is recorded when services are rendered on the date services are provided at amounts billable to individual residents and consists of fees for basic housing and assisted living care. Residency agreements are generally for a term of 30 days, with resident fees billed monthly in advance. For patients under reimbursement arrangements with Medicaid, revenue is recorded based on contractually agreed-upon amounts or rate on a per resident, daily basis or as services rendered. Revenue for certain ancillary charges is recognized as services are provided, and such fees are billed monthly in arrears.

Home Health Revenue

Medicare Revenue

Net service revenue is recorded under the Medicare prospective payment system based on a 60-day episode payment rate that is subject to adjustment based on certain variables including, but not limited to: (a) an outlier payment if patient care was unusually costly; (b) a low utilization payment adjustment if the number of visits was fewer than five; (c) a partial payment if the patient transferred to another provider or the Company received a patient from another provider before completing the episode; (d) a payment adjustment based upon the level of therapy services required; (e) the number of episodes of care provided to a patient, regardless of whether the same home health provider provided care for the entire series of episodes; (f) changes in the base episode payments established by the Medicare program; (g) adjustments to the base episode payments for case mix and geographic wages; and (h) recoveries of overpayments.

The Company makes adjustments to Medicare revenue on completed episodes to reflect differences between estimated and actual payment amounts, an inability to obtain appropriate billing documentation or authorizations acceptable to the payor and other reasons unrelated to credit risk. Therefore, the Company believes that its reported net service revenue and patient accounts receivable will be the net amounts to be realized from Medicare for services rendered.

121

Table of Contents

THE ENSIGN GROUP, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

In addition to revenue recognized on completed episodes, the Company also recognizes a portion of revenue associated with episodes in progress. Episodes in progress are 60-day episodes of care that begin during the reporting period, but were not completed as of the end of the period. As such, the Company estimates revenue and recognizes it on a daily basis. The primary factors underlying this estimate are the number of episodes in progress at the end of the reporting period, expected Medicare revenue per episode and its estimate of the average percentage complete based on visits performed.

Non-Medicare Revenue

Episodic Based Revenue - The Company recognizes revenue in a similar manner as it recognizes Medicare revenue for episodic-based rates that are paid by other insurance carriers, including Medicare Advantage programs; however, these rates can vary based upon the negotiated terms.

Non-episodic Based Revenue - Revenue is recorded on an accrual basis based upon the date of service at amounts equal to its established or estimated per-visit rates, as applicable.

Hospice Revenue

Revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are daily rates for each of the levels of care the Company delivers. The Company makes adjustments to revenue for an inability to obtain appropriate billing documentation or authorizations acceptable to the payor and other reasons unrelated to credit risk. Additionally, as Medicare hospice revenue is subject to an inpatient cap limit and an overall payment cap, the Company monitors its provider numbers and estimates amounts due back to Medicare if a cap has been exceeded. The Company records these adjustments as a reduction to revenue and increases to other accrued liabilities.

Accounts Receivable and Allowance for Doubtful Accounts — Accounts receivable consist primarily of amounts due from Medicare and Medicaid programs, other government programs, managed care health plans and private payor sources. Estimated provisions for doubtful accounts are recorded to the extent it is probable that a portion or all of a particular account will not be collected.

In evaluating the collectability of accounts receivable, the Company considers a number of factors, including the age of the accounts, changes in collection patterns, the composition of patient accounts by payor type and the status of ongoing disputes with third-party payors. On an annual basis, the historical collection percentages are reviewed by payor and by state and are updated to reflect the recent collection experience of the Company. In order to determine the appropriate reserve rate percentages which ultimately establish the allowance, the Company analyzes historical cash collection patterns by payor and by state. The percentages applied to the aged receivable balances are based on the Company’s historical experience and time limits, if any, for managed care, Medicare, Medicaid and other payors. The Company periodically refines its estimates of the allowance for doubtful accounts based on experience with the estimation process and changes in circumstances.

Cash and Cash Equivalents — Cash and cash equivalents consist of bank term deposits, money market funds and treasury bill related investments with original maturities of three months or less at time of purchase and therefore approximate fair value. The fair value of money market funds is determined based on “Level 1” inputs, which consist of unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets. The Company places its cash and short-term investments with high credit quality financial institutions.

Insurance Subsidiary Deposits and Investments — The Company's captive insurance subsidiary cash and cash equivalents, deposits and investments are designated to support long-term insurance subsidiary liabilities and have been classified as short-term and long-term assets based on the timing of expected future payments of the Company's captive insurance liabilities. The majority of these deposits and investments are currently held in AA, A and BBB+ rated debt security investments and the remainder is held in a bank account with a high credit quality financial institution. See further discussion at Note 5, Fair Value Measurements.

The Company evaluates securities for other-than-temporary impairment (“OTTI”) on at least a quarterly basis, and more frequently when economic or market conditions warrant such an evaluation. If securities are in an unrealized loss position, the Company considers the extent and duration of the unrealized loss, and the financial condition and near-term prospects of the issuer. The Company also assesses whether it intends to sell, or it is more likely than not that it will be required to sell, a security in an unrealized loss position before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the entire difference between amortized cost and fair value is recognized as impairment through earnings. For the years ended December 31, 2016 and 2017, the Company did not recognize any OTTI for its investments.

Property and Equipment — Property and equipment are initially recorded at their historical cost. Repairs and maintenance are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the depreciable

122

Table of Contents

THE ENSIGN GROUP, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

assets (ranging from three to 59 years). Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the remaining lease term.

Impairment of Long-Lived Assets — The Company reviews the carrying value of long-lived assets that are held and used in the Company’s operating subsidiaries for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of these assets is determined based upon expected undiscounted future net cash flows from the operating subsidiaries to which the assets relate, utilizing management’s best estimate, appropriate assumptions, and projections at the time. If the carrying value is determined to be unrecoverable from future operating cash flows, the asset is deemed impaired and an impairment loss would be recognized to the extent the carrying value exceeded the estimated fair value of the asset. The Company estimates the fair value of assets based on the estimated future discounted cash flows of the asset. Management has evaluated its long-lived assets and recorded an impairment charge of $111 and $137 related to the closure of facilities during the years ended December 31, 2017 and 2016, respectively. The Company did not identify any asset impairment during the year ended December 31, 2015.

Leases and Leasehold Improvements - At the inception of each lease, the Company performs an evaluation to determine whether the lease should be classified as an operating or capital lease. The Company records rent expense for operating leases that contain scheduled rent increases on a straight-line basis over the term of the lease. The lease term used for straight-line rent expense is calculated from the date the Company is given control of the leased premises through the end of the lease term. The lease term used for this evaluation also provides the basis for establishing depreciable lives for buildings subject to lease and leasehold improvements, as well as the period over which the Company records straight-line rent expense.

Intangible Assets and Goodwill — Definite-lived intangible assets consist primarily of favorable leases, lease acquisition costs, patient base, facility trade names and customer relationships. Favorable leases and lease acquisition costs are amortized over the life of the lease of the facility. Patient base is amortized over a period of four to eight months, depending on the classification of the patients and the level of occupancy in a new acquisition on the acquisition date. Trade names at affiliated facilities are amortized over 30 years and customer relationships are amortized over a period of up to 20 years.

The Company's indefinite-lived intangible assets consist of trade names and Medicare and Medicaid licenses. The Company tests indefinite-lived intangible assets for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the carrying amount of the intangible asset may not be recoverable. The Company did not identify any asset impairment during the years ended December 31, 2017, 2016 and 2015.

Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in business combinations. Goodwill is subject to annual testing for impairment. In addition, goodwill is tested for impairment if events occur or circumstances change that would reduce the fair value of a reporting unit below its carrying amount. The Company performs its annual test for impairment during the fourth quarter of each year. See further discussion at Note 11, Goodwill and Other Indefinite-Lived Intangible Assets.

Deferred Rent - Deferred rent represents rental expense, determined on a straight-line basis over the life of the related lease, in excess of actual rent payments.

Self-Insurance — The Company is partially self-insured for general and professional liability up to a base amount per claim (the self-insured retention) with an aggregate, one-time deductible above this limit. Losses beyond these amounts are insured through third-party policies with coverage limits per claim, per location and on an aggregate basis for the Company. Starting on January 1, 2017, the combined self-insured retention was $500 per claim, subject to an additional one-time deductible of $750 for California affiliated operations and a separate, one-time, deductible of $1,000 for non-California operations. For all affiliated operations, except those located in Colorado, the third-party coverage above these limits was $1,000 per claim, $3,000 per operation, with a $5,000 blanket aggregate limit and an additional state-specific aggregate where required by state law. In Colorado, the third-party coverage above these limits was $1,000 per claim and $3,000 per operation, which is independent of the aforementioned blanket aggregate limits that apply outside of Colorado.

The Company’s policy is to accrue amounts equal to the actuarially estimated costs to settle open claims of insureds, as well as an estimate of the cost of insured claims that have been incurred but not reported. The Company develops information about

123

Table of Contents

THE ENSIGN GROUP, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

the size of the ultimate claims based on historical experience, current industry information and actuarial analysis, and evaluates the estimates for claim loss exposure on a quarterly basis.

The Company’s operating subsidiaries are self-insured for workers’ compensation in California. To protect itself against loss exposure in California with this policy, the Company has purchased individual specific excess insurance coverage that insures individual claims that exceed $500 per occurrence. In Texas, the operating subsidiaries have elected non-subscriber status for workers’ compensation claims and, effective February 1, 2011, the Company has purchased individual stop-loss coverage that insures individual claims that exceed $750 per occurrence. As of July 1, 2014, the Company’s operating subsidiaries in all other states, with the exception of Washington, are under a loss sensitive plan that insures individual claims that exceed $350 per occurrence. In Washington, the operating subsidiaries' coverage is financed through premiums paid by the employers and employees. The claims and pay benefits are managed through a state insurance pool. Outside of California, Texas and Washington, the Company has purchased insurance coverage that insures individual claims that exceed $350 per accident. In all states except Washington, the Company accrues amounts equal to the estimated costs to settle open claims, as well as an estimate of the cost of claims that have been incurred but not reported. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information.

In addition, the Company has recorded an asset and equal liability of $5,394 and $4,104 at December 31, 2017 and 2016, respectively, in order to present the ultimate costs of malpractice and workers' compensation claims and the anticipated insurance recoveries on a gross basis. See Note 12, Restricted and Other Assets.

The Company self-funds medical (including prescription drugs) and dental healthcare benefits to the majority of its employees. The Company is fully liable for all financial and legal aspects of these benefit plans. To protect itself against loss exposure with this policy, the Company has purchased individual stop-loss insurance coverage that insures individual claims that exceed $300 for each covered person with an additional one-time aggregate individual stop loss deductible of $75. Beginning 2016, the Company's policy does not include the additional one-time aggregate individual stop loss deductible of $75.

The Company believes that adequate provision has been made in the Financial Statements for liabilities that may arise out of patient care, workers’ compensation, healthcare benefits and related services provided to date. The amount of the Company’s reserves was determined based on an estimation process that uses information obtained from both company-specific and industry data. This estimation process requires the Company to continuously monitor and evaluate the life cycle of the claims. Using data obtained from this monitoring and the Company’s assumptions about emerging trends, the Company, with the assistance of an independent actuary, develops information about the size of ultimate claims based on the Company’s historical experience and other available industry information. The most significant assumptions used in the estimation process include determining the trend in costs, the expected cost of claims incurred but not reported and the expected costs to settle or pay damage awards with respect to unpaid claims. The self-insured liabilities are based upon estimates, and while management believes that the estimates of loss are reasonable, the ultimate liability may be in excess of or less than the recorded amounts. Due to the inherent volatility of actuarially determined loss estimates, it is reasonably possible that the Company could experience changes in estimated losses that could be material to net income. If the Company’s actual liability exceeds its estimates of loss, its future earnings, cash flows and financial condition would be adversely affected.

Income Taxes — Deferred tax assets and liabilities are established for temporary differences between the financial reporting basis and the tax basis of the Company’s assets and liabilities at tax rates in effect when such temporary differences are expected to reverse. The Company generally expects to fully utilize its deferred tax assets; however, when necessary, the Company records a valuation allowance to reduce its net deferred tax assets to the amount that is more likely than not to be realized.

In determining the need for a valuation allowance or the need for and magnitude of liabilities for uncertain tax positions, the Company makes certain estimates and assumptions. These estimates and assumptions are based on, among other things, knowledge of operations, markets, historical trends and likely future changes and, when appropriate, the opinions of advisors with knowledge and expertise in certain fields. Due to certain risks associated with the Company’s estimates and assumptions, actual results could differ.

The Tax Cuts and Jobs Act (the Tax Act), which was enacted in December 2017, increased the Company's income tax expense by $3,915 for the year ended December 31, 2017. The Tax Act will decrease the corporate income tax rate from 35.0% to 21.0% beginning on January 1, 2018. The Company expects meaningful benefits from this reduction to continue from its enactment in future periods. See Note 14, Income Taxes for further detail.

Noncontrolling Interest — The noncontrolling interest in a subsidiary is initially recognized at estimated fair value on the acquisition date and is presented within total equity in the Company's consolidated balance sheets. The Company presents the noncontrolling interest and the amount of consolidated net income attributable to The Ensign Group, Inc. in its consolidated

124

Table of Contents

THE ENSIGN GROUP, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

statements of income and net income per share is calculated based on net income attributable to The Ensign Group, Inc.'s stockholders. The carrying amount of the noncontrolling interest is adjusted based on an allocation of subsidiary earnings based on ownership interest.

Share-Based Compensation — The Company measures and recognizes compensation expense for all share-based payment awards made to employees and directors including employee stock options based on estimated fair values, ratably over the requisite service period of the award. Net income has been reduced as a result of the recognition of the fair value of all stock options and restricted stock awards issued, the amount of which is contingent upon the number of future grants and other variables.

Recent Accounting Pronouncements — Except for rules and interpretive releases of the Securities and Exchange Commission (SEC) under authority of federal securities laws and a limited number of grandfathered standards, the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) is the sole source of authoritative GAAP literature recognized by the FASB and applicable to the Company. For any new pronouncements announced, the Company considers whether the new pronouncements could alter previous generally accepted accounting principles and determines whether any new or modified principles will have a material impact on the Company's reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company's financial management and certain standards are under consideration.

Recent Accounting Standards Adopted by the Company

In March 2016, the FASB issued a new standard to simplify several aspects of the accounting for employee share-based payment transactions, which includes the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The new standard was effective for the Company in the first quarter of fiscal year 2017. Under the previous guidance, excess tax benefits and deficiencies from share-based compensation arrangements were recorded in equity when the awards vested or were settled. The new guidance requires prospective recognition of excess tax benefits and deficiencies in the income statement, resulting in the recognition of excess tax benefits in income tax expense, of $3,423, rather than in paid-in-capital, for the year ended December 31, 2017.

In addition, under the new guidance, excess income tax benefits from share-based compensation arrangements are classified as cash flow from operations, rather than as cash flow from financing activities. The Company has elected to apply the cash flow classification guidance prospectively, resulting in an increase to operating cash flow for the year ended December 31, 2017 and the prior year period has not been adjusted.

The Company has also elected to continue to estimate the expected forfeitures rather than electing to account for forfeitures as they occur. Finally, the adoption of the guidance requires excess tax benefits and deficiencies to be prospectively excluded from assumed future proceeds in the calculation of diluted shares, resulting in an increase in diluted weighted average shares outstanding.

Accounting Standards Recently Issued But Not Yet Adopted by the Company

In May 2017, the FASB issued amended authoritative guidance to provide guidance on types of changes to the terms or conditions of share-based payments awards to which an entity would be required to apply modification accounting under ASC 718. This guidance is effective for annual and interim periods beginning after December 15, 2017, which will be the Company's fiscal year 2018, with early adoption permitted in certain cases. The adoption of this standard is not expected to have a material impact on the Company's consolidated financial statements.

In January 2017, the FASB issued amended authoritative guidance to clarify the definition of a business and reduce diversity in practice related to the evaluation of whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The new provisions provide the requirements needed for an integrated set of assets and activities (the set) to be a business and also establish a practical way to determine when a set is not a business. The ASU provides a screen to determine when an integrated set of assets and activities is not a business. The more robust framework helps entities to narrow the definition of outputs created by the set and align it with how outputs are described in the new revenue standard. This guidance is effective for annual and interim periods beginning after December 15, 2017, which will be the Company's fiscal year 2018, with early adoption permitted in certain cases. The new guidance is required to be applied on a prospective basis. The effect of the implementation will depend upon the nature of the Company's future acquisitions.

125

Table of Contents

THE ENSIGN GROUP, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

zero or negative carrying amount to perform a qualitative assessment or step 2 of the goodwill impairment test. The new guidance does not amend the optional qualitative assessment of goodwill impairment. This guidance is effective for annual periods beginning after December 15, 2019, which will be the Company's fiscal year 2020, with early adoption permitted. The adoption of this standard is not expected to have a material impact on the Company's consolidated financial statements.

In October 2016, the FASB issued amended authoritative guidance to require companies to recognize the income tax consequences of an intra-entity transfer of an asset, other than inventory, when the transfer occurs. The amendments will be effective for the Company’s fiscal year beginning January 1, 2018. The new guidance is required to be applied on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. The adoption of this standard is not expected to have a material impact on the Company's consolidated financial statements based on the Company's historical activity. Furthermore, the actual impact of implementation will largely depend on future intra-entity asset transfers, if any.

In August 2016, the FASB issued amended authoritative guidance to reduce the diversity in practice related to the presentation and classification of certain cash receipts and cash payments in the statement of cash flows. The new provisions target cash flow issues related to (i) debt prepayment or debt extinguishment costs, (ii) settlement of debt instruments with coupon rates that are insignificant relative to effective interest rates, (iii) contingent consideration payments made after a business combination, (iv) proceeds from settlement of insurance claims, (v) proceeds from the settlement of corporate-owned life insurance and bank-owned life insurance policies, (vi) distributions received from equity method investees, (vii) beneficial interests in securitization transactions and (viii) separately identifiable cash flows and application of the predominance principle. This guidance will be effective for fiscal years beginning after December 15, 2017, which will be the Company's fiscal year 2018, with early adoption permitted. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements.

In February 2016, the FASB issued amended authoritative guidance on accounting for leases. The new provisions require that a lessee of operating leases recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. The lease liability will be equal to the present value of lease payments, with the right-of-use asset based upon the lease liability. The classification criteria for distinguishing between finance (or capital) leases and operating leases are substantially similar to the previous lease guidance, but with no explicit bright lines. As such, operating leases will result in straight-line rent expense similar to current practice. For short term leases (term of 12 months or less), a lessee is permitted to make an accounting election not to recognize lease assets and lease liabilities, which would generally result in lease expense being recognized on a straight-line basis over the lease term. This guidance applies to all entities and is effective for annual periods beginning after December 15, 2018, which will be the Company's fiscal year 2019, with early adoption permitted. The Company is currently evaluating the impact this guidance will have on its consolidated financial statements but expects this adoption will result in a significant increase in the assets and liabilities on its consolidated balance sheets.

In January 2016, the FASB issued amended authoritative guidance which makes targeted improvements for financial instruments. The new provisions impact certain aspects of recognition, measurement, presentation and disclosure requirements of financial instruments. Specifically, the guidance will (1) require equity investments to be measured at fair value with changes in fair value recognized in net income, (2) simplify the impairment assessment of equity investments without readily determinable fair values, (3) eliminate the requirement to disclose the method and assumptions used to estimate fair value for financial instruments measured at amortized cost, and (4) require separate presentation of financial assets and financial liabilities by measurement category. The guidance is effective for annual and interim periods beginning after December 15, 2017, which will be the Company's fiscal year 2018. Early adoption is not permitted. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements.

In March 2016, the FASB issued its standard to amend the principal-versus-agent implementation guidance and illustrations in the Board’s new revenue standard, which includes accounting implication related to (1) determining the appropriate unit of account under the revenue standard’s principal-versus-agent guidance and (2) applying the indicators of whether an entity is a principal or an agent in accordance with the revenue standard’s control principle. The guidance will be effective for fiscal years beginning after December 15, 2017, which will be the Company's fiscal year 2018. The guidance has the same effective date as the new revenue standard and the Company is required to adopt the guidance by using the same transition method it would use to adopt the new revenue standard. The Company's evaluation of the adoption method and impact to the consolidated financial statements is performed concurrently with the new revenue standard below.

126

Table of Contents

THE ENSIGN GROUP, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

with customers. The new standard supersedes most current revenue recognition guidance, including industry-specific guidance, and may be applied retrospectively to each period presented (full retrospective method) or retrospectively with the cumulative effect recognized in beginning retained earnings as of the date of adoption (modified retrospective method). In July 2015, the FASB formally deferred for one year the effective date of the new revenue standard and decided to permit entities to early adopt the standard. In December 2016, the FASB made certain technical corrections to further clarify the core revenue recognition principles, primarily in response to feedback from several sources, including the FASB/IASB Transition Resource Group. The guidance will be effective for fiscal years beginning after December 15, 2017, which will be the Company's fiscal year 2018. The Company initiated an adoption plan in fiscal year 2015, beginning with preliminary evaluation of the standard, and subsequently performed additional analysis of revenue streams and transactions under the new standard. In particular, the Company performed analysis into the application of the portfolio approach as a practical expedient to group patient contracts with similar characteristics, such that revenue for a given portfolio would not be materially different than if it were evaluated on a contract-by-contract basis. The adoption plan has been completed and the impact to the consolidated financial statements for periods subsequent to adoption is not material. As part of the impact assessment, the Company evaluated any variable consideration, potential constraints on the estimate of variable consideration, and significant financing components, in particular as it related to third party settlements. The Company anticipates that for periods subsequent to adoption, the majority of what is currently classified as bad debt expense under operating expenses will be treated as an implicit price concession factored into net revenue, consistent with the intent of the standard. The new standard also requires enhanced disclosures related to the disaggregation of revenue, information about contract balances, and other disclosures about contracts with customers, including revenue recognition policies to identify performance obligations and significant judgments in measurement and recognition. The Company adopted the new revenue standard as of January 1, 2018 using the modified retrospective method and the adoption did not have a material impact.

3. COMMON STOCK

On February 8, 2017, the Company announced that its Board of Directors authorized a stock repurchase program, under which the Company may repurchase up to $30,000 of its common stock under the program for a period of 12 months. Under this program, the Company is authorized to repurchase its issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. The stock repurchase program expired on February 8, 2018. During the year ended December 31, 2017, the Company repurchased 412 shares of its common stock for a total of $7,288.

On November 4, 2015 and February 9, 2016, the Company announced that its Board of Directors authorized two stock repurchase programs, under which the Company could repurchase up to $15,000 of its common stock under each program for a period of 12 months. During the first quarter of 2016, the Company repurchased 1,452 shares of its common stock for a total of $30,000 and these repurchase programs expired upon the repurchase of the full authorized amount under such plans.

4. COMPUTATION OF NET INCOME PER COMMON SHARE

Basic net income per share is computed by dividing income from continuing operations attributable to The Ensign Group, Inc. stockholders by the weighted average number of outstanding common shares for the period. The computation of diluted net income per share is similar to the computation of basic net income per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued.

The adoption of ASU No. 2016-09, Improvements to Employee Share-Based Payment Accounting: Topic 718 requires excess tax benefits and deficiencies to be prospectively excluded from assumed future proceeds in the calculation of diluted shares, resulting in an increase in diluted weighted average shares outstanding. A reconciliation of the numerator and denominator used in the calculation of basic net income per common share follows:

127

Table of Contents

THE ENSIGN GROUP, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)



	Year Ended December 31,
	2017		2016		2015
Numerator:
Net income	$	40,833	$	52,843	$	55,917
Less: net income attributable to noncontrolling interests	358		2,853		485
Net income attributable to The Ensign Group, Inc.	$	40,475	$	49,990	$	55,432

Denominator:
Weighted average shares outstanding for basic net income per share	50,932		50,555		50,316
Basic net income per common share attributable to The Ensign Group, Inc.	$	0.79	$	0.99	$	1.10

A reconciliation of the numerator and denominator used in the calculation of diluted net income per common share follows:



	Year Ended December 31,
	2017		2016		2017
Numerator:
Net income	$	40,833	$	52,843	$	55,917
Less: net income attributable to noncontrolling interests	358		2,853		485
Net income attributable to The Ensign Group, Inc.	$	40,475	$	49,990	$	55,432

Denominator:
Weighted average common shares outstanding	50,932		50,555		50,316
Plus: incremental shares from assumed conversion⁽¹⁾	1,897		1,578		1,894
Adjusted weighted average common shares outstanding	52,829		52,133		52,210
Diluted net income per common share attributable to The Ensign Group, Inc.	$	0.77	$	0.96	$	1.06

5. FAIR VALUE MEASUREMENTS

Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs such as quoted market prices in active markets; Level 2, defined as inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions.

The following table summarizes the financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2017 and 2016:



	December 31,
	2017						2016
	Level 1		Level 2		Level 3		Level 1		Level 2		Level 3
Cash and cash equivalents	$	42,337	$	—	$	—	$	57,706	$	—	$	—

Our non-financial assets, which include long-lived assets, including goodwill, intangible assets and property and equipment, are not required to be measured at fair value on a recurring basis. However, on a periodic basis, or whenever events or changes in circumstances indicate that their carrying value may not be recoverable, we assess our long-lived assets for impairment. When impairment has occurred, such long-lived assets are written down to fair value. See Note 2, Summary of Significant Accounting Policies for further discussion of the Company's significant accounting policies.

Debt Security Investments - Held to Maturity

128

Table of Contents

THE ENSIGN GROUP, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

At December 31, 2017 and 2016, the Company had approximately $41,777 and $35,184, respectively, in debt security investments which were classified as held to maturity and carried at amortized cost. The carrying value of the debt securities approximates fair value based on Level 1. The Company has the intent and ability to hold these debt securities to maturity. Further, as of December 31, 2017, the debt security investments were held in AA, A and BBB+ rated debt securities.

6. REVENUE AND ACCOUNTS RECEIVABLE

Revenue for the years ended December 31, 2017, 2016 and 2015 is summarized in the following tables:



	Year Ended December 31,
	2017				2016				2015
	Revenue		% of Revenue		Revenue		% of Revenue		Revenue		% of Revenue
Medicaid	$	644,803	34.9	%	$	557,958	33.7	%	$	458,956	34.2	%
Medicare	515,884		27.9		477,019		28.8		395,503		29.5
Medicaid — skilled	102,875		5.6		87,517		5.3		71,905		5.4
Total Medicaid and Medicare	1,263,562		68.4		1,122,494		67.8		926,364		69.1
Managed care	303,386		16.4		265,508		16.0		206,770		15.4
Private and other payors⁽¹⁾	282,369		15.2		266,862		16.2		208,692		15.5
Revenue	$	1,849,317	100.0	%	$	1,654,864	100.0	%	$	1,341,826	100.0	%

(1) Private and other payors also includes revenue from all payors generated in other ancillary services for the years ended December 31, 2017, 2016 and 2015 and urgent care centers for the years ended December 31, 2016 and 2015.

Accounts receivable as of December 31, 2017 and 2016 is summarized in the following table:



	December 31,
	2017			2016
Medicaid	$	119,441		$	111,031
Managed care	68,930			66,346
Medicare	55,667			55,500
Private and other payors	64,991			51,347
	309,029			284,224
Less: allowance for doubtful accounts	(43,961		)	(39,791		)
Accounts receivable, net	$	265,068		$	244,433

7. BUSINESS SEGMENTS

The Company has three reportable operating segments: (1) transitional and skilled services, which includes the operation of skilled nursing facilities; (2) assisted and independent living services, which includes the operation of assisted and independent living facilities; and (3) home health and hospice services, which includes the Company's home health, home care and hospice businesses. The Company's Chief Executive Officer, who is its chief operating decision maker, or CODM, reviews financial information at the operating segment level.

The Company also reports an “all other” category that includes results from its mobile diagnostics and other ancillary operations for the years ended December 31, 2017, 2016 and 2015 and urgent care centers for the years ended December 31, 2016 and 2015. The Company completed the sale of its urgent care centers in 2016 and recognized a pretax gain of $41,492. These operations are neither significant individually nor in aggregate and therefore do not constitute a reportable segment. The reporting segments are business units that offer different services and are managed separately to provide greater visibility into those operations.

129

Table of Contents

THE ENSIGN GROUP, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

and hospice services were provided to patients through 46 affiliated agencies. As of December 31, 2017, the Company held majority membership interests in other ancillary operations, which operating results are included in the "all other" category.

The Company evaluates performance and allocates capital resources to each segment based on an operating model that is designed to maximize the quality of care provided and profitability. General and administrative expenses are not allocated to any segment for purposes of determining segment profit or loss, and are included in the "all other" category in the selected segment financial data that follows. The accounting policies of the reporting segments are the same as those described in Note 2, Summary of Significant Accounting Policies. The Company's CODM does not review assets by segment in his resource allocation and therefore assets by segment are not disclosed below.

Segment revenues by major payor source were as follows:



	Year Ended December 31, 2017
	Transitional and Skilled Services		Assisted and Independent Living Services		Home Health and Hospice Services		All Other			Total Revenue		Revenue %
Medicaid	$	603,104	$	30,469	$	11,230	$	—		$	644,803	34.9	%
Medicare	417,870		—		98,014		—			515,884		27.9
Medicaid-skilled	102,875		—		—		—			102,875		5.6
Subtotal	1,123,849		30,469		109,244		—			1,263,562		68.4
Managed care	281,563		—		21,823		—			303,386		16.4
Private and other	139,798		106,177		11,336		25,058		(1)	282,369		15.2
Total revenue	$	1,545,210	$	136,646	$	142,403	$	25,058		$	1,849,317	100.0	%
(1) Private and other payors also includes revenue from all payors generated in other ancillary services for the year ended December 31, 2017.



	Year Ended December 31, 2016
	Transitional and Skilled Services		Assisted and Independent Living Services		Home Health and Hospice Services		All Other			Total Revenue		Revenue %
Medicaid	$	521,063	$	26,397	$	10,498	$	—		$	557,958	33.7	%
Medicare	396,519		—		80,500		—			477,019		28.8
Medicaid-skilled	87,517		—		—		—			87,517		5.3
Subtotal	1,005,099		26,397		90,998		—			1,122,494		67.8
Managed care	247,844		—		17,664		—			265,508		16.0
Private and other	121,860		97,239		7,151		40,612		(1)	266,862		16.2
Total revenue	$	1,374,803	$	123,636	$	115,813	$	40,612		$	1,654,864	100.0	%
(1) Private and other payors also includes revenue from all payors generated in other ancillary services and urgent care centers for the year ended December 31, 2016.

130

Table of Contents

THE ENSIGN GROUP, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)



	Year Ended December 31, 2015
	Transitional and Skilled Services		Assisted and Independent Living Services		Home Health and Hospice Services		All Other			Total Revenue		Revenue %
Medicaid	$	430,368	$	19,642	$	8,946	$	—		$	458,956	34.2	%
Medicare	332,429		—		63,074		—			395,503		29.5
Medicaid-skilled	71,905		—		—		—			71,905		5.4
Subtotal	834,702		19,642		72,020		—			926,364		69.1
Managed care	194,743		—		12,027		—			206,770		15.4
Private and other	96,943		68,487		6,309		36,953		(1)	208,692		15.5
Total revenue	$	1,126,388	$	88,129	$	90,356	$	36,953		$	1,341,826	100.0	%
(1) Private and other payors also includes revenue from all payors generated in other ancillary services and urgent care centers for the year ended December 31, 2015.

The following table sets forth selected financial data consolidated by business segment:



	Year Ended December 31, 2017
	Transitional and Skilled Services(3)		Assisted and Independent Living Services(3)		Home Health and Hospice Services		All Other			Elimination			Total
Revenue from external customers	$	1,545,210	$	136,646	$	142,403	$	25,058		$	—		$	1,849,317
Intersegment revenue (1)	3,023		—		—		3,035			(6,058		)	—
Total revenue	$	1,548,233	$	136,646	$	142,403	$	28,093		$	(6,058	)	$	1,849,317
Segment income (loss) (2)	$	140,272	$	16,736	$	19,717	$	(95,440	)	$	—		$	81,285
Interest expense, net of interest income													$	(12,007	)
Income before provision for income taxes													$	69,278
Depreciation and amortization	$	29,928	$	6,334	$	945	$	7,265		$	—		$	44,472

(1) Intersegment revenue represents services provided at the Company's operating subsidiaries to the Company's other business lines.

(2) Segment income (loss) includes depreciation and amortization expense and excludes general and administrative expense and interest expense for transitional and skilled services, assisted and independent living services and home health and hospice businesses. General and administrative expense is included in the "All Other" category.

(3) The Company's campuses represent facilities that offer skilled nursing, assisted and/or independent living services. Revenue and expenses related to skilled nursing, assisted and independent living services have been allocated and recorded in the respective reportable segment.



	Year Ended December 31, 2016
	Transitional and Skilled Services(3)		Assisted and Independent Living Services(3)		Home Health and Hospice Services		All Other			Elimination			Total
Revenue from external customers	$	1,374,803	$	123,636	$	115,813	$	40,612		$	—		$	1,654,864
Intersegment revenue (1)	2,929		—		—		2,184			(5,113		)	—
Total revenue	$	1,377,732	$	123,636	$	115,813	$	42,796		$	(5,113	)	$	1,654,864
Segment income (loss) (2)	$	118,118	$	11,701	$	16,571	$	(54,543	)	$	—		$	91,847
Interest expense, net of interest income													$	(6,029	)
Income before provision for income taxes													$	85,818
Depreciation and amortization	$	26,298	$	4,157	$	924	$	7,303		$	—		$	38,682

(1) Intersegment revenue represents services provided at the Company's operating subsidiaries to the Company's other business lines.

131

Table of Contents

THE ENSIGN GROUP, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)



	Year Ended December 31, 2015
	Transitional and Skilled Services(3)		Assisted and Independent Living Services(3)		Home Health and Hospice Services		All Other			Elimination			Total
Revenue from external customers	$	1,126,388	$	88,129	$	90,356	$	36,953		$	—		$	1,341,826
Intersegment revenue (1)	2,447		—		—		881			(3,328		)	—
Total revenue	$	1,128,835	$	88,129	$	90,356	$	37,834		$	(3,328	)	$	1,341,826
Segment income (loss) (2)	$	136,744	$	11,463	$	13,584	$	(68,709	)	$	—		$	93,082
Interest expense, net of interest income													$	(1,983	)
Income before provision for income taxes													$	91,099
Depreciation and amortization	$	18,008	$	3,338	$	980	$	5,785		$	—		$	28,111

(1) Intersegment revenue represents services provided at the Company's operating subsidiaries to the Company's other business lines.

The Company's transitional and skilled services segment income for the years ended December 31, 2017 and 2016 included continued obligations under the lease related to closed operations, lease termination costs and related closing expenses of $4,017 and $7,935, respectively. These amounts included the present value of future rental payments of approximately $2,715 and $6,512 and long-lived assets impairment of $111 and $137 for the years ended December 31, 2017 and 2016, respectively. These costs were not incurred for the year ended December 31, 2015. See Note 17, Leases for further detail. Included in the year ended December 31, 2017 is the loss recovery of $1,286 related to a facility that was closed in the prior year.

8. ACQUISITIONS

The Company’s acquisition focus is to purchase or lease operating subsidiaries that are complementary to the Company’s current affiliated operations, accretive to the Company's business or otherwise advance the Company's strategy. The results of all the Company’s operating subsidiaries are included in the accompanying Financial Statements subsequent to the date of acquisition. Acquisitions are accounted for using the acquisition method of accounting. The Company also enters into long-term leases that may include options to purchase the affiliated facilities. As a result, from time to time, the Company will acquire affiliated facilities that the Company has been operating under third-party leases.

During the year ended December 31, 2017, the Company expanded its operations through a combination of long-term leases and purchases, with the addition of eight stand-alone skilled nursing operations, nine stand-alone assisted and independent living operations, one campus operation, three home health agencies, three hospice agencies and one home care agency. The Company did not acquire any material assets or assume any liabilities other than the tenant's post-assumption rights and obligations under the long-term leases. The Company has also invested in ancillary services that are complementary to its existing transitional and skilled services, assisted and independent living services, and home health and hospice businesses. The aggregate purchase price for these acquisitions for the year ended December 31, 2017 was $89,683. The addition of these operations added 905 operational skilled nursing beds and 594 assisted living units operated by the Company's operating subsidiaries. The Company entered into a separate operations transfer agreement with the prior operator as part of each transaction. Additionally, the Company's operating subsidiaries also opened four newly constructed stand-alone skilled nursing operations under long-term lease agreements, which added 455 operational skilled nursing beds.

132

Table of Contents

THE ENSIGN GROUP, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

acquired the real estate at two of the skilled nursing operations and one post-acute care campus and entered into long term leases for sixteen skilled nursing operations. The Company did not acquire any material assets or assume any liabilities other than the tenant's post-assumption rights and obligations under the long-term lease. The Company also invested in new ancillary services that are complementary to its existing transitional and skilled services; assisted and independent living services and home health and hospice businesses. The aggregate purchase price for these acquisitions for the year ended December 31, 2016 was $64,521. The expansion of skilled nursing operations added 2,336 operational skilled nursing beds and ten assisted living units operated by the Company's operating subsidiaries. The Company entered into a separate operations transfer agreement with the prior operator as part of each transaction. Additionally, the Company's operating subsidiaries opened six newly constructed post-acute care campuses under long-term lease agreements, which added 463 operational skilled nursing beds and 142 assisted living units.

During the year ended December 31, 2015, the Company continued to expand its operations with the addition of 50 stand-alone skilled nursing and assisted living operations, seven home health, hospice and home care agencies and three urgent care centers to its operations through a combination of long-term leases and purchases. The Company did not acquire any material assets or assume any liabilities other than the tenant's post-assumption rights and obligations under the long-term leases. As part of these transactions, we acquired the real estate at 18 of the skilled nursing and assisted and independent living operations. In addition, the Company has invested in new business lines that are complementary to its existing transitional and skilled services; assisted and independent living services and home health and hospice businesses. The aggregate purchase price conveyed in all acquisitions was $119,965, including the assumption of liabilities of $8,939. The expansion of skilled nursing and assisted and independent living operations added 2,580 and 2,013 operational skilled nursing beds and assisted and independent living units, respectively, operated by the Company's operating subsidiaries. The Company also entered into a separate operations transfer agreement with the prior operator as part of each transaction.

The table below presents the allocation of the purchase price for the operations acquired in business combinations during the year ended December 31, 2017, 2016 and 2015. As of the date of this filing, the preliminary allocation of the purchase price for certain acquisitions in the fourth quarter was not completed as necessary valuation information was not yet available.



	December 31,
	2017		2016		2015
Land	$	9,732	$	1,054	$	12,811
Building and improvements	53,735		21,057		73,502
Equipment, furniture, and fixtures	4,382		8,265		4,612
Assembled occupancy	762		1,299		895
Definite-lived intangible assets	—		363		360
Goodwill	13,962		30,343		10,617
Favorable leases	—		393		10,901
Other indefinite-lived intangible assets	7,018		1,741		6,285
Other assets acquired, net of liabilities assumed	92		6		(18		)
Total acquisitions	$	89,683	$	64,521	$	119,965

In addition to the business combinations above, during the year ended December 31, 2017, the Company acquired Medicare and Medicaid licenses to add to its existing operations for an aggregate purchase price of $195. For year ended December 31, 2016, the Company acquired the underlying real estate of fifteen assisted living operations, which the Company previously operated under a long-term lease agreement for an aggregate purchase price of $127,348. For year ended December 31, 2015, the Company acquired the underlying real estate and assets of three skilled nursing operations that the Company previously operated under long-term lease agreements for an aggregate purchase price of $23,998, which included a promissory note of $6,248. These asset acquisitions did not impact the Company's operational bed or unit counts.

Subsequent to December 31, 2017, the Company acquired two stand-alone assisted and independent living operations for an aggregate purchase price of $4,298. The addition of these operations added 74 assisted living units operated by the Company's operating subsidiaries.

133

Table of Contents

THE ENSIGN GROUP, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

especially with underperforming operating subsidiaries, is often inadequate, inaccurate or unavailable. Consequently, the Company believes that prior operating results are not a meaningful representation of the Company’s current operating results or indicative of the integration potential of its newly acquired operating subsidiaries. The businesses acquired during the year ended December 31, 2017 were not material acquisitions to the Company individually or in the aggregate. Accordingly, pro forma financial information is not presented. These acquisitions have been included in the December 31, 2017 consolidated balance sheets of the Company, and the operating results have been included in the consolidated statements of operations of the Company since the dates the Company gained effective control.

9. PROPERTY AND EQUIPMENT— Net

Property and equipment, net consist of the following:



	December 31,
	2017			2016
Land	$	49,081		$	47,565
Buildings and improvements	342,641			304,263
Equipment	181,530			153,170
Furniture and fixtures	5,244			6,931
Leasehold improvements	97,221			80,164
Construction in progress	5,460			2,441
	681,177			594,534
Less: accumulated depreciation	(144,093		)	(110,036		)
Property and equipment, net	$	537,084		$	484,498

The Company disposed of $24,847 of land, building and equipment as part of the sale-leaseback transaction during the year ended December 31, 2017. See Note 17, Leases for information on the sale-leaseback transaction. See also Note 8, Acquisitions for information on acquisitions during the year ended December 31, 2017.

10. INTANGIBLE ASSETS — Net



	Weighted Average Life (Years)	December 31,
		2017							2016
		Gross Carrying Amount		Accumulated Amortization					Gross Carrying Amount		Accumulated Amortization
Intangible Assets		Gross Carrying Amount		Accumulated Amortization			Net		Gross Carrying Amount		Accumulated Amortization			Net
Lease acquisition costs	24.8	$	483	$	(99	)	$	384	$	483	$	(78	)	$	405
Favorable leases	33.0	35,116		(6,568		)	28,548		35,116		(4,589		)	30,527
Assembled occupancy	0.7	2,659		(2,631		)	28		1,897		(1,897		)	—
Facility trade name	30.0	733		(293		)	440		733		(269		)	464
Customer relationships	18.7	4,933		(1,530		)	3,403		4,933		(1,253		)	3,680
Total		$	43,924	$	(11,121	)	$	32,803	$	43,162	$	(8,086	)	$	35,076

Amortization expense was $3,035, $4,634 and $3,824 for the years ended December 31, 2017, 2016 and 2015, respectively. Of the $3,035 in amortization expense incurred during the year ended December 31, 2017, approximately $734 related to the amortization of patient base intangible assets at recently acquired facilities, which is typically amortized over a period of four to eight months, depending on the classification of the patients and the level of occupancy in a new acquisition on the acquisition date. As of December 31, 2016, the Company removed $582 in customer relationships as part of the sale of urgent care centers and $7,190 of favorable leases as part of the acquisition of the real estate of fifteen assisted living operations.

Estimated amortization expense for each of the years ending December 31 is as follows:

134

Table of Contents

THE ENSIGN GROUP, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)



Year	Amount
2018	2,329
2019	2,301
2020	1,593
2021	1,497
2022	1,471
Thereafter	23,612
	$	32,803

11. GOODWILL AND OTHER INDEFINITE-LIVED INTANGIBLE ASSETS

The Company tests goodwill during the fourth quarter of each year or more often if events or circumstances indicate there may be impairment. The Company performs its analysis for each reporting unit that constitutes a business for which discrete financial information is produced and reviewed by operating segment management and provides services that are distinct from the other components of the operating segment, in accordance with the provisions of Accounting Standards Codification topic 350, Intangibles—Goodwill and Other (ASC 350). This guidance provides the option to first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value, a "Step 0" analysis. If, based on a review of qualitative factors, it is more likely than not that the fair value of a reporting unit is less than its carrying value, the Company performs "Step 1" of the traditional two-step goodwill impairment test by comparing the net assets of each reporting unit to their respective fair values. The Company determines the estimated fair value of each reporting unit using a discounted cash flow analysis. In the event a unit's net assets exceed its fair value, an implied fair value of goodwill must be determined by assigning the unit's fair value to each asset and liability of the unit. The excess of the fair value of the reporting unit over the amounts assigned to its assets and liabilities is the implied fair value of goodwill. An impairment loss is measured by the difference between the goodwill carrying value and the implied fair value.

The Company performs its goodwill impairment test annually and evaluates goodwill when events or changes in circumstances indicate that its carrying value may not be recoverable. The Company performs the annual impairment testing of goodwill using October 1 as the measurement date. The Company completed its goodwill impairment test as of October 1, 2017 and no impairments were identified. As of December 31, 2016, the Company removed $4,103 in goodwill as part of the sale of urgent care centers.

The following table represents activity in goodwill by segment as of and for the year ended December 31, :



	Goodwill
	Transitional and Skilled Services		Assisted and Independent Living Services		Home Health and Hospice Services		All Other			Total
January 1, 2015	$	14,221	$	1,756	$	10,929	$	3,363		$	30,269
Additions	—		1,782		5,173		3,662			10,617
December 31, 2015	$	14,221	$	3,538	$	16,102	$	7,025		$	40,886
Less: Dispositions	—		—		—		(4,103		)	(4,103		)
Purchase price adjustment	—		—		—		(26		)	(26		)
Additions	26,415		—		1,799		2,129			30,343
December 31, 2016	$	40,636	$	3,538	$	17,901	$	5,025		$	67,100
Additions	4,850		420		6,421		2,271			13,962
December 31, 2017	$	45,486	$	3,958	$	24,322	$	7,296		$	81,062

There was no impairment charge to goodwill for the years ended December 31, 2017, 2016 and 2015. The Company anticipates that the majority of total goodwill recognized will be fully deductible for tax purposes as of December 31, 2017. See further discussion of goodwill acquired at Note 8, Acquisitions.

135

Table of Contents

THE ENSIGN GROUP, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

During the year ended December 31, 2017, the Company recorded $7,178 in Medicare and Medicaid licenses and $35 in trade name indefinite-lived intangible assets as part of its acquisitions. In addition, the Company disposed of $500 in Medicare license in fiscal year 2017.

Other indefinite-lived intangible assets consists of the following:



	December 31, 2017		December 31, 2016
Trade name	$	1,181	$	1,146
Medicare and Medicaid licenses	24,068		18,440
	$	25,249	$	19,586

12. RESTRICTED AND OTHER ASSETS

Restricted and other assets consist of the following:



	December 31,
	2017		2016
Debt issuance costs, net	$	2,799	$	3,611
Long-term insurance losses recoverable asset	5,394		4,104
Deposits with landlords	5,981		3,526
Capital improvement reserves with landlords and lenders	2,327		673
Note receivable from sale of urgent care centers	—		700
Restricted and other assets	$	16,501	$	12,614

Included in restricted and other assets as of December 31, 2017 and 2016, are anticipated insurance recoveries related to the Company's workers' compensation, general and professional liability claims that are recorded on a gross rather than net basis in accordance with an Accounting Standards Update issued by the FASB. Note receivable from sale of urgent centers was reclassified to current assets. The Company collected the receivable in January 2018.

13. OTHER ACCRUED LIABILITIES

Other accrued liabilities consist of the following:



	December 31,
	2017		2016
Quality assurance fee	$	4,864	$	4,604
Refunds payable	21,661		18,368
Deferred revenue	7,066		6,994
Cash held in trust for patients	2,609		2,373
Resident deposits	6,574		6,099
Dividends payable	2,328		2,186
Property taxes	10,088		9,130
Income tax payable	—		1,182
Operational closure liability	910		1,972
Other	7,715		5,855
Other accrued liabilities	$	63,815	$	58,763

136

Table of Contents

THE ENSIGN GROUP, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

payables related to overpayments, duplicate payments and credit balances from various payor sources. Deferred revenue occurs when the Company receives payments in advance of services provided. Resident deposits include refundable deposits to patients. Cash held in trust for patients reflects monies received from, or on behalf of, patients. Maintaining a trust account for patients is a regulatory requirement and, while the trust assets offset the liabilities, the Company assumes a fiduciary responsibility for these funds. The cash balance related to this liability is included in other current assets in the accompanying consolidated balance sheets. Operational closure liability includes the short-term portion of the closing costs that are payable within the next 12 months. The remaining long-term portion is included in other long-term liabilities in the accompanying consolidated balance sheets.

14. INCOME TAXES

The Tax Act was enacted on December 22, 2017. Effective January 1, 2018 the Tax Act reduces the corporate rate from 35.0% to 21.0%. As of December 31, 2017, the Company has not completed its accounting for the tax effects of the enactment of the Act; however, the Company has made a reasonable estimate of the effects on its existing deferred tax balances. The Company recognized an income tax expense of $3,915 in the year ended December 31, 2017 to reflect the revaluation of the Company's net deferred tax assets based on the U.S. federal tax rate of 21.0%.

The Company is currently analyzing the Tax Act and refining its calculations, which could potentially impact the measurement of the Company's tax balances. The expected impact of the enactment of the Tax Act for fiscal year 2017 is reflected in the table below.

The provision for income taxes on continuing operations for the years ended December 31, 2017, 2016 and 2015 is summarized as follows:



	Year Ended December 31,
	2017		2016			2015
Current:
Federal	$	15,141	$	30,043		$	28,149
State	2,975		5,183			5,761
	18,116		35,226			33,910
Deferred:
Federal	5,428		(1,034		)	2,026
State	986		(1,217		)	(754		)
	6,414		(2,251		)	1,272
Adjustment to deferred taxes for tax rate change	3,915		—			—
Total	$	28,445	$	32,975		$	35,182

A reconciliation of the federal statutory rate to the effective tax rate for income from continuing operations for the years ended December 31, 2017, 2016 and 2015, respectively, is comprised as follows:



	December 31,
	2017		2016		2015
Income tax expense at statutory rate	35.0	%	35.0	%	35.0	%
State income taxes - net of federal benefit	3.1		3.0		3.6
Non-deductible expenses	1.7		0.9		0.6
Equity compensation	(4.5	)	—		—
Revaluation of deferred	5.7		—		—
Other adjustments	0.1		(0.5	)	(0.6	)
Total income tax provision	41.1	%	38.4	%	38.6	%

The Company's deferred tax assets and liabilities as of December 31, 2017 and 2016 are summarized below. The deferred taxes in 2017 reflect the federal tax rate of 21.0%, whereas 2016 reflect a federal tax rate of 35.0%.

137

Table of Contents

THE ENSIGN GROUP, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)



	December 31,
	2017			2016
Deferred tax assets (liabilities):
Accrued expenses	$	16,500		$	21,732
Allowance for doubtful accounts	11,090			15,956
Tax credits	3,334			3,461
Insurance	5,135			7,333
	36,059			48,482
Valuation allowance	(530		)	—
Total deferred tax assets	35,529			48,482
State taxes	(911		)	(1,023		)
Depreciation and amortization	(18,248		)	(20,643		)
Prepaid expenses	(3,625		)	(3,743		)
Total deferred tax liabilities	(22,784		)	(25,409		)
Net deferred tax assets	$	12,745		$	23,073

The Company has recorded a decrease related to deferred tax assets and deferred tax liabilities of $17,995 and $14,080, respectively, with a net adjustment to deferred income tax expense of $3,915 for the year ended December 31, 2017 as a result of the Tax Act.

The Company had state credit carryforwards as of December 31, 2017 and 2016 of $3,302 and $3,430, respectively. These carryforwards almost entirely relate to state limitations on the application of Enterprise Zone employment-related tax credits. Unless the Company uses the Enterprise Zone credits before hand, the carryforward will begin to expire in 2023. The remainder of these carryforwards relates to credits against the Texas margin tax and is expected to carry forward until 2027. As of December 31, 2017 a valuation allowance of $530 was recorded against the Enterprise Zone credits as the Company believes it is more likely than not that some of the benefit of the credits will not be realized.

The Company's operating loss carry forwards for both federal and states were not material during the year ended December 31, 2017 and 2016.

The Federal statutes of limitations on the Company's 2011, 2012, and 2013 income tax years lapsed during the third quarter of 2015, 2016, and 2017, respectively. During the fourth quarter of each year, various state statutes of limitations also lapsed. The lapses for the years ended December 31, 2017, 2016, and 2015 had no impact on the Company's unrecognized tax benefits.

As of December 31, 2017, 2016 and 2015, the Company did not have any unrecognized tax benefits, net of their state benefits, that would affect the Company's effective tax rate. The Company classifies interest and/or penalties on income tax liabilities or refunds as additional income tax expense or income. Such amounts are not material.

15. DEBT

Long-term debt consists of the following:



	December 31,
	2017			2016
Term loan with SunTrust, interest payable quarterly	$	140,625		$	148,125
Credit facility with SunTrust	50,000			122,000
Mortgage loans and promissory note, principal and interest payable monthly, interest at fixed rate	125,394			14,032
	316,019			284,157
Less: current maturities	(9,939		)	(8,129		)
Less: debt issuance costs	(3,090		)	(542		)
	$	302,990		$	275,486

138

Table of Contents

THE ENSIGN GROUP, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Credit Facility with a Lending Consortium Arranged by SunTrust

The Company maintains a credit facility with a lending consortium arranged by SunTrust (as amended to date, the Credit Facility). The Company originally entered into the Credit Facility in an aggregate principal amount of $150,000 in May 2014. Under the Credit Facility, the Company could seek to obtain incremental revolving or term loans in an aggregate amount not to exceed $75,000. The interest rates applicable to loans under the Credit Facility are, at the Company’s option, equal to either a base rate plus a margin ranging from 1.25% to 2.25% per annum or LIBOR plus a margin ranging from 2.25% to 3.25% per annum, based on the debt to Consolidated EBITDA ratio of the Company and its operating subsidiaries as defined in the agreement. In addition, the Company will pay a commitment fee on the unused portion of the commitments under the Credit Facility that will range from 0.30% to 0.50% per annum, depending on the debt to Consolidated EBITDA ratio of the Company and its operating subsidiaries. Loans made under the Credit Facility are not subject to interim amortization. The Company is not required to repay any loans under the Credit Facility prior to maturity, other than to the extent the outstanding borrowings exceed the aggregate commitments under the Credit Facility.

On February 5, 2016, the Company amended its existing revolving credit facility to increase its aggregate principal amount available to $250,000 (the Amended Credit Facility). Under the credit facility, the Company may seek to obtain incremental revolving or term loans in an aggregate amount not to exceed $150,000. The interest rates applicable to loans under the credit facility are, at the Company's option, equal to either a base rate plus a margin ranging from 0.75% to 1.75% per annum or LIBOR plus a margin ranging from 1.75% to 2.75% per annum, based on the Consolidated Total Net Debt to Consolidated EBITDA ratio (as defined in the agreement). In addition, the Company will pay a commitment fee on the unused portion of the commitments under the credit facility that will range from 0.30% to 0.50% per annum, depending on the Consolidated Total Net Debt to Consolidated EBITDA ratio of the Company and its subsidiaries. The Company is permitted to prepay all or any portion of the loans under the credit facility prior to maturity without premium or penalty, subject to reimbursement of any LIBOR breakage costs of the lenders.

On July 19, 2016, the Company entered into the second amendment to the credit facility (Second Amended Credit Facility), which amended the existing credit agreement to increase the aggregate principal amount up to $450,000. The Second Amended Credit Facility is comprised of a $300,000 revolving credit facility and a $150,000 term loan. Borrowings under the term loan portion of the Second Amended Credit Facility mature on February 5, 2021 and amortize in equal quarterly installments, in an aggregate annual amount equal to 5.0% per annum of the original principal amount. The interest rates and commitment fee applicable to the Second Amended Credit Facility are similar to the Amended Credit Facility discussed below. Except as set forth in the Second Amended Credit Facility, all other terms and conditions of the Amended Credit Facility remained in full force and effect as described below.

The Credit Facility is guaranteed, jointly and severally, by certain of the Company’s wholly owned subsidiaries, and is secured by a pledge of stock of the Company's material operating subsidiaries as well as a first lien on substantially all of its personal property. The credit facility contains customary covenants that, among other things, restrict, subject to certain exceptions, the ability of the Company and its operating subsidiaries to grant liens on their assets, incur indebtedness, sell assets, make investments, engage in acquisitions, mergers or consolidations, amend certain material agreements and pay certain dividends and other restricted payments. Under the Credit Facility, the Company must comply with financial maintenance covenants to be tested quarterly, consisting of a maximum Consolidated Total Net Debt to consolidated EBITDA ratio (which shall be increased to 3.50:1.00 for the first fiscal quarter and the immediate following three fiscal quarters), and a minimum interest/rent coverage ratio (which cannot be below 1.50:1.00). The majority of lenders can require that the Company and its operating subsidiaries mortgage certain of its real property assets to secure the Amended Credit Facility if an event of default occurs, the Consolidated Total Net Debt to consolidated EBITDA ratio is above 2.75:1.00 for two consecutive fiscal quarters, or its liquidity is equal or less than 10% of the Aggregate Revolving Commitment Amount (as defined in the agreement) for ten consecutive business days, provided that such mortgages will no longer be required if the event of default is cured, the Consolidated Total Net Debt to consolidated EBITDA ratio is below 2.75:1.00 for two consecutive fiscal quarters, or its liquidity is above 10% of the Aggregate Revolving Commitment Amount (as defined in the agreement) or ninety consecutive days, as applicable. As of December 31, 2017, the Company's operating subsidiaries had $190,625 outstanding under the Credit Facility. The outstanding balance on the term loan was $140,625, of which $7,500 is classified as short-term and the remaining $133,125 is classified as long-term. The outstanding balance on the revolving Credit Facility was $50,000, which is classified as long-term. The Company was in compliance with all loan covenants as of December 31, 2017.

As of February 2, 2018, there was approximately $195,625 outstanding under the Credit Facility.

Mortgage Loans and Promissory Note

139

Table of Contents

THE ENSIGN GROUP, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

In December 2017, seventeen of the Company's subsidiaries entered into mortgage loans in the aggregate amount of $112,000. The mortgage loans are insured with Department of Housing and Urban Development (HUD), which subjects these subsidiaries to HUD oversight and periodic inspections. The mortgage loans and note bear fixed interest rates of 3.3% per annum. Amounts borrowed under the mortgage loans may be prepaid, subject to prepayment fees of the principal balance on the date of prepayment. During the first three years, the prepayment fee is 10% and is reduced by 3% in the fourth year of the loan, and reduced by 1.0% per year for years five through ten of the loan. There is no prepayment penalty after year ten. The terms of the mortgage loans are 30 to 35-years. The borrowings were arranged by Lancaster Pollard Mortgage Company, LLC, and insured by HUD. Loan proceeds were used to pay down previously drawn amounts on Ensign's revolving line of credit. In addition to refinancing existing borrowings, the proceeds of the HUD-insured debt helped fund acquisitions, to renovate and upgrade existing and future facilities, to cover working capital needs and for other business purposes.

In addition to the HUD mortgage loans above, the Company had outstanding indebtedness under mortgage loans insured with HUD and a promissory note issued in connection with various acquisitions. These mortgage loans and note bear fixed interest rates between 2.6% and 5.3% per annum. Amounts borrowed under the mortgage loans may be prepaid starting after the second anniversary of the notes subject to prepayment fees of the principal balance on the date of prepayment. These prepayment fees are reduced by 1.0% per year for years three through eleven of the loan. There is no prepayment penalty after year eleven. The term of the mortgage loans and the note is between 12 and 33 years. The mortgage loans and note are secured by the real property comprising the facilities and the rents, issues and profits thereof, as well as all personal property used in the operation of the facilities.

As of December 31, 2017, the Company's operating subsidiaries had $125,394 outstanding under the mortgage loans and note, of which $2,439 is classified as short-term and the remaining $122,955 is classified as long-term. The Company was in compliance with all loan covenants as of December 31, 2017.

Based on Level 2, the carrying value of the Company's long-term debt is considered to approximate the fair value of such debt for all periods presented based upon the interest rates that the Company believes it can currently obtain for similar debt.

Future principal payments due under the long-term debt arrangements discussed above are as follows:



Years Ending
December 31,	Amount
2018	9,939
2019	10,106
2020	10,203
2021	170,926
2022	2,904
Thereafter	111,941
	$	316,019

Off-Balance Sheet Arrangements

During the year ended December 31, 2017, the Company increased the letters of credit by $3,994. As of December 31, 2017, the Company had approximately $6,304 on the credit facility of borrowing capacity pledged as collateral to secure outstanding letters of credit.

16. OPTIONS AND AWARDS

Stock-based compensation expense consists of share-based payment awards made to employees and directors, including employee stock options and restricted stock awards, based on estimated fair values. As stock-based compensation expense recognized in the Company’s consolidated statements of income for the years ended December 31, 2017, 2016 and 2015 was based on awards ultimately expected to vest, it has been reduced for estimated forfeitures. The Company estimates forfeitures at the time of grant and, if necessary, revises the estimate in subsequent periods if actual forfeitures differ.

140

Table of Contents

THE ENSIGN GROUP, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Company retired the 2001 Stock Option, Deferred Stock and Restricted Stock Plan (2001 Plan), the 2005 Stock Incentive Plan (2005 Plan), and the 2007 Omnibus Incentive Plan (2007 Plan) as a result of the approval of the 2017 Plan.

2007 Omnibus Incentive Plan - The 2007 Plan authorizes the sale of up to 2,000 shares of common stock to officers, employees, directors and consultants of the Company. In addition, the number of shares of common stock reserved under the 2007 Plan will automatically increase on the first day of each fiscal year, beginning on January 1, 2008, in an amount equal to the lesser of (i) 1,000 shares of common stock, or (ii) 2% of the number of shares outstanding as of the last day of the immediately preceding fiscal year, or (iii) such lesser number as determined by the Company's board of directors. Granted non-employee director options vest and become exercisable in three equal annual installments, or the length of the term if less than 3 years, on the completion of each year of service measured from the grant date. All other granted options vest over 5 years at 20% per year on the anniversary of the grant date. Options expire 10 years from the date of grant. The Company granted 156 options and 61 restricted stock awards from the 2007 Plan in the first half of 2017 prior to the retirement of the 2007 Plan.

2017 Omnibus Incentive Plan - The 2017 Plan provides for the issuance of 6,881 shares of common stock. The number of shares available to be issued under the 2017 Plan will be reduced by (i) one share for each share that relates to an option or stock appreciation right award and (ii) 2.5 shares for each share which relates to an award other than a stock option or stock appreciation right award (a full-value award). Granted non-employee director options vest and become exercisable in three equal annual installments, or the length of the term if less than 3 years, on the completion of each year of service measured from the grant date. All other options generally vest over 5 years at 20% per year on the anniversary of the grant date. Options expire 10 years from the date of grant. At December 31, 2017, there were 6,277 unissued shares of common stock available for issuance under this plan.

The Company uses the Black-Scholes option-pricing model to recognize the value of stock-based compensation expense for all share-based payment awards. Determining the appropriate fair-value model and calculating the fair value of stock-based awards at the grant date requires considerable judgment, including estimating stock price volatility, expected option life and forfeiture rates. The Company develops estimates based on historical data and market information, which can change significantly over time. The Black-Scholes model required the Company to make several key judgments including:


•	The expected option term is calculated by the average of the contractual term of the options and the weighted average vesting period for all options. The calculation of the expected option term is based on the Company's experience due to sufficient history.


•	Estimated volatility also reflects the application of ASC 718 interpretive guidance and, accordingly, incorporates historical volatility of similar public entities until sufficient information regarding the volatility of the Company's share price becomes available. The Company has utilized its own experience to calculate estimated volatility for options granted.


•	The dividend yield is based on the Company's historical pattern of dividends as well as expected dividend patterns.


•	The risk-free rate is based on the implied yield of U.S. Treasury notes as of the grant date with a remaining term approximately equal to the expected term.


•	Estimated forfeiture rate of approximately 9.73% per year is based on the Company's historical forfeiture activity of unvested stock options.

Stock Options

The Company granted 481 options and 173 restricted stock awards from the 2007 and 2017 Plans during the year ended December 31, 2017. The Company used the following assumptions for stock options granted during the years ended December 31, 2017, 2016 and 2015:



Grant Year	Options Granted	Weighted Average Risk-Free Rate	Expected Life	Weighted Average Volatility	Weighted Average Dividend Yield
2017	481	2.0%	6.2 years	35.2%	0.8%
2016	497	1.4%	6.3 years	37.8%	0.8%
2015	637	1.7%	6.5 years	39.5%	0.6%

For the years ended December 31, 2017, 2016 and 2015, the following represents the exercise price and fair value displayed at grant date for stock option grants:

141

Table of Contents

THE ENSIGN GROUP, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)



Grant Year	Granted	Weighted Average Exercise Price		Weighted Average Fair Value of Options
2017	481	$	20.31	$	7.00
2016	497	$	19.43	$	7.00
2015	637	$	23.27	$	9.08

The weighted average exercise price equaled the weighted average fair value of common stock on the grant date for all options granted during the periods ended December 31, 2017, 2016 and 2015 and therefore, the intrinsic value was $0 at date of grant.

The following table represents the employee stock option activity during the years ended December 31, 2017, 2016 and 2015:



	Number of Options Outstanding		Weighted Average Exercise Price		Number of Options Vested	Weighted Average Exercise Price of Options Vested
January 1, 2015	5,532		$	8.51	2,218	$	4.70
Granted	637		23.27
Forfeited	(233	)	12.55
Exercised	(488	)	5.20
December 31, 2015	5,448		$	10.36	2,526	$	6.35
Granted	497		19.43
Forfeited	(127	)	14.46
Exercised	(642	)	6.47
December 31, 2016	5,176		$	11.62	2,704	$	8.18
Granted	481		20.31
Forfeited	(178	)	15.82
Exercised	(740	)	6.93
December 31, 2017	4,739		$	13.08	2,776	$	10.07

The following summary information reflects stock options outstanding, vested and related details as of December 31, 2017:



								Stock Options Vested
	Stock Options Outstanding							Stock Options Vested
				Number Outstanding	Black-Scholes Fair Value		Remaining Contractual Life (Years)	Vested and Exercisable
Year of Grant	Exercise Price			Number Outstanding	Black-Scholes Fair Value		Remaining Contractual Life (Years)	Vested and Exercisable
2008	2.56	-	4.06	185	$	292	1	185
2009	4.06	-	4.56	420	907		2	420
2010	4.77	-	4.96	116	281		3	116
2011	5.90	-	7.99	134	454		4	134
2012	6.56	-	7.96	435	1,603		5	435
2013	7.98	-	11.49	522	2,539		6	390
2014	10.55	-	18.94	1,458	8,272		7	789
2015	21.47	-	25.24	549	5,000		8	219
2016	18.79	-	19.89	450	3,140		9	88
2017	18.64	-	22.90	470	3,291		10	—
Total				4,739	$	25,779		2,776

142

Table of Contents

THE ENSIGN GROUP, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Restricted Stock Awards

The Company granted 173, 299 and 323 restricted stock awards during the years ended December 31, 2017, 2016 and 2015, respectively. All awards were granted at an exercise price of $0 and generally vest over five years. The fair value per share of restricted awards granted during the 2017, 2016 and 2015 ranged from $18.47 to $22.90, $18.79 to $23.23 and $21.00 to $26.55, respectively. The fair value per share includes quarterly stock awards to non-employee directors.

A summary of the status of the Company's non-vested restricted stock awards as of December 31, 2017 and changes during the years ended December 31, 2017, 2016 and 2015 is presented below:



	Non-Vested Restricted Awards		Weighted Average Grant Date Fair Value
Nonvested at January 1, 2015	366		$	15.15
Granted	323		22.99
Vested	(234	)	17.36
Forfeited	(30	)	16.81
Nonvested at December 31, 2015	425		$	19.79
Granted	299		20.55
Vested	(279	)	19.58
Forfeited	(16	)	20.85
Nonvested at December 31, 2016	429		$	20.42
Granted	173		20.21
Vested	(195	)	19.79
Forfeited	(24	)	20.34
Nonvested at December 31, 2017	383		$	20.65

During the year ended December 31, 2017, the Company granted 30 automatic quarterly stock awards to non-employee directors for their service on the Company's board of directors. The fair value per share of these stock awards ranged from $18.47 to $21.96 based on the market price on the grant date.

Share-based compensation expense recognized for the Company's equity incentive plans for the years ended December 31, 2017, 2016 and 2015 was as follows:



	Year Ended December 31,
	2017		2016		2015
Share-based compensation expense related to stock options	$	4,773	$	4,793	4,164
Share-based compensation expense related to restricted stock awards	2,322		2,371		1,931
Share-based compensation expense related to stock options and restricted stock awards to non-employee directors	1,236		612		582
Total	$	8,331	$	7,776	$	6,677

In future periods, the Company expects to recognize approximately $11,063 and $6,916 in share-based compensation expense for unvested options and unvested restricted stock awards, respectively, that were outstanding as of December 31, 2017. Future share-based compensation expense will be recognized over 2.9 and 3.4 weighted average years for unvested options and restricted stock awards, respectively. There were 1,963 unvested and outstanding options at December 31, 2017, of which 1,864 are expected to vest. The weighted average contractual life for options outstanding, vested and expected to vest at December 31, 2017 was 5.7 years.

The aggregate intrinsic value of options outstanding, vested, expected to vest and exercised as of and for the years ended December 31, 2017, 2016 and 2015 is as follows:

143

Table of Contents

THE ENSIGN GROUP, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)



	December 31,
Options	2017		2016		2015
Outstanding	$	44,060	$	55,610	$	67,508
Vested	33,976		38,101		41,128
Expected to vest	9,311		15,983		23,508
Exercisable	10,481		9,199		8,709

The intrinsic value is calculated as the difference between the market value of the underlying common stock and the exercise price of the options.

Equity Instrument Denominated in the Shares of a Subsidiary

On May 26, 2016, the Company implemented a management equity plan and granted stock options and restricted stock awards of a subsidiary of the Company to employees and management of that subsidiary (Subsidiary Equity Plan). These awards generally vest over a period of five years or upon the occurrence of certain prescribed events. The value of the stock options and restricted stock awards is tied to the value of the common stock of the subsidiary. The awards can be put to the Company at various prescribed dates, which in no event is earlier than six months after vesting of the restricted awards or exercise of the stock options. The Company can also call the awards, generally upon employee termination.

The grant-date fair value of the awards is recognized as compensation expense over the relevant vesting periods, with a corresponding adjustment to noncontrolling interests. The grant value was determined based on an independent valuation of the subsidiary shares. For the years ended December 31, 2017 and 2016, the Company expensed $1,364 and $1,325, respectively, in share-based compensation related to the Subsidiary Equity Plan. There was no expense incurred for the year ended December 31, 2015 as the plan was implemented in the second quarter of 2016.

The aggregate number of the Company's common shares that would be required to settle these awards at current estimated fair values, including vested and unvested awards, at December 31, 2017 and 2016 is 264 and 212, respectively. There was no comparable amount at December 31, 2015 as the plan was implemented in the second quarter of 2016.

17. LEASES

The Company leases from CareTrust REIT, Inc. (CareTrust) real property associated with 92 affiliated skilled nursing, assisted living and independent living facilities used in the Company’s operations under eight “triple-net” master lease agreements (collectively, the Master Leases), which range in terms from 12 to 19 years. At the Company’s option, the Master Leases may be extended for two or three five-year renewal terms beyond the initial term, on the same terms and conditions. The extension of the term of any of the Master Leases is subject to the following conditions: (1) no event of default under any of the Master Leases having occurred and being continuing; and (2) the tenants providing timely notice of their intent to renew. The term of the Master Leases is subject to termination prior to the expiration of the then current term upon default by the tenants in their obligations, if not cured within any applicable cure periods set forth in the Master Leases. If the Company elects to renew the term of a Master Lease, the renewal will be effective to all, but not less than all, of the leased property then subject to the Master Lease.

The Company does not have the ability to terminate the obligations under a Master Lease prior to its expiration without CareTrust’s consent. If a Master Lease is terminated prior to its expiration other than with CareTrust’s consent, the Company may be liable for damages and incur charges such as continued payment of rent through the end of the lease term as well as maintenance and repair costs for the leased property.

Commencing the third year, the rent structure under the Master Leases includes a fixed component, subject to annual escalation equal to the lesser of (1) the percentage change in the Consumer Price Index (but not less than zero) or (2) 2.5%. In addition to rent, the Company is required to pay the following: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. Total rent expense under the Master Leases was approximately $57,169, $56,271 and $56,000 for the years ended December 31, 2017, 2016 and 2015, respectively.

144

Table of Contents

THE ENSIGN GROUP, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Among other things, under the Master Leases, the Company must maintain compliance with specified financial covenants measured on a quarterly basis, including a portfolio coverage ratio and a minimum rent coverage ratio. The Master Leases also include certain reporting, legal and authorization requirements. The Company is not aware of any defaults as of December 31, 2017.

The Company also leases certain affiliated operations and its administrative offices under non-cancelable operating leases, most of which have initial lease terms ranging from five to 20 years. The Company has entered into multiple lease agreements with various landlords to operate newly constructed state-of-the-art, full-service healthcare resorts upon completion of construction. The term of each lease is 15 years with two five-year renewal options and is subject to annual escalation equal to the percentage change in the Consumer Price Index with a stated cap percentage. In addition, the Company leases certain of its equipment under non-cancelable operating leases with initial terms ranging from three to five years years. Most of these leases contain renewal options, certain of which involve rent increases. Total rent expense, inclusive of straight-line rent adjustments and rent associated with the Master Leases noted above, was $132,932, $125,221 and $89,264 for the years ended December 31, 2017, 2016 and 2015, respectively.

Twenty-five of the Company’s affiliated facilities, excluding the facilities that are operated under the Master Leases with CareTrust, are operated under six separate master lease arrangements. Under these master leases, a breach at a single facility could subject one or more of the other facilities covered by the same master lease to the same default risk. Failure to comply with Medicare and Medicaid provider requirements is a default under several of the Company’s leases, master lease agreements and debt financing instruments. In addition, other potential defaults related to an individual facility may cause a default of an entire master lease portfolio and could trigger cross-default provisions in the Company’s outstanding debt arrangements and other leases. With an indivisible lease, it is difficult to restructure the composition of the portfolio or economic terms of the lease without the consent of the landlord.

In March 2017, the Company voluntarily discontinued operations at one of its skilled nursing facilities after determining that the facility could not competitively operate in the marketplace without substantial investment renovating the building. After careful consideration, the Company determined that the costs to renovate the facility could outweigh the future returns from the operation. As part of this closure, the Company entered into an agreement with its landlord allowing for the closure of the property, as well as other provisions, to allow its landlord to transfer the property and the licenses free and clear of the applicable master lease. This arrangement does not impact the rent expense paid in 2017, or expected to be paid in future periods, and has no material impact on the Company's lease coverage ratios under the Master Leases. The Company recorded a continued obligation liability under the lease and related closing expenses of $2,830, including the present value of rental payments of approximately $2,715, in 2017. Residents of the affected facility were transferred to local skilled nursing facilities.

During the first quarter of 2016, the Company voluntarily discontinued operations at one of its skilled nursing facilities in order to preserve the overall ability to serve the residents in surrounding counties after careful consideration and some clinical survey challenges. As part of this closure, the Company entered into an agreement with its landlord allowing for the closure of the property as well as other provisions to allow its landlord to transfer the property and the licenses free and clear of the applicable master lease. This arrangement does not impact the rental payments and has no material impact on the Company's lease coverage ratios under the Master Leases. The Company recorded a continued obligation liability under the lease and related closing expenses of $7,935, including the present value of rental payments of approximately $6,512, in 2016. Residents of the affected facility were transferred to local skilled nursing facilities. In 2017, the Company recovered $1,286 of certain losses that were recorded in 2016 related to the closure of the operation. The loss recovery was recorded as a gain in 2017.

In March 2017, the Company entered into definitive agreements to sell the properties of two skilled nursing facilities and one assisted living community. The transaction closed in the second quarter of 2017. Upon closing the transaction, the Company leased the properties under a triple-net master lease with an initial 20-year term, with three 5-year optional extensions, at CPI-based annual escalators. The Company received $38,000 in proceeds. The carrying value for the sale was $24,847. Under applicable accounting guidance, the master lease was classified as an operating lease. The Company recognized a deferred gain on the transaction of $13,153 in 2017 that is amortized over the life of the lease.

During the first quarter of 2017, the Company terminated its lease obligations on four transitional care facilities that are currently under development and one newly constructed stand-alone skilled nursing operation. The Company recorded $1,187 in lease termination costs and long-lived asset impairment.

Future minimum lease payments for all leases as of December 31, 2017 are as follows:

145

Table of Contents

THE ENSIGN GROUP, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)



Year	Amount
2018	135,841
2019	135,395
2020	135,149
2021	134,942
2022	133,446
Thereafter	1,080,348
	$	1,755,121

18. SELF INSURANCE RESERVES

The following table represents activity in our insurance reserves as of and for the years ended December 31, 2017 and 2016:



	General and Professional Liability
				Workers' Compensation
				Workers' Compensation			Health			Total
Balance January 1, 2016	30,710			20,219			5,074			$	56,003
Current year provisions	23,149			12,887			38,151			74,187
Claims paid and direct expenses	(18,186		)	(10,290		)	(37,586		)	(66,062		)
Change in long-term insurance losses recoverable	637			586			—			1,223
Balance December 31, 2016	36,310			23,402			5,639			65,351
Current year provisions	20,396			15,202			53,796			89,394
Claims paid and direct expenses	(16,133		)	(12,455		)	(54,712		)	(83,300		)
Change in long-term insurance losses recoverable	361			930			—			1,291
Balance December 31, 2017	$	40,934		$	27,079		$	4,723		$	72,736

Included in long-term insurance losses recoverable as of December 31, 2017 and 2016, are anticipated insurance recoveries related to the Company's general and professional liability claims that are recorded on a gross rather than net basis in accordance with GAAP.

19. COMMITMENTS AND CONTINGENCIES

Regulatory Matters — Laws and regulations governing Medicare and Medicaid programs are complex and subject to interpretation. Compliance with such laws and regulations can be subject to future governmental review and interpretation, as well as significant regulatory action including fines, penalties, and exclusion from certain governmental programs. Included in these laws and regulations is the Health Insurance Portability and Accountability Act of 1996 (HIPAA), which requires healthcare providers (among other things) to safeguard and keep confidential protected health information. In late December 2016, the Company learned of a potential issue at one of its independent operating entities in Arizona which involved the limited and inadvertent disclosure of certain confidential information. The issue has been internally investigated, addressed and disclosed as per the HIPAA obligations. The Company believes that it is presently in compliance in all material respects with all applicable laws and regulations.

Indemnities — From time to time, the Company enters into certain types of contracts that contingently require the Company to indemnify parties against third-party claims. These contracts primarily include (i) certain real estate leases, under which the Company may be required to indemnify property owners or prior facility operators for post-transfer environmental or other liabilities and other claims arising from the Company’s use of the applicable premises, (ii) operations transfer agreements, in which the Company agrees to indemnify past operators of facilities the Company acquires against certain liabilities arising from the transfer of the operation and/or the operation thereof after the transfer, (iii) certain lending agreements, under which the Company may be

146

Table of Contents

THE ENSIGN GROUP, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

required to indemnify the lender against various claims and liabilities, and (iv) certain agreements with the Company’s officers, directors and employees, under which the Company may be required to indemnify such persons for liabilities arising out of their employment relationships. The terms of such obligations vary by contract and, in most instances, a specific or maximum dollar amount is not explicitly stated therein. Generally, amounts under these contracts cannot be reasonably estimated until a specific claim is asserted. Consequently, because no claims have been asserted, no liabilities have been recorded for these obligations on the Company’s balance sheets for any of the periods presented.

Litigation — The skilled nursing business involves a significant risk of liability given the age and health of the patients and residents served by the Company's operating subsidiaries. The Company, its operating subsidiaries, and others in the industry are subject to an increasing number of claims and lawsuits, including professional liability claims, alleging that services provided have resulted in personal injury, elder abuse, wrongful death or other related claims. The defense of these lawsuits may result in significant legal costs, regardless of the outcome, and can result in large settlement amounts or damage awards.

In addition to the potential lawsuits and claims described above, the Company is also subject to potential lawsuits under the Federal False Claims Act and comparable state laws alleging submission of fraudulent claims for services to any healthcare program (such as Medicare) or payor. A violation may provide the basis for exclusion from federally-funded healthcare programs. Such exclusions could have a correlative negative impact on the Company’s financial performance. Some states, including California, Arizona and Texas, have enacted similar whistleblower and false claims laws and regulations. In addition, the Deficit Reduction Act of 2005 created incentives for states to enact anti-fraud legislation modeled on the Federal False Claims Act. As such, the Company could face increased scrutiny, potential liability and legal expenses and costs based on claims under state false claims acts in markets in which it does business.

Healthcare litigation (including class action litigation) is common and is filed based upon a wide variety of claims and theories, and the Company is routinely subjected to varying types of claims. One particular type of suit arises from alleged violations of minimum staffing requirements for skilled nursing facilities in those states which have enacted such requirements. Failure to meet these requirements can, among other things, jeopardize a facility's compliance with conditions of participation under certain state and federal healthcare programs; it may also subject the facility to a notice of deficiency, a citation, a civil money penalty, or litigation. These class-action “staffing” suits have the potential to result in large jury verdicts and settlements. The Company expects the plaintiff's bar to continue to be aggressive in their pursuit of these staffing and similar claims.

The Company has in the past been subject to class action litigation involving claims of alleged violations of regulatory requirements related to staffing. While the Company has been able to settle these claims without a material ongoing adverse effect on its business, future claims could be brought that may materially affect its business, financial condition and results of operations. Other claims and suits, including class actions, continue to be filed against the Company and other companies in its industry. If there were a significant increase in the number of these claims or an increase in amounts owing should plaintiffs be successful in their prosecution of these claims, this could materially adversely affect the Company’s business, financial condition, results of operations and cash flows.

The Company and its operating subsidiaries have been, and continue to be, subject to claims and legal actions that arise in the ordinary course of business, including potential claims related to patient care and treatment as well as employment related claims. Since 2011, the Company has been involved in a class action litigation claim alleging violations of state and federal wage and hour laws. In January 2017, the Company participated in an initial mediation session with plaintiffs' counsel. As a result of this discussion and due to (i) the fact no class had been certified (ii) the lack of specificity as to legal theories put forth by the plaintiffs, (iii) the nature of the remedies sought and (iv) the lack of any basis on which to compute estimated compensatory and/or exemplary damages, the Company could not predict what the outcome of the pending purported class action lawsuit would be, what the timing of the ultimate resolution of this lawsuit would be, or an estimate and/or range of possible loss related to it. In light of the inherent uncertainties involved in the pending class action lawsuit, the Company determined that we were not able to estimate the related costs or range of costs for the year ended December 31, 2016.

147

Table of Contents

THE ENSIGN GROUP, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

In March 2017, the Company was invited to engage in further mediation discussions to determine whether settlement in advance of a decision on class certification was possible. In April 2017, the Company reached an agreement in principle to settle the subject class action litigation, without any admission of liability and subject to approval by the California Superior Court. Based upon the recent change in case status, the Company recorded an accrual for estimated probable losses of $11,000, exclusive of legal fees, in the first quarter of 2017. The Company funded the settlement amount of $11,000 in December 2017, and it will be distributed to the class members in Q1 of 2018.

Other claims and suits continue to be filed against the Company and other companies in its industry. By way of recent example, a general/premises liability lawsuit was filed against one of the Company’s independent operating entities in San Luis Obispo, California, in connection with an alleged injury to a non-employee/contractor. Further, another one of the Company’s independent operating entities was sued on allegations of professional negligence, which claim was recently settled. The Company does not expect that there will be any material ongoing adverse effect on the Company's business, financial condition or results of operations in connection with the resolution of these matters.

The Company cannot predict or provide any assurance as to the possible outcome of any litigation. If any litigation were to proceed, and the Company and its operating subsidiaries are subjected to, alleged to be liable for, or agrees to a settlement of, claims or obligations under Federal Medicare statutes, the Federal False Claims Act, or similar State and Federal statutes and related regulations, the Company's business, financial condition and results of operations and cash flows could be materially and adversely affected and its stock price could be adversely impacted. Among other things, any settlement or litigation could involve the payment of substantial sums to settle any alleged civil violations, and may also include the assumption of specific procedural and financial obligations by the Company or its subsidiaries going forward under a corporate integrity agreement and/or other arrangement with the government.

Medicare Revenue Recoupments — The Company is subject to reviews relating to Medicare services, billings and potential overpayments as a result of Recovery Audit Contractors (RAC), Zone Program Integrity Contractors (ZPIC), Program Safeguard Contractors (PSC) and Medicaid Integrity Contributors (MIC) programs. As of December 31, 2017, seven of the Company's operating subsidiaries had probes scheduled and in process, both pre- and post-payment. The Company anticipates that these probe reviews will increase in frequency in the future. If a facility fails a probe review and subsequent re-probes, the facility could then be subject to extended pre-pay review or extrapolation of the identified error rate to all billing in the same time period. None of the Company's operating subsidiaries are currently on extended prepayment review, although that may occur in the future.

U.S. Government Inquiry — In October 2013, the Company completed and executed a settlement agreement (the Settlement Agreement) with the DOJ, which received the final approval of the Office of Inspector General-HHS and the United States District Court for the Central District of California. Pursuant to the Settlement Agreement, the Company made a single lump-sum remittance to the government in the amount of $48,000 in October 2013. The Company has denied engaging in any illegal conduct and has agreed to the settlement amount without any admission of wrongdoing in order to resolve the allegations and to avoid the uncertainty and expense of protracted litigation.

In connection with the settlement and effective as of October 1, 2013, the Company entered into a five-year corporate integrity agreement (the CIA) with the Office of Inspector General-HHS. The CIA acknowledges the existence of the Company’s current compliance program, which is in accord with the Office of the Inspector General (OIG)’s guidance related to an effective compliance program, and requires that the Company continue during the term of the CIA to maintain a program designed to promote compliance with the statutes, regulations, and written directives of Medicare, Medicaid, and all other Federal health care programs. The Company is also required to notify the Office of Inspector General-HHS in writing, of, among other things: (i) any ongoing government investigation or legal proceeding involving an allegation that the Company has committed a crime or has engaged in fraudulent activities; (ii) any other matter that a reasonable person would consider a probable violation of applicable criminal, civil, or administrative laws related to compliance with federal healthcare programs; and (iii) any change in location, sale, closing, purchase, or establishment of a new business unit or location related to items or services that may be reimbursed by federal health care programs. The Company is also required to retain an Independent Review Organization (IRO) to review certain clinical documentation annually for the term of the CIA.

The Company has continued to meet the requirements under the Settlement Agreement and pass its IRO audits. Participation in federal healthcare programs by the Company is not affected by the Settlement Agreement or the CIA. In the event of an uncured material breach of the CIA, the Company could be excluded from participation in federal healthcare programs and/or subject to prosecution.

Concentrations

148

Table of Contents

THE ENSIGN GROUP, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Credit Risk — The Company has significant accounts receivable balances, the collectability of which is dependent on the availability of funds from certain governmental programs, primarily Medicare and Medicaid. These receivables represent the only significant concentration of credit risk for the Company. The Company does not believe there are significant credit risks associated with these governmental programs. The Company believes that an appropriate allowance has been recorded for the possibility of these receivables proving uncollectible, and continually monitors and adjusts these allowances as necessary. The Company’s receivables from Medicare and Medicaid payor programs accounted for approximately 56.7% and 58.6% of its total accounts receivable as of December 31, 2017 and 2016, respectively. Revenue from reimbursement under the Medicare and Medicaid programs accounted for 68.4%, 67.8% and 69.1% of the Company's revenue for the years ended December 31, 2017, 2016 and 2015, respectively.

Cash in Excess of FDIC Limits — The Company currently has bank deposits with financial institutions in the U.S. that exceed FDIC insurance limits. FDIC insurance provides protection for bank deposits up to $250. In addition, the Company has uninsured bank deposits with a financial institution outside the U.S. As of February 2, 2018, the Company had approximately $965 in uninsured cash deposits. All uninsured bank deposits are held at high quality credit institutions.

20. DIVESTITURES

In 2016, the Company completed the sale of seventeen urgent care centers for an aggregate sale price of $41,492. As a result of the sale, the Company recognized a pretax gain of $19,160, which is included in operating income. Due to the disposition of the clinics, the Company is no longer the primary beneficiary and the variable interest entities associated with the urgent care operations was deconsolidated from the Company's consolidated financial statements as of December 31, 2016. At deconsolidation, the Company eliminated intercompany balances that previously existed. The sale of this investment supports the Company's increased focus on growth opportunities in its business lines that are complementary to its existing transitional and skilled services.

The sale transactions did not meet the criteria of a discontinued operation as they do not represent a strategic shift that has or will have a major effect on the Company’s operations and financial results.


21.	DEFINED CONTRIBUTION PLAN

The Company has a 401(k) defined contribution plan (the 401(k) Plan), whereby eligible employees may contribute up to 15% of their annual basic earnings. Additionally, the 401(k) Plan provides for discretionary matching contributions (as defined in the 401(k) Plan) by the Company. The Company expensed matching contributions to the 401(k) Plan of $1,028, $862 and $682 during the years ended December 31, 2017, 2016 and 2015, respectively. Beginning in 2007, the 401(k) Plan allowed eligible employees to contribute up to 90% of their eligible compensation, subject to applicable annual Internal Revenue Code limits.


(b)	Financial Statement Schedules

THE ENSIGN GROUP, INC. and SUBSIDIARIES

Schedule II

Valuation and Qualifying Accounts



				Additions Charged to Costs and Expenses
	Balance at Beginning of Year								Balances at End of Year

							Deductions
				(In thousands)
Year Ended December 31, 2015
Allowance for doubtful accounts	$	(20,438	)	$	(19,802	)	$	9,932	$	(30,308	)
Year Ended December 31, 2016
Allowance for doubtful accounts	$	(30,308	)	$	(28,512	)	$	19,029	$	(39,791	)
Year Ended December 31, 2017
Allowance for doubtful accounts	$	(39,791	)	$	(31,023	)	$	26,853	$	(43,961	)

All other schedules have been omitted because the information required to be set forth therein is not applicable or is shown in the consolidated financial statements or notes thereto.

149

EX-10.87 2 ensgex1087.htm EXHIBIT 10.87 Exhibit

Exhibit 10.87

Notice of Stock Options



Optionee: «Participant_First_Name» «Participant_Last_Name»	Option Number: «Option_Number»
Address: «Street_Address» «City» «State» «Zip»	Plan: 2017 Omnibus Incentive Plan

Notice is hereby given of the following Option Award grant (the “Option”) to purchase shares of the Common Stock of The Ensign Group, Inc. (the “Corporation”):



Grant Date: «Grant_Date»	Number of Option Shares: *«Options_Award»*
Type of Options: Non-Incentive	Exercise Price Per Share: «Exercise_Price_Per_Share»

V E S T I N G

Vesting Schedule: 20% annually, with the first block vesting on the first (1^st) anniversary of the Grant Date.

Expiration Date: Month, Date, Year, or upon earlier termination of the Option

Except as otherwise provided in the Option Agreement, the Option may be exercised for vested Shares by Optionee in accordance with the following schedule:



On or after each of the following dates		Number of Stock Options vested
«Vesting_Y1»		«OPTION_Y1»
«Vesting_Y2»		«OPTION_Y2»
«Vesting_Y3»		«OPTION_Y3»
«Vesting_Y4»		«OPTION_Y4»
«Vesting_Y5»		«OPTION_Y5»

By accepting this Option Award, Optionee acknowledges and agrees that the option rights herein are granted only subject to and in accordance with the terms of (i) the enclosed NON-INCENTIVE STOCK OPTION AWARD TERMS AND CONDITIONS (together with this Notice of Grant of Stock Options, the “Option Agreement”), and (ii) THE ENSIGN GROUP, INC. 2017 OMNIBUS INCENTIVE PLAN (the “Plan”), both of which are incorporated herein by this reference. Option Shares purchased pursuant to this Option Award can only be acquired subject to the terms set forth in the Plan and the Option Agreement, whether said options are purchased electronically or in person. All capitalized terms in this Notice of Grant of Stock Options shall have the meaning assigned to them in the Option Agreement or the Plan.

EXECUTIVED AND DELIVERED as of the Grant Date set forth above.

THE ENSIGN GROUP, INC.

a Delaware corporation

By: Chad A Keetch

Executive Vice President and Secretary

THE ENSIGN GROUP, INC.

NON-INCENTIVE STOCK OPTION AWARD

TERMS AND CONDITIONS

These NON-INCENTIVE STOCK OPTION AWARD TERMS AND CONDITIONS are an integral

part of the foregoing Notice of Grant of Stock Options (the “Notice,” and together with these Terms and Conditions, the “Option Agreement”) made by The Ensign Group, Inc., a Delaware corporation (the “Company”) to the individual “Optionee” named therein. All capitalized terms used herein but not defined in the Option Agreement shall have the meanings given to them in The Ensign Group, Inc. 2017 Omnibus Incentive Plan (the “Plan”), the terms and conditions of which are incorporated herein by this reference.

1.Grant of Option. The Company hereby grants Optionee, on the date such grant was approved by the Committee (the “Grant Date”), the option (the “Option”) to purchase all or any part of the number of Option Shares set forth in the Notice (the “Shares”) of Common Stock of the Company at the exercise price per share set forth in the Notice, according to the terms and conditions set forth in this Option Agreement and in the Plan. The Option will not be treated as an incentive stock option within the meaning of Section 422 of the Internal Revenue Code of 1986, as amended (the “Code”). The Option is issued under the Plan and is subject to its terms and conditions. A copy of the Plan will be furnished upon request of Optionee.

The Option shall terminate at the close of business on the Expiration Date set forth in the Notice (the “Expiration Date”) unless sooner terminated or cancelled in accordance with this Option Agreement or the Plan.


2.	Vesting of Option Rights.

(a) Except as otherwise provided in this Option Agreement, the Option may be exercised for vested Shares by Optionee in accordance with the schedule set forth in the Notice.

(b) During the lifetime of Optionee, the Option shall be exercisable only by Optionee and shall not be assignable or transferable by Optionee, other than by will or the laws of descent and distribution; provided however, that Optionee may transfer the Option to any “Family Member” (as such term is defined in the General Instructions to Form S-8 (or any successor to such Instructions or such Form) under the Securities Act), provided that the Participant may not receive any consideration for such transfer, the Family Member may not make any subsequent transfers other than by will or by the laws of descent and distribution and the Company receives written notice of such transfer.

3.Exercise of Option after Death or Termination of Service. The Option shall terminate and may no longer be exercised if Optionee ceases to provide Service to the Company or its affiliates, except that:

(a) If Optionee’s Service shall be terminated for any reason, voluntary or involuntary, other than for “Cause” (as defined in Section 3(e)) or Optionee’s death or disability (within the meaning of Section 22(e)(3) of the Code), Optionee may at any time within a period of 3 months after such termination exercise the Option to the extent the Option was vested and exercisable by Optionee on the date of the termination of Optionee’s Service.

(b) If Optionee’s Service is terminated for Cause, the Option shall be terminated as of the date of the act giving rise to such termination.

(c) If Optionee shall die while the Option is still exercisable according to its terms or if Optionee’s Service is terminated because Optionee has become disabled (within the meaning of Section 22(e)(3) of the Code) while providing Service to the Company and Optionee shall not have fully exercised the Option, such Option may be exercised at any time within 12 months after Optionee’s deathor date of termination of Service for disability by Optionee, personal representatives or administrators or guardians of Optionee as applicable, or by any person or persons to whom the Option is transferred by will or the applicable laws of descent and distribution, to the extent of the full number of Shares Optionee was entitled to purchase under the Option on (i) the earlier of the date of death or termination of Service or (ii) the date of termination for such disability, as applicable.

(d) Notwithstanding the above, in no case may the Option be exercised to any extent by anyone after the Expiration Date.

(e) "Cause" shall mean, with respect to a Optionee, the occurrence of any of the following: (i) Optionee’s personal dishonesty, willful misconduct, or breach of fiduciary duty involving personal profit, (ii) Optionee’s continuing intentional or habitual failure to perform stated duties, (iii) Optionee’s violation of any law (other than minor traffic violations or similar misdemeanor offenses not involving moral turpitude), (iv) Optionee’s material breach of any provision of an employment or independent contractor agreement with the Company, or (v) any other act or omission by a Optionee that, in the opinion of the Committee, could reasonably be expected to adversely affect the Company’s business, financial condition, prospects and/or reputation. In each of the foregoing subclauses (i) through (v), whether or not a “Cause” event has occurred will be determined by the Committee in its sole discretion or, in the case of Optionees who are Directors or officers or persons subject to Section 16 of the Exchange Act, the Board, each of whose determination shall be final, conclusive and binding. A Optionee’s Service shall be deemed to have terminated for Cause if, after the Optionee’s Service has terminated, facts and circumstances are discovered that would have justified a termination for Cause, including, without limitation, violation of material Company policies or breach of noncompetition, confidentiality or other restrictive covenants that may apply to the Optionee. The foregoing definition shall not in any way preclude or restrict the right of the Company (or any Affiliate) to discharge or dismiss Optionee or other person providing Service to the Company (or any Affiliate) for any other acts or omissions but such other acts or omissions shall not be deemed, for purposes of this Option Agreement, to constitute grounds for termination for Cause.

4.Method of Exercise of Option. Subject to the foregoing, the Option may be exercised in whole or in part from time to time by serving written notice of exercise on the Company at its principal office or the Company’s designated agent for such purposes, within the Option period. The notice shall state the number of Shares as to which the Option is being exercised and shall be accompanied by payment of the exercise price. Payment of the exercise price shall be made (i) in cash (including bank check, valid personal check or money order payable to the Company), or (ii) with the approval of the Company (which may be given in its sole discretion), by delivering to the Company for cancellation shares of the Company’s Common Stock already owned by Optionee having a Fair Market Value (as defined in the Plan) equal to the full exercise price of the Shares being acquired. Only that portion of the Option covering vested Option Shares is exercisable at any time. Subject to Section 402 of the Sarbanes- Oxley Act of 2002, to the extent this Option is exercised for vested Shares, the Option may be exercised in whole or in part from time to time through a special sale and remittance procedure pursuant to which Optionee shall concurrently provide irrevocable instructions (1) to Optionee’s brokerage firm to effect the immediate sale of the purchased Shares and remit to the Company, out of the sale proceeds available on the settlement date, sufficient funds to cover the aggregate exercise price payable for the purchased Shares plus all applicable income and employment taxes required to be withheld by the Company by reason of such exercise, and (2) to the Company to deliver the certificates for the purchased Shares directly to such brokerage firm in order to complete the sale.


5.	Miscellaneous.

(a) Plan Provisions Control. The Option award memorialized in this Option Agreement is made solely upon the terms and conditions set forth herein and in the Plan and any related documents. The Option Agreement and the Plan together constitute the entire agreement between the parties hereto with regard to the subject matter hereof. In the event that any provision of the Option Agreement conflicts with or is inconsistent in any respect with the terms of the Plan, the terms of the Plan shall control.

No Rights of Stockholders. Neither Optionee, Optionee’s legal representative nor a permissible assignee of this Option shall have any of the rights and privileges of a stockholder of theCompany with respect to the Shares, unless and until such Shares have been issued in the name of Optionee, Optionee’s legal representative or permissible assignee, as applicable.

(b) No Right to Employment. The grant of the Option shall not be construed as giving Optionee the right to be retained in the employ of, or as giving a director of the Company or an Affiliate (as defined in the Plan) the right to continue as a director of the Company or an Affiliate with, the Company or an Affiliate, nor will it affect in any way the right of the Company or an Affiliate to terminate such employment or position at any time, with or

without cause. In addition, the Company or an Affiliate may at any time dismiss Optionee from employment, or terminate the term of a director of the Company or an Affiliate, free from any liability or any claim under the Plan or the Option Agreement. Nothing in the Option Agreement shall confer on any person any legal or equitable right against the Company or any Affiliate, directly or indirectly, or give rise to any cause of action at law or in equity against the Company or an Affiliate. The Option granted hereunder shall not form any part of the wages or salary of Optionee for purposes of severance pay or termination indemnities, irrespective of the reason for termination of employment. Under no circumstances shall any person ceasing to be an employee of the Company or any Affiliate be entitled to any compensation for any loss of any right or benefit under the Option Agreement or Plan which such employee might otherwise have enjoyed but for termination of employment, whether such compensation is claimed by way of damages for wrongful or unfair dismissal, breach of contract or otherwise. By participating in the Plan, Optionee shall be deemed to have accepted all the conditions of the Plan and the Option Agreement and the terms and conditions of any rules and regulations adopted by the Committee and shall be fully bound thereby.

(c) Governing Law. The validity, construction and effect of the Plan and the Option Agreement, and any rules and regulations relating to the Plan and the Option Agreement, shall be determined in accordance with the internal laws, and not the law of conflicts, of the State of Delaware.

(d) Severability. If any provision of the Option Agreement is or becomes or is deemed to be invalid, illegal or unenforceable in any jurisdiction or would disqualify the Option Agreement under any law deemed applicable by the Committee (as defined in the Plan), such provision shall be construed or deemed amended to conform to applicable laws, or if it cannot be so construed or deemed amended without, in the determination of the Committee, materially altering the purpose or intent of the Plan or the Option Agreement, such provision shall be stricken as to such jurisdiction or the Option Agreement, and the remainder of the Option Agreement shall remain in full force and effect.

(e) No Trust or Fund Created. Neither the Plan nor the Option Agreement shall create or be construed to create a trust or separate fund of any kind or a fiduciary relationship between the Company or any Affiliate and Optionee or any other person.

(f) Headings. Headings are given to the Sections and subsections of the Option Agreement solely as a convenience to facilitate reference. Such headings shall not be deemed in any way material or relevant to the construction or interpretation of the Option Agreement or any provision thereof.

(g) Conditions Precedent to Issuance of Shares. Shares shall not be issued, and the Company shall not have any liability for failure to issue Shares, pursuant to the exercise of the Option unless such exercise and the issuance and delivery of the applicable Shares pursuant thereto shall comply with all relevant provisions of law, including, without limitation, the Securities Act of 1933, as amended, the Exchange Act of 1934, as amended, the rules and regulations promulgated thereunder, the requirements of any applicable Stock Exchange and the Delaware General Corporation Law. As a condition to the exercise of the purchase price relating to the Option, the Company may require that the person exercising or paying the purchase price represent and warrant that the Shares are being purchased only for investment and without any present intention to sell or distribute such Shares if, in the opinion of counsel for the Company, such a representation and warranty is required by law.

(h) Withholding. In order to provide the Company with the opportunity to claim the benefit of any income tax deduction which may be available to it upon the exercise of the Option and in order to comply with all applicable federal or state income tax laws or regulations, the Company may take such action as it deems appropriate to insure that, if necessary, all applicable federal or state payroll, withholding, income or other taxes are withheld or collected from Optionee.

(i) Consultation With Professional Tax and Investment Advisors. The holder of this Option Agreement acknowledges that the grant, exercise, vesting or any payment with respect to this Option Agreement, and the sale or other taxable disposition of the Shares acquired pursuant to the exercise thereof, may have tax consequences pursuant to the Code or under local, state or international tax laws. The holder further acknowledges that such holder is relying solely and exclusively on the holder’s own professional tax and investment advisors with respect to any and all such matters (and is not relying, in any manner, on the Company or any of its employees or representatives). Finally, the holder understands and agrees that any and all tax consequences resulting from the Option Agreement and its grant,

exercise, vesting or any payment with respect thereto, and the sale or other taxable disposition of the Shares acquired pursuant to the Plan, is solely and exclusively the responsibility of the holder without any expectation or understanding that the Company or any of its employees or representatives will pay or reimburse such holder for such taxes or other items.

EX-10.88 3 ensgex1088.htm EXHIBIT 10.88 Exhibit

Exhibit 10.88

Notice of Restricted Stock Award



Grantee: «Participant_First_Name» «Participant_Last_Name»	Restricted Stock Number: «RSA_Number»
Address: «Street_Address» «City» «State» «Zip»	Plan: 2017 Omnibus Incentive Plan

Notice is hereby given of the following award (the “Restricted Stock Award”) of Common Stock of The Ensign Group, Inc. (the “Corporation”):



Grant Date: «Grant_Date»	Number of Restricted Stock Shares: *«RSA_Award»*
Type of Award: Restricted Stock Award

V E S T I N G

Vesting Schedule: 20% annually, with the first block vesting on the first (1^st) anniversary of the Grant Date.

Except as otherwise provided in the Restricted Stock Agreement, the Restricted Stock will be vested in the Grantee in accordance with the following schedule:



On or after each of the following dates		Number of Restricted Stock Shares vested
«Vesting_Y1»		«RSA_Y1»
«Vesting_Y2»		«RSA_Y2»
«Vesting_Y3»		«RSA_Y3»
«Vesting_Y4»		«RSA_Y4»
«Vesting_Y5»		«RSA_Y5»

By accepting this Restricted Stock Award, Grantee acknowledges and agrees that the Restricted Stock Shares granted herein are subject to and in accordance with the terms of (i) the enclosed RESTRICTED STOCK AWARD TERMS AND CONDITIONS (together with this Notice of Restricted Stock Award, the “Restricted Stock Agreement”), and (ii) THE ENSIGN GROUP, INC. 2017 OMNIBUS INCENTIVE PLAN (the “Plan”), both of which are incorporated herein by this reference. All capitalized terms in this Notice of Restricted Stock Award shall have the meaning assigned to them in the Restricted Stock Agreement of the Plan.

EXECUTIVED AND DELIVERED as of the Grant Date set forth above.

THE ENSIGN GROUP, INC

a Delaware corporation

By: Chad A Keetch

Executive Vice President and Secretary

THE ENSIGN GROUP, INC. RESTRICTED STOCK AWARD TERMS AND CONDITIONS

These RESTRICTED STOCK AWARD TERMS AND CONDITIONS are an integral part of the foregoing Notice Restricted Stock Award (the “Notice,” and together with these Terms and Conditions, the “Restricted Stock Agreement” or this “Agreement”) made by The Ensign Group, Inc., a Delaware corporation (the “Company”) to the individual “Grantee” named therein. All capitalized terms used herein but not defined in this Restricted Stock Agreement shall have the meanings given to them in The Ensign Group, Inc. 2017 Omnibus Incentive Plan (the “Plan”), the terms and conditions of which are incorporated herein by this reference.

1.Definitions. For the purposes of this Agreement, the following terms shall have the meanings set forth below:

(a)"Cause" shall mean, with respect to a Grantee, the occurrence of any of the following: (i) Grantee’s personal dishonesty, willful misconduct, or breach of fiduciary duty involving personal profit, (ii) Grantee’s continuing intentional or habitual failure to perform stated duties, (iii) Grantee’s violation of any law (other than minor traffic violations or similar misdemeanor offenses not involving moral turpitude), (iv) Grantee’s material breach of any provision of an employment or independent contractor agreement with the Company, or (v) any other act or omission by a Grantee that, in the opinion of the Committee, could reasonably be expected to adversely affect the Company’s business, financial condition, prospects and/or reputation. In each of the foregoing subclauses (i) through (v), whether or not a “Cause” event has occurred will be determined by the Committee in its sole discretion or, in the case of Grantees who are Directors or officers or persons subject to Section 16 of the Exchange Act, the Board, each of whose determination shall be final, conclusive and binding. A Grantee’s Service shall be deemed to have terminated for Cause if, after the Grantee’s Service has terminated, facts and circumstances are discovered that would have justified a termination for Cause, including, without limitation, violation of material Company policies or breach of noncompetition, confidentiality or other restrictive covenants that may apply to the Grantee. However, if the term or concept has been defined in an employment agreement between the Company and Grantee, then Cause shall have the definition set forth in such employment agreement. The foregoing definition shall not in any way preclude or restrict the right of the Company (or any Affiliate) to discharge or dismiss Grantee or other person providing Service to the Company (or any Affiliate) for any other acts or omissions but such other acts or omissions shall not be deemed, for purposes of this Agreement, to constitute grounds for termination for Cause.

"Disability" shall mean Grantee’s inability, due to illness, accident, injury, physical or mental incapacity or other disability, to carry out effectively his or her duties and obligations as an employee of the Company or to participate effectively and actively in the management of the Company for a period of at least 90 consecutive days or for shorter periods aggregating at least 120 days (whether or not consecutive) during any twelve-month period, as determined in the reasonable judgment of the Board.

"Vested Shares" shall mean (i) all Shares issued pursuant to this Agreement that are vested pursuant to Section 3 hereof and (ii) all Shares issued with respect to the Common Stock referred to in clause

(i)above by way of stock dividend or stock split or in connection with any conversion, merger, consolidation or recapitalization or other reorganization affecting the Shares. Vested Shares shall continue to be Vested Shares in the hands of any holder other than Grantee (except for the Company and purchasers pursuant to a public offering under the Securities Act), and each such transferee thereof shall succeed to the rights and obligations of a holder of Vested Shares hereunder.

2.Issuance of Stock. In partial consideration for Grantee’s services to the Company, Grantee has been issued the number of Shares as set forth in the Notice (the “Restricted Stock”).


3.	Vesting.

(a)Normal Vesting. Except as set forth in this Restricted Stock Agreement, the Restricted Stock shall vest in accordance with the schedule set forth in the Notice and shall become fully vested on the fifth anniversary of the date hereof (the “Vesting Date”). The Corporation shall deliver a certificate(s) (or other evidence of ownership, such as book entry) for the Vested Shares to Grantee as soon as practical after each Vesting Date pursuant to the Section 4(d) hereof.

(b)If Grantee’s employment with the Company terminates for any reason prior to the Vesting Date (except as provided in Section 3(c)) all unvested Restricted Stock shall be forfeited and automatically transferred to the

Company without consideration on the date of Grantee’s employment termination and Grantee shall have no further rights with respect to the Restricted Stock. For purposes of this Agreement, employment with a Subsidiary of the Corporation shall be considered employment with the Corporation.

(c)Effect on Vesting in Case of Employment Termination. Notwithstanding Section 3(b) above, the following special vesting rules shall apply if Grantee’s employment with the Company terminates prior to the Vesting Date:

(i) Death or Disability. If Grantee dies or becomes subject to any Disability prior to the Vesting Date, his or her Restricted Stock shall vest on a pro rata basis according to the number of days elapsed since the date hereof and the date of his or her death or Disability. Any portion of Grantee’s Restricted Stock that was not vested on the date of Grantee’s death or Disability pursuant to this Section 3(b)(i) shall be forfeited to the Company.

(ii) Termination by the Company Without Cause. If Grantee is terminated by the Company without Cause prior to the Vesting Date, his or her Restricted Stock shall vest in accordance with the schedule set forth in the Notice. Any portion of Grantee’s Restricted Stock that was not vested on the date of such termination without cause pursuant to this Section 3(b)(ii) shall be forfeited to the Company.


4.	Restrictions on Transfer.

(a)Non-Transferability. Restricted Stock, and any rights and interests with respect thereto, issued under this Agreement and the Plan shall not, prior to vesting, be sold, exchanged, transferred, assigned or otherwise disposed of in any way by the Grantee (or any beneficiary(ies) of the Grantee), other than by testamentary disposition by the Grantee or the laws of descent and distribution. Any such Restricted Stock, and any rights and interests with respect thereto, shall not, prior to vesting, be pledged or encumbered in any way by the Grantee (or any beneficiary(ies) of the Grantee) and shall not, prior to vesting, be subject to execution, attachment or similar legal process. Any attempt to sell, exchange, transfer, assign, pledge, encumber or otherwise dispose of in any way any of the Restricted Stock, or the levy of any execution, attachment or similar legal process upon the Restricted Stock, contrary to the terms and provisions of this Agreement and/or the Plan shall be null and void and without legal force or effect.

(b)Securities Laws Restrictions on Transfer of Vested Shares. Grantee understands and hereby acknowledges that, in addition to transfer restrictions in this Agreement, federal and state securities laws govern and restrict Grantee’s right to offer, sell or otherwise dispose of any Vested Shares unless such offer, sale or other disposition thereof is registered or qualified under the Securities Act and applicable state securities laws, or in the opinion of the Company's counsel, such offer, sale or other disposition is exempt from registration or qualification thereunder. Grantee agrees that he or she shall not offer, sell or otherwise dispose of any Vested Shares in any manner which would: (i) require the Company to file any registration statement with the Securities and Exchange Commission (or any similar filing under state law) or to amend or supplement any such filing or (ii) violate or cause the Company to violate the Securities Act, the rules and regulations promulgated thereunder or any other state or federal law. Grantee further understands that the certificates for any Vested Shares shall bear such legends as the Company deems necessary or desirable in connection with the Securities Act or other rules, regulations or laws. Grantee may not sell, transfer or dispose of any Vested Shares (except pursuant to an effective registration statement under the Securities Act) without first obtaining from the Company an opinion of the Company’s counsel that registration under the Securities Act or any applicable state securities law is not required in connection with such transfer. If requested, Grantee agrees to provide the Company with written assurances, in form and substance satisfactory to the Company, that (1) the proposed disposition does not require registration of the Shares under the Securities Act or (2) all appropriate action necessary for compliance with the registration requirements of the Securities Act or any exemption from registration available under the Securities Act (including Rule 144) has been taken. When shares of Restricted Stock awarded by this Agreement become

Vested Shares and after the conditions of this section 4(d) have been satisfied, the Grantee shall be entitled to receive unrestricted Shares and if the Grantee’s stock is certificated and contain legends restricting the transfer of such Shares, the Grantee shall be entitled to receive new stock certificates free of such legends (except any legends requiring compliance with securities laws). In connection with the delivery of the unrestricted Shares pursuant to this Agreement, the Grantee agrees to execute any documents reasonably requested by the Company.

(c)Restrictive Legend. The certificates representing the Restricted Stock, if any, shall bear the following legend:

"THE SECURITIES REPRESENTED BY THIS CERTIFICATE WERE ORIGINALLY ISSUED ON , HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), OR UNDER ANY STATE SECURITIES LAWS AND MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS OR AN EXEMPTION FROM REGISTRATION THEREUNDER. THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE ALSO SUBJECT TO ADDITIONAL RESTRICTIONS ON TRANSFER, REPURCHASE RIGHTS AND FORFEITURE PROVISIONS AND CERTAIN OTHER AGREEMENTS SET FORTH IN A RESTRICTED STOCK AGREEMENT BETWEEN THE COMPANY AND DATED AS OF ,____, A COPY OF WHICH MAY BE OBTAINED BY THE HOLDER HEREOF AT THE COMPANY'S PRINCIPAL PLACE OF BUSINESS WITHOUT CHARGE."

(d)Restrictions on Transfer after Vesting. The transfer or sale of Vested Shares in accordance with this Section 4 of this Agreement shall be subject to the Company Policy Regarding Insider Trading, as amended from time to time, including any preclearance procedures or black-out periods that specifically apply to Grantee.

5.Conformity with Plan. The Restricted Stock is intended to conform in all respects with, and is subject to all applicable provisions of, the Plan (which is incorporated herein by reference). Inconsistencies between this Agreement and the Plan shall be resolved in accordance with the terms of the Plan. By executing and returning the enclosed copy of this Agreement, Grantee acknowledges receipt of this Agreement and the Plan and agrees to be bound by all of the terms of this Agreement and the Plan.

6.Rights of Employment. Nothing in this Agreement shall interfere with or limit in any way the right of the Company to terminate Grantee’s employment at any time (with or without Cause), nor confer upon Grantee any right to continue in the employ of the Company for any period of time or to continue his or her present (or any other) rate of compensation, and in the event of Grantee’s termination of employment (including, but not limited to, termination by the Company without Cause), any portion of Grantee’s Restricted Stock that was not previously vested shall be forfeited, except as otherwise provided herein. Nothing in this Agreement shall confer upon Grantee any right to be selected again as a Plan participant, and nothing in the Plan or this Agreement shall provide for any adjustment to the number of shares of Restricted Stock upon the occurrence of subsequent events except as provided in Section 8 below.


7.	Withholding of Taxes.

(a) The Grantee shall, immediately upon notification of the amount due, if any, pay to the Company in cash or by check or direct a broker to sell a sufficient number of shares from the Grantee’s brokerage account and deliver the proceeds to the Company, in either case in the amount necessary to satisfy any applicable federal, state and local tax withholding requirements. If additional withholding is or becomes required (as a result of the vesting of any Restricted Stock or as a result of disposition of Vested Shares) beyond any amount deposited before delivery of the certificates, the Grantee shall pay such amount to the Company, in cash or by check, on demand. The Company shall be entitled, if necessary or desirable, to withhold from Grantee any amounts due and payable by the Company, including wages, to Grantee (or secure payment from Grantee in lieu of withholding), the amount of any withholding or other tax due from the

Company with respect to any Restricted Stock issuable under this Agreement, and the Company may defer such issuance unless indemnified by Grantee to its satisfaction. Grantee acknowledges that he or she has reviewed with his or her own tax advisors the federal, state, local and foreign tax consequences of this investment and the transactions contemplated by this Agreement. Grantee is relying solely on such advisors and not on any statements or representations of the Company or any of its agents. Grantee understands that he or she (and not the Company) shall be responsible for any tax liability that may arise as a result of the transactions contemplated by this Agreement. Grantee further understands that Section 83 of the Code, taxes as ordinary income the difference between the purchase price, if any, for the Shares and the fair market value of the Shares as of the date the forfeiture provisions in Section 3 lapse. Grantee understands that the he or she may elect to be taxed at the time the Restricted Stock is issued rather than when and as the forfeiture provisions lapse expires by filing an election under Section 83(b) of the Code with the IRS within 30 days from the date of hereof. THE FORM FOR MAKING THIS SECTION 83(b) ELECTION IS ATTACHED TO THIS AGREEMENT AS EXHIBIT A AND GRANTEE (AND NOT THE COMPANY OR ANY OF ITS AGENTS) SHALL BE SOLELY RESPONSIBLE FOR APPROPRIATELY FILING SUCH FORM, EVEN IF GRANTEE REQUESTS THE COMPANY OR ITS AGENTS TO MAKE THIS FILING ON GRANTEE’S BEHALF.

8.Adjustments. In the event of a reorganization, recapitalization, stock dividend or stock split, or combination or other change in the Shares, the Board or the Committee shall make such adjustments in the number and type of shares of Grantee’s Restricted Stock as the Board or Committee reasonably determine to be appropriate, provided that any such adjustments shall not adversely affect the Grantee.

9.Rights as a Shareholder. Except as otherwise provided in this Agreement and the Plan, Grantee shall have all of the rights of a shareholder of the Company with respect to the Shares of Restricted Stock, including the right to vote such shares and the right to receive dividends. There is no guarantee by the Company that dividends will be paid. All dividends and other distributions paid with respect to Restricted Stock, including with respect to unvested Restricted Stock and whether paid in cash, Shares, or other property, shall be paid by the Company on the same date that dividend payments are made with respect to all of the Company’s outstanding Shares.

10.Remedies. The parties hereto shall be entitled to enforce their rights under this Agreement specifically, to recover damages by reason of any breach of any provision of this Agreement and to exercise all other rights existing in their favor. The parties hereto acknowledge and agree that money damages would not be an adequate remedy for any breach of the provisions of this Agreement and that any party hereto shall be entitled to specific performance and/or injunctive relief (without posting bond or other security) from any court of law or equity of competent jurisdiction in order to enforce or prevent any violation of the provisions of this Agreement.

11.Amendment. Except as otherwise provided herein, any provision of this Agreement may be amended or waived only with the prior written consent of Grantee and the Company.

12.Successors and Assigns. Except as otherwise expressly provided herein, all covenants and agreements contained in this Agreement by or on behalf of any of the parties hereto shall bind and inure to the benefit of the respective successors and permitted assigns of the parties hereto whether so expressed or not.

13.Severability. Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable law, such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of this Agreement.

14.Counterparts. This Agreement may be executed simultaneously in two or more counterparts, each of which shall constitute an original, but all of which taken together shall constitute one and the same Agreement.

15.Descriptive Headings. The descriptive headings of this Agreement are inserted for convenience only and do not constitute a part of this Agreement.

16.Governing Law. The corporate law of the state of Delaware shall govern all questions concerning the relative rights of the Company and its stockholders. All other questions concerning the construction, validity and interpretation of this Agreement shall be governed by the internal law, and not the law of conflicts, of the state of Delaware.

17.Entire Agreement. This Agreement and the Plan constitute the entire understanding between Grantee and the Company, and supersedes all other agreements, whether written or oral, with respect to the acquisition by Grantee of Common Stock of the Company. If there are any conflicts in terms and conditions between this Agreement and the Plan, the terms and conditions of the Plan shall govern, unless otherwise determined by the Committee or the Board.

EX-21.1 4 ensg123117ex211.htm EXHIBIT 21.1 Exhibit

EXHIBIT 21.1



LEGAL NAME	PRESIDENT COMPANY	JURISDICTION
1000 WP Euless Holdings LLC	The Ensign Group, Inc.	Nevada
2016 Health Holdings LLC	The Ensign Group, Inc.	Nevada
2410 Stillhouse Health Holdings LLC	The Ensign Group, Inc.	Nevada
2410 Stillhouse Senior Living, Inc.	Bridgestone Living LLC	Nevada
24th Street Healthcare Associates LLC	Bandera Healthcare, Inc.	Nevada
Adipiscor LLC	The Ensign Group, Inc.	Nevada
Agape Health Holdings LLC	The Ensign Group, Inc.	Nevada
ALH Enterprise LLC	ALH Health Holdings LLC	California
ALH Health Holdings LLC	The Ensign Group, Inc.	Nevada
ALH Health Northwest LLC	ALH Health Holdings LLC	Nevada
Allen Creek Healthcare, Inc.	Pennant Healthcare, Inc.	Nevada
Alpowa Healthcare, Inc.	Paragon Healthcare, Inc.	Nevada
Anza Healthcare, Inc.	Signum Healthcare South, Inc.	Nevada
Apache Trail Healthcare, Inc.	Bandera Healthcare, Inc.	Nevada
Armstrong Healthcare, Inc.	Keystone Care LLC	Nevada
Arvada Healthcare, Inc.	Endura Healthcare, Inc.	Nevada
Atlantic Memorial Healthcare Associates, Inc.	Signum Healthcare South, Inc.	Nevada
Aurora Health Holdings LLC	The Ensign Group, Inc.	Nevada
Avenues Healthcare, Inc.	Milestone Healthcare LLC	Nevada
Avocado Health Holdings LLC	The Ensign Group, Inc.	Nevada
Aztec Healthcare, Inc.	Bandera Healthcare, Inc.	Nevada
Bainbridge Health Holdings LLC	The Ensign Group, Inc.	Nevada
Bakorp L.L.C.	PMD Investments, LLC	Nevada
Bandera Healthcare, Inc.	The Ensign Group, Inc.	Nevada
Bannock Health Holdings LLC	The Ensign Group, Inc.	Nevada
Bayshore Healthcare, Inc.	Signum Healthcare Central, Inc.	Nevada
Bayside Healthcare, Inc.	Signum Healthcare South, Inc.	Nevada
Beacon Hill Healthcare, Inc.	Pennant Healthcare, Inc.	Nevada
Bell Villa Care Associates LLC	Signum Healthcare South, Inc.	Nevada
Bernardo Heights Healthcare, Inc.	Signum Healthcare South, Inc.	Nevada
Bertetti Healthcare, Inc.	Keystone Care LLC	Nevada
Best SW Health Holdings LLC	The Ensign Group, Inc.	Nevada
Big Blue Healthcare, Inc.	Gateway Healthcare, Inc.	Nevada
Bijou Health Holdings LLC	The Ensign Group, Inc.	Nevada
Bijou Healthcare, Inc.	Endura Healthcare, Inc.	Nevada
Brackenridge Healthcare, Inc.	Keystone Care, Inc.	Nevada
Brenwood Park Health Holdings LLC	The Ensign Group, Inc.	Nevada
Brenwood Park Senior Living, Inc.	Bridgestone Living LLC	Nevada
Bridgestone Living LLC	The Ensign Group, Inc.	Nevada
Brown Road Senior Housing LLC	Bridgestone Living LLC	Nevada
Brownsville Care Associates, Inc.	Keystone Care LLC	Nevada
Bruce Neenah Health Holdings LLC	The Ensign Group, Inc.	Nevada
Bruce Neenah Senior Living, Inc.	Bridgestone Living LLC	Nevada
C Street Health Associates LLC	Signum Healthcare Central, Inc.	Nevada



Camarillo Community Care, Inc.	Signum Healthcare Central, Inc.	Nevada
Cane Island Healthcare, Inc.	Keystone Care LLC	Nevada
Canyon Springs Senior Living, Inc.	Bridgestone Living LLC	Nevada
Capitol Healthcare, Inc.	Cornerstone Healthcare, Inc.	Nevada
Capstone Resources, Inc.	Capstone Transportation Investments, Inc.	Nevada
Capstone Transportation Investments, Inc.	The Ensign Group, Inc.	Nevada
Cardiff Healthcare, Inc.	Milestone Healthcare LLC	Nevada
Carolina Healthcare, Inc.	Hopewell Healthcare, Inc.	Nevada
Carrollton Heights Healthcare, Inc.	Keystone Care LLC	Nevada
Cedar Senior Living, Inc.	Bridgestone Living LLC	Nevada
Central Avenue Healthcare, Inc.	Gateway Healthcare, Inc.	Nevada
Chaparral Healthcare, Inc.	Keystone Care LLC	Nevada
Chateau Julia Healthcare, Inc.	Endura Healthcare, Inc.	Nevada
Cherokee Healthcare, Inc.	Gateway Healthcare, Inc.	Nevada
Cherry Hills Healthcare, Inc.,	Endura Healthcare, Inc.	Nevada
Circle Health Holdings LLC	The Ensign Group, Inc.	Nevada
City Heights Health Associates LLC	Signum Healthcare South, Inc.	Nevada
Claremont Foothills Health Associates LLC	Signum Healthcare Central, Inc.	Nevada
Claydelle Healthcare, Inc.	Signum Healthcare South, Inc.	Nevada
Cloverleaf Healthcare, Inc.	Gateway Healthcare, Inc.	Nevada
Concord Avenue Health Holdings LLC	The Ensign Group, Inc.	Nevada
Congaree Health Holdings LLC	The Ensign Group, Inc.	Nevada
Connected Healthcare, Inc.	Cornerstone Healthcare, Inc.	Nevada
Constitution Road Healthcare, Inc.	Endura Healthcare, Inc.	Nevada
Conway Health Holdings LLC	The Ensign Group, Inc.	Nevada
Copeland Healthcare, Inc.	Keystone Care LLC	Nevada
Copper Basin Healthcare, Inc.	Cornerstone Healthcare, Inc.	Nevada
Cornerstone Healthcare, Inc.	The Ensign Group, Inc.	Nevada
Cornerstone Service Center, Inc.	Cornerstone Healthcare, Inc.	Nevada
Cornet Limited, Inc.	The Ensign Group, Inc.	Arizona
Costa Victoria Healthcare LLC	Signum Healthcare South, Inc.	Nevada
Cow Creek Healthcare, Inc.	Keystone Care LLC	Nevada
Custom Care Healthcare, Inc.	Cornerstone Healthcare, Inc.	Nevada
Cypresswood Healthcare, Inc.	Keystone Care LLC	Nevada
Da Vinci Healthcare, Inc.	Bandera Healthcare, Inc.	Nevada
Daffodil Healthcare, Inc.	Keystone Care LLC	Nevada
De Moisy Healthcare, Inc.	Milestone Healthcare LLC	Nevada
De Soto Senior Living, Inc.	Bridgestone Living LLC	Nevada
Deer Creek Health Holdings LLC	The Ensign Group, Inc.	Nevada
Denmark Senior Living, Inc.	Bridgestone Living LLC	Nevada
Desert Cove Healthcare, Inc.	Bandera Healthcare, Inc.	Nevada
Dessau Healthcare, Inc.	Keystone Care LLC	Nevada
Diamond Valley Health Holdings LLC	The Ensign Group, Inc.	Nevada
Discovery Trail Healthcare, Inc.	Gateway Healthcare, Inc.	Nevada
Dorothy Health Holdings LLC	The Ensign Group, Inc.	Nevada
Downey Community Care LLC	Signum Healthcare South, Inc.	Nevada



Drinkwater Senior Living, Inc.	Bridgestone Living LLC	Nevada
Duck Creek Healthcare, Inc.	Keystone Care LLC	Nevada
Eagle Harbor Healthcare, Inc.	Pennant Healthcare, Inc.	Nevada
Echo Canyon Healthcare, Inc.	Bandera Healthcare, Inc.	Nevada
Eiffel Healthcare, Inc.	Keystone Care LLC	Nevada
Elkhorn Health Holdings LLC	The Ensign Group, Inc.	Nevada
Emblem Healthcare, Inc.	Cornerstone Healthcare, Inc.	Nevada
Emerald City PubCo, Inc.	Gateway Healthcare, Inc.	Kansas
Emerald Healthcare, Inc.	Cornerstone Healthcare, Inc.	Nevada
Empirecare Health Associates, Inc.	Signum Healthcare Central, Inc.	Nevada
Endura Healthcare, Inc.	The Ensign Group, Inc.	Nevada
Ensign Cloverdale LLC	Signum Healthcare North, Inc.	Nevada
Ensign Montgomery LLC	Signum Healthcare North, Inc.	Nevada
Ensign Napa LLC	The Ensign Group, Inc.	Nevada
Ensign Palm I LLC	Signum Healthcare Central, Inc.	Nevada
Ensign Panorama LLC	Signum Healthcare Central, Inc.	Nevada
Ensign Pleasanton LLC	Signum Healthcare North, Inc.	Nevada
Ensign Sabino LLC	Bandera Healthcare, Inc.	Nevada
Ensign San Dimas LLC	Signum Healthcare Central, Inc.	Nevada
Ensign Santa Rosa LLC	Signum Healthcare North, Inc.	Nevada
Ensign Services, Inc.	The Ensign Group, Inc.	Nevada
Ensign Sonoma LLC	Signum Healthcare North, Inc.	Nevada
Ensign Whittier East LLC	Signum Healthcare South, Inc.	Nevada
Ensign Whittier West LLC	Signum Healthcare South, Inc.	Nevada
Ensign Willits LLC	Signum Healthcare North, Inc.	Nevada
Eureka Healthcare, Inc.	Cornerstone Healthcare, Inc.	Nevada
Exemplar Healthcare, Inc.	The Ensign Group, Inc.	Nevada
Finding Home Healthcare, Inc.	Cornerstone Healthcare, Inc.	Nevada
Forrest Hill Healthcare, Inc.	Keystone Care LLC	Nevada
Fossil Creek Healthcare, Inc.	Keystone Care LLC	Nevada
Gate Three Healthcare LLC	Signum Healthcare South, Inc.	Nevada
Gateway Gilbert Holdings LLC	The Ensign Group, Inc.	Nevada
Gateway Healthcare, Inc.	The Ensign Group, Inc.	Nevada
GEM Healthcare, Inc.	Pennant Healthcare, Inc.	Nevada
Getzendaner Healthcare, Inc.	Keystone Care LLC	Nevada
Glacier Peak Healthcare, Inc.	Cornerstone Healthcare, Inc.	Nevada
Glendale Healthcare Associates LLC	Bandera Healthcare, Inc.	Nevada
GO Assisted, Inc.	Bridgestone Living LLC	Nevada
Golden Oaks Healthcare, Inc.	Gateway Healthcare, Inc.	Nevada
Golden Years Program, Inc.	Milestone Healthcare LLC	Nevada
Good Hope Healthcare, Inc.	Gateway Healthcare, Inc.	Nevada
Graceland Senior Living, Inc.	Bridegstone Living LLC	Nevada
Grand Villa PHX, Inc.	Keystone Care LLC	Nevada
Granite Healthcare, Inc.	Cornerstone Healthcare, Inc.	Nevada
Granite Hills Senior Living, Inc.	Bridgestone Living LLC	Nevada
Grassland Healthcare and Rehabilitation, Inc.	Keystone Care LLC	Nevada



Great Plains Healthcare, Inc.	Cornerstone Healthcare, Inc.	Nevada
Green Bay Health Holdings LLC	The Ensign Group, Inc.	Nevada
Green Bay Senior Living, Inc.	Bridgestone Living LLC	Nevada
Gypsum Creek Healthcare, Inc.	Gateway Healthcare, Inc.	Nevada
Harlan Heights Health Holdings LLC	The Ensign Group, Inc.	Nevada
Harlingen Healthcare, Inc.	Keystone Care LLC	Nevada
Harmony Health Holdings LLC	The Ensign Group, Inc.	Nevada
Harrison Health Holdings LLC	The Ensign Group, Inc.	Nevada
HB Healthcare Associates LLC	Signum Healthcare South, Inc.	Nevada
Healthlift Medical Transportation, Inc.	Capstone Transportation Investments, Inc.	Nevada
Heartwood Home Health and Hospice, Inc.	Cornerstone Healthcare, Inc.	Nevada
Highland Healthcare LLC	Bandera Healthcare, Inc.	Nevada
Higley Healthcare, Inc.	Bandera Healthcare, Inc.	Nevada
Hill Country Health Holdings LLC	The Ensign Group, Inc.	Nevada
Homedale Healthcare, Inc.	Pennant Healthcare, Inc.	Nevada
Hopewell Healthcare, Inc.	The Ensign Group, Inc.	Nevada
Hoquiam Healthcare, Inc.	Pennant Healthcare, Inc.	Nevada
Hub City Healthcare, Inc.	Keystone Care LLC	Nevada
Hueneme Healthcare, Inc.	Milestone Healthcare LLC	Nevada
Hutchins Healthcare, Inc.	Keystone Care LLC	Nevada
ICare Private Duty, Inc.	Cornerstone Healthcare, Inc.	Nevada
Immediate Clinic Healthcare, Inc.	Bandera Healthcare, Inc.	Nevada
Immediate Clinic Seattle, Inc.	Immediate Clinic Healthcare, Inc.	Nevada
Indian Hills Healthcare, Inc.	Gateway Healthcare, Inc.	Nevada
Iron Horse Healthcare, Inc.	Gateway Healthcare, Inc.	Nevada
J.A.R.R. Transportation Group, Inc.	Capstone Transportation Investments, Inc.	Nevada
Jack Finney Healthcare, Inc.	Keystone Care LLC	Nevada
Jefferson Healthcare, Inc.	Signum Healthcare South, Inc.	Nevada
Jordan Health Associates, Inc.	Milestone Healthcare LLC	Nevada
Joshua Tree Healthcare, Inc.	Cornerstone Healthcare, Inc.	Nevada
JRT Healthcare, Inc.	Pennant Healthcare, Inc.	Nevada
Kenosha Health Holdings LLC	The Ensign Group, Inc.	Nevada
Kenosha Senior Living, Inc.	Bridgestone Living LLC	Nevada
Kettle Creek Health Holdings LLC	The Ensign Group, Inc.	Nevada
Keystone Care LLC	The Ensign Group, Inc.	Nevada
Keystone Hospice Care, Inc.	Cornerstone Healthcare, Inc.	Nevada
Kingwood Health Holdings LLC	The Ensign Group, Inc.	Nevada
Klement Healthcare, Inc.	Keystone Care LLC	Nevada
Knight Health Holdings LLC	The Ensign Group, Inc.	Nevada
La Jolla Skilled, Inc.	Signum Healthcare South, Inc.	Nevada
Laguna Healthcare, Inc.	Cornerstone Healthcare, Inc.	Nevada
Lake Cassidy Health Holdings LLC	The Ensign Group, Inc.	Nevada
Lake Pleasant Healthcare, Inc.	Bandera Healthcare, Inc.	Nevada
Lake Pointe Health Holdings LLC	The Ensign Group, Inc.	Nevada
Lake Pointe Senior Living, Inc.	Bridgestone Living LLC	Nevada
Lakewood Healthcare, Inc.	Endura Healthcare, Inc.	Nevada



Layton Health Holdings LLC	The Ensign Group, Inc.	Nevada
Legend Lake Health Holdings LLC	The Ensign Group, Inc.	Nevada
Lemon Grove Health Associates LLC	Signum Healthcare South, Inc.	Nevada
Lil’ Tots Day Program, Inc.	Milestone Healthcare LLC	Nevada
Lilly Road Health Holdings LLC	The Ensign Group, Inc.	Nevada
Lindahl Healthcare, Inc.	Gateway Healthcare, Inc.	Nevada
Little Blue Health Holdings LLC	The Ensign Group, Inc.	Nevada
Livingston Care Associates, Inc.	Keystone Care LLC	Nevada
Lone Peak Healthcare, Inc.	Milestone Healthcare LLC	Nevada
Lone Star MTC, Inc.	Capstone Transportation Investments, Inc.	Nevada
Lowell Healthcare, Inc.	Endura Healthcare, Inc.	Nevada
Lynnwood Health Services, Inc.	Pennant Healthcare, Inc.	Nevada
Madison Health Holdings LLC	The Ensign Group, Inc.	Nevada
Madison Pointe Health Holdings LLC	The Ensign Group, Inc.	Nevada
Madison Senior Living, Inc.	Bridgestone Living LLC	Nevada
Magic Valley Senior Living, Inc.	Bridgestone Living LLC	Nevada
Manitowoc Health Holdings LLC	The Ensign Group, Inc.	Nevada
Manitowoc Senior Living, Inc.	Bridgestone Living LLC	Nevada
Manor Park Healthcare LLC	Pennant Healthcare, Inc.	Nevada
Maple Hills Healthcare, Inc.	Gateway Healthcare, Inc.	Nevada
Marian Healthcare LLC	Milestone Healthcare LLC	Nevada
Marion Health Associates, Inc.	Bridgestone Living LLC	Nevada
Market Bayou Healthcare, Inc.	Keystone Care LLC	Nevada
McAllen Care Associates, Inc.	Keystone Care LLC	Nevada
McAllen Community Healthcare, Inc.	Keystone Care LLC	Nevada
McFarland Health Holdings LLC	The Ensign Group, Inc.	Nevada
McFarland Senior Living, Inc.	Bridgestone Living LLC	Nevada
McPherson Health Holdings LLC	The Ensign Group, Inc.	Nevada
Medical Transportation Company of Arizona LLC	Capstone Transportation Investments, Inc.	Nevada
Medical Transportation Company of Tucson LLC	Capstone Transportation Investments, Inc.	Nevada
Menomonee Health Holdings LLC	The Ensign Group, Inc.	Nevada
Mesa Grande Senior Living, Inc.	Bridgestone Living LLC	Nevada
Midland Nampa Health Holdings LLC	The Ensign Group, Inc.	Nevada
Midland Nampa Healthcare, Inc.	Pennant Healthcare, Inc.	Nevada
Milestone Healthcare LLC (registered in Utah as Milestone Post Acute Healthcare, Inc.)	The Ensign Group, Inc.	Nevada
Mission Trails Healthcare, Inc.	Signum Healthcare South, Inc.	Nevada
Misty Willow Healthcare, Inc.	Keystone Care LLC	Nevada
Mohave Healthcare, Inc.	Cornerstone Healthcare, Inc.	Nevada
Monroe Healthcare, Inc.	Gateway Healthcare, Inc.	Nevada
Montebella Health Holdings LLC	The Ensign Group, Inc.	Nevada
Moss Bay Senior Living, Inc.	Bridgestone Living LLC	Nevada
Mountain View Retirement, Inc.	Bridgestone Living LLC	Nevada
Mountain Vista Senior Living, Inc.	Bridgestone Living LLC	Nevada
Nautilus Healthcare, Inc.	Signum Healthcare South, Inc.	Nevada
NB Brown Rock Healthcare, Inc.	Keystone Care LLC	Nevada
Nobel Health Properties LLC	The Ensign Group, Inc.	Nevada



Nordic Valley Health Holdings LLC	The Ensign Group, Inc.	Nevada
North Mountain Healthcare LLC	Bandera Healthcare, Inc.	Nevada
North Parkway Health Holdings LLC	The Ensign Group, Inc.	Nevada
North Parkway Healthcare, Inc.	Milestone Healthcare LLC	Nevada
Northern Oaks Healthcare, Inc.	Keystone Care LLC	Nevada
Oak Point Healthcare, Inc.	Keystone Care LLC	Nevada
Oceano Senior Living, Inc.	Bridgestone Living LLC	Nevada
Oceanside Healthcare, Inc.	Cornerstone Healthcare, Inc.	Nevada
Oceanview Healthcare, Inc.	Keystone Care LLC	Nevada
Ocotillo Healthcare, Inc.	Bandera Healthcare, Inc.	Nevada
Olympus Health, Inc.	Milestone Healthcare LLC	Nevada
Orangewood Senior Living, Inc.	Bridgestone Living LLC	Nevada
Osmond Marketing Holdings LLC	The Ensign Group, Inc.	Nevada
Palo Duro Healthcare, Inc.	Keystone Care LLC	Nevada
Panorama Health Holdings LLC	The Ensign Group, Inc.	Nevada
Paragon Healthcare, Inc.	The Ensign Group, Inc.	Nevada
Park Waverly Healthcare LLC	Bandera Healthcare, Inc.	Nevada
Parkside Healthcare, Inc.	Signum Healthcare South, Inc.	Nevada
Peak Construction, Inc.	The Ensign Group, Inc.	Nevada
Pennant Healthcare, Inc.	The Ensign Group, Inc.	Nevada
Permunitum LLC	The Ensign Group, Inc.	Nevada
Pikes Peak Healthcare, Inc.	Endura Healthcare, Inc.	Nevada
Pineridge Healthcare, Inc.	Endura Healthcare, Inc.	Nevada
Piney Lufkin Healthcare, Inc.	Keystone Care LLC	Nevada
Pleasant Run Health Holdings LLC	The Ensign Group, Inc.	Nevada
Pleasant Run Senior Living, Inc.	Bridgestone Living LLC	Nevada
PMD Investments, LLC	The Ensign Group, Inc.	Nevada
PMDCA, LLC	Bakorp L.L.C.	Nevada
PMDLAB, LLC	Bakorp L.L.C.	Nevada
PMDTC, LLC	Bakorp L.L.C.	Nevada
Pocatello Health Services, Inc.	Pennant Healthcare, Inc.	Nevada
Pointe Meadow Healthcare, Inc.	Milestone Healthcare LLC	Nevada
Pomerado Ranch Healthcare LLC	Keystone Care LLC	Nevada
Ponderosa Health Holdings LLC	The Ensign Group, Inc.	Nevada
Portside Healthcare, Inc.	Signum Healthcare South, Inc.	Nevada
Prairie Creek Healthcare, Inc.	Gateway Healthcare, Inc.	Nevada
Prairie Ridge Health Holdings LLC	The Ensign Group, Inc.	Nevada
Prairie View Healthcare, Inc.	Cornerstone Healthcare, Inc.	Nevada
Presidio Health Associates LLC	Bandera Healthcare, Inc.	Nevada
Price Healthcare, Inc.	Milestone Healthcare LLC	Nevada
Primrose Health Holdings LLC	The Ensign Group, Inc.	Nevada
Primrose Senior Living, Inc.	Bridgestone Living LLC	Nevada
Prospect Senior Living, Inc.	Bridgestone Living LLC	Nevada
Prospector Park Health Holdings LLC	The Ensign Group, Inc.	Nevada
Purple Horse PubCo, Inc.	Gateway Healthcare, Inc.	Kansas
Quail Creek Health Holdings LLC	The Ensign Group, Inc.	Nevada



Queenston Healthcare, Inc.	Keystone Care LLC	Nevada
Racine Health Holdings LLC	The Ensign Group, Inc.	Nevada
Racine Senior Living, Inc.	Bridgestone Living LLC	Nevada
Radiant Hills Health Associates LLC	Bandera Healthcare, Inc.	Nevada
Raintree Grove Healthcare, Inc.	The Ensign Group, Inc.	Nevada
Ramon Healthcare Associates, Inc.	Signum Healthcare Central, Inc.	Nevada
Randolph Healthcare, Inc.	Gateway Healthcare, Inc.	Nevada
Red Cliffs Healthcare, Inc.	Milestone Healthcare LLC	Nevada
Red Mountain Healthcare, Inc.	Bandera Healthcare, Inc.	Nevada
Red Rock Healthcare, Inc.	Cornerstone Healthcare, Inc.	Nevada
Redbrook Healthcare Associates LLC	Signum Healthcare Central, Inc.	Nevada
RenewCare of Scottsdale, Inc.	Bandera Healthcare, Inc.	Nevada
Richmond Senior Services, Inc.	Keystone Care LLC	Nevada
Rio Mesa Health Holdings LLC	The Ensign Group, Inc.	Nevada
Riverside Healthcare, Inc.	Gateway Healthcare, Inc.	Nevada
Riverview Healthcare, Inc.	Milestone Healthcare LLC	Nevada
Riverview Village Health Holdings LLC	The Ensign Group, Inc.	Nevada
Riverview Village Senior Living, Inc.	Bridgestone Living LLC	Nevada
Riverwalk Healthcare, Inc.	Keystone Care LLC	Nevada
Rock Canyon Healthcare, Inc.	Endura Healthcare, Inc.	Nevada
Rock Hill Healthcare, Inc.	Hopewell Healthcare, Inc.	Nevada
Rose Park Healthcare Associates, Inc.	Signum Healthcare South, Inc.	Nevada
Rosemead Health Holdings LLC	The Ensign Group, Inc.	Nevada
Rosenburg Senior Living, Inc.	Bridgestone Living LLC	Nevada
Ruby Reds PubCo, Inc.	Gateway Healthcare, Inc.	Kansas
Saguaro Senior Living, Inc.	Bridgestone Living LLC	Nevada
Salado Creek Senior Care, Inc.	Keystone Care LLC	Nevada
San Gabriel Senior Living, Inc.	Bridgestone Living. Inc.	Nevada
Sand Hollow Healthcare, Inc.	Milestone Healthcare LLC	Nevada
Sand Lily Healthcare, Inc.	Cornerstone Healthcare, Inc.	Nevada
Savoy Healthcare, Inc.	Keystone Care LLC	Nevada
Sawtooth Healthcare, Inc.	Pennant Healthcare, Inc.	Nevada
Scandinavian Court Health Holdings LLC	The Ensign Group, Inc.	Nevada
Sedgewood Health Holdings LLC	The Ensign Group, Inc.	Nevada
Sentinel Peak Healthcare, Inc	Bandera Healthcare, Inc.	Nevada
Sheboygan Health Holdings LLC	The Ensign Group, Inc.	Nevada
Sheboygen Senior Living, Inc.	Bridgestone Living LLC	Nevada
Sherman Health Holdings LLC	The Ensign Group, Inc.	Nevada
Sherwood Health Holdings LLC	The Ensign Group, Inc	Nevada
Shoshone Health Holdings LLC	The Ensign Group, Inc.	Nevada
Signum Healthcare Central, Inc.	The Ensign Group, Inc.	Nevada
Signum Healthcare North, Inc.	The Ensign Group, Inc.	Nevada
Signum Healthcare South, Inc.	The Ensign Group, Inc.	Nevada
Silver Lake Healthcare, Inc.	Cornerstone Healthcare, Inc.	Nevada
Somers Kenosha Health Holdings LLC	The Ensign Group, Inc.	Nevada
Somers Kenosha Senior Living, Inc.	Bridgestone Living LLC	Nevada



South Bay Healthcare, Inc.	Cornerstone Healthcare, Inc.	Nevada
South C Health Holdings LLC	The Ensign Group, Inc.	Nevada
South Plains Healthcare, Inc.	Cornerstone Healthcare, Inc.	Nevada
South Valley Healthcare, Inc.	Milestone Healthcare LLC	Nevada
Southern Charm Healthcare, Inc.	Hopewell Healthcare, Inc.	Nevada
Southern Oaks Healthcare, Inc.	Keystone Care LLC	Nevada
Southland Management LLC	Signum Healthcare South, Inc.	Nevada
Southside Healthcare, Inc.	Gateway Healthcare, Inc.	Nevada
Spokane Healthcare, Inc.	Cornerstone Healthcare, Inc.	Nevada
Spring Creek Healthcare, Inc.	Keystone Care LLC	Nevada
Spring Valley Assisted Living, Inc.	Bridgestone Living LLC	Nevada
Standardbearer Insurance Company, Ltd.	The Ensign Group, Inc.	Nevada
Stanton Lake Healthcare, Inc.	Gateway Healthcare, Inc.	Nevada
Stevens Point Health Holdings LLC	The Ensign Group, Inc.	Nevada
Stevens Point Senior Living, Inc.	Bridgestone Living LLC	Nevada
Stockyards Healthcare, Inc.	Keystone Care LLC	Nevada
Stonebridge Healthcare, Inc	Cornerstone Healthcare, Inc.	Nevada
Stoney Hill Healthcare, Inc.	Hopewell Healthcare, Inc.	Nevada
Stoughton Health Holdings LLC	The Ensign Group, Inc.	Nevada
Stoughton Senior Living, Inc.	Bridgestone Living LLC	Nevada
Successor Healthcare LLC	Milestone Healthcare LLC	Nevada
Summerlin Healthcare, Inc.	Cornerstone Healthcare, Inc.	Nevada
Summit Healthcare, Inc.	The Ensign Group, Inc.	Nevada
Sunland Health Associates LLC	Bandera Healthcare, Inc.	Nevada
Sunny Acres Health Holdings LLC	The Ensign Group, Inc.	Nevada
Sunny Acres Healthcare, Inc.	Endura Healthcare, Inc.	Nevada
Sycamore Senior Living, Inc.	Bridgestone Living LLC	Nevada
Symbol Healthcare, Inc.	Paragon Healthcare, Inc.	Nevada
Telemus Telemachus PubCo, Inc.	Keystone Care LLC	Nevada
Terrace Court Health Holdings LLC	The Ensign Group, Inc.	Nevada
Terrace Court Senior Living, Inc.	Bridgestone Living LLC	Nevada
Teton Healthcare, Inc.	Cornerstone Healthcare, Inc.	Nevada
The Ensign Emergency Fund	The Ensign Group, Inc.	Nevada
The Ensign Group, Inc. (registered in Utah as Ensign Healthcare, Inc.)	The Ensign Group, Inc.	Delaware
TheraTroopers CA, Inc.	Theratroopers Holdings LLC	Nevada
Theratroopers Holdings LLC	The Ensign Group, Inc.	Nevada
TheraTroopers, Inc.	Theratroopers Holdings LLC	Nevada
Thomas Road Senior Housing, Inc.	Bridgestone Living LLC	Nevada
Thunderbird Health Holdings LLC	The Ensign Group, Inc.	Nevada
Timpanogos Home Care and Hospice, Inc.	Cornerstone Healthcare, Inc.	Nevada
Top City Healthcare, Inc.	Gateway Healthcare, Inc.	Nevada
Tortolita Healthcare, Inc	Bandera Healthcare, Inc.	Nevada
Towers Park Health Holdings LLC	The Ensign Group, Inc.	Nevada
Towers Park Healthcare, Inc.	Keystone Care LLC	Nevada
Towers Park Personal Care, Inc.	Keystone Care LLC	Nevada
Town East Healthcare, Inc.	Keystone Care LLC	Nevada



Town Square Healthcare, Inc.	Keystone Care LLC	Nevada
Tradewind Healthcare, Inc.	Keystone Care LLC	Nevada
Treasure Valley Senior Living, Inc.	Bridgestone Living LLC	Nevada
Treaty Healthcare, Inc.	Keystone Care LLC	Nevada
Tree City Healthcare, Inc.	Keystone Care LLC	Nevada
Two Rivers Health Holdings LLC	The Ensign Group, Inc.	Nevada
Two Rivers Senior Living, Inc.	Bridgestone Living LLC	Nevada
Two Trails Healthcare, Inc.,	Gateway Healthcare, Inc.	Nevada
Union Hill Healthcare, Inc.	Pennant Healthcare, Inc.	Nevada
Upland Community Care, Inc.	Signum Healthcare Central, Inc.	Nevada
Valley View Health Services, Inc.	Pennant Healthcare, Inc.	Nevada
Velda Rose Health Holdings LLC	The Ensign Group, Inc.	Nevada
Vesper Healthcare, Inc.	Cornerstone Healthcare, Inc.	Nevada
Victoria Ventura Assisted Living Community, Inc.	Bridgestone Living LLC	Nevada
Victoria Ventura Healthcare LLC	Signum Healthcare Central, Inc.	Nevada
Victory Medical Transportation, Inc.	Capstone Transportation Investments, Inc.	Nevada
Viewpoint Healthcare, Inc.	Bandera Healthcare, Inc.	Nevada
Virgin River Healthcare, Inc.	Cornerstone Healthcare, Inc.	Nevada
Vista Woods Health Associates LLC	Signum Healthcare South, Inc.	Nevada
W. Forman PubCo, Inc.	Keystone Care LLC	Nevada
Wallsville Healthcare, Inc.	Keystone Care LLC	Nevada
Walnut Grove CampusCare LLC	The Ensign Group, Inc.	Nevada
Washington Heights Healthcare, Inc.	Milestone Healthcare LLC	Nevada
Waterfront Healthcare, Inc.	Cornerstone Healthcare, Inc.	Nevada
Watson Woods Healthcare, Inc.	Bandera Healthcare, Inc.	Nevada
Wellington Healthcare, Inc.	Keystone Care LLC	Nevada
West 1020 Health Holdings LLC	The Ensign Group, Inc.	Nevada
West 1020 Healthcare, Inc.	Milestone Healthcare LLC	Nevada
West 5600 Health Holdings LLC	The Ensign Group, Inc.	Nevada
West 5600 Healthcare, Inc.	Milestone Healthcare LLC	Nevada
West Escondido Healthcare LLC	Signum Healthcare South, Inc.	Nevada
West Owyhee Health Holdings LLC	The Ensign Group, Inc.	Nevada
Wildcreek Healthcare, Inc.	Pennant Healthcare, Inc.	Nevada
Wildwood Healthcare, Inc.	Pennant Healthcare, Inc.	Nevada
Willow Canyon Healthcare, Inc.	Bandera Healthcare, Inc.	Nevada
Willow Creek Senior Living, Inc.	Bridgestone Living LLC	Nevada
Windsor Lake Healthcare, Inc.	Bridgestone Living LLC	Nevada
Wisconsin Rapids Health Holdings LLC	The Ensign Group, Inc.	Nevada
Wisconsin Rapids Senior Living, Inc.	Bridgestone Living LLC	Nevada
Wolf River Healthcare, Inc.	Gateway Healthcare, Inc.	Nevada
Wood Bayou Healthcare, Inc.	Keystone Care LLC	Nevada
Woodard Creek Healthcare, Inc.	Pennant Healthcare, Inc.	Nevada
Woodway Healthcare, Inc.	Keystone Care LLC	Nevada
Yellow Bricks PubCo, Inc.	Gateway Healthcare, Inc.	Kansas
Yellow Rose Health Holdings LLC	The Ensign Group, Inc.	Nevada
Yosemite Healthcare, Inc.	Signum Healthcare North, Inc.	Nevada



Youngtown Health, Inc.	Bandera Healthcare, Inc.	Nevada
Yucca Flats Health Holdings LLC	The Ensign Group, Inc.	Nevada
Zebulon Pike PubCo, Inc.	Endura Healthcare, Inc.	Nevada
Zion Healthcare, Inc.	Milestone Healthcare LLC	Nevada

EX-23.1 5 ensg123117ex231.htm EXHIBIT 23.1 Exhibit

EXHIBIT 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in Registration Statement No. 333-219666 on Form S-8 and No. 333-197426 on Form S-3 of our reports dated February 8, 2018, relating to the consolidated financial statements and financial statement schedule of The Ensign Group, Inc. and subsidiaries (the “Company”) and the effectiveness of the Company’s internal control over financial reporting, appearing in this Annual Report on Form 10-K of The Ensign Group, Inc. for the year ended December 31, 2017.

/s/ DELOITTE & TOUCHE LLP

Costa Mesa, California

February 8, 2018

EX-31.1 6 ensgq42017ex311.htm EXHIBIT 31.1 Exhibit

EXHIBIT 31.1

I, Christopher R. Christensen, certify that:


1.	I have reviewed this Annual Report on Form 10-K of The Ensign Group, Inc.;


2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;


3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;


4.	The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:


(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;


(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external reporting purposes in accordance with generally accepted accounting principles;


(c)	Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and


(d)	Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and


5.	The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):


(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and


(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: February 8, 2018




	/s/ Christopher R. Christensen
	Name:	Christopher R. Christensen
	Title:	Chief Executive Officer

EX-31.2 7 ensgq42017ex312.htm EXHIBIT 31.2 Exhibit

EXHIBIT 31.2

I, Suzanne D. Snapper, certify that:


1.	I have reviewed this Annual Report on Form 10-K of The Ensign Group, Inc.;


2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;


3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;


4.	The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:


(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;


(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external reporting purposes in accordance with generally accepted accounting principles;


(c)	Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and


(d)	Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and


5.	The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):


(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and


(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: February 8, 2018




						/s/ Suzanne D. Snapper
						Name:	Suzanne D. Snapper
						Title:	Chief Financial Officer

EX-32.1 8 ensg123117ex321.htm EXHIBIT 32.1 Exhibit

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. §1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of The Ensign Group, Inc. (the Company) on Form 10-K for the period ended December 31, 2017, as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Christopher R. Christensen, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:



1	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

		/s/ Christopher R. Christensen
		Name:	Christopher R. Christensen
		Title:	Chief Executive Officer

		February 8, 2018

A signed original of this written statement required by 18 U.S.C. Section 1350 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2 9 ensg12312017ex322.htm EXHIBIT 32.2 Exhibit

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. §1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of The Ensign Group, Inc. (the Company) on Form 10-K for the period ended December 31, 2017, as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Suzanne D. Snapper, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:



1	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

		/s/ Suzanne D. Snapper
		Name:	Suzanne D. Snapper
		Title:	Chief Financial Officer

		February 8, 2018

EX-101.INS 10 ensg-20171231.xml XBRL INSTANCE DOCUMENT 0001125376 2017-01-01 2017-12-31 0001125376 2018-02-05 0001125376 2017-06-30 0001125376 2017-12-31 0001125376 2016-12-31 0001125376 2016-01-01 2016-12-31 0001125376 2015-01-01 2015-12-31 0001125376 us-gaap:RetainedEarningsMember 2015-01-01 2015-12-31 0001125376 us-gaap:TreasuryStockMember 2016-12-31 0001125376 us-gaap:NoncontrollingInterestMember 2016-01-01 2016-12-31 0001125376 us-gaap:CommonStockMember 2015-12-31 0001125376 us-gaap:NoncontrollingInterestMember 2015-12-31 0001125376 us-gaap:AdditionalPaidInCapitalMember 2015-01-01 2015-12-31 0001125376 us-gaap:CommonStockMember 2017-01-01 2017-12-31 0001125376 us-gaap:CommonStockMember 2016-01-01 2016-12-31 0001125376 us-gaap:TreasuryStockMember 2014-12-31 0001125376 us-gaap:RetainedEarningsMember 2017-12-31 0001125376 us-gaap:CommonStockMember 2015-01-01 2015-12-31 0001125376 us-gaap:TreasuryStockMember 2017-01-01 2017-12-31 0001125376 us-gaap:NoncontrollingInterestMember 2014-12-31 0001125376 us-gaap:CommonStockMember 2016-12-31 0001125376 us-gaap:NoncontrollingInterestMember 2015-01-01 2015-12-31 0001125376 us-gaap:TreasuryStockMember 2015-12-31 0001125376 us-gaap:RetainedEarningsMember 2016-12-31 0001125376 us-gaap:RetainedEarningsMember 2017-01-01 2017-12-31 0001125376 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-12-31 0001125376 us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-12-31 0001125376 us-gaap:RetainedEarningsMember 2016-01-01 2016-12-31 0001125376 us-gaap:NoncontrollingInterestMember 2016-12-31 0001125376 us-gaap:TreasuryStockMember 2016-01-01 2016-12-31 0001125376 us-gaap:CommonStockMember 2017-12-31 0001125376 2015-12-31 0001125376 us-gaap:NoncontrollingInterestMember 2017-01-01 2017-12-31 0001125376 us-gaap:CommonStockMember 2014-12-31 0001125376 us-gaap:TreasuryStockMember 2015-01-01 2015-12-31 0001125376 us-gaap:RetainedEarningsMember 2014-12-31 0001125376 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0001125376 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0001125376 us-gaap:AdditionalPaidInCapitalMember 2014-12-31 0001125376 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001125376 us-gaap:TreasuryStockMember 2017-12-31 0001125376 2014-12-31 0001125376 us-gaap:RetainedEarningsMember 2015-12-31 0001125376 us-gaap:NoncontrollingInterestMember 2017-12-31 0001125376 us-gaap:MaximumMember 2017-01-01 2017-12-31 0001125376 ensg:AggregateDeductibleMember stpr:CA us-gaap:ParentCompanyMember us-gaap:GeneralLiabilityMember 2017-12-31 0001125376 ensg:StopLossInsuranceLimitPerClaimMember ensg:HealthLiabilityInsuranceMember 2017-12-31 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember 2015-01-01 2015-12-31 0001125376 ensg:LossSensitivelimitperclaimMemberMember ensg:OtherstatesexceptCaliforniaTexasandWashingtonDomain ensg:WorkersCompensationMember 2017-12-31 0001125376 us-gaap:MinimumMember 2017-01-01 2017-12-31 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember 2017-01-01 2017-12-31 0001125376 ensg:StopLossInsuranceLimitPerClaimMember stpr:TX ensg:WorkersCompensationMember 2017-12-31 0001125376 ensg:AssembledOccupancyAcquiredMember us-gaap:MaximumMember 2017-01-01 2017-12-31 0001125376 ensg:PerOccurenceMember ensg:AllStatesExceptColoradoDomain us-gaap:ThirdPartyPayorMember us-gaap:GeneralLiabilityMember 2017-12-31 0001125376 us-gaap:CustomerRelationshipsMember 2017-01-01 2017-12-31 0001125376 ensg:PerFacilityMember stpr:CO us-gaap:ThirdPartyPayorMember us-gaap:GeneralLiabilityMember 2017-12-31 0001125376 ensg:PerOccurenceMember stpr:CO us-gaap:ThirdPartyPayorMember us-gaap:GeneralLiabilityMember 2017-12-31 0001125376 ensg:AggregateDeductibleMember ensg:NonCaliforniaDomain us-gaap:ParentCompanyMember us-gaap:GeneralLiabilityMember 2017-12-31 0001125376 ensg:StopLossInsuranceLimitPerClaimMember ensg:WorkersCompensationMember 2017-12-31 0001125376 ensg:AssembledOccupancyAcquiredMember us-gaap:MinimumMember 2017-01-01 2017-12-31 0001125376 ensg:StopLossDeductibleMember ensg:HealthLiabilityInsuranceMember 2017-12-31 0001125376 ensg:PerFacilityMember ensg:AllStatesExceptColoradoDomain us-gaap:ThirdPartyPayorMember us-gaap:GeneralLiabilityMember 2017-12-31 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember 2016-01-01 2016-12-31 0001125376 ensg:BlanketAggregateMember ensg:AllStatesExceptColoradoDomain us-gaap:ThirdPartyPayorMember us-gaap:GeneralLiabilityMember 2017-12-31 0001125376 us-gaap:TradeNamesMember 2017-01-01 2017-12-31 0001125376 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember 2016-01-01 2016-12-31 0001125376 ensg:SelfInsuranceRetentionPerClaimMember us-gaap:ParentCompanyMember us-gaap:GeneralLiabilityMember 2017-12-31 0001125376 us-gaap:CommonStockMember 2016-01-01 2016-12-31 0001125376 us-gaap:CommonStockMember 2017-02-08 0001125376 2015-11-04 0001125376 us-gaap:CommonStockMember 2015-11-04 0001125376 us-gaap:CommonStockMember 2017-01-01 2017-12-31 0001125376 2017-02-08 2017-02-08 0001125376 2015-11-04 2015-11-04 0001125376 us-gaap:CommonClassAMember 2017-01-01 2017-12-31 0001125376 us-gaap:CommonClassAMember 2016-01-01 2016-12-31 0001125376 us-gaap:CommonClassAMember 2015-01-01 2015-12-31 0001125376 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001125376 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0001125376 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001125376 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0001125376 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0001125376 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0001125376 us-gaap:DomesticCorporateDebtSecuritiesMember 2016-12-31 0001125376 us-gaap:DomesticCorporateDebtSecuritiesMember 2017-12-31 0001125376 ensg:MedicaidMember 2017-01-01 2017-12-31 0001125376 ensg:MedicaidMember 2015-01-01 2015-12-31 0001125376 ensg:ManagedCareMember 2016-01-01 2016-12-31 0001125376 ensg:MedicareMember 2016-01-01 2016-12-31 0001125376 ensg:MedicaidMember 2016-01-01 2016-12-31 0001125376 ensg:MedicaidSkilledMember 2016-01-01 2016-12-31 0001125376 ensg:MedicaidSkilledMember 2015-01-01 2015-12-31 0001125376 ensg:ManagedCareMember 2017-01-01 2017-12-31 0001125376 us-gaap:SelfPayMember 2017-01-01 2017-12-31 0001125376 ensg:MedicaidSkilledMember 2017-01-01 2017-12-31 0001125376 us-gaap:SelfPayMember 2015-01-01 2015-12-31 0001125376 ensg:ManagedCareMember 2015-01-01 2015-12-31 0001125376 ensg:MedicareMember 2017-01-01 2017-12-31 0001125376 ensg:MedicareMember 2015-01-01 2015-12-31 0001125376 us-gaap:SelfPayMember 2016-01-01 2016-12-31 0001125376 ensg:MedicaidMember 2017-12-31 0001125376 ensg:MedicaidMember 2016-12-31 0001125376 ensg:MedicareMember 2016-12-31 0001125376 ensg:MedicareMember 2017-12-31 0001125376 ensg:PrivatePayAndOtherMember 2016-12-31 0001125376 ensg:ManagedCareMember 2016-12-31 0001125376 ensg:PrivatePayAndOtherMember 2017-12-31 0001125376 ensg:ManagedCareMember 2017-12-31 0001125376 us-gaap:IntersegmentEliminationMember 2017-01-01 2017-12-31 0001125376 ensg:TransitionalandSkilledServicesSegmentMember 2017-01-01 2017-12-31 0001125376 ensg:HomeHealthandHospiceSegmentMember 2017-01-01 2017-12-31 0001125376 ensg:AssistedandIndependentLivingServicesSegmentMember 2017-01-01 2017-12-31 0001125376 ensg:AllOtherMember 2017-01-01 2017-12-31 0001125376 ensg:MedicareMember ensg:AllOtherMember 2015-01-01 2015-12-31 0001125376 ensg:MedicaidMember ensg:HomeHealthandHospiceSegmentMember 2015-01-01 2015-12-31 0001125376 ensg:ManagedCareMember ensg:HomeHealthandHospiceSegmentMember 2015-01-01 2015-12-31 0001125376 ensg:MedicareMember ensg:TransitionalandSkilledServicesSegmentMember 2015-01-01 2015-12-31 0001125376 ensg:ManagedCareMember ensg:TransitionalandSkilledServicesSegmentMember 2015-01-01 2015-12-31 0001125376 ensg:MedicareMember ensg:HomeHealthandHospiceSegmentMember 2015-01-01 2015-12-31 0001125376 ensg:MedicaidSkilledMember ensg:HomeHealthandHospiceSegmentMember 2015-01-01 2015-12-31 0001125376 ensg:MedicaidMember ensg:TransitionalandSkilledServicesSegmentMember 2015-01-01 2015-12-31 0001125376 ensg:MedicaidMember ensg:AllOtherMember 2015-01-01 2015-12-31 0001125376 ensg:HomeHealthandHospiceSegmentMember 2015-01-01 2015-12-31 0001125376 ensg:MedicaidSkilledMember ensg:AllOtherMember 2015-01-01 2015-12-31 0001125376 ensg:TransitionalandSkilledServicesSegmentMember 2015-01-01 2015-12-31 0001125376 ensg:ManagedCareMember ensg:AllOtherMember 2015-01-01 2015-12-31 0001125376 ensg:AllOtherMember 2015-01-01 2015-12-31 0001125376 ensg:MedicareMember ensg:AssistedandIndependentLivingServicesSegmentMember 2015-01-01 2015-12-31 0001125376 ensg:MedicaidSkilledMember ensg:TransitionalandSkilledServicesSegmentMember 2015-01-01 2015-12-31 0001125376 ensg:MedicaidSkilledMember ensg:AssistedandIndependentLivingServicesSegmentMember 2015-01-01 2015-12-31 0001125376 ensg:AssistedandIndependentLivingServicesSegmentMember 2015-01-01 2015-12-31 0001125376 us-gaap:SelfPayMember ensg:HomeHealthandHospiceSegmentMember 2015-01-01 2015-12-31 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember ensg:HomeHealthandHospiceSegmentMember 2015-01-01 2015-12-31 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember ensg:AllOtherMember 2015-01-01 2015-12-31 0001125376 us-gaap:SelfPayMember ensg:AssistedandIndependentLivingServicesSegmentMember 2015-01-01 2015-12-31 0001125376 ensg:MedicaidMember ensg:AssistedandIndependentLivingServicesSegmentMember 2015-01-01 2015-12-31 0001125376 us-gaap:SelfPayMember ensg:TransitionalandSkilledServicesSegmentMember 2015-01-01 2015-12-31 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember ensg:TransitionalandSkilledServicesSegmentMember 2015-01-01 2015-12-31 0001125376 ensg:ManagedCareMember ensg:AssistedandIndependentLivingServicesSegmentMember 2015-01-01 2015-12-31 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember ensg:AssistedandIndependentLivingServicesSegmentMember 2015-01-01 2015-12-31 0001125376 us-gaap:SelfPayMember ensg:AllOtherMember 2015-01-01 2015-12-31 0001125376 ensg:MedicaidMember ensg:AssistedandIndependentLivingServicesSegmentMember 2016-01-01 2016-12-31 0001125376 ensg:AllOtherMember 2016-01-01 2016-12-31 0001125376 ensg:MedicaidMember ensg:AllOtherMember 2016-01-01 2016-12-31 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember ensg:HomeHealthandHospiceSegmentMember 2016-01-01 2016-12-31 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember ensg:AssistedandIndependentLivingServicesSegmentMember 2016-01-01 2016-12-31 0001125376 ensg:MedicaidSkilledMember ensg:HomeHealthandHospiceSegmentMember 2016-01-01 2016-12-31 0001125376 ensg:ManagedCareMember ensg:TransitionalandSkilledServicesSegmentMember 2016-01-01 2016-12-31 0001125376 ensg:AssistedandIndependentLivingServicesSegmentMember 2016-01-01 2016-12-31 0001125376 ensg:HomeHealthandHospiceSegmentMember 2016-01-01 2016-12-31 0001125376 ensg:MedicareMember ensg:TransitionalandSkilledServicesSegmentMember 2016-01-01 2016-12-31 0001125376 us-gaap:SelfPayMember ensg:AssistedandIndependentLivingServicesSegmentMember 2016-01-01 2016-12-31 0001125376 ensg:MedicareMember ensg:HomeHealthandHospiceSegmentMember 2016-01-01 2016-12-31 0001125376 ensg:MedicareMember ensg:AllOtherMember 2016-01-01 2016-12-31 0001125376 ensg:MedicareMember ensg:AssistedandIndependentLivingServicesSegmentMember 2016-01-01 2016-12-31 0001125376 ensg:ManagedCareMember ensg:AssistedandIndependentLivingServicesSegmentMember 2016-01-01 2016-12-31 0001125376 ensg:ManagedCareMember ensg:AllOtherMember 2016-01-01 2016-12-31 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember ensg:AllOtherMember 2016-01-01 2016-12-31 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember ensg:TransitionalandSkilledServicesSegmentMember 2016-01-01 2016-12-31 0001125376 ensg:MedicaidSkilledMember ensg:TransitionalandSkilledServicesSegmentMember 2016-01-01 2016-12-31 0001125376 ensg:MedicaidSkilledMember ensg:AllOtherMember 2016-01-01 2016-12-31 0001125376 us-gaap:SelfPayMember ensg:TransitionalandSkilledServicesSegmentMember 2016-01-01 2016-12-31 0001125376 ensg:MedicaidMember ensg:HomeHealthandHospiceSegmentMember 2016-01-01 2016-12-31 0001125376 ensg:TransitionalandSkilledServicesSegmentMember 2016-01-01 2016-12-31 0001125376 ensg:ManagedCareMember ensg:HomeHealthandHospiceSegmentMember 2016-01-01 2016-12-31 0001125376 us-gaap:SelfPayMember ensg:AllOtherMember 2016-01-01 2016-12-31 0001125376 ensg:MedicaidMember ensg:TransitionalandSkilledServicesSegmentMember 2016-01-01 2016-12-31 0001125376 us-gaap:SelfPayMember ensg:HomeHealthandHospiceSegmentMember 2016-01-01 2016-12-31 0001125376 ensg:MedicaidSkilledMember ensg:AssistedandIndependentLivingServicesSegmentMember 2016-01-01 2016-12-31 0001125376 us-gaap:IntersegmentEliminationMember 2015-01-01 2015-12-31 0001125376 us-gaap:IntersegmentEliminationMember 2016-01-01 2016-12-31 0001125376 us-gaap:FacilityClosingMember 2017-04-01 2017-06-30 0001125376 ensg:ContractTerminationandFacilityClosingMember 2017-01-01 2017-12-31 0001125376 us-gaap:FacilityClosingMember 2016-01-01 2016-12-31 0001125376 ensg:MedicaidSkilledMember ensg:AllOtherMember 2017-01-01 2017-12-31 0001125376 ensg:MedicaidMember ensg:HomeHealthandHospiceSegmentMember 2017-01-01 2017-12-31 0001125376 us-gaap:SelfPayMember ensg:AllOtherMember 2017-01-01 2017-12-31 0001125376 ensg:MedicaidMember ensg:TransitionalandSkilledServicesSegmentMember 2017-01-01 2017-12-31 0001125376 ensg:MedicareMember ensg:TransitionalandSkilledServicesSegmentMember 2017-01-01 2017-12-31 0001125376 ensg:ManagedCareMember ensg:AllOtherMember 2017-01-01 2017-12-31 0001125376 ensg:MedicaidSkilledMember ensg:HomeHealthandHospiceSegmentMember 2017-01-01 2017-12-31 0001125376 ensg:MedicaidMember ensg:AllOtherMember 2017-01-01 2017-12-31 0001125376 us-gaap:SelfPayMember ensg:AssistedandIndependentLivingServicesSegmentMember 2017-01-01 2017-12-31 0001125376 us-gaap:SelfPayMember ensg:TransitionalandSkilledServicesSegmentMember 2017-01-01 2017-12-31 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember ensg:AssistedandIndependentLivingServicesSegmentMember 2017-01-01 2017-12-31 0001125376 ensg:ManagedCareMember ensg:TransitionalandSkilledServicesSegmentMember 2017-01-01 2017-12-31 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember ensg:HomeHealthandHospiceSegmentMember 2017-01-01 2017-12-31 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember ensg:TransitionalandSkilledServicesSegmentMember 2017-01-01 2017-12-31 0001125376 ensg:ManagedCareMember ensg:HomeHealthandHospiceSegmentMember 2017-01-01 2017-12-31 0001125376 ensg:ManagedCareMember ensg:AssistedandIndependentLivingServicesSegmentMember 2017-01-01 2017-12-31 0001125376 ensg:MedicaidSkilledMember ensg:AssistedandIndependentLivingServicesSegmentMember 2017-01-01 2017-12-31 0001125376 ensg:MedicaidSkilledMember ensg:TransitionalandSkilledServicesSegmentMember 2017-01-01 2017-12-31 0001125376 ensg:MedicareMember ensg:AllOtherMember 2017-01-01 2017-12-31 0001125376 ensg:MedicareMember ensg:HomeHealthandHospiceSegmentMember 2017-01-01 2017-12-31 0001125376 ensg:MedicareMember ensg:AssistedandIndependentLivingServicesSegmentMember 2017-01-01 2017-12-31 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember ensg:AllOtherMember 2017-01-01 2017-12-31 0001125376 us-gaap:SelfPayMember ensg:HomeHealthandHospiceSegmentMember 2017-01-01 2017-12-31 0001125376 ensg:MedicaidMember ensg:AssistedandIndependentLivingServicesSegmentMember 2017-01-01 2017-12-31 0001125376 us-gaap:FacilityClosingMember 2015-01-01 2015-12-31 0001125376 ensg:ContractTerminationandFacilityClosingMember 2016-01-01 2016-12-31 0001125376 ensg:ContractTerminationandFacilityClosingMember 2015-01-01 2015-12-31 0001125376 us-gaap:LandMember 2015-01-01 2015-12-31 0001125376 ensg:AssembledOccupancyAcquiredMember 2015-01-01 2015-12-31 0001125376 us-gaap:OtherIntangibleAssetsMember 2017-01-01 2017-12-31 0001125376 us-gaap:GoodwillMember 2015-01-01 2015-12-31 0001125376 us-gaap:BuildingAndBuildingImprovementsMember 2015-01-01 2015-12-31 0001125376 us-gaap:OffMarketFavorableLeaseMember 2017-01-01 2017-12-31 0001125376 us-gaap:OffMarketFavorableLeaseMember 2015-01-01 2015-12-31 0001125376 us-gaap:BuildingAndBuildingImprovementsMember 2017-01-01 2017-12-31 0001125376 ensg:AssembledOccupancyAcquiredMember 2016-01-01 2016-12-31 0001125376 us-gaap:BuildingAndBuildingImprovementsMember 2016-01-01 2016-12-31 0001125376 ensg:AssembledOccupancyAcquiredMember 2017-01-01 2017-12-31 0001125376 us-gaap:IndefinitelivedIntangibleAssetsMember 2015-01-01 2015-12-31 0001125376 us-gaap:IndefinitelivedIntangibleAssetsMember 2017-01-01 2017-12-31 0001125376 us-gaap:OtherIntangibleAssetsMember 2015-01-01 2015-12-31 0001125376 us-gaap:LandMember 2017-01-01 2017-12-31 0001125376 us-gaap:FurnitureAndFixturesMember 2015-01-01 2015-12-31 0001125376 us-gaap:LandMember 2016-01-01 2016-12-31 0001125376 us-gaap:GoodwillMember 2017-01-01 2017-12-31 0001125376 us-gaap:FurnitureAndFixturesMember 2016-01-01 2016-12-31 0001125376 us-gaap:IndefinitelivedIntangibleAssetsMember 2016-01-01 2016-12-31 0001125376 us-gaap:OtherIntangibleAssetsMember 2016-01-01 2016-12-31 0001125376 us-gaap:OffMarketFavorableLeaseMember 2016-01-01 2016-12-31 0001125376 us-gaap:FurnitureAndFixturesMember 2017-01-01 2017-12-31 0001125376 us-gaap:GoodwillMember 2016-01-01 2016-12-31 0001125376 ensg:AssistedLivingFacilityMember ensg:AssistedLivingFacilityMember 2016-12-31 0001125376 ensg:AssistedLivingandIndependentLivingFacilityMemberMember us-gaap:SubsequentEventMember 2018-02-01 2018-02-01 0001125376 sic:Z8051 2015-01-01 2015-12-31 0001125376 ensg:AssistedLivingandIndependentLivingFacilityMemberMember 2015-12-31 0001125376 sic:Z8051 2016-01-01 2016-12-31 0001125376 ensg:AssistedLivingandIndependentLivingFacilityMemberMember ensg:AssistedLivingandIndependentLivingFacilityMemberMember 2016-01-01 2016-12-31 0001125376 ensg:SkilledNursingAssistedLivingHomeHealthHomeCareHospiceandUrgentCareMember 2015-01-01 2015-12-31 0001125376 sic:Z8051 sic:Z8051 2017-12-31 0001125376 sic:Z8082 2017-01-01 2017-12-31 0001125376 ensg:AssistedLivingandIndependentLivingFacilityMemberMember us-gaap:SubsequentEventMember 2018-02-01 0001125376 ensg:SkilledNursingAssistedLivingHomeHealthHomeCareHospiceandUrgentCareMember 2015-12-31 0001125376 ensg:TransitionalandSkilledServicesandAssistedandIndependentCampusesMember 2016-01-01 2016-12-31 0001125376 sic:Z8051 2016-12-31 0001125376 ensg:HomeHealthHospiceandHomeCareAgencyMember 2015-01-01 2015-12-31 0001125376 sic:Z8082 2016-01-01 2016-12-31 0001125376 sic:Z8051 2015-01-01 2015-12-31 0001125376 sic:Z8051 2016-01-01 2016-12-31 0001125376 sic:Z8051 sic:Z8051 2017-01-01 2017-12-31 0001125376 ensg:UrgentCareCentersMember 2015-01-01 2015-12-31 0001125376 ensg:TransitionalandSkilledServicesandAssistedandIndependentCampusesMember 2017-01-01 2017-12-31 0001125376 sic:Z8051 2015-12-31 0001125376 ensg:AssistedLivingFacilityMember 2016-01-01 2016-12-31 0001125376 sic:Z8051 sic:Z8051 2016-12-31 0001125376 ensg:HospiceAgencyMember 2016-01-01 2016-12-31 0001125376 ensg:SkilledNursingAssistedLivingandIndependentLivingFacilitiesMember 2015-01-01 2015-12-31 0001125376 ensg:AssistedLivingFacilityMember 2017-12-31 0001125376 ensg:HospiceAgencyMember 2017-01-01 2017-12-31 0001125376 ensg:AssistedLivingFacilityMember 2016-12-31 0001125376 ensg:HomeCareAgencyMember 2017-01-01 2017-12-31 0001125376 sic:Z8051 2017-12-31 0001125376 ensg:TransitionalandSkilledServicesandAssistedandIndependentCampusesMember 2016-01-01 2016-12-31 0001125376 sic:Z8051 2017-01-01 2017-12-31 0001125376 ensg:AssistedLivingandIndependentLivingFacilityMemberMember 2017-01-01 2017-12-31 0001125376 sic:Z8051 2016-01-01 2016-12-31 0001125376 2017-06-01 0001125376 us-gaap:EquipmentMember 2016-12-31 0001125376 us-gaap:BuildingAndBuildingImprovementsMember 2017-12-31 0001125376 us-gaap:LeaseholdImprovementsMember 2016-12-31 0001125376 us-gaap:ConstructionInProgressMember 2017-12-31 0001125376 us-gaap:ConstructionInProgressMember 2016-12-31 0001125376 us-gaap:LandMember 2016-12-31 0001125376 us-gaap:BuildingAndBuildingImprovementsMember 2016-12-31 0001125376 us-gaap:FurnitureAndFixturesMember 2017-12-31 0001125376 us-gaap:FurnitureAndFixturesMember 2016-12-31 0001125376 us-gaap:LandMember 2017-12-31 0001125376 us-gaap:LeaseholdImprovementsMember 2017-12-31 0001125376 us-gaap:EquipmentMember 2017-12-31 0001125376 us-gaap:CustomerRelationshipsMember 2017-12-31 0001125376 us-gaap:LeasesAcquiredInPlaceMember 2016-12-31 0001125376 us-gaap:LeasesAcquiredInPlaceMember 2017-12-31 0001125376 us-gaap:CustomerRelationshipsMember 2016-12-31 0001125376 ensg:AssembledOccupancyAcquiredMember 2017-12-31 0001125376 us-gaap:OffMarketFavorableLeaseMember 2017-12-31 0001125376 us-gaap:TradeNamesMember 2017-12-31 0001125376 us-gaap:TradeNamesMember 2016-12-31 0001125376 ensg:AssembledOccupancyAcquiredMember 2016-12-31 0001125376 us-gaap:OffMarketFavorableLeaseMember 2016-12-31 0001125376 us-gaap:LeasesAcquiredInPlaceMember 2017-01-01 2017-12-31 0001125376 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember ensg:UrgentCareCentersMember us-gaap:CustomerRelationshipsMember 2016-12-31 0001125376 ensg:AssistedLivingFacilityMember us-gaap:OffMarketFavorableLeaseMember 2016-12-31 0001125376 ensg:HomeHealthAndHospiceMedicareLicenseMember ensg:HomeHealthandHospiceSegmentMember 2017-01-01 2017-12-31 0001125376 us-gaap:TradeNamesMember ensg:HomeHealthandHospiceSegmentMember 2017-01-01 2017-12-31 0001125376 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember ensg:AllOtherMember 2016-01-01 2016-12-31 0001125376 ensg:HomeHealthAndHospiceMedicareLicenseMember ensg:HomeHealthandHospiceSegmentMember 2017-12-31 0001125376 us-gaap:TradeNamesMember ensg:HomeHealthandHospiceSegmentMember 2017-12-31 0001125376 us-gaap:TradeNamesMember ensg:HomeHealthandHospiceSegmentMember 2016-12-31 0001125376 ensg:HomeHealthAndHospiceMedicareLicenseMember ensg:HomeHealthandHospiceSegmentMember 2016-12-31 0001125376 ensg:HomeHealthandHospiceSegmentMember 2015-12-31 0001125376 ensg:TransitionalandSkilledServicesSegmentMember 2014-12-31 0001125376 ensg:AssistedandIndependentLivingServicesSegmentMember 2014-12-31 0001125376 ensg:AllOtherMember 2014-12-31 0001125376 ensg:AllOtherMember 2016-12-31 0001125376 ensg:AssistedandIndependentLivingServicesSegmentMember 2015-12-31 0001125376 ensg:AllOtherMember 2015-12-31 0001125376 ensg:AssistedandIndependentLivingServicesSegmentMember 2016-12-31 0001125376 ensg:HomeHealthandHospiceSegmentMember 2016-12-31 0001125376 ensg:AllOtherMember 2017-12-31 0001125376 ensg:TransitionalandSkilledServicesSegmentMember 2015-12-31 0001125376 ensg:AssistedandIndependentLivingServicesSegmentMember 2017-12-31 0001125376 ensg:HomeHealthandHospiceSegmentMember 2014-12-31 0001125376 ensg:HomeHealthandHospiceSegmentMember 2017-12-31 0001125376 ensg:TransitionalandSkilledServicesSegmentMember 2017-12-31 0001125376 ensg:TransitionalandSkilledServicesSegmentMember 2016-12-31 0001125376 us-gaap:RevolvingCreditFacilityMember ensg:SunTrustBankMember ensg:SecondAmendedCreditFacilityMember 2017-12-31 0001125376 us-gaap:RevolvingCreditFacilityMember ensg:SunTrustBankMember ensg:SecondAmendedCreditFacilityMember 2016-12-31 0001125376 us-gaap:NotesPayableOtherPayablesMember us-gaap:CollateralizedDebtObligationsMember 2017-12-31 0001125376 us-gaap:RevolvingCreditFacilityMember ensg:SunTrustBankMember 2016-12-31 0001125376 us-gaap:RevolvingCreditFacilityMember ensg:SunTrustBankMember 2017-12-31 0001125376 us-gaap:NotesPayableOtherPayablesMember us-gaap:CollateralizedDebtObligationsMember 2016-12-31 0001125376 us-gaap:MortgagesMember us-gaap:CollateralizedDebtObligationsMember 2017-12-27 0001125376 us-gaap:RevolvingCreditFacilityMember ensg:SunTrustBankMember us-gaap:MinimumMember 2014-05-30 0001125376 us-gaap:RevolvingCreditFacilityMember ensg:SunTrustBankMember us-gaap:MinimumMember 2014-05-30 2014-05-30 0001125376 us-gaap:MortgagesMember us-gaap:CollateralizedDebtObligationsMember 2015-12-31 0001125376 us-gaap:MortgagesMember us-gaap:CollateralizedDebtObligationsMember us-gaap:MinimumMember 2017-10-30 2017-12-27 0001125376 us-gaap:RevolvingCreditFacilityMember ensg:SunTrustBankMember us-gaap:MaximumMember 2014-05-30 0001125376 us-gaap:RevolvingCreditFacilityMember ensg:SunTrustBankMember 2016-02-05 0001125376 us-gaap:RevolvingCreditFacilityMember ensg:SunTrustBankMember ensg:SecondAmendedCreditFacilityMember 2016-07-19 0001125376 us-gaap:RevolvingCreditFacilityMember ensg:SunTrustBankMember us-gaap:MinimumMember 2016-02-05 0001125376 us-gaap:MortgagesMember us-gaap:CollateralizedDebtObligationsMember us-gaap:MinimumMember 2014-12-31 2014-12-31 0001125376 us-gaap:RevolvingCreditFacilityMember ensg:SunTrustBankMember 2014-05-30 0001125376 us-gaap:NotesPayableToBanksMember us-gaap:CollateralizedDebtObligationsMember us-gaap:MinimumMember 2015-12-31 0001125376 us-gaap:SeniorDebtObligationsMember us-gaap:SecuredDebtMember 2017-12-31 0001125376 us-gaap:RevolvingCreditFacilityMember ensg:SunTrustBankMember ensg:SecondAmendedCreditFacilityMember us-gaap:SubsequentEventMember 2018-02-02 0001125376 us-gaap:NotesPayableToBanksMember us-gaap:CollateralizedDebtObligationsMember 2017-12-27 0001125376 us-gaap:MortgagesMember us-gaap:CollateralizedDebtObligationsMember us-gaap:MaximumMember 2014-12-31 2014-12-31 0001125376 us-gaap:MortgagesMember us-gaap:CollateralizedDebtObligationsMember us-gaap:MaximumMember 2017-10-30 2017-12-27 0001125376 us-gaap:RevolvingCreditFacilityMember ensg:SunTrustBankMember us-gaap:MaximumMember 2016-02-05 0001125376 us-gaap:RevolvingCreditFacilityMember ensg:SunTrustBankMember us-gaap:MinimumMember 2016-02-05 2016-02-05 0001125376 us-gaap:NotesPayableToBanksMember us-gaap:CollateralizedDebtObligationsMember us-gaap:MaximumMember 2015-12-31 0001125376 us-gaap:RevolvingCreditFacilityMember ensg:SunTrustBankMember us-gaap:MaximumMember 2016-02-05 2016-02-05 0001125376 us-gaap:RevolvingCreditFacilityMember ensg:SunTrustBankMember us-gaap:MaximumMember 2014-05-30 2014-05-30 0001125376 ensg:ExercisePriceRangeEightMember 2017-12-31 0001125376 ensg:ExercisePriceRangeNineMember 2017-12-31 0001125376 ensg:ExercisePriceRangeTwoMember 2017-01-01 2017-12-31 0001125376 ensg:ExercisePriceRangeSixMember 2017-12-31 0001125376 ensg:ExercisePriceRangeOneMember 2017-12-31 0001125376 ensg:ExercisePriceRangeOneMember 2017-01-01 2017-12-31 0001125376 ensg:ExercisePriceRangeFourMember 2017-12-31 0001125376 ensg:ExercisePriceRangeThreeMember 2017-01-01 2017-12-31 0001125376 ensg:ExercisePriceRangeSevenMember 2017-12-31 0001125376 ensg:ExercisePriceRangeNineMember 2017-01-01 2017-12-31 0001125376 ensg:ExercisePriceRangeTwoMember 2017-12-31 0001125376 ensg:ExercisePriceRangeFiveMember 2017-12-31 0001125376 ensg:ExercisePriceRangeSixMember 2017-01-01 2017-12-31 0001125376 ensg:ExercisePriceRangeSevenMember 2017-01-01 2017-12-31 0001125376 ensg:ExercisePriceRangeFiveMember 2017-01-01 2017-12-31 0001125376 ensg:ExercisePriceRangeTenMember 2017-01-01 2017-12-31 0001125376 ensg:ExercisePriceRangeThreeMember 2017-12-31 0001125376 ensg:ExercisePriceRangeFourMember 2017-01-01 2017-12-31 0001125376 ensg:ExercisePriceRangeTenMember 2017-12-31 0001125376 ensg:ExercisePriceRangeEightMember 2017-01-01 2017-12-31 0001125376 ensg:A2017PlanMemberMember 2017-05-25 2017-05-25 0001125376 ensg:A2007PlanMember 2007-11-08 2007-11-08 0001125376 ensg:A2017PlanMemberMember us-gaap:DirectorMember 2017-05-25 2017-05-25 0001125376 us-gaap:EmployeeStockOptionMember 2017-12-31 0001125376 ensg:SubsidiariesStockawardsMember us-gaap:SubsidiariesMember 2016-12-31 0001125376 ensg:A2007PlanMember 2017-01-01 2017-12-31 0001125376 ensg:A2017PlanMemberMember 2017-12-31 0001125376 ensg:SubsidiariesStockawardsMember us-gaap:SubsidiariesMember 2017-01-01 2017-12-31 0001125376 us-gaap:RestrictedStockMember 2017-01-01 2017-12-31 0001125376 ensg:A2017PlanMemberMember 2017-05-25 0001125376 us-gaap:DirectorMember 2017-01-01 2017-12-31 0001125376 ensg:SubsidiariesStockawardsMember us-gaap:SubsidiariesMember 2016-01-01 2016-12-31 0001125376 us-gaap:RestrictedStockMember 2017-12-31 0001125376 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-12-31 0001125376 ensg:A2007PlanMember 2007-11-08 0001125376 ensg:A2007PlanMember us-gaap:DirectorMember 2007-11-08 2007-11-08 0001125376 ensg:SubsidiariesStockawardsMember us-gaap:SubsidiariesMember 2017-12-31 0001125376 ensg:StockAwardsMember 2016-01-01 2016-12-31 0001125376 ensg:StockAwardsMember 2015-01-01 2015-12-31 0001125376 us-gaap:RestrictedStockMember 2016-01-01 2016-12-31 0001125376 ensg:StockAwardsMember 2017-01-01 2017-12-31 0001125376 us-gaap:RestrictedStockMember 2015-01-01 2015-12-31 0001125376 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-12-31 0001125376 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-12-31 0001125376 us-gaap:EmployeeStockOptionMember 2015-12-31 0001125376 us-gaap:EmployeeStockOptionMember 2016-12-31 0001125376 ensg:SubsidiariesStockawardsMember us-gaap:SubsidiariesMember 2015-12-31 0001125376 ensg:SubsidiariesStockawardsMember us-gaap:SubsidiariesMember 2015-01-01 2015-12-31 0001125376 ensg:VariousLandlordsMemberMember 2017-01-01 2017-12-31 0001125376 ensg:NumberofOptionalLeaseExtensionMemberMember 2017-06-01 2017-06-01 0001125376 ensg:CareTrustREITMember us-gaap:MinimumMember 2014-06-01 2014-06-01 0001125376 ensg:VariousLandlordsMemberMember us-gaap:MinimumMember 2017-01-01 2017-12-31 0001125376 sic:Z8051 2017-01-01 2017-12-31 0001125376 us-gaap:DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember sic:Z8051 2016-01-01 2016-12-31 0001125376 ensg:CareTrustREITMember 2014-06-01 0001125376 ensg:CareTrustREITMember us-gaap:MaximumMember 2014-06-01 2014-06-01 0001125376 ensg:AssistedLivingFacilityMember 2017-06-01 2017-06-01 0001125376 ensg:CareTrustREITMember 2017-01-01 2017-12-31 0001125376 ensg:CareTrustREITMember 2016-01-01 2016-12-31 0001125376 ensg:SkilledNursingAssistedLivingandIndependentLivingFacilitiesMember 2017-01-01 2017-12-31 0001125376 ensg:CareTrustREITMember 2014-06-01 2014-06-01 0001125376 us-gaap:DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember sic:Z8051 2017-01-01 2017-12-31 0001125376 2017-06-01 2017-06-01 0001125376 us-gaap:FacilityClosingMember 2017-01-01 2017-12-31 0001125376 ensg:VariousLandlordsMemberMember us-gaap:MaximumMember 2017-01-01 2017-12-31 0001125376 ensg:OptionalLeaseExtensionMember 2017-06-01 2017-06-01 0001125376 ensg:CareTrustREITMember 2015-01-01 2015-12-31 0001125376 sic:Z8051 2017-06-01 2017-06-01 0001125376 us-gaap:ContractTerminationMember 2017-01-01 2017-12-31 0001125376 ensg:WorkersCompensationMember 2017-01-01 2017-12-31 0001125376 us-gaap:HealthInsuranceProductLineMember 2017-01-01 2017-12-31 0001125376 us-gaap:HealthInsuranceProductLineMember 2017-12-31 0001125376 us-gaap:ProfessionalMalpracticeLiabilityMember 2017-01-01 2017-12-31 0001125376 us-gaap:HealthInsuranceProductLineMember 2015-12-31 0001125376 ensg:WorkersCompensationMember 2015-12-31 0001125376 ensg:WorkersCompensationMember 2016-01-01 2016-12-31 0001125376 us-gaap:ProfessionalMalpracticeLiabilityMember 2016-01-01 2016-12-31 0001125376 us-gaap:HealthInsuranceProductLineMember 2016-01-01 2016-12-31 0001125376 us-gaap:HealthInsuranceProductLineMember 2016-12-31 0001125376 us-gaap:ProfessionalMalpracticeLiabilityMember 2016-12-31 0001125376 ensg:WorkersCompensationMember 2016-12-31 0001125376 ensg:WorkersCompensationMember 2017-12-31 0001125376 us-gaap:ProfessionalMalpracticeLiabilityMember 2017-12-31 0001125376 us-gaap:ProfessionalMalpracticeLiabilityMember 2015-12-31 0001125376 2013-01-01 2013-12-31 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember 2016-12-31 0001125376 ensg:TotalMedicaidAndMedicareRevenueMember 2017-12-31 0001125376 us-gaap:SubsequentEventMember 2018-02-02 0001125376 2006-01-01 2006-12-31 utreg:Rate xbrli:shares ensg:business iso4217:USD xbrli:shares ensg:Agreements ensg:Beds ensg:facilities iso4217:USD ensg:Operations ensg:Renewals ensg:Segments xbrli:pure ensg:Centers false --12-31 FY 2017 2017-12-31 10-K 0001125376 51484963 Yes Large Accelerated Filer 780000000 ENSIGN GROUP, INC No Yes 0.586 0.567 0.100 0.10 49 P5Y0M P3Y0M 2373000 2609000 0 212000 264000 P11Y0M P3Y0M P10Y0M P5Y0M 9124000 11268000 1023000 911000 1.00 1.00 1.00 1.00 0.000 0.000 -0.045 1963000 16153000 400000 1582000 25 7 46 -10785000 -467000 -6592000 17995000 14080000 3994000 23634000 28685000 0 881000 0 0 2447000 -3328000 0 2184000 0 0 2929000 -5113000 0 3035000 0 0 3023000 -6058000 11699000 0 0 3 2 2 8939000 0.0175 0.0075 0.0225 0.0125 0.0275 0.0175 0.0325 0.0225 48000000 275486000 302990000 0 7205000 2210000 6 8 160 167 9 11 210 230 1 1 4 1 17 2 10 5000 594 74 2013 2580 142 2336 463 18900 905 455 30000 17750000 23998000 120935000 127348000 195000 -5961000 0 0 0.10 0.03 0.010 0.010 4604000 4864000 6099000 6574000 18368000 21661000 26.55 23.23 22.90 21.96 21.00 18.79 18.47 18.47 1.000 0.154 0.342 0.054 0.295 0.691 0.155 1.000 0.160 0.337 0.053 0.288 0.678 0.162 1.000 0.164 0.349 0.056 0.279 0.684 0.152 1341826000 37834000 88129000 90356000 1128835000 -3328000 1654864000 42796000 123636000 115813000 1377732000 -5113000 1849317000 28093000 136646000 142403000 1548233000 -6058000 41492000 1864000 23508000 15983000 9311000 2218000 2526000 2704000 2776000 0.0973 0 25779000 5000000 1603000 454000 3140000 292000 8272000 2539000 3291000 281000 907000 1 2.5 0.02 92 148125000 140625000 7500000 133125000 150000000 190625000 195625000 2.75 2.75 3.50 1.50 160 21 17 0.006 0.008 0.008

38991000

39043000

284224000

66346000

111031000

55500000

51347000

309029000

68930000

119441000

55667000

64991000

244433000

265068000

244433000

265068000

9130000

10088000

110036000

144093000

P7M30D

P18Y7M30D

P24Y8M31D

P33Y0M0D

P30Y0M0D

252493000

266058000

6677000

582000

4164000

1931000

6677000

7776000

612000

1325000

4793000

2371000

7776000

8331000

1236000

1364000

4773000

2322000

8331000

39791000

43961000

591000

825000

1039000

3824000

4634000

3035000

734000

258000

838000

1252000

137000

111000

1001025000

1102433000

333862000

368076000

-18000

6000

92000

-11225000

7935000

-1286000

2321000

4017000

1187000

2830000

4171000

6828000

3550000

50408000

41569000

57706000

42337000

57706000

42337000

-8839000

16137000

-15369000

250000

965000

0.1525

0.1625

0.1725

0.001

75000000

52787000

53675000

22591000

51370000

50838000

51360000

52000

53000

1067694000

1341814000

1497703000

1248744000

1563017000

1768032000

28149000

30043000

15141000

33910000

35226000

18116000

5761000

5183000

2975000

284157000

316019000

0.053

0.026

0.033

P33Y0M

P12Y0M

P35Y0M

P30Y0M

542000

3090000

5082000

2026000

-1034000

5428000

1272000

-2251000

6414000

3611000

2799000

1251000

-2208000

10329000

25409000

22784000

6994000

7066000

-754000

-1217000

986000

48482000

36059000

23073000

12745000

48482000

35529000

3461000

3334000

3430000

3302000

21732000

16500000

15956000

11090000

7333000

5135000

530000

3743000

3625000

20643000

18248000

682000

862000

1028000

0.90

0.15

1582000

228000

28111000

5785000

3338000

980000

18008000

38682000

7303000

4157000

924000

26298000

44472000

7265000

6334000

945000

29928000

7858000

8282000

8867000

2186000

2328000

1.10

0.99

0.79

1.06

0.96

0.77

0.386

0.384

0.411

0.350

0.000

0.057

0.006

0.009

0.017

-0.006

-0.005

0.001

0.036

0.030

0.031

84686000

90508000

11063000

6916000

P2Y9M40D

P3Y4M15D

3680000

3079000

4104000

5394000

3700000

3181000

3680000

3079000

7190000

P8M0D

P4M0D

P20Y0M0D

P30Y0M0D

8086000

1897000

1253000

78000

4589000

269000

11121000

2631000

1530000

99000

6568000

293000

23612000

2329000

1471000

1593000

1497000

2301000

43162000

582000

1897000

7190000

4933000

483000

35116000

733000

43924000

2659000

4933000

483000

35116000

733000

35076000

3680000

405000

30527000

464000

32803000

28000

3403000

384000

28548000

440000

6512000

2715000

19160000

-205000

-164000

-278000

-11000000

64163000

69165000

80617000

30269000

3363000

1756000

10929000

14221000

40886000

7025000

3538000

16102000

14221000

67100000

5025000

3538000

17901000

40636000

81062000

7296000

3958000

24322000

45486000

10617000

3662000

1782000

5173000

30343000

2129000

1799000

26415000

13962000

2271000

420000

6421000

4850000

-4103000

-26000

1341826000

206770000

12027000

194743000

458956000

19642000

8946000

430368000

71905000

395503000

63074000

332429000

926364000

19642000

72020000

834702000

208692000

36953000

68487000

6309000

96943000

36953000

88129000

90356000

1126388000

1654864000

265508000

17664000

247844000

557958000

26397000

10498000

521063000

87517000

477019000

80500000

396519000

1122494000

26397000

90998000

1005099000

266862000

40612000

97239000

7151000

121860000

40612000

123636000

115813000

1374803000

1849317000

303386000

21823000

281563000

644803000

30469000

11230000

603104000

102875000

515884000

98014000

417870000

1263562000

30469000

109244000

1123849000

282369000

25058000

106177000

11336000

139798000

25058000

136646000

142403000

1545210000

35184000

41777000

137000

111000

91099000

85818000

69278000

55917000

52843000

40833000

3423000

35182000

32975000

28445000

3915000

35490000

23163000

38382000

1780000

577000

3329000

100324000

63617000

52301000

987000

-1182000

22178000

-4978000

5822000

314000

956000

483000

2813000

-365000

2236000

21403000

12588000

5777000

10340000

1465000

9380000

5149000

-7839000

19145000

5418000

8125000

6095000

1894000

1578000

1897000

19586000

18440000

1146000

25249000

24068000

1181000

500000

7178000

35000

2828000

7136000

13616000

2773000

6428000

13284000

845000

1107000

1609000

89264000

125221000

132932000

P5Y0M0D

P5Y0M

P19Y0M

P12Y0M

P15Y0M

P20Y0M

P5Y0M

540530000

602374000

1001025000

1102433000

211928000

225821000

56003000

20219000

5074000

30710000

65351000

23402000

5639000

36310000

72736000

27079000

4723000

40934000

1223000

586000

637000

1291000

930000

361000

66062000

10290000

37586000

18186000

83300000

12455000

54712000

16133000

74187000

12887000

38151000

23149000

89394000

15202000

53796000

20396000

300000000

250000000

450000000

150000000

122000000

50000000

0.050

150000000

75000000

0.0050

0.0030

0.0050

0.0030

11000000

700000

316019000

8129000

9939000

111941000

9939000

2904000

170926000

10203000

10106000

275486000

302990000

122955000

4046000

7662000

-83000

-39000

-44000

126330000

152885000

18272000

-168538000

-210636000

-106593000

33369000

73888000

72952000

55432000

49990000

40475000

485000

2853000

358000

3488000

700000

224000

100000

1325000

1432000

-107000

1364000

3302000

-1938000

6248000

14032000

125394000

112000000

2439000

93082000

-68709000

11463000

13584000

136744000

91847000

-54543000

11701000

16571000

118118000

81285000

-95440000

16736000

19717000

140272000

1755121000

135841000

133446000

134942000

135149000

135395000

1080348000

0.025

58763000

63815000

12614000

16501000

88776000

124581000

131919000

58763000

63815000

1972000

910000

5855000

7715000

-1983000

-6029000

-12007000

673000

2327000

12614000

16501000

400000

1582000

228000

56000000

56271000

57169000

30000000

7288000

7494000

8173000

8717000

3278000

2775000

4298000

119965000

895000

10901000

360000

10617000

6285000

73502000

4612000

12811000

64521000

1299000

393000

363000

30343000

1741000

21057000

8265000

1054000

89683000

762000

13962000

7018000

53735000

4382000

9732000

110802000

119965000

64310000

89565000

60018000

65699000

57166000

83000

6304000

19871000

28132000

302000

19447000

2000000

40734000

477000

112078000

334000000

844000000

1022015000

87000

106000

10000

391000

3215000

4337000

6563000

5274000

55917000

52843000

40833000

594534000

304263000

2441000

153170000

6931000

47565000

80164000

681177000

342641000

5460000

181530000

5244000

49081000

97221000

484498000

537084000

P59Y0M0D

P3Y0M0D

19802000

28512000

31023000

314417000

659514000

990154000

235021000

264691000

421000

13153000

12075000

38000000

24847000

38000000

1341826000

1654864000

1849317000

3526000

5981000

1000000

750000

5000000

350000

3000000

1000000

500000

75000

750000

300000

500000

21359000

22516000

43992000

50220000

6677000

9101000

9695000

P3Y0M0D

P3Y0M

P5Y0M0D

P3Y0M0D

P5Y0M

P3Y0M

P5Y0M

16.81

20.85

20.34

22.99

20.55

20.21

366000

425000

429000

383000

15.15

19.79

20.42

20.65

234000

279000

195000

17.36

19.58

19.79

0.017

0.014

0.020

0.395

0.378

0.352

1000

6881000

2000000

6277000

4.70

6.35

8.18

10.07

8709000

9199000

10481000

233000

127000

178000

12.55

14.46

15.82

637000

497000

481000

156000

9.08

7.00

67508000

55610000

44060000

5532000

5448000

5176000

4739000

8.51

10.36

11.62

13.08

5.20

6.47

6.93

23.27

19.43

20.31

21.47

6.56

5.90

18.79

2.56

10.55

7.98

18.64

4.77

4.06

2776000

219000

435000

134000

88000

185000

789000

390000

116000

420000

4739000

549000

435000

134000

450000

185000

1458000

522000

470000

116000

420000

25.24

7.96

7.99

19.89

4.06

18.94

11.49

22.90

4.96

4.56

0.20

P10Y0M0D

P10Y0M

P6Y6M

P6Y4M

P6Y2M0D

41128000

38101000

33976000

P5Y8M0D

P8Y0M

P5Y0M

P4Y0M

P9Y0M

P1Y0M

P7Y0M

P6Y0M

P10Y0M

P3Y0M

P2Y0M

150000

123000

1520000

1932000

11550000

13092000

2734000

255000

-27000

668000

-55000

807000

30000

16000

24000

323000

299000

173000

61000

105000

252000

127000

488000

642000

740000

25685000

106120000

106117000

3000

2530000

2443000

87000

4152000

4045000

1000

106000

5128000

5127000

1000

1892000

2517000

146000

-26000

26000

15000000

30000000

2018-02-08

P0Y12M

1452000

-1452000

412000

-412000

456449000

492397000

257803000

114293000

22000

-1048000

145846000

-1310000

426985000

235076000

51000

-339000

193420000

-1223000

460495000

252493000

52000

4046000

235021000

-31117000

500059000

266058000

53000

7662000

264691000

-38405000

1182000

1520000

1932000

31117000

38405000

530000

52210000

52133000

52829000

50316000

50555000

50932000

321000

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">COMMON STOCK </font></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 8, 2017, the Company announced that its Board of Directors authorized a stock repurchase program, under which the Company may repurchase up to </font><font style="font-family:inherit;font-size:10pt;">$30,000</font><font style="font-family:inherit;font-size:10pt;"> of its common stock under the program for a period of </font><font style="font-family:inherit;font-size:10pt;">12 months</font><font style="font-family:inherit;font-size:10pt;">. Under this program, the Company is authorized to repurchase its issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. The stock repurchase program expired on </font><font style="font-family:inherit;font-size:10pt;">February 8, 2018</font><font style="font-family:inherit;font-size:10pt;">. During the year ended December 31, 2017, the Company repurchased </font><font style="font-family:inherit;font-size:10pt;">412</font><font style="font-family:inherit;font-size:10pt;"> shares of its common stock for a total of </font><font style="font-family:inherit;font-size:10pt;">$7,288</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 4, 2015 and February 9, 2016, the Company announced that its Board of Directors authorized </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> stock repurchase programs, under which the Company could repurchase up to </font><font style="font-family:inherit;font-size:10pt;">$15,000</font><font style="font-family:inherit;font-size:10pt;"> of its common stock under each program for a period of </font><font style="font-family:inherit;font-size:10pt;">12 months</font><font style="font-family:inherit;font-size:10pt;">. During the first quarter of 2016, the Company repurchased </font><font style="font-family:inherit;font-size:10pt;">1,452</font><font style="font-family:inherit;font-size:10pt;"> shares of its common stock for a total of </font><font style="font-family:inherit;font-size:10pt;">$30,000</font><font style="font-family:inherit;font-size:10pt;"> and these repurchase programs expired upon the repurchase of the full authorized amount under such plans.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Deferred Rent </font><font style="font-family:inherit;font-size:10pt;">- Deferred rent represents rental expense, determined on a straight-line basis over the life of the related lease, in excess of actual rent payments.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Insurance Subsidiary Deposits and Investments — </font><font style="font-family:inherit;font-size:10pt;">The Company's captive insurance subsidiary cash and cash equivalents, deposits and investments are designated to support long-term insurance subsidiary liabilities and have been classified as short-term and long-term assets based on the timing of expected future payments of the Company's captive insurance liabilities. The majority of these deposits and investments are currently held in AA, A and BBB+ rated debt security investments and the remainder is held in a bank account with a high credit quality financial institution. See further discussion at Note 5, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurements.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluates securities for other-than-temporary impairment (“OTTI”) on at least a quarterly basis, and more frequently when economic or market conditions warrant such an evaluation.  If securities are in an unrealized loss position, the Company considers the extent and duration of the unrealized loss, and the financial condition and near-term prospects of the issuer. The Company also assesses whether it intends to sell, or it is more likely than not that it will be required to sell, a security in an unrealized loss position before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the entire difference between amortized cost and fair value is recognized as impairment through earnings. For the years ended December 31, 2016 and 2017, the Company did not recognize any OTTI for its investments.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Noncontrolling Interest — </font><font style="font-family:inherit;font-size:10pt;">The noncontrolling interest in a subsidiary is initially recognized at estimated fair value on the acquisition date and is presented within total equity in the Company's consolidated balance sheets. The Company presents the noncontrolling interest and the amount of consolidated net income attributable to The Ensign Group, Inc. in its consolidated statements of income and net income per share is calculated based on net income attributable to The Ensign Group, Inc.'s stockholders. The carrying amount of the noncontrolling interest is adjusted based on an allocation of subsidiary earnings based on ownership interest. </font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">REVENUE AND ACCOUNTS RECEIVABLE</font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue for the </font><font style="font-family:inherit;font-size:10pt;">years ended December 31, 2017, 2016 and 2015</font><font style="font-family:inherit;font-size:10pt;"> is summarized in the following tables:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="20" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">% of</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">% of</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">% of</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicaid</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">644,803</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">557,958</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">458,956</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicare</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">515,884</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">477,019</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">395,503</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicaid — skilled</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">102,875</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87,517</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,905</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Medicaid and Medicare</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,263,562</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,122,494</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">926,364</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Managed care</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">303,386</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">265,508</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">206,770</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Private and other payors</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">282,369</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">266,862</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">208,692</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,849,317</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,654,864</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,341,826</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1) Private and other payors also includes revenue from all payors generated in other ancillary services for the years ended December 31, 2017, 2016 and 2015 and urgent care centers for the years ended December 31, 2016 and 2015.</font></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and 2016 is summarized in the following table: </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicaid</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119,441</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">111,031</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Managed care</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68,930</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66,346</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicare</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,667</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Private and other payors</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,991</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,347</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">309,029</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">284,224</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: allowance for doubtful accounts</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(43,961</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(39,791</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">265,068</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">244,433</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table represents activity in our insurance reserves as of and for the years ended December 31, 2017 and 2016: </font></div><div style="line-height:120%;text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;"> </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="3" rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">General and Professional Liability</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Workers' Compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Health</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance January 1, 2016</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,710</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,219</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,074</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56,003</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current year provisions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,149</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,887</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,151</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74,187</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Claims paid and direct expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,186</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,290</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37,586</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(66,062</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in long-term insurance losses recoverable</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">637</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">586</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,223</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance December 31, 2016</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,310</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,402</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,639</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,351</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current year provisions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,396</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,202</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,796</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89,394</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Claims paid and direct expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16,133</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,455</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(54,712</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(83,300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in long-term insurance losses recoverable</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">361</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">930</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,291</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,934</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,079</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,723</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,736</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The aggregate intrinsic value of options outstanding, vested, expected to vest and exercised as of and for the </font><font style="font-family:inherit;font-size:10pt;">years ended December 31, 2017, 2016 and 2015</font><font style="font-family:inherit;font-size:10pt;"> is as follows:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,060</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,610</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67,508</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,976</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,101</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,128</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected to vest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,311</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,983</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,508</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,481</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,199</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,709</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation —</font><font style="font-family:inherit;font-size:10pt;"> The accompanying consolidated financial statements (Financial Statements) have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The Company is the sole member or shareholder of various consolidated limited liability companies and corporations established to operate various acquired skilled nursing and assisted living operations, home health, hospice and home care operations, and related ancillary services. All intercompany transactions and balances have been eliminated in consolidation. The consolidated financial statements include the accounts of all entities controlled by the Company through its ownership of a majority voting interest. The Company presents noncontrolling interest within the equity section of its consolidated balance sheets. The Company presents the amount of consolidated net income that is attributable to The Ensign Group, Inc. and the noncontrolling interest in its consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consolidated financial statements include the accounts of all entities controlled by the Company through its ownership of a majority voting interest and the accounts of any variable interest entities (VIEs) where the Company is subject to a majority of the risk of loss from the VIE's activities, or entitled to receive a majority of the entity's residual returns, or both. The Company assesses the requirements related to the consolidation of VIEs, including a qualitative assessment of power and economics that considers which entity has the power to direct the activities that "most significantly impact" the VIE's economic performance and has the obligation to absorb losses of, or the right to receive benefits that could be potentially significant to, the VIE. The Company's relationship with variable interest entities was not material during the year ended December 31, 2017.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2016, the Company completed the sale of its urgent care centers for an aggregate purchase price of </font><font style="font-family:inherit;font-size:10pt;">$41,492</font><font style="font-family:inherit;font-size:10pt;">. The sale transactions do not meet the criteria of discontinued operations as they do not represent a strategic shift that has, or will have, a major effect on the Company’s operations and financial results.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cash and Cash Equivalents</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> —</font><font style="font-family:inherit;font-size:10pt;"> Cash and cash equivalents consist of bank term deposits, money market funds and treasury bill related investments with original maturities of three months or less at time of purchase and therefore approximate fair value. The fair value of money market funds is determined based on “Level 1” inputs, which consist of unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets. The Company places its cash and short-term investments with high credit quality financial institutions.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DEBT</font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term debt consists of the following:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Term loan with SunTrust, interest payable quarterly</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">140,625</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">148,125</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Credit facility with SunTrust</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">122,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mortgage loans and promissory note, principal and interest payable monthly, interest at fixed rate</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">125,394</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,032</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">316,019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">284,157</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: current maturities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,939</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,129</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: debt issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,090</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(542</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">302,990</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">275,486</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Credit Facility with a Lending Consortium Arranged by SunTrust </font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company maintains a credit facility with a lending consortium arranged by SunTrust (as amended to date, the Credit Facility). The Company originally entered into the Credit Facility in an aggregate principal amount of </font><font style="font-family:inherit;font-size:10pt;">$150,000</font><font style="font-family:inherit;font-size:10pt;"> in May 2014. Under the Credit Facility, the Company could seek to obtain incremental revolving or term loans in an aggregate amount not to exceed </font><font style="font-family:inherit;font-size:10pt;">$75,000</font><font style="font-family:inherit;font-size:10pt;">.</font><font style="font-family:inherit;font-size:10pt;color:#ff0000;"> </font><font style="font-family:inherit;font-size:10pt;">The interest rates applicable to loans under the Credit Facility are, at the Company’s option, equal to either a base rate plus a margin ranging from </font><font style="font-family:inherit;font-size:10pt;">1.25%</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;"> per annum or LIBOR plus a margin ranging from </font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">3.25%</font><font style="font-family:inherit;font-size:10pt;"> per annum, based on the debt to Consolidated EBITDA ratio of the Company and its operating subsidiaries as defined in the agreement. In addition, the Company will pay a commitment fee on the unused portion of the commitments under the Credit Facility that will range from </font><font style="font-family:inherit;font-size:10pt;">0.30%</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">0.50%</font><font style="font-family:inherit;font-size:10pt;"> per annum, depending on the debt to Consolidated EBITDA ratio of the Company and its operating subsidiaries. Loans made under the Credit Facility are not subject to interim amortization. The Company is not required to repay any loans under the Credit Facility prior to maturity, other than to the extent the outstanding borrowings exceed the aggregate commitments under the Credit Facility. </font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 5, 2016, the Company amended its existing revolving credit facility to increase its aggregate principal amount available to </font><font style="font-family:inherit;font-size:10pt;">$250,000</font><font style="font-family:inherit;font-size:10pt;"> (the Amended Credit Facility). Under the credit facility, the Company may seek to obtain incremental revolving or term loans in an aggregate amount not to exceed </font><font style="font-family:inherit;font-size:10pt;">$150,000</font><font style="font-family:inherit;font-size:10pt;">. The interest rates applicable to loans under the credit facility are, at the Company's option, equal to either a base rate plus a margin ranging from </font><font style="font-family:inherit;font-size:10pt;">0.75%</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">1.75%</font><font style="font-family:inherit;font-size:10pt;"> per annum or LIBOR plus a margin ranging from </font><font style="font-family:inherit;font-size:10pt;">1.75%</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">2.75%</font><font style="font-family:inherit;font-size:10pt;"> per annum, based on the Consolidated Total Net Debt to Consolidated EBITDA ratio (as defined in the agreement). In addition, the Company will pay a commitment fee on the unused portion of the commitments under the credit facility that will range from </font><font style="font-family:inherit;font-size:10pt;">0.30%</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">0.50%</font><font style="font-family:inherit;font-size:10pt;"> per annum, depending on the Consolidated Total Net Debt to Consolidated EBITDA ratio of the Company and its subsidiaries. The Company is permitted to prepay all or any portion of the loans under the credit facility prior to maturity without premium or penalty, subject to reimbursement of any LIBOR breakage costs of the lenders. </font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On July 19, 2016, the Company entered into the second amendment to the credit facility (Second Amended Credit Facility), which amended the existing credit agreement to increase the aggregate principal amount up to </font><font style="font-family:inherit;font-size:10pt;">$450,000</font><font style="font-family:inherit;font-size:10pt;">. The Second Amended Credit Facility is comprised of a </font><font style="font-family:inherit;font-size:10pt;">$300,000</font><font style="font-family:inherit;font-size:10pt;"> revolving credit facility and a </font><font style="font-family:inherit;font-size:10pt;">$150,000</font><font style="font-family:inherit;font-size:10pt;"> term loan. Borrowings under the term loan portion of the Second Amended Credit Facility mature on February 5, 2021 and amortize in equal quarterly installments, in an aggregate annual amount equal to </font><font style="font-family:inherit;font-size:10pt;">5.0%</font><font style="font-family:inherit;font-size:10pt;"> per annum of the original principal amount. The interest rates and commitment fee applicable to the Second Amended Credit Facility are similar to the Amended Credit Facility discussed below. Except as set forth in the Second Amended Credit Facility, all other terms and conditions of the Amended Credit Facility remained in full force and effect as described below.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Credit Facility is guaranteed, jointly and severally, by certain of the Company’s wholly owned subsidiaries, and is secured by a pledge of stock of the Company's material operating subsidiaries as well as a first lien on substantially all of its personal property. The credit facility contains customary covenants that, among other things, restrict, subject to certain exceptions, the ability of the Company and its operating subsidiaries to grant liens on their assets, incur indebtedness, sell assets, make investments, engage in acquisitions, mergers or consolidations, amend certain material agreements and pay certain dividends and other restricted payments. Under the Credit Facility, the Company must comply with financial maintenance covenants to be tested quarterly, consisting of a maximum Consolidated Total Net Debt to consolidated EBITDA ratio (which shall be increased to </font><font style="font-family:inherit;font-size:10pt;">3.50</font><font style="font-family:inherit;font-size:10pt;">:</font><font style="font-family:inherit;font-size:10pt;">1.00</font><font style="font-family:inherit;font-size:10pt;"> for the first fiscal quarter and the immediate following </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> fiscal quarters), and a minimum interest/rent coverage ratio (which cannot be below </font><font style="font-family:inherit;font-size:10pt;">1.50</font><font style="font-family:inherit;font-size:10pt;">:</font><font style="font-family:inherit;font-size:10pt;">1.00</font><font style="font-family:inherit;font-size:10pt;">). The majority of lenders can require that the Company and its operating subsidiaries mortgage certain of its real property assets to secure the Amended Credit Facility if an event of default occurs, the Consolidated Total Net Debt to consolidated EBITDA ratio is above </font><font style="font-family:inherit;font-size:10pt;">2.75</font><font style="font-family:inherit;font-size:10pt;">:</font><font style="font-family:inherit;font-size:10pt;">1.00</font><font style="font-family:inherit;font-size:10pt;"> for </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> consecutive fiscal quarters, or its liquidity is equal or less than </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;"> of the Aggregate Revolving Commitment Amount (as defined in the agreement) for </font><font style="font-family:inherit;font-size:10pt;">ten</font><font style="font-family:inherit;font-size:10pt;"> consecutive business days, provided that such mortgages will no longer be required if the event of default is cured, the Consolidated Total Net Debt to consolidated EBITDA ratio is below </font><font style="font-family:inherit;font-size:10pt;">2.75</font><font style="font-family:inherit;font-size:10pt;">:</font><font style="font-family:inherit;font-size:10pt;">1.00</font><font style="font-family:inherit;font-size:10pt;"> for </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> consecutive fiscal quarters, or its liquidity is above </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;"> of the Aggregate Revolving Commitment Amount (as defined in the agreement) or </font><font style="font-family:inherit;font-size:10pt;">ninety</font><font style="font-family:inherit;font-size:10pt;"> consecutive days, as applicable. As of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company's operating subsidiaries had </font><font style="font-family:inherit;font-size:10pt;">$190,625</font><font style="font-family:inherit;font-size:10pt;"> outstanding under the Credit Facility. The outstanding balance on the term loan was </font><font style="font-family:inherit;font-size:10pt;">$140,625</font><font style="font-family:inherit;font-size:10pt;">, of which </font><font style="font-family:inherit;font-size:10pt;">$7,500</font><font style="font-family:inherit;font-size:10pt;"> is classified as short-term and the remaining </font><font style="font-family:inherit;font-size:10pt;">$133,125</font><font style="font-family:inherit;font-size:10pt;"> is classified as long-term. The outstanding balance on the revolving Credit Facility was </font><font style="font-family:inherit;font-size:10pt;">$50,000</font><font style="font-family:inherit;font-size:10pt;">, which is classified as long-term. The Company was in compliance with all loan covenants as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">February 2, 2018</font><font style="font-family:inherit;font-size:10pt;">, there was approximately </font><font style="font-family:inherit;font-size:10pt;">$195,625</font><font style="font-family:inherit;font-size:10pt;"> outstanding under the Credit Facility.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Mortgage Loans and Promissory Note</font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2017, </font><font style="font-family:inherit;font-size:10pt;">seventeen</font><font style="font-family:inherit;font-size:10pt;"> of the Company's subsidiaries entered into mortgage loans in the aggregate amount of </font><font style="font-family:inherit;font-size:10pt;">$112,000</font><font style="font-family:inherit;font-size:10pt;">. The mortgage loans are insured with Department of Housing and Urban Development (HUD), which subjects these subsidiaries to HUD oversight and periodic inspections. The mortgage loans and note bear fixed interest rates of </font><font style="font-family:inherit;font-size:10pt;">3.3%</font><font style="font-family:inherit;font-size:10pt;"> per annum. Amounts borrowed under the mortgage loans may be prepaid, subject to prepayment fees of the principal balance on the date of prepayment. During the first three years, the prepayment fee is </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;"> and is reduced by </font><font style="font-family:inherit;font-size:10pt;">3%</font><font style="font-family:inherit;font-size:10pt;"> in the fourth year of the loan, and reduced by</font><font style="font-family:inherit;font-size:10pt;color:#ff0000;"> </font><font style="font-family:inherit;font-size:10pt;">1.0%</font><font style="font-family:inherit;font-size:10pt;"> per year for years </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> through </font><font style="font-family:inherit;font-size:10pt;">ten</font><font style="font-family:inherit;font-size:10pt;"> of the loan. There is no prepayment penalty after year </font><font style="font-family:inherit;font-size:10pt;">ten</font><font style="font-family:inherit;font-size:10pt;">. The terms of the mortgage loans are </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">35</font><font style="font-family:inherit;font-size:10pt;">-years. The borrowings were arranged by Lancaster Pollard Mortgage Company, LLC, and insured by HUD. Loan proceeds were used to pay down previously drawn amounts on Ensign's revolving line of credit. In addition to refinancing existing borrowings, the proceeds of the HUD-insured debt helped fund acquisitions, to renovate and upgrade existing and future facilities, to cover working capital needs and for other business purposes.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the HUD mortgage loans above, the Company had outstanding indebtedness under mortgage loans insured with HUD and a promissory note issued in connection with various acquisitions. These mortgage loans and note bear fixed interest rates between </font><font style="font-family:inherit;font-size:10pt;">2.6%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">5.3%</font><font style="font-family:inherit;font-size:10pt;"> per annum. Amounts borrowed under the mortgage loans may be prepaid starting after the second anniversary of the notes subject to prepayment fees of the principal balance on the date of prepayment. These prepayment fees are reduced by </font><font style="font-family:inherit;font-size:10pt;">1.0%</font><font style="font-family:inherit;font-size:10pt;"> per year for years </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> through </font><font style="font-family:inherit;font-size:10pt;">eleven</font><font style="font-family:inherit;font-size:10pt;"> of the loan. There is no prepayment penalty after year </font><font style="font-family:inherit;font-size:10pt;">eleven</font><font style="font-family:inherit;font-size:10pt;">. The term of the mortgage loans and the note is between </font><font style="font-family:inherit;font-size:10pt;">12</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">33</font><font style="font-family:inherit;font-size:10pt;"> years. The mortgage loans and note are secured by the real property comprising the facilities and the rents, issues and profits thereof, as well as all personal property used in the operation of the facilities. </font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> As of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company's operating subsidiaries had </font><font style="font-family:inherit;font-size:10pt;">$125,394</font><font style="font-family:inherit;font-size:10pt;"> outstanding under the mortgage loans and note, of which </font><font style="font-family:inherit;font-size:10pt;">$2,439</font><font style="font-family:inherit;font-size:10pt;"> is classified as short-term and the remaining </font><font style="font-family:inherit;font-size:10pt;">$122,955</font><font style="font-family:inherit;font-size:10pt;"> is classified as long-term. The Company was in compliance with all loan covenants as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on Level 2, the carrying value of the Company's long-term debt is considered to approximate the fair value of such debt for all periods presented based upon the interest rates that the Company believes it can currently obtain for similar debt.</font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Future principal payments due under the long-term debt arrangements discussed above are as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90167158308752%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:76%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Years Ending</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,939</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,106</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,203</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">170,926</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,904</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">111,941</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">316,019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Off-Balance Sheet Arrangements</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the year ended December 31, 2017, the Company increased the letters of credit by </font><font style="font-family:inherit;font-size:10pt;">$3,994</font><font style="font-family:inherit;font-size:10pt;">. </font><font style="font-family:inherit;font-size:10pt;">As of December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company had approximately </font><font style="font-family:inherit;font-size:10pt;">$6,304</font><font style="font-family:inherit;font-size:10pt;"> on the credit facility of borrowing capacity pledged as collateral to secure outstanding letters of credit.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OPTIONS AND AWARDS</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation expense consists of share-based payment awards made to employees and directors, including employee stock options and restricted stock awards, based on estimated fair values. As stock-based compensation expense recognized in the Company’s consolidated statements of income for the </font><font style="font-family:inherit;font-size:10pt;">years ended December 31, 2017, 2016 and 2015</font><font style="font-family:inherit;font-size:10pt;"> was based on awards ultimately expected to vest, it has been reduced for estimated forfeitures. The Company estimates forfeitures at the time of grant and, if necessary, revises the estimate in subsequent periods if actual forfeitures differ.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> During the second quarter of 2017, the Company's shareholders approved the 2017 Omnibus Incentive Plan (the 2017 Plan). The total number of shares available under all of the Company’s stock incentive plans was </font><font style="font-family:inherit;font-size:10pt;">6,277</font><font style="font-family:inherit;font-size:10pt;"> as of December 31, 2017. The Company retired the 2001 Stock Option, Deferred Stock and Restricted Stock Plan (2001 Plan), the 2005 Stock Incentive Plan (2005 Plan), and the 2007 Omnibus Incentive Plan (2007 Plan) as a result of the approval of the 2017 Plan.</font></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">2007 Omnibus Incentive Plan</font><font style="font-family:inherit;font-size:10pt;"> - The 2007 Plan authorizes the sale of up to </font><font style="font-family:inherit;font-size:10pt;">2,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock to officers, employees, directors and consultants of the Company. In addition, the number of shares of common stock reserved under the 2007 Plan will automatically increase on the first day of each fiscal year, beginning on January 1, 2008, in an amount equal to the lesser of (i) </font><font style="font-family:inherit;font-size:10pt;">1,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock, or (ii) </font><font style="font-family:inherit;font-size:10pt;">2%</font><font style="font-family:inherit;font-size:10pt;"> of the number of shares outstanding as of the last day of the immediately preceding fiscal year, or (iii) such lesser number as determined by the Company's board of directors. Granted non-employee director options vest and become exercisable in </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> equal annual installments, or the length of the term if less than </font><font style="font-family:inherit;font-size:10pt;">3 years</font><font style="font-family:inherit;font-size:10pt;">, on the completion of each year of service measured from the grant date. All other granted options vest over </font><font style="font-family:inherit;font-size:10pt;">5 years</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">20%</font><font style="font-family:inherit;font-size:10pt;"> per year on the anniversary of the grant date. Options expire </font><font style="font-family:inherit;font-size:10pt;">10 years</font><font style="font-family:inherit;font-size:10pt;"> from the date of grant. The Company granted </font><font style="font-family:inherit;font-size:10pt;">156</font><font style="font-family:inherit;font-size:10pt;"> options and </font><font style="font-family:inherit;font-size:10pt;">61</font><font style="font-family:inherit;font-size:10pt;"> restricted stock awards from the 2007 Plan in the first half of 2017 prior to the retirement of the 2007 Plan. </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">2017 Omnibus Incentive Plan</font><font style="font-family:inherit;font-size:10pt;"> - The 2017 Plan provides for the issuance of </font><font style="font-family:inherit;font-size:10pt;">6,881</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock. The number of shares available to be issued under the 2017 Plan will be reduced by (i) </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> share for each share that relates to an option or stock appreciation right award and (ii) </font><font style="font-family:inherit;font-size:10pt;">2.5</font><font style="font-family:inherit;font-size:10pt;"> shares for each share which relates to an award other than a stock option or stock appreciation right award (a full-value award). Granted non-employee director options vest and become exercisable in </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> equal annual installments, or the length of the term if less than </font><font style="font-family:inherit;font-size:10pt;">3 years</font><font style="font-family:inherit;font-size:10pt;">, on the completion of each year of service measured from the grant date. All other options generally vest over </font><font style="font-family:inherit;font-size:10pt;">5 years</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">20%</font><font style="font-family:inherit;font-size:10pt;"> per year on the anniversary of the grant date. Options expire </font><font style="font-family:inherit;font-size:10pt;">10 years</font><font style="font-family:inherit;font-size:10pt;"> from the date of grant. At </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, there were </font><font style="font-family:inherit;font-size:10pt;">6,277</font><font style="font-family:inherit;font-size:10pt;"> unissued shares of common stock available for issuance under this plan. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company uses the Black-Scholes option-pricing model to recognize the value of stock-based compensation expense for all share-based payment awards. Determining the appropriate fair-value model and calculating the fair value of stock-based awards at the grant date requires considerable judgment, including estimating stock price volatility, expected option life and forfeiture rates. The Company develops estimates based on historical data and market information, which can change significantly over time. The Black-Scholes model required the Company to make several key judgments including: </font></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The expected option term is calculated by the average of the contractual term of the options and the weighted average vesting period for all options. The calculation of the expected option term is based on the Company's experience due to sufficient history.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated volatility also reflects the application of ASC 718 interpretive guidance and, accordingly, incorporates historical volatility of similar public entities until sufficient information regarding the volatility of the Company's share price becomes available. The Company has utilized its own experience to calculate estimated volatility for options granted. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The dividend yield is based on the Company's historical pattern of dividends as well as expected dividend patterns.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The risk-free rate is based on the implied yield of U.S. Treasury notes as of the grant date with a remaining term approximately equal to the expected term.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated forfeiture rate of approximately </font><font style="font-family:inherit;font-size:10pt;">9.73%</font><font style="font-family:inherit;font-size:10pt;"> per year is based on the Company's historical forfeiture activity of unvested stock options.</font></div></td></tr></table><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock Options</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company granted </font><font style="font-family:inherit;font-size:10pt;">481</font><font style="font-family:inherit;font-size:10pt;"> options and </font><font style="font-family:inherit;font-size:10pt;">173</font><font style="font-family:inherit;font-size:10pt;"> restricted stock awards from the 2007 and 2017 Plans during the </font><font style="font-family:inherit;font-size:10pt;">year ended December 31, </font><font style="font-family:inherit;font-size:10pt;">2017. The Company used the following assumptions for stock options granted during the </font><font style="font-family:inherit;font-size:10pt;">years ended December 31, 2017, 2016 and 2015</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grant Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Options Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Risk-Free Rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Expected Life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Dividend Yield</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">481</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.0%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.2 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35.2%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.8%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">497</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.4%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.3 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37.8%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.8%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">637</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.7%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.5 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39.5%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.6%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the </font><font style="font-family:inherit;font-size:10pt;">years ended December 31, 2017, 2016 and 2015</font><font style="font-family:inherit;font-size:10pt;">, the following represents the exercise price and fair value displayed at grant date for stock option grants:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grant Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Fair Value of Options</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">481</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20.31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">497</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19.43</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.00</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">637</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23.27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.08</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The weighted average exercise price equaled the weighted average fair value of common stock on the grant date for all options granted during the periods ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017, 2016 and 2015</font><font style="font-family:inherit;font-size:10pt;"> and therefore, the intrinsic value was </font><font style="font-family:inherit;font-size:10pt;">$0</font><font style="font-family:inherit;font-size:10pt;"> at date of grant. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table represents the employee stock option activity during the </font><font style="font-family:inherit;font-size:10pt;">years ended December 31, 2017, 2016 and 2015</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number of</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Options</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number of</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Options Vested</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Exercise Price</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">of Options</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Vested</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">January 1, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,532</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.51</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,218</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.70</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">637</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23.27</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(233</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(488</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.20</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,448</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.36</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,526</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">497</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19.43</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(127</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.46</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(642</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.47</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,176</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,704</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">481</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20.31</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(178</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.82</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(740</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.93</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,739</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.08</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,776</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.07</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following summary information reflects stock options outstanding, vested and related details as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:39%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Stock Options Vested</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Stock Options Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Black-Scholes Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Remaining Contractual Life (Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Vested and Exercisable</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year of Grant</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2008</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.56</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.06</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">185</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">292</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">185</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2009</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.06</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.56</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">420</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">907</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">420</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2010</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.96</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">281</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2011</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.90</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.99</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">134</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">454</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">134</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2012</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.56</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.96</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">435</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,603</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">435</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.98</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.49</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">522</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,539</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">390</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18.94</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,458</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,272</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">789</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21.47</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25.24</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">549</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">219</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18.79</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19.89</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">450</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,140</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18.64</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22.90</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">470</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,291</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,739</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,779</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,776</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restricted Stock Awards</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company granted </font><font style="font-family:inherit;font-size:10pt;">173</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">299</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">323</font><font style="font-family:inherit;font-size:10pt;"> restricted stock awards during the </font><font style="font-family:inherit;font-size:10pt;">years ended December 31, 2017, 2016 and 2015</font><font style="font-family:inherit;font-size:10pt;">, respectively. All awards were granted at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$0</font><font style="font-family:inherit;font-size:10pt;"> and generally vest over </font><font style="font-family:inherit;font-size:10pt;">five years</font><font style="font-family:inherit;font-size:10pt;">. The fair value per share of restricted awards granted during the 2017, 2016 and 2015 ranged from </font><font style="font-family:inherit;font-size:10pt;">$18.47</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">$22.90</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$18.79</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">$23.23</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$21.00</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">$26.55</font><font style="font-family:inherit;font-size:10pt;">, respectively. The fair value per share includes quarterly stock awards to non-employee directors. </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of the status of the Company's non-vested restricted stock awards as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and changes during the </font><font style="font-family:inherit;font-size:10pt;">years ended December 31, 2017, 2016 and 2015</font><font style="font-family:inherit;font-size:10pt;"> is presented below:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Non-Vested Restricted Awards</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Grant Date Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nonvested at January 1, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">366</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">323</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22.99</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(234</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17.36</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(30</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.81</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nonvested at December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">425</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19.79</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">299</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20.55</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(279</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19.58</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20.85</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nonvested at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">429</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">173</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20.21</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(195</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19.79</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(24</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20.34</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nonvested at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">383</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;">year ended December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company granted </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;"> automatic quarterly stock awards to non-employee directors for their service on the Company's board of directors. The fair value per share of these stock awards ranged from </font><font style="font-family:inherit;font-size:10pt;">$18.47</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">$21.96</font><font style="font-family:inherit;font-size:10pt;"> based on the market price on the grant date. </font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share-based compensation expense recognized for the Company's equity incentive plans for the </font><font style="font-family:inherit;font-size:10pt;">years ended December 31, 2017, 2016 and 2015</font><font style="font-family:inherit;font-size:10pt;"> was as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share-based compensation expense related to stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,773</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,793</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,164</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share-based compensation expense related to restricted stock awards</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,322</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,371</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,931</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share-based compensation expense related to stock options and restricted stock awards to non-employee directors</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,236</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">612</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">582</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,331</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,776</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,677</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In future periods, the Company expects to recognize approximately </font><font style="font-family:inherit;font-size:10pt;">$11,063</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$6,916</font><font style="font-family:inherit;font-size:10pt;"> in share-based compensation expense for unvested options and unvested restricted stock awards, respectively, that were outstanding as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">. Future share-based compensation expense will be recognized over </font><font style="font-family:inherit;font-size:10pt;">2.9</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">3.4</font><font style="font-family:inherit;font-size:10pt;"> weighted average years for unvested options and restricted stock awards, respectively. There were </font><font style="font-family:inherit;font-size:10pt;">1,963</font><font style="font-family:inherit;font-size:10pt;"> unvested and outstanding options at </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, of which </font><font style="font-family:inherit;font-size:10pt;">1,864</font><font style="font-family:inherit;font-size:10pt;"> are expected to vest. The weighted average contractual life for options outstanding, vested and expected to vest at </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">5.7</font><font style="font-family:inherit;font-size:10pt;"> years.</font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The aggregate intrinsic value of options outstanding, vested, expected to vest and exercised as of and for the </font><font style="font-family:inherit;font-size:10pt;">years ended December 31, 2017, 2016 and 2015</font><font style="font-family:inherit;font-size:10pt;"> is as follows:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,060</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,610</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67,508</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,976</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,101</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,128</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected to vest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,311</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,983</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,508</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,481</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,199</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,709</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The intrinsic value is calculated as the difference between the market value of the underlying common stock and the exercise price of the options.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Equity Instrument Denominated in the Shares of a Subsidiary</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 26, 2016, the Company implemented a management equity plan and granted stock options and restricted stock awards of a subsidiary of the Company to employees and management of that subsidiary (Subsidiary Equity Plan). These awards generally vest over a period of </font><font style="font-family:inherit;font-size:10pt;">five years</font><font style="font-family:inherit;font-size:10pt;"> or upon the occurrence of certain prescribed events. The value of the stock options and restricted stock awards is tied to the value of the common stock of the subsidiary. The awards can be put to the Company at various prescribed dates, which in no event is earlier than six months after vesting of the restricted awards or exercise of the stock options. The Company can also call the awards, generally upon employee termination. </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The grant-date fair value of the awards is recognized as compensation expense over the relevant vesting periods, with a corresponding adjustment to noncontrolling interests. The grant value was determined based on an independent valuation of the subsidiary shares. For the </font><font style="font-family:inherit;font-size:10pt;">years ended December 31, 2017 and 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company expensed </font><font style="font-family:inherit;font-size:10pt;">$1,364</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1,325</font><font style="font-family:inherit;font-size:10pt;">, respectively, in share-based compensation related to the Subsidiary Equity Plan. There was no expense incurred for the year ended December 31, 2015 as the plan was implemented in the second quarter of 2016.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The aggregate number of the Company's common shares that would be required to settle these awards at current estimated fair values, including vested and unvested awards, at </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> is </font><font style="font-family:inherit;font-size:10pt;">264</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">212</font><font style="font-family:inherit;font-size:10pt;">, respectively. There was no comparable amount at December 31, 2015 as the plan was implemented in the second quarter of 2016.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the financial assets and liabilities measured at fair value on a recurring basis as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and 2016:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,337</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,706</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value of Financial Instruments —</font><font style="font-family:inherit;font-size:10pt;">The Company’s financial instruments consist principally of cash and cash equivalents, debt security investments, accounts receivable, insurance subsidiary deposits, accounts payable and borrowings. The Company believes all of the financial instruments’ recorded values approximate fair values because of their nature or respective short durations. </font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill —</font><font style="font-family:inherit;font-size:10pt;"> Definite-lived intangible assets consist primarily of favorable leases, lease acquisition costs, patient base, facility trade names and customer relationships. Favorable leases and lease acquisition costs are amortized over the life of the lease of the facility. Patient base is amortized over a period of </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">eight</font><font style="font-family:inherit;font-size:10pt;"> months, depending on the classification of the patients and the level of occupancy in a new acquisition on the acquisition date. Trade names at affiliated facilities are amortized over </font><font style="font-family:inherit;font-size:10pt;">30 years</font><font style="font-family:inherit;font-size:10pt;"> and customer relationships are amortized over a period of up to </font><font style="font-family:inherit;font-size:10pt;">20 years</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's indefinite-lived intangible assets consist of trade names and Medicare and Medicaid licenses. The Company tests indefinite-lived intangible assets for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the carrying amount of the intangible asset may not be recoverable. The Company did not identify any asset impairment during the years ended December 31, 2017, 2016 and 2015. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in business combinations. Goodwill is subject to annual testing for impairment. In addition, goodwill is tested for impairment if events occur or circumstances change that would reduce the fair value of a reporting unit below its carrying amount. The Company performs its annual test for impairment during the fourth quarter of each year. See further discussion at Note 11, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Goodwill and Other Indefinite-Lived Intangible Assets</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition — </font><font style="font-family:inherit;font-size:10pt;">The Company recognizes revenue when the following four conditions have been met: (i) there is persuasive evidence that an arrangement exists; (ii) delivery has occurred or service has been rendered; (iii) the price is fixed or determinable; and (iv) collection is reasonably assured. The Company's revenue is derived primarily from providing healthcare services to patients and is recognized on the date services are provided at amounts billable to the individual. For reimbursement arrangements with third-party payors, including Medicaid, Medicare and private insurers, revenue is recorded based on contractually agreed-upon amounts on a per patient basis.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from the Medicare and Medicaid programs accounted for </font><font style="font-family:inherit;font-size:10pt;">68.4%</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">67.8%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">69.1%</font><font style="font-family:inherit;font-size:10pt;"> of the Company's revenue for the </font><font style="font-family:inherit;font-size:10pt;">years ended December 31, 2017, 2016 and 2015</font><font style="font-family:inherit;font-size:10pt;">, respectively. The Company records revenue from these governmental and managed care programs as services are performed at their expected net realizable amounts under these programs. The Company’s revenue from governmental and managed care programs is subject to audit and retroactive adjustment by governmental and third-party agencies. Consistent with healthcare industry accounting practices, any changes to these governmental revenue estimates are recorded in the period the change or adjustment becomes known based on final settlement. The Company recorded adjustments to revenue which were not material to the Company's consolidated revenue or Financial Statements for the </font><font style="font-family:inherit;font-size:10pt;">years ended December 31, 2017, 2016 and 2015</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company’s service specific revenue recognition policies are as follows:</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Skilled Nursing Revenue</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company’s revenue is derived primarily from providing long-term healthcare services to patients and is recognized on the date services are provided at amounts billable to individual patients. For patients under reimbursement arrangements with third-party payors, including Medicaid, Medicare and private insurers, revenue is recorded based on contractually agreed-upon amounts or rate on a per patient, daily basis or as services are performed. </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assisted and Independent Living Revenue</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's revenue is recorded when services are rendered on the date services are provided at amounts billable to individual residents and consists of fees for basic housing and assisted living care. Residency agreements are generally for a term of 30 days, with resident fees billed monthly in advance. For patients under reimbursement arrangements with Medicaid, revenue is recorded based on contractually agreed-upon amounts or rate on a per resident, daily basis or as services rendered. Revenue for certain ancillary charges is recognized as services are provided, and such fees are billed monthly in arrears.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Home Health Revenue</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Medicare Revenue </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net service revenue is recorded under the Medicare prospective payment system based on a 60-day episode payment rate that is subject to adjustment based on certain variables including, but not limited to: (a) an outlier payment if patient care was unusually costly; (b) a low utilization payment adjustment if the number of visits was fewer than five; (c) a partial payment if the patient transferred to another provider or the Company received a patient from another provider before completing the episode; (d) a payment adjustment based upon the level of therapy services required; (e) the number of episodes of care provided to a patient, regardless of whether the same home health provider provided care for the entire series of episodes; (f) changes in the base episode payments established by the Medicare program; (g) adjustments to the base episode payments for case mix and geographic wages; and (h) recoveries of overpayments.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company makes adjustments to Medicare revenue on completed episodes to reflect differences between estimated and actual payment amounts, an inability to obtain appropriate billing documentation or authorizations acceptable to the payor and other reasons unrelated to credit risk. Therefore, the Company believes that its reported net service revenue and patient accounts receivable will be the net amounts to be realized from Medicare for services rendered.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to revenue recognized on completed episodes, the Company also recognizes a portion of revenue associated with episodes in progress. Episodes in progress are 60-day episodes of care that begin during the reporting period, but were not completed as of the end of the period. As such, the Company estimates revenue and recognizes it on a daily basis. The primary factors underlying this estimate are the number of episodes in progress at the end of the reporting period, expected Medicare revenue per episode and its estimate of the average percentage complete based on visits performed. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Non-Medicare Revenue</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Episodic Based Revenue -</font><font style="font-family:inherit;font-size:10pt;"> The Company recognizes revenue in a similar manner as it recognizes Medicare revenue for episodic-based rates that are paid by other insurance carriers, including Medicare Advantage programs; however, these rates can vary based upon the negotiated terms.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Non-episodic Based Revenue -</font><font style="font-family:inherit;font-size:10pt;"> Revenue is recorded on an accrual basis based upon the date of service at amounts equal to its established or estimated per-visit rates, as applicable.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Hospice Revenue </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are daily rates for each of the levels of care the Company delivers. The Company makes adjustments to revenue for an inability to obtain appropriate billing documentation or authorizations acceptable to the payor and other reasons unrelated to credit risk. Additionally, as Medicare hospice revenue is subject to an inpatient cap limit and an overall payment cap, the Company monitors its provider numbers and estimates amounts due back to Medicare if a cap has been exceeded. The Company records these adjustments as a reduction to revenue and increases to other accrued liabilities.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Impairment of Long-Lived Assets —</font><font style="font-family:inherit;font-size:10pt;"> The Company reviews the carrying value of long-lived assets that are held and used in the Company’s operating subsidiaries for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of these assets is determined based upon expected undiscounted future net cash flows from the operating subsidiaries to which the assets relate, utilizing management’s best estimate, appropriate assumptions, and projections at the time. If the carrying value is determined to be unrecoverable from future operating cash flows, the asset is deemed impaired and an impairment loss would be recognized to the extent the carrying value exceeded the estimated fair value of the asset. The Company estimates the fair value of assets based on the estimated future discounted cash flows of the asset. Management has evaluated its long-lived assets and recorded an impairment charge of </font><font style="font-family:inherit;font-size:10pt;">$111</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$137</font><font style="font-family:inherit;font-size:10pt;"> related to the closure of facilities during the </font><font style="font-family:inherit;font-size:10pt;">years ended December 31, 2017 and 2016</font><font style="font-family:inherit;font-size:10pt;">, respectively. The Company did not identify any asset impairment during the </font><font style="font-family:inherit;font-size:10pt;">year ended December 31, </font><font style="font-family:inherit;font-size:10pt;">2015. </font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes</font><font style="font-family:inherit;font-size:10pt;"> — Deferred tax assets and liabilities are established for temporary differences between the financial reporting basis and the tax basis of the Company’s assets and liabilities at tax rates in effect when such temporary differences are expected to reverse. The Company generally expects to fully utilize its deferred tax assets; however, when necessary, the Company records a valuation allowance to reduce its net deferred tax assets to the amount that is more likely than not to be realized. </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In determining the need for a valuation allowance or the need for and magnitude of liabilities for uncertain tax positions, the Company makes certain estimates and assumptions. These estimates and assumptions are based on, among other things, knowledge of operations, markets, historical trends and likely future changes and, when appropriate, the opinions of advisors with knowledge and expertise in certain fields. Due to certain risks associated with the Company’s estimates and assumptions, actual results could differ.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Tax Cuts and Jobs Act (the Tax Act), which was enacted in December 2017, increased the Company's income tax expense by </font><font style="font-family:inherit;font-size:10pt;">$3,915</font><font style="font-family:inherit;font-size:10pt;"> for the year ended December 31, 2017. The Tax Act will decrease the corporate income tax rate from 35.0% to 21.0% beginning on January 1, 2018. The Company expects meaningful benefits from this reduction to continue from its enactment in future periods. See Note 14, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes </font><font style="font-family:inherit;font-size:10pt;">for further detail.</font></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;padding-left:30px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SELF INSURANCE RESERVES</font></div><div style="line-height:120%;text-align:left;padding-left:30px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;"> </font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table represents activity in our insurance reserves as of and for the years ended December 31, 2017 and 2016: </font></div><div style="line-height:120%;text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;"> </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="3" rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">General and Professional Liability</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Workers' Compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Health</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance January 1, 2016</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,710</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,219</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,074</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56,003</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current year provisions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,149</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,887</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,151</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74,187</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Claims paid and direct expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,186</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,290</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37,586</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(66,062</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in long-term insurance losses recoverable</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">637</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">586</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,223</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance December 31, 2016</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,310</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,402</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,639</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,351</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current year provisions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,396</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,202</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,796</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89,394</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Claims paid and direct expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16,133</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,455</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(54,712</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(83,300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in long-term insurance losses recoverable</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">361</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">930</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,291</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,934</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,079</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,723</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,736</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;"> </font></div><div style="line-height:120%;text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Included in long-term insurance losses recoverable as of December 31, 2017 and 2016, are anticipated insurance recoveries related to the Company's general and professional liability claims that are recorded on a gross rather than net basis in accordance with GAAP.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Self-Insurance</font><font style="font-family:inherit;font-size:10pt;"> — The Company is partially self-insured for general and professional liability up to a base amount per claim (the self-insured retention) with an aggregate, one-time deductible above this limit. Losses beyond these amounts are insured through third-party policies with coverage limits per claim, per location and on an aggregate basis for the Company. Starting on January 1, 2017, the combined self-insured retention was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$500</font><font style="font-family:inherit;font-size:10pt;"> per claim, subject to an additional one-time deductible of </font><font style="font-family:inherit;font-size:10pt;">$750</font><font style="font-family:inherit;font-size:10pt;"> for California affiliated operations and a separate, one-time, deductible of </font><font style="font-family:inherit;font-size:10pt;">$1,000</font><font style="font-family:inherit;font-size:10pt;"> for non-California operations. For all affiliated operations, except those located in Colorado, the third-party coverage above these limits was </font><font style="font-family:inherit;font-size:10pt;">$1,000</font><font style="font-family:inherit;font-size:10pt;"> per claim, </font><font style="font-family:inherit;font-size:10pt;">$3,000</font><font style="font-family:inherit;font-size:10pt;"> per operation, with a </font><font style="font-family:inherit;font-size:10pt;">$5,000</font><font style="font-family:inherit;font-size:10pt;"> blanket aggregate limit and an additional state-specific aggregate where required by state law. In Colorado, the third-party coverage above these limits was </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1,000</font><font style="font-family:inherit;font-size:10pt;"> per claim and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$3,000</font><font style="font-family:inherit;font-size:10pt;"> per operation, which is independent of the aforementioned blanket aggregate limits that apply outside of Colorado. </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The self-insured retention and deductible limits for general and professional liability and workers' compensation for all states (except Texas and Washington for workers' compensation) are self-insured through the Captive, the related assets and liabilities of which are included in the accompanying consolidated balance sheets. The Captive is subject to certain statutory requirements as an insurance provider. These requirements include, but are not limited to, maintaining statutory capital. </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company’s policy is to accrue amounts equal to the actuarially estimated costs to settle open claims of insureds, as well as an estimate of the cost of insured claims that have been incurred but not reported. The Company develops information about the size of the ultimate claims based on historical experience, current industry information and actuarial analysis, and evaluates the estimates for claim loss exposure on a quarterly basis. </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:1pt;"> </font><font style="font-family:inherit;font-size:10pt;">The Company’s operating subsidiaries are self-insured for workers’ compensation in California. To protect itself against loss exposure in California with this policy, the Company has purchased individual specific excess insurance coverage that insures individual claims that exceed </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$500</font><font style="font-family:inherit;font-size:10pt;"> per occurrence. In Texas, the operating subsidiaries have elected non-subscriber status for workers’ compensation claims and, effective February 1, 2011, the Company has purchased individual stop-loss coverage that insures individual claims that exceed </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$750</font><font style="font-family:inherit;font-size:10pt;"> per occurrence. As of July 1, 2014, the Company’s operating subsidiaries in all other states, with the exception of Washington, are under a loss sensitive plan that insures individual claims that exceed </font><font style="font-family:inherit;font-size:10pt;">$350</font><font style="font-family:inherit;font-size:10pt;"> per occurrence. In Washington, the operating subsidiaries' coverage is financed through premiums paid by the employers and employees. The claims and pay benefits are managed through a state insurance pool. Outside of California, Texas and Washington, the Company has purchased insurance coverage that insures individual claims that exceed </font><font style="font-family:inherit;font-size:10pt;">$350</font><font style="font-family:inherit;font-size:10pt;"> per accident. In all states except Washington, the Company accrues amounts equal to the estimated costs to settle open claims, as well as an estimate of the cost of claims that have been incurred but not reported. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information. </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, the Company has recorded an asset and equal liability of </font><font style="font-family:inherit;font-size:10pt;">$5,394</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$4,104</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and 2016, respectively, in order to present the ultimate costs of malpractice and workers' compensation claims and the anticipated insurance recoveries on a gross basis. See Note 12, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted and Other Assets.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company self-funds medical (including prescription drugs) and dental healthcare benefits to the majority of its employees. The Company is fully liable for all financial and legal aspects of these benefit plans. To protect itself against loss exposure with this policy, the Company has purchased individual stop-loss insurance coverage that insures individual claims that exceed </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$300</font><font style="font-family:inherit;font-size:10pt;"> for each covered person with an additional one-time aggregate individual stop loss deductible of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$75</font><font style="font-family:inherit;font-size:10pt;">. Beginning 2016, the Company's policy does not include the additional one-time aggregate individual stop loss deductible of </font><font style="font-family:inherit;font-size:10pt;">$75</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> The Company believes that adequate provision has been made in the Financial Statements for liabilities that may arise out of patient care, workers’ compensation, healthcare benefits and related services provided to date. The amount of the Company’s reserves was determined based on an estimation process that uses information obtained from both company-specific and industry data. This estimation process requires the Company to continuously monitor and evaluate the life cycle of the claims. Using data obtained from this monitoring and the Company’s assumptions about emerging trends, the Company, with the assistance of an independent actuary, develops information about the size of ultimate claims based on the Company’s historical experience and other available industry information. The most significant assumptions used in the estimation process include determining the trend in costs, the expected cost of claims incurred but not reported and the expected costs to settle or pay damage awards with respect to unpaid claims. The self-insured liabilities are based upon estimates, and while management believes that the estimates of loss are reasonable, the ultimate liability may be in excess of or less than the recorded amounts. Due to the inherent volatility of actuarially determined loss estimates, it is reasonably possible that the Company could experience changes in estimated losses that could be material to net income. If the Company’s actual liability exceeds its estimates of loss, its future earnings, cash flows and financial condition would be adversely affected.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements —</font><font style="font-family:inherit;font-size:10pt;"> Except for rules and interpretive releases of the Securities and Exchange Commission (SEC) under authority of federal securities laws and a limited number of grandfathered standards, the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) is the sole source of authoritative GAAP literature recognized by the FASB and applicable to the Company. For any new pronouncements announced, the Company considers whether the new pronouncements could alter previous generally accepted accounting principles and determines whether any new or modified principles will have a material impact on the Company's reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company's financial management and certain standards are under consideration.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recent Accounting Standards Adopted by the Company</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued a new standard to simplify several aspects of the accounting for employee share-based payment transactions, which includes the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The new standard was effective for the Company in the first quarter of fiscal year 2017. Under the previous guidance, excess tax benefits and deficiencies from share-based compensation arrangements were recorded in equity when the awards vested or were settled. The new guidance requires prospective recognition of excess tax benefits and deficiencies in the income statement, resulting in the recognition of excess tax benefits in income tax expense, of </font><font style="font-family:inherit;font-size:10pt;">$3,423</font><font style="font-family:inherit;font-size:10pt;">, rather than in paid-in-capital, for the </font><font style="font-family:inherit;font-size:10pt;">year ended December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, under the new guidance, excess income tax benefits from share-based compensation arrangements are classified as cash flow from operations, rather than as cash flow from financing activities. The Company has elected to apply the cash flow classification guidance prospectively, resulting in an increase to operating cash flow for the </font><font style="font-family:inherit;font-size:10pt;">year ended December 31, </font><font style="font-family:inherit;font-size:10pt;">2017 and the prior year period has not been adjusted.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has also elected to continue to estimate the expected forfeitures rather than electing to account for forfeitures as they occur. Finally, the adoption of the guidance requires excess tax benefits and deficiencies to be prospectively excluded from assumed future proceeds in the calculation of diluted shares, resulting in an increase in diluted weighted average shares outstanding.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accounting Standards Recently Issued But Not Yet Adopted by the Company</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2017, the FASB issued amended authoritative guidance to provide guidance on types of changes to the terms or conditions of share-based payments awards to which an entity would be required to apply modification accounting under ASC 718. This guidance is effective for annual and interim periods beginning after December 15, 2017, which will be the Company's fiscal year 2018, with early adoption permitted in certain cases. The adoption of this standard is not expected to have a material impact on the Company's consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued amended authoritative guidance to clarify the definition of a business and reduce diversity in practice related to the evaluation of whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The new provisions provide the requirements needed for an integrated set of assets and activities (the set) to be a business and also establish a practical way to determine when a set is not a business. The ASU provides a screen to determine when an integrated set of assets and activities is not a business. The more robust framework helps entities to narrow the definition of outputs created by the set and align it with how outputs are described in the new revenue standard. This guidance is effective for annual and interim periods beginning after December 15, 2017, which will be the Company's fiscal year 2018, with early adoption permitted in certain cases. The new guidance is required to be applied on a prospective basis. The effect of the implementation will depend upon the nature of the Company's future acquisitions. </font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued amended authoritative guidance to simplify and reduce the cost and complexity of the goodwill impairment test. The new provisions eliminate step 2 from the goodwill impairment test and shifts the concept of impairment from a measure of loss when comparing the implied fair value of goodwill to its carrying amount to comparing the fair value of a reporting unit with its carrying amount. The Board also eliminated the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment or step 2 of the goodwill impairment test. The new guidance does not amend the optional qualitative assessment of goodwill impairment. This guidance is effective for annual periods beginning after December 15, 2019, which will be the Company's fiscal year 2020, with early adoption permitted. The adoption of this standard is not expected to have a material impact on the Company's consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2016, the FASB issued amended authoritative guidance to require companies to recognize the income tax consequences of an intra-entity transfer of an asset, other than inventory, when the transfer occurs. The amendments will be effective for the Company’s fiscal year beginning January 1, 2018. The new guidance is required to be applied on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. The adoption of this standard is not expected to have a material impact on the Company's consolidated financial statements based on the Company's historical activity. Furthermore, the actual impact of implementation will largely depend on future intra-entity asset transfers, if any.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued amended authoritative guidance to reduce the diversity in practice related to the presentation and classification of certain cash receipts and cash payments in the statement of cash flows. The new provisions target cash flow issues related to (i) debt prepayment or debt extinguishment costs, (ii) settlement of debt instruments with coupon rates that are insignificant relative to effective interest rates, (iii) contingent consideration payments made after a business combination, (iv) proceeds from settlement of insurance claims, (v) proceeds from the settlement of corporate-owned life insurance and bank-owned life insurance policies, (vi) distributions received from equity method investees, (vii) beneficial interests in securitization transactions and (viii) separately identifiable cash flows and application of the predominance principle. This guidance will be effective for fiscal years beginning after December 15, 2017, which will be the Company's fiscal year 2018, with early adoption permitted. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued amended authoritative guidance on accounting for leases. The new provisions require that a lessee of operating leases recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. The lease liability will be equal to the present value of lease payments, with the right-of-use asset based upon the lease liability. The classification criteria for distinguishing between finance (or capital) leases and operating leases are substantially similar to the previous lease guidance, but with no explicit bright lines. As such, operating leases will result in straight-line rent expense similar to current practice. For short term leases (term of 12 months or less), a lessee is permitted to make an accounting election not to recognize lease assets and lease liabilities, which would generally result in lease expense being recognized on a straight-line basis over the lease term. This guidance applies to all entities and is effective for annual periods beginning after December 15, 2018, which will be the Company's fiscal year 2019, with early adoption permitted. The Company is currently evaluating the impact this guidance will have on its consolidated financial statements but expects this adoption will result in a significant increase in the assets and liabilities on its consolidated balance sheets.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, the FASB issued amended authoritative guidance which makes targeted improvements for financial instruments. The new provisions impact certain aspects of recognition, measurement, presentation and disclosure requirements of financial instruments. Specifically, the guidance will (1) require equity investments to be measured at fair value with changes in fair value recognized in net income, (2) simplify the impairment assessment of equity investments without readily determinable fair values, (3) eliminate the requirement to disclose the method and assumptions used to estimate fair value for financial instruments measured at amortized cost, and (4) require separate presentation of financial assets and financial liabilities by measurement category. The guidance is effective for annual and interim periods beginning after December 15, 2017, which will be the Company's fiscal year 2018. Early adoption is not permitted. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued its standard to amend the principal-versus-agent implementation guidance and illustrations in the Board’s new revenue standard, which includes accounting implication related to (1) determining the appropriate unit of account under the revenue standard’s principal-versus-agent guidance and (2) applying the indicators of whether an entity is a principal or an agent in accordance with the revenue standard’s control principle. The guidance will be effective for fiscal years beginning after December 15, 2017, which will be the Company's fiscal year 2018. The guidance has the same effective date as the new revenue standard and the Company is required to adopt the guidance by using the same transition method it would use to adopt the new revenue standard. The Company's evaluation of the adoption method and impact to the consolidated financial statements is performed concurrently with the new revenue standard below.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB and International Accounting Standards Board issued their final standard on revenue from contracts with customers that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers. The new standard supersedes most current revenue recognition guidance, including industry-specific guidance, and may be applied retrospectively to each period presented (full retrospective method) or retrospectively with the cumulative effect recognized in beginning retained earnings as of the date of adoption (modified retrospective method). In July 2015, the FASB formally deferred for one year the effective date of the new revenue standard and decided to permit entities to early adopt the standard. In December 2016, the FASB made certain technical corrections to further clarify the core revenue recognition principles, primarily in response to feedback from several sources, including the FASB/IASB Transition Resource Group. The guidance will be effective for fiscal years beginning after December 15, 2017, which will be the Company's fiscal year 2018. The Company initiated an adoption plan in fiscal year 2015, beginning with preliminary evaluation of the standard, and subsequently performed additional analysis of revenue streams and transactions under the new standard. In particular, the Company performed analysis into the application of the portfolio approach as a practical expedient to group patient contracts with similar characteristics, such that revenue for a given portfolio would not be materially different than if it were evaluated on a contract-by-contract basis. The adoption plan has been completed and the impact to the consolidated financial statements for periods subsequent to adoption is not material. As part of the impact assessment, the Company evaluated any variable consideration, potential constraints on the estimate of variable consideration, and significant financing components, in particular as it related to third party settlements. The Company anticipates that for periods subsequent to adoption, the majority of what is currently classified as bad debt expense under operating expenses will be treated as an implicit price concession factored into net revenue, consistent with the intent of the standard. The new standard also requires enhanced disclosures related to the disaggregation of revenue, information about contract balances, and other disclosures about contracts with customers, including revenue recognition policies to identify performance obligations and significant judgments in measurement and recognition. The Company adopted the new revenue standard as of January 1, 2018 using the modified retrospective method and the adoption did not have a material impact.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Property and Equipment —</font><font style="font-family:inherit;font-size:10pt;"> Property and equipment are initially recorded at their historical cost. Repairs and maintenance are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the depreciable assets (ranging from </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">59 years</font><font style="font-family:inherit;font-size:10pt;">). Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the remaining lease term.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:13px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net consist of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Land</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,081</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,565</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Buildings and improvements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">342,641</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">304,263</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">181,530</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">153,170</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,244</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,931</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">97,221</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80,164</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,460</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,441</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">681,177</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">594,534</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: accumulated depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(144,093</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(110,036</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">537,084</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">484,498</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Segment revenues by major payor source were as follows:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="25" rowspan="1"></td></tr><tr><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="22" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Transitional and Skilled Services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assisted and Independent Living Services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Home Health and Hospice Services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">All Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue %</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicaid</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">603,104</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,469</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,230</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">644,803</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicare</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">417,870</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98,014</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">515,884</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicaid-skilled</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">102,875</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">102,875</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subtotal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,123,849</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,469</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109,244</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,263,562</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Managed care</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">281,563</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,823</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">303,386</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Private and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">139,798</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">106,177</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,336</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,058</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">(1)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">282,369</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenue</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,545,210</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">136,646</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">142,403</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,058</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,849,317</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td colspan="25" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1) Private and other payors also includes revenue from all payors generated in other ancillary services for the year ended December 31, 2017.</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25" rowspan="1"></td></tr><tr><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="22" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Transitional and Skilled Services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assisted and Independent Living Services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Home Health and Hospice Services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">All Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue %</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicaid</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">521,063</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,397</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,498</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">557,958</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicare</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">396,519</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80,500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">477,019</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicaid-skilled</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87,517</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87,517</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subtotal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,005,099</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,397</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90,998</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,122,494</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Managed care</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">247,844</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,664</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">265,508</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Private and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">121,860</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">97,239</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,151</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,612</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">(1)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">266,862</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenue</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,374,803</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">123,636</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">115,813</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,612</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,654,864</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td colspan="25" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1) Private and other payors also includes revenue from all payors generated in other ancillary services and urgent care centers for the year ended December 31, 2016.</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">     </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="25" rowspan="1"></td></tr><tr><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="22" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Transitional and Skilled Services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assisted and Independent Living Services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Home Health and Hospice Services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">All Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue %</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicaid</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">430,368</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,642</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,946</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">458,956</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicare</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">332,429</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63,074</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">395,503</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicaid-skilled</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,905</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,905</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subtotal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">834,702</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,642</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,020</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">926,364</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Managed care</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">194,743</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,027</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">206,770</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Private and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">96,943</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68,487</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,309</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,953</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">(1)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">208,692</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenue</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,126,388</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88,129</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90,356</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,953</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,341,826</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td colspan="25" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1) Private and other payors also includes revenue from all payors generated in other ancillary services and urgent care centers for the year ended December 31, 2015.</font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other accrued liabilities consist of the following:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Quality assurance fee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,864</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,604</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Refunds payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,661</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,368</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,066</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,994</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash held in trust for patients</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,609</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,373</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Resident deposits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,574</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,099</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividends payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,328</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,186</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property taxes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,088</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,130</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,182</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operational closure liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">910</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,972</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,715</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,855</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other accrued liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63,815</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58,763</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other indefinite-lived intangible assets consists of the following:</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trade name</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,181</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,146</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicare and Medicaid licenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,068</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,440</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,249</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,586</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.22027290448344%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Land</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,732</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,054</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,811</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Building and improvements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,735</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,057</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73,502</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equipment, furniture, and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,382</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,265</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,612</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assembled occupancy</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">762</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,299</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">895</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Definite-lived intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">363</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">360</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,962</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,343</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,617</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Favorable leases</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">393</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,901</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other indefinite-lived intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,018</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,741</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,285</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets acquired, net of liabilities assumed</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">    Total acquisitions</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89,683</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,521</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119,965</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table represents the employee stock option activity during the </font><font style="font-family:inherit;font-size:10pt;">years ended December 31, 2017, 2016 and 2015</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number of</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Options</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number of</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Options Vested</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Exercise Price</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">of Options</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Vested</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">January 1, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,532</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.51</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,218</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.70</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">637</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23.27</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(233</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(488</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.20</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,448</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.36</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,526</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">497</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19.43</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(127</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.46</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(642</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.47</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,176</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,704</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">481</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20.31</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(178</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.82</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(740</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.93</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,739</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.08</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,776</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.07</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The provision for income taxes on continuing operations for the years ended December 31, 2017, 2016 and 2015 is summarized as follows: </font></div><div style="line-height:120%;text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;"> </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:68%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,141</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,043</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,149</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,975</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,183</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,761</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,116</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,226</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,910</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,428</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,034</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,026</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">986</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,217</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(754</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,414</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,251</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,272</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adjustment to deferred taxes for tax rate change</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,915</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,445</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,975</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,182</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term debt consists of the following:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Term loan with SunTrust, interest payable quarterly</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">140,625</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">148,125</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Credit facility with SunTrust</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">122,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mortgage loans and promissory note, principal and interest payable monthly, interest at fixed rate</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">125,394</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,032</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">316,019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">284,157</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: current maturities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,939</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,129</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: debt issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,090</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(542</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">302,990</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">275,486</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's deferred tax assets and liabilities as of December 31, 2017 and 2016 are summarized below. The deferred taxes in 2017 reflect the federal tax rate of 21.0%, whereas 2016 reflect a federal tax rate of 35.0%. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:79%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax assets (liabilities):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,732</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allowance for doubtful accounts</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,090</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,956</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tax credits</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,334</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,461</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Insurance</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,135</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,333</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,059</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,482</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(530</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,529</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,482</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State taxes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(911</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,248</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,643</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,625</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,743</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred tax liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(22,784</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25,409</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net deferred tax assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,745</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,073</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,833</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,843</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,917</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: net income attributable to noncontrolling interests</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">358</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,853</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">485</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income attributable to The Ensign Group, Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,475</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,990</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,432</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average shares outstanding for basic net income per share</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,932</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,555</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,316</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net income per common share attributable to The Ensign Group, Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.79</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.99</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.10</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A reconciliation of the numerator and denominator used in the calculation of diluted net income per common share follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,833</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,843</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,917</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: net income attributable to noncontrolling interests</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">358</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,853</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">485</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income attributable to The Ensign Group, Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,475</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,990</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,432</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,932</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,555</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,316</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Plus: incremental shares from assumed conversion</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> (1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,897</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,578</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,894</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adjusted weighted average common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,829</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,133</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,210</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted net income per common share attributable to The Ensign Group, Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.77</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.96</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.06</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;">(1) Options outstanding which are anti-dilutive and therefore not factored into the weighted average common shares amount above were </font><font style="font-family:inherit;font-size:9pt;">1,252</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:9pt;">838</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:9pt;">258</font><font style="font-family:inherit;font-size:9pt;"> for the </font><font style="font-family:inherit;font-size:9pt;">years ended December 31, 2017, 2016 and 2015</font><font style="font-family:inherit;font-size:9pt;">, respectively.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A reconciliation of the federal statutory rate to the effective tax rate for income from continuing operations for the years ended December 31, 2017, 2016 and 2015, respectively, is comprised as follows: </font></div><div style="line-height:120%;text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;"> </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:68%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax expense at statutory rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> %</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> %</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> %</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State income taxes - net of federal benefit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-deductible expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revaluation of deferred</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other adjustments</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total income tax provision</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> %</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> %</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> %</font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share-based compensation expense recognized for the Company's equity incentive plans for the </font><font style="font-family:inherit;font-size:10pt;">years ended December 31, 2017, 2016 and 2015</font><font style="font-family:inherit;font-size:10pt;"> was as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share-based compensation expense related to stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,773</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,793</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,164</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share-based compensation expense related to restricted stock awards</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,322</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,371</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,931</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share-based compensation expense related to stock options and restricted stock awards to non-employee directors</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,236</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">612</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">582</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,331</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,776</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,677</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="27" rowspan="1"></td></tr><tr><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td rowspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Life (Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross Carrying Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross Carrying Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intangible Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lease acquisition costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24.8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">483</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(99</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">384</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">483</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(78</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">405</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Favorable leases </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,116</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,568</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,548</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,116</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,589</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,527</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assembled occupancy</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,659</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,631</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,897</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,897</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Facility trade name</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">733</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(293</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">440</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">733</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(269</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">464</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer relationships</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18.7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,933</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,530</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,403</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,933</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,253</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,680</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,924</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,121</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,803</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,162</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,086</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,076</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Future minimum lease payments for all leases as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> are as follows: </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:88%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">135,841</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">135,395</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">135,149</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">134,942</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133,446</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,080,348</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,755,121</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table represents activity in goodwill by segment as of and for the </font><font style="font-family:inherit;font-size:10pt;">year ended December 31, </font><font style="font-family:inherit;font-size:10pt;">: </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Goodwill</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Transitional and Skilled Services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assisted and Independent Living Services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Home Health and Hospice Services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">All Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">January 1, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,221</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,756</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,929</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,363</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,269</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,782</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,173</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,662</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,617</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,221</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,538</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,102</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,025</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,886</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: Dispositions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,103</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,103</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchase price adjustment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,415</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,799</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,129</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,343</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,636</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,538</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,901</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,025</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67,100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,850</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">420</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,421</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,271</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,962</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,486</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,958</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,322</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,296</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81,062</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of the status of the Company's non-vested restricted stock awards as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and changes during the </font><font style="font-family:inherit;font-size:10pt;">years ended December 31, 2017, 2016 and 2015</font><font style="font-family:inherit;font-size:10pt;"> is presented below:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Non-Vested Restricted Awards</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Grant Date Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nonvested at January 1, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">366</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">323</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22.99</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(234</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17.36</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(30</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.81</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nonvested at December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">425</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19.79</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">299</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20.55</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(279</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19.58</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20.85</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nonvested at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">429</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">173</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20.21</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(195</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19.79</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(24</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20.34</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nonvested at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">383</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:13px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted and other assets consist of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Debt issuance costs, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,799</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,611</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term insurance losses recoverable asset</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,394</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,104</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deposits with landlords</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,981</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,526</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Capital improvement reserves with landlords and lenders</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,327</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">673</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Note receivable from sale of urgent care centers</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">700</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted and other assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,501</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,614</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue for the </font><font style="font-family:inherit;font-size:10pt;">years ended December 31, 2017, 2016 and 2015</font><font style="font-family:inherit;font-size:10pt;"> is summarized in the following tables:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="20" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">% of</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">% of</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">% of</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicaid</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">644,803</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">557,958</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">458,956</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicare</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">515,884</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">477,019</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">395,503</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicaid — skilled</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">102,875</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87,517</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,905</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Medicaid and Medicare</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,263,562</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,122,494</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">926,364</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Managed care</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">303,386</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">265,508</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">206,770</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Private and other payors</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">282,369</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">266,862</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">208,692</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,849,317</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,654,864</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,341,826</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1) Private and other payors also includes revenue from all payors generated in other ancillary services for the years ended December 31, 2017, 2016 and 2015 and urgent care centers for the years ended December 31, 2016 and 2015.</font></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth selected financial data consolidated by business segment:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25" rowspan="1"></td></tr><tr><td style="width:26%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Transitional and Skilled Services</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assisted and Independent Living Services</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Home Health and Hospice Services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">All Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Elimination</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from external customers</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,545,210</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">136,646</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">142,403</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,058</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,849,317</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intersegment revenue </font><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,023</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,035</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,058</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenue </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,548,233</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">136,646</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">142,403</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,093</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,058</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,849,317</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Segment income (loss) </font><font style="font-family:inherit;font-size:8pt;">(2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">140,272</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,736</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,717</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(95,440</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81,285</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense, net of interest income</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,007</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income before provision for income taxes </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69,278</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation and amortization</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,928</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,334</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">945</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,265</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,472</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1) Intersegment revenue represents services provided at the Company's operating subsidiaries to the Company's other business lines. </font></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(2) Segment income (loss) includes depreciation and amortization expense and excludes general and administrative expense and interest expense for transitional and skilled services, assisted and independent living services and home health and hospice businesses. General and administrative expense is included in the "All Other" category. </font></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(3) The Company's campuses represent facilities that offer skilled nursing, assisted and/or independent living services. Revenue and expenses related to skilled nursing, assisted and independent living services have been allocated and recorded in the respective reportable segment. </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="25" rowspan="1"></td></tr><tr><td style="width:26%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Transitional and Skilled Services</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assisted and Independent Living Services</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Home Health and Hospice Services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">All Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Elimination</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from external customers</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,374,803</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">123,636</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">115,813</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,612</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,654,864</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intersegment revenue </font><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,929</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,184</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,113</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenue </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,377,732</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">123,636</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">115,813</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,796</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,113</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,654,864</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Segment income (loss) </font><font style="font-family:inherit;font-size:8pt;">(2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118,118</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,701</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,571</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(54,543</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91,847</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense, net of interest income</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,029</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income before provision for income taxes </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85,818</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation and amortization</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,298</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,157</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">924</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,303</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,682</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1) Intersegment revenue represents services provided at the Company's operating subsidiaries to the Company's other business lines. </font></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(2) Segment income (loss) includes depreciation and amortization expense and excludes general and administrative expense and interest expense for transitional and skilled services, assisted and independent living services and home health and hospice businesses. General and administrative expense is included in the "All Other" category. </font></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(3) The Company's campuses represent facilities that offer skilled nursing, assisted and/or independent living services. Revenue and expenses related to skilled nursing, assisted and independent living services have been allocated and recorded in the respective reportable segment. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25" rowspan="1"></td></tr><tr><td style="width:26%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Transitional and Skilled Services</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assisted and Independent Living Services</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Home Health and Hospice Services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">All Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Elimination</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from external customers</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,126,388</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88,129</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90,356</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,953</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,341,826</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intersegment revenue </font><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,447</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">881</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,328</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenue </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,128,835</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88,129</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90,356</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,834</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,328</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,341,826</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Segment income (loss) </font><font style="font-family:inherit;font-size:8pt;">(2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">136,744</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,463</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,584</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(68,709</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93,082</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense, net of interest income</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,983</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income before provision for income taxes </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91,099</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation and amortization</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,008</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,338</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">980</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,785</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,111</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1) Intersegment revenue represents services provided at the Company's operating subsidiaries to the Company's other business lines. </font></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(2) Segment income (loss) includes depreciation and amortization expense and excludes general and administrative expense and interest expense for transitional and skilled services, assisted and independent living services and home health and hospice businesses. General and administrative expense is included in the "All Other" category. </font></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(3) The Company's campuses represent facilities that offer skilled nursing, assisted and/or independent living services. Revenue and expenses related to skilled nursing, assisted and independent living services have been allocated and recorded in the respective reportable segment. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following summary information reflects stock options outstanding, vested and related details as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:39%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Stock Options Vested</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Stock Options Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Black-Scholes Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Remaining Contractual Life (Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Vested and Exercisable</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year of Grant</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2008</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.56</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.06</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">185</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">292</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">185</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2009</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.06</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.56</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">420</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">907</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">420</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2010</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.96</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">281</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2011</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.90</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.99</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">134</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">454</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">134</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2012</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.56</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.96</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">435</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,603</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">435</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.98</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.49</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">522</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,539</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">390</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18.94</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,458</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,272</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">789</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21.47</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25.24</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">549</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">219</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18.79</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19.89</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">450</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,140</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18.64</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22.90</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">470</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,291</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,739</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,779</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,776</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company used the following assumptions for stock options granted during the </font><font style="font-family:inherit;font-size:10pt;">years ended December 31, 2017, 2016 and 2015</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grant Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Options Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Risk-Free Rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Expected Life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Dividend Yield</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">481</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.0%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.2 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35.2%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.8%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">497</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.4%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.3 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37.8%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.8%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">637</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.7%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.5 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39.5%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.6%</font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated amortization expense for each of the years ending December 31 is as follows:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:89%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,329</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,301</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,593</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,497</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,471</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,612</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,803</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">BUSINESS SEGMENTS</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has</font><font style="font-family:inherit;font-size:10pt;color:#ff0000;"> </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;color:#ff0000;"> </font><font style="font-family:inherit;font-size:10pt;">reportable operating segments: (1) transitional and skilled services, which includes the operation of skilled nursing facilities; (2) assisted and independent living services, which includes the operation of assisted and independent living facilities; and (3) home health and hospice services, which includes the Company's home health, home care and hospice businesses. The Company's Chief Executive Officer, who is its chief operating decision maker, or CODM, reviews financial information at the operating segment level.</font></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company also reports an “all other” category that includes results from its mobile diagnostics and other ancillary operations for the </font><font style="font-family:inherit;font-size:10pt;">years ended December 31, 2017, 2016 and 2015</font><font style="font-family:inherit;font-size:10pt;"> and urgent care centers for the years ended December 31, 2016 and 2015. The Company completed the sale of its urgent care centers in 2016 and recognized a pretax gain of </font><font style="font-family:inherit;font-size:10pt;">$41,492</font><font style="font-family:inherit;font-size:10pt;">. These operations are neither significant individually nor in aggregate and therefore do not constitute a reportable segment. The reporting segments are business units that offer different services and are managed separately to provide greater visibility into those operations. </font></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, transitional and skilled services included </font><font style="font-family:inherit;font-size:10pt;">160</font><font style="font-family:inherit;font-size:10pt;"> wholly-owned affiliated skilled nursing facilities and </font><font style="font-family:inherit;font-size:10pt;">21</font><font style="font-family:inherit;font-size:10pt;"> campuses that provide skilled nursing and rehabilitative care services. The Company provided room and board and social services through </font><font style="font-family:inherit;font-size:10pt;">49</font><font style="font-family:inherit;font-size:10pt;"> wholly-owned affiliated assisted and independent living facilities and </font><font style="font-family:inherit;font-size:10pt;">21</font><font style="font-family:inherit;font-size:10pt;"> campuses. Home health, home care and hospice services were provided to patients through </font><font style="font-family:inherit;font-size:10pt;">46</font><font style="font-family:inherit;font-size:10pt;"> affiliated agencies. As of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company held majority membership interests in other ancillary operations, which operating results are included in the "all other" category. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluates performance and allocates capital resources to each segment based on an operating model that is designed to maximize the quality of care provided and profitability. General and administrative expenses are not allocated to any segment for purposes of determining segment profit or loss, and are included in the "all other" category in the selected segment financial data that follows. The accounting policies of the reporting segments are the same as those described in Note 2</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">, Summary of Significant Accounting Policies. </font><font style="font-family:inherit;font-size:10pt;">The Company's CODM does not review assets by segment in his resource allocation and therefore assets by segment are not disclosed below.</font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Segment revenues by major payor source were as follows:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="25" rowspan="1"></td></tr><tr><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="22" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Transitional and Skilled Services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assisted and Independent Living Services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Home Health and Hospice Services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">All Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue %</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicaid</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">603,104</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,469</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,230</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">644,803</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicare</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">417,870</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98,014</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">515,884</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicaid-skilled</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">102,875</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">102,875</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subtotal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,123,849</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,469</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109,244</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,263,562</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Managed care</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">281,563</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,823</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">303,386</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Private and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">139,798</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">106,177</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,336</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,058</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">(1)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">282,369</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenue</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,545,210</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">136,646</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">142,403</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,058</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,849,317</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td colspan="25" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1) Private and other payors also includes revenue from all payors generated in other ancillary services for the year ended December 31, 2017.</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25" rowspan="1"></td></tr><tr><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="22" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Transitional and Skilled Services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assisted and Independent Living Services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Home Health and Hospice Services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">All Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue %</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicaid</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">521,063</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,397</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,498</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">557,958</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicare</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">396,519</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80,500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">477,019</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicaid-skilled</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87,517</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87,517</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subtotal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,005,099</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,397</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90,998</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,122,494</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Managed care</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">247,844</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,664</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">265,508</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Private and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">121,860</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">97,239</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,151</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,612</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">(1)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">266,862</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenue</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,374,803</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">123,636</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">115,813</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,612</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,654,864</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td colspan="25" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1) Private and other payors also includes revenue from all payors generated in other ancillary services and urgent care centers for the year ended December 31, 2016.</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">     </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="25" rowspan="1"></td></tr><tr><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="22" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Transitional and Skilled Services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assisted and Independent Living Services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Home Health and Hospice Services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">All Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue %</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicaid</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">430,368</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,642</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,946</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">458,956</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicare</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">332,429</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63,074</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">395,503</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicaid-skilled</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,905</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,905</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subtotal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">834,702</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,642</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,020</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">926,364</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Managed care</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">194,743</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,027</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">206,770</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Private and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">96,943</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68,487</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,309</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,953</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">(1)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">208,692</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenue</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,126,388</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88,129</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90,356</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,953</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,341,826</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td colspan="25" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1) Private and other payors also includes revenue from all payors generated in other ancillary services and urgent care centers for the year ended December 31, 2015.</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth selected financial data consolidated by business segment:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25" rowspan="1"></td></tr><tr><td style="width:26%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Transitional and Skilled Services</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assisted and Independent Living Services</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Home Health and Hospice Services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">All Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Elimination</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from external customers</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,545,210</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">136,646</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">142,403</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,058</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,849,317</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intersegment revenue </font><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,023</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,035</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,058</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenue </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,548,233</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">136,646</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">142,403</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,093</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,058</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,849,317</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Segment income (loss) </font><font style="font-family:inherit;font-size:8pt;">(2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">140,272</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,736</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,717</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(95,440</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81,285</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense, net of interest income</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,007</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income before provision for income taxes </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69,278</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation and amortization</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,928</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,334</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">945</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,265</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,472</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1) Intersegment revenue represents services provided at the Company's operating subsidiaries to the Company's other business lines. </font></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(2) Segment income (loss) includes depreciation and amortization expense and excludes general and administrative expense and interest expense for transitional and skilled services, assisted and independent living services and home health and hospice businesses. General and administrative expense is included in the "All Other" category. </font></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(3) The Company's campuses represent facilities that offer skilled nursing, assisted and/or independent living services. Revenue and expenses related to skilled nursing, assisted and independent living services have been allocated and recorded in the respective reportable segment. </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="25" rowspan="1"></td></tr><tr><td style="width:26%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Transitional and Skilled Services</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assisted and Independent Living Services</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Home Health and Hospice Services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">All Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Elimination</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from external customers</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,374,803</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">123,636</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">115,813</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,612</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,654,864</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intersegment revenue </font><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,929</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,184</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,113</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenue </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,377,732</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">123,636</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">115,813</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,796</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,113</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,654,864</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Segment income (loss) </font><font style="font-family:inherit;font-size:8pt;">(2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118,118</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,701</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,571</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(54,543</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91,847</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense, net of interest income</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,029</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income before provision for income taxes </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85,818</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation and amortization</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,298</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,157</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">924</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,303</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,682</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1) Intersegment revenue represents services provided at the Company's operating subsidiaries to the Company's other business lines. </font></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(2) Segment income (loss) includes depreciation and amortization expense and excludes general and administrative expense and interest expense for transitional and skilled services, assisted and independent living services and home health and hospice businesses. General and administrative expense is included in the "All Other" category. </font></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(3) The Company's campuses represent facilities that offer skilled nursing, assisted and/or independent living services. Revenue and expenses related to skilled nursing, assisted and independent living services have been allocated and recorded in the respective reportable segment. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25" rowspan="1"></td></tr><tr><td style="width:26%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Transitional and Skilled Services</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assisted and Independent Living Services</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Home Health and Hospice Services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">All Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Elimination</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from external customers</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,126,388</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88,129</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90,356</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,953</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,341,826</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intersegment revenue </font><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,447</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">881</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,328</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenue </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,128,835</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88,129</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90,356</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,834</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,328</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,341,826</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Segment income (loss) </font><font style="font-family:inherit;font-size:8pt;">(2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">136,744</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,463</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,584</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(68,709</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93,082</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense, net of interest income</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,983</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income before provision for income taxes </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91,099</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation and amortization</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,008</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,338</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">980</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,785</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,111</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1) Intersegment revenue represents services provided at the Company's operating subsidiaries to the Company's other business lines. </font></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(2) Segment income (loss) includes depreciation and amortization expense and excludes general and administrative expense and interest expense for transitional and skilled services, assisted and independent living services and home health and hospice businesses. General and administrative expense is included in the "All Other" category. </font></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(3) The Company's campuses represent facilities that offer skilled nursing, assisted and/or independent living services. Revenue and expenses related to skilled nursing, assisted and independent living services have been allocated and recorded in the respective reportable segment. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's transitional and skilled services segment income for the </font><font style="font-family:inherit;font-size:10pt;">years ended December 31, 2017 and 2016</font><font style="font-family:inherit;font-size:10pt;"> included continued obligations under the lease related to closed operations, lease termination costs and related closing expenses of </font><font style="font-family:inherit;font-size:10pt;">$4,017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$7,935</font><font style="font-family:inherit;font-size:10pt;">, respectively. These amounts included the present value of future rental payments of approximately </font><font style="font-family:inherit;font-size:10pt;">$2,715</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$6,512</font><font style="font-family:inherit;font-size:10pt;"> and long-lived assets impairment of </font><font style="font-family:inherit;font-size:10pt;">$111</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$137</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">years ended December 31, 2017 and 2016</font><font style="font-family:inherit;font-size:10pt;">, respectively. These costs were not incurred for the year ended December 31, 2015. See Note 17, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;"> for further detail. Included in the </font><font style="font-family:inherit;font-size:10pt;">year ended December 31, </font><font style="font-family:inherit;font-size:10pt;">2017 is the loss recovery of </font><font style="font-family:inherit;font-size:10pt;">$1,286</font><font style="font-family:inherit;font-size:10pt;"> related to a facility that was closed in the prior year.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the </font><font style="font-family:inherit;font-size:10pt;">years ended December 31, 2017, 2016 and 2015</font><font style="font-family:inherit;font-size:10pt;">, the following represents the exercise price and fair value displayed at grant date for stock option grants:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grant Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Fair Value of Options</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">481</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20.31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">497</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19.43</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.00</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">637</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23.27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.08</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Share-Based Compensation — </font><font style="font-family:inherit;font-size:10pt;">The Company measures and recognizes compensation expense for all share-based payment awards made to employees and directors including employee stock options based on estimated fair values, ratably over the requisite service period of the award. Net income has been reduced as a result of the recognition of the fair value of all stock options and restricted stock awards issued, the amount of which is contingent upon the number of future grants and other variables.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Accounts Receivable and Allowance for Doubtful Accounts —</font><font style="font-family:inherit;font-size:10pt;"> Accounts receivable consist primarily of amounts due from Medicare and Medicaid programs, other government programs, managed care health plans and private payor sources. Estimated provisions for doubtful accounts are recorded to the extent it is probable that a portion or all of a particular account will not be collected.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In evaluating the collectability of accounts receivable, the Company considers a number of factors, including the age of the accounts, changes in collection patterns, the composition of patient accounts by payor type and the status of ongoing disputes with third-party payors. On an annual basis, the historical collection percentages are reviewed by payor and by state and are updated to reflect the recent collection experience of the Company. In order to determine the appropriate reserve rate percentages which ultimately establish the allowance, the Company analyzes historical cash collection patterns by payor and by state. The percentages applied to the aged receivable balances are based on the Company’s historical experience and time limits, if any, for managed care, Medicare, Medicaid and other payors. The Company periodically refines its estimates of the allowance for doubtful accounts based on experience with the estimation process and changes in circumstances.</font></div></div>

(1) Options outstanding which are anti-dilutive and therefore not factored into the weighted average common shares amount above were 1,252, 838 and 258 for the years ended December 31, 2017, 2016 and 2015, respectively. (1) Private and other payors also includes revenue from all payors generated in other ancillary services for the years ended December 31, 2017, 2016 and 2015 and urgent care centers for the years ended December 31, 2016 and 2015.

EX-101.SCH 11 ensg-20171231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2128100 - Disclosure - Acquisitions link:presentationLink link:calculationLink link:definitionLink 2428402 - Disclosure - Acquisitions Acquisition Summary (Details) link:presentationLink link:calculationLink link:definitionLink 2428404 - Disclosure - Acquisitions (Details) link:presentationLink link:calculationLink link:definitionLink 2428403 - Disclosure - Acquisitions Prior Period Acquisitions (Details) link:presentationLink link:calculationLink link:definitionLink 2328301 - Disclosure - Acquisitions (Tables) link:presentationLink link:calculationLink link:definitionLink 2125100 - Disclosure - Business Segments link:presentationLink link:calculationLink link:definitionLink 2425402 - Disclosure - Business Segments (Details) link:presentationLink link:calculationLink link:definitionLink 2425403 - Disclosure - Business Segments Revenue by Segment (Details) link:presentationLink link:calculationLink link:definitionLink 2425404 - Disclosure - Business Segments Schedule of Segment Reporting Information, by Segment (Details) link:presentationLink link:calculationLink link:definitionLink 2325301 - Disclosure - Business Segments (Tables) link:presentationLink link:calculationLink link:definitionLink 2150100 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2450406 - Disclosure - Commitments and Contingencies Cash in Excess of FDIC Limits (Details) link:presentationLink link:calculationLink link:definitionLink 2450405 - Disclosure - Commitments and Contingencies Concentrations (Details) link:presentationLink link:calculationLink link:definitionLink 2450402 - Disclosure - Commitments and Contingencies General Liability Claim (Details) link:presentationLink link:calculationLink link:definitionLink 2450401 - Disclosure - Commitments and Contingencies Litigation (Details) link:presentationLink link:calculationLink link:definitionLink 2450403 - Disclosure - Commitments and Contingencies Medicare Revenue Recoupments (Details) link:presentationLink link:calculationLink link:definitionLink 2450404 - Disclosure - Commitments and Contingencies Other Matters (Details) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Common Stock link:presentationLink link:calculationLink link:definitionLink 2406401 - Disclosure - Common Stock (Details) link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - Computation of Net Income Per Common Share link:presentationLink link:calculationLink link:definitionLink 2413403 - Disclosure - Computation of Net Income Per Common Share Antidilutive Shares (Details) link:presentationLink link:calculationLink link:definitionLink 2413402 - Disclosure - Computation of Net Income Per Common Share (Details) link:presentationLink link:calculationLink link:definitionLink 2313301 - Disclosure - Computation of Net Income Per Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1001001 - Statement - Consolidated Balance Sheets Balance Sheet (Paranthetical) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Consolidated Statement of Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 1003001 - Statement - Consolidated Statement of Comprehensive Income Comprehensive Income Paranthetical link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - Consolidated Statement of Stockholders' Equity Statement link:presentationLink link:calculationLink link:definitionLink 1006000 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Consolidated Statements of Income link:presentationLink link:calculationLink link:definitionLink 2146100 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 2446403 - Disclosure - Debt Additional Disclosures (Details) link:presentationLink link:calculationLink link:definitionLink 2446402 - Disclosure - Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2446405 - Disclosure - Debt Future Principal Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 2446404 - Disclosure - Debt Other Additional Disclosures (Details) link:presentationLink link:calculationLink link:definitionLink 2346301 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 2152100 - Disclosure - Defined Contribution Plan link:presentationLink link:calculationLink link:definitionLink 2452402 - Disclosure - Defined Contribution Plan (Details) link:presentationLink link:calculationLink link:definitionLink 2352301 - Disclosure - Defined Contribution Plan (Tables) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - DEI Info Cover Page Document link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Description of Business link:presentationLink link:calculationLink link:definitionLink 2401401 - Disclosure - Description of Business (Details) link:presentationLink link:calculationLink link:definitionLink 2151100 - Disclosure - Divestitures link:presentationLink link:calculationLink link:definitionLink 2451402 - Disclosure - Divestitures (Details) link:presentationLink link:calculationLink link:definitionLink 2351301 - Disclosure - Divestitures (Tables) link:presentationLink link:calculationLink link:definitionLink 2116100 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2416402 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 2416403 - Disclosure - Fair Value Measurements Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2316301 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2140100 - Disclosure - Goodwill and Other Indefinite-Lived Intangible Assets link:presentationLink link:calculationLink link:definitionLink 2440402 - Disclosure - Goodwill and Other Indefinite-Lived Intangible Assets Goodwill Rollforward (Details) link:presentationLink link:calculationLink link:definitionLink 2440403 - Disclosure - Goodwill and Other Indefinite-Lived Intangible Assets Indefinite-lived intangble assets (Details) link:presentationLink link:calculationLink link:definitionLink 2340301 - Disclosure - Goodwill and Other Indefinite-Lived Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 2145100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2445404 - Disclosure - Income Taxes Deferred (Details) link:presentationLink link:calculationLink link:definitionLink 2445402 - Disclosure - Income Taxes Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2445405 - Disclosure - Income Taxes Other Disclosures (Details) link:presentationLink link:calculationLink link:definitionLink 2445403 - Disclosure - Income Taxes Rate Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 2345301 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 2137100 - Disclosure - Intangible Assets - Net link:presentationLink link:calculationLink link:definitionLink 2437403 - Disclosure - Intangible Assets - Net Additional Disclosures (Details) link:presentationLink link:calculationLink link:definitionLink 2437402 - Disclosure - Intangible Assets - Net (Details) link:presentationLink link:calculationLink link:definitionLink 2437404 - Disclosure - Intangible Assets - Net Future Amortization (Details) link:presentationLink link:calculationLink link:definitionLink 2337301 - Disclosure - Intangible Assets - Net (Tables) link:presentationLink link:calculationLink link:definitionLink 2148100 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 2448403 - Disclosure - Leases Additional Disclosures (Details) link:presentationLink link:calculationLink link:definitionLink 2448402 - Disclosure - Leases (Details) link:presentationLink link:calculationLink link:definitionLink 2448405 - Disclosure - Leases Future minimum lease payments (Details) link:presentationLink link:calculationLink link:definitionLink 2448404 - Disclosure - Leases Sale Leaseback Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 2348301 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 2147100 - Disclosure - Options and Awards link:presentationLink link:calculationLink link:definitionLink 2447409 - Disclosure - Options and Awards Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2447404 - Disclosure - Options and Awards Exercise Price and Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 2447410 - Disclosure - Options and Awards Intrinsic Values (Details) link:presentationLink link:calculationLink link:definitionLink 2447402 - Disclosure - Options and Awards Lead Paragraphs (Details) link:presentationLink link:calculationLink link:definitionLink 2447406 - Disclosure - Options and Awards Options Outstanding by Exercise Price (Details) link:presentationLink link:calculationLink link:definitionLink 2447405 - Disclosure - Options and Awards Options Outstanding Rollforward (Details) link:presentationLink link:calculationLink link:definitionLink 2447408 - Disclosure - Options and Awards Restricted Award Rollforward (Details) link:presentationLink link:calculationLink link:definitionLink 2447407 - Disclosure - Options and Awards Restricted Awards Granted (Details) link:presentationLink link:calculationLink link:definitionLink 2447411 - Disclosure - Options and Awards Subsidiary Equity Plan (Details) link:presentationLink link:calculationLink link:definitionLink 2347301 - Disclosure - Options and Awards (Tables) link:presentationLink link:calculationLink link:definitionLink 2447403 - Disclosure - Options and Awards Valuation Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 2142100 - Disclosure - Other Accrued Liabilities link:presentationLink link:calculationLink link:definitionLink 2442402 - Disclosure - Other Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2342301 - Disclosure - Other Accrued Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 2134100 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 2434403 - Disclosure - Property and Equipment Additional Disclosures (Details) link:presentationLink link:calculationLink link:definitionLink 2434402 - Disclosure - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 2334301 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 2141100 - Disclosure - Restricted and Other Assets link:presentationLink link:calculationLink link:definitionLink 2441402 - Disclosure - Restricted and Other Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2341301 - Disclosure - Restricted and Other Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 2119100 - Disclosure - Revenue and Accounts Receivable link:presentationLink link:calculationLink link:definitionLink 2419403 - Disclosure - Revenue and Accounts Receivable Accounts Receivable (Details) link:presentationLink link:calculationLink link:definitionLink 2419402 - Disclosure - Revenue and Accounts Receivable Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 2319301 - Disclosure - Revenue and Accounts Receivable (Tables) link:presentationLink link:calculationLink link:definitionLink 2149100 - Disclosure - Self-Insurance Reserves link:presentationLink link:calculationLink link:definitionLink 2449402 - Disclosure - Self-Insurance Reserves (Details) link:presentationLink link:calculationLink link:definitionLink 2349301 - Disclosure - Self-Insurance Reserves (Tables) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2404412 - Disclosure - Significant Accounting Policies Accumulated Other Comprehensive Income (Details) link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - Significant Accounting Policies Divestiture (Details) link:presentationLink link:calculationLink link:definitionLink 2404405 - Disclosure - Significant Accounting Policies Impairment (Details) link:presentationLink link:calculationLink link:definitionLink 2404413 - Disclosure - Significant Accounting Policies Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2404406 - Disclosure - Significant Accounting Policies Intangible Assets and Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 2204201 - Disclosure - Significant Accounting Policies Level 2 (Policies) link:presentationLink link:calculationLink link:definitionLink 2404404 - Disclosure - Significant Accounting Policies Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 2404414 - Disclosure - Significant Accounting Policies Recent Accounting Standards Adopted (Details) link:presentationLink link:calculationLink link:definitionLink 2404403 - Disclosure - Significant Accounting Policies Revenue and Accounts Receivable (Details) link:presentationLink link:calculationLink link:definitionLink 2404408 - Disclosure - Significant Accounting Policies Self-Insurance General and Professional (Details) link:presentationLink link:calculationLink link:definitionLink 2404411 - Disclosure - Significant Accounting Policies Self-Insurance Health Insurance (Details) link:presentationLink link:calculationLink link:definitionLink 2404407 - Disclosure - Significant Accounting Policies Self Insurance Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2404410 - Disclosure - Significant Accounting Policies Self Insurance Recoveries (Details) link:presentationLink link:calculationLink link:definitionLink 2404409 - Disclosure - Significant Accounting Policies Self-Insurance Workers' Compensation (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 12 ensg-20171231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 13 ensg-20171231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 14 ensg-20171231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Self-Insurance Reserves [Abstract] Self-Insurance Reserves [Abstract] Schedule of Self-Insurance Reserves [Table] Schedule of Self-Insurance Reserves [Table] Schedule of Self-Insurance Reserves [Table] Insurance Type and Tier Identifier [Axis] Insurance Type and Tier Identifier [Axis] Type and Tier Identifier [Domain] Type and Tier Identifier [Domain] Professional Malpractice Liability Insurance [Member] Professional Malpractice Liability Insurance [Member] Workers' Compensation [Member] Workers' Compensation [Member] Workers' Compensation [Member] Health Insurance Product Line [Member] Health Insurance Product Line [Member] Schedule of Self-Insurance Reserves [Line Items] Schedule of Self-Insurance Reserves [Line Items] [Line Items] for Schedule of Self-Insurance Reserves [Table] Balance January 1, Liability for Future Policy Benefits Current year provisions Liability for Future Policy Benefits, Period Increase (Decrease) Claims paid and direct expenses Liability for Future Policy Benefits, Payment for Benefits Change in long-term insurance losses recoverable Liability for Future Policy Benefits, Contract Terminations Balance December 31, Subsidiary Equity Plan [Abstract] Subsidiary Equity Plan [Abstract] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Consolidated Entities [Axis] Consolidated Entities [Axis] Consolidated Entities [Domain] Consolidated Entities [Domain] Subsidiaries [Member] Subsidiaries [Member] Award Type [Axis] Award Type [Axis] Award Type [Domain] Equity Award [Domain] Subsidiaries Stock awards [Member] Subsidiaries Stock awards [Member] Subsidiaries Stock awards [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Award Vesting Period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Employee stock award compensation Allocated Share-based Compensation Expense Common Stock Required to Settle Subsidiary Shares Common Stock Required to Settle Subsidiary Shares Common Stock Required to Settle Subsidiary Shares Intangible Assets, Net (Excluding Goodwill) [Abstract] Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] 2018 Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months 2019 Finite-Lived Intangible Assets, Amortization Expense, Year Two 2020 Finite-Lived Intangible Assets, Amortization Expense, Year Four 2021 Finite-Lived Intangible Assets, Amortization Expense, Year Three 2022 Finite-Lived Intangible Assets, Amortization Expense, Year Five Thereafter Finite-Lived Intangible Assets, Amortization Expense, after Year Five Intangible assets, net Finite-Lived Intangible Assets, Net Accounting Policies [Abstract] Liability for Claims and Claims Adjustment Expense [Table] Liability for Claims and Claims Adjustment Expense [Table] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Insurance Coverage Limit Type [Axis] Insurance Coverage Limit Type [Axis] Insurance Coverage Limit Type [Axis] Insurance Coverage Limit Type [Domain] Insurance Coverage Limit Type [Domain] Insurance Coverage Limit Type [Domain] Payor [Axis] Payor [Axis] Payor [Axis] Payor [Domain] Payor [Domain] Payor [Domain] Location, State [Axis] Location, State [Axis] Location, State [Axis] Location, State [Domain] Location, State [Domain] Location, State [Domain] Liability for Claims and Claims Adjustment Expense [Line Items] Liability for Claims and Claims Adjustment Expense [Line Items] Other Assets [Abstract] Schedule of Other Assets [Table Text Block] Schedule of Other Assets [Table Text Block] Business Combinations [Abstract] Schedule of Business Acquisitions, by Acquisition [Table Text Block] Schedule of Business Acquisitions, by Acquisition [Table Text Block] COMPUTATION OF NET INCOME PER COMMON SHARE [Abstract] COMPUTATION OF NET INCOME PER COMMON SHARE [Abstract] Earnings Per Share, Diluted, Other Disclosures [Abstract] Earnings Per Share, Diluted, Other Disclosures [Abstract] Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table] Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Common Class A [Member] Common Class A [Member] Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Numerator: Net Income (Loss) Attributable to Parent [Abstract] Net income Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Less: net income attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Net income attributable to The Ensign Group, Inc. Net Income (Loss) Attributable to Parent Denominator: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Weighted average shares outstanding for basic net income per share Weighted Average Number of Shares Outstanding, Basic Plus: incremental shares from assumed conversion (1) Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Adjusted weighted average common shares outstanding Weighted Average Number of Shares Outstanding, Diluted Basic net income (loss) per common share: Earnings Per Share, Basic [Abstract] Basic net income per common share attributable to The Ensign Group, Inc. Earnings Per Share, Basic Diluted net (loss) income per common share: Earnings Per Share, Diluted [Abstract] Diluted net income per common share attributable to The Ensign Group, Inc. Earnings Per Share, Diluted Options and Awards [Abstract] Options and Awards [Abstract] Statement [Table] Statement [Table] Stock Options Employee Stock Option [Member] Statement [Line Items] Statement [Line Items] Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Vested Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Expected to Vest Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value Exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Divestitures [Abstract] Divestitures [Abstract] Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Common Stock [Abstract] Common Stock [Abstract] Common stock offering [Text Block] Common stock offering [Text Block] Common stock offering [Text Block] REVENUE AND ACCOUNTS RECEIVABLE [Abstract] REVENUE AND ACCOUNTS RECEIVABLE [Abstract] Schedule of Revenue Sources, Health Care Organization [Table] Schedule of Revenue Sources, Health Care Organization [Table] Health Care Organization, Revenue Sources [Axis] Health Care Organization, Revenue Sources [Axis] Health Care Organization, Revenue Sources [Domain] Health Care Organization, Revenue Sources [Domain] Medicaid Medicaid [Member] Revenue from Medicaid for custodial services [Member] Medicare Medicare [Member] Revenue from Medicare [Member] Medicaid — skilled Medicaid-skilled [Member] Revenue from Medicaid for skilled services [Member] Total Medicaid and Medicare Total Medicaid and Medicare Revenue [Member] Total revenue from Medicaid and Medicare [Member] Managed care Managed Care [Member] Revenue from managed care payors [Member] Private and other payors(1) Self-Pay [Member] Health Care Organization, Receivable and Revenue Disclosures [Line Items] Health Care Organization, Receivable and Revenue Disclosures [Line Items] Revenue Health Care Organization, Patient Service Revenue Revenue by payor as a percent of total revenue Revenue by payor as a percent of total revenue Revenue by payor as a percent of total revenue [Line Items] Debt Disclosure [Abstract] Schedule of Long-term Debt Instruments [Table Text Block] Schedule of Long-term Debt Instruments [Table Text Block] Segment Reporting [Abstract] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Restructuring Type [Axis] Restructuring Type [Axis] Type of Restructuring [Domain] Type of Restructuring [Domain] Contract Termination and Facility Closing [Member] Contract Termination and Facility Closing [Member] Contract Termination and Facility Closing [Member] Facility Closing [Member] Facility Closing [Member] Transitional and Skilled Services and Assisted and Independent Living Campuses [Axis] Transitional and Skilled Services and Assisted and Independent Living Campuses [Axis] Transitional and Skilled Services and Assisted and Independent Living Campuses [Axis] Transitional and Skilled Services and Assisted and Independent Living Facilities [Domain] Transitional and Skilled Services and Assisted and Independent Living Facilities [Domain] [Domain] for Transitional and Skilled Services and Assisted and Independent Living Facilities [Axis] Disposal Group Classification [Axis] Disposal Group Classification [Axis] Disposal Group Classification [Domain] Disposal Group Classification [Domain] Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] Segments [Axis] Segments [Axis] Segments [Domain] Segments [Domain] Transitional and Skilled Services Segment Transitional and Skilled Services Segment [Member] Transitional and Skilled Services Segment Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Number of Reportable Segments Number of Reportable Segments Sale Price from Divestiture of Businesses Sale Price from Divestiture of Businesses The price associated with the amount received from the sale of a portion of the Company's businesses. Transitional and Skilled Service Facilities Transitional and Skilled Service Facilities Transitional and Skilled Service Facilities Transitional and Skilled Services and Assistant and Independent Living Campuses Transitional and Skilled Services and Assistant and Independent Living Campuses Transitional and Skilled Services and Assistant and Independent Living Campuses Assisted and Independent Living Facilities Assisted and Independent Living Facilities Number of Assisted and Independent Living Facilities Home Health, Hospice and Home Care Operations Home Health, Hospice and Home Care Operations Home Health, Hospice and Home Care Operations Business Exit Costs Business Exit Costs Gain (Loss) on Contract Termination Gain (Loss) on Contract Termination Impairment of Long-Lived Assets to be Disposed of Impairment of Long-Lived Assets to be Disposed of Statement of Cash Flows [Abstract] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Scenario [Axis] Scenario [Axis] Scenario, Unspecified [Domain] Scenario, Unspecified [Domain] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Net income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization Amortization of deferred financing fees Amortization of Debt Issuance Costs and Discounts Amortization of deferred gain on sale-leaseback Sale Leaseback Transaction, Current Period Gain Recognized Impairment of long-lived assets Asset Impairment Charges Write-off of deferred financing fees Write off of Deferred Debt Issuance Cost Deferred income taxes Deferred Income Tax Expense (Benefit) Provision for doubtful accounts Provision for Doubtful Accounts Share-based compensation Share-based Compensation Excess tax benefit from share-based compensation (Note 2) Excess Tax Benefit from Share-based Compensation, Operating Activities Insurance proceeds received for damage to property Proceeds from Insurance Settlement, Operating Activities Gain on disposition of intangibles, property and equipment Gain (Loss) on Disposition of Property Plant Equipment Gain on sale of urgent care centers Gain (Loss) on Disposition of Business Change in operating assets and liabilities Increase (Decrease) in Operating Capital [Abstract] Accounts receivable Increase (Decrease) in Accounts Receivable Prepaid income taxes Increase (Decrease) in Prepaid Taxes Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Insurance subsidiary deposits and investments Increase (Decrease) in Insurance subsidiary deposits and investments Change in captive insurance subsidiary cash and cash equivalents and debt security investements Liabilities related to operational closures (Note 7 and 17) Losses related to operational closure net of fixed asset impairment Losses related to operational closure net of fixed asset impairment Accounts payable Increase (Decrease) in Accounts Payable Accrued wages and related liabilities Increase (Decrease) in Employee Related Liabilities Income taxes payable Increase (Decrease) in Income Taxes Payable Other accrued liabilities Increase (Decrease) in Other Operating Liabilities Accrued self-insurance liabilities Increase (Decrease) in Self Insurance Reserve Deferred rent liability Increase (Decrease) in Other Deferred Liability Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchase of property and equipment Payments to Acquire Property, Plant, and Equipment Cash payments for business acquisitions Payments to Acquire Businesses, Net of Cash Acquired Cash payments for asset acquisitions Payments to acquire leased assets Cash paid to acquire tangible assets of previously leased facilities Escrow deposits Payments for (Proceeds from) Deposits on Real Estate Acquisitions Escrow deposits used to fund business acquisitions Escrow deposits used to fund business acquisitions Outflow of cash previously included in escrow deposits used to fund business acquisitions in the current period. Use of restricted cash Decrease in Restricted Cash Cash received from sale of urgent care centers and franchising businesses, net of note receivable Proceeds from Divestiture of Businesses Cash proceeds from sale-leaseback Sale Leaseback Transaction, Net Proceeds, Investing Activities Cash proceeds from the sale of fixed assets and insurance proceeds Proceeds from Sales of Assets, Investing Activities Restricted and other assets Increase (Decrease) in Other Noncurrent Assets Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Proceeds from revolving credit facility and other debt (Note 15) Proceeds from Issuance of Secured Debt Payments on revolving credit facility and other debt (Note 15) Repayments of Long-term Debt Proceeds from common stock offering (Note 3) Proceeds from Issuance of Common Stock Issuance costs in connection with common stock offering (Note 3) Payments of underwriter discounts and commissions Payments of underwriter discounts and commissions Issuance of treasury stock upon exercise of options Proceeds from Sale of Treasury Stock Issuance of common stock upon exercise of options Proceeds from Stock Options Exercised Repurchase of common stock (Note 3) Payments for Repurchase of Common Stock Dividends paid Payments of Dividends Excess tax benefit from share-based compensation (Note 2) Excess Tax Benefit from Share-based Compensation, Financing Activities Purchase of non-controlling interest Payments to Noncontrolling Interests Payments of deferred financing costs Payments of Financing Costs Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Net (decrease)/increase in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Cash and cash equivalents beginning of period Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents end of period Supplemental disclosures of cash flow information: Supplemental Cash Flow Information [Abstract] Cash paid during the period for: Additional Cash Flow Elements, Operating Activities [Abstract] Interest Interest Paid Income taxes Income Taxes Paid Non-cash financing and investing activity: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Accrued capital expenditures Capital Expenditures Incurred but Not yet Paid Note receivable from sale of urgent care centers and franchising business Noncash or Part Noncash Divestiture, Amount of Consideration Received Favorable lease included in the fair value of assets acquisitions Fair Value of Assets Acquired Refundable deposits assumed as part of business acquisition Noncash or Part Noncash Acquisition, Other Liabilities Assumed Debt assumed as part of asset acquisition Issuance costs of common stock included in accounts payable Issuance costs of common stock included in accounts payable Fair Value Disclosures [Abstract] EX-101.PRE 15 ensg-20171231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 16 ensggraph2017.jpg begin 644 ensggraph2017.jpg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

3B/YL*/D M'R\FM_PYX?N]+O-0U'6-1BU'4M0\I99H;8V\82-<(H0NYZEV)W#[70;F.Z\6:'"[:MJ4@6 M34H5)5[Z=E;!;H58$'N"#WKT2N;\!_\ (NW7_8:U7_TX7% !_P +'\$?]#EX M?_\ !I!_\51_PL?P1_T.7A__ ,&D'_Q5=)10!S?_ L?P1_T.7A__P &D'_Q M5'_"Q_!'_0Y>'_\ P:0?_%5TE% '-_\ "Q_!'_0Y>'__ :0?_%4?\+'\$?] M#EX?_P#!I!_\57244 '_\ P:0?_%5TE% ' M-_\ "Q_!'_0Y>'__ :0?_%4?\+'\$?]#EX?_P#!I!_\57244 '_\ P:0?_%5TE% '-_\ "Q_!'_0Y>'__ :0?_%4?\+' M\$?]#EX?_P#!I!_\57244 '_\ P:0?_%5T ME% '-_\ "Q_!'_0Y>'__ :0?_%4?\+'\$?]#EX?_P#!I!_\57244 '_\ P:0?_%5TE% '-_\ "Q_!'_0Y>'__ :0?_%4 M?\+'\$?]#EX?_P#!I!_\57244 '_\ P:0? M_%5TE% '-_\ "Q_!'_0Y>'__ :0?_%4?\+'\$?]#EX?_P#!I!_\57244 66U\2:7>F)=QBL[R.:0_15)-.\4>,;+PY&(0#=: MA+Q#:Q\L2>A/H/U/:L71_"%]KFH+K?C=O-EZPV'\$0[ C^GYYK6,%;FGL4EU M9RUQXPTOQMJCQ^(/%.DZ'I%O)@V4NHQ1S2$?W@6S^)&!V!ZUW%AXW^'NEV4= MI8>*_#L$$8PJ+J<'Y_>Y/O76 !5 4 # [4M*'_\ P:0?_%5TE% '-_\ "Q_!'_0Y>'__ :0?_%4?\+' M\$?]#EX?_P#!I!_\57244 '_\ P:0?_%5T ME% '-_\ "Q_!'_0Y>'__ :0?_%4?\+'\$?]#EX?_P#!I!_\57244 '_\ P:0?_%5TE% '-_\ "Q_!'_0Y>'__ :0?_%4 M?\+'\$?]#EX?_P#!I!_\57244 '_\ P:0? M_%5TE% '-_\ "Q_!'_0Y>'__ :0?_%4?\+'\$?]#EX?_P#!I!_\57244 '_\ P:0?_%5TE% '-_\ "Q_!'_0Y>'__ :0 M?_%4?\+'\$?]#EX?_P#!I!_\57244 '_\ MP:0?_%5TE% '-_\ "Q_!'_0Y>'__ :0?_%4?\+'\$?]#EX?_P#!I!_\5724 M4 '_\ P:0?_%5TE% '-_\ "Q_!'_0Y>'__ M :0?_%4?\+'\$?]#EX?_P#!I!_\57244 M'_\ P:0?_%5TE% '-_\ "Q_!'_0Y>'__ :0?_%4?\+'\$?]#EX?_P#!I!_\ M57244 '_\ P:0?_%5TE% '-_\ "Q_!'_0Y M>'__ :0?_%4?\+'\$?]#EX?_P#!I!_\57244 '_\ P:0?_%5TE% '-_\ "Q_!'_0Y>'__ :0?_%4?\+'\$?]#EX?_P#! MI!_\57,?%?7+FQETR'2M3EMY/WIG2VN"K?P;=P4Y]<9]ZI?"S6=3U#Q1U_4+K0]3L]2MTM;>-I;.X69%8-,2I*DC."#CW%=!6;!_ MR-5]_P!>5M_Z'/6E0!^;E%%% 'W_ /#C_DEGA3_L"V?_ *(2NDKF_AQ_R2SP MI_V!;/\ ]$)724 %%%% !1110 5S?@/_ )%VZ_[#6J_^G"XKI*YOP'_R+MU_ MV&M5_P#3A<4 =)1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%17-S#9VTEQ=2I M##&-SNYP%% $M<5X@\:SS7QT3PA']MU)N'F7F.'U.>A(]>@]^E4+S6M7\>W< MFF^&=]GI*G;<7[@@N/0?X=3WP*Z_P_X;^PI4_XL_DM?QV*]S\3([N';=6\U[(>3)+.RG/T4@5KZ/X2T30+M[G2; M+[/,Z&-F\UVRN0T/P9 M=:A?C7/&DGVJ\;F*T/,<([ CI^'3UR:[CI6O-&GI'5]_\AW2V(;.SM["TCM; M*%(8(QA$08 J:BBL"0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH ***Y_5_'&@:+N6YOTEE7_ )8V_P"\ M;/IQP/Q(I-I;EPISJ.T%:EK$BS>,->GNCG/V>W.$'T)&!^"BL_:7^%7.KZJ MH?QI*/EN_N1J:M\1_#^F,8XKAK^?H([4;AG_ 'NGY$UD_P!L^.?$G&D:;'HU MJW2>Y^_C\1_)?QKK-)\,:-H@']FZ?#$X_P"6I&Y_^^CS6K1RR?Q/[@]M0I_P MX7?>7^6WYG"VOPRAN9Q=>)]4NM5G[J7*H/;.2_ MEH 6^IZG\:N45481CLC&IB*M723T[=/N"BBBK, HHHH **** "BBB@ HHHH M**** "BBB@#-@_Y&J^_Z\K;_ -#GK2K-@_Y&J^_Z\K;_ -#GK2H _-RBBB@# M[O\ "5A%J/P9\+PW-]=6-NNCV4DTEK<&!BBPH2ID'S*/4J5/N.:YG3;F_P!0 M;2-*_M#5?[ U?7+DV-PUW*MS-91VS2*//W>;L:8,RL6W&,+SM(K^(M6G MO;.Z^U6FHE;99K=MA0A0L(0J59P0R-]X^@P 2ZN;-;J'?+R\WD2 MR1JS>I81@D]R:M2>"-/_ +!TK3;*ZO+%](D$UG>P.AG23:RNY+JRL7$C[LJ0 M=Q.,XQ?TGP_;Z+I]G864\_V.U@:$P2;&$Y8@F1R5W%L[CP0#O;(/& #RD^(= M8\/>%S>6^IWUS=:IX/.K2274SS+%=[HQYD:L2(Q_I!^1<+A%XX.>[\)"73/% MWB'P^MW>W=G9Q6=S ]] M]U"TN-/_ ++CBNY%(MK3G]S&553CD?,Q9OE7YN!6KX?\-Q:"UW,U_>:E>7C( M9[R^9#(X10J+\BJH /0=22

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ȋ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end XML 17 R1.htm IDEA: XBRL DOCUMENT

DEI Info Cover Page Document - USD ($)	12 Months Ended
DEI Info Cover Page Document - USD ($)	Dec. 31, 2017	Feb. 05, 2018	Jun. 30, 2017
Entity Information [Abstract]
Entity Registrant Name	ENSIGN GROUP, INC
Entity Central Index Key	0001125376
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-K
Current Reporting Status	Yes
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Common Stock, Shares Outstanding		51,484,963
Entity Public Float			$ 780,000,000

XML 18 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 42,337	$ 57,706
Accounts receivable—less allowance for doubtful accounts of $43,961 and $39,791 at December 31, 2017 and 2016, respectively	265,068	244,433
Investments—current	13,092	11,550
Prepaid income taxes	19,447	302
Prepaid expenses and other current assets	28,132	19,871
Total current assets	368,076	333,862
Property and equipment, net	537,084	484,498
Insurance subsidiary deposits and investments	28,685	23,634
Escrow deposits	228	1,582
Deferred tax asset	12,745	23,073
Restricted and other assets	16,501	12,614
Intangible assets, net	32,803	35,076
Goodwill	81,062	67,100
Other indefinite-lived intangibles	25,249	19,586
Total assets	1,102,433	1,001,025
Current liabilities:
Accounts payable	39,043	38,991
Accrued wages and related liabilities	90,508	84,686
Accrued self-insurance liabilities—current	22,516	21,359
Other accrued liabilities	63,815	58,763
Current maturities of long-term debt	9,939	8,129
Total current liabilities	225,821	211,928
Long-term debt—less current maturities	302,990	275,486
Accrued self-insurance liabilities—less current portion	50,220	43,992
Deferred rent and other long-term liabilities	11,268	9,124
Deferred gain related to sale-leaseback (Note 17)	12,075	0
Total liabilities	602,374	540,530
Commitments and contingencies (Notes 15, 17 and 19)
Equity:
Common stock; $0.001 par value; 75,000 shares authorized; 53,675 and 51,360 shares issued and outstanding at December 31, 2017, respectively, and 52,787 and 50,838 shares issued and outstanding at December 31, 2016, respectively (Note 3)	53	52
Additional paid-in capital (Note 3)	266,058	252,493
Retained earnings	264,691	235,021
Common stock in treasury, at cost, 1,932 and 1,520 shares at December 31, 2017 and 2016, respectively (Note 3)	(38,405)	(31,117)
Total Ensign Group, Inc. stockholders' equity	492,397	456,449
Non-controlling interest	7,662	4,046
Total equity	500,059	460,495
Total liabilities and equity	$ 1,102,433	$ 1,001,025

XML 19 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets Balance Sheet (Paranthetical) - USD ($) shares in Thousands, $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Current assets:
Allowance for doubtful accounts	$ 43,961	$ 39,791
Equity:
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	75,000	75,000
Common stock, shares issued	53,675	52,787
Common stock, shares outstanding	51,360	50,838
Common stock in treasury, at cost	1,932	1,520

XML 20 R4.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Income - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Revenue	$ 1,849,317	$ 1,654,864	$ 1,341,826
Expense:
Cost of services	1,497,703	1,341,814	1,067,694
Charge related to class action lawsuit (Note 19)	11,000	0	0
(Gains)/losses related to divestitures (Note 7 and 17)	2,321	(11,225)	0
Rent—cost of services (Note 17)	131,919	124,581	88,776
General and administrative expense	80,617	69,165	64,163
Depreciation and amortization	44,472	38,682	28,111
Total expenses	1,768,032	1,563,017	1,248,744
Income from operations	81,285	91,847	93,082
Other income (expense):
Interest expense	(13,616)	(7,136)	(2,828)
Interest income	1,609	1,107	845
Other expense, net	(12,007)	(6,029)	(1,983)
Income before provision for income taxes	69,278	85,818	91,099
Provision for income taxes	28,445	32,975	35,182
Net income	40,833	52,843	55,917
Less: net income attributable to noncontrolling interests	358	2,853	485
Net income attributable to The Ensign Group, Inc.	$ 40,475	$ 49,990	$ 55,432
Basic:
Basic net income per common share attributable to The Ensign Group, Inc.	$ 0.79	$ 0.99	$ 1.10
Diluted:
Diluted net income per common share attributable to The Ensign Group, Inc.	$ 0.77	$ 0.96	$ 1.06
Weighted average common shares outstanding:
Basic	50,932	50,555	50,316
Adjusted weighted average common shares outstanding	52,829	52,133	52,210
Dividends per share	$ 0.1725	$ 0.1625	$ 0.1525

XML 21 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statement of Stockholders' Equity Statement - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Treasury Stock [Member]	Noncontrolling Interest [Member]
Balance - January 1 at Dec. 31, 2014	$ 257,803	$ 22	$ 114,293	$ 145,846	$ (1,310)	$ (1,048)
Balance - January 1 (in shares) at Dec. 31, 2014		22,591
Balance - January 1 (in treasury shares) at Dec. 31, 2014					150
Issuance of common stock to employees and directors resulting from the exercise of stock options and grant of stock awards (in shares)		255			(27)
Issuance of common stock to employees and directors resulting from the exercise of stock options and grant of stock awards	2,530	$ 0	2,443		$ 87
Issuance of restricted stock to employees (in shares)		105
Issuance of restricted stock to employees	1,892		1,892
Issuance of common stock through public offering, net of issuance costs (in shares)		2,734
Issuance of common stock through public offering, net of issuance costs	106,120	$ 3	106,117
Repurchase of common stock (Note 3)	0
Dividends declared	(7,858)			(7,858)
Employee stock award compensation	6,677		6,677
Excess tax benefit from share-based compensation	3,680		3,680
Stock issued to effect stock split (in shares)		25,685
Stock issued to effect stock split	0	$ 26	(26)
Noncontrolling interest assumed related to acquisition	224					224
Less: net income attributable to noncontrolling interests	485					485
Net income attributable to The Ensign Group, Inc.	55,432			55,432
Balance - December 31 at Dec. 31, 2015	426,985	$ 51	235,076	193,420	$ (1,223)	(339)
Balance - December 31 (in shares) at Dec. 31, 2015		51,370
Balance - December 31 (in treasury shares) at Dec. 31, 2015					123
Issuance of common stock to employees and directors resulting from the exercise of stock options and grant of stock awards (in shares)		668			(55)
Issuance of common stock to employees and directors resulting from the exercise of stock options and grant of stock awards	4,152	$ 1	4,045		$ 106
Issuance of restricted stock to employees (in shares)		252
Issuance of restricted stock to employees	2,517		2,517
Repurchase of common stock (Note 3) (in shares)		(1,452)			1,452
Repurchase of common stock (Note 3)	(30,000)				$ (30,000)
Dividends declared	(8,282)			(8,282)
Employee stock award compensation	7,776		7,776
Excess tax benefit from share-based compensation	3,079		3,079
Noncontrolling interest attributable to subsidiary equity plan (Note 16)	1,325			(107)		1,432
Noncontrolling interest assumed related to acquisition	100					100
Less: net income attributable to noncontrolling interests	2,853					2,853
Net income attributable to The Ensign Group, Inc.	49,990			49,990
Balance - December 31 at Dec. 31, 2016	$ 460,495	$ 52	252,493	235,021	$ (31,117)	4,046
Balance - December 31 (in shares) at Dec. 31, 2016	50,838	50,838
Balance - December 31 (in treasury shares) at Dec. 31, 2016					1,520
Issuance of common stock to employees and directors resulting from the exercise of stock options and grant of stock awards (in shares)		807			0
Issuance of common stock to employees and directors resulting from the exercise of stock options and grant of stock awards	$ 5,128	$ 1	5,127		$ 0
Issuance of restricted stock to employees (in shares)		127
Issuance of restricted stock to employees	146		146
Repurchase of common stock (Note 3) (in shares)		(412)			412
Repurchase of common stock (Note 3)	(7,288)				$ (7,288)
Dividends declared	(8,867)			(8,867)
Employee stock award compensation	8,331		8,331
Acquisition of noncontrolling interest, net of tax	(83)		(39)			(44)
Noncontrolling interest attributable to subsidiary equity plan (Note 16)	1,364			(1,938)		3,302
Less: net income attributable to noncontrolling interests	358					358
Net income attributable to The Ensign Group, Inc.	40,475			40,475
Balance - December 31 at Dec. 31, 2017	$ 500,059	$ 53	$ 266,058	$ 264,691	$ (38,405)	$ 7,662
Balance - December 31 (in shares) at Dec. 31, 2017	51,360	51,360
Balance - December 31 (in treasury shares) at Dec. 31, 2017					1,932

XML 22 R6.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Cash flows from operating activities:
Net income	$ 40,833	$ 52,843	$ 55,917
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	44,472	38,682	28,111
Amortization of deferred financing fees	1,039	825	591
Amortization of deferred gain on sale-leaseback	(421)	0	0
Impairment of long-lived assets	111	137	0
Write-off of deferred financing fees	0	321	0
Deferred income taxes	10,329	(2,208)	1,251
Provision for doubtful accounts	31,023	28,512	19,802
Share-based compensation	9,695	9,101	6,677
Excess tax benefit from share-based compensation (Note 2)	0	(3,079)	(3,680)
Insurance proceeds received for damage to property	477	0	0
Gain on disposition of intangibles, property and equipment	278	164	205
Gain on sale of urgent care centers	0	(19,160)	0
Change in operating assets and liabilities
Accounts receivable	(52,301)	(63,617)	(100,324)
Prepaid income taxes	(19,145)	7,839	(5,149)
Prepaid expenses and other assets	(9,380)	(1,465)	(10,340)
Insurance subsidiary deposits and investments	(6,592)	(467)	(10,785)
Liabilities related to operational closures (Note 7 and 17)	2,210	7,205	0
Accounts payable	3,329	577	1,780
Accrued wages and related liabilities	5,822	(4,978)	22,178
Income taxes payable	(1,182)	987	0
Other accrued liabilities	5,777	12,588	21,403
Accrued self-insurance liabilities	6,095	8,125	5,418
Deferred rent liability	483	956	314
Net cash provided by operating activities	72,952	73,888	33,369
Cash flows from investing activities:
Purchase of property and equipment	(57,166)	(65,699)	(60,018)
Cash payments for business acquisitions	(89,565)	(64,310)	(110,802)
Cash payments for asset acquisitions	(195)	(120,935)	(17,750)
Escrow deposits	(228)	(1,582)	(400)
Escrow deposits used to fund business acquisitions	1,582	400	16,153
Use of restricted cash	0	0	5,082
Cash received from sale of urgent care centers and franchising businesses, net of note receivable	0	40,734	2,000
Cash proceeds from sale-leaseback	38,000	0	0
Cash proceeds from the sale of fixed assets and insurance proceeds	3,215	391	10
Restricted and other assets	(2,236)	365	(2,813)
Net cash used in investing activities	(106,593)	(210,636)	(168,538)
Cash flows from financing activities:
Proceeds from revolving credit facility and other debt (Note 15)	1,022,015	844,000	334,000
Payments on revolving credit facility and other debt (Note 15)	(990,154)	(659,514)	(314,417)
Proceeds from common stock offering (Note 3)	0	0	112,078
Issuance costs in connection with common stock offering (Note 3)	0	0	(5,961)
Issuance of treasury stock upon exercise of options	0	106	87
Issuance of common stock upon exercise of options	5,274	6,563	4,337
Repurchase of common stock (Note 3)	(7,288)	(30,000)	0
Dividends paid	(8,717)	(8,173)	(7,494)
Excess tax benefit from share-based compensation (Note 2)	0	3,181	3,700
Purchase of non-controlling interest	(83)	0	0
Payments of deferred financing costs	(2,775)	(3,278)	0
Net cash provided by financing activities	18,272	152,885	126,330
Net (decrease)/increase in cash and cash equivalents	(15,369)	16,137	(8,839)
Cash and cash equivalents beginning of period	57,706	41,569	50,408
Cash and cash equivalents end of period	42,337	57,706	41,569
Cash paid during the period for:
Interest	13,284	6,428	2,773
Income taxes	38,382	23,163	35,490
Non-cash financing and investing activity:
Accrued capital expenditures	3,550	6,828	4,171
Note receivable from sale of urgent care centers and franchising business	0	700	0
Favorable lease included in the fair value of assets acquisitions	0	7,190	0
Refundable deposits assumed as part of business acquisition	0	0	3,488
Debt assumed as part of asset acquisition	$ 0	$ 0	$ 11,699

XML 23 R7.htm IDEA: XBRL DOCUMENT

Description of Business	12 Months Ended
Description of Business	Dec. 31, 2017
DESCRIPTION OF BUSINESS [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	DESCRIPTION OF BUSINESS The Company - The Ensign Group, Inc. (collectively, Ensign or the Company), is a holding company with no direct operating assets, employees or revenue. The Company, through its operating subsidiaries, is a provider of health care services across the post-acute care continuum, as well as other ancillary businesses. As of December 31, 2017, the Company operated 230 facilities, 46 home health, hospice and home care agencies and other ancillary operations located in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, Oklahoma, Oregon, South Carolina, Texas, Utah, Washington and Wisconsin. The Company's operating subsidiaries, each of which strives to be the operation of choice in the community it serves, provide a broad spectrum of skilled nursing, assisted living, home health, home care, hospice and other ancillary services. The Company's operating subsidiaries have a collective capacity of approximately 18,900 operational skilled nursing beds and 5,000 assisted living and independent living units. As of December 31, 2017, the Company owned 63 of its 230 affiliated facilities and leased an additional 167 facilities through long-term lease arrangements and had options to purchase 11 of those 167 facilities. As of December 31, 2016, the Company owned 50 of its 210 affiliated facilities and leased an additional 160 facilities through long-term lease arrangements, and had options to purchase nine of those 160 facilities. Certain of the Company’s wholly-owned independent subsidiaries, collectively referred to as the Service Center, provide certain accounting, payroll, human resources, information technology, legal, risk management and other centralized services to the other operating subsidiaries through contractual relationships with such subsidiaries. The Company also has a wholly-owned captive insurance subsidiary (the Captive) that provides some claims-made coverage to the Company’s operating subsidiaries for general and professional liability, as well as coverage for certain workers’ compensation insurance liabilities. Each of the Company's affiliated operations are operated by separate, wholly-owned, independent subsidiaries that have their own management, employees and assets. References herein to the consolidated “Company” and “its” assets and activities in this Annual Report is not meant to imply, nor should it be construed as meaning, that The Ensign Group, Inc. has direct operating assets, employees or revenue, or that any of the subsidiaries, are operated by The Ensign Group, Inc.

XML 24 R8.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies	12 Months Ended
Significant Accounting Policies	Dec. 31, 2017
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies [Text Block]	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation — The accompanying consolidated financial statements (Financial Statements) have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The Company is the sole member or shareholder of various consolidated limited liability companies and corporations established to operate various acquired skilled nursing and assisted living operations, home health, hospice and home care operations, and related ancillary services. All intercompany transactions and balances have been eliminated in consolidation. The consolidated financial statements include the accounts of all entities controlled by the Company through its ownership of a majority voting interest. The Company presents noncontrolling interest within the equity section of its consolidated balance sheets. The Company presents the amount of consolidated net income that is attributable to The Ensign Group, Inc. and the noncontrolling interest in its consolidated statements of income. The consolidated financial statements include the accounts of all entities controlled by the Company through its ownership of a majority voting interest and the accounts of any variable interest entities (VIEs) where the Company is subject to a majority of the risk of loss from the VIE's activities, or entitled to receive a majority of the entity's residual returns, or both. The Company assesses the requirements related to the consolidation of VIEs, including a qualitative assessment of power and economics that considers which entity has the power to direct the activities that "most significantly impact" the VIE's economic performance and has the obligation to absorb losses of, or the right to receive benefits that could be potentially significant to, the VIE. The Company's relationship with variable interest entities was not material during the year ended December 31, 2017. In 2016, the Company completed the sale of its urgent care centers for an aggregate purchase price of $41,492. The sale transactions do not meet the criteria of discontinued operations as they do not represent a strategic shift that has, or will have, a major effect on the Company’s operations and financial results. Estimates and Assumptions — The preparation of Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Financial Statements and the reported amounts of revenue and expenses during the reporting periods. The most significant estimates in the Company’s Financial Statements relate to revenue, allowance for doubtful accounts, intangible assets and goodwill, impairment of long-lived assets, general and professional liability, workers' compensation and healthcare claims included in accrued self-insurance liabilities, and income taxes. Actual results could differ from those estimates. Fair Value of Financial Instruments —The Company’s financial instruments consist principally of cash and cash equivalents, debt security investments, accounts receivable, insurance subsidiary deposits, accounts payable and borrowings. The Company believes all of the financial instruments’ recorded values approximate fair values because of their nature or respective short durations. Revenue Recognition — The Company recognizes revenue when the following four conditions have been met: (i) there is persuasive evidence that an arrangement exists; (ii) delivery has occurred or service has been rendered; (iii) the price is fixed or determinable; and (iv) collection is reasonably assured. The Company's revenue is derived primarily from providing healthcare services to patients and is recognized on the date services are provided at amounts billable to the individual. For reimbursement arrangements with third-party payors, including Medicaid, Medicare and private insurers, revenue is recorded based on contractually agreed-upon amounts on a per patient basis. Revenue from the Medicare and Medicaid programs accounted for 68.4%, 67.8% and 69.1% of the Company's revenue for the years ended December 31, 2017, 2016 and 2015, respectively. The Company records revenue from these governmental and managed care programs as services are performed at their expected net realizable amounts under these programs. The Company’s revenue from governmental and managed care programs is subject to audit and retroactive adjustment by governmental and third-party agencies. Consistent with healthcare industry accounting practices, any changes to these governmental revenue estimates are recorded in the period the change or adjustment becomes known based on final settlement. The Company recorded adjustments to revenue which were not material to the Company's consolidated revenue or Financial Statements for the years ended December 31, 2017, 2016 and 2015. The Company’s service specific revenue recognition policies are as follows: Skilled Nursing Revenue The Company’s revenue is derived primarily from providing long-term healthcare services to patients and is recognized on the date services are provided at amounts billable to individual patients. For patients under reimbursement arrangements with third-party payors, including Medicaid, Medicare and private insurers, revenue is recorded based on contractually agreed-upon amounts or rate on a per patient, daily basis or as services are performed. Assisted and Independent Living Revenue The Company's revenue is recorded when services are rendered on the date services are provided at amounts billable to individual residents and consists of fees for basic housing and assisted living care. Residency agreements are generally for a term of 30 days, with resident fees billed monthly in advance. For patients under reimbursement arrangements with Medicaid, revenue is recorded based on contractually agreed-upon amounts or rate on a per resident, daily basis or as services rendered. Revenue for certain ancillary charges is recognized as services are provided, and such fees are billed monthly in arrears. Home Health Revenue Medicare Revenue Net service revenue is recorded under the Medicare prospective payment system based on a 60-day episode payment rate that is subject to adjustment based on certain variables including, but not limited to: (a) an outlier payment if patient care was unusually costly; (b) a low utilization payment adjustment if the number of visits was fewer than five; (c) a partial payment if the patient transferred to another provider or the Company received a patient from another provider before completing the episode; (d) a payment adjustment based upon the level of therapy services required; (e) the number of episodes of care provided to a patient, regardless of whether the same home health provider provided care for the entire series of episodes; (f) changes in the base episode payments established by the Medicare program; (g) adjustments to the base episode payments for case mix and geographic wages; and (h) recoveries of overpayments. The Company makes adjustments to Medicare revenue on completed episodes to reflect differences between estimated and actual payment amounts, an inability to obtain appropriate billing documentation or authorizations acceptable to the payor and other reasons unrelated to credit risk. Therefore, the Company believes that its reported net service revenue and patient accounts receivable will be the net amounts to be realized from Medicare for services rendered. In addition to revenue recognized on completed episodes, the Company also recognizes a portion of revenue associated with episodes in progress. Episodes in progress are 60-day episodes of care that begin during the reporting period, but were not completed as of the end of the period. As such, the Company estimates revenue and recognizes it on a daily basis. The primary factors underlying this estimate are the number of episodes in progress at the end of the reporting period, expected Medicare revenue per episode and its estimate of the average percentage complete based on visits performed. Non-Medicare Revenue Episodic Based Revenue - The Company recognizes revenue in a similar manner as it recognizes Medicare revenue for episodic-based rates that are paid by other insurance carriers, including Medicare Advantage programs; however, these rates can vary based upon the negotiated terms. Non-episodic Based Revenue - Revenue is recorded on an accrual basis based upon the date of service at amounts equal to its established or estimated per-visit rates, as applicable. Hospice Revenue Revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are daily rates for each of the levels of care the Company delivers. The Company makes adjustments to revenue for an inability to obtain appropriate billing documentation or authorizations acceptable to the payor and other reasons unrelated to credit risk. Additionally, as Medicare hospice revenue is subject to an inpatient cap limit and an overall payment cap, the Company monitors its provider numbers and estimates amounts due back to Medicare if a cap has been exceeded. The Company records these adjustments as a reduction to revenue and increases to other accrued liabilities. Accounts Receivable and Allowance for Doubtful Accounts — Accounts receivable consist primarily of amounts due from Medicare and Medicaid programs, other government programs, managed care health plans and private payor sources. Estimated provisions for doubtful accounts are recorded to the extent it is probable that a portion or all of a particular account will not be collected. In evaluating the collectability of accounts receivable, the Company considers a number of factors, including the age of the accounts, changes in collection patterns, the composition of patient accounts by payor type and the status of ongoing disputes with third-party payors. On an annual basis, the historical collection percentages are reviewed by payor and by state and are updated to reflect the recent collection experience of the Company. In order to determine the appropriate reserve rate percentages which ultimately establish the allowance, the Company analyzes historical cash collection patterns by payor and by state. The percentages applied to the aged receivable balances are based on the Company’s historical experience and time limits, if any, for managed care, Medicare, Medicaid and other payors. The Company periodically refines its estimates of the allowance for doubtful accounts based on experience with the estimation process and changes in circumstances. Cash and Cash Equivalents — Cash and cash equivalents consist of bank term deposits, money market funds and treasury bill related investments with original maturities of three months or less at time of purchase and therefore approximate fair value. The fair value of money market funds is determined based on “Level 1” inputs, which consist of unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets. The Company places its cash and short-term investments with high credit quality financial institutions. Insurance Subsidiary Deposits and Investments — The Company's captive insurance subsidiary cash and cash equivalents, deposits and investments are designated to support long-term insurance subsidiary liabilities and have been classified as short-term and long-term assets based on the timing of expected future payments of the Company's captive insurance liabilities. The majority of these deposits and investments are currently held in AA, A and BBB+ rated debt security investments and the remainder is held in a bank account with a high credit quality financial institution. See further discussion at Note 5, Fair Value Measurements. The Company evaluates securities for other-than-temporary impairment (“OTTI”) on at least a quarterly basis, and more frequently when economic or market conditions warrant such an evaluation. If securities are in an unrealized loss position, the Company considers the extent and duration of the unrealized loss, and the financial condition and near-term prospects of the issuer. The Company also assesses whether it intends to sell, or it is more likely than not that it will be required to sell, a security in an unrealized loss position before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the entire difference between amortized cost and fair value is recognized as impairment through earnings. For the years ended December 31, 2016 and 2017, the Company did not recognize any OTTI for its investments. Property and Equipment — Property and equipment are initially recorded at their historical cost. Repairs and maintenance are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the depreciable assets (ranging from three to 59 years). Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the remaining lease term. Impairment of Long-Lived Assets — The Company reviews the carrying value of long-lived assets that are held and used in the Company’s operating subsidiaries for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of these assets is determined based upon expected undiscounted future net cash flows from the operating subsidiaries to which the assets relate, utilizing management’s best estimate, appropriate assumptions, and projections at the time. If the carrying value is determined to be unrecoverable from future operating cash flows, the asset is deemed impaired and an impairment loss would be recognized to the extent the carrying value exceeded the estimated fair value of the asset. The Company estimates the fair value of assets based on the estimated future discounted cash flows of the asset. Management has evaluated its long-lived assets and recorded an impairment charge of $111 and $137 related to the closure of facilities during the years ended December 31, 2017 and 2016, respectively. The Company did not identify any asset impairment during the year ended December 31, 2015. Leases and Leasehold Improvements - At the inception of each lease, the Company performs an evaluation to determine whether the lease should be classified as an operating or capital lease. The Company records rent expense for operating leases that contain scheduled rent increases on a straight-line basis over the term of the lease. The lease term used for straight-line rent expense is calculated from the date the Company is given control of the leased premises through the end of the lease term. The lease term used for this evaluation also provides the basis for establishing depreciable lives for buildings subject to lease and leasehold improvements, as well as the period over which the Company records straight-line rent expense. Intangible Assets and Goodwill — Definite-lived intangible assets consist primarily of favorable leases, lease acquisition costs, patient base, facility trade names and customer relationships. Favorable leases and lease acquisition costs are amortized over the life of the lease of the facility. Patient base is amortized over a period of four to eight months, depending on the classification of the patients and the level of occupancy in a new acquisition on the acquisition date. Trade names at affiliated facilities are amortized over 30 years and customer relationships are amortized over a period of up to 20 years. The Company's indefinite-lived intangible assets consist of trade names and Medicare and Medicaid licenses. The Company tests indefinite-lived intangible assets for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the carrying amount of the intangible asset may not be recoverable. The Company did not identify any asset impairment during the years ended December 31, 2017, 2016 and 2015. Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in business combinations. Goodwill is subject to annual testing for impairment. In addition, goodwill is tested for impairment if events occur or circumstances change that would reduce the fair value of a reporting unit below its carrying amount. The Company performs its annual test for impairment during the fourth quarter of each year. See further discussion at Note 11, Goodwill and Other Indefinite-Lived Intangible Assets. Deferred Rent - Deferred rent represents rental expense, determined on a straight-line basis over the life of the related lease, in excess of actual rent payments. Self-Insurance — The Company is partially self-insured for general and professional liability up to a base amount per claim (the self-insured retention) with an aggregate, one-time deductible above this limit. Losses beyond these amounts are insured through third-party policies with coverage limits per claim, per location and on an aggregate basis for the Company. Starting on January 1, 2017, the combined self-insured retention was $500 per claim, subject to an additional one-time deductible of $750 for California affiliated operations and a separate, one-time, deductible of $1,000 for non-California operations. For all affiliated operations, except those located in Colorado, the third-party coverage above these limits was $1,000 per claim, $3,000 per operation, with a $5,000 blanket aggregate limit and an additional state-specific aggregate where required by state law. In Colorado, the third-party coverage above these limits was $1,000 per claim and $3,000 per operation, which is independent of the aforementioned blanket aggregate limits that apply outside of Colorado. The self-insured retention and deductible limits for general and professional liability and workers' compensation for all states (except Texas and Washington for workers' compensation) are self-insured through the Captive, the related assets and liabilities of which are included in the accompanying consolidated balance sheets. The Captive is subject to certain statutory requirements as an insurance provider. These requirements include, but are not limited to, maintaining statutory capital. The Company’s policy is to accrue amounts equal to the actuarially estimated costs to settle open claims of insureds, as well as an estimate of the cost of insured claims that have been incurred but not reported. The Company develops information about the size of the ultimate claims based on historical experience, current industry information and actuarial analysis, and evaluates the estimates for claim loss exposure on a quarterly basis. The Company’s operating subsidiaries are self-insured for workers’ compensation in California. To protect itself against loss exposure in California with this policy, the Company has purchased individual specific excess insurance coverage that insures individual claims that exceed $500 per occurrence. In Texas, the operating subsidiaries have elected non-subscriber status for workers’ compensation claims and, effective February 1, 2011, the Company has purchased individual stop-loss coverage that insures individual claims that exceed $750 per occurrence. As of July 1, 2014, the Company’s operating subsidiaries in all other states, with the exception of Washington, are under a loss sensitive plan that insures individual claims that exceed $350 per occurrence. In Washington, the operating subsidiaries' coverage is financed through premiums paid by the employers and employees. The claims and pay benefits are managed through a state insurance pool. Outside of California, Texas and Washington, the Company has purchased insurance coverage that insures individual claims that exceed $350 per accident. In all states except Washington, the Company accrues amounts equal to the estimated costs to settle open claims, as well as an estimate of the cost of claims that have been incurred but not reported. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information. In addition, the Company has recorded an asset and equal liability of $5,394 and $4,104 at December 31, 2017 and 2016, respectively, in order to present the ultimate costs of malpractice and workers' compensation claims and the anticipated insurance recoveries on a gross basis. See Note 12, Restricted and Other Assets. The Company self-funds medical (including prescription drugs) and dental healthcare benefits to the majority of its employees. The Company is fully liable for all financial and legal aspects of these benefit plans. To protect itself against loss exposure with this policy, the Company has purchased individual stop-loss insurance coverage that insures individual claims that exceed $300 for each covered person with an additional one-time aggregate individual stop loss deductible of $75. Beginning 2016, the Company's policy does not include the additional one-time aggregate individual stop loss deductible of $75. The Company believes that adequate provision has been made in the Financial Statements for liabilities that may arise out of patient care, workers’ compensation, healthcare benefits and related services provided to date. The amount of the Company’s reserves was determined based on an estimation process that uses information obtained from both company-specific and industry data. This estimation process requires the Company to continuously monitor and evaluate the life cycle of the claims. Using data obtained from this monitoring and the Company’s assumptions about emerging trends, the Company, with the assistance of an independent actuary, develops information about the size of ultimate claims based on the Company’s historical experience and other available industry information. The most significant assumptions used in the estimation process include determining the trend in costs, the expected cost of claims incurred but not reported and the expected costs to settle or pay damage awards with respect to unpaid claims. The self-insured liabilities are based upon estimates, and while management believes that the estimates of loss are reasonable, the ultimate liability may be in excess of or less than the recorded amounts. Due to the inherent volatility of actuarially determined loss estimates, it is reasonably possible that the Company could experience changes in estimated losses that could be material to net income. If the Company’s actual liability exceeds its estimates of loss, its future earnings, cash flows and financial condition would be adversely affected. Income Taxes — Deferred tax assets and liabilities are established for temporary differences between the financial reporting basis and the tax basis of the Company’s assets and liabilities at tax rates in effect when such temporary differences are expected to reverse. The Company generally expects to fully utilize its deferred tax assets; however, when necessary, the Company records a valuation allowance to reduce its net deferred tax assets to the amount that is more likely than not to be realized. In determining the need for a valuation allowance or the need for and magnitude of liabilities for uncertain tax positions, the Company makes certain estimates and assumptions. These estimates and assumptions are based on, among other things, knowledge of operations, markets, historical trends and likely future changes and, when appropriate, the opinions of advisors with knowledge and expertise in certain fields. Due to certain risks associated with the Company’s estimates and assumptions, actual results could differ. The Tax Cuts and Jobs Act (the Tax Act), which was enacted in December 2017, increased the Company's income tax expense by $3,915 for the year ended December 31, 2017. The Tax Act will decrease the corporate income tax rate from 35.0% to 21.0% beginning on January 1, 2018. The Company expects meaningful benefits from this reduction to continue from its enactment in future periods. See Note 14, Income Taxes for further detail. Noncontrolling Interest — The noncontrolling interest in a subsidiary is initially recognized at estimated fair value on the acquisition date and is presented within total equity in the Company's consolidated balance sheets. The Company presents the noncontrolling interest and the amount of consolidated net income attributable to The Ensign Group, Inc. in its consolidated statements of income and net income per share is calculated based on net income attributable to The Ensign Group, Inc.'s stockholders. The carrying amount of the noncontrolling interest is adjusted based on an allocation of subsidiary earnings based on ownership interest. Share-Based Compensation — The Company measures and recognizes compensation expense for all share-based payment awards made to employees and directors including employee stock options based on estimated fair values, ratably over the requisite service period of the award. Net income has been reduced as a result of the recognition of the fair value of all stock options and restricted stock awards issued, the amount of which is contingent upon the number of future grants and other variables. Recent Accounting Pronouncements — Except for rules and interpretive releases of the Securities and Exchange Commission (SEC) under authority of federal securities laws and a limited number of grandfathered standards, the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) is the sole source of authoritative GAAP literature recognized by the FASB and applicable to the Company. For any new pronouncements announced, the Company considers whether the new pronouncements could alter previous generally accepted accounting principles and determines whether any new or modified principles will have a material impact on the Company's reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company's financial management and certain standards are under consideration. Recent Accounting Standards Adopted by the Company In March 2016, the FASB issued a new standard to simplify several aspects of the accounting for employee share-based payment transactions, which includes the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The new standard was effective for the Company in the first quarter of fiscal year 2017. Under the previous guidance, excess tax benefits and deficiencies from share-based compensation arrangements were recorded in equity when the awards vested or were settled. The new guidance requires prospective recognition of excess tax benefits and deficiencies in the income statement, resulting in the recognition of excess tax benefits in income tax expense, of $3,423, rather than in paid-in-capital, for the year ended December 31, 2017. In addition, under the new guidance, excess income tax benefits from share-based compensation arrangements are classified as cash flow from operations, rather than as cash flow from financing activities. The Company has elected to apply the cash flow classification guidance prospectively, resulting in an increase to operating cash flow for the year ended December 31, 2017 and the prior year period has not been adjusted. The Company has also elected to continue to estimate the expected forfeitures rather than electing to account for forfeitures as they occur. Finally, the adoption of the guidance requires excess tax benefits and deficiencies to be prospectively excluded from assumed future proceeds in the calculation of diluted shares, resulting in an increase in diluted weighted average shares outstanding. Accounting Standards Recently Issued But Not Yet Adopted by the Company In May 2017, the FASB issued amended authoritative guidance to provide guidance on types of changes to the terms or conditions of share-based payments awards to which an entity would be required to apply modification accounting under ASC 718. This guidance is effective for annual and interim periods beginning after December 15, 2017, which will be the Company's fiscal year 2018, with early adoption permitted in certain cases. The adoption of this standard is not expected to have a material impact on the Company's consolidated financial statements. In January 2017, the FASB issued amended authoritative guidance to clarify the definition of a business and reduce diversity in practice related to the evaluation of whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The new provisions provide the requirements needed for an integrated set of assets and activities (the set) to be a business and also establish a practical way to determine when a set is not a business. The ASU provides a screen to determine when an integrated set of assets and activities is not a business. The more robust framework helps entities to narrow the definition of outputs created by the set and align it with how outputs are described in the new revenue standard. This guidance is effective for annual and interim periods beginning after December 15, 2017, which will be the Company's fiscal year 2018, with early adoption permitted in certain cases. The new guidance is required to be applied on a prospective basis. The effect of the implementation will depend upon the nature of the Company's future acquisitions. In January 2017, the FASB issued amended authoritative guidance to simplify and reduce the cost and complexity of the goodwill impairment test. The new provisions eliminate step 2 from the goodwill impairment test and shifts the concept of impairment from a measure of loss when comparing the implied fair value of goodwill to its carrying amount to comparing the fair value of a reporting unit with its carrying amount. The Board also eliminated the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment or step 2 of the goodwill impairment test. The new guidance does not amend the optional qualitative assessment of goodwill impairment. This guidance is effective for annual periods beginning after December 15, 2019, which will be the Company's fiscal year 2020, with early adoption permitted. The adoption of this standard is not expected to have a material impact on the Company's consolidated financial statements. In October 2016, the FASB issued amended authoritative guidance to require companies to recognize the income tax consequences of an intra-entity transfer of an asset, other than inventory, when the transfer occurs. The amendments will be effective for the Company’s fiscal year beginning January 1, 2018. The new guidance is required to be applied on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. The adoption of this standard is not expected to have a material impact on the Company's consolidated financial statements based on the Company's historical activity. Furthermore, the actual impact of implementation will largely depend on future intra-entity asset transfers, if any. In August 2016, the FASB issued amended authoritative guidance to reduce the diversity in practice related to the presentation and classification of certain cash receipts and cash payments in the statement of cash flows. The new provisions target cash flow issues related to (i) debt prepayment or debt extinguishment costs, (ii) settlement of debt instruments with coupon rates that are insignificant relative to effective interest rates, (iii) contingent consideration payments made after a business combination, (iv) proceeds from settlement of insurance claims, (v) proceeds from the settlement of corporate-owned life insurance and bank-owned life insurance policies, (vi) distributions received from equity method investees, (vii) beneficial interests in securitization transactions and (viii) separately identifiable cash flows and application of the predominance principle. This guidance will be effective for fiscal years beginning after December 15, 2017, which will be the Company's fiscal year 2018, with early adoption permitted. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements. In February 2016, the FASB issued amended authoritative guidance on accounting for leases. The new provisions require that a lessee of operating leases recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. The lease liability will be equal to the present value of lease payments, with the right-of-use asset based upon the lease liability. The classification criteria for distinguishing between finance (or capital) leases and operating leases are substantially similar to the previous lease guidance, but with no explicit bright lines. As such, operating leases will result in straight-line rent expense similar to current practice. For short term leases (term of 12 months or less), a lessee is permitted to make an accounting election not to recognize lease assets and lease liabilities, which would generally result in lease expense being recognized on a straight-line basis over the lease term. This guidance applies to all entities and is effective for annual periods beginning after December 15, 2018, which will be the Company's fiscal year 2019, with early adoption permitted. The Company is currently evaluating the impact this guidance will have on its consolidated financial statements but expects this adoption will result in a significant increase in the assets and liabilities on its consolidated balance sheets. In January 2016, the FASB issued amended authoritative guidance which makes targeted improvements for financial instruments. The new provisions impact certain aspects of recognition, measurement, presentation and disclosure requirements of financial instruments. Specifically, the guidance will (1) require equity investments to be measured at fair value with changes in fair value recognized in net income, (2) simplify the impairment assessment of equity investments without readily determinable fair values, (3) eliminate the requirement to disclose the method and assumptions used to estimate fair value for financial instruments measured at amortized cost, and (4) require separate presentation of financial assets and financial liabilities by measurement category. The guidance is effective for annual and interim periods beginning after December 15, 2017, which will be the Company's fiscal year 2018. Early adoption is not permitted. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements. In March 2016, the FASB issued its standard to amend the principal-versus-agent implementation guidance and illustrations in the Board’s new revenue standard, which includes accounting implication related to (1) determining the appropriate unit of account under the revenue standard’s principal-versus-agent guidance and (2) applying the indicators of whether an entity is a principal or an agent in accordance with the revenue standard’s control principle. The guidance will be effective for fiscal years beginning after December 15, 2017, which will be the Company's fiscal year 2018. The guidance has the same effective date as the new revenue standard and the Company is required to adopt the guidance by using the same transition method it would use to adopt the new revenue standard. The Company's evaluation of the adoption method and impact to the consolidated financial statements is performed concurrently with the new revenue standard below. In May 2014, the FASB and International Accounting Standards Board issued their final standard on revenue from contracts with customers that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers. The new standard supersedes most current revenue recognition guidance, including industry-specific guidance, and may be applied retrospectively to each period presented (full retrospective method) or retrospectively with the cumulative effect recognized in beginning retained earnings as of the date of adoption (modified retrospective method). In July 2015, the FASB formally deferred for one year the effective date of the new revenue standard and decided to permit entities to early adopt the standard. In December 2016, the FASB made certain technical corrections to further clarify the core revenue recognition principles, primarily in response to feedback from several sources, including the FASB/IASB Transition Resource Group. The guidance will be effective for fiscal years beginning after December 15, 2017, which will be the Company's fiscal year 2018. The Company initiated an adoption plan in fiscal year 2015, beginning with preliminary evaluation of the standard, and subsequently performed additional analysis of revenue streams and transactions under the new standard. In particular, the Company performed analysis into the application of the portfolio approach as a practical expedient to group patient contracts with similar characteristics, such that revenue for a given portfolio would not be materially different than if it were evaluated on a contract-by-contract basis. The adoption plan has been completed and the impact to the consolidated financial statements for periods subsequent to adoption is not material. As part of the impact assessment, the Company evaluated any variable consideration, potential constraints on the estimate of variable consideration, and significant financing components, in particular as it related to third party settlements. The Company anticipates that for periods subsequent to adoption, the majority of what is currently classified as bad debt expense under operating expenses will be treated as an implicit price concession factored into net revenue, consistent with the intent of the standard. The new standard also requires enhanced disclosures related to the disaggregation of revenue, information about contract balances, and other disclosures about contracts with customers, including revenue recognition policies to identify performance obligations and significant judgments in measurement and recognition. The Company adopted the new revenue standard as of January 1, 2018 using the modified retrospective method and the adoption did not have a material impact.

XML 25 R9.htm IDEA: XBRL DOCUMENT

Common Stock	12 Months Ended
Common Stock	Dec. 31, 2017
Common Stock [Abstract]
Common stock offering [Text Block]	COMMON STOCK On February 8, 2017, the Company announced that its Board of Directors authorized a stock repurchase program, under which the Company may repurchase up to $30,000 of its common stock under the program for a period of 12 months. Under this program, the Company is authorized to repurchase its issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. The stock repurchase program expired on February 8, 2018. During the year ended December 31, 2017, the Company repurchased 412 shares of its common stock for a total of $7,288. On November 4, 2015 and February 9, 2016, the Company announced that its Board of Directors authorized two stock repurchase programs, under which the Company could repurchase up to $15,000 of its common stock under each program for a period of 12 months. During the first quarter of 2016, the Company repurchased 1,452 shares of its common stock for a total of $30,000 and these repurchase programs expired upon the repurchase of the full authorized amount under such plans.

XML 26 R10.htm IDEA: XBRL DOCUMENT

Computation of Net Income Per Common Share

12 Months Ended

Dec. 31, 2017

COMPUTATION OF NET INCOME PER COMMON SHARE [Abstract]

Earnings Per Share [Text Block]

COMPUTATION OF NET INCOME PER COMMON SHARE



	Year Ended December 31,
	2017		2016		2015
Numerator:
Net income	$	40,833	$	52,843	$	55,917
Less: net income attributable to noncontrolling interests	358		2,853		485
Net income attributable to The Ensign Group, Inc.	$	40,475	$	49,990	$	55,432

Denominator:
Weighted average shares outstanding for basic net income per share	50,932		50,555		50,316
Basic net income per common share attributable to The Ensign Group, Inc.	$	0.79	$	0.99	$	1.10

A reconciliation of the numerator and denominator used in the calculation of diluted net income per common share follows:



	Year Ended December 31,
	2017		2016		2017
Numerator:
Net income	$	40,833	$	52,843	$	55,917
Less: net income attributable to noncontrolling interests	358		2,853		485
Net income attributable to The Ensign Group, Inc.	$	40,475	$	49,990	$	55,432

Denominator:
Weighted average common shares outstanding	50,932		50,555		50,316
Plus: incremental shares from assumed conversion⁽¹⁾	1,897		1,578		1,894
Adjusted weighted average common shares outstanding	52,829		52,133		52,210
Diluted net income per common share attributable to The Ensign Group, Inc.	$	0.77	$	0.96	$	1.06

XML 27 R11.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

12 Months Ended

Dec. 31, 2017

Fair Value Disclosures [Abstract]

Fair Value Disclosures [Text Block]

FAIR VALUE MEASUREMENTS

The following table summarizes the financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2017 and 2016:



	December 31,
	2017						2016
	Level 1		Level 2		Level 3		Level 1		Level 2		Level 3
Cash and cash equivalents	$	42,337	$	—	$	—	$	57,706	$	—	$	—

Debt Security Investments - Held to Maturity

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 28 R12.htm IDEA: XBRL DOCUMENT

Revenue and Accounts Receivable

12 Months Ended

Dec. 31, 2017

REVENUE AND ACCOUNTS RECEIVABLE [Abstract]

Revenue and Accounts receivable [Text Block]

REVENUE AND ACCOUNTS RECEIVABLE

Revenue for the years ended December 31, 2017, 2016 and 2015 is summarized in the following tables:



	Year Ended December 31,
	2017				2016				2015
	Revenue		% of Revenue		Revenue		% of Revenue		Revenue		% of Revenue
Medicaid	$	644,803	34.9	%	$	557,958	33.7	%	$	458,956	34.2	%
Medicare	515,884		27.9		477,019		28.8		395,503		29.5
Medicaid — skilled	102,875		5.6		87,517		5.3		71,905		5.4
Total Medicaid and Medicare	1,263,562		68.4		1,122,494		67.8		926,364		69.1
Managed care	303,386		16.4		265,508		16.0		206,770		15.4
Private and other payors⁽¹⁾	282,369		15.2		266,862		16.2		208,692		15.5
Revenue	$	1,849,317	100.0	%	$	1,654,864	100.0	%	$	1,341,826	100.0	%

Accounts receivable as of December 31, 2017 and 2016 is summarized in the following table:



	December 31,
	2017			2016
Medicaid	$	119,441		$	111,031
Managed care	68,930			66,346
Medicare	55,667			55,500
Private and other payors	64,991			51,347
	309,029			284,224
Less: allowance for doubtful accounts	(43,961		)	(39,791		)
Accounts receivable, net	$	265,068		$	244,433

XML 29 R13.htm IDEA: XBRL DOCUMENT

Business Segments

12 Months Ended

Dec. 31, 2017

Segment Reporting [Abstract]

Segment Reporting Disclosure [Text Block]

BUSINESS SEGMENTS

As of December 31, 2017, transitional and skilled services included 160 wholly-owned affiliated skilled nursing facilities and 21 campuses that provide skilled nursing and rehabilitative care services. The Company provided room and board and social services through 49 wholly-owned affiliated assisted and independent living facilities and 21 campuses. Home health, home care and hospice services were provided to patients through 46 affiliated agencies. As of December 31, 2017, the Company held majority membership interests in other ancillary operations, which operating results are included in the "all other" category.

Segment revenues by major payor source were as follows:



	Year Ended December 31, 2017
	Transitional and Skilled Services		Assisted and Independent Living Services		Home Health and Hospice Services		All Other			Total Revenue		Revenue %
Medicaid	$	603,104	$	30,469	$	11,230	$	—		$	644,803	34.9	%
Medicare	417,870		—		98,014		—			515,884		27.9
Medicaid-skilled	102,875		—		—		—			102,875		5.6
Subtotal	1,123,849		30,469		109,244		—			1,263,562		68.4
Managed care	281,563		—		21,823		—			303,386		16.4
Private and other	139,798		106,177		11,336		25,058		(1)	282,369		15.2
Total revenue	$	1,545,210	$	136,646	$	142,403	$	25,058		$	1,849,317	100.0	%
(1) Private and other payors also includes revenue from all payors generated in other ancillary services for the year ended December 31, 2017.



	Year Ended December 31, 2016
	Transitional and Skilled Services		Assisted and Independent Living Services		Home Health and Hospice Services		All Other			Total Revenue		Revenue %
Medicaid	$	521,063	$	26,397	$	10,498	$	—		$	557,958	33.7	%
Medicare	396,519		—		80,500		—			477,019		28.8
Medicaid-skilled	87,517		—		—		—			87,517		5.3
Subtotal	1,005,099		26,397		90,998		—			1,122,494		67.8
Managed care	247,844		—		17,664		—			265,508		16.0
Private and other	121,860		97,239		7,151		40,612		(1)	266,862		16.2
Total revenue	$	1,374,803	$	123,636	$	115,813	$	40,612		$	1,654,864	100.0	%
(1) Private and other payors also includes revenue from all payors generated in other ancillary services and urgent care centers for the year ended December 31, 2016.



	Year Ended December 31, 2015
	Transitional and Skilled Services		Assisted and Independent Living Services		Home Health and Hospice Services		All Other			Total Revenue		Revenue %
Medicaid	$	430,368	$	19,642	$	8,946	$	—		$	458,956	34.2	%
Medicare	332,429		—		63,074		—			395,503		29.5
Medicaid-skilled	71,905		—		—		—			71,905		5.4
Subtotal	834,702		19,642		72,020		—			926,364		69.1
Managed care	194,743		—		12,027		—			206,770		15.4
Private and other	96,943		68,487		6,309		36,953		(1)	208,692		15.5
Total revenue	$	1,126,388	$	88,129	$	90,356	$	36,953		$	1,341,826	100.0	%
(1) Private and other payors also includes revenue from all payors generated in other ancillary services and urgent care centers for the year ended December 31, 2015.

The following table sets forth selected financial data consolidated by business segment:



	Year Ended December 31, 2017
	Transitional and Skilled Services(3)		Assisted and Independent Living Services(3)		Home Health and Hospice Services		All Other			Elimination			Total
Revenue from external customers	$	1,545,210	$	136,646	$	142,403	$	25,058		$	—		$	1,849,317
Intersegment revenue (1)	3,023		—		—		3,035			(6,058		)	—
Total revenue	$	1,548,233	$	136,646	$	142,403	$	28,093		$	(6,058	)	$	1,849,317
Segment income (loss) (2)	$	140,272	$	16,736	$	19,717	$	(95,440	)	$	—		$	81,285
Interest expense, net of interest income													$	(12,007	)
Income before provision for income taxes													$	69,278
Depreciation and amortization	$	29,928	$	6,334	$	945	$	7,265		$	—		$	44,472

(1) Intersegment revenue represents services provided at the Company's operating subsidiaries to the Company's other business lines.



	Year Ended December 31, 2016
	Transitional and Skilled Services(3)		Assisted and Independent Living Services(3)		Home Health and Hospice Services		All Other			Elimination			Total
Revenue from external customers	$	1,374,803	$	123,636	$	115,813	$	40,612		$	—		$	1,654,864
Intersegment revenue (1)	2,929		—		—		2,184			(5,113		)	—
Total revenue	$	1,377,732	$	123,636	$	115,813	$	42,796		$	(5,113	)	$	1,654,864
Segment income (loss) (2)	$	118,118	$	11,701	$	16,571	$	(54,543	)	$	—		$	91,847
Interest expense, net of interest income													$	(6,029	)
Income before provision for income taxes													$	85,818
Depreciation and amortization	$	26,298	$	4,157	$	924	$	7,303		$	—		$	38,682

(1) Intersegment revenue represents services provided at the Company's operating subsidiaries to the Company's other business lines.



	Year Ended December 31, 2015
	Transitional and Skilled Services(3)		Assisted and Independent Living Services(3)		Home Health and Hospice Services		All Other			Elimination			Total
Revenue from external customers	$	1,126,388	$	88,129	$	90,356	$	36,953		$	—		$	1,341,826
Intersegment revenue (1)	2,447		—		—		881			(3,328		)	—
Total revenue	$	1,128,835	$	88,129	$	90,356	$	37,834		$	(3,328	)	$	1,341,826
Segment income (loss) (2)	$	136,744	$	11,463	$	13,584	$	(68,709	)	$	—		$	93,082
Interest expense, net of interest income													$	(1,983	)
Income before provision for income taxes													$	91,099
Depreciation and amortization	$	18,008	$	3,338	$	980	$	5,785		$	—		$	28,111

(1) Intersegment revenue represents services provided at the Company's operating subsidiaries to the Company's other business lines.

XML 30 R14.htm IDEA: XBRL DOCUMENT

Acquisitions

12 Months Ended

Dec. 31, 2017

Business Combinations [Abstract]

Business Combination Disclosure [Text Block]

ACQUISITIONS

During the year ended December 31, 2016, the Company expanded its operations with the addition of two home health agencies and five hospice agencies. In addition, the Company acquired eighteen stand-alone skilled nursing operations and one post-acute care campus through a combination of long-term leases and purchases. As part of these acquisitions, the Company acquired the real estate at two of the skilled nursing operations and one post-acute care campus and entered into long term leases for sixteen skilled nursing operations. The Company did not acquire any material assets or assume any liabilities other than the tenant's post-assumption rights and obligations under the long-term lease. The Company also invested in new ancillary services that are complementary to its existing transitional and skilled services; assisted and independent living services and home health and hospice businesses. The aggregate purchase price for these acquisitions for the year ended December 31, 2016 was $64,521. The expansion of skilled nursing operations added 2,336 operational skilled nursing beds and ten assisted living units operated by the Company's operating subsidiaries. The Company entered into a separate operations transfer agreement with the prior operator as part of each transaction. Additionally, the Company's operating subsidiaries opened six newly constructed post-acute care campuses under long-term lease agreements, which added 463 operational skilled nursing beds and 142 assisted living units.



	December 31,
	2017		2016		2015
Land	$	9,732	$	1,054	$	12,811
Building and improvements	53,735		21,057		73,502
Equipment, furniture, and fixtures	4,382		8,265		4,612
Assembled occupancy	762		1,299		895
Definite-lived intangible assets	—		363		360
Goodwill	13,962		30,343		10,617
Favorable leases	—		393		10,901
Other indefinite-lived intangible assets	7,018		1,741		6,285
Other assets acquired, net of liabilities assumed	92		6		(18		)
Total acquisitions	$	89,683	$	64,521	$	119,965

The Company’s acquisition strategy has been focused on identifying both opportunistic and strategic acquisitions within its target markets that offer strong opportunities for return on invested capital. The operating subsidiaries acquired by the Company are frequently underperforming financially and can have regulatory and clinical challenges to overcome. Financial information, especially with underperforming operating subsidiaries, is often inadequate, inaccurate or unavailable. Consequently, the Company believes that prior operating results are not a meaningful representation of the Company’s current operating results or indicative of the integration potential of its newly acquired operating subsidiaries. The businesses acquired during the year ended December 31, 2017 were not material acquisitions to the Company individually or in the aggregate. Accordingly, pro forma financial information is not presented. These acquisitions have been included in the December 31, 2017 consolidated balance sheets of the Company, and the operating results have been included in the consolidated statements of operations of the Company since the dates the Company gained effective control.

XML 31 R15.htm IDEA: XBRL DOCUMENT

Property and Equipment

12 Months Ended

Dec. 31, 2017

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment Disclosure [Text Block]

PROPERTY AND EQUIPMENT— Net

Property and equipment, net consist of the following:



	December 31,
	2017			2016
Land	$	49,081		$	47,565
Buildings and improvements	342,641			304,263
Equipment	181,530			153,170
Furniture and fixtures	5,244			6,931
Leasehold improvements	97,221			80,164
Construction in progress	5,460			2,441
	681,177			594,534
Less: accumulated depreciation	(144,093		)	(110,036		)
Property and equipment, net	$	537,084		$	484,498

XML 32 R16.htm IDEA: XBRL DOCUMENT

Intangible Assets - Net

12 Months Ended

Dec. 31, 2017

Intangible Assets, Net (Excluding Goodwill) [Abstract]

Intangible Assets Disclosure [Text Block]

INTANGIBLE ASSETS — Net



	Weighted Average Life (Years)	December 31,
		2017							2016
		Gross Carrying Amount		Accumulated Amortization					Gross Carrying Amount		Accumulated Amortization
Intangible Assets		Gross Carrying Amount		Accumulated Amortization			Net		Gross Carrying Amount		Accumulated Amortization			Net
Lease acquisition costs	24.8	$	483	$	(99	)	$	384	$	483	$	(78	)	$	405
Favorable leases	33.0	35,116		(6,568		)	28,548		35,116		(4,589		)	30,527
Assembled occupancy	0.7	2,659		(2,631		)	28		1,897		(1,897		)	—
Facility trade name	30.0	733		(293		)	440		733		(269		)	464
Customer relationships	18.7	4,933		(1,530		)	3,403		4,933		(1,253		)	3,680
Total		$	43,924	$	(11,121	)	$	32,803	$	43,162	$	(8,086	)	$	35,076

Estimated amortization expense for each of the years ending December 31 is as follows:



Year	Amount
2018	2,329
2019	2,301
2020	1,593
2021	1,497
2022	1,471
Thereafter	23,612
	$	32,803

XML 33 R17.htm IDEA: XBRL DOCUMENT

Goodwill and Other Indefinite-Lived Intangible Assets

12 Months Ended

Dec. 31, 2017

Indefinite-Lived Intangible Assets (Including Goodwill) [Abstract]

Goodwill and Other Indefinite-Lived Intangibles [Text Block]

GOODWILL AND OTHER INDEFINITE-LIVED INTANGIBLE ASSETS

The following table represents activity in goodwill by segment as of and for the year ended December 31, :



	Goodwill
	Transitional and Skilled Services		Assisted and Independent Living Services		Home Health and Hospice Services		All Other			Total
January 1, 2015	$	14,221	$	1,756	$	10,929	$	3,363		$	30,269
Additions	—		1,782		5,173		3,662			10,617
December 31, 2015	$	14,221	$	3,538	$	16,102	$	7,025		$	40,886
Less: Dispositions	—		—		—		(4,103		)	(4,103		)
Purchase price adjustment	—		—		—		(26		)	(26		)
Additions	26,415		—		1,799		2,129			30,343
December 31, 2016	$	40,636	$	3,538	$	17,901	$	5,025		$	67,100
Additions	4,850		420		6,421		2,271			13,962
December 31, 2017	$	45,486	$	3,958	$	24,322	$	7,296		$	81,062

Other indefinite-lived intangible assets consists of the following:



	December 31, 2017		December 31, 2016
Trade name	$	1,181	$	1,146
Medicare and Medicaid licenses	24,068		18,440
	$	25,249	$	19,586

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

XML 34 R18.htm IDEA: XBRL DOCUMENT

Restricted and Other Assets

12 Months Ended

Dec. 31, 2017

Other Assets [Abstract]

Other Assets Disclosure [Text Block]

RESTRICTED AND OTHER ASSETS

Restricted and other assets consist of the following:



	December 31,
	2017		2016
Debt issuance costs, net	$	2,799	$	3,611
Long-term insurance losses recoverable asset	5,394		4,104
Deposits with landlords	5,981		3,526
Capital improvement reserves with landlords and lenders	2,327		673
Note receivable from sale of urgent care centers	—		700
Restricted and other assets	$	16,501	$	12,614

XML 35 R19.htm IDEA: XBRL DOCUMENT

Other Accrued Liabilities

12 Months Ended

Dec. 31, 2017

Accrued Liabilities [Abstract]

Other Liabilities Disclosure [Text Block]

OTHER ACCRUED LIABILITIES

Other accrued liabilities consist of the following:



	December 31,
	2017		2016
Quality assurance fee	$	4,864	$	4,604
Refunds payable	21,661		18,368
Deferred revenue	7,066		6,994
Cash held in trust for patients	2,609		2,373
Resident deposits	6,574		6,099
Dividends payable	2,328		2,186
Property taxes	10,088		9,130
Income tax payable	—		1,182
Operational closure liability	910		1,972
Other	7,715		5,855
Other accrued liabilities	$	63,815	$	58,763

Quality assurance fee represents amounts payable to Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, Utah, Washington and Wisconsin as a result of a mandated fee based on patient days or licensed beds. Refunds payable includes payables related to overpayments, duplicate payments and credit balances from various payor sources. Deferred revenue occurs when the Company receives payments in advance of services provided. Resident deposits include refundable deposits to patients. Cash held in trust for patients reflects monies received from, or on behalf of, patients. Maintaining a trust account for patients is a regulatory requirement and, while the trust assets offset the liabilities, the Company assumes a fiduciary responsibility for these funds. The cash balance related to this liability is included in other current assets in the accompanying consolidated balance sheets. Operational closure liability includes the short-term portion of the closing costs that are payable within the next 12 months. The remaining long-term portion is included in other long-term liabilities in the accompanying consolidated balance sheets.

XML 36 R20.htm IDEA: XBRL DOCUMENT

Income Taxes

12 Months Ended

Dec. 31, 2017

Income Tax Disclosure [Abstract]

Income Tax Disclosure [Text Block]

INCOME TAXES

The provision for income taxes on continuing operations for the years ended December 31, 2017, 2016 and 2015 is summarized as follows:



	Year Ended December 31,
	2017		2016			2015
Current:
Federal	$	15,141	$	30,043		$	28,149
State	2,975		5,183			5,761
	18,116		35,226			33,910
Deferred:
Federal	5,428		(1,034		)	2,026
State	986		(1,217		)	(754		)
	6,414		(2,251		)	1,272
Adjustment to deferred taxes for tax rate change	3,915		—			—
Total	$	28,445	$	32,975		$	35,182



	December 31,
	2017		2016		2015
Income tax expense at statutory rate	35.0	%	35.0	%	35.0	%
State income taxes - net of federal benefit	3.1		3.0		3.6
Non-deductible expenses	1.7		0.9		0.6
Equity compensation	(4.5	)	—		—
Revaluation of deferred	5.7		—		—
Other adjustments	0.1		(0.5	)	(0.6	)
Total income tax provision	41.1	%	38.4	%	38.6	%



	December 31,
	2017			2016
Deferred tax assets (liabilities):
Accrued expenses	$	16,500		$	21,732
Allowance for doubtful accounts	11,090			15,956
Tax credits	3,334			3,461
Insurance	5,135			7,333
	36,059			48,482
Valuation allowance	(530		)	—
Total deferred tax assets	35,529			48,482
State taxes	(911		)	(1,023		)
Depreciation and amortization	(18,248		)	(20,643		)
Prepaid expenses	(3,625		)	(3,743		)
Total deferred tax liabilities	(22,784		)	(25,409		)
Net deferred tax assets	$	12,745		$	23,073

The Company's operating loss carry forwards for both federal and states were not material during the year ended December 31, 2017 and 2016.

XML 37 R21.htm IDEA: XBRL DOCUMENT

Debt

12 Months Ended

Dec. 31, 2017

Debt Disclosure [Abstract]

Debt Disclosure [Text Block]

DEBT

Long-term debt consists of the following:



	December 31,
	2017			2016
Term loan with SunTrust, interest payable quarterly	$	140,625		$	148,125
Credit facility with SunTrust	50,000			122,000
Mortgage loans and promissory note, principal and interest payable monthly, interest at fixed rate	125,394			14,032
	316,019			284,157
Less: current maturities	(9,939		)	(8,129		)
Less: debt issuance costs	(3,090		)	(542		)
	$	302,990		$	275,486

Credit Facility with a Lending Consortium Arranged by SunTrust

As of February 2, 2018, there was approximately $195,625 outstanding under the Credit Facility.

Mortgage Loans and Promissory Note

Future principal payments due under the long-term debt arrangements discussed above are as follows:



Years Ending
December 31,	Amount
2018	9,939
2019	10,106
2020	10,203
2021	170,926
2022	2,904
Thereafter	111,941
	$	316,019

Off-Balance Sheet Arrangements

XML 38 R22.htm IDEA: XBRL DOCUMENT

Options and Awards

12 Months Ended

Dec. 31, 2017

Options and Awards [Abstract]

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

OPTIONS AND AWARDS

During the second quarter of 2017, the Company's shareholders approved the 2017 Omnibus Incentive Plan (the 2017 Plan). The total number of shares available under all of the Company’s stock incentive plans was 6,277 as of December 31, 2017. The Company retired the 2001 Stock Option, Deferred Stock and Restricted Stock Plan (2001 Plan), the 2005 Stock Incentive Plan (2005 Plan), and the 2007 Omnibus Incentive Plan (2007 Plan) as a result of the approval of the 2017 Plan.


•	The expected option term is calculated by the average of the contractual term of the options and the weighted average vesting period for all options. The calculation of the expected option term is based on the Company's experience due to sufficient history.


•	Estimated volatility also reflects the application of ASC 718 interpretive guidance and, accordingly, incorporates historical volatility of similar public entities until sufficient information regarding the volatility of the Company's share price becomes available. The Company has utilized its own experience to calculate estimated volatility for options granted.


•	The dividend yield is based on the Company's historical pattern of dividends as well as expected dividend patterns.


•	The risk-free rate is based on the implied yield of U.S. Treasury notes as of the grant date with a remaining term approximately equal to the expected term.


•	Estimated forfeiture rate of approximately 9.73% per year is based on the Company's historical forfeiture activity of unvested stock options.

Stock Options



Grant Year	Options Granted	Weighted Average Risk-Free Rate	Expected Life	Weighted Average Volatility	Weighted Average Dividend Yield
2017	481	2.0%	6.2 years	35.2%	0.8%
2016	497	1.4%	6.3 years	37.8%	0.8%
2015	637	1.7%	6.5 years	39.5%	0.6%

For the years ended December 31, 2017, 2016 and 2015, the following represents the exercise price and fair value displayed at grant date for stock option grants:



Grant Year	Granted	Weighted Average Exercise Price		Weighted Average Fair Value of Options
2017	481	$	20.31	$	7.00
2016	497	$	19.43	$	7.00
2015	637	$	23.27	$	9.08

The following table represents the employee stock option activity during the years ended December 31, 2017, 2016 and 2015:



	Number of Options Outstanding		Weighted Average Exercise Price		Number of Options Vested	Weighted Average Exercise Price of Options Vested
January 1, 2015	5,532		$	8.51	2,218	$	4.70
Granted	637		23.27
Forfeited	(233	)	12.55
Exercised	(488	)	5.20
December 31, 2015	5,448		$	10.36	2,526	$	6.35
Granted	497		19.43
Forfeited	(127	)	14.46
Exercised	(642	)	6.47
December 31, 2016	5,176		$	11.62	2,704	$	8.18
Granted	481		20.31
Forfeited	(178	)	15.82
Exercised	(740	)	6.93
December 31, 2017	4,739		$	13.08	2,776	$	10.07

The following summary information reflects stock options outstanding, vested and related details as of December 31, 2017:



								Stock Options Vested
	Stock Options Outstanding							Stock Options Vested
				Number Outstanding	Black-Scholes Fair Value		Remaining Contractual Life (Years)	Vested and Exercisable
Year of Grant	Exercise Price			Number Outstanding	Black-Scholes Fair Value		Remaining Contractual Life (Years)	Vested and Exercisable
2008	2.56	-	4.06	185	$	292	1	185
2009	4.06	-	4.56	420	907		2	420
2010	4.77	-	4.96	116	281		3	116
2011	5.90	-	7.99	134	454		4	134
2012	6.56	-	7.96	435	1,603		5	435
2013	7.98	-	11.49	522	2,539		6	390
2014	10.55	-	18.94	1,458	8,272		7	789
2015	21.47	-	25.24	549	5,000		8	219
2016	18.79	-	19.89	450	3,140		9	88
2017	18.64	-	22.90	470	3,291		10	—
Total				4,739	$	25,779		2,776

Restricted Stock Awards

A summary of the status of the Company's non-vested restricted stock awards as of December 31, 2017 and changes during the years ended December 31, 2017, 2016 and 2015 is presented below:



	Non-Vested Restricted Awards		Weighted Average Grant Date Fair Value
Nonvested at January 1, 2015	366		$	15.15
Granted	323		22.99
Vested	(234	)	17.36
Forfeited	(30	)	16.81
Nonvested at December 31, 2015	425		$	19.79
Granted	299		20.55
Vested	(279	)	19.58
Forfeited	(16	)	20.85
Nonvested at December 31, 2016	429		$	20.42
Granted	173		20.21
Vested	(195	)	19.79
Forfeited	(24	)	20.34
Nonvested at December 31, 2017	383		$	20.65

Share-based compensation expense recognized for the Company's equity incentive plans for the years ended December 31, 2017, 2016 and 2015 was as follows:



	Year Ended December 31,
	2017		2016		2015
Share-based compensation expense related to stock options	$	4,773	$	4,793	4,164
Share-based compensation expense related to restricted stock awards	2,322		2,371		1,931
Share-based compensation expense related to stock options and restricted stock awards to non-employee directors	1,236		612		582
Total	$	8,331	$	7,776	$	6,677

The aggregate intrinsic value of options outstanding, vested, expected to vest and exercised as of and for the years ended December 31, 2017, 2016 and 2015 is as follows:



	December 31,
Options	2017		2016		2015
Outstanding	$	44,060	$	55,610	$	67,508
Vested	33,976		38,101		41,128
Expected to vest	9,311		15,983		23,508
Exercisable	10,481		9,199		8,709

The intrinsic value is calculated as the difference between the market value of the underlying common stock and the exercise price of the options.

Equity Instrument Denominated in the Shares of a Subsidiary

XML 39 R23.htm IDEA: XBRL DOCUMENT

Leases

12 Months Ended

Dec. 31, 2017

Leases [Abstract]

Leases of Lessee Disclosure [Text Block]

LEASES

Future minimum lease payments for all leases as of December 31, 2017 are as follows:



Year	Amount
2018	135,841
2019	135,395
2020	135,149
2021	134,942
2022	133,446
Thereafter	1,080,348
	$	1,755,121

XML 40 R24.htm IDEA: XBRL DOCUMENT

Self-Insurance Reserves

12 Months Ended

Dec. 31, 2017

Self-Insurance Reserves [Abstract]

Insurance Disclosure [Text Block]

SELF INSURANCE RESERVES

The following table represents activity in our insurance reserves as of and for the years ended December 31, 2017 and 2016:



	General and Professional Liability
				Workers' Compensation
				Workers' Compensation			Health			Total
Balance January 1, 2016	30,710			20,219			5,074			$	56,003
Current year provisions	23,149			12,887			38,151			74,187
Claims paid and direct expenses	(18,186		)	(10,290		)	(37,586		)	(66,062		)
Change in long-term insurance losses recoverable	637			586			—			1,223
Balance December 31, 2016	36,310			23,402			5,639			65,351
Current year provisions	20,396			15,202			53,796			89,394
Claims paid and direct expenses	(16,133		)	(12,455		)	(54,712		)	(83,300		)
Change in long-term insurance losses recoverable	361			930			—			1,291
Balance December 31, 2017	$	40,934		$	27,079		$	4,723		$	72,736

XML 41 R25.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies	12 Months Ended
Commitments and Contingencies	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	COMMITMENTS AND CONTINGENCIES Regulatory Matters — Laws and regulations governing Medicare and Medicaid programs are complex and subject to interpretation. Compliance with such laws and regulations can be subject to future governmental review and interpretation, as well as significant regulatory action including fines, penalties, and exclusion from certain governmental programs. Included in these laws and regulations is the Health Insurance Portability and Accountability Act of 1996 (HIPAA), which requires healthcare providers (among other things) to safeguard and keep confidential protected health information. In late December 2016, the Company learned of a potential issue at one of its independent operating entities in Arizona which involved the limited and inadvertent disclosure of certain confidential information. The issue has been internally investigated, addressed and disclosed as per the HIPAA obligations. The Company believes that it is presently in compliance in all material respects with all applicable laws and regulations. Cost-Containment Measures — Both government and private pay sources have instituted cost-containment measures designed to limit payments made to providers of healthcare services, and there can be no assurance that future measures designed to limit payments made to providers will not adversely affect the Company. Indemnities — From time to time, the Company enters into certain types of contracts that contingently require the Company to indemnify parties against third-party claims. These contracts primarily include (i) certain real estate leases, under which the Company may be required to indemnify property owners or prior facility operators for post-transfer environmental or other liabilities and other claims arising from the Company’s use of the applicable premises, (ii) operations transfer agreements, in which the Company agrees to indemnify past operators of facilities the Company acquires against certain liabilities arising from the transfer of the operation and/or the operation thereof after the transfer, (iii) certain lending agreements, under which the Company may be required to indemnify the lender against various claims and liabilities, and (iv) certain agreements with the Company’s officers, directors and employees, under which the Company may be required to indemnify such persons for liabilities arising out of their employment relationships. The terms of such obligations vary by contract and, in most instances, a specific or maximum dollar amount is not explicitly stated therein. Generally, amounts under these contracts cannot be reasonably estimated until a specific claim is asserted. Consequently, because no claims have been asserted, no liabilities have been recorded for these obligations on the Company’s balance sheets for any of the periods presented. Litigation — The skilled nursing business involves a significant risk of liability given the age and health of the patients and residents served by the Company's operating subsidiaries. The Company, its operating subsidiaries, and others in the industry are subject to an increasing number of claims and lawsuits, including professional liability claims, alleging that services provided have resulted in personal injury, elder abuse, wrongful death or other related claims. The defense of these lawsuits may result in significant legal costs, regardless of the outcome, and can result in large settlement amounts or damage awards. In addition to the potential lawsuits and claims described above, the Company is also subject to potential lawsuits under the Federal False Claims Act and comparable state laws alleging submission of fraudulent claims for services to any healthcare program (such as Medicare) or payor. A violation may provide the basis for exclusion from federally-funded healthcare programs. Such exclusions could have a correlative negative impact on the Company’s financial performance. Some states, including California, Arizona and Texas, have enacted similar whistleblower and false claims laws and regulations. In addition, the Deficit Reduction Act of 2005 created incentives for states to enact anti-fraud legislation modeled on the Federal False Claims Act. As such, the Company could face increased scrutiny, potential liability and legal expenses and costs based on claims under state false claims acts in markets in which it does business. In May 2009, Congress passed the Fraud Enforcement and Recovery Act (FERA) of 2009 which made significant changes to the Federal False Claims Act (FCA), expanding the types of activities subject to prosecution and whistleblower liability. Following changes by FERA, health care providers face significant penalties for the knowing retention of government overpayments, even if no false claim was involved. Health care providers can now be liable for knowingly and improperly avoiding or decreasing an obligation to pay money or property to the government. This includes the retention of any government overpayment. The government can argue, therefore, that a FCA violation can occur without any affirmative fraudulent action or statement, as long as it is knowingly improper. In addition, FERA extended protections against retaliation for whistleblowers, including protections not only for employees, but also contractors and agents. Thus, there is generally no need for an employment relationship in order to qualify for protection against retaliation for whistleblowing. Healthcare litigation (including class action litigation) is common and is filed based upon a wide variety of claims and theories, and the Company is routinely subjected to varying types of claims. One particular type of suit arises from alleged violations of minimum staffing requirements for skilled nursing facilities in those states which have enacted such requirements. Failure to meet these requirements can, among other things, jeopardize a facility's compliance with conditions of participation under certain state and federal healthcare programs; it may also subject the facility to a notice of deficiency, a citation, a civil money penalty, or litigation. These class-action “staffing” suits have the potential to result in large jury verdicts and settlements. The Company expects the plaintiff's bar to continue to be aggressive in their pursuit of these staffing and similar claims. The Company has in the past been subject to class action litigation involving claims of alleged violations of regulatory requirements related to staffing. While the Company has been able to settle these claims without a material ongoing adverse effect on its business, future claims could be brought that may materially affect its business, financial condition and results of operations. Other claims and suits, including class actions, continue to be filed against the Company and other companies in its industry. If there were a significant increase in the number of these claims or an increase in amounts owing should plaintiffs be successful in their prosecution of these claims, this could materially adversely affect the Company’s business, financial condition, results of operations and cash flows. The Company and its operating subsidiaries have been, and continue to be, subject to claims and legal actions that arise in the ordinary course of business, including potential claims related to patient care and treatment as well as employment related claims. Since 2011, the Company has been involved in a class action litigation claim alleging violations of state and federal wage and hour laws. In January 2017, the Company participated in an initial mediation session with plaintiffs' counsel. As a result of this discussion and due to (i) the fact no class had been certified (ii) the lack of specificity as to legal theories put forth by the plaintiffs, (iii) the nature of the remedies sought and (iv) the lack of any basis on which to compute estimated compensatory and/or exemplary damages, the Company could not predict what the outcome of the pending purported class action lawsuit would be, what the timing of the ultimate resolution of this lawsuit would be, or an estimate and/or range of possible loss related to it. In light of the inherent uncertainties involved in the pending class action lawsuit, the Company determined that we were not able to estimate the related costs or range of costs for the year ended December 31, 2016. In March 2017, the Company was invited to engage in further mediation discussions to determine whether settlement in advance of a decision on class certification was possible. In April 2017, the Company reached an agreement in principle to settle the subject class action litigation, without any admission of liability and subject to approval by the California Superior Court. Based upon the recent change in case status, the Company recorded an accrual for estimated probable losses of $11,000, exclusive of legal fees, in the first quarter of 2017. The Company funded the settlement amount of $11,000 in December 2017, and it will be distributed to the class members in Q1 of 2018. Other claims and suits continue to be filed against the Company and other companies in its industry. By way of recent example, a general/premises liability lawsuit was filed against one of the Company’s independent operating entities in San Luis Obispo, California, in connection with an alleged injury to a non-employee/contractor. Further, another one of the Company’s independent operating entities was sued on allegations of professional negligence, which claim was recently settled. The Company does not expect that there will be any material ongoing adverse effect on the Company's business, financial condition or results of operations in connection with the resolution of these matters. The Company cannot predict or provide any assurance as to the possible outcome of any litigation. If any litigation were to proceed, and the Company and its operating subsidiaries are subjected to, alleged to be liable for, or agrees to a settlement of, claims or obligations under Federal Medicare statutes, the Federal False Claims Act, or similar State and Federal statutes and related regulations, the Company's business, financial condition and results of operations and cash flows could be materially and adversely affected and its stock price could be adversely impacted. Among other things, any settlement or litigation could involve the payment of substantial sums to settle any alleged civil violations, and may also include the assumption of specific procedural and financial obligations by the Company or its subsidiaries going forward under a corporate integrity agreement and/or other arrangement with the government. Medicare Revenue Recoupments — The Company is subject to reviews relating to Medicare services, billings and potential overpayments as a result of Recovery Audit Contractors (RAC), Zone Program Integrity Contractors (ZPIC), Program Safeguard Contractors (PSC) and Medicaid Integrity Contributors (MIC) programs. As of December 31, 2017, seven of the Company's operating subsidiaries had probes scheduled and in process, both pre- and post-payment. The Company anticipates that these probe reviews will increase in frequency in the future. If a facility fails a probe review and subsequent re-probes, the facility could then be subject to extended pre-pay review or extrapolation of the identified error rate to all billing in the same time period. None of the Company's operating subsidiaries are currently on extended prepayment review, although that may occur in the future. U.S. Government Inquiry — In October 2013, the Company completed and executed a settlement agreement (the Settlement Agreement) with the DOJ, which received the final approval of the Office of Inspector General-HHS and the United States District Court for the Central District of California. Pursuant to the Settlement Agreement, the Company made a single lump-sum remittance to the government in the amount of $48,000 in October 2013. The Company has denied engaging in any illegal conduct and has agreed to the settlement amount without any admission of wrongdoing in order to resolve the allegations and to avoid the uncertainty and expense of protracted litigation. In connection with the settlement and effective as of October 1, 2013, the Company entered into a five-year corporate integrity agreement (the CIA) with the Office of Inspector General-HHS. The CIA acknowledges the existence of the Company’s current compliance program, which is in accord with the Office of the Inspector General (OIG)’s guidance related to an effective compliance program, and requires that the Company continue during the term of the CIA to maintain a program designed to promote compliance with the statutes, regulations, and written directives of Medicare, Medicaid, and all other Federal health care programs. The Company is also required to notify the Office of Inspector General-HHS in writing, of, among other things: (i) any ongoing government investigation or legal proceeding involving an allegation that the Company has committed a crime or has engaged in fraudulent activities; (ii) any other matter that a reasonable person would consider a probable violation of applicable criminal, civil, or administrative laws related to compliance with federal healthcare programs; and (iii) any change in location, sale, closing, purchase, or establishment of a new business unit or location related to items or services that may be reimbursed by federal health care programs. The Company is also required to retain an Independent Review Organization (IRO) to review certain clinical documentation annually for the term of the CIA. The Company has continued to meet the requirements under the Settlement Agreement and pass its IRO audits. Participation in federal healthcare programs by the Company is not affected by the Settlement Agreement or the CIA. In the event of an uncured material breach of the CIA, the Company could be excluded from participation in federal healthcare programs and/or subject to prosecution. Concentrations Credit Risk — The Company has significant accounts receivable balances, the collectability of which is dependent on the availability of funds from certain governmental programs, primarily Medicare and Medicaid. These receivables represent the only significant concentration of credit risk for the Company. The Company does not believe there are significant credit risks associated with these governmental programs. The Company believes that an appropriate allowance has been recorded for the possibility of these receivables proving uncollectible, and continually monitors and adjusts these allowances as necessary. The Company’s receivables from Medicare and Medicaid payor programs accounted for approximately 56.7% and 58.6% of its total accounts receivable as of December 31, 2017 and 2016, respectively. Revenue from reimbursement under the Medicare and Medicaid programs accounted for 68.4%, 67.8% and 69.1% of the Company's revenue for the years ended December 31, 2017, 2016 and 2015, respectively. Cash in Excess of FDIC Limits — The Company currently has bank deposits with financial institutions in the U.S. that exceed FDIC insurance limits. FDIC insurance provides protection for bank deposits up to $250. In addition, the Company has uninsured bank deposits with a financial institution outside the U.S. As of February 2, 2018, the Company had approximately $965 in uninsured cash deposits. All uninsured bank deposits are held at high quality credit institutions.

XML 42 R26.htm IDEA: XBRL DOCUMENT

Divestitures	12 Months Ended
Divestitures	Dec. 31, 2017
Divestitures [Abstract]
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]	DIVESTITURES In 2016, the Company completed the sale of seventeen urgent care centers for an aggregate sale price of $41,492. As a result of the sale, the Company recognized a pretax gain of $19,160, which is included in operating income. Due to the disposition of the clinics, the Company is no longer the primary beneficiary and the variable interest entities associated with the urgent care operations was deconsolidated from the Company's consolidated financial statements as of December 31, 2016. At deconsolidation, the Company eliminated intercompany balances that previously existed. The sale of this investment supports the Company's increased focus on growth opportunities in its business lines that are complementary to its existing transitional and skilled services. The sale transactions did not meet the criteria of a discontinued operation as they do not represent a strategic shift that has or will have a major effect on the Company’s operations and financial results.

XML 43 R27.htm IDEA: XBRL DOCUMENT

Defined Contribution Plan	12 Months Ended
Defined Contribution Plan	Dec. 31, 2017
Defined Contribution Plan [Abstract]
Compensation and Employee Benefit Plans [Text Block]	DEFINED CONTRIBUTION PLAN The Company has a 401(k) defined contribution plan (the 401(k) Plan), whereby eligible employees may contribute up to 15% of their annual basic earnings. Additionally, the 401(k) Plan provides for discretionary matching contributions (as defined in the 401(k) Plan) by the Company. The Company expensed matching contributions to the 401(k) Plan of $1,028, $862 and $682 during the years ended December 31, 2017, 2016 and 2015, respectively. Beginning in 2007, the 401(k) Plan allowed eligible employees to contribute up to 90% of their eligible compensation, subject to applicable annual Internal Revenue Code limits

XML 44 R28.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies Level 2 (Policies)	12 Months Ended
Significant Accounting Policies Level 2 (Policies)	Dec. 31, 2017
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation — The accompanying consolidated financial statements (Financial Statements) have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The Company is the sole member or shareholder of various consolidated limited liability companies and corporations established to operate various acquired skilled nursing and assisted living operations, home health, hospice and home care operations, and related ancillary services. All intercompany transactions and balances have been eliminated in consolidation. The consolidated financial statements include the accounts of all entities controlled by the Company through its ownership of a majority voting interest. The Company presents noncontrolling interest within the equity section of its consolidated balance sheets. The Company presents the amount of consolidated net income that is attributable to The Ensign Group, Inc. and the noncontrolling interest in its consolidated statements of income. The consolidated financial statements include the accounts of all entities controlled by the Company through its ownership of a majority voting interest and the accounts of any variable interest entities (VIEs) where the Company is subject to a majority of the risk of loss from the VIE's activities, or entitled to receive a majority of the entity's residual returns, or both. The Company assesses the requirements related to the consolidation of VIEs, including a qualitative assessment of power and economics that considers which entity has the power to direct the activities that "most significantly impact" the VIE's economic performance and has the obligation to absorb losses of, or the right to receive benefits that could be potentially significant to, the VIE. The Company's relationship with variable interest entities was not material during the year ended December 31, 2017. In 2016, the Company completed the sale of its urgent care centers for an aggregate purchase price of $41,492. The sale transactions do not meet the criteria of discontinued operations as they do not represent a strategic shift that has, or will have, a major effect on the Company’s operations and financial results.
Use of Estimates, Policy [Policy Text Block]	Estimates and Assumptions — The preparation of Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Financial Statements and the reported amounts of revenue and expenses during the reporting periods. The most significant estimates in the Company’s Financial Statements relate to revenue, allowance for doubtful accounts, intangible assets and goodwill, impairment of long-lived assets, general and professional liability, workers' compensation and healthcare claims included in accrued self-insurance liabilities, and income taxes. Actual results could differ from those estimates.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments —The Company’s financial instruments consist principally of cash and cash equivalents, debt security investments, accounts receivable, insurance subsidiary deposits, accounts payable and borrowings. The Company believes all of the financial instruments’ recorded values approximate fair values because of their nature or respective short durations.
Revenue Recognition, Sales of Services [Policy Text Block]	Revenue Recognition — The Company recognizes revenue when the following four conditions have been met: (i) there is persuasive evidence that an arrangement exists; (ii) delivery has occurred or service has been rendered; (iii) the price is fixed or determinable; and (iv) collection is reasonably assured. The Company's revenue is derived primarily from providing healthcare services to patients and is recognized on the date services are provided at amounts billable to the individual. For reimbursement arrangements with third-party payors, including Medicaid, Medicare and private insurers, revenue is recorded based on contractually agreed-upon amounts on a per patient basis. Revenue from the Medicare and Medicaid programs accounted for 68.4%, 67.8% and 69.1% of the Company's revenue for the years ended December 31, 2017, 2016 and 2015, respectively. The Company records revenue from these governmental and managed care programs as services are performed at their expected net realizable amounts under these programs. The Company’s revenue from governmental and managed care programs is subject to audit and retroactive adjustment by governmental and third-party agencies. Consistent with healthcare industry accounting practices, any changes to these governmental revenue estimates are recorded in the period the change or adjustment becomes known based on final settlement. The Company recorded adjustments to revenue which were not material to the Company's consolidated revenue or Financial Statements for the years ended December 31, 2017, 2016 and 2015. The Company’s service specific revenue recognition policies are as follows: Skilled Nursing Revenue The Company’s revenue is derived primarily from providing long-term healthcare services to patients and is recognized on the date services are provided at amounts billable to individual patients. For patients under reimbursement arrangements with third-party payors, including Medicaid, Medicare and private insurers, revenue is recorded based on contractually agreed-upon amounts or rate on a per patient, daily basis or as services are performed. Assisted and Independent Living Revenue The Company's revenue is recorded when services are rendered on the date services are provided at amounts billable to individual residents and consists of fees for basic housing and assisted living care. Residency agreements are generally for a term of 30 days, with resident fees billed monthly in advance. For patients under reimbursement arrangements with Medicaid, revenue is recorded based on contractually agreed-upon amounts or rate on a per resident, daily basis or as services rendered. Revenue for certain ancillary charges is recognized as services are provided, and such fees are billed monthly in arrears. Home Health Revenue Medicare Revenue Net service revenue is recorded under the Medicare prospective payment system based on a 60-day episode payment rate that is subject to adjustment based on certain variables including, but not limited to: (a) an outlier payment if patient care was unusually costly; (b) a low utilization payment adjustment if the number of visits was fewer than five; (c) a partial payment if the patient transferred to another provider or the Company received a patient from another provider before completing the episode; (d) a payment adjustment based upon the level of therapy services required; (e) the number of episodes of care provided to a patient, regardless of whether the same home health provider provided care for the entire series of episodes; (f) changes in the base episode payments established by the Medicare program; (g) adjustments to the base episode payments for case mix and geographic wages; and (h) recoveries of overpayments. The Company makes adjustments to Medicare revenue on completed episodes to reflect differences between estimated and actual payment amounts, an inability to obtain appropriate billing documentation or authorizations acceptable to the payor and other reasons unrelated to credit risk. Therefore, the Company believes that its reported net service revenue and patient accounts receivable will be the net amounts to be realized from Medicare for services rendered. In addition to revenue recognized on completed episodes, the Company also recognizes a portion of revenue associated with episodes in progress. Episodes in progress are 60-day episodes of care that begin during the reporting period, but were not completed as of the end of the period. As such, the Company estimates revenue and recognizes it on a daily basis. The primary factors underlying this estimate are the number of episodes in progress at the end of the reporting period, expected Medicare revenue per episode and its estimate of the average percentage complete based on visits performed. Non-Medicare Revenue Episodic Based Revenue - The Company recognizes revenue in a similar manner as it recognizes Medicare revenue for episodic-based rates that are paid by other insurance carriers, including Medicare Advantage programs; however, these rates can vary based upon the negotiated terms. Non-episodic Based Revenue - Revenue is recorded on an accrual basis based upon the date of service at amounts equal to its established or estimated per-visit rates, as applicable. Hospice Revenue Revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are daily rates for each of the levels of care the Company delivers. The Company makes adjustments to revenue for an inability to obtain appropriate billing documentation or authorizations acceptable to the payor and other reasons unrelated to credit risk. Additionally, as Medicare hospice revenue is subject to an inpatient cap limit and an overall payment cap, the Company monitors its provider numbers and estimates amounts due back to Medicare if a cap has been exceeded. The Company records these adjustments as a reduction to revenue and increases to other accrued liabilities.
Trade and Other Accounts Receivable, Policy [Policy Text Block]	Accounts Receivable and Allowance for Doubtful Accounts — Accounts receivable consist primarily of amounts due from Medicare and Medicaid programs, other government programs, managed care health plans and private payor sources. Estimated provisions for doubtful accounts are recorded to the extent it is probable that a portion or all of a particular account will not be collected. In evaluating the collectability of accounts receivable, the Company considers a number of factors, including the age of the accounts, changes in collection patterns, the composition of patient accounts by payor type and the status of ongoing disputes with third-party payors. On an annual basis, the historical collection percentages are reviewed by payor and by state and are updated to reflect the recent collection experience of the Company. In order to determine the appropriate reserve rate percentages which ultimately establish the allowance, the Company analyzes historical cash collection patterns by payor and by state. The percentages applied to the aged receivable balances are based on the Company’s historical experience and time limits, if any, for managed care, Medicare, Medicaid and other payors. The Company periodically refines its estimates of the allowance for doubtful accounts based on experience with the estimation process and changes in circumstances.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents — Cash and cash equivalents consist of bank term deposits, money market funds and treasury bill related investments with original maturities of three months or less at time of purchase and therefore approximate fair value. The fair value of money market funds is determined based on “Level 1” inputs, which consist of unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets. The Company places its cash and short-term investments with high credit quality financial institutions.
Insurance Subsidiary Deposits and Investments [Policy Text Block]	Insurance Subsidiary Deposits and Investments — The Company's captive insurance subsidiary cash and cash equivalents, deposits and investments are designated to support long-term insurance subsidiary liabilities and have been classified as short-term and long-term assets based on the timing of expected future payments of the Company's captive insurance liabilities. The majority of these deposits and investments are currently held in AA, A and BBB+ rated debt security investments and the remainder is held in a bank account with a high credit quality financial institution. See further discussion at Note 5, Fair Value Measurements. The Company evaluates securities for other-than-temporary impairment (“OTTI”) on at least a quarterly basis, and more frequently when economic or market conditions warrant such an evaluation. If securities are in an unrealized loss position, the Company considers the extent and duration of the unrealized loss, and the financial condition and near-term prospects of the issuer. The Company also assesses whether it intends to sell, or it is more likely than not that it will be required to sell, a security in an unrealized loss position before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the entire difference between amortized cost and fair value is recognized as impairment through earnings. For the years ended December 31, 2016 and 2017, the Company did not recognize any OTTI for its investments.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment — Property and equipment are initially recorded at their historical cost. Repairs and maintenance are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the depreciable assets (ranging from three to 59 years). Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the remaining lease term.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets — The Company reviews the carrying value of long-lived assets that are held and used in the Company’s operating subsidiaries for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of these assets is determined based upon expected undiscounted future net cash flows from the operating subsidiaries to which the assets relate, utilizing management’s best estimate, appropriate assumptions, and projections at the time. If the carrying value is determined to be unrecoverable from future operating cash flows, the asset is deemed impaired and an impairment loss would be recognized to the extent the carrying value exceeded the estimated fair value of the asset. The Company estimates the fair value of assets based on the estimated future discounted cash flows of the asset. Management has evaluated its long-lived assets and recorded an impairment charge of $111 and $137 related to the closure of facilities during the years ended December 31, 2017 and 2016, respectively. The Company did not identify any asset impairment during the year ended December 31, 2015.
Lease, Policy [Policy Text Block] (Deprecated 2017-01-31)	Leases and Leasehold Improvements - At the inception of each lease, the Company performs an evaluation to determine whether the lease should be classified as an operating or capital lease. The Company records rent expense for operating leases that contain scheduled rent increases on a straight-line basis over the term of the lease. The lease term used for straight-line rent expense is calculated from the date the Company is given control of the leased premises through the end of the lease term. The lease term used for this evaluation also provides the basis for establishing depreciable lives for buildings subject to lease and leasehold improvements, as well as the period over which the Company records straight-line rent expense.
Goodwill and Intangible Assets, Policy [Policy Text Block]	Intangible Assets and Goodwill — Definite-lived intangible assets consist primarily of favorable leases, lease acquisition costs, patient base, facility trade names and customer relationships. Favorable leases and lease acquisition costs are amortized over the life of the lease of the facility. Patient base is amortized over a period of four to eight months, depending on the classification of the patients and the level of occupancy in a new acquisition on the acquisition date. Trade names at affiliated facilities are amortized over 30 years and customer relationships are amortized over a period of up to 20 years. The Company's indefinite-lived intangible assets consist of trade names and Medicare and Medicaid licenses. The Company tests indefinite-lived intangible assets for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the carrying amount of the intangible asset may not be recoverable. The Company did not identify any asset impairment during the years ended December 31, 2017, 2016 and 2015. Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in business combinations. Goodwill is subject to annual testing for impairment. In addition, goodwill is tested for impairment if events occur or circumstances change that would reduce the fair value of a reporting unit below its carrying amount. The Company performs its annual test for impairment during the fourth quarter of each year. See further discussion at Note 11, Goodwill and Other Indefinite-Lived Intangible Assets.
Deferred Rent [Policy Text Block]	Deferred Rent - Deferred rent represents rental expense, determined on a straight-line basis over the life of the related lease, in excess of actual rent payments.
Liability Reserve Estimate, Policy [Policy Text Block]	Self-Insurance — The Company is partially self-insured for general and professional liability up to a base amount per claim (the self-insured retention) with an aggregate, one-time deductible above this limit. Losses beyond these amounts are insured through third-party policies with coverage limits per claim, per location and on an aggregate basis for the Company. Starting on January 1, 2017, the combined self-insured retention was $500 per claim, subject to an additional one-time deductible of $750 for California affiliated operations and a separate, one-time, deductible of $1,000 for non-California operations. For all affiliated operations, except those located in Colorado, the third-party coverage above these limits was $1,000 per claim, $3,000 per operation, with a $5,000 blanket aggregate limit and an additional state-specific aggregate where required by state law. In Colorado, the third-party coverage above these limits was $1,000 per claim and $3,000 per operation, which is independent of the aforementioned blanket aggregate limits that apply outside of Colorado. The self-insured retention and deductible limits for general and professional liability and workers' compensation for all states (except Texas and Washington for workers' compensation) are self-insured through the Captive, the related assets and liabilities of which are included in the accompanying consolidated balance sheets. The Captive is subject to certain statutory requirements as an insurance provider. These requirements include, but are not limited to, maintaining statutory capital. The Company’s policy is to accrue amounts equal to the actuarially estimated costs to settle open claims of insureds, as well as an estimate of the cost of insured claims that have been incurred but not reported. The Company develops information about the size of the ultimate claims based on historical experience, current industry information and actuarial analysis, and evaluates the estimates for claim loss exposure on a quarterly basis. The Company’s operating subsidiaries are self-insured for workers’ compensation in California. To protect itself against loss exposure in California with this policy, the Company has purchased individual specific excess insurance coverage that insures individual claims that exceed $500 per occurrence. In Texas, the operating subsidiaries have elected non-subscriber status for workers’ compensation claims and, effective February 1, 2011, the Company has purchased individual stop-loss coverage that insures individual claims that exceed $750 per occurrence. As of July 1, 2014, the Company’s operating subsidiaries in all other states, with the exception of Washington, are under a loss sensitive plan that insures individual claims that exceed $350 per occurrence. In Washington, the operating subsidiaries' coverage is financed through premiums paid by the employers and employees. The claims and pay benefits are managed through a state insurance pool. Outside of California, Texas and Washington, the Company has purchased insurance coverage that insures individual claims that exceed $350 per accident. In all states except Washington, the Company accrues amounts equal to the estimated costs to settle open claims, as well as an estimate of the cost of claims that have been incurred but not reported. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information. In addition, the Company has recorded an asset and equal liability of $5,394 and $4,104 at December 31, 2017 and 2016, respectively, in order to present the ultimate costs of malpractice and workers' compensation claims and the anticipated insurance recoveries on a gross basis. See Note 12, Restricted and Other Assets. The Company self-funds medical (including prescription drugs) and dental healthcare benefits to the majority of its employees. The Company is fully liable for all financial and legal aspects of these benefit plans. To protect itself against loss exposure with this policy, the Company has purchased individual stop-loss insurance coverage that insures individual claims that exceed $300 for each covered person with an additional one-time aggregate individual stop loss deductible of $75. Beginning 2016, the Company's policy does not include the additional one-time aggregate individual stop loss deductible of $75. The Company believes that adequate provision has been made in the Financial Statements for liabilities that may arise out of patient care, workers’ compensation, healthcare benefits and related services provided to date. The amount of the Company’s reserves was determined based on an estimation process that uses information obtained from both company-specific and industry data. This estimation process requires the Company to continuously monitor and evaluate the life cycle of the claims. Using data obtained from this monitoring and the Company’s assumptions about emerging trends, the Company, with the assistance of an independent actuary, develops information about the size of ultimate claims based on the Company’s historical experience and other available industry information. The most significant assumptions used in the estimation process include determining the trend in costs, the expected cost of claims incurred but not reported and the expected costs to settle or pay damage awards with respect to unpaid claims. The self-insured liabilities are based upon estimates, and while management believes that the estimates of loss are reasonable, the ultimate liability may be in excess of or less than the recorded amounts. Due to the inherent volatility of actuarially determined loss estimates, it is reasonably possible that the Company could experience changes in estimated losses that could be material to net income. If the Company’s actual liability exceeds its estimates of loss, its future earnings, cash flows and financial condition would be adversely affected.
Income Tax, Policy [Policy Text Block]	Income Taxes — Deferred tax assets and liabilities are established for temporary differences between the financial reporting basis and the tax basis of the Company’s assets and liabilities at tax rates in effect when such temporary differences are expected to reverse. The Company generally expects to fully utilize its deferred tax assets; however, when necessary, the Company records a valuation allowance to reduce its net deferred tax assets to the amount that is more likely than not to be realized. In determining the need for a valuation allowance or the need for and magnitude of liabilities for uncertain tax positions, the Company makes certain estimates and assumptions. These estimates and assumptions are based on, among other things, knowledge of operations, markets, historical trends and likely future changes and, when appropriate, the opinions of advisors with knowledge and expertise in certain fields. Due to certain risks associated with the Company’s estimates and assumptions, actual results could differ. The Tax Cuts and Jobs Act (the Tax Act), which was enacted in December 2017, increased the Company's income tax expense by $3,915 for the year ended December 31, 2017. The Tax Act will decrease the corporate income tax rate from 35.0% to 21.0% beginning on January 1, 2018. The Company expects meaningful benefits from this reduction to continue from its enactment in future periods. See Note 14, Income Taxes for further detail.
Noncontrolling Interest [Policy Text Block]	Noncontrolling Interest — The noncontrolling interest in a subsidiary is initially recognized at estimated fair value on the acquisition date and is presented within total equity in the Company's consolidated balance sheets. The Company presents the noncontrolling interest and the amount of consolidated net income attributable to The Ensign Group, Inc. in its consolidated statements of income and net income per share is calculated based on net income attributable to The Ensign Group, Inc.'s stockholders. The carrying amount of the noncontrolling interest is adjusted based on an allocation of subsidiary earnings based on ownership interest.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Share-Based Compensation — The Company measures and recognizes compensation expense for all share-based payment awards made to employees and directors including employee stock options based on estimated fair values, ratably over the requisite service period of the award. Net income has been reduced as a result of the recognition of the fair value of all stock options and restricted stock awards issued, the amount of which is contingent upon the number of future grants and other variables.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements — Except for rules and interpretive releases of the Securities and Exchange Commission (SEC) under authority of federal securities laws and a limited number of grandfathered standards, the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) is the sole source of authoritative GAAP literature recognized by the FASB and applicable to the Company. For any new pronouncements announced, the Company considers whether the new pronouncements could alter previous generally accepted accounting principles and determines whether any new or modified principles will have a material impact on the Company's reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company's financial management and certain standards are under consideration. Recent Accounting Standards Adopted by the Company In March 2016, the FASB issued a new standard to simplify several aspects of the accounting for employee share-based payment transactions, which includes the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The new standard was effective for the Company in the first quarter of fiscal year 2017. Under the previous guidance, excess tax benefits and deficiencies from share-based compensation arrangements were recorded in equity when the awards vested or were settled. The new guidance requires prospective recognition of excess tax benefits and deficiencies in the income statement, resulting in the recognition of excess tax benefits in income tax expense, of $3,423, rather than in paid-in-capital, for the year ended December 31, 2017. In addition, under the new guidance, excess income tax benefits from share-based compensation arrangements are classified as cash flow from operations, rather than as cash flow from financing activities. The Company has elected to apply the cash flow classification guidance prospectively, resulting in an increase to operating cash flow for the year ended December 31, 2017 and the prior year period has not been adjusted. The Company has also elected to continue to estimate the expected forfeitures rather than electing to account for forfeitures as they occur. Finally, the adoption of the guidance requires excess tax benefits and deficiencies to be prospectively excluded from assumed future proceeds in the calculation of diluted shares, resulting in an increase in diluted weighted average shares outstanding. Accounting Standards Recently Issued But Not Yet Adopted by the Company In May 2017, the FASB issued amended authoritative guidance to provide guidance on types of changes to the terms or conditions of share-based payments awards to which an entity would be required to apply modification accounting under ASC 718. This guidance is effective for annual and interim periods beginning after December 15, 2017, which will be the Company's fiscal year 2018, with early adoption permitted in certain cases. The adoption of this standard is not expected to have a material impact on the Company's consolidated financial statements. In January 2017, the FASB issued amended authoritative guidance to clarify the definition of a business and reduce diversity in practice related to the evaluation of whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The new provisions provide the requirements needed for an integrated set of assets and activities (the set) to be a business and also establish a practical way to determine when a set is not a business. The ASU provides a screen to determine when an integrated set of assets and activities is not a business. The more robust framework helps entities to narrow the definition of outputs created by the set and align it with how outputs are described in the new revenue standard. This guidance is effective for annual and interim periods beginning after December 15, 2017, which will be the Company's fiscal year 2018, with early adoption permitted in certain cases. The new guidance is required to be applied on a prospective basis. The effect of the implementation will depend upon the nature of the Company's future acquisitions. In January 2017, the FASB issued amended authoritative guidance to simplify and reduce the cost and complexity of the goodwill impairment test. The new provisions eliminate step 2 from the goodwill impairment test and shifts the concept of impairment from a measure of loss when comparing the implied fair value of goodwill to its carrying amount to comparing the fair value of a reporting unit with its carrying amount. The Board also eliminated the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment or step 2 of the goodwill impairment test. The new guidance does not amend the optional qualitative assessment of goodwill impairment. This guidance is effective for annual periods beginning after December 15, 2019, which will be the Company's fiscal year 2020, with early adoption permitted. The adoption of this standard is not expected to have a material impact on the Company's consolidated financial statements. In October 2016, the FASB issued amended authoritative guidance to require companies to recognize the income tax consequences of an intra-entity transfer of an asset, other than inventory, when the transfer occurs. The amendments will be effective for the Company’s fiscal year beginning January 1, 2018. The new guidance is required to be applied on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. The adoption of this standard is not expected to have a material impact on the Company's consolidated financial statements based on the Company's historical activity. Furthermore, the actual impact of implementation will largely depend on future intra-entity asset transfers, if any. In August 2016, the FASB issued amended authoritative guidance to reduce the diversity in practice related to the presentation and classification of certain cash receipts and cash payments in the statement of cash flows. The new provisions target cash flow issues related to (i) debt prepayment or debt extinguishment costs, (ii) settlement of debt instruments with coupon rates that are insignificant relative to effective interest rates, (iii) contingent consideration payments made after a business combination, (iv) proceeds from settlement of insurance claims, (v) proceeds from the settlement of corporate-owned life insurance and bank-owned life insurance policies, (vi) distributions received from equity method investees, (vii) beneficial interests in securitization transactions and (viii) separately identifiable cash flows and application of the predominance principle. This guidance will be effective for fiscal years beginning after December 15, 2017, which will be the Company's fiscal year 2018, with early adoption permitted. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements. In February 2016, the FASB issued amended authoritative guidance on accounting for leases. The new provisions require that a lessee of operating leases recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. The lease liability will be equal to the present value of lease payments, with the right-of-use asset based upon the lease liability. The classification criteria for distinguishing between finance (or capital) leases and operating leases are substantially similar to the previous lease guidance, but with no explicit bright lines. As such, operating leases will result in straight-line rent expense similar to current practice. For short term leases (term of 12 months or less), a lessee is permitted to make an accounting election not to recognize lease assets and lease liabilities, which would generally result in lease expense being recognized on a straight-line basis over the lease term. This guidance applies to all entities and is effective for annual periods beginning after December 15, 2018, which will be the Company's fiscal year 2019, with early adoption permitted. The Company is currently evaluating the impact this guidance will have on its consolidated financial statements but expects this adoption will result in a significant increase in the assets and liabilities on its consolidated balance sheets. In January 2016, the FASB issued amended authoritative guidance which makes targeted improvements for financial instruments. The new provisions impact certain aspects of recognition, measurement, presentation and disclosure requirements of financial instruments. Specifically, the guidance will (1) require equity investments to be measured at fair value with changes in fair value recognized in net income, (2) simplify the impairment assessment of equity investments without readily determinable fair values, (3) eliminate the requirement to disclose the method and assumptions used to estimate fair value for financial instruments measured at amortized cost, and (4) require separate presentation of financial assets and financial liabilities by measurement category. The guidance is effective for annual and interim periods beginning after December 15, 2017, which will be the Company's fiscal year 2018. Early adoption is not permitted. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements. In March 2016, the FASB issued its standard to amend the principal-versus-agent implementation guidance and illustrations in the Board’s new revenue standard, which includes accounting implication related to (1) determining the appropriate unit of account under the revenue standard’s principal-versus-agent guidance and (2) applying the indicators of whether an entity is a principal or an agent in accordance with the revenue standard’s control principle. The guidance will be effective for fiscal years beginning after December 15, 2017, which will be the Company's fiscal year 2018. The guidance has the same effective date as the new revenue standard and the Company is required to adopt the guidance by using the same transition method it would use to adopt the new revenue standard. The Company's evaluation of the adoption method and impact to the consolidated financial statements is performed concurrently with the new revenue standard below. In May 2014, the FASB and International Accounting Standards Board issued their final standard on revenue from contracts with customers that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers. The new standard supersedes most current revenue recognition guidance, including industry-specific guidance, and may be applied retrospectively to each period presented (full retrospective method) or retrospectively with the cumulative effect recognized in beginning retained earnings as of the date of adoption (modified retrospective method). In July 2015, the FASB formally deferred for one year the effective date of the new revenue standard and decided to permit entities to early adopt the standard. In December 2016, the FASB made certain technical corrections to further clarify the core revenue recognition principles, primarily in response to feedback from several sources, including the FASB/IASB Transition Resource Group. The guidance will be effective for fiscal years beginning after December 15, 2017, which will be the Company's fiscal year 2018. The Company initiated an adoption plan in fiscal year 2015, beginning with preliminary evaluation of the standard, and subsequently performed additional analysis of revenue streams and transactions under the new standard. In particular, the Company performed analysis into the application of the portfolio approach as a practical expedient to group patient contracts with similar characteristics, such that revenue for a given portfolio would not be materially different than if it were evaluated on a contract-by-contract basis. The adoption plan has been completed and the impact to the consolidated financial statements for periods subsequent to adoption is not material. As part of the impact assessment, the Company evaluated any variable consideration, potential constraints on the estimate of variable consideration, and significant financing components, in particular as it related to third party settlements. The Company anticipates that for periods subsequent to adoption, the majority of what is currently classified as bad debt expense under operating expenses will be treated as an implicit price concession factored into net revenue, consistent with the intent of the standard. The new standard also requires enhanced disclosures related to the disaggregation of revenue, information about contract balances, and other disclosures about contracts with customers, including revenue recognition policies to identify performance obligations and significant judgments in measurement and recognition. The Company adopted the new revenue standard as of January 1, 2018 using the modified retrospective method and the adoption did not have a material impact.

XML 45 R29.htm IDEA: XBRL DOCUMENT

Computation of Net Income Per Common Share (Tables)

12 Months Ended

Dec. 31, 2017

COMPUTATION OF NET INCOME PER COMMON SHARE [Abstract]

Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table Text Block]



	Year Ended December 31,
	2017		2016		2015
Numerator:
Net income	$	40,833	$	52,843	$	55,917
Less: net income attributable to noncontrolling interests	358		2,853		485
Net income attributable to The Ensign Group, Inc.	$	40,475	$	49,990	$	55,432

Denominator:
Weighted average shares outstanding for basic net income per share	50,932		50,555		50,316
Basic net income per common share attributable to The Ensign Group, Inc.	$	0.79	$	0.99	$	1.10

Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table Text Block]

A reconciliation of the numerator and denominator used in the calculation of diluted net income per common share follows:



	Year Ended December 31,
	2017		2016		2017
Numerator:
Net income	$	40,833	$	52,843	$	55,917
Less: net income attributable to noncontrolling interests	358		2,853		485
Net income attributable to The Ensign Group, Inc.	$	40,475	$	49,990	$	55,432

Denominator:
Weighted average common shares outstanding	50,932		50,555		50,316
Plus: incremental shares from assumed conversion⁽¹⁾	1,897		1,578		1,894
Adjusted weighted average common shares outstanding	52,829		52,133		52,210
Diluted net income per common share attributable to The Ensign Group, Inc.	$	0.77	$	0.96	$	1.06

XML 46 R30.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2017

Fair Value Disclosures [Abstract]

Fair Value, Assets Measured on Recurring Basis [Table Text Block]

The following table summarizes the financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2017 and 2016:



	December 31,
	2017						2016
	Level 1		Level 2		Level 3		Level 1		Level 2		Level 3
Cash and cash equivalents	$	42,337	$	—	$	—	$	57,706	$	—	$	—

XML 47 R31.htm IDEA: XBRL DOCUMENT

Revenue and Accounts Receivable (Tables)

12 Months Ended

Dec. 31, 2017

REVENUE AND ACCOUNTS RECEIVABLE [Abstract]

Schedule of Revenue Sources, Health Care Organization [Table Text Block]

Revenue for the years ended December 31, 2017, 2016 and 2015 is summarized in the following tables:



	Year Ended December 31,
	2017				2016				2015
	Revenue		% of Revenue		Revenue		% of Revenue		Revenue		% of Revenue
Medicaid	$	644,803	34.9	%	$	557,958	33.7	%	$	458,956	34.2	%
Medicare	515,884		27.9		477,019		28.8		395,503		29.5
Medicaid — skilled	102,875		5.6		87,517		5.3		71,905		5.4
Total Medicaid and Medicare	1,263,562		68.4		1,122,494		67.8		926,364		69.1
Managed care	303,386		16.4		265,508		16.0		206,770		15.4
Private and other payors⁽¹⁾	282,369		15.2		266,862		16.2		208,692		15.5
Revenue	$	1,849,317	100.0	%	$	1,654,864	100.0	%	$	1,341,826	100.0	%

Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]

Accounts receivable as of December 31, 2017 and 2016 is summarized in the following table:



	December 31,
	2017			2016
Medicaid	$	119,441		$	111,031
Managed care	68,930			66,346
Medicare	55,667			55,500
Private and other payors	64,991			51,347
	309,029			284,224
Less: allowance for doubtful accounts	(43,961		)	(39,791		)
Accounts receivable, net	$	265,068		$	244,433

XML 48 R32.htm IDEA: XBRL DOCUMENT

Business Segments (Tables)

12 Months Ended

Dec. 31, 2017

Segment Reporting [Abstract]

Reconciliation of Revenue from Segments to Consolidated [Table Text Block]

Segment revenues by major payor source were as follows:



	Year Ended December 31, 2017
	Transitional and Skilled Services		Assisted and Independent Living Services		Home Health and Hospice Services		All Other			Total Revenue		Revenue %
Medicaid	$	603,104	$	30,469	$	11,230	$	—		$	644,803	34.9	%
Medicare	417,870		—		98,014		—			515,884		27.9
Medicaid-skilled	102,875		—		—		—			102,875		5.6
Subtotal	1,123,849		30,469		109,244		—			1,263,562		68.4
Managed care	281,563		—		21,823		—			303,386		16.4
Private and other	139,798		106,177		11,336		25,058		(1)	282,369		15.2
Total revenue	$	1,545,210	$	136,646	$	142,403	$	25,058		$	1,849,317	100.0	%
(1) Private and other payors also includes revenue from all payors generated in other ancillary services for the year ended December 31, 2017.



	Year Ended December 31, 2016
	Transitional and Skilled Services		Assisted and Independent Living Services		Home Health and Hospice Services		All Other			Total Revenue		Revenue %
Medicaid	$	521,063	$	26,397	$	10,498	$	—		$	557,958	33.7	%
Medicare	396,519		—		80,500		—			477,019		28.8
Medicaid-skilled	87,517		—		—		—			87,517		5.3
Subtotal	1,005,099		26,397		90,998		—			1,122,494		67.8
Managed care	247,844		—		17,664		—			265,508		16.0
Private and other	121,860		97,239		7,151		40,612		(1)	266,862		16.2
Total revenue	$	1,374,803	$	123,636	$	115,813	$	40,612		$	1,654,864	100.0	%
(1) Private and other payors also includes revenue from all payors generated in other ancillary services and urgent care centers for the year ended December 31, 2016.



	Year Ended December 31, 2015
	Transitional and Skilled Services		Assisted and Independent Living Services		Home Health and Hospice Services		All Other			Total Revenue		Revenue %
Medicaid	$	430,368	$	19,642	$	8,946	$	—		$	458,956	34.2	%
Medicare	332,429		—		63,074		—			395,503		29.5
Medicaid-skilled	71,905		—		—		—			71,905		5.4
Subtotal	834,702		19,642		72,020		—			926,364		69.1
Managed care	194,743		—		12,027		—			206,770		15.4
Private and other	96,943		68,487		6,309		36,953		(1)	208,692		15.5
Total revenue	$	1,126,388	$	88,129	$	90,356	$	36,953		$	1,341,826	100.0	%
(1) Private and other payors also includes revenue from all payors generated in other ancillary services and urgent care centers for the year ended December 31, 2015.

Schedule of Segment Reporting Information, by Segment [Table Text Block]

The following table sets forth selected financial data consolidated by business segment:



	Year Ended December 31, 2017
	Transitional and Skilled Services(3)		Assisted and Independent Living Services(3)		Home Health and Hospice Services		All Other			Elimination			Total
Revenue from external customers	$	1,545,210	$	136,646	$	142,403	$	25,058		$	—		$	1,849,317
Intersegment revenue (1)	3,023		—		—		3,035			(6,058		)	—
Total revenue	$	1,548,233	$	136,646	$	142,403	$	28,093		$	(6,058	)	$	1,849,317
Segment income (loss) (2)	$	140,272	$	16,736	$	19,717	$	(95,440	)	$	—		$	81,285
Interest expense, net of interest income													$	(12,007	)
Income before provision for income taxes													$	69,278
Depreciation and amortization	$	29,928	$	6,334	$	945	$	7,265		$	—		$	44,472

(1) Intersegment revenue represents services provided at the Company's operating subsidiaries to the Company's other business lines.



	Year Ended December 31, 2016
	Transitional and Skilled Services(3)		Assisted and Independent Living Services(3)		Home Health and Hospice Services		All Other			Elimination			Total
Revenue from external customers	$	1,374,803	$	123,636	$	115,813	$	40,612		$	—		$	1,654,864
Intersegment revenue (1)	2,929		—		—		2,184			(5,113		)	—
Total revenue	$	1,377,732	$	123,636	$	115,813	$	42,796		$	(5,113	)	$	1,654,864
Segment income (loss) (2)	$	118,118	$	11,701	$	16,571	$	(54,543	)	$	—		$	91,847
Interest expense, net of interest income													$	(6,029	)
Income before provision for income taxes													$	85,818
Depreciation and amortization	$	26,298	$	4,157	$	924	$	7,303		$	—		$	38,682

(1) Intersegment revenue represents services provided at the Company's operating subsidiaries to the Company's other business lines.



	Year Ended December 31, 2015
	Transitional and Skilled Services(3)		Assisted and Independent Living Services(3)		Home Health and Hospice Services		All Other			Elimination			Total
Revenue from external customers	$	1,126,388	$	88,129	$	90,356	$	36,953		$	—		$	1,341,826
Intersegment revenue (1)	2,447		—		—		881			(3,328		)	—
Total revenue	$	1,128,835	$	88,129	$	90,356	$	37,834		$	(3,328	)	$	1,341,826
Segment income (loss) (2)	$	136,744	$	11,463	$	13,584	$	(68,709	)	$	—		$	93,082
Interest expense, net of interest income													$	(1,983	)
Income before provision for income taxes													$	91,099
Depreciation and amortization	$	18,008	$	3,338	$	980	$	5,785		$	—		$	28,111

(1) Intersegment revenue represents services provided at the Company's operating subsidiaries to the Company's other business lines.

XML 49 R33.htm IDEA: XBRL DOCUMENT

Acquisitions (Tables)

12 Months Ended

Dec. 31, 2017

Business Combinations [Abstract]

Schedule of Business Acquisitions, by Acquisition [Table Text Block]



	December 31,
	2017		2016		2015
Land	$	9,732	$	1,054	$	12,811
Building and improvements	53,735		21,057		73,502
Equipment, furniture, and fixtures	4,382		8,265		4,612
Assembled occupancy	762		1,299		895
Definite-lived intangible assets	—		363		360
Goodwill	13,962		30,343		10,617
Favorable leases	—		393		10,901
Other indefinite-lived intangible assets	7,018		1,741		6,285
Other assets acquired, net of liabilities assumed	92		6		(18		)
Total acquisitions	$	89,683	$	64,521	$	119,965

XML 50 R34.htm IDEA: XBRL DOCUMENT

Property and Equipment (Tables)

12 Months Ended

Dec. 31, 2017

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment [Table Text Block]

Property and equipment, net consist of the following:



	December 31,
	2017			2016
Land	$	49,081		$	47,565
Buildings and improvements	342,641			304,263
Equipment	181,530			153,170
Furniture and fixtures	5,244			6,931
Leasehold improvements	97,221			80,164
Construction in progress	5,460			2,441
	681,177			594,534
Less: accumulated depreciation	(144,093		)	(110,036		)
Property and equipment, net	$	537,084		$	484,498

XML 51 R35.htm IDEA: XBRL DOCUMENT

Intangible Assets - Net (Tables)

12 Months Ended

Dec. 31, 2017

Intangible Assets, Net (Excluding Goodwill) [Abstract]

Schedule of Finite-Lived Intangible Assets [Table Text Block]



	Weighted Average Life (Years)	December 31,
		2017							2016
		Gross Carrying Amount		Accumulated Amortization					Gross Carrying Amount		Accumulated Amortization
Intangible Assets		Gross Carrying Amount		Accumulated Amortization			Net		Gross Carrying Amount		Accumulated Amortization			Net
Lease acquisition costs	24.8	$	483	$	(99	)	$	384	$	483	$	(78	)	$	405
Favorable leases	33.0	35,116		(6,568		)	28,548		35,116		(4,589		)	30,527
Assembled occupancy	0.7	2,659		(2,631		)	28		1,897		(1,897		)	—
Facility trade name	30.0	733		(293		)	440		733		(269		)	464
Customer relationships	18.7	4,933		(1,530		)	3,403		4,933		(1,253		)	3,680
Total		$	43,924	$	(11,121	)	$	32,803	$	43,162	$	(8,086	)	$	35,076

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

Estimated amortization expense for each of the years ending December 31 is as follows:



Year	Amount
2018	2,329
2019	2,301
2020	1,593
2021	1,497
2022	1,471
Thereafter	23,612
	$	32,803

XML 52 R36.htm IDEA: XBRL DOCUMENT

Goodwill and Other Indefinite-Lived Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2017

Indefinite-Lived Intangible Assets (Including Goodwill) [Abstract]

Schedule of Goodwill [Table Text Block]

The following table represents activity in goodwill by segment as of and for the year ended December 31, :



	Goodwill
	Transitional and Skilled Services		Assisted and Independent Living Services		Home Health and Hospice Services		All Other			Total
January 1, 2015	$	14,221	$	1,756	$	10,929	$	3,363		$	30,269
Additions	—		1,782		5,173		3,662			10,617
December 31, 2015	$	14,221	$	3,538	$	16,102	$	7,025		$	40,886
Less: Dispositions	—		—		—		(4,103		)	(4,103		)
Purchase price adjustment	—		—		—		(26		)	(26		)
Additions	26,415		—		1,799		2,129			30,343
December 31, 2016	$	40,636	$	3,538	$	17,901	$	5,025		$	67,100
Additions	4,850		420		6,421		2,271			13,962
December 31, 2017	$	45,486	$	3,958	$	24,322	$	7,296		$	81,062

Schedule of Acquired Indefinite-lived Intangible Assets by Major Class [Table Text Block]

Other indefinite-lived intangible assets consists of the following:



	December 31, 2017		December 31, 2016
Trade name	$	1,181	$	1,146
Medicare and Medicaid licenses	24,068		18,440
	$	25,249	$	19,586

XML 53 R37.htm IDEA: XBRL DOCUMENT

Restricted and Other Assets (Tables)

12 Months Ended

Dec. 31, 2017

Other Assets [Abstract]

Schedule of Other Assets [Table Text Block]

Restricted and other assets consist of the following:



	December 31,
	2017		2016
Debt issuance costs, net	$	2,799	$	3,611
Long-term insurance losses recoverable asset	5,394		4,104
Deposits with landlords	5,981		3,526
Capital improvement reserves with landlords and lenders	2,327		673
Note receivable from sale of urgent care centers	—		700
Restricted and other assets	$	16,501	$	12,614

XML 54 R38.htm IDEA: XBRL DOCUMENT

Other Accrued Liabilities (Tables)

12 Months Ended

Dec. 31, 2017

Accrued Liabilities [Abstract]

Schedule of Accrued Liabilities [Table Text Block]

Other accrued liabilities consist of the following:



	December 31,
	2017		2016
Quality assurance fee	$	4,864	$	4,604
Refunds payable	21,661		18,368
Deferred revenue	7,066		6,994
Cash held in trust for patients	2,609		2,373
Resident deposits	6,574		6,099
Dividends payable	2,328		2,186
Property taxes	10,088		9,130
Income tax payable	—		1,182
Operational closure liability	910		1,972
Other	7,715		5,855
Other accrued liabilities	$	63,815	$	58,763

XML 55 R39.htm IDEA: XBRL DOCUMENT

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2017

Income Tax Disclosure [Abstract]

Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]

The provision for income taxes on continuing operations for the years ended December 31, 2017, 2016 and 2015 is summarized as follows:



	Year Ended December 31,
	2017		2016			2015
Current:
Federal	$	15,141	$	30,043		$	28,149
State	2,975		5,183			5,761
	18,116		35,226			33,910
Deferred:
Federal	5,428		(1,034		)	2,026
State	986		(1,217		)	(754		)
	6,414		(2,251		)	1,272
Adjustment to deferred taxes for tax rate change	3,915		—			—
Total	$	28,445	$	32,975		$	35,182

Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]



	December 31,
	2017		2016		2015
Income tax expense at statutory rate	35.0	%	35.0	%	35.0	%
State income taxes - net of federal benefit	3.1		3.0		3.6
Non-deductible expenses	1.7		0.9		0.6
Equity compensation	(4.5	)	—		—
Revaluation of deferred	5.7		—		—
Other adjustments	0.1		(0.5	)	(0.6	)
Total income tax provision	41.1	%	38.4	%	38.6	%

Schedule of Deferred Tax Assets and Liabilities [Table Text Block]



	December 31,
	2017			2016
Deferred tax assets (liabilities):
Accrued expenses	$	16,500		$	21,732
Allowance for doubtful accounts	11,090			15,956
Tax credits	3,334			3,461
Insurance	5,135			7,333
	36,059			48,482
Valuation allowance	(530		)	—
Total deferred tax assets	35,529			48,482
State taxes	(911		)	(1,023		)
Depreciation and amortization	(18,248		)	(20,643		)
Prepaid expenses	(3,625		)	(3,743		)
Total deferred tax liabilities	(22,784		)	(25,409		)
Net deferred tax assets	$	12,745		$	23,073

XML 56 R40.htm IDEA: XBRL DOCUMENT

Debt (Tables)

12 Months Ended

Dec. 31, 2017

Debt Disclosure [Abstract]

Schedule of Long-term Debt Instruments [Table Text Block]

Long-term debt consists of the following:



	December 31,
	2017			2016
Term loan with SunTrust, interest payable quarterly	$	140,625		$	148,125
Credit facility with SunTrust	50,000			122,000
Mortgage loans and promissory note, principal and interest payable monthly, interest at fixed rate	125,394			14,032
	316,019			284,157
Less: current maturities	(9,939		)	(8,129		)
Less: debt issuance costs	(3,090		)	(542		)
	$	302,990		$	275,486

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21475-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21538-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28541-108399

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28551-108399

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21521-112644

+ Details

XML 57 R41.htm IDEA: XBRL DOCUMENT

Options and Awards (Tables)

12 Months Ended

Dec. 31, 2017

Options and Awards [Abstract]

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

The Company used the following assumptions for stock options granted during the years ended December 31, 2017, 2016 and 2015:



Grant Year	Options Granted	Weighted Average Risk-Free Rate	Expected Life	Weighted Average Volatility	Weighted Average Dividend Yield
2017	481	2.0%	6.2 years	35.2%	0.8%
2016	497	1.4%	6.3 years	37.8%	0.8%
2015	637	1.7%	6.5 years	39.5%	0.6%

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]

For the years ended December 31, 2017, 2016 and 2015, the following represents the exercise price and fair value displayed at grant date for stock option grants:



Grant Year	Granted	Weighted Average Exercise Price		Weighted Average Fair Value of Options
2017	481	$	20.31	$	7.00
2016	497	$	19.43	$	7.00
2015	637	$	23.27	$	9.08

Schedule of Common Stock Outstanding Roll Forward [Table Text Block]

The following table represents the employee stock option activity during the years ended December 31, 2017, 2016 and 2015:



	Number of Options Outstanding		Weighted Average Exercise Price		Number of Options Vested	Weighted Average Exercise Price of Options Vested
January 1, 2015	5,532		$	8.51	2,218	$	4.70
Granted	637		23.27
Forfeited	(233	)	12.55
Exercised	(488	)	5.20
December 31, 2015	5,448		$	10.36	2,526	$	6.35
Granted	497		19.43
Forfeited	(127	)	14.46
Exercised	(642	)	6.47
December 31, 2016	5,176		$	11.62	2,704	$	8.18
Granted	481		20.31
Forfeited	(178	)	15.82
Exercised	(740	)	6.93
December 31, 2017	4,739		$	13.08	2,776	$	10.07

Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]

The following summary information reflects stock options outstanding, vested and related details as of December 31, 2017:



								Stock Options Vested
	Stock Options Outstanding							Stock Options Vested
				Number Outstanding	Black-Scholes Fair Value		Remaining Contractual Life (Years)	Vested and Exercisable
Year of Grant	Exercise Price			Number Outstanding	Black-Scholes Fair Value		Remaining Contractual Life (Years)	Vested and Exercisable
2008	2.56	-	4.06	185	$	292	1	185
2009	4.06	-	4.56	420	907		2	420
2010	4.77	-	4.96	116	281		3	116
2011	5.90	-	7.99	134	454		4	134
2012	6.56	-	7.96	435	1,603		5	435
2013	7.98	-	11.49	522	2,539		6	390
2014	10.55	-	18.94	1,458	8,272		7	789
2015	21.47	-	25.24	549	5,000		8	219
2016	18.79	-	19.89	450	3,140		9	88
2017	18.64	-	22.90	470	3,291		10	—
Total				4,739	$	25,779		2,776

Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]

A summary of the status of the Company's non-vested restricted stock awards as of December 31, 2017 and changes during the years ended December 31, 2017, 2016 and 2015 is presented below:



	Non-Vested Restricted Awards		Weighted Average Grant Date Fair Value
Nonvested at January 1, 2015	366		$	15.15
Granted	323		22.99
Vested	(234	)	17.36
Forfeited	(30	)	16.81
Nonvested at December 31, 2015	425		$	19.79
Granted	299		20.55
Vested	(279	)	19.58
Forfeited	(16	)	20.85
Nonvested at December 31, 2016	429		$	20.42
Granted	173		20.21
Vested	(195	)	19.79
Forfeited	(24	)	20.34
Nonvested at December 31, 2017	383		$	20.65

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]

Share-based compensation expense recognized for the Company's equity incentive plans for the years ended December 31, 2017, 2016 and 2015 was as follows:



	Year Ended December 31,
	2017		2016		2015
Share-based compensation expense related to stock options	$	4,773	$	4,793	4,164
Share-based compensation expense related to restricted stock awards	2,322		2,371		1,931
Share-based compensation expense related to stock options and restricted stock awards to non-employee directors	1,236		612		582
Total	$	8,331	$	7,776	$	6,677

Share-based Compensation, Schedule of Intrisice Values by Option Category [Table Text Block]

The aggregate intrinsic value of options outstanding, vested, expected to vest and exercised as of and for the years ended December 31, 2017, 2016 and 2015 is as follows:



	December 31,
Options	2017		2016		2015
Outstanding	$	44,060	$	55,610	$	67,508
Vested	33,976		38,101		41,128
Expected to vest	9,311		15,983		23,508
Exercisable	10,481		9,199		8,709

XML 58 R42.htm IDEA: XBRL DOCUMENT

Leases (Tables)

12 Months Ended

Dec. 31, 2017

Leases [Abstract]

Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]

Future minimum lease payments for all leases as of December 31, 2017 are as follows:



Year	Amount
2018	135,841
2019	135,395
2020	135,149
2021	134,942
2022	133,446
Thereafter	1,080,348
	$	1,755,121

XML 59 R43.htm IDEA: XBRL DOCUMENT

Self-Insurance Reserves (Tables)

12 Months Ended

Dec. 31, 2017

Self-Insurance Reserves [Abstract]

Self-Insurance Reserves [Table Text Block]

The following table represents activity in our insurance reserves as of and for the years ended December 31, 2017 and 2016:



	General and Professional Liability
				Workers' Compensation
				Workers' Compensation			Health			Total
Balance January 1, 2016	30,710			20,219			5,074			$	56,003
Current year provisions	23,149			12,887			38,151			74,187
Claims paid and direct expenses	(18,186		)	(10,290		)	(37,586		)	(66,062		)
Change in long-term insurance losses recoverable	637			586			—			1,223
Balance December 31, 2016	36,310			23,402			5,639			65,351
Current year provisions	20,396			15,202			53,796			89,394
Claims paid and direct expenses	(16,133		)	(12,455		)	(54,712		)	(83,300		)
Change in long-term insurance losses recoverable	361			930			—			1,291
Balance December 31, 2017	$	40,934		$	27,079		$	4,723		$	72,736

XML 60 R44.htm IDEA: XBRL DOCUMENT

Description of Business (Details)	Dec. 31, 2017 business Beds facilities	Dec. 31, 2016 facilities
Skilled nursing, assisted living and independent living facilities [Abstract]
Number of Real Estate Properties	63	50
Number of Real Estate Properties Leased	167	160
Number of Real Estate Properties Leased with an Option to Purchase	11	9
Number of Real Estate Properties Operated	230	210
Home Health, Hospice and Home Care Operations \| business	46
Operational Skilled Nursing Beds \| Beds	18,900
Operational Skilled Nursing, Assisted Living and Independent Living Beds [Abstract]
Operational Skilled Nursing, Assisted Living and Independent Living Beds \| Beds	5,000

XML 61 R45.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies Divestiture (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2016 USD ($)
Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Sale Price from Divestiture of Businesses	$ 41,492

XML 62 R46.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies Revenue and Accounts Receivable (Details)	12 Months Ended
	Dec. 31, 2017 Rate	Dec. 31, 2016 Rate	Dec. 31, 2015 Rate
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
% of Revenue	100.00%	100.00%	100.00%
Total Medicaid and Medicare
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
% of Revenue	68.40%	67.80%	69.10%

XML 63 R47.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies Property and Equipment (Details)	12 Months Ended
	Dec. 31, 2017
Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	59 years

XML 64 R48.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies Impairment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Accounting Policies [Abstract]
Impairment of Long-Lived Assets to be Disposed of	$ 111	$ 137	$ 0
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)	$ 0	$ 0	$ 0

XML 65 R49.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies Intangible Assets and Goodwill (Details)	12 Months Ended
	Dec. 31, 2017
Assembled occupancy \| Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	4 months
Assembled occupancy \| Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	8 months
Trade name
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	30 years
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	20 years

XML 66 R50.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies Self-Insurance General and Professional (Details) - General and Professional Liability Insurance [Member] $ in Thousands	Dec. 31, 2017 USD ($)
Self-insurance retention per claim [Member] \| Parent Company [Member]
Liability for Claims and Claims Adjustment Expense [Line Items]
Self Insurance Reserve	$ 500
Aggregate Deductible [Member] \| Parent Company [Member] \| CALIFORNIA
Liability for Claims and Claims Adjustment Expense [Line Items]
Self Insurance Reserve	750
Aggregate Deductible [Member] \| Parent Company [Member] \| Non-California [Domain]
Liability for Claims and Claims Adjustment Expense [Line Items]
Self Insurance Reserve	1,000
Blanket Aggregate [Member] \| Third-Party Payor [Member] \| All States Except Colorado [Domain]
Liability for Claims and Claims Adjustment Expense [Line Items]
Self Insurance Reserve	5,000
Per Facility [Member] \| Third-Party Payor [Member] \| All States Except Colorado [Domain]
Liability for Claims and Claims Adjustment Expense [Line Items]
Self Insurance Reserve	3,000
Per Facility [Member] \| Third-Party Payor [Member] \| COLORADO
Liability for Claims and Claims Adjustment Expense [Line Items]
Self Insurance Reserve	3,000
Per Occurence [Member] \| Third-Party Payor [Member] \| All States Except Colorado [Domain]
Liability for Claims and Claims Adjustment Expense [Line Items]
Self Insurance Reserve	1,000
Per Occurence [Member] \| Third-Party Payor [Member] \| COLORADO
Liability for Claims and Claims Adjustment Expense [Line Items]
Self Insurance Reserve	$ 1,000

XML 67 R51.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies Self-Insurance Workers' Compensation (Details) - Workers' Compensation [Member] $ in Thousands	Dec. 31, 2017 USD ($)
Stop-Loss Insurance limit per claim [Member]
Liability for Claims and Claims Adjustment Expense [Line Items]
Self Insurance Reserve	$ 500
Stop-Loss Insurance limit per claim [Member] \| TEXAS
Liability for Claims and Claims Adjustment Expense [Line Items]
Self Insurance Reserve	750
Loss-Sensitive limit per claim [Member] [Member] \| Other states, except California, Texas and Washington [Domain]
Liability for Claims and Claims Adjustment Expense [Line Items]
Self Insurance Reserve	$ 350

XML 68 R52.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies Self Insurance Recoveries (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Accounting Policies [Abstract]
Long-term insurance losses recoverable asset	$ 5,394	$ 4,104

XML 69 R53.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies Self-Insurance Health Insurance (Details) - Health Liability Insurance [Member] $ in Thousands	Dec. 31, 2017 USD ($)
Stop-Loss Insurance limit per claim [Member]
Liability for Claims and Claims Adjustment Expense [Line Items]
Self Insurance Reserve	$ 300
Stop Loss Deductible [Member]
Liability for Claims and Claims Adjustment Expense [Line Items]
Self Insurance Reserve	$ 75

XML 70 R54.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Accounting Policies [Abstract]
Adjustment to deferred taxes for tax rate change	$ 3,915	$ 0	$ 0

XML 71 R55.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies Recent Accounting Standards Adopted (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2017 USD ($)
Accounting Policies [Abstract]
Income Tax Effects Allocated Directly to Equity, Employee Stock Options	$ 3,423

XML 72 R56.htm IDEA: XBRL DOCUMENT

Common Stock (Details) shares in Thousands, $ in Thousands			12 Months Ended
Common Stock (Details) shares in Thousands, $ in Thousands	Feb. 08, 2017 USD ($)	Nov. 04, 2015 USD ($) Agreements	Dec. 31, 2017 USD ($) shares	Dec. 31, 2016 USD ($) shares	Dec. 31, 2015 USD ($)
Common Stock Transactions [Line Items]
Stock Repurchase Program, Period in Force	12 months	12 months
Stock Repurchase Program Expiration Date	Feb. 08, 2018
Repurchase of common stock (Note 3)			$ (7,288)	$ (30,000)	$ 0
Number of Stock Repurchase Programs \| Agreements		2
Common Stock [Member]
Common Stock Transactions [Line Items]
Stock Repurchase Program, Authorized Amount	$ 30,000	$ 15,000
Stock Repurchased During Period, Shares \| shares			412	1,452
Repurchase of common stock (Note 3)			$ (7,288)	$ (30,000)

XML 73 R57.htm IDEA: XBRL DOCUMENT

Computation of Net Income Per Common Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands

12 Months Ended

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Numerator:

Net income

$ 40,833

$ 52,843

$ 55,917

Less: net income attributable to noncontrolling interests

358

2,853

485

Net income attributable to The Ensign Group, Inc.

$ 40,475

$ 49,990

$ 55,432

Denominator:

Weighted average shares outstanding for basic net income per share

50,932

50,555

50,316

Adjusted weighted average common shares outstanding

52,829

52,133

52,210

Basic net income (loss) per common share:

Basic net income per common share attributable to The Ensign Group, Inc.

$ 0.79

$ 0.99

$ 1.10

Diluted net (loss) income per common share:

Diluted net income per common share attributable to The Ensign Group, Inc.

$ 0.77

$ 0.96

$ 1.06

Common Class A [Member]

Denominator:

Weighted average shares outstanding for basic net income per share

50,932

50,555

50,316

Plus: incremental shares from assumed conversion (1)

^[1]

1,897

1,578

1,894

[1]	(1) Options outstanding which are anti-dilutive and therefore not factored into the weighted average common shares amount above were 1,252, 838 and 258 for the years ended December 31, 2017, 2016 and 2015, respectively.

XML 74 R58.htm IDEA: XBRL DOCUMENT

Computation of Net Income Per Common Share Antidilutive Shares (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Earnings Per Share, Diluted, Other Disclosures [Abstract]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,252	838	258

XML 75 R59.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Details) - Cash and cash equivalents - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Level 1
Cash and cash equivalents	$ 42,337	$ 57,706
Level 2
Cash and cash equivalents	0	0
Level 3
Cash and cash equivalents	$ 0	$ 0

XML 76 R60.htm IDEA: XBRL DOCUMENT

Fair Value Measurements Investments (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Domestic Corporate Debt Securities [Member]
Schedule of Held-to-maturity Securities [Line Items]
Held-to-maturity Securities	$ 41,777	$ 35,184

XML 77 R61.htm IDEA: XBRL DOCUMENT

Revenue and Accounts Receivable Revenue (Details) - USD ($)
$ in Thousands

12 Months Ended

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Health Care Organization, Receivable and Revenue Disclosures [Line Items]

Revenue

$ 1,849,317

$ 1,654,864

$ 1,341,826

Revenue by payor as a percent of total revenue

100.00%

Medicaid

Health Care Organization, Receivable and Revenue Disclosures [Line Items]

Revenue

$ 644,803

$ 557,958

$ 458,956

Revenue by payor as a percent of total revenue

34.90%

33.70%

34.20%

Medicare

Health Care Organization, Receivable and Revenue Disclosures [Line Items]

Revenue

$ 515,884

$ 477,019

$ 395,503

Revenue by payor as a percent of total revenue

27.90%

28.80%

29.50%

Medicaid — skilled

Health Care Organization, Receivable and Revenue Disclosures [Line Items]

Revenue

$ 102,875

$ 87,517

$ 71,905

Revenue by payor as a percent of total revenue

5.60%

5.30%

5.40%

Total Medicaid and Medicare

Health Care Organization, Receivable and Revenue Disclosures [Line Items]

Revenue

$ 1,263,562

$ 1,122,494

$ 926,364

Revenue by payor as a percent of total revenue

68.40%

67.80%

69.10%

Managed care

Health Care Organization, Receivable and Revenue Disclosures [Line Items]

Revenue

$ 303,386

$ 265,508

$ 206,770

Revenue by payor as a percent of total revenue

16.40%

16.00%

15.40%

Private and other payors(1)

Health Care Organization, Receivable and Revenue Disclosures [Line Items]

Revenue

$ 282,369

^[1]

$ 266,862

^[1]

$ 208,692

Revenue by payor as a percent of total revenue

15.20%

16.20%

15.50%

[1]	(1) Private and other payors also includes revenue from all payors generated in other ancillary services for the years ended December 31, 2017, 2016 and 2015 and urgent care centers for the years ended December 31, 2016 and 2015.

XML 78 R62.htm IDEA: XBRL DOCUMENT

Revenue and Accounts Receivable Accounts Receivable (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts Receivable, Gross	$ 309,029	$ 284,224
Less: allowance for doubtful accounts	(43,961)	(39,791)
Accounts receivable, net	265,068	244,433
Medicaid
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts Receivable, Gross	119,441	111,031
Managed care
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts Receivable, Gross	68,930	66,346
Medicare
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts Receivable, Gross	55,667	55,500
Private and other payors
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts Receivable, Gross	$ 64,991	$ 51,347

XML 79 R63.htm IDEA: XBRL DOCUMENT

Business Segments (Details) $ in Thousands	3 Months Ended	12 Months Ended
Business Segments (Details) $ in Thousands	Jun. 30, 2017 USD ($)	Dec. 31, 2017 USD ($) business facilities Segments	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)
Segment Reporting Information [Line Items]
Number of Reportable Segments \| Segments		3
Transitional and Skilled Service Facilities \| facilities		160
Transitional and Skilled Services and Assistant and Independent Living Campuses \| facilities		21
Assisted and Independent Living Facilities \| facilities		49
Home Health, Hospice and Home Care Operations \| business		46
Business Exit Costs		$ 2,321	$ (11,225)	$ 0
Gain (Loss) on Contract Termination		2,715	6,512	0
Impairment of Long-Lived Assets to be Disposed of		111	137	0
Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]
Segment Reporting Information [Line Items]
Sale Price from Divestiture of Businesses			41,492
Contract Termination and Facility Closing [Member]
Segment Reporting Information [Line Items]
Business Exit Costs		4,017	0	0
Facility Closing [Member]
Segment Reporting Information [Line Items]
Business Exit Costs	$ (1,286)	$ 2,830	$ 7,935	$ 0

XML 80 R64.htm IDEA: XBRL DOCUMENT

Business Segments Revenue by Segment (Details) - USD ($)
$ in Thousands

12 Months Ended

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Segment Reporting, Revenue Reconciling Item [Line Items]

Revenue

$ 1,849,317

$ 1,654,864

$ 1,341,826

Revenue by payor as a percent of total revenue

100.00%

Transitional and Skilled Services Segment

Segment Reporting, Revenue Reconciling Item [Line Items]

Revenue

$ 1,545,210

$ 1,374,803

$ 1,126,388

Assisted and Independent Living Services Segment

Segment Reporting, Revenue Reconciling Item [Line Items]

Revenue

136,646

123,636

88,129

Home Health and Hospice Services

Segment Reporting, Revenue Reconciling Item [Line Items]

Revenue

142,403

115,813

90,356

All Other

Segment Reporting, Revenue Reconciling Item [Line Items]

Revenue

25,058

40,612

36,953

Medicaid

Segment Reporting, Revenue Reconciling Item [Line Items]

Revenue

$ 644,803

$ 557,958

$ 458,956

Revenue by payor as a percent of total revenue

34.90%

33.70%

34.20%

Medicaid | Transitional and Skilled Services Segment

Segment Reporting, Revenue Reconciling Item [Line Items]

Revenue

$ 603,104

$ 521,063

$ 430,368

Medicaid | Assisted and Independent Living Services Segment

Segment Reporting, Revenue Reconciling Item [Line Items]

Revenue

30,469

26,397

19,642

Medicaid | Home Health and Hospice Services

Segment Reporting, Revenue Reconciling Item [Line Items]

Revenue

11,230

10,498

8,946

Medicaid | All Other

Segment Reporting, Revenue Reconciling Item [Line Items]

Revenue

Medicare

Segment Reporting, Revenue Reconciling Item [Line Items]

Revenue

$ 515,884

$ 477,019

$ 395,503

Revenue by payor as a percent of total revenue

27.90%

28.80%

29.50%

Medicare | Transitional and Skilled Services Segment

Segment Reporting, Revenue Reconciling Item [Line Items]

Revenue

$ 417,870

$ 396,519

$ 332,429

Medicare | Assisted and Independent Living Services Segment

Segment Reporting, Revenue Reconciling Item [Line Items]

Revenue

Medicare | Home Health and Hospice Services

Segment Reporting, Revenue Reconciling Item [Line Items]

Revenue

98,014

80,500

63,074

Medicare | All Other

Segment Reporting, Revenue Reconciling Item [Line Items]

Revenue

Medicaid — skilled

Segment Reporting, Revenue Reconciling Item [Line Items]

Revenue

$ 102,875

$ 87,517

$ 71,905

Revenue by payor as a percent of total revenue

5.60%

5.30%

5.40%

Medicaid — skilled | Transitional and Skilled Services Segment

Segment Reporting, Revenue Reconciling Item [Line Items]

Revenue

$ 102,875

$ 87,517

$ 71,905

Medicaid — skilled | Assisted and Independent Living Services Segment

Segment Reporting, Revenue Reconciling Item [Line Items]

Revenue

Medicaid — skilled | Home Health and Hospice Services

Segment Reporting, Revenue Reconciling Item [Line Items]

Revenue

Medicaid — skilled | All Other

Segment Reporting, Revenue Reconciling Item [Line Items]

Revenue

Total Medicaid and Medicare

Segment Reporting, Revenue Reconciling Item [Line Items]

Revenue

$ 1,263,562

$ 1,122,494

$ 926,364

Revenue by payor as a percent of total revenue

68.40%

67.80%

69.10%

Total Medicaid and Medicare | Transitional and Skilled Services Segment

Segment Reporting, Revenue Reconciling Item [Line Items]

Revenue

$ 1,123,849

$ 1,005,099

$ 834,702

Total Medicaid and Medicare | Assisted and Independent Living Services Segment

Segment Reporting, Revenue Reconciling Item [Line Items]

Revenue

30,469

26,397

19,642

Total Medicaid and Medicare | Home Health and Hospice Services

Segment Reporting, Revenue Reconciling Item [Line Items]

Revenue

109,244

90,998

72,020

Total Medicaid and Medicare | All Other

Segment Reporting, Revenue Reconciling Item [Line Items]

Revenue

Managed care

Segment Reporting, Revenue Reconciling Item [Line Items]

Revenue

$ 303,386

$ 265,508

$ 206,770

Revenue by payor as a percent of total revenue

16.40%

16.00%

15.40%

Managed care | Transitional and Skilled Services Segment

Segment Reporting, Revenue Reconciling Item [Line Items]

Revenue

$ 281,563

$ 247,844

$ 194,743

Managed care | Assisted and Independent Living Services Segment

Segment Reporting, Revenue Reconciling Item [Line Items]

Revenue

Managed care | Home Health and Hospice Services

Segment Reporting, Revenue Reconciling Item [Line Items]

Revenue

21,823

17,664

12,027

Managed care | All Other

Segment Reporting, Revenue Reconciling Item [Line Items]

Revenue

Private and other payors

Segment Reporting, Revenue Reconciling Item [Line Items]

Revenue

$ 282,369

^[1]

$ 266,862

^[1]

$ 208,692

Revenue by payor as a percent of total revenue

15.20%

16.20%

15.50%

Private and other payors | Transitional and Skilled Services Segment

Segment Reporting, Revenue Reconciling Item [Line Items]

Revenue

$ 139,798

$ 121,860

$ 96,943

Private and other payors | Assisted and Independent Living Services Segment

Segment Reporting, Revenue Reconciling Item [Line Items]

Revenue

106,177

97,239

68,487

Private and other payors | Home Health and Hospice Services

Segment Reporting, Revenue Reconciling Item [Line Items]

Revenue

11,336

7,151

6,309

Private and other payors | All Other

Segment Reporting, Revenue Reconciling Item [Line Items]

Revenue

$ 25,058

$ 40,612

$ 36,953

[1]	(1) Private and other payors also includes revenue from all payors generated in other ancillary services for the years ended December 31, 2017, 2016 and 2015 and urgent care centers for the years ended December 31, 2016 and 2015.

XML 81 R65.htm IDEA: XBRL DOCUMENT

Business Segments Schedule of Segment Reporting Information, by Segment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Segment Reporting Information [Line Items]
Revenue	$ 1,849,317	$ 1,654,864	$ 1,341,826
Intersegment revenue (1)	0	0	0
Revenue including intersegment revenue	1,849,317	1,654,864	1,341,826
Segment income (loss) (2)	81,285	91,847	93,082
Interest expense, net of interest income	(12,007)	(6,029)	(1,983)
Income before provision for income taxes	69,278	85,818	91,099
Depreciation and amortization	44,472	38,682	28,111
Transitional and Skilled Services Segment
Segment Reporting Information [Line Items]
Revenue	1,545,210	1,374,803	1,126,388
Intersegment revenue (1)	3,023	2,929	2,447
Revenue including intersegment revenue	1,548,233	1,377,732	1,128,835
Segment income (loss) (2)	140,272	118,118	136,744
Depreciation and amortization	29,928	26,298	18,008
Assisted and Independent Living Services Segment
Segment Reporting Information [Line Items]
Revenue	136,646	123,636	88,129
Intersegment revenue (1)	0	0	0
Revenue including intersegment revenue	136,646	123,636	88,129
Segment income (loss) (2)	16,736	11,701	11,463
Depreciation and amortization	6,334	4,157	3,338
Home Health and Hospice Services
Segment Reporting Information [Line Items]
Revenue	142,403	115,813	90,356
Intersegment revenue (1)	0	0	0
Revenue including intersegment revenue	142,403	115,813	90,356
Segment income (loss) (2)	19,717	16,571	13,584
Depreciation and amortization	945	924	980
All Other
Segment Reporting Information [Line Items]
Revenue	25,058	40,612	36,953
Intersegment revenue (1)	3,035	2,184	881
Revenue including intersegment revenue	28,093	42,796	37,834
Segment income (loss) (2)	(95,440)	(54,543)	(68,709)
Depreciation and amortization	7,265	7,303	5,785
Elimination
Segment Reporting Information [Line Items]
Intersegment revenue (1)	(6,058)	(5,113)	(3,328)
Revenue including intersegment revenue	(6,058)	(5,113)	(3,328)
Segment income (loss) (2)	0	0	0
Depreciation and amortization	$ 0	$ 0	$ 0

XML 82 R66.htm IDEA: XBRL DOCUMENT

Acquisitions Acquisition Summary (Details) $ in Thousands		12 Months Ended
Acquisitions Acquisition Summary (Details) $ in Thousands	Feb. 01, 2018 USD ($) Beds Operations	Dec. 31, 2017 USD ($) Beds Operations	Dec. 31, 2016 USD ($) Beds Operations	Dec. 31, 2015 USD ($) Beds Operations
Business Acquisition [Line Items]
Payments to acquire leased assets \| $		$ 195	$ 120,935	$ 17,750
Payments to Acquire Businesses, Gross \| $		$ 89,683	64,521	119,965
Operational Skilled Nursing Beds \| Beds		18,900
Operational Assisted Living Units \| Beds		5,000
Payments to Acquire Businesses, Net of Cash Acquired \| $		$ 89,565	$ 64,310	$ 110,802
8051 Services, Skilled Nursing Care Facilities [Member]
Business Acquisition [Line Items]
Number of Businesses Acquired		8	18	50
Payments to acquire leased assets \| $				$ 23,998
Notes Issued \| $				$ 6,248
Operational Skilled Nursing Beds \| Beds		905	2,336	2,580
Home Health, Hospice and Home Care Agency [Member]
Business Acquisition [Line Items]
Number of Businesses Acquired				7
Assisted Living and Independent Living Facility [Member] [Member]
Business Acquisition [Line Items]
Number of Businesses Acquired		9
Operational Assisted Living and Independent Living Units \| Beds				2,013
Transitional and Skilled Services and Assisted and Independent Campuses [Member]
Business Acquisition [Line Items]
Number of Businesses Acquired		1	1
8082 Services, Home Health Care Services [Member]
Business Acquisition [Line Items]
Number of Businesses Acquired		3	2
Hospice Agency [Member]
Business Acquisition [Line Items]
Number of Businesses Acquired		3	5
Home Care Agency [Member]
Business Acquisition [Line Items]
Number of Businesses Acquired		1
Urgent Care Centers [Member]
Business Acquisition [Line Items]
Number of Businesses Acquired				3
Assisted Living Facility [Member]
Business Acquisition [Line Items]
Operational Assisted Living Units \| Beds		594	10
Skilled Nursing, Assisted Living, Home Health, Home Care, Hospice and Urgent Care [Member]
Business Acquisition [Line Items]
Payments to Acquire Businesses, Net of Cash Acquired \| $				$ 119,965
Liability Assumed, Refundable Deposits \| $				$ 8,939
Transitional and Skilled Services and Assisted and Independent Campuses [Member]
Business Acquisition [Line Items]
Number of Businesses Acquired			1
Skilled Nursing, Assisted Living and Independent Living Facilities [Member]
Business Acquisition [Line Items]
Number of Businesses Acquired				18
8051 Services, Skilled Nursing Care Facilities [Member]
Business Acquisition [Line Items]
Number of Businesses Acquired			2
Assisted Living Facility [Member]
Business Acquisition [Line Items]
Number of Businesses Acquired			15
Payments to acquire leased assets \| $			$ 127,348
8051 Services, Skilled Nursing Care Facilities [Member]
Business Acquisition [Line Items]
Number of Businesses Acquired				3
Assisted Living Facility [Member] \| Assisted Living Facility [Member]
Business Acquisition [Line Items]
Operational Skilled Nursing Beds \| Beds			142
Assisted Living and Independent Living Facility [Member] [Member] \| Assisted Living and Independent Living Facility [Member] [Member]
Business Acquisition [Line Items]
Number of Businesses Acquired			6
8051 Services, Skilled Nursing Care Facilities [Member]
Business Acquisition [Line Items]
Number of Businesses Acquired			16
8051 Services, Skilled Nursing Care Facilities [Member] \| 8051 Services, Skilled Nursing Care Facilities [Member]
Business Acquisition [Line Items]
Number of Businesses Acquired		4
Operational Skilled Nursing Beds \| Beds		455	463
Subsequent Event [Member] \| Assisted Living and Independent Living Facility [Member] [Member]
Business Acquisition [Line Items]
Number of Businesses Acquired	2
Payments to Acquire Businesses, Gross \| $	$ 4,298
Operational Assisted Living Units \| Beds	74

XML 83 R67.htm IDEA: XBRL DOCUMENT

Acquisitions (Details) - USD ($) $ in Thousands	12 Months Ended
Acquisitions (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Business Acquisition [Line Items]
Payments to Acquire Businesses, Gross	$ 89,683	$ 64,521	$ 119,965
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net	92	6	(18)
Land
Business Acquisition [Line Items]
Payments to Acquire Businesses, Gross	9,732	1,054	12,811
Building and improvements
Business Acquisition [Line Items]
Payments to Acquire Businesses, Gross	53,735	21,057	73,502
Equipment, furniture, and fixtures
Business Acquisition [Line Items]
Payments to Acquire Businesses, Gross	4,382	8,265	4,612
Assembled occupancy
Business Acquisition [Line Items]
Payments to Acquire Businesses, Gross	762	1,299	895
Definite-lived intangible assets
Business Acquisition [Line Items]
Payments to Acquire Businesses, Gross	0	363	360
Favorable leases
Business Acquisition [Line Items]
Payments to Acquire Businesses, Gross	0	393	10,901
Goodwill
Business Acquisition [Line Items]
Payments to Acquire Businesses, Gross	13,962	30,343	10,617
Other indefinite-lived intangible assets
Business Acquisition [Line Items]
Payments to Acquire Businesses, Gross	$ 7,018	$ 1,741	$ 6,285

XML 84 R68.htm IDEA: XBRL DOCUMENT

Property and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Property and equipment	$ 681,177	$ 594,534
Less: accumulated depreciation	(144,093)	(110,036)
Property and equipment, net	537,084	484,498
Land
Property, Plant and Equipment [Line Items]
Property and equipment	49,081	47,565
Building and improvements
Property, Plant and Equipment [Line Items]
Property and equipment	342,641	304,263
Equipment
Property, Plant and Equipment [Line Items]
Property and equipment	181,530	153,170
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property and equipment	5,244	6,931
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment	97,221	80,164
Construction in progress
Property, Plant and Equipment [Line Items]
Property and equipment	$ 5,460	$ 2,441

XML 85 R69.htm IDEA: XBRL DOCUMENT

Property and Equipment Additional Disclosures (Details) $ in Thousands	Jun. 01, 2017 USD ($)
Property, Plant and Equipment, Type [Abstract]
Sale Leaseback Transaction, Historical Cost	$ 24,847

XML 86 R70.htm IDEA: XBRL DOCUMENT

Intangible Assets - Net (Details) - USD ($) $ in Thousands	12 Months Ended
Intangible Assets - Net (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 43,924	$ 43,162
Accumulated Amortization	(11,121)	(8,086)
Intangible assets, net	$ 32,803	35,076
Lease acquisition costs
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted Average Life (Years)	24 years 8 months 31 days
Finite-Lived Intangible Assets, Gross	$ 483	483
Accumulated Amortization	(99)	(78)
Intangible assets, net	$ 384	405
Favorable leases
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted Average Life (Years)	33 years
Finite-Lived Intangible Assets, Gross	$ 35,116	35,116
Accumulated Amortization	(6,568)	(4,589)
Intangible assets, net	$ 28,548	30,527
Assembled occupancy
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted Average Life (Years)	7 months 30 days
Finite-Lived Intangible Assets, Gross	$ 2,659	1,897
Accumulated Amortization	(2,631)	(1,897)
Intangible assets, net	$ 28	0
Trade name
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted Average Life (Years)	30 years
Finite-Lived Intangible Assets, Gross	$ 733	733
Accumulated Amortization	(293)	(269)
Intangible assets, net	$ 440	464
Customer relationships
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted Average Life (Years)	18 years 7 months 30 days
Finite-Lived Intangible Assets, Gross	$ 4,933	4,933
Accumulated Amortization	(1,530)	(1,253)
Intangible assets, net	$ 3,403	$ 3,680

XML 87 R71.htm IDEA: XBRL DOCUMENT

Intangible Assets - Net Additional Disclosures (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($) Operations	Dec. 31, 2015 USD ($)
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	$ 3,035	$ 4,634	$ 3,824
Finite-Lived Intangible Assets, Gross	43,924	43,162
Assembled occupancy
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	734
Finite-Lived Intangible Assets, Gross	$ 2,659	1,897
Assembled occupancy \| Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	4 months
Assembled occupancy \| Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	8 months
Assisted Living Facility [Member] \| Favorable leases
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross		7,190
Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] \| Urgent Care Centers [Member] \| Customer relationships
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross		$ 582
Assisted Living Facility [Member]
Finite-Lived Intangible Assets [Line Items]
Number of Businesses Acquired \| Operations		15

XML 88 R72.htm IDEA: XBRL DOCUMENT

Intangible Assets - Net Future Amortization (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
2018	$ 2,329
2019	2,301
2020	1,593
2021	1,497
2022	1,471
Thereafter	23,612
Intangible assets, net	$ 32,803	$ 35,076

XML 89 R73.htm IDEA: XBRL DOCUMENT

Goodwill and Other Indefinite-Lived Intangible Assets Goodwill Rollforward (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Goodwill [Line Items]
January 1,	$ 67,100	$ 40,886	$ 30,269
Less: Dispositions		(4,103)
Purchase price adjustment		(26)
Additions	13,962	30,343	10,617
December 31,	81,062	67,100	40,886
Goodwill, Impairment Loss	0	0	0
Transitional and Skilled Services Segment
Goodwill [Line Items]
January 1,	40,636	14,221	14,221
Less: Dispositions		0
Purchase price adjustment		0
Additions	4,850	26,415	0
December 31,	45,486	40,636	14,221
Assisted and Independent Living Services Segment
Goodwill [Line Items]
January 1,	3,538	3,538	1,756
Less: Dispositions		0
Purchase price adjustment		0
Additions	420	0	1,782
December 31,	3,958	3,538	3,538
Home Health and Hospice Services
Goodwill [Line Items]
January 1,	17,901	16,102	10,929
Less: Dispositions		0
Purchase price adjustment		0
Additions	6,421	1,799	5,173
December 31,	24,322	17,901	16,102
All Other
Goodwill [Line Items]
January 1,	5,025	7,025	3,363
Less: Dispositions		(4,103)
Purchase price adjustment		(26)
Additions	2,271	2,129	3,662
December 31,	$ 7,296	5,025	$ 7,025
Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] \| All Other
Goodwill [Line Items]
Less: Dispositions		$ (4,103)

XML 90 R74.htm IDEA: XBRL DOCUMENT

Goodwill and Other Indefinite-Lived Intangible Assets Indefinite-lived intangble assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Indefinite-lived Intangible Assets [Line Items]
Other indefinite-lived intangibles	$ 25,249	$ 19,586
Home Health and Hospice Services \| Trade name
Indefinite-lived Intangible Assets [Line Items]
Other indefinite-lived intangibles	1,181	1,146
Indefinite-lived Intangible Assets Acquired	35
Home Health and Hospice Services \| Medicare and Medicaid licenses
Indefinite-lived Intangible Assets [Line Items]
Other indefinite-lived intangibles	24,068	$ 18,440
Indefinite-lived Intangible Assets Acquired	7,178
Indefinite-lived Intangible Assets, Period Increase (Decrease)	$ 500

XML 91 R75.htm IDEA: XBRL DOCUMENT

Restricted and Other Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Other Assets [Abstract]
Debt issuance costs, net	$ 2,799	$ 3,611
Long-term insurance losses recoverable asset	5,394	4,104
Deposits with landlords	5,981	3,526
Capital improvement reserves with landlords and lenders	2,327	673
Note receivable from sale of urgent care centers	0	700
Restricted and other assets	$ 16,501	$ 12,614

XML 92 R76.htm IDEA: XBRL DOCUMENT

Other Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Accrued Liabilities [Abstract]
Quality assurance fee	$ 4,864	$ 4,604
Refunds payable	21,661	18,368
Deferred revenue	7,066	6,994
Cash held in trust for patients	2,609	2,373
Resident deposits	6,574	6,099
Dividends payable	2,328	2,186
Property taxes	10,088	9,130
Income tax payable	0	1,182
Operational closure liability	910	1,972
Other	7,715	5,855
Other accrued liabilities	$ 63,815	$ 58,763

XML 93 R77.htm IDEA: XBRL DOCUMENT

Income Taxes Expense (Details) - USD ($) $ in Thousands	12 Months Ended
Income Taxes Expense (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Current Federal	$ 15,141	$ 30,043	$ 28,149
Current State	2,975	5,183	5,761
Current Income Tax Expense	18,116	35,226	33,910
Deferred Federal	5,428	(1,034)	2,026
Deferred State	986	(1,217)	(754)
Deferred income taxes	6,414	(2,251)	1,272
Adjustment to deferred taxes for tax rate change	3,915	0	0
Provision for income taxes	$ 28,445	$ 32,975	$ 35,182

XML 94 R78.htm IDEA: XBRL DOCUMENT

Income Taxes Rate Reconciliation (Details)	12 Months Ended
Income Taxes Rate Reconciliation (Details)	Dec. 31, 2017 Rate	Dec. 31, 2016 Rate	Dec. 31, 2015 Rate
Income tax expense at statutory rate	35.00%	35.00%	35.00%
State income taxes - net of federal benefit	3.10%	3.00%	3.60%
Non-deductible expenses	1.70%	0.90%	0.60%
Equity compensation	(4.50%)	0.00%	0.00%
Revaluation of deferred	5.70%	0.00%	0.00%
Other adjustments	0.10%	(0.50%)	(0.60%)
Total income tax provision	41.10%	38.40%	38.60%

XML 95 R79.htm IDEA: XBRL DOCUMENT

Income Taxes Deferred (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Accrued expenses	$ 16,500	$ 21,732
Allowance for doubtful accounts	11,090	15,956
Tax credits	3,334	3,461
Insurance	5,135	7,333
Deferred tax assets	36,059	48,482
Valuation allowance	(530)	0
Deferred Tax Assets, Net of Valuation Allowance	35,529	48,482
State taxes	(911)	(1,023)
Depreciation and amortization	(18,248)	(20,643)
Prepaid expenses	(3,625)	(3,743)
Total deferred tax liabilities	(22,784)	(25,409)
Net deferred tax assets	$ 12,745	$ 23,073

XML 96 R80.htm IDEA: XBRL DOCUMENT

Income Taxes Other Disclosures (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Operating Loss Carryforwards [Line Items]
Increase (Decrease) in Deferred Tax Asset	$ 17,995
Increase (Decrease) in Deferred Tax Liability	14,080
Adjustment to deferred taxes for tax rate change	3,915	$ 0	$ 0
Deferred Tax Assets, Tax Credit Carryforwards, General Business	3,302	3,430
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	530
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	$ 0	$ 0	$ 0

XML 97 R81.htm IDEA: XBRL DOCUMENT

Debt (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Long-term Debt, Gross	$ 316,019	$ 284,157
Current maturities of long-term debt	(9,939)	(8,129)
Long Term Debt, net of Current Maturities and Debt Discount	302,990	275,486
SunTrust Bank [Member] \| Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Credit facility with SunTrust	50,000	122,000
Second Amended Credit Facility [Member] \| SunTrust Bank [Member] \| Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Term loan with SunTrust, interest payable quarterly	140,625	148,125
Less: debt issuance costs	(3,090)	(542)
Collateralized Debt Obligations [Member] \| Notes Payable, Other Payables [Member]
Debt Instrument [Line Items]
Mortgage loans and promissory note, principal and interest payable monthly, interest at fixed rate	$ 125,394	$ 14,032

XML 98 R82.htm IDEA: XBRL DOCUMENT

Debt Additional Disclosures (Details) $ in Thousands	Feb. 05, 2016 USD ($) Rate	May 30, 2014 USD ($) Rate	Feb. 02, 2018 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Jul. 19, 2016 USD ($) Rate
Secured Debt [Member] \| Senior Debt Obligations [Member]
Long-Term Debt Additional Disclosures [Line Items]
Increase in Letters of Credit				$ 3,994
Pledged Financial Instruments, Not Separately Reported, Securities for Letter of Credit Facilities				6,304
SunTrust Bank [Member] \| Revolving Credit Facility [Member]
Long-Term Debt Additional Disclosures [Line Items]
Credit facility with SunTrust				50,000	$ 122,000
Line of Credit Facility, Current Borrowing Capacity	$ 250,000	$ 150,000
Line of Credit Facility, Maximum Borrowing Capacity	$ 150,000	$ 75,000
Total Net Debt Ratio, Maximum	3.50
Total Net Debt Ratio, Minimum	1.50
EBITDA Ratio, Maximum	1.00
EBITDA Ratio, Minimum	1.00
Total Net Debt Ratio, Default	2.75
EBITDA Ratio, Default	1.00
Aggregate Revolving Commitment Percentage \| Rate	10.00%
Total Net Debt Ratio, Cured	2.75
EBITDA Ratio, Cured	1.00
SunTrust Bank [Member] \| Revolving Credit Facility [Member] \| Second Amended Credit Facility [Member]
Long-Term Debt Additional Disclosures [Line Items]
Term Loan, Amount Outstanding, Current				7,500
Term Loan, Amount Outstanding, Noncurrent				133,125
Line of Credit Facility, Current Borrowing Capacity						$ 450,000
Long-term Line of Credit						300,000
Term Loan, Borrowing Capacity						$ 150,000
Line of Credit Facility, Interest Rate at Period End \| Rate						5.00%
Term loan with SunTrust, interest payable quarterly				140,625	$ 148,125
Term Loan and Line of Credit Facility, Amount Outstanding				$ 190,625
SunTrust Bank [Member] \| Revolving Credit Facility [Member] \| Subsequent Event [Member] \| Second Amended Credit Facility [Member]
Long-Term Debt Additional Disclosures [Line Items]
Term Loan and Line of Credit Facility, Amount Outstanding			$ 195,625
SunTrust Bank [Member] \| Revolving Credit Facility [Member] \| Minimum [Member]
Long-Term Debt Additional Disclosures [Line Items]
Line of Credit Facility, Interest Rate, Additional Margin \| Rate	0.75%	1.25%
Line of Credit Facility, Interest Rate, LIBOR \| Rate	1.75%	2.25%
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage \| Rate	0.30%	0.30%
SunTrust Bank [Member] \| Revolving Credit Facility [Member] \| Maximum [Member]
Long-Term Debt Additional Disclosures [Line Items]
Line of Credit Facility, Interest Rate, Additional Margin \| Rate	1.75%	2.25%
Line of Credit Facility, Interest Rate, LIBOR \| Rate	2.75%	3.25%
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage \| Rate	0.50%	0.50%

XML 99 R83.htm IDEA: XBRL DOCUMENT

Debt Other Additional Disclosures (Details) - Collateralized Debt Obligations [Member] $ in Thousands		2 Months Ended
	Dec. 31, 2014	Dec. 27, 2017 USD ($) facilities Rate	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2015 Rate
Mortgages [Member]
Debt Instrument [Line Items]
Number of Operating Subsidiaries \| facilities		17
Prepayment Penalty Reduced Rate During First Three Years		10.00%
Prepayment Penalty Reduced Rate During the Fourth Year		3.00%
Prepayment Penalty Reduced Rate for the Fifth through Tenth Years		1.00%
Prepayment penalty reduced rate					1.00%
Notes Payable \| $		$ 112,000
Mortgages [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Debt Instrument, pre-payment fee reduction, term	3 years	5 years
Debt Instrument, Term	12 years	30 years
Mortgages [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Debt Instrument, pre-payment fee reduction, term	11 years	10 years
Debt Instrument, Term	33 years	35 years
Notes Payable, Other Payables [Member]
Debt Instrument [Line Items]
Notes Payable \| $			$ 125,394	$ 14,032
Notes Payable, Current \| $			2,439
Notes Payable, Noncurrent \| $			$ 122,955
Notes Payable to Banks [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		3.30%
Notes Payable to Banks [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage					2.60%
Notes Payable to Banks [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage					5.30%

XML 100 R84.htm IDEA: XBRL DOCUMENT

Debt Future Principal Obligations (Details) $ in Thousands	Dec. 31, 2017 USD ($)
Debt Disclosure [Abstract]
2018	$ 9,939
2019	10,106
2020	10,203
2021	170,926
2022	2,904
Thereafter	111,941
Long-term Debt	$ 316,019

XML 101 R85.htm IDEA: XBRL DOCUMENT

Options and Awards Lead Paragraphs (Details)			12 Months Ended
Options and Awards Lead Paragraphs (Details)	May 25, 2017 shares	Nov. 08, 2007 Rate shares	Dec. 31, 2017 Rate shares	Dec. 31, 2016 shares	Dec. 31, 2015 shares
Stock Issued or Granted During Period, Share-based Compensation [Abstract]
Award Vesting Period			5 years
Estimated Forfeiture Rate \| Rate			9.73%
Options Granted			481,000	497,000	637,000
Nonvested Restricted Awards, Granted			173,000	299,000	323,000
2017 Plan [Member] [Member]
Stock Issued or Granted During Period, Share-based Compensation [Abstract]
Number of Shares Available for Grant			6,277,000
Number of Shares Authorized	6,881,000
Conversion to Reduce Shares Availability	1
Other than Options, Conversion to Reduce Shares Availability	2.5
Award Vesting Period	5 years
Award Vesting Rights, Percentage	20.00%
Expiration Period	10 years
2007 Plan [Member]
Stock Issued or Granted During Period, Share-based Compensation [Abstract]
Number of Shares Authorized		2,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized		1,000
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Additional Shares Authorized \| Rate		2.00%
Award Vesting Period		5 years
Award Vesting Rights, Percentage		20.00%
Expiration Period		10 years
Options Granted			156,000
Nonvested Restricted Awards, Granted			61,000
Director [Member] \| 2017 Plan [Member] [Member]
Stock Issued or Granted During Period, Share-based Compensation [Abstract]
Award Vesting Period	3 years
Award Requisite Service Period	3 years
Director [Member] \| 2007 Plan [Member]
Stock Issued or Granted During Period, Share-based Compensation [Abstract]
Award Vesting Period		3 years
Award Requisite Service Period		3 years

XML 102 R86.htm IDEA: XBRL DOCUMENT

Options and Awards Valuation Assumptions (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Fair Value Assumptions and Methodology
Options Granted	481	497	637
Weighted Average Risk-Free Rate	2.00%	1.40%	1.70%
Expected Life	6 years 2 months	6 years 4 months	6 years 6 months
Weighted Average Volatility	35.20%	37.80%	39.50%
Weighted Average Dividend Yield	0.80%	0.80%	0.60%

XML 103 R87.htm IDEA: XBRL DOCUMENT

Options and Awards Exercise Price and Fair Value (Details) - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures [Abstract]
Options Granted	481	497	637
Weighted Average Exercise Price	$ 20.31	$ 19.43	$ 23.27
Weighted Average Fair Value of Options	7.00	7.00	9.08
Intrinsic Value of Options Granted on Grant Date [Abstract]
Grant Date Intrinsic Value	$ 0	$ 0	$ 0

XML 104 R88.htm IDEA: XBRL DOCUMENT

Options and Awards Options Outstanding Rollforward (Details) - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Options outstanding January 1,	5,176	5,448	5,532
Weighted average exercise price January 1,	$ 11.62	$ 10.36	$ 8.51
Options vested January 1,	2,704	2,526	2,218
Weighted Average Exercise Price of Options Vested January 1,	$ 8.18	$ 6.35	$ 4.70
Options Granted	481	497	637
Weighted Average Exercise Price, Options Granted	$ 20.31	$ 19.43	$ 23.27
Options Forfeited in Period	(178)	(127)	(233)
Weighted Average Exercise Price, Options Forfeited in Period	$ 15.82	$ 14.46	$ 12.55
Options Exercised in Period	(740)	(642)	(488)
Weighted Average Exercise Price, Options Exercised in Period	$ 6.93	$ 6.47	$ 5.20
Options outstanding December 31,	4,739	5,176	5,448
Weighted average exercise price December 31,	$ 13.08	$ 11.62	$ 10.36
Options vested December 31,	2,776	2,704	2,526
Weighted Average Exercise Price of Options Vested December 31,	$ 10.07	$ 8.18	$ 6.35

XML 105 R89.htm IDEA: XBRL DOCUMENT

Options and Awards Options Outstanding by Exercise Price (Details) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2017 USD ($) $ / shares shares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Outstanding Options	4,739
Black-Scholes Fair Value \| $	$ 25,779
Stock Options Vested and Exercisable	2,776
2008
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price, Lower Range Limit \| $ / shares	$ 2.56
Exercise Price, Upper Range Limit \| $ / shares	$ 4.06
Number of Outstanding Options	185
Black-Scholes Fair Value \| $	$ 292
Remaining Contractual Life (Years)	1 year
Stock Options Vested and Exercisable	185
2009
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price, Lower Range Limit \| $ / shares	$ 4.06
Exercise Price, Upper Range Limit \| $ / shares	$ 4.56
Number of Outstanding Options	420
Black-Scholes Fair Value \| $	$ 907
Remaining Contractual Life (Years)	2 years
Stock Options Vested and Exercisable	420
2010
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price, Lower Range Limit \| $ / shares	$ 4.77
Exercise Price, Upper Range Limit \| $ / shares	$ 4.96
Number of Outstanding Options	116
Black-Scholes Fair Value \| $	$ 281
Remaining Contractual Life (Years)	3 years
Stock Options Vested and Exercisable	116
2011
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price, Lower Range Limit \| $ / shares	$ 5.90
Exercise Price, Upper Range Limit \| $ / shares	$ 7.99
Number of Outstanding Options	134
Black-Scholes Fair Value \| $	$ 454
Remaining Contractual Life (Years)	4 years
Stock Options Vested and Exercisable	134
2012
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price, Lower Range Limit \| $ / shares	$ 6.56
Exercise Price, Upper Range Limit \| $ / shares	$ 7.96
Number of Outstanding Options	435
Black-Scholes Fair Value \| $	$ 1,603
Remaining Contractual Life (Years)	5 years
Stock Options Vested and Exercisable	435
2013
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price, Lower Range Limit \| $ / shares	$ 7.98
Exercise Price, Upper Range Limit \| $ / shares	$ 11.49
Number of Outstanding Options	522
Black-Scholes Fair Value \| $	$ 2,539
Remaining Contractual Life (Years)	6 years
Stock Options Vested and Exercisable	390
2014
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price, Lower Range Limit \| $ / shares	$ 10.55
Exercise Price, Upper Range Limit \| $ / shares	$ 18.94
Number of Outstanding Options	1,458
Black-Scholes Fair Value \| $	$ 8,272
Remaining Contractual Life (Years)	7 years
Stock Options Vested and Exercisable	789
2015
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price, Lower Range Limit \| $ / shares	$ 21.47
Exercise Price, Upper Range Limit \| $ / shares	$ 25.24
Number of Outstanding Options	549
Black-Scholes Fair Value \| $	$ 5,000
Remaining Contractual Life (Years)	8 years
Stock Options Vested and Exercisable	219
2016
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price, Lower Range Limit \| $ / shares	$ 18.79
Exercise Price, Upper Range Limit \| $ / shares	$ 19.89
Number of Outstanding Options	450
Black-Scholes Fair Value \| $	$ 3,140
Remaining Contractual Life (Years)	9 years
Stock Options Vested and Exercisable	88
2017
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price, Lower Range Limit \| $ / shares	$ 18.64
Exercise Price, Upper Range Limit \| $ / shares	$ 22.90
Number of Outstanding Options	470
Black-Scholes Fair Value \| $	$ 3,291
Remaining Contractual Life (Years)	10 years
Stock Options Vested and Exercisable	0

XML 106 R90.htm IDEA: XBRL DOCUMENT

Options and Awards Restricted Awards Granted (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Restricted awards granted [Line Items]
Restricted Awards Grant Date Fair Value Range, Minimum	$ 18.47	$ 18.79	$ 21.00
Restricted Awards Grant Date Fair Value Range, Maximum	$ 22.90	$ 23.23	$ 26.55
Share-based Compensation, Restricted Awards, Exercise Price	$ 0
Issuance of restricted stock to employees (in shares)	173	299	323
Award Vesting Period	5 years
Director [Member]
Restricted awards granted [Line Items]
Restricted Awards Grant Date Fair Value Range, Minimum	$ 18.47
Restricted Awards Grant Date Fair Value Range, Maximum	$ 21.96
Options Granted to Non-employee Directors	30

XML 107 R91.htm IDEA: XBRL DOCUMENT

Options and Awards Restricted Award Rollforward (Details) - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Restricted Stock Rollforward [Line Items]
Nonvested Restricted Awards, Nonvested at January 1,	429	425	366
Weighted Average Grant Date Fair Value, Nonvested at January 1,	$ 20.42	$ 19.79	$ 15.15
Nonvested Restricted Awards, Granted	173	299	323
Weighted Average Grant Date Fair Value, Restricted Awards Granted in the Period	$ 20.21	$ 20.55	$ 22.99
Nonvested Restricted Awards, Vested in the Period	(195)	(279)	(234)
Weighted Average Grant Date Fair Value, Restricted Awards Vested in the Period	$ 19.79	$ 19.58	$ 17.36
Nonvested Restricted Awards, Forfeited in the Period	(24)	(16)	(30)
Weighted Average Grant Date Fair Value, Restricted Awards Forfeited in the Period	$ 20.34	$ 20.85	$ 16.81
Nonvested Restricted Awards, Nonvested at December 31,	383	429	425
Weighted Average Grant Date Fair Value, Nonvested at December 31,	$ 20.65	$ 20.42	$ 19.79

XML 108 R92.htm IDEA: XBRL DOCUMENT

Options and Awards Compensation Expense (Details) - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 8,331	$ 7,776	$ 6,677
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	5 years 8 months
Stock Options
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 4,773	4,793	4,164
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized [Abstract]
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized	$ 11,063
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition	2 years 9 months 40 days
Employee Service Share-based Compensation, Nonvested Awards	1,963
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Number	1,864
Restricted Stock Awards
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 2,322	2,371	1,931
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized [Abstract]
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized	$ 6,916
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition	3 years 4 months 15 days
Stock awards
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 1,236	$ 612	$ 582

XML 109 R93.htm IDEA: XBRL DOCUMENT

Options and Awards Intrinsic Values (Details) - Stock Options - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Outstanding	$ 44,060	$ 55,610	$ 67,508
Vested	33,976	38,101	41,128
Expected to Vest	9,311	15,983	23,508
Exercised	$ 10,481	$ 9,199	$ 8,709

XML 110 R94.htm IDEA: XBRL DOCUMENT

Options and Awards Subsidiary Equity Plan (Details) - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award Vesting Period	5 years
Employee stock award compensation	$ 8,331	$ 7,776	$ 6,677
Subsidiaries [Member] \| Subsidiaries Stock awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award Vesting Period	5 years
Employee stock award compensation	$ 1,364	$ 1,325	$ 0
Common Stock Required to Settle Subsidiary Shares	264	212	0

XML 111 R95.htm IDEA: XBRL DOCUMENT

Leases (Details) $ in Thousands		12 Months Ended
Leases (Details) $ in Thousands	Jun. 01, 2014 facilities Renewals	Dec. 31, 2017 USD ($) facilities Renewals	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)
Operating Leased Assets [Line Items]
Operating Leases, Rent Expense \| $		$ 132,932	$ 125,221	$ 89,264
Facilities under Master Lease Arrangement		25
Master Lease Agreements		6
Various Landlords [Member] [Member]
Operating Leased Assets [Line Items]
Lessee, Operating Lease, Term of Contract		15 years
Lessee Leasing Arrangements, Operating Leases, Number of Renewal Terms \| Renewals		2
Lessee, Operating Lease, Renewal Term		5 years
CareTrust REIT [Member]
Operating Leased Assets [Line Items]
Skilled Nursing, Assisted Living and Independent Living Facilities	92
Operating Leases of Lessee, Contingent Rentals, Description of Variable Rate Basis	0.025
Payments for Rent \| $		$ 57,169	$ 56,271	$ 56,000
Lessee, Operating Lease, Renewal Term	5 years
Master Lease Agreements	8
Minimum [Member] \| Various Landlords [Member] [Member]
Operating Leased Assets [Line Items]
Lessee, Operating Lease, Term of Contract		5 years
Average Term of Non-Cancellable Equipment Leases		3 years
Minimum [Member] \| CareTrust REIT [Member]
Operating Leased Assets [Line Items]
Lessee, Operating Lease, Term of Contract	12 years
Lessee Leasing Arrangements, Operating Leases, Number of Renewal Terms \| Renewals	2
Maximum [Member] \| Various Landlords [Member] [Member]
Operating Leased Assets [Line Items]
Lessee, Operating Lease, Term of Contract		20 years
Average Term of Non-Cancellable Equipment Leases		5 years
Maximum [Member] \| CareTrust REIT [Member]
Operating Leased Assets [Line Items]
Lessee, Operating Lease, Term of Contract	19 years
Lessee Leasing Arrangements, Operating Leases, Number of Renewal Terms \| Renewals	3

XML 112 R96.htm IDEA: XBRL DOCUMENT

Leases Additional Disclosures (Details) $ in Thousands	3 Months Ended	12 Months Ended
Leases Additional Disclosures (Details) $ in Thousands	Jun. 30, 2017 USD ($)	Dec. 31, 2017 USD ($) facilities	Dec. 31, 2016 USD ($) facilities	Dec. 31, 2015 USD ($)
Operating Leased Assets [Line Items]
Gain (Loss) on Contract Termination		$ 2,715	$ 6,512	$ 0
Business Exit Costs		$ 2,321	$ (11,225)	0
Skilled Nursing, Assisted Living and Independent Living Facilities [Member]
Operating Leased Assets [Line Items]
Number of Businesses with Lease Terminations \| facilities		4
8051 Services, Skilled Nursing Care Facilities [Member]
Operating Leased Assets [Line Items]
Number of Businesses with Lease Terminations \| facilities		1
Disposal Group, Disposed of by Means Other than Sale, Not Discontinued Operations [Member] \| 8051 Services, Skilled Nursing Care Facilities [Member]
Operating Leased Assets [Line Items]
Number of Businesses Closed \| facilities		1	1
Facility Closing [Member]
Operating Leased Assets [Line Items]
Business Exit Costs	$ (1,286)	$ 2,830	$ 7,935	$ 0
Contract Termination [Member]
Operating Leased Assets [Line Items]
Business Exit Costs		$ 1,187

XML 113 R97.htm IDEA: XBRL DOCUMENT

Leases Sale Leaseback Transactions (Details) $ in Thousands	Jun. 01, 2017 USD ($)
Sale Leaseback Transaction [Line Items]
Sale Leaseback Transaction, Lease Terms	20
Sale Leaseback Transaction, Gross Proceeds, Investing Activities	$ 38,000
Sale Leaseback Transaction, Historical Cost	24,847
Sale Leaseback Transaction, Current Period Gain Recognized	$ 13,153
Number of Optional Lease Extension [Member] [Member]
Sale Leaseback Transaction [Line Items]
Sale Leaseback Transaction, Lease Terms	3
Optional Lease Extension [Member]
Sale Leaseback Transaction [Line Items]
Sale Leaseback Transaction, Lease Terms	5
8051 Services, Skilled Nursing Care Facilities [Member]
Sale Leaseback Transaction [Line Items]
Sale Leaseback Transaction, Description of Asset(s)	2
Assisted Living Facility [Member]
Sale Leaseback Transaction [Line Items]
Sale Leaseback Transaction, Description of Asset(s)	1

XML 114 R98.htm IDEA: XBRL DOCUMENT

Leases Future minimum lease payments (Details) $ in Thousands	Dec. 31, 2017 USD ($)
Leases [Abstract]
2018	$ 135,841
2019	135,395
2020	135,149
2021	134,942
2022	133,446
Thereafter	1,080,348
Operating Leases, Future Minimum Payments Due	$ 1,755,121

XML 115 R99.htm IDEA: XBRL DOCUMENT

Self-Insurance Reserves (Details) - USD ($) $ in Thousands	12 Months Ended
Self-Insurance Reserves (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Schedule of Self-Insurance Reserves [Line Items]
Balance January 1,	$ 65,351	$ 56,003
Current year provisions	89,394	74,187
Claims paid and direct expenses	(83,300)	(66,062)
Change in long-term insurance losses recoverable	1,291	1,223
Balance December 31,	72,736	65,351
Professional Malpractice Liability Insurance [Member]
Schedule of Self-Insurance Reserves [Line Items]
Balance January 1,	36,310	30,710
Current year provisions	20,396	23,149
Claims paid and direct expenses	(16,133)	(18,186)
Change in long-term insurance losses recoverable	361	637
Balance December 31,	40,934	36,310
Workers' Compensation [Member]
Schedule of Self-Insurance Reserves [Line Items]
Balance January 1,	23,402	20,219
Current year provisions	15,202	12,887
Claims paid and direct expenses	(12,455)	(10,290)
Change in long-term insurance losses recoverable	930	586
Balance December 31,	27,079	23,402
Health Insurance Product Line [Member]
Schedule of Self-Insurance Reserves [Line Items]
Balance January 1,	5,639	5,074
Current year provisions	53,796	38,151
Claims paid and direct expenses	(54,712)	(37,586)
Change in long-term insurance losses recoverable	0	0
Balance December 31,	$ 4,723	$ 5,639

XML 116 R100.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies Litigation (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2017 USD ($)
Litigation [Line Items]
Litigation Settlement, Amount Awarded to Other Party	$ 11,000

XML 117 R101.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies Medicare Revenue Recoupments (Details)	12 Months Ended
	Dec. 31, 2017 facilities
Medicare Probe Reviews [Abstract]
Facilities under Medicare Probe Reviews	7

XML 118 R102.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies Other Matters (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2013 USD ($)
Other Commitments [Line Items]
Litigation Settlement Paid to U.S. Government	$ 48,000

XML 119 R103.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies Concentrations (Details)	12 Months Ended
Commitments and Contingencies Concentrations (Details)	Dec. 31, 2017 Rate	Dec. 31, 2016 Rate	Dec. 31, 2015 Rate
Concentration Risk [Line Items]
% of Revenue	100.00%	100.00%	100.00%
Total Medicaid and Medicare
Concentration Risk [Line Items]
Accounts receivable by payor as a percent of total accounts receivable	56.70%	58.60%
% of Revenue	68.40%	67.80%	69.10%

XML 120 R104.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies Cash in Excess of FDIC Limits (Details) - USD ($) $ in Thousands	Feb. 02, 2018	Dec. 31, 2017
Cash in Excess of FDIC limits [Line Items]
Cash, FDIC Insured Amount		$ 250
Subsequent Event [Member]
Cash in Excess of FDIC limits [Line Items]
Cash, Uninsured Amount	$ 965

XML 121 R105.htm IDEA: XBRL DOCUMENT

Divestitures (Details) $ in Thousands	12 Months Ended
Divestitures (Details) $ in Thousands	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($) Centers	Dec. 31, 2015 USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain (Loss) on Disposition of Business	$ 0	$ 19,160	$ 0
Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Urgent Care Centers Operated \| Centers		17
Sale Price from Divestiture of Businesses		$ 41,492
Gain (Loss) on Disposition of Business		$ 19,160

XML 122 R106.htm IDEA: XBRL DOCUMENT

Defined Contribution Plan (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2006
Defined Contribution Plan [Abstract]
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent	15.00%			90.00%
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 1,028	$ 862	$ 682

EXCEL 123 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

J$R\<9IUNT!8 "[B6TTK+0Y3S6>47!$#DO$V"(W;MA6*9O)#Q9'&)?WN+Y MK=!86F7($;H\&SN8'K[G:9%.F#YU.*#0#+(](U+5345OC8//B$CG.L @P::H MCG&67!J:>BJ0TA\1..SVUP?;+L]C+_M3'(@C:$\PB ]&PAY'*/09V!3F6DBF MU_L*;"]R:3FQTCV[X#4ZQH/O- )]T;[B,[W9PP2/^NK/55/?QJWMG)N_>727 M^Z\!;<\-'O<=?!:V5V>254YB[I"^^HG[E9POWWGWP7Z.VO$"VC8ZRYO\B^.N M$CUM,J--A3O<12Y/D9CGT8=(+)AVF7TN-I_QE17\OOO:\5#GG=.^T'#N98!>U=;UX J8C M[EYV^AUH!_03GJ)&-DITG])O+Q+ MT+1E^W7=]6Y+QK5?!!F7WZOB]K)G[:\OKEY]O/SPZ?+]N^C]F^CESU>7[RZN MK@XD(+XO;].=J/!QY&T=#B,T7_]BG[4DD8Q='2T%;0;L ;RXPM;-TM8>KP+1..13[_39&ZGC(-ICCH^HLFGP;=#]X M16(0G1._;$??8[LO,F&@N=%XJ+*/9CR9P68!(^")QO ?U3U,DHZ>_D#32C6K MPRC7;C8^Z 8FW(J^ C?MO,S_!LHTD%2ZR8$S[7+\N=C U5P7<*3K] [_*1[@ MU_^2@@4$DWF779=I]4N*/WU.U_#O^U\V\-P6?RJS6Z30JV(/&_HJ!6F2X_! M;OCJSW4*L_\S<"TXE5IH]\] EC"M?!<EJSO[''Y 71!8'FJ2 MUQEMIULJB4?,PE,B.6W%TEW[&V?FKA:P;R .6 M@5SI'A;P)=_"F6X>HV01+X?#P%!JK &V:"D*!;1OZ-6[; M\93\@.&;V9C,5[B*2-#IS0T0-%&>IVVV+3.RLE.@!Q\L2F9S^YQ>;)-617(C M+4NT6WV"TQV@0%(GH ;NQ#*')C_ )P+./#F\8S798\\O&^6I0/;U7S, ID> M#GO%U$QY[5GI[]-*OBX>&KHM8#.BA@G78[]-4>.O"E@*<663B5]GJ[L=<*%; MX.B;[#:%Y\N\^B6"5U+>%IOJRNGTF 3CN3?,CE@!/=%SK73W2>T%J;N' R)? M ^[R77Y?L42J]LAES(O!K8W2357 \:!,"?83KBA=U;PK.?:$CH.?.(6)I+7N M6A55Q$,V:;ZMSK8I[F,A86195/,8>Y:'5OFMR?F #]R .&)"= Z+0(2Y+^&[ M>GP/1?D+:';RN= 7UNDJ&407PJ'K@+N9NV*D$4HN)_BND3>"N@7_$0?;&??2 M)^\>L4CX'"B-F%+O"25N1!=9EQA$'Y&.05XB>X4?4#X4(B*,(QD7/1K^8'9\ ME/Q X\A?.Y80/0!-G?5[T6TCQQ0B#$!@YAVH/GBWC_QV8.J[]7//_UT M_O$OJ/9B*<_EF\M7Y^\^1>>O7KW_^=VGRW<_1A_>O[U\=7EQ%75/0)*R:(>0 M[1'9L(YKJ.K&:>>5U\Y/NG3V4R;LZRS;P?W%F\%Z&XY=KNGB$8_R+!8> U,J MO]_ 4N7V ]>&OV?WM;>N?L;\=8F3P*=_/#__:=@[\D3PB:JM@%5C%27^\JFL.957FP#+< MB9VJVBMKM/%>/TT48A734=BJ%#C4*,,Z'=Q4==OPY;0:2V - 1LM4:S1^\ A M_UJ4>#B?B]KZ>T(JN&?BKOJ"BD1]0E,2;JW$8R9*4K!&V:2(J@JKGD_16K>X M5'9[F?=M( TY%EIR1Z5^T1'AP'WK0)=I<[95$$7D[_[C'IQ;8O Y& OO$NV. M>])-X.1/EQ? 8QY0 @;?AXT%$?!7E"*HY_F/BGP@;8RB@95Q8,-HWU9&^)%H MH8]M^'J+5[YC0'H*E0288+YF3:S>ESL>XQKTN(;6A79UE3&UE!EQ"=YY$RT* MQ;D0)2XYEO,A3A+].WPNKSD3EL?58.=]\4!VVSK"6&ZQS5>B;I#!BGEV8H3R M]$GXLL, WZN=*X./Q>D$-,0W6\S@])/]XI'Y-/ M%< ];T5KAI.ZKHKR.I+LXN(F5M=+B1F)]@@DUNG6@SK'-=_@KR+^5 74N4EEJUW1$?6;NH&%M0\VE*WYFQ[^(N^:M-YN2=Y]J MY\R8R_&%%C7^B6+6V.01V'VYE6K'F+C/@42/^"AK4JS%;T,[D3@6:6-\(H-QA3]I7,'O[249 M6KRY]BXT3\-?JMR\0?*@JE7Y)O:)E-@7/HHYC@FZTIZDH*F/C;T ]W&7N-N- MH($.\XXD.+!.6I1E\8 )U*'PO ;--$.?*6HC0O^=ZU*;'U.92CPH"LA4UN5H M C4845NE^TKO%/Q^AS68&5N;6EV&%BZ8P'!5F%>A+9?\ M][]13@B_ JJ+Q(L*)']*,"KV6!ZP8Z>;5UUAM>B9'%?K*@^=$W6D3C"\/?TP1*E68G% MC/ B?U=$35Y)F!^O:H:N/]A_.#=V+ISDGT^=VPW=++A@! F 1TCW@4U=M^4P M;TF.V;8E75SXUA9D,;Q#EX%=3+A'YBY:E]D]G(AC?/11V?"UBAQBF3Y&HM4Q M2!NX:\(>K]& $H4N/.O")4D"-D6Y/L.PVR,2 M=%$&&MM/V1I89[Z.Y:M:U2NS0=D'7!Q;]$!N,.3 M$#;/4GS->I1?4=6@ 59.F0CXYJ-(7*G-!L2[R?_&?$DV=X\W0[ZJXPXZ.6XP MS2,GV+!?]IA,PC8^&%PILZ'4I6NB]=4:V-*@1M8&%'I%I\..35][D8#(8;SR M,73&X,=6++Q 7:4<._5.-_=;%VK4I#+SE"OJ@:01D/+)*7NHU9JU9"@@JXBQ M11RY(W\'"S6KP1;#Y[I( L^OF<.J;!:MG ?DFH'V'GJDOVT8T/HV3+!3B?DJ MRNXF$F6]2/.H6;EOET:FW*L/D.YJ)3*C^CZZ$N_2._$NZ0T_1(['L%D?U_E/ M9+B>V;KAF>NZC_'=^R_"A&&BI*8WF#%H4"GN^#7[8W]75.I=-:YEB\SD=-DZH5@A;1G^K6/; M0%4$7C>(_HA&S!\Y[T2GX2Z2_@+3WY2Q=6V5DZ'^59B.T[,E/S>J'H$\MGYC MTV@V/(.SCK+[O"K6_D':3'6L6OEII(L['=DO]?54GC?$T?6^)CFAH8"Z +T[ M/46MNMC78'R4[IOYC5.O: 'H(-KO]A6?.J83;AY!?;Z&EX&=/D3[.M]H+8.. M8>:7LQ:UVW/$XB;"DH&:_4XW&7GE0&B"-/P,JO;)"D=%#I<3LWRT0^BLR/UC M8MX[CBG[_*$@M\DG'J=N!!(*K?>DN%P\6.HUD".!N:UY;JT5\@G0/< 7-D 7 M:L25Z?VCI7..G&CZ@>CW9XV MM9C^$>GFXU^V^1?VAF0XS#VH.PRJ)/;8W2G=NL]N]OBCCA*J4NCIJIHS<--T M*M'.^"[=:9#&=8-6GS@Q.$!]G=4/%% 2Q7"M0>:](5MABLB'(K0E.?2&,;5K M9FQHLX-XQCN.C DI;BW@=^+J*QV>B'H1*6QH+3E2!$SR!9NE>&4M) 9G;V.0 M@/:F)%(//;?.!\'\AKP=XF3;=; ]TBWD/G7X1]A7*OE?^+Z*",X*8_M#JP'< M8=QXF]V*A4N?LF-UX% W:Y]>N#Y*"S$.BU3QHP+?8545*\Z((,GH""'?,4'# MQ1M$%QV_)?D2LG%_F6E+*;OYD$.2V;33Z?V"TLI'9=;Z([]#J5(HY,+%>HO% MGI=9?5ZSX#%B>2"N9E2='S%KB4J^2:1M'GG.>>5&CE*)4'7PL&!;ZN;$V\MV MIFGK5J(.H3R"-/+:S$#&4TP'>!;C"@+O0%OGI:-(':.#8KIV2\#SR0*O>4DO MZJ_/GO)ZX76.*A"NH*B@!;RC.BK<9?-P:W5([IE\40K;2CHT]G@A$T6_!18H MU8S#HBY'& 887Y_.Q0Q,B%S/[D($ELMK7^(HZ^Y6S&&T\PP@@J>(-(8,;YG@N M'.89G2LOAQ*G@*F"28D<"%4ZSC+PWLS_L'D2B?N)&?5-KE7/'^F0^0[R?Q-) MF&0MTB8L(_%D*%[/8Z2=);A_,&GDT4@VG/KFR%B31(RB;55@7(975.]9M64Y MO"-M 'WINMGP0,@@P03(B;\15U!-B7F9()AYIX^<]GJ/#(7A)-PL&NY@Y^/C^V?/AS(584OVJZ: D_ *E=C0.4K:#+JQH5'<3LH"[ LQ\)UH12DA3T=S2Y*[%Q135C_>9"[M6A!I-ZO;NMB 6 MD5?W>[PD/1ZJ0?2>.2QG6Q*#Y1F ,@$K0G2_8)9.B.OI?<[!2ES["5$<[9%3 M>_BZPV/[^[5R%]776=58T>WWXZ.J 9)3JP#]OM/I(:%PFHA$@"1?R/!&P=MD MT]S.ECVR"(\CB?].;O$8>@\;6BDPOD=4#NQV8&RRX^2Z]T#4-KMO* ,]P=,- M,[?:)<:11T05I*Y MYF3V3[[@98,2B.62 MK!'B%SFS'>MU J7/:<)/(46[A9F9"XTZ:4R;BP6JE?CWS,7)2Y!]B I&/,>5 M'=(/%Z;L4/EG?V&BPDK!B3K(&]YWS;.1F\T&84\8F8\HK/_K MF#7YW^7:&*^AY&6_);=(HKG9(+OWN'J^-6:+]KM44=O^?5\PER=SD%(2R(W& M7S5:,NHA5<5Y%'SQM[1Y[.\D_8W@_] 3B;05DS[B0:HE ST@Q$VZ$M)S.0,4 M)N?H0>L<[G*L6V#%AM/7'AL1_+S>2W3=XU)<^:J3\^ND] G/E-+DY:OWN4_>-&E=27 M@!/5F*A+9<#.-KS94^;"O2EWKI_8DD!!HER?,,FQR@[OAP!- RNZRS9 M1^?T[,N7+__OB!/P>S-'3+H2=NI V9)7;JR4V8'7*3!M_'A"&D17<,5O]B4Q M4TRXVE/V#UX!*A*>QC:WYB=_(QJD+BH+%KKP&K16A=CT&;IGX:"VF")>/MJ< MI!.YVN\_?;J4>WT:\02P:JKF3,ZR1O^!2GZ*$".KN4%O*&\NQ7!<7B4)$6(K M)F7D@8(6-;OS4Z]FX39?CILP_6V7I253N,8 '-$27EG94;;DLFC5LXMJZJXFP "\DAFFA16E M:*^TD9O\%]0VR(N.*JFX[YP#3KW._OW4$NNAG5*7N'A:'S654U!G4Z^K<[HVODZ)E5XVM8)# MAF UB5N1O#E8]E3 VX6ZYR'EK$&;X?11^1QE%.!E8&E#.9F.%PRBH'_#A>*_ M./[>W=Y!Z#F7#&"?%J!I'8$:C=4"'Q'81VQ8Y#JPX9RC7#I88=Z7'>=)#:( M53BOR#8@A%<.:;+B7Z:8L'RV09T8#NFN6).1W?!\[*L,M; -%0 +&:QE>)/F M>((12 ,CBHM&+A2UX@&#GF8"I)P!R889SDPBC3HVDCB/) MO.R=:VD8-64*4-TG7E^@[" /DQH=O*60TCDOISLU#@T7YBKHK2,/JE.?6KF< M7IDA\8"'I\@Q79KY@0I#0^_(6-'K%Z$_@<.S?2HN!;U7+MP8S-K7?J A1Y + MV_11[5]A#NQR^ZC_X>Q=\7?P(KM41$%.$2D/FB0F;4MV%HM\A\]FH'%P@GU5 MI(5HE60F\(=9?XXE6(FO^&QHMZG7E!@O]!$'5I])C8XUV_:OF58;U:JS9,0% M.XX\7#C'0)#KNJT3P!]>L%^87W;LE\.C99C=Q8>M\:>=/7SBY ]:1F!X8N@' MZ9BL.K :=SLT -QL&LJ$L]/JELW0I>B9X7GMYOC-F8NV>EEY:5GD7GM22#HAM75!UR/A/S"Z6=1$ZJ4/L* M?24V',W\4VIGK[.&,9!:4#L*^3+R#;W5EQRY<_CRK)ZZ 3;B()5"(/)G8R.] M]7Z3"1Z<=Z,^+3,T <=<^OFZ?>O\%H1[ORB7-_T[59E)/* MK_NZ0RE_Z'1SWX1P2%6L*S38KH2M%=ML9+@T#B(-9KX&X95NMLWNQ/X>]V&D S4S_ ^T'FL2%V'.A031'3C9Y"LJ M70JY8)TQ!-Z3WVNH@$7+^TX&=L,"SV]^,Q61!4HXJUYU\5?+OV.3E >>+;AJ M/[7X5Y),1<3;J#_4^Q4J,C)%YHN4W&+0T 00P,&:@35UC47G[/MSTVA&,^F M:D&*"P\Q2(")77T8(0)DE98QF$TRQXG%,'2HP4E*GCJ=(ZN(%'_,NI0VDZ^! MB$.8)U0\B&,T./V6)Y_U!7:NN>4UYVH.%-E.?:<^(Z>,X#D_Z>Q*X-S=WN*I MU"LNB75- UK/R MG2%#AWN#D5*7T':%57C><=QE<>:59DYBJ;"KVA/R>+I44)A=RA)";C1U=L'B M0$;("88M,RI-+G:GXKPTE;PQ[$AV1N&&-8>VB1M<%X0* U.EX!&HJ5P8?9T] M%BPNW*?5E$(>E_,QC^I$PUM0U)US1E1U[]2>("%[5 M*1,^/.]Z@,3&%<1W.UOW[ LEN;Z8#H=V,F$.@X&BZMHP-$SFTR%-S2/"]0'W MH UHX'ITP+@Y8D(P8S@F@HR:;=(?.8G^802*(V5^*EIZY M>A3_ J,M.#^I"RYOT@=BO;_=DMC [%X5J MQ&<[1SF-N$K'3-P:0X+:%0>T-A+=ZV43>V1I\R,_2#SA75F>D0 MNTZSKI(P^(2F?%/A'25RN!"7CZE9)Y>DMQ,G(/<,TE_2A=A2XC],VI0KVV556. M!XO68_):';(>1;%VW$_ O&HIA?V47L!*Y3=500';%HC3 YYB(K5L(V6Q( KQ MKZLR1T-"4IV>VD:9#YQY+%@@R!/>9->ET1:28_>E+N[/:+^_:A]046CN P-I M_O-^HW.9!'-YBJS04,<\.%*FF8G')HWFBW$<>D[.^'1<"Y4R_8#^C"8]UD!A M\Y_GK&K- MRKD'[<$5:^Z3CIZ*'F'8?5$ 7WYO9+-!^>T2BH<)YU?=&MU7$ )DS[*5Z66U MB.J^N;#LJ)Y*A3X@,(X5$K]*..S)H>:XM/.!TIS<%]D^4W7FL%203)&V0&B8 MZTR>:C$F7QJBX1J'L*Z2$=9MN MM!S^@ IG*)[T DRARN]%W5<*M+58*,IN":I;Q!B:[FRDCV(L@W5Y5\Y,/^_( MP")IQIEE6_*-;; /E2:_XLH+:=/F %%F87C! MC35]LT?E9\-N'M5D?;8'NVEO\:<@NZ-RW^1*4RRMFV&76X_P?^*N="+H& -#AH1W9_ ?] KOZ]MNC7GQA[0+^).2K;@ MF*Y<.B8;4,G,.0Z&:M=R9N>+=M<65H4<5:K#W,AB<:Z$"%0&PD8 MH]OR3I@E:IZFJLQ^Q.&6V3N %A8CNA7[:N/*. *=VWO;5H^KC1I]U=)3#V^M%]< MIT"1-%8J)16D(?][!;X[J.#-0.F@9'/M]R:M<155X5XL]_V.E$ EDY:O),AS M=9GSG+VB]AT;?P]WV&/0P.V%_"6T"!6SDXL=!%)*G!GNC+U^L"6E,_08:WXW MI0"R$T15#5;.!M'KO8%^0G<7S.IS@8$P7Y?B[7W#"5A ^?5QXJ'!O@+1Q9G7 M;FT^LQ(#"X;>3&#)*XB"C!F"7EHX&P\QZY)K6C>27>9^EUB@=50.<.8FN;8X MW413 6.;;1)B-?JL3I=-DZZQ\ [3+ADBD8M_" ?O$W6U,[%G 2I(O_1B'Y99 M4.-(;FB7;]M5=D[!$H,EJ?$9=F/K=: &B@J*WAI/58)_QHQ?WF\!>341[-/C ?J<^1IRRINHVBMVY"E0?[(7Y5+=C/PZHK1&*<4LP&B)) M/GQO$-9JDZUOI>N9CQ!(F49LI0\+2"$YVDJYA\H;R)%"!VS2[]3"ATW%.2&W M6H-FAN6;Q,7]%!3[$^Z#="63+;C)L\W:,T+]-=:@5JVJ_Z[+TKM%L8_8M3$O MF?J!)T2O]G+5_KFXKA FDP-J^"?XCU,- * BENW2E413G-G',2?-8@H4$\I# M4 Q.EWYT_8B!AF4R#4"]^M%\/_G)<.JX=GD36YPAXC/[*?IO4IW&T\'P=Y0I MD> /IH];,W"V:*0+"A>03@J8C^NT7*^4!<6QBN@K73AKV2\.?.]I,KN_)=( MD,C$EA<:I?88%(QFD//5;4 M\Z"17^?4WV=/Y=N*6SAR$P5U\W4GMO0>O5;<-VPG9/,^.\IV0A>UPS_M0>4] M\#]W3&:XA5?6)],5_I>2-Y_N*J@3@3/'YD^2K\_T5':X-:P?DZF+3K*@6POC MIU/AO//%Z!/:AU-$AZ_ [*!VQ*%+:](@788$67Q ^0ZNS21B$?'AQ 8$PB4G M;'!=4:JOM98>&;'/M?!X@RXI+LAP(9^GG3GOH/-3\1]E6ZAT9QTW;H.+WAJH M:P^GX:NXF3G=8BU39>POA]E%&?19HU%*6>P*E/IA/> %^V?Q),O])M,*-J = MN-'D:B\S22B495^9*BDL0?DB:4! 0=NG:KKGL$>V#RXR=84!3:5 M5IOT07,.-"CI5XI+7-^DN#J^V;LU;E_<\)R895[I,]'+ OZ)3MZ<7[T\[7[B M5;'V>8A:$"Z&QE#=Q+@/#0-UB4Q"C(ABF+[Q^_R6MR."(-2$U) MC( +A_F+]^'9I#O^KW5?C9G-D.YXGU6'=%,3:E?VF5JN=#2-Z>XNP_Y/,=W\ MMW2NE/>WYA1L\Y8#M2=,>[&[N.]!PYWPK8&$\N:'AQ$H;3)*KE R:6FRDW5; MO=FY>W34T0BETTU%'\1&BFG:)9]^%HU&9"8,+R3C0U)Z&N+;:%\X3V?GZ^*^ MSEK-0$#+_RDMX<)[WR41#O,&26UUJT(_!+:3PIS&*OO,R11A/: Y3_*_.H;: MP9YM]P.7-L+^E:IK,(O/3C7Z-QEWEA6 1)8#KG+IR\G-<\TFAQCY 5!FUH#^%<7+X9V+?/C,&9D8-LXH M)H\>J+7?!9VA]V]:A,B&L#IJ$;)ADKS==G.;8^IK23^"A[(VH$RSQPIMVCV"<(N"F%YL%Q9R<= M#DS]B:-/'L::K79Y[2>[FF2'^C15)&V<&X33L) \3H^*EG4GG6!(H5)UMKTV*AXQ"W3V6#.@ZBOW/<\) M=I<&(3=)X:K@R2@SSVNK%HK^#TAS(* HC@05]U:M:U^MH^X/^W""O<<7.36, MH4*E\[3:EMK37GO8BADB4UGG&ZJ>)=JL#APCH@'*LP]4:H&T*6$[?IG2^)!M MPMN#;A'%X@NF?,G"Y^6>,J*COX"6?$A\/9HTUD!X;9ER0LW);6WM"H?\[U!+ M>+P7N,, 4)WAXRC_W-?RHR74EFN5,E!7OHD4PEV<3!6CKV7GB[6UFJ"1?,Q0 M0#.,YNQSR+UP0#TCE#^2G^XTZ'RK#@3CRTAO4!*Y&Y5,-1-8/#<&\-)J*('4 M6D@X"/X3]3DEX'O4V6KM2R>Z"\*@"F\)*1W5)*,RX9VUCM=C=;DG>Z81CU;W MS==2"_"Z$C4??%-R\64AJ6G]OG,5"&O"M!.7ADM/:-1CFEHVBX)K^T+YRL.P MVT-:!4WKHY."Z@E BP7&=FK*5*G0S3<,5_EM,,?T(CC;51,W=UP^Z]#VZNRV ME&!M;;X@"83:A$P2[.M3X4B-_6&^ZS"E4MT<.+*']+%5B$G.J,PU-O6#\5+. MKW[V%8#P)+"DK%W-N7O._'N^1'[SLH!?(O R$ R&N['*_;[R7<@PSI-B;YP. M.@$>B%A!"(J2&FZF&33I!ATZN;9_@"'T!8&TH82^M3=('AR^GMZB__+\(5 L M\RK@D]>9 P1C6':C;IH\4VUD)A5A!' MGZ8C%YNI*>Q+++ MH+&SV_U+:&*HPH4S5W@W/JA>CX7I1.VH5U+(NR.?:[S: M;\D(^9R="2\W/0K8;;]YY.V5K"<7A/#XXB9R9U'&.>3*5/;WI+G.+*=O@_PF M44C03\NQO:U#NI!QYQ:%1.D/7 M(86^+'Y-P?AB!+-,WH17V8\B8(2\AT0X&AB23C"M=NSX-ITJ5ZLAPNHDK/JU"QPKB#Q%2G@NP!@\\ *! M@ZM+N(T,@QF0YGDN6G\Q'E)1;:$][LU"]R9,0&-+-I87; M+UZ8P(ZKA[/CQ*0/&N6W4,)^/%K@=X$ WR&>$'YDPD!7M =NBLNXHR7YLZFR M?BAZ=Z;J)\R5 &DT23.9/D&:5&YQ#&V:?6^%Q]KKMAN>Q)/IL[9<[E/J0!DZ MML)1B7,)F(%'Y':ZG M@V5]^/G3^:=+X%OOWT3O+CY%E^_@EQ?1AXN/D3*T/YY_O#C *2]4-<:OT6>> M8I/'?O,EM0OLS6A2Z,UK3*Z5II7R(#$-B;:0AFZ0'XY+NK)Y3NI&:T4>? [' M ?XE%I#V(/ITE\G46U&0OI5JLQQ%V O?ON[?)0<\H3WCLQVI!5@&0BEW+D6R M".J&_+I,!5&X+(.'XPL-[2Y()SI:&Q6S%H2?T!KH+EU+E2))@[8.@.[7=\6 M;NW9$-A6@,P',[_0% "; _9!M&YN8]B*:#./% M> P_3$?Q8D(_3.,EO/H6SN;[0VF*/4F&532>+B(8;#J.)HNI_=J1UY\F-9E/ M\8=EO%P.>5*3\0A6Z+;O^^C/3Q^+Z7S:>4FGPW@)P$_T^D4_QG#?G6ROF#S MCU[(<#!?TC]+_"<9),/?EDYZN->OH)3Y?PM*"=F@)9A.BOBPV<,*B35(RVVK M("L#@C62'P1S_9)3T&46RSG\_W2^H)\GT;GFWK88RH'YP/Z,EOA/ IL/_XR MAEX?<>S/H=$YT^B,:'0XH^F_ER13.QF/28/EU6=.OJ1!=PZT$[D/$-&M2,XG MUBP*%P,444I2$H] %XRCQ7C!1>1 ++]%2_NF4M33?.# 8Z_!M&:DW>J ;M;W MP@'][,WYY+=Y^NN#\"1TI,QY!&9YPT(H#RLQJ[ MY-[!_V'JWR,K"Y1%@UX/R;WCMB;,6>!\-.;3Z*6"*3S8O4_UD^\CZ8X2<^B3 M*1-1_XN;N/+0XV!Z^UU[V83!0C<$AI9ZSEVARZ=* MWNQ+K@6DI?8L0&V(ZW@UCX3"VU1=2P90\;!K%4,)5RL-@YBQOT$VE40C3W*^#S\[()J]X-@@K;I6'("&%WV_#E33#0 M/V/DRH1 ,2E/P''6,?.(#@QTA)3$+IK M:8(4?LZLP871XEYN%;>FW-BO3+M:'-- ":FA*;X_FGZ8'7TN6X]?_.GB'8CZ M\W>OH_-7K][_C*+^X\6KB\L_G;]\>\CMT_DATSKOD([QU%=U[*]2M:@R0@21 MLUD:HNIXFU6G\CL\T&9WW*=_Z:"J7T2SR21>#,?1>#)8PD-H)S2$H\&"A3 >S:#&/I[# Z6 +R81_&P-L6HYG['7ZN M=RZ4X^,J1UR+8+*\N'4N/L751Y)Z)F@A:&1O4$(X$FO(FK\85_>*A!.A(G, MJ!4?,YB%]NZZJ4^I5D?=J%[]R]R )%G&DTE"/R7Q<-P@F!E0_W@8P2F/)S-# M_=-X-IOC/PA>V'M$LPD8WPG<%7A[#L2WC(#2:B'_@J4:8)Y-QO)PE MT6ET,E[&\R7^U+%C,1F]+XBHA[,%_@1W>S(>-_G<2PUZ7V6WG0:=_!X;44EJ M6#_#;3_K3;J#W/;ESU>7[RZNKJ*KBQ_9EFM+/NPJQ?EI1!(&(5!F_CU=$ JI MJ4.8,OJ$Q2AU=U99.>\[Y;/+&[M]2>A"OB_!#]')Z%20?R0L:%%_0$?C"1W[ MI:=&LE^FL/OX%"3]UG57QM]I8^V#7S7)-?[UF/_#-2W0D9J)TO[E5V PWT07 M7T"XDVWZ_@:T0 ;Q*,A=CX$H>L8?SSI;,>P6HEB4I(J_>O_ZI]CUU++]$ U& M4FVWRQ\S-Z#H:+;'M$'8@]+)T&%=:IM25.EOJ3B.8=0W.]#M\I6M[O7\TH1L_JX5,F(6+JKK2\ HW5@6TP#3,S#@ M@+AV%$ $230!4:;^#ANLHI9>[!ZP=H&';L.0-_D+#+!;Z I;%V1*89(.]XD??0)+,A7B/8+DGZ,5#M_1R)R2"!8]W>[QWT MDBZA^1Z?\QW;#2Z7U_..)I:$8-"51<%@Y]><3HSK*#B93Y>AF8N39>\BCF=V MS46A=?\DUW)3(0O%XN>Y'C9NDK-@7K<<1#MXCE8W]&P ]5!U*5>V M*)$9M&=MRH"Z8,R_<5SL&\>_^CJ^2A*VRR 3P(JLZ+U^<&/GXMG8M^- CTZ1JA ME5";(%J4 M7*.81T 5PB1C"B/%MDD??[\KX00 0+TZ3/\'?)D>DZO!Z[PRYY M4DLCW8>=L")/)>V,A(XD+MSVAWCLBD[6Q8QZFW%U9%$URES8CQ,]QY'3$ML@ M;WT2O93?:_\^OZDY8>0Z&K%X)R&_;K^J![9F?0]3'K"QS$#52C5(Z"6Z.ZP4 M*[@#W=FT.C(*]ZG)5:^$SUTI#SBWO.;2\)JWS&O<@\18_NBUJ3\*-_$C 7$P MK"U;H&U;VAK08% BQ.\+T.[CR8RBF6"!S[5A9CLS8@(JP@*,3GURN0 S M>N+^,["Q]:-G30M:GV[^:RWL*[ J:#%H*8_1'M7Y)F"4@*7@WPHMZ\ 8&BT2 M^,O8/3M":]7_9V!F2[:EC5O?FFLZ.ED M2E$^^'D\BV<3"LM-P.X?8M!5QNDRM_\N9G0_5-#F+I\G2/;D8DN6L_QDXD%J4+OZA/D(W[B-#Y\,A M$,1RJ;-=#L$47Q@R#SQ&(9E/X%;:*S$'8]__9^ VZB!SO!6@V2WGP :6T3Q. MI@F&XV?)B(G<>HS:1#Z>,ZN G^&BSL9$Y,@'DC&']7&<+O_1?QJ1'V/$]-DP M!XE_^H]+_!/@EF/RJB1+X#QX HMX.0DC:WVNTO$8*&WD:1_XZW#NZ:G37^IH M7QRB?;1O_*6.]A?C23P?CG2J\U$\'!D9T^L<39;PWL3S\P1?]-?N"0\I7/ E MO#Q;Q)/%/()O#$'&P.^F8R9[ZQMMDWV"LUK@!B\6\!\H1^'&CJ>XPS+*W]5! M^BN(?MH3F);88'WG=4L%^M-*%WZ>@;A0\_XU9=2/4I*I/A M#>,RE2^P?Y3"*8T]J^?(>'_IO+0GL,(>'S%GX=9Z1Z=#81L,/0:F_[>UT$Z*\?:L9,N[*8$M',)-PZ[L/Q3&*]<%U M*P(C)31\D5=NG[1P/?: .3CF'D^[KX]U/XMWI-M;;'V\3UODDHH=FLWN'/W@-OKD<>^. M4(=I:3;$)QUT.B]_I9[_C\>8\Q*Y M_OQ9S'E&X8%+NT(WCR+1V293<#\0(&R'$V(-X_I^/RLQZ"5+?Z'-_\/ M;_X?WOP<,_0?CSCPTIS GKQ8CSMGLX< M_H3LR(UCYW.0*\-*YI,)<^7)C'7R>+J@P<#RG ^73:X,:C[PMV>IS/%R,7X> M5P;>CZZFI[@RR)3A$(\(UCW&?Y<+JLR(YXM08QZA\$G^ARO_#U?^[\65PUUY M.I1>A71Y5$Z&22'3TU((U'547&_R6\ES\+@#!,-N-THB7C;"R\]P3%(:+U(7 M*]X%?A-?(\!]W7M*M(AU4B_F\7+<*LN1! SMT^DF77OL&)]\++6>)1=C.=03 M3#P*DZA!,99\E!?HF!_1C^VT[>UF\210,E$:!W"3L M.+^:;PXRCZ.W#);?U1;DLG$O#R+L"A(]@;Q)HC_W]43OR\R20:JW5/*+'@A< MNS!EB1ZEMY44?6[P]7IS]%YY8)I#)55=SQ^;B7?^ZE]_OKRZQ-KW( G/=.?R M#4UN"M ZI/NXAPHHA?K[!(V6'G&J$E4*EH\-^>,^ISV[3;Z&O6?8MS93/*!0 M?CG)A4CV>/X/V$0H77]F:*:PH &Y=W;[J"E&G(XAW22ZIG6@;_?!/O2=729Q M" )"0(=R7,N'PPF0/<> M65,1M\%2PN0:0NFA!90]XT6MUG2N M;X@_%>76>;D^NT^QY(C7:N$2AD8Q,I$T8V MRW;=5O@"@G#'VD\&$SI+881V I>E_1W"NMJ'GY+/]F5\GO4,_^M8LFP##4B2 MH_S?6!O2WW.<99?9I"S\4R-':9VO.:%'3Y:@?P1 SD/T8K#6#';2B/_T_GC5ASWL-F49N'%D,4E^=ND3/X HK M8F0*N\;X;.YRLL#FAQEM&ID)757,G3/P3<#E' [))NQBV&]S$;$A4!2Q<*S MS!XVW&"F+O?2K>@89B DWB!OOR*7<\C',ID^?2S'7#DYBD+8W:RPOQCCNHR?_Q*'D]R3\FE?>MZYLYF M$7:"(]Q&,M]ADR2#\.L704:>O0PX^O]SG\%MMZAWUB.CIB7 M_X%<_8??WMWP'\349\S49Y-X.DJ$J=/UU:K?0^1&C&1$.7M'<7@L5?[OQ^&% MN<.]ZN#MW5S8WGXV/.X)D,NH^@F-Y_;35"$T<)9A,3GS_**X_'1[DS.14 M:TS3JJ[8=6O7K&,2*:$7RBNB*DU8?>U*VI$;_NNU^O\*O+%++#5ZD&4'I5&R MZ!-&P;D]:8(<$.1W!&P2,NS0#_U?EED3^-&C6!9JZ2K+)FZ,%:C+&?K]/*Y& MS:@L>N:--M+HC,*ZU.4Q+/QYA^38_'3!Z)&C>)@^@IQGB94PZ^3!=Z5 M\9\C$/#;[+.F:H>P^6[8+9:&[A3Z+9EFU*T-1YQ*A MXJ*#!7W[XC_F8&/Y>-SL%8D\H&)7?(U>5X=I^B#MR'Q](OY"N[Z;7NJV!E1? M>D0,W<]IOL&]'AP$0WA+#NEHJ6D@\7!* <)1O$B2Z.4^YVZ(1),6I'$ZAC>F M6,,PG,ZC^3B>#D?1A8>HN=F7.VIB%HMM\H4[FDWB\6(4+2C+;4(9+^? !K;7 M>"40Q@7H+!(N_ M1UBL,9Z,,>%^!HM_DWXN"'Q&A9)/):9GEL-$8LEX"Y_X-";>(Q#;?))$,\HO MY%<5>$8(U$5,+2-2A+?E*$)P- SEF9T2"ND*[ MKP$!H,7'WH8>6\NE9..)NO3N#5 WA6.0?:S7+9G2J/I-=_W4I3:PL7;7W#QZ;BLM@OM5SN.6.IH#72Z> M7N[T^(1TEIP.U1KE+86G3*0Y"Y6!Z+7'_OT,/S# '/^32#A*9^VWW9" MR/X:/_)1.S2AY+.C?8;S_Q!/8&?\2L,^/H) $:V,ZF"EH0%1XC6HX_ 5#%'O M,=:?KUB;Y/?QOP(]CK'VJ Z=&VH(AE\0NZ_+@O92!JT5@*O,0++L: :J TOU M+B^HSY>HI]EH#TG8IB53!1 _T;S4"5/1M0:D-@IPM>/P/9PG(J@B]=+O04V@ MCBQPNG#IM"LDAD,QV#XPD2TCP>.(M#L>GE2LYO>[5Q-C4+&X09\!#+N&V<,^ MHT:<(C(:L3\D?:,3O-)F0G7#-D?5+ >+T57&>_6N67K-_>ZV68IEQ(BZXO(O M D6H+T39'E10$E><&:+-V*0!'X[H$:<%I(&=!.XL#Q&VMSG\\\=JAR["[@U2 M2\!A+#6$TB/#-E:P=-NNJ]\"DDSGMI> M35@8DVXHP%O=94Y8N*7$X@K(.@ZK_XO!^*9]47%CN5?XI0@.1_O^2#\;_[=; MZ=CDNIH([F\K*^"#!4QTVFC?4W'T89,*-)Q[^$">P.'WCDP8^/#Q_8>+CY_^ M0DAI%__Z\^4'!/!1%13!BC_TH#ZB!DE]>2K7J-!51?5C9;)^/UG&PP5JCI-Y M/ 7%417[JJW9CR>C> ;:['@XP6)FL$$"YC'6,(VCI/Y$+'Q6,W4DRF5!IT2G\"$K]<#R+3@]N[0NP:4";IVS(R6)" MM;FA?PK;I&9KUF(FE*Z."CT,%0-S,8:2&]A:P^0!2C=@2>"67*?[3^;L?+Q&V\/SJZN+3562OIT/]/A?$Z;?8 M;.H$4Z*KT[YK^&.)^5"O%.[RG&&ISPWUGMNDSV<^WEXI3A3_]Y95=*/#<>39?1"?PS3F@0 3@_X7]\DO0;ERN&S7ZB'0* MC+&,=3X>P_MTT['FC_]SAI^>(&^1-&]IA ;$>Y??5\#*X-L38%%87DM,#0L= ML2;1_7(T'=,O9XNAF.58R!QS*0CPE#@9);QM(RGK@;\F,_2BG"R C\SXC]-X M.)^%QZ4IK^2_Y$+*&-7^&; U8M?C> %?^1J,K&::X'MF//(5=#UU3<3E#1[M M'VCD0\YAYHW&?,&'@/$J!#AYG3X4=*:T/A(YW;JF4]B>X4_TB5'X)0(_7%T2YN)4=& MS=TJ-(/-_VK-^EXG4%(S%:#,M@5ZF5Y,%R/\P*J;=CN$"O[<%:J1O-AD20V8 M;IKWN#%2L!2%X'FF!V4078"YM^44YBY:0ZHFS[!\P5$WP1_Z'8H8(3P$N!%& M2(VX1O$8T2 )]R(>#Q/J&(L%Q\ *X,<$NSXMD?V.T); OSX_OWK M/U^^?4MZZ/M/?[SX&%V^>WWQYO+=Y:>+L[>7?[IX';4%H56(:H+N]H M^+(U%D L!8Z?>J*+M7ICX<7[,,6SDO'#K[-&;V+CKV(3F2$5TUVZ>42(>4=L MC4;-9-IZ^+S*=K/T>/L(SE1F==9OEP$3Q':EFJV/.%'L46C#,#)V'FN%N[7O M/M_.IUB3XW15^U:8'-S$4$"Q4TLJ-,KD*X3=W>R!QZ$*U[,4^R]Y"*PKZ<2( MR<]KSPEKZJLTG@YC2U BBSO(\.3\ZA4^?MKL2.G6R?-53S4WV<[]^;'121ZO(^Y [[Q')^KRTE2E^9!I_'5;RN[#.P-)JEV_J/HY'BJ^?P6>QI?9WX-=,M1 M#-[N=+ODXC35+%",:2?U0^9-!5WV]; ]U=]JOWQ M \R\EUZY][SX83VHHWN>>IP_NWE%^[+UM*[HF3(="?'AOB)#8AZ5V2'L1HV_QF:KJ)$[ ]H$]=5,Y M7CWM1O8QU9G:S3P8WZ(H:L)M/Y<#6\ 78"F-OS,9JI&#+G '>[)-M\9PS6 M[H+Q&)+AB% -AJ,I U L%C/QJ[TF9U?C@\U_3_CP3_T/'\)H5DJ=R>BH>L<8 MH9W,_^^7.)K%DV1J5XI0=%0)+;'\-H$RA 9!6+@USBF8CS7"O,89V$+#H?G0 M)%Y,A]$$# ?X(NS/*!Z!H2!I VU?#J*4Q9,%?V,Y99QXL$-X'T<$EK% H+\1 M&QN2D6&O)^P/W 1DTHZBO\;0;R3RP/5=Y?>^$3PQ$H7^:+"KM2LX+W,8(VFAG*)/"WS4:J\\'Q^>@2%# MZPZ'H@*=6#JZ"X0]L&!VE-B.#=U;";2/S1*2!:%M$<#8:+)D)*[I8M;N+P-V M;;Y2SLKKZ[:=[=\.&,3!8T=Z=S]>7'WZ>/GJ$]BWWO05\[8QP\*F\CP[]$)- MG; %+AE"Y'=U;2:(H2$3F25)]-9E5.0[F#X]CAI75EE]0[3(:3Q>3A"89CA! MQ 1DTI(VC)&(38&FW#1>PB$"%P2V^DJ0K$W\!;5UD%!9ZSW2%?': 1M"]\H< M&.:8KZMI+D)FZ2&ODT-7!&H_M*,,"L3H0"/8B4E0:5P>>/.I_B:QZR;)7'%M M=E:V- ^+]\,$B8>B_ 56\BVI6T#K$IRWL N(EIT1GX-?>+5^M4GSK3'F'7\B MP_&6_/I@L[MD9:0';H?78;G#WSM-]9_O*2>1VRNK+O[F_.KEX+C#DG-"X02/ M^BY>6)NO]<.TT4W=OKW\='EQI-D/%24%](3Y%6#$0SJZ7N3@J5'XV_+,D&/ M[7(^DHV?$Z["%)2RZ8&C>($8L M2:Z>+> Y:6TM"C&2=)%#Z>9G_#:85 MPSYNA='?X:C %JH!<#ES^BF ')!1[DKY68_SQ;O,#D],M/ 3H,CZ_2QXDZB)&'7 M4EG8)!(''2._"#@9,C>%KL",3S"UR;IU:_"&M7#ZG):;\!4CS MU)RP0834;K%B^[JABP%'X&GQIW '!$ <^N;8#N##KK4FOF2UDS+=7\SO2D& M3Y(_#(#<"AUQ.V;V-#MN[TYM=6#CK[.[=',#DXO-R#^EJ&-Q9[2^*!+ M[EQW%5_)1N2A+15A6S2I)Q!PZ%-T-Z\!MR,>YH#Y=P(R',@=&CQQV8,&2]5= M4=:L])!;RX><%.:% ]5.D"KM2[(@^R>!PR\I%L563L[GJ>H'.M=LTEFM ME^R92V_'?H@O?D*.V?^W0%X=R&/H?/Y@ L.K]S]=1)_._Y\+#MG@N^/#JIA40*Y*5>J/=@#K^+LQF7RLSQ$DH^PS5)-L8:F>PSEP(%"W!<;Q,ID5.0/B\15.:Q%\Z@%I'F314SMF1X?U<9TZC'>/1?5U\ M&<\K/J3OHS=RKF!23<&$3]B!.)P(V'8"YCDAZ2!R+'8W 25MC!!ZK'-BYLX8 MC'BP&\=(H4,G_/W(TW@RPH8C\7 \P8R=>(BP@S3FF\U#3TV7$VO4\N#%*_9C8L&?130& PMQ] DG2:9CS)P;WVYU]J_DR5>[[$SU'B01)3Y-9B!G;D[ M,\Y"A\F6#.;1<+"$_\TH<[1^#&SHZ&0RF)JL+OWW8\C5'$5,!VT,33$,' E5 M\+$D.AG2P"?X8:VC,KS77^5) D_#^K$_#_TS@W\^!3RGBX4VXVA/MEBE/G'^ M4ANVTJ!W;BHX#[A\+WM&AHI9+!5_1-]).]\@,=Q;__>Z8Y4G9HFGWSN3W1VO MN&S(V9=0S>#Y$PU8L2WL$G.&J;D'\F2V/2J"\9Q@UAWPGDOGGH&+.YXBU/(8 M:_GBX7093; IQBCZDZ,0W_3UA%/W0H;0=7S $*8C-Q13/6__R3*A]K )]3DX M?0*&] 2X))8D8+@8MMK&L\N*P^W=_/V@+G04JE+#GC9BO@E-)94':NE22!<^\4 .M"!SCGB_]'_B]5E&6C#!=G39^X0_2T:1#_O)%/$KUX:6V:ML?3J"2KO'1FI MI,2;16A(Z#;?"5!%3C!]F$HWME;6FG.[ZHYMX)F2Q:[?3+&*HV+V!K8+:>$E M?0/)$*L0*J_:X7LX8*1S0A-@@S.8][>=3$U9M&<1%'>!TWL(;H:93-\FI>&F MNKJHI])[*J1Q(4X5G6K;RM"TPRZE(-V@A&CBM_KD+LJ^"+:#50VJLE.^S_5U MM.GM:J5CZYR4_GDN;P(MB1E!!_WZ*<.K/-(HUJ'&]M*S7K1)[ZLPUYAP!VVZ M("M&XLGG@>;-V_?ZJ'S#V'FU^/[UK85J(7AFO'CZ^5DJ7>SU>60_$O9% Z6Y M3_N=L1')P&$RZ6^IVE(:PQ CU\!211;=_[[Q71DZ9VWQEO@_,@PKF6HIZ<"- M>;<5XT: 0$,)E8>>3AE9&;A]NF%I$MC$@9PIQ>M'=R]UZ$&=>+:3UYP OS^N+E)Q/;6^.KSPK5UFS(*4<&C:,$[ ;[!?W(2'4P)XIDHC(! M:N08[@^W,.2>&YR&H@Y).$VX[:PJ+0FZY12++!+J_\&/KMO15E2_4/<\Q9XC M(R['&(*%N"3U=$@4D+*47W)JAQ*%A28\PFW!4RDBK+?J&PQ#5!G\ W MV-/#'0^*#=7#4Z^L?_KBY>6GU^<1>2::I;8- MW+%693P9P)3CZBJ7!>+A0)X+J31P^1D$# 0KPV!DF4YSOR.D@*:WWSU[Z(18 M,%'F$KF#:'N&@S$[F<'R'P;;TZKS^8VW: !L'4F*W,@'Z8J(%E[]*PG3@NDT MWP8V9EQ0Z<#I5PLT9='XCAX_U8\!A%1.6--1B=M\+MX&I$U;-8W,#GJ+ %@\BW0L:[O\OJ(^R7J=)UEV,9R6 M)E1A3&#-C$A]5%TK.;GB!_N8AX,5546-F*MP-!G,(T)91A9RUA8CV]\3!YL$ M;.'P9,*X :6:O!@/^?U^YDKN3<]_'.,:1"^]-/!'[?[>I(DGYD:40/NF$$"^!:%4ZAM]CTK:M \47(!LN*<2!TP5X4['PMX.?S7FN\MB/\.2 M%%[*3G/>-4+>,Q/V[3$SQ:1P_+9 Q;+]SPIBM2KSZS"NT4&2MW"0*6PL(N#] MM<@EC+PF3-J2<8&Q[$QP$7L @Q[N"D+2>2!HX #V2/R&<*.U+"D%692M;SGA MJ :[O!U2=FZQ?@7X(>-*EE0J%3=Y1N7=^%R=:@R;-IJSP6&DJF#BXFPYR<9I M7#B,&Y*%R+7=>!,P&Q7!:CG7)4::1#D@:AO>P-CEP@;\4G,V9HP RD:_!DF!E;*(++S9N >VZ2^90'#);SXH<#.[4"O3BUHP\YAA7K*X>J?I"W>A+O@5N](1H7_4K M.BQM*@04HU)HD29K-A&GP^A[4+: C:O/DDE74A_4.>IK\+:P"QS;=@58!!,8 MOE"=QB(FL&T;+D 9Y7?DFN'\]-LLG.0*."^[MQGI-3'3$Y^%+4_1I'-$4Q/+ M)VI!$CY!P%OU61ENDE,>H+F5&N_"> SQC(.L,$<=1,I).2J=4N")\A_C8Q2U M_M/,!923U.+@Y![X-9@>U].&QT&9B[BN30[[M!8^RZ*/6DEIU7 ",E!9O1.8 M'YTJ\,K+-D%5.*A(\]2R73 U5S./>:NQ[Z'(81!TR^JAN) 'Y=L!&5+@0\%[ M)8&GN<^X>M^7_ I/_4]!1([F.A6.O.0TV W.)ZCG&>S U>S"EG ,_3%QN@9N.3 M0)4M^?S-%\EX3)[KUFLN9?/)J7G-M^7FQ:F*VFO 90Y^R%F.*5<1HY#(3;4& M$#AM@Y<-_25S?(Q.'1Y)DB6=HM0--C!VDN7T.8?F7/AOG0O_@W?A4YG(I6TA1046!2;<-@01/M,' G)R-CT31>Y&9P7%].&_H:HOQ!S9.8@$(#1V%:-H1%>?C+T7I0WUV#68-19M>5VF#SL7SH2SO-@A MKL.WE6%FV-,!U\?61>#CDG1AUEEWM]X?X=>G!RTSDGV"N9[IU,E=?I=M[K%: M8H_*7]B("3^Q*SXKSO3^_I9*2-VWJ"*?>ZE:""^2T@A;@>5UY(Z0VL1=IDT0 M;K3YI-N$&>K<:HXH]"S;M%:,W,46$S-\"#_"*G 3HEHJ\$@8 M[';,./@=S3H(JX0_$3]Z/D]1<(W18,:7;!_$NY1[:A5C=?R4#D;<]#^EB(J"I" >YPI WP M>!P9MM)WUN0:\EX+5E:LH2+./,>N?3]/KRJQ3PQIT,7H;W(6>V6&-4W6DX'> M[J:3@CF1,'*7R.PQ:(*>I+]>[920?[<&T[-35HTA"]8;;O.8"K!5SO M;:RTL5:1MO*D\X6RL46UW(V:B J+(AJ0@7& #\AY(H0/F SC9#@3@,!A/!HJ M0N 7P5@8;PX M%-*HJ33;"7=D#I@@"]?FR$M(=ZUA.\SB,:Q-02\;/DD8TBD'*)+A]QC&(2\J M712L^T9/'#O7Q6]B+W%KUNT*<.F C/?SG#(8GW[B4!J6S\"";[ZR!08?)4?V M%>,M7-T!]9PQW7]04CQ8&_Z!>WDC-L3YG\\_OKZ*KM"-+&,$Q0R:C&:SNBKS M014V*:^'T@4P^$H9O9DP[75>9@H[Q?^TVM%&P3@]'#3"![K@N%*@H$ M]^@77Y0W&>&3-UL@RB.5?42#YM1J&Y%KRE2K>/,;WWDI)O _S:]V58/YSG8E M5\:+_L-5C9XY^R$&30N,,5&YP@S8>5.V$FDAF#I!N]X3G@>S#>("[[>['+1F M+ ;"]'-@G A3S_D/] #^ISA?&0\(5,=K_AP-79D,"NEPPP&.+CI@VLO=M^XW MJ;1DF\6C^;Q/.#9+)6O7R&8T'"9\U:+WDJ[@*E3XUT@L!D^$?\EKI)=I?;$. M-I4'FMM!?Y)'55V W_7O'_V17N@J/^!S2-T^N9T>'!SUC/;!#1VE^QJT&+AX M4AZMB!T4"6:GB9P1,MEBNZ5V++@^3$BYNTQO%4+4K,+?(L(8N?#.GUTN=JF0#/FVH.=I$,$ M=X3XQ9#W\+/D8ZFLQ2/D=^80LJ&=[YZP+=#>@4U^,<1#]22!75X]V9 M$Q3Z=RPFL>7L2U:N\DH!6]ARXNU3O,(@UBY<''O7U ZMF5&*;DR8 M0:P==/=J]P\JWQ8[P@#_.@ (#R/I$&Z9VPI8M@M?W\I"@R61!V$J7TU1V3.6 MH9;4M&U7^P75-:2T)1FJ*TJGHW8JO12R+)U3,IT%8GF6]$EF/ZR_([F]!P)! MP:S#I<^P&5/G86&T&V)PD.DK>Q%>Y&%X53B[3&D8=Q8O%DG/1>'%'Q 4'/X4 M1XAE!XEE!]>!-8^WDSK9WE&W)05IYO\D*\34#\$0@AN,Q@;OZ[TIT2O9BTM5 M0G@0?*L'4YUJ8W@V)M<1'SY)*5?B3'!.\7>G_XTNJBY% +* M$_Z]KNIYW6;E)0 MLZ]6H*MEFGQYAI"8*!FVQ3K;L ]5=&UZQ]OQ3^GH:M[W6QI8\LLB115,TE)@ M!A3O!Z- ")7G0OJ!@C8X?U/@6S!S$J8FZK(_*XWG>J\%;=]?]VL'3>ZL&U:; MR4M$N\UPH9\+G "G9#B%7Z[@!INLB(=8-&GV6C0QIBDD5!D=WUD5<&AP[:@I M&\PWI=&XT5S8@LUE,"CX ($\(S0ZNSX(>#G?2NU3>-:\H3YYVTR-,B)_R33U M*?HE>W2;4_G-^9Z*F4>S'T*L"X5.IVOM,3:\RI!*&H9+4]V1Z4S:D?%E6I&% M__V@W6ST_<^"5"R]-)38Y#W%&'(('PY]HV>BC1Q?5TGV!<U1B M"06+#PH44]T)WU+"DPA7[#F0)R%R6TB+D/3S9,%>KGL4I2 ='3 ]67:I[<.& MYJM V5266,PW\2J(N^M^?PT?HT)?\LIR@:I9A6T5@)'0TK6F#@?LL/'D/K \ MJ&PK7TOK:/[N<9R_238]1I+,QE(-K9"),8O-UV^,%!*]9A"0GR9718\Y 6WU MGJ?9KOL4G4$,X^!SL[PCVE&*&US>J,)OEWGUR]D-RKXR%4>[_;9BB//,X&,$ M:_.I)(GU**$*K[4;/B6E6-Y%S)[CP&,6F!7>^4#.XC95-G@2Y7L%PRT'\[$1 M?4?MHQG4X6"C1:A-+@//T""PG*M.C74"2IZ]_H@;?9S*JB6XI- =W_VK*1S7 M$B_6=#/?HIVUM-#7I=-N?.UHC]+WK'XQ@H[NBVIDK29>'Y':WB"U?<03O- C MI^9>K:?_Y.]0ZV\*IAC]A2B3]@VW?H0AK-E@)*L83P=@>@X'B]_QO+%733*8 MX".JJ8WG^%=]9!K-QOC('!]1I6J\'$SQD=GOJ(?PLSL>9;\MRHXD-Z#N-!/?J!/MO[^!K__)U5,]%S=+K^ M'P=C_'>.:5YN:Q&3>$ H2/I[WD\$T1B,\-_E8,@-_UHBL;$+Q!NR'O$9ZDV! M2BF7O;%11KAVD;RZ$H\\3Q'K)>$[Q!KD@=$JD%4\+/7W]57WG#$P]T??&^?(4D;3?_A/SR*=>;+_11.B?QM,QHKLO!E-"AT^H M;=Y@/G04C%3$-/2&.3;\[F0T1M27!,S0J?LF_'JR0.08N/G##I#^:3R9$&H] M$/ ,OH7HS2^0'4S=MXA)$!V;;R4CA-M*)H/)S'YK1B7/L\&D"_,;NP90MX%D M,,/0UWPXH47"\GXTXH+ODOT6M05,IH/%R'YK/AG2MY9M8'YLLS&#)?\$'X#EL;+"$;1[13[#P(=+NG/Z\A/<1/PR1POFG M89( ;2Z'\.?Y8+F$ YM$DRG\CWY"6 ^4/#/^,PP.A)G$L^$83'S\F= ^X"\+ M> #H:K*,IA16G<+IST!2T00F>/!P*3Z2):$"KKED,;J8?@7;3K\"1CIFS*41Y6G3+V=(,1WH2]TS M=3BSOHHL. (8LM,AAR%2QX+$;""XF&;$!($V80#A.GTG?0AC2GL1?2TUY$%2 M!R:W?T^(?,)5#.D*T;8$(3.8UZ@!&,8%8R@OK5NB<#PCOCT=)%X@(:GC,2Z5 MH8'D0Q@ST/Y!AAG!03!MR6P W";X2%L,3ABV9(DDH9_!FS4BON$^,T?H#W@* MN(>53PC^!T\",SSX&62-2U8604S^:*XQ_&:4N,\DRRE_!CYGQ?N$/P-K/?B9 M>32F;KKPZ&QZ;'Y((YU#[QCLH NJ/9NTU>^/H#_BVVW9GEVAID/LH.;D:OO] MOHN>H+P(3%YQO E_:FK&@R!OXZE,!8UI&/<2(T\VH]-?G9GP%8BL1RS (?*% MJ@VV!IC/Q_SO$CL28Y/TYXS7QY)&U*H(.P)@=U3LS_[ULSR0BG* #)-X!'P! M6Z]BCUO%;UW$8S;91#>Z7O3DX(2(BHP!DC6RI_K1!29Y[!/*69Y#/H M-L>M:YO" M:-V6<7-,?NGA;>=82<-0F\OHZE:4C#"@Y\->[X),U#C:;NYG7/ M40%ZT8$#KXAG2=9V >:"S9L0"6LZC6?)D+NC3<'"$-F' -!P&\>+.!DFT03[ MG2^\7TS7M(S'8#4@NBL(NM&8!K &33*,T9!+MUER,K#(8,%*GX<@=W8$^!M-?9KMCFN]3 @U^Y M2&$:76ER\R."3Q TUJP+>P*]U!2_S];<_$-[ (N$NJ?<'U3,1@[[JW)9#1:*(Q5U[Y#B9X[JBF]/CS"@4LB*5;EINF!R7[7"Z>F5F:YR:-HW* M99+NJ-A'&WBV6B>8&\") (/C_.@.*35J*R74N.=%$H]1K.WXQU'3?HT/:B*- MQF3==],)8^XQJ5M/0 UE]G1/5'88,ZLE/D25#X9A"=_K3$Z=-:6C3Q$*57&] M>LP\#<*HK0"GM/*ZYEXYGMM@DW9!@.S,:;8Y!4;6>Y5$+D"GK'NR8;]^5YOIZ&\Q;;*5+,^_/9 @+P_ J(B.F67' M8I:^O3B_DIXQ2M(;'HILNE=PB Q0^?'B\A/VAE\-HA/WV],VV$*!V5*9%-(M M1X@K2\T8D'M+W]W=OJQ(<4JU[^Z&^^QR-:6_O?)K4PIERY?:R(VN+P-G[9 > MR=';X0_ :N%(SG993;](?@#Y2!6>M%P+.'(B;>^<3I^!O*='>9-=U3$C?>4[ MJ3]E\+,1P:8M5:,\/XPRV1I-_Q=ROAZ*V%OG#$G@TLSCA\X W!T*C/F.BU.?B372[Y% MNW!7U%X+S$L2+#O!((,M;%< 'ERHEZ)A\B:EK 72IL:.:XWN2WBI"#Q0A%S< 8V@R+M!,/3K4R-G,;/2I8RR"Z#-7&;..-:MB* M\.2#=V.1[TQS:I(:B.@"8YMQ=+UGO$.?B4B_UFQJKGUR+(.VJ$%&]JN-=*\B MJSST-6DIUPXV4@^&_V V42DM&-B?'0-3NK-3]#K'Y8)2& 9%;>X-*:/Z^77O MT";CE/AC[R?:6)37W%E-\A/7Z99 5IAC(E 3MYFN...)&ISI@.!0,JY'YVN <.^<&B\T MA,UJROV*W!\^B;AQ[=2OGTJ1- KC8D?;8RA&/@=(\Z -5A*^ T[P7^)3MKT_+>L_/_:>[/F-I(L7?#YSJ^ E659D39! M%/8EVZ;-*$K*8INV2RJKIF\_!8D@&9T@P$$ 4K*M?OR 88D)%(R:]O(LG17OQ!*(" 93*?1%$>A =7BIWT M62I; F)UR3(N=$S4(V*+GZC=!8+.MEBP6L6*[X=;4[, )[;>G/X330<'0$%F M+O68&W&U'%UF%,%%VC#3)#78!&:7XH^WPTZ+TB7?@<$,935,(5_%#XK3[[]G MQR/N^,ZC&3:? ;F QO)*452IT9%8I46T<=DD^4?8TW_.DG;%_,KBM2@/36&F:.Q1)C=VP4G@'MK- M)W6[D'?4'HV?A8HT6X4C)Q!,.*_EN@Z"%N*E)6#2^!8+EYAT=ZU^JB82H*TU MX3-DL('W@K4?D(LM.AI#NR*C0BVH4,E-9(VVY'7;!)?%X 'JF(P(;V1L16?+ M%SAO5$M("N#4-+URT2MPBSO!H?6FQ(GL(A7/<:9ANM55>/474A4"#-^)M#'H M!5YL&R8;XA5A7BD(_[&H'R!W^++HF&%'(\62HU^7#-)%UU4A*;!GZ[LS(, S M():,$T'4R_8 "M'VX9;A+!#ROV*9+TR^< TZ4XS*7)26L529HJ]Q?\SD0 ]( MB/_66!:*JGNNQN,N0K'?T/PQ?^#)O-\"NUPCIC6#]"$-,Y#3083"G5NUID83 M@@NRM@9)4<'>KUT5[ZIPPV%S^YD.BDUUG &B_M3_*H\DR0IE]"^ M6B%B&)[34)DW( T&![0*'T,[$0%-H\",%?70*+$L+'8KU;.0XX3Y:^L-EX%2 M=P+=5&9^Q/0+EZ)!&G8N?JEQYQL@Z!AW!+C8#GC> MIEPR^+33#^V=+F3./+IFKPL@BZ!O_>SU2!,?$!<4] MBG13.38^4*&$7C5=17&M;RFU:4Z0,S6Y\F;/%OJ(V:H)5M:2]ZZ * 9L#K(9 MU9ST&@=O!87]>=?&0?_CQJT$ ;AL M-NN=UN?"?#['V9*LA+:0BCW>@DA'.5O0Q)?B&:7G):9C"^K./^;DMQW\W^VY MMY3\7_\(3T$H'W^/(SS)QN29Y",\^0V/\.4J(2O@$K$D^T,_&\PF-H@#BY,Z MQVZQ*?QZRF#KSNP:N9I+$G>%:IU*?\^UFJTHS]YSY27A9"WR37"D"'F;! XK MSA(KD%@)8TO#@8%FW2;NH!RX*B*')?JZ=RN'F4V+G[/=#V>]Q_D+\_GY21YU MIG+?1$*-7M2'KHX-[]T,1>6O3EQES7G0$]L!>P9%W\2S+>"XH@BCT4#]@>Q/ MO_ATJ7@ @5'!10T;VBE*A KZ83C34H**/:O9Y $LHK(U@D B[78PRF8CM$RQ MZF:XC%09QYPIZ;O86CWI_F/7' M0Z5,/@[(\Z2TS<)'Q%#(HA7E]]Z;-7VX8-%8B9=7$*HJ@,E#-JQ3C3F,F1@)7,H"0[ _'0'F8!H<@ MDD-$+\4T)T21A#_Z(TQ*0!C)X2B;CP8=@I%$U/K1:!( 26*Y]&S(R7W9= RO M#OKUR(OK8GEW=NF<&U?RP_7/5^QV*$1H09#HH ^R.FS*87)CON=Z8A(^V*9EX\5*R<>X]$+!R=]>'R& MN2HGB$?*-6J'TVS,WTV@YPEF;UXX,ZS'2_7K*E>OW):T'YB,BHUH?AM-Z=ZC'@AG M(RH$#/L]YVR+ 26(@$TG&!L$[IB%D>,HBWEB_4?-MUM2\3&Y6 P?TBHG;*H MZ@*3EW+OS2EXLJ? RZBWO ..NSNF2^ZL^PV)5[GW Z.(0*XM+M.$#WM/V4_G MYY^BB+0+4P 1!W)!0O,]^O=C=M7Z\&$EMP]OHH6G77Q\__[R\_LW'SXSLNO% MQP^?+S_\].;#Q25PMJOB?D>RRS.(DPQEJX3T+O^JMOE[@;R!?<"=(C-7HSWV M?I,_,HHY>WI^96VQ5@D646GDIKRH>RD)*C#5NT0HF[;$^,'#\A5)R^*K1(38 MK@*+D($VTCYP%42P\7H+%J[!"C]:Q3V39 ;R;Z"\@38O50F"<>A:=(,#)>%!=<.R75(+\KL'P=<[)?BN()!: [4KM*GMB652YNUF:MDV9"N#NVP,HD M$N$W:'FDR"IO)R=L'580_!@IYORO\ 5A ZJ51I?RPU-!;$K 5L M#H6[+0(09=V\8([!E/#^Y\$YX%VBK)5 ?%*$-\8"([#28K$I&,*;KH%*])^< M*N7Q!N,>6;DUE!8=]CB+TEN3\TJ]6;=^23%EWDH@CJO*([<;G2%%=%V"BSZ[ M8"\@B;[O.0[ 6XY3I#HVL#<[L@Q@R[>FY4=M M>5'@\1/-'#?)2[ *%>W)%+;(D*^&WS@(6V0TS!=6:P+6X4-#BR?LX67]2MTN M=%8B3!^:(]C68&FY2S[AQQ63HZ[86S*$(YXRWF3P;T)#KUA!5^K;/C\I&!\G M>*"=)>2AW#W3 8WTM-18Z,J-^5F<8;?Z@6I:2V^&]C*1[9% M:@P&HE3Z. Q2<='7[;QDK"[Q@0NB3S@\ST9WF:&I20VK67*6#$<'>CAV.M^: ML_N$U..,.Y]>8HX)%>NE>1*@ MIK')NM%X4PI9IN*5H >J^MY46S-'S!FR2JEY^5:XMNZBLSC9V=8GYP97-R_A MPOQ9M [_Y98K99CJ)]I )I"]KELY)T93I0Z! )VD!$OVC$)AP)1$FT=1^H-?.A5=SC^*R$X[[4#Y5 MM6I-U+"U8WQ!'>WFV1U2QNS#NJ 8PD$@J"OF@1K3=4LN>2FTN:!:39JG(<%0 MH(H A9=;RIQG*1M)H(3[[2=-D\I<^:6=B17PK,(7M\3@#[AU;Y;/)D&%D0#- MF&A;.6&SPKMWT:6(&@:+IQ*X!7N[,<&$28 N$;IB]9V,BB>:I?:/.!E?M.K8 M')2B#RW-4V$A"[&9^-C[J'9(%U3MK=K$'7S*0VS]<2&((H14%$IAQ,RRHAP\ MK[/>(,CWZ"LS&\J!B;=<;X.1+BDV6CGP;HO1Q;RL7.!56UEBC+ID?K%,I67/ M-*3= =HF:G]YD=D-DCU2M/:^0G6B(%@IX9:VE%7R.6$B()"$J9L(?6#-,#$4WVWRW6*WI)!0;H;0\G2/B::>:XH*ZD^=$XWD M5Y63(LY!<%MO$+?F2[F6D#[<*"$5#HL@[9Y0L$-U[8XGM7P^PQIO3H^QO2*N M)';KWJPD_H%(4)(WEQSIN<(\0/R0]-$YMN-C;H%J2;L )@3=H!^5EB\X*1?Y MLH2'5F6>.14'UQQ4_1P>I&& 3LHF:4%F_8H@FLOB9KG^6G"]XSO:-EGOM/P? MQ2N^+A#(==NY0MAR6EC1,*E^!)YY/GR",*((EHHJ3H,B4\\9;3F>DK+2+4*4 M8!^:W41=7+(%UC\D7MZ!N_S6EH &8M\!*X.S;PBYM/HR'U-GBF/*16.[2Y:5 M!9)0L2VG 9N5H\N/RG)CB$[E9;Y2'+K*^L4Q]TR 9!E>=O<;*N675^JT>DN+ M\F9%Q>6=/G6ECC]KQE:0('PFI]B/.,Q%% &TT2VEO !N0D!P M=1'"O8W"Z'JU9#QG(]YCIA(C HCHJBI ?J_) KM*L?%+"^X 5(0U.44H;!+@ M@Z ;#"1']>".=UL&=\C,*&3O+_[N67HY\\1/F!RXNA/^D5,NDT5 M7J(V@\)=D#MO#)6(71-F_(CU[%CH"_J]I5J^B527G0_8$;R7>-JK5\Y]"-+6P\(9+\$QXW%')""<[&:*(499)\%P5C MLM^B9M>!2UWMX/#Y"ZAJS*6D(B@%&7KZ4;*7Q/04L2$$F( M#!4E';@$XB<@%R1! ]HF%$8=B]QD]0";/",Z$!EN2-\T-V3#J90[1\YMR?I] MFNB-UR$@NP!XC$?;[?SMH5R&=C]GBM9B- &.A'3N6+PW$0,YKQEPA*R:DK>, M4A#NH0HRF=I.I:%;1:ZXH9S9+=\M2(S:L#>/UMHQJ69R'%2=I:!X I-2$QLP MDL""1YZCF@YI5Q[S5$(J8![H[9_&K.;M@_2-\ [Q,I"6JTGA"O05ZN^NEI?0 M10#\X=><;P[[L%/N&.OW@=;2$73%/JU;3'U$9=43KQ'":IUD$E))+=D=:#%5 M>_M'V]YDZ8T1';9ZZ-QAR$@M5TXRX!I+X(J])E.\!;-A6>U0.>L!)_W)12]> MW=(O/E6O0#,9K,&&]78_+R,M.%8D;9O3)=:5CG-C;E&W89'<5&VHB0#&;G"- M2A"A!]?KD#HOD7BCD @:608+K$YM#KE$?#-\=;8B##9!I8ZD+0WMB,.F_,4C M(_%A<%S #0=1L5F&+RY/FW^B@&"@*%+)PA* I2M8JV=:*IJ@_T"NI:V8]BJN MA$RK@I<>!Z21@9W,PCG#4ZGEL.0H7G33$!VHK$+H5 SJ(-8O/U2U6]/1S+ 922PN(4NKE MTK"0LDHT(K*NEO2423&J"PHNZTKR>SA$U1V@+)7'S1TG08?7E;LO%L) P=&MHO.=/FW*9#&+.;Q_((6W"ZRD8E4I5UZ4'QY ;^%46*HX+8^,+[2[6 M7*RU0M5F[:Q;G>L=6=PW,%Q8/JT@[@#T,(K6&3O(^YU7BDX=QVISN#3%\VRD M^JPYNC"&FUP)62+5^UPL,U-+'^=X,M>Y*]@FUQR?&MZ#8DVD-:R;=FUGT**- MCIAF!PWXY%>(KGE?_=E$+,FH>D[BT:OD/*?67*]Y4RE M' -\4)T0!?K/ZCLUE.#835[51B!A'BD197_8QS7L\KL=L+./-V7UM,X"@VD2 M><*)X>PK4%W)H_7^V5L+,,Z6SC)NC53Z>_%H<>94<6\M8_"W>^ /617WP$H+ M"N664FS.E,5+CNHX$=:B 0V(-::.IO1M/&(N>S?WZ@"A0ZE=BD?6FI05&V!) MZG<1YR%3U%D$Z&@OR_7&F?6)6%V,1^Z,G^Z*,O941UBM"8U[+J(.V)^6Q4RFNR^ MU*5JN-=.BM3'M9$@E\A,(WM2:XAJPJN\@HFSJ;;5[K,PER?@@O--L2/$R.Q.1 ML])H2 WY>%W5+ROJ,O4M=AK>ZI?7DD+HZ\5YT-)8:N0C#<1&=5DU(<95]J.0 MM?L-78 F?V&QA/>/&D&B$ [,% F2 MK(AK0]0NK@ON#00]9=+Q^INU^M?+D7OO"6A]6U=[!JV^)U?G%Z=9Y_\@^_XD M'L5+MQ+!D__GTR4^JD]=NS#(X*E/UQ>G8=!KK3F\M^G)]]"<\2>>-\1(9P1. ML*I=+HWN?-*C4))!?0;ENMW2A3@R+>$AO<&8/6"@9[**U?8L\!UX#J>J8>5N M#8*$6U.0!V\8W2'6H'&WH1".VVRQ6:"I_=<0.Y_R-0IHB2P[KB25@[A2+!HS6),KNL>.J8P0F^>NU_.==? M3CT[>/WQ7WQPL>2WL72,$HP3\V7%/E(D%OYUN:+ 5%A^"38Z^\M?KMU]^_.J MY&I#1(>O2\:#9HW %[DH\!0N_<_0K!?ZNIU/:.O-5PX&+C63.IS@HO!P)TM@ MSF<5P58]EMMM+I5$0R:HVV.$^I'+[K,;$5N3@0Z)"%%=%)HC'KG4,!+"+7/) MO[0O3OR/]8E&)8RB7A9KZ<*YJ4CZ4JQ((X72'JS9NX/PO9/&ED#+JW M-NQ2"22KM+QGQXSM.(!,SA;1U6(^.&S+"RZA0=FG MRW/0&=&/"]'>.QDUD"DIE@#V#)95@C,I@@2Z54$@<_I![FQ[PT0._P=C=H=E"1/L=T7A^FB0GK MM#_26FC:+%@?\P%J>DV3*%,^WJ#;@8(P[[Z),#$^@(WRE\:,<,5"S=_KRHZB.:IB*#\G!Z"R D[ODJ]J![>= MH]>=X:.=)41@S_RJI"SW!$,N*5P4Q?!TS&Q$QTI'5U% ]"U)-GP=7Z#18TM5 MF9,JU4,M=TV "H1Q^A82H"SB-2"XJ[V.(_GAR*),UN)6,,%U]V3:-&L#LAQ MRTP623(S4*,)_"@KGT+-GA",XPGBV^S"D/F>EX;"J&N5SQK,89)*):8P4C-M M![Z]*@4^6!5-"7VVLS!="QFZP:TEJ!EB=LXG6(]9%]N56_)MM$YD_(++ HA7 M /EOED7@2Z5C#K=4Z0.="&"QDM;<,$AS=BB[P42S[!@M^3V;2DU/47 ^].)0X1&M4?05%YQVF MJJ4M+%[=) ++5[_@H49H/4F0\>8DS- \VL+PM M;C;L",\8RZ+>W:*.,32?C'$]_"#(7JF#X(JS32-$>GK :O>PA \(BT?1@&B_ M8.9B%SU**']=DJ2(BGZ4/VY_:\D1?XW.#Q"".C]MUKNG*I-<8V07KRVRV$=G MD?+S__?/7F6M"1)DWF!3:>+#GFCRY<9'6[S;V+K[B5I$<) MK/3E<^@U7ZUWU,]&\T$G$6Y0B+!7]_DYN!I*]/Y5P&K0VS;/^A-T[1E=S"=B M>QL.@\ C&(U3^!>TK $^)4M9591.@@#Z!<0SYQF.(81@F ML3)FR828=* MM=@.HA-;+$M?( YF4$I=[RK,$"-%6GQ62B9;#GYVF);5[NF) M4*+#B?A _SN0;BDXXWZS_HKI//3\;N5<@C;NK(-8PQ;K9ZV%B')V_7%!BI)+ M=NI'LH[\>0ABZ1:!\"()/_D,?]WU'!2?KM4':#0L2">FI@?(5A8L?!F M;!PL%MPZ^,%V- L/3H/C>:/5V%[16=E2 U4[2WKS]O+#&P:QN+I\]?/GRX\? M.I_>G7^(1.2\,^KU3WXY90"T@B4E-U0J3T6V(GF**OXAHX!S>4,4?D_N1%]( MD)!YM8U"[K;^6"6";A^TRH\.'5$;*C6L*[+O.\PJBWE5@K![W>-%XD$E_1=!IOBX0!![LR[YE=<>_<&OK+ M:K$I#E6-M_!2P!V<7'FQ7J@L%&%&&87BW(.R?5ICLBT,\!V"BG4&G1/]YK3> MPBL..KLSKV?\_G/GW^3?EC/A7O_$3"3.4T7)EO9?-GS/Q7#RUGU[[;X]-5FW MY,R0\B-UX!R#2^?"BVQ^!?Q>/)EB<*'E_P1Q=TXCFPG=_6O$UF3*6DLM[HN9V=PG^8/%,7W<+*$YN2B?2=L8BM'XK-K U+3GY4NXV5K1H:XMH( M6P\8CBIO-7KSL:A?[FJWE6*PL'Q+BBKTU] Y>>+,I1M<1_BVNX7] MA@47=B>XV06(<"]1!'YLU=@XM-U+,5JR,LI-[FBI)0JF(/P'S**A.Y)N,MR< M+VN1QE@X"JG @:TU5,;4@F!D\.%*D57A0 HE&,K/,4P!;^@J]/,$[R-XE-0. MC/[@),1_/7R#? 8NG_K K9EU;Y3#>W5G'H,375R,+3VI\J8PMDA*OLM$ M@_04*_85@_,+NCFU@6[UF@,=(PDKE[Z7SN/8!ELE1(E3#LOJL.Z8BX\,VU7+ M]9/+Z%5D? \/4PE<#2DY/'P2@=BV])6]?X)'Q]OB,CZIB3\0J(0QC+F@FC^8 MQ72(_"9YV?DJR7X7Y$#F-]5Z<^,#+3.US&XH6-AL 6M*'NY&#*XN\*-F%<0H M*QE5L!%_TK@2R=!S%6T:*([+FFZ]);@FSC1),]UC5&&R@ARB!*O?(J4(-V@> MZV;%HQ%3_'B](PL4C^RWTCQ^9O_R&PG5K8X1@-Q+U->Y"[(*#68LM+C#EY)Q MY')$ZB88:04"](Y44TFZ%:E@++TM.4KES:CAJS#1N_\H>#%>42U%2F#KK#,0L2D.U MD>3(F&&*@PO'D1G[.>E'Z]W-%E.D]&9!]KG%ZD=L-';K+Y!H,P.=R[=$ MB*SK2X1WFI$E02U4@-7;N@YK_#T2PFE-3!2%3E:$Y=V9-:K6$(Y4DL#*A%V, MW=SYHR(<$:NI8(D=ON$PV]6M<728WF)1OK\JQKI?ZDM?L>:(\]7Y]7'Y8P77 M0?'__$'K"_SAD#Y2]NH$&(:IH\.W6;55U8&8/Q(_VF-=("D>QB_YDJ=!I6K0 MF;9A %XU)^'*QHZ%S-BP30%TM>::=Y[R9]$(X39:;S:4NM?D^:$8A3L7!Q7- M2V;M73]*Y)1836?:&-T9\P@W6SR=FCI9IP,;I7F_$M/[=;[D M@(MK=6P?P&(3+26]$*?3.X87\&4 M3O\KOZ9I.T@1&I2 F&3BC4,7<&41L2A"O1:C;UQ%Y'C=$!?R7E/V*[MZS0G$ M0Y.RZ$K<&?NW7,7$_]TK!N^"7!3*ZS'N4145?,O7HD)(CTW-AQ:4@A+[M,<5 M)$=@(,GZ")[ YZ:8D>Q)V5!LD%L1=S8\*(M$W;)WD\/ASAC60&\LBDS"^AZ2 MR4GY>S5WX'\1UU_]&&'YQ4UM'G6'-$>:KR@*J!9S4-5H@(5V)@(QC&DY(=1E M$>6Q_ _F> D$N*3GVSB,S3 /'&!-KZ.P;;9]@"*:2YB@*Q*(6FG4L*7!7%"1 M&5^.PO8DAMT<)(]E9HU4V)G@B3[7,'7JZZT3-3)?K>P'\0\2C5@HYX@EBHKR M$_;9ZY MKNN,S]Y_$28L$?5U9@RR65XN74[UIIDGH:]7#*@X0AL&]XX-JHGM#N]3-W 2 M-X)N](K_+OOE,1@E^@;'S5BNA3AQV/_SL-XUFH=Q+UPAH]OGH,XD@ID[8SF9 M"5S8WK '8W^N,E?SG$;"'=_P\7B$W7I@D&A))7X187G2^=ZTH:-N)0[=,7.1 MKSU4CK>* W?=(+,.CV5$9K*[F62>W#[PDN%OB64#49&*Y?X%-3*!#=-A1/E/ M'PJ'4IE=XJGLD+7D\L=X1QW-CC; M^]/<+FYW9+W4!E9YWL 67A/J(MDNP:Y.\-O6DP@LB4P MM@6/+9KA39C OB0'( N/F_SIV=(Y^Y2@K>*TMBK2#6-L!4R*S.".QX:HHXHJ MP#9(=#QY[Y.?F&N**R/)^A1<8+;B2AQF"#"\NU,G&8F0@Y.LDV?H1!-'@B5\ M%/V@M?O3NA33W"*=?/SEL>1"$O<%-O,$X@X!H6B0^,-IQ]01P114DRX8BE)H MMJOJ(W##="+1RMATW6Z0Q'6'6I]89 IRM=T4VZ_D:'-0 \3WV9#C2.11;%:$ MOV*J,JYOF+&9N%'-2PLCNI%/[K:@]LOYJL2=:C4Y#LOT"?VLEN*1M4'X/O*U MR_6:%#"PN0Q!Y2V&JP3;X\AO/D^ID$[-0R.H8S%I/(J5YCL?ME9E]N^>(QUW)7 M[.8#QM)UJ&IU*E"&41VA^N!N! MM)=+*4QX%OTM^%&7SM^.G467?"\L\!K&)5$OS[;9_6BG"E-O@<- M>%5L!"[3/!S-CM!*I$>I,;CQF;G$1-%N<:,)/=Z8B94$RR*E ,!+YR@*TCKX MS)J']5>LB)Z)FLO=(#0H0\^'5]BJN%]O^1009CTO5M&T-E<)28CLY0Z6A<6^ M6B_JN5#.8J3Q CVC+FK/7#(AO$NQ.:-]Y>D04*D/[D&1CJ,OO#7S-QLGD;@? MF!'?Y%@U_$B;S&>0_R:2,!DJ)$U81F*!DLCJ>%R!O7;!<\8 M0;L.2.\%U2>I[T+W\,K50M;%A@=JJ<":/$%<024EYF52/<(;?62W$>WL!M'# MK/Q08F@$]N]LS!Q97X=L41L?GS^[/X)MH.#;9KO$5[3AXHZX5[2HZF8R?J7( M)_1YDPO+9*R@<[VBKXQSY'"?:^)U]KX&_KK7ZJ]SCZO3X#PA(1CGCQAKT$%J MUKHM&<7E(?&2F'1,_U-@B52AF&).K6&$259J&G6=2WIA*P$FG9&A,5"9P*]D MBM0J3I)/*2F83N#8J LIMR"ZTK O1'3CDKE$"BK0890[W23.]$KZP,*X!8T? MR>!-8J!<8@\4:ZIPLC@_6O"Z2,Y\48,6(P;K!YJ!ODB M85ZR;#$LGT!K&NQ?B$-,_-N'XLH($'09.-4M)=K[43H107?&LZ^;9 MH##B8[NGA?(NU098D&&H,M\^"C*;,I%"3KOG4O,]+!PMK>&\6L^=%'\[6K;W M*LP?5V'A6Y';T'-8DWF!K3ZCZ&&7 WVJB9U+KX$(A7;=\(;U!$\G+)&+R/86 M%;]2,0%F3&;=B!@PZYG#;S-BL(CV?T<%;_R)SA(IY.;F40*Q/)CE3>R1:FM1 MJ;] I/1%QMOC$/S$S,A=(H>T1HO+^"QL/30'I]S S2I5?>*ZD^K^I@]OK/O[ M<([=V(CCR1=-7G;'F6$Q*/N)+)+>:=O]W]A 8M3D M,7!HDVY/!?2:([G[BGD-TL8.9R](;7Z)=BN^S0LL<[[FFX,46(H((<.?UI%P MG&KA*)Y@1_X>"Y.64I6237=%:/[/+Q#F%M=K,[%-SE6I7(IH![ M>KQ7IRT+8K>SG44.ZWA)K,C(H5QA.&Q5M*^'23\M"$JM=<[IV5>O7OW? M='$MFJ-T3#0:@HW@?5A6KJVNCD//8A8";O$#CD)4)R!8N+GFU7 0N77S$MDP0S5=RXVS9P9%[T5"0 M#\W V17.: C.[D;QTRJC-8F(1J"E",6=CZ?$GVK->3C%)L3 59%OF,+5*^*( MELJM;FJAUFBQ<_'6:NNF)%N$V1*$OB7#D+#$30NY+']!"8FK/J^W:M!T)DF+ MQL'OYY98VU9*G00;!:"3H%]06T",Q\?10:+V--B'HJ1!:TZI!NVR&5^CZ!G' MP@23Z\AH2H6@6(G!WMNAG1FZUCN%X/J[+W*7&8+5<'^?OO;V@! Y_RO 0]K M=J3KCF(L\##P;;:U":#QM?))2N=DE 7&\T#!Y8F1O Z7?;2AL 5W;P0_%^YG M/B>EQ*#[ P-H E4"LQ7N2IP'2N)>J&-Y"CY3>$S[P@[FB/2NGBE0;N"% M4S<4A2P@KO%<-OBTVWF'Y@5,K>)J/E^,:]H3%AF+P[&)+U>'1K>9(_5RTSC6 MC;D *":#4 :1+<2"AHGFW71<[CMT\0XORW?DUSN7R-YOC'"U?27:;XA_9,!$ M.MO D,E,[B3.*/K8RW\,(;"BI7&!1 U1]77403I*?K!X5Z!IEW%O:'V;- V* M;+AU/N5@U#[Q*>=2G Q^Y,I_$K]CN^J5_E'#,)%)IJ1J,J8ZP06$;\Q8D! \ MEF+01V1P8UTH7\,B W[:J[2,:L3AQ=G3A1>*63JH1\H3]Q/RT,S\=;@T+&? M+B<%]K=L/C1')0:K5LH:6PEU)C>:FGSDU.5MI&:E9%?3/,_=;+_9\[##]S[W M@M#/1"9C'U!\M-2_I8CP9I$X;H0SF_M]3FCN#Z=1PI;/OC#5I@[->M8K<=(: MZ:DWI("4/GCA#V B2W%;H!!"QD%P72QZ%E0S$[U:%DFJZ1 *[/0CU_T$I.U2< M]$;X_?>@15TS M _*W'/-\+J)IVPF&B,)!OD2[< #XLX$O9HOUMR] MC:-DMZ_?-!++'8Z!A')HX56U2I+UUH@C2U$]VR\.=PO:<%):22S M%7J\]YM7/2[KK;O>O,"1J/&3I!")M<%E&1TM7?QS]#(UZ=I7.8(P-4 =$#86 M)S8E_2-W^9:KBXXB!8I-D#R<1E\RCCQ#J_Q1L^)W(-8^:I7D MTE4L?UOKR>].W%E=6-2SL"SOBI#4-&U&1H- @7Z4E%8=MI*[G;[C/!)$A*:4 M4C859H)I1YQ@)7R<><5MH*P&@;W.LTK.AMO;'5 -@ULS9*2=H"+EF:\6;!BW M"TF9?^6RE$O471^)A1GVY"9I7OW4:W8E&/=BH W5$T_0L'(@<>'JU @B[7$# MJJ?TP)"]@@RP/:B_FM"ZCMPV9.6HF4'*N^\FU/)-%8ZJ4<#]YAO[T-CYKF<+ M+CE7S2ZWIK)X/5U8SUBGR.1U:BKD2]J-8%K!T#B\)5,\;Q(C@5#(WC+J3 MG38(=UEJ#9A)US#>[DT3^(+<'F:1S'82\CEN:K"3DC[!99_HZB>W>)$2,TT8 M$>&ZWA08C,K6[V#W(Q<0"R)LX733JX_5;"BRG>V#K01$4@[N\UZ+(U:*"VX6 M]L9?^@/#.F9\9Z3 FCCF]0K'=\ ]%+YPUG%_TSUHZ&W#V2YR,V96B=DO[E@6 MKP*U"(#ERI!QKEFNZ*+7.,U(['3(+5?B"'WC-+7#+^!K3+_U+H6&0A4294PE M=C1=5VAV?XZP<."2-$ ,JPU=$:.K@6'@1"+ MNED3DBE6<$-7:+?SCL$5;HKG-=]AKFLU\G)?7M8S_G+-M)%"M1(SQTY6/_*, M/CJ 9'*GKH+!&F$O\&]?;W,^C6M?FM Q/8D)N"&:2J\+!83_,.[U[&#">)_< MA0HE%PSUN^FX1T,S]<;,O5R#*4"K+V$$F!W(ZBUR!2]L$TM'F79M$=.W$M&1 M[(M*C8&*U.$\;EI<9L87ZR6(6 M!N+#;Y39(J0#W6C:+%HJ'99;JAZ'[QG6= MJ0OEAS']>+/,5^A&\)L9!$V9]27?_YG+W?(O,&*+LZ"[4(EE_I7N@^\W)=;3 MT[/R^(X&T5BL!VB??V2:P@&FIZRFN*:4LD7XJE$&CR0 M<>!/:7R!.R$B*6M](E0#C"YG>OU;3GK55IY-MG+*J,=VX%;UNV"/8!:PZP: MB;4"1S-O\3 '&@^4QAA+0BVI(S*0+FPQ[%U<%YD5_0B$=N.AI&6* M1,OVA*JM+$KBSTV:AW3TN*2H?.HI>,V\E<<0R7=1MTH>D1E*1*84G.^>F]K=96**D@ MQ G(R@E]B7UN%;M1TQO85L:M?N?+:5+HAN!D(JLVA6<^KQ4'&:5(:,A5. P' M&KSF0MB4KF)49)7R%S8#T?%@$:5,#+@R5/9OTEPJ^ZJE%(%[=A>LH"10QB"P M;6(R69O!G4BM6$H*.5R%^.OMID3M1@+W]BVCKU>9F6HF#K^9I85$:>7TNFS7 M3V>TWB]:!Q04ZNO >-+_LEOJ6$;!6/:15;DRQ4N8B6_DJ4"MICK@TR)6!=/= M&EU7N 1(R6;5U]_5B%(KGXVPX'[&H.,KZO1%JWH?6$2 -U07E MVMH4_NY;2[KW8[Y4Z(@6$EUZJZ- M;V4)HA62+8A:X(RD:FT*$"<45J^(U$;%\XOTV8Y%3(YP"/_DI%17 R4 /T^ M [![72M_LL!#N2U\LH3/@Z%J>Z(N-**-6(7#55P"_E-1:5^;/,"1WBWR19:D M9 NPZU)+;7+UPD6YA];B&&:$+%(*R!^'#7NV;"._:5+$6:T\S$E7ZMFCXIVB M3QFEV_).&"5*GB8#TW9B*K\9V_Q:R\4P*K^D/ 4RMS?AW3[?+OUU0@3?[?Q, M84G8=VW$=/"D086]2"V:Q4=D-0/V?G//&/P8PQ=0LQ&7&$,CETP*T@.]JL]W MU'-VJ#K3J,JDAMQ\D4GV%9=,6A8-%QM24@20:-?!AOPD]E+/KY*8J]>'Z\59 M-^3>8Z%2(FIJ]W_CA>\V*G@S$#HH=0+V_)%L-5A;N'(()$^BN>]6) 0JF42V MDB "VN6!_2A7!869S/D+Z%&J+B_G+JCY>RR\,KV\H$4;PO,T)I9 M0,&A; 1148.%LZ L2+E",Z@O5P_-95E[?-YR +R@_/PY)-3AQKFIYHD C M>CL,O1EOEQ<0!5TW!,ZUT$\>IMK%*$4GDNWP?I7X0DODP7!,+YFV.&I'@T0S M&[03XKWZ>-^O<>5N+>B6R"<@/,S/^:_'^=GUK:*R7G5!!LE_;41.W11!4C'9 MLETX=PKG@=Q !M16/4]L"]*#I_ S=L0G*%5SD!N-1*GP)MA.'=Z<%I MF.FM2TVCA0ZO:P\NQ(_246=AC<1N*JB,45>9!%Y!T;(:+9 M4S0LB9Z<&8WO7\6[2<=R!_ 1I$;4&>6JD#U-#TD<%_XIBMY%1+(= MZYEV:_ !5Q^7AJR1X#5T"4Z[U@<;08+5=MF,(FS3YE*E2+..JUI+_,RX&23+ M*+-7&-^R0G*TE'*8E<&0-88VV(1"JID %A7'A"QO >(=YDO35>"'0,($LJUM MR:7"=0GNRF*Y\-Q4OVXLOA<=EL8ERKPO,4;,9>H'GM"YV,E1^Y?U384@N^R5 MPY_@CU/U(GRERJIBOF_7& HM<,*_[9 M#X8S$Q:%%%QGA=Z7/79=T=\D?PW'W=X?*0:DCQ]NG(80>=]F<448Y */18[/ M8UBV$Y6]9!=DH[OBP?0[71.X7EH=6[.0%"#::[ C*H'@>32NB_.58Q749703 M? BK)%PJC/M+@[J;VK,^X9;*#+E-ZR)_DTT/T(R*;4/\;#IPJ"/(@F)OD". MW(7*(THQBS DO([C>' YBZ:Y.0O%WG(7!Y:Y.+2,A>0!N>;1JD:U76H1CTY$ M/WHH?\*P/R 0+A:CILAT1%#CUBN"1DV_PUO$AY49VE#1R#_MBV?X B=1H ). M7(!?+@)-]N.3-O@UN&+T*=8)PX7PECF6Q*J M720**<%PT!S:HPF8(UK'@74)PT\(RL!"HXRR4"@.6X/0PI6ZX,4@$HG,P';D MO(+.=,<_RK)0GMLBJQT^Y] VL/\>C@2M5F MO5JC/',L*/P_7S'606-;CJ;>L"D<*62S6Q::1@I' ,LU(AEO"@DHE>6\-JF* MF*_UJX2!76 A= ZG.KE^7[\Z33]QL5[XN-.3\VL8LZUFQ1@C M1#,R!R[]0C4GEI@9R+#OYFX1-POVR7/RMY"O^:]&4 MZ&E#[Q/OLX"5+[<$)LAE'E,UOM+%P-C4+%JR[TO'2G&?"X[M-V^%Q0]%Q>4R M-37+S9\,4IU7TCS^R,;&_92*<)5O3-B[+JO7\%?/CCIJ40O$ =#X M*[CXK>"VNA -%'Q10L+['%^V81^!6ZP6]RT[[8005UB"[!:\[\&"D";@W-*U M #=M[J[<5%L;"WI75JAGD:S/@OW/#@36GY5=N6!T%K%$D:G FJ@75#V60 M- E9,-EGMPV9W*]2 #)QQ:9:+U<)E2LC#\4P&PV&'9(''A1-%@$(\W)Q5J[. M),(G.T@KJ]>M]GB^=HTR'XOAAA0J48?MG521,8E-CCZY&:O)X3K"XU0L:DM8.B(-75/*^5 MM2C0HDN2@ROWFB_63U9>'+5W!VN.+'(7'",9H$RD\#@@Z$,B2*WDP MHDW)4!;EDE+-B3:KEFU$D%)Y]BNEVB!MBH>47Z:(262;\'8W?47Q]05#ON3+ MY]6.(N([_PK2=]OU]6PBAH/+ZY$I)Y2K21H;CYF*" 9=J9LF2G]Y8!R M1GC_2'Z"DZ#+1S6S&(M/?H>V9?Q\2FM8A":OK*&HZIQP M>6C".ZA.36(U95#R^ HCQ1BP0CT(3B?6&-D5)WP[$-!M<;\1O_C6]""QFEHS M4G(9MJ?"D6KKPWS7@='ENCBP95_SYRC#EVQJG-V.!.(;XZF<7__L4TOA26!) M19PFO#IF_ T]D7=ALX8O$0\>" 8C"Q"7X:GR12/1I99C,; $G0 /1$ P1";* M#3?38*5\B7:I4JO20!/Z@N!*4>SDPBLD7QWLIYZB__+\(1 LRRK@DS>%0Q+D M:A%&W#0AO5IW4C+X$-;9(]**V1S# HRY1&JG14H9WY+VE'T73N*4*,,MV((O M=E8&H_[5U)SUJ7(&B<>50*X=9U?,&>BB>.H,?#)X4S.L0&%93T$F65.*/AEA M_9,L0JC=S_G6Z7A1+(I+@*,)%G5L"->[P#373:PD@]EF]B3P$8$UYN^Q\46$ M/%?=.F)Q=V($2;6==_ZCV*R1@:XP_@GW,3%F21!LJ#<=N;@@+2(K M<;))@%9S,>!$!X>RAD/9P?P8=C#H[6$'_W#IX./M=BU.O)0A9.^9%IHR]>.W MIG: U6M1ALKM_"54, M%;APY(KAR!O5:+$PI3?]YGDZ2'H)CV'8SFA')=Q"WMWQ8=VWNT=20KX49\++ M3>D4=@!Y]*9.-_=HZSS\B/A;K:# M9&%Q0_KTGQB6P4@,#PPA_"3B&WWC-+!#+7GFTMSB MPQ>V3[@S[#R04M& JY0:KU!@)?9+1-XV9NUY,L<_XQ*FSD; 9JI@+B8@6G(. M3J(W1,(U;[E A3/T>"XXF-0WA;N)H)[I7S4K&;O"[2@K]O#2'KK"3=2SV#4% M$(]A! MY$UYE.XH@@O(:$N&H8T@*5 6Z&(X-WZ9=Y41@!)VP* JU0#?Q$P2X M(G PUH^<+./]%_7[..S"8/@F M,#LQV*@ 6M"ARP6SW-\!H=ZQG4/9+0552M"E9*"1*42L^*<6BRC:-\KKW-T@ M#2NR@U3D\;-D?PP/T=OSJ>X2SG"U1I)'I@33XC5'T(O*E%F*NA7X%@H:(-]> M(ZB7&8YFR^KUR?Y;+O%-\%O2^(G"B?4'-7#TT\Q3,1?.%EU<*3 /3D>A>/\2 M1>F)7#"=3&QJL('$GH7SD.W*.W[]I/D5%PI7L*/.EN?:!R,24*UEG2QT<@XV M++2SS4@8U3>I/;.C>.K$)YJDJ(\6G:M<(>PSFU\1Q"372>"J=)RYV[KXWH? M*&I)!E4CRCS(1K"F?I) &P $L.H1YZ%!I3C63@O/T?/LM!6U'!H^:*T<-\B M:R6YO*RL*Q[J'=K&RYA9M/TL%E41R$? ( /K0L#]@Y%<2]*.]P*%VWK2/W47 MD(OP\ZCHK%[)H"BBT!A+6*3T^0#F)W/$2ALJ!U+1X-1;II3DQ#@16A<2P\$> M,8<&B&11FAP'3NZS05@GPU-CH*J98\ANRTO)OXGP5@]YIH08ZZ8S,VS<_6"U M0@!LCB X&?DE5_$NW.I@.\T9\%_:TW#S'-1H0!"7>U#9F0I_#S;:;N=-R)A$ MAON]R7QM,2K(;VR$BK>3B6B=+\]0^=Q59SGI0S5=V=\:N-[+)>9GA9$_9$AT M(TZ9W:/H%7.+THD2&<;JDOW3* W!(@N3$7+MRC.9N()ZYQY$#W?8()XR,G? MZ.X5AL+#^$KC@/(>RY+*7FK+'78$R4*RM+!1IJ7B7M/X%&\T4'GJ;.\_5>.I M#>!!D$*I+JX?!8=@5XU.EWHJ8]T,1L MEFR[W10/"*:!%7C6BV+)46S&N;=C&:BF1+KR>YNR:!%\@Z M*!%49?U:W=J 8=G2:YI7ZE.!_5.2411MN'Z+AKM'_3<5\4MYH-SI=E0"1&W%=K@!S2RS!?R-YG9)!S M>6/%[<-*"D=L-HHH3XEXG UCHQ%NUZ9"K"45'QR;&4Q@S*DJJB=T05"+1;&@ M&I5BX..X3JEN6*_OAR/]\R4.][-G6%>%Q"E33L7OA*O[*,Q2"M,2O()J8$N. M^:N]"_WYP1 UPUE@877SG."I7@ @!^KNIG)(M)Y/&D@%A;%B[4+I"H1FA0"Q MQL8PE#"@(5\",@F:3I.5GD"$7*MT$5DB00:^ XZ_9M$#64!>!0$9*-DM2I', M[W%[/;I"R-[44H'0^9@;MT$3S6V523XJD@H85%;#' MI@:(B(W6[V-$<9& 7Y)AKUP%)4BE9K5QY92;18<1'+WAOQ9;ZG%NY#;>OX:\ M(A9?YJND_7HI)(R-OJG=)=)#KW0=J8PV856(V,A>VOP)D.1+9 #I.*\!GVN'AA0RUL7JD[-:08_ M*3R+'&PWDACAPIP*+KF9F90@VTGX>%V L9="\MI1Y%B,\U 0;&%-;(6_69;W M!E;5TMR_[Q;WSHEGU6>39>:]MXZ>)$"T^=)FI+;0A6V$\%;)PB<_ZGE6C.^T MMAO7YZ2J36Z+,*%,\EP_PXEOH2^/X;E97P;7HM MPQ+KY6V&FH4T=X%G@1(<9:L^?UWSEYWW/*M_HZZ.SI#M_"O>EF\:PK()K1RO MTLZ'W2,>M/7F1YM!]T-GU,MFPR%\& ^RV8@^C+,YO/H.3M>/;>F;#[ M0"'9)NGRTW(',R3C_R-#O\F;038!S)'".U!#ZY\"=<\V, MCK(#6L8#ZS.8XS]]6'SX9]#O*6E^MY,RY9,RH9/2F]#P/XJ-V0[&HQJCX')& MU$=1=RM;61@OA% R0,K=,V>)(V2(:Q)K^]E@/.ADG=EPQC"$0"PV(^;04A'U MLE+U ]E0V+3Q!O+/9UIRX+U:U$D+1#D,5^L5.>KVCG7&N-7OJCZ(6*$MG&MNOY?" T/A@]4 M^'%SGZ\T"&;_7EX9W>YH0J5T6=EWQ_%KE'$H'Q^[:?W1SO'P+UW]FA\ZD]$H MF_6&G>&H.X>'D,=.LSD]+][OZ!301F%^_!^P/^/NX.^G,IMD8)CCN M#CO3?C;OX;>CSF?"_@C*V+O>@8-,AMEX,NA,9O!H/^L/!MD(&/%D"B.8#R;9 M< )_S+M]J9FW(*S$SK WS(:S2:<_@;<&$QSH#/_HP<).LNFTU^ECUY\V0&1; MBW#WE#^C!P'9YV &!#Z9XY,#:&.2S6 8T ;\T9MED_D ?_&;] ->$7"'#6&& M_5X/NOHC?3<9P]+#(.UWPQ$\.YBX[["[QK&0*N4<,H%=&(,"Y"F.3)!\!$'K M0Q%EB5J" W]\$5'CA]WF7H$H.YC=AL;G0QHS]7[:#K >_(S@<^"?=^M<5*JW M3G4W3.$ (4U9R<:_M8]M'G1\&WFK.6[]_CP;C?KTJ9_UAC7JG,!1&_8Z0%+# MT<00'.D&]R0P_ 2,9#8?UU7ZE M89?7Q7W[W7L5B9 M<8Z9)<;,W7)TX'"(^?P#4$ VFI"*!-QRV ONW!K?=Z0V@E,^ RZH3\YGP-=' M[L^ Z6NG9W66KD_7_[4L_QHHCR:#K'N(#%+'VP?"!6KR;X6L/C@P@QD(X9.A M>W: [-/_&7#[^-STB<2!_P/K[X.D#.LT',(5"S0--V#$ZGGQ-X:MCT=C$MKA M\W"2348D98/X,^JA#B7MI/C_/X2O-\.NM5#ZY/=+Z6/8[=Z$5AH8YAPESCZ0 MT'P6"IRA0.,H?3B?@- Q=T_.>L1=]<] HHDH7026)D(W\HRA\UX/"&(^U]'. M01V%L7HR#T28D,Q'<"KMD9C"A>#_#.28!)GCJ9CT.O,IL(%Y9YKUQWW4KB?] M 1.Y%6%B(A].F57 9SBHDR$1.?*!_I"U=&PG)=#\IQ'Y(7)(DQC22OSCWR_Q MCX!;#NGF!9%B,L(= .%A%&I63;+[< B4-O"T#_RU-_7TE!3@'>V+A-Y$^T: M=[0_&XY ZQOH4*<#D$S,'=,HK??G\-[(\_,^ONB/W1Z1'0[X'%X&H6HTFW:@ MCQ[<,?#=>,AD;X7UF.S[.*H9+O!L!G_@/0HG=CC&%996_J$2^S<0?;O(K>+2 ME4L7O?1N%C*9ZA,OM*XGC2)2#Q7=K I8XBTC!+8>AMP^^XR>BH?SS0(;QFT> M?)KQX2-.]!N)!T71-CS=G,CS*P4'+4T$SQ'RA3_P7M*@<*,JE'R)..&H&PG) M'7E01L:=DPFU>.K!$!,BSPQND6'3D$! M-IC210*'FB\9D,[Z>*N? #\:C7K4FI\KB'Z#V=C#ESH I%4AJ5L.LU3,W"?( M/WI3:$=<4S=LU?1U&NH@7"@I@S0ZG75>2]UN%P\MX;7\!V1JD,:E&4*$]#\UEET*M;N><$(_E%5OP+U]@]"<'G'XI@N?+VL8QYZJ?4KUU="TRJ8(@ M1]160%CR$0TXY -!6OHC^B!'U,*%_+1_O*4K0>"T_S^XP_T'$_>,;"$,4[S- M'Y]VG$&E"46F%#;'Z6'XAYOI:K=!GVTXT3\383;.M=NQUE+G]#>>]-;66Y?1 METP2I%=YQP*L<52L@4;#JT,8^SWGYG^CCO'[8\X'RL66.:N$W,BN)3NF5N;Q9PG9*XZBC?/<&H'\.9)-B"M< 2J#UXH\\&(>/.0 MML^/>@@2X>Q_>//_\.;_X32*#3ZS61\FE T' M[4)S'^3BV7"<'LX4?D)VY-JQXVGERC"3Z6C$7'DT89D\&\^H,=!ZI[UYG2N# MF _\[2B1.9O/AL=Q9>#]:.;:QY7A3NGU<(M@WD/\=SZC((]L.@LEY@%>/OW_ MXW'EV'-IL1 /B'YPSC?[)EEPS!P%B?.&+\;K=9$=IL)DFI MOS+T[ BX_: S(V5[1((WAN\\WN#^(5844-;M*1FX0!>>=V7R,5;$PXU0E]-P5G5 K8G-<$Q/B: X7'TYQ-,W&0"-*@55, M@D-0DR:P[,/>"!V/9NA]=#8.T=P\S/K3'H)6,3&&M#@F[R4(&4,,FP)20)#V ML _TQ,"*SWI9'S2O"TIED-I"A!ZUOM_@L1W#K=XCR0.H #I''^5X#KLU=.[\ M6\E#PQ!Z>^^<]$:EA9L71)$>20^CV0C]:'%Q.4>G M$AUW1I&=A_"BMTSP[XC@XX9>RH1<^.>YA!Z^0S"E$Q1HX4YN((J?J+CPA>(< MGG-\XKE9RW-[91_Y>#PY7"/\[QV#BAC>RX4F!Z,N::=T&D_F++4-92?HNRG+ MA:/>..8SPV&WUQFB2C]!)7H\P6=!9AJ/9NYKH)D9-@LL:SR8)IECKPNKDTW& MP0'!ATS=,303(T69??E8#RD+R<@(S(W0Q=8QHH\ M4#A(U7U>MH$89>#7_@0OGQ.0,V<3_G&<]::3EY-I!F>>#GRPX6]$Y-G/VMZX MJCU)F="53A;VYN*GD.P,+7KJ:],,G*4LN>6@&#;.QC0$> M:?Z_GR*H_:/^V,X4XRU(Y19I+;8]LZV6;*5NCE,2UU 9Y3E.IC#0GNEHE,W& MO/ M%EM?$X0F"/(,/K=>G5_1G!H'D!2*B*CMHE"D=LZH.;A M?(1&\-X(K3-X3B7Q$03UQ9)*UHZS.>P(' 0X61<,,&=EUXZO^!Z^1UD+R.[@ MQL+K9PIG9L@U+TV@+2?@Y[S J>@%%T4"IZUM1=D!P9X($%?ZHS0Y@Y"V03"- M=T8_.F3O4^\=>H1R>=?J9$<3P/\FX&L"KY5=O2LH4XM\-?CO!#;QJKC;827; MI_R9Q@9Z\V32QQ."H4&N[+,:RH!C3R:HF0 54 +'0[%D8\2&$/\I(I92WW$/ M)SV2'F 782,HR155#"8:=/Z@CD-VOA(M;<$PR)")7JN)5SG8.HBJR&S6F6=] MD/(N/5RTOFJBX>".^JBU?M# *^!C'K1QWD>99CX=R%&=9E/@_6/@S$Y=3FS% M#QCM-*.[;3S+II-(P G*LQY"+!T.3U0LFFQKI+.0$5\ M"/C9UW#[#EDI!\<^>SO/!>>E_]AY*S4'?T!$BSY%N,.%VQM)4$@?^/0UP@F@ MAQ,C@&%[AVCJ96I%'05D\P'PG"&6"^XYVO4MP_TYP*!<4&5'J)O S3R1-N>S M">D(?5113J9C_!T%@1&J,H,Q*@9]"BXY]W(%E<_P5;;JIJ__HRL71E+0>BQN MKY[LJP0$Z M4Y.9KI(4F^H,NW#MH2;=G<"UM3I;<+EGW -G'>Z#GMKKSN&_"=F%ML]A);.3 M47=LM&3]]RJ$57%T-^[&'B5A7(Y0*^BLWSGI4<,GV+&:\PS8OF<8HSX\#?/' M2'GZ9]+Y8QLYNCN"JF[[!,3C+K[0?I^J9E]/:MR;<<.XM8XW";P6=E0[MG!] MT9N;XFY)U2C-"7 4#GU147"J)8 PG]R)OI,GWZ!ZXMUF$2V>Y8F9XNF/3HIP M]"-2"PFO?;*-G^_)Q\$LH3F:'"F.%S?I%OK$*WA(<6;#; 0L]-+)?L!_AF., M;!BBS3KKC>>=$<:_#BBM57Q2KL\3MK6$?"VU?<#7Q@/7%!\K7OZ3>9^RA?H4 M5GBZQ^MW LQ^,)J1Y@9*%X6-?$*H^=*LT@F(M@,B]R%%_YZF!F:)Z60 0O%L M1*W"-4%N3[2WI69"\N*4N/8 HYZCZY]$[T.N?2]ZTRN7!H9S_XGQ+Q-\RU$Z M%:M1A(>\SEW ^AG!@. V#8W?8RJ#@<8]8UDAH8)[-A[CQ)^QA M/Y5'%[$FA72%A^H48Y<&;!CL#01C8# E13T2[4T9ZW,N?G<(C=ABYI^DG@*] MGL$AP@K8TFYFCN>Y08$]BO4*9FQ@&K.0LG=4I<<6Y::BV>@ZV+F"1$?)CS]V M?L(66%K4)?I)&HU,\U=E]!; P =_A/MS]D<>-]H\^]T1/C+41Z;XJSXR!MT M'YGB(V-]9-X=XR.3^")M*%7?.?<532E>OID*W/[_Q/7+X3;[1!A163QK7NO7 MN'8&V& _B;Q]&;)"2$C&NDI2Y*_%YK;T!KM54 D+B_0M\V<.OR B8\S!.@5* MU?: C!K)YXUV^8FZC'XW:X+6&Z%&1QMPM'O=(?X[[?9ZGB#0?-0E/46_9RK M^Z$[H&C!;B]RA=7T/P(WX@-M,#6N8/40PAZW^MN-VK3LKMJT745G[G[Y.?[@ MJL'KPMF)[-N+^.V_JXO9&A$ MLK8O\@3VQUT0PTQ?4\J.F'3GL8$;/6O3(9E)0;U!L\R4>^YU>]-#[R[+W3+^ MI>J<,WH]BN<,.V>O-'+^<[!);<^O2+,^]CBP+O <0+Z)^%[5;C4#:Y-IC6\. MOU%'^38OE\TZR(_AW:R4&7YICX>0O_WJU3*__>4,EG,-(H)E35?%8\YXV!>" M/8=(Z('7^J]^R+)TM%3$'=%-1KRRMJ@##*4#:I^ @CM"G)\^!=$-,+^-/L,# M<_X%'X#GT'JRG]/(?W4?M&2S!_ZH&4/^Z"A'0&;'(^!UH: M=49C^(\^P<\#O#$G_#,T#F>FGTUZP\Z8/L,#0_QE!@\ R8\0]0C)?@R$.8$; ME@: F:-X7L_0(8PB8#8:SS"H9SKH3#O3V9R/*2AR(QSF ([QJ#/&MD@XA?GW MYWRZT*$\QW;F77AK- :M/@/1MS/OP/FG/88G)B-L9("3&DWQB<$H;@'D"UL#]%CF[8**F]_4D7"#SH)+X41JPMS9&@ MM!N,(!L0J;INIJAQP%- L)9;H[4&GD0$M+9N\#3.64*!2T.[0?\L?#/HNV[Z M\S%W ]W9RV[$W@9%2Q0QQ2+?<@@.QP&-HNQ M\'1UD$)L>PAL:FKR,_#:M:*.B 6O]3K0CX2V303 ?:%1_&N>B*[8;PH_8 (^ MM#2XK]";,YT.^=\Y!KU@5-@Q[34=^@&YF-&)@R$?&)#V\E'R#9KNAX$ SYQT MRB4L,9<9D4PB5:5DBCQ#/( M\2T2R(7$&!\H:RC(+)>/Q,*$M[[T5XMLD07%0;YHK>'"26?I:)-CN&NCI3S0 M!'"5M#E MLPG&7]7K\SHG0%KYWKG#"%MT^& M2. A@R$U8,43A-X =CK/^AA?B\D'D MG7GK[Y4ZYQO7N.'Y[QIQM=YM3#2""Q@X\A@8S$*;;O!IL[YCB&H2F]47_+?U MYI=B4_TIM,-(B!6SG5=2I2L4)";HIYSV40#-4'X<$Q(&G)4)")5#=7!R?)@I MJ348TDYB0/ML2D<'U-,I<&[XZX(JA7:>%+2.N:&Q;Z/'DR(23^#0#-@2.9QB M# M^FDPP#@@^7; /$BO)'1;E@9HP-F*0DT @TGG'0L=P F>ZAW,9]3 @;(+2 M.- K3*5QWD"2J!V,LP&^,J2,TMF<3+;[YSTAI--32L0?C<=L@875'Y#==I@- M>[V7S'LX ;XS[-EY@RC?-.\I1WS-*>EJ,(7]GO/5.R CT #1!V*G0'6[*5V) M*)=8AILZ\*A:5SV1I>V72_-AU8UJ*I*$T9*>8%)I_.[^I M2/6,3KDWY%S!T>F\H1( &L.1&,R^YYDW+U[XFI2H7^F%#E>1!@H>W2)?%_%0 M3"AFYN(P.283?F"<4.\#_[M+@XH=!#Y41;?H V]1!_<=7L5_CG@M\_&D[_S. M)L)*J?GF/?UN7:1G<&V0[4U5HT^*D/^Z1/&!\R3<<8&#!L?[\\-Z5T&/[4?A MY^O7G9,?XA-&D:8P)X$\YK\+JG^.-O<<40H_K+?X@P0TP(]F+__M/;&%:+TD MW.!:JU]DCI-<8WU'=@'Y@B>O35$!Z#<<5H HWCB0=UC[\Q)ZJV*U"&/EV,1# MH1EV-0TC2K")/=NR%UWW(,Z&CIS6S=OWP#CU0!-(;V8'B /72=@]:%M-BX); M_XT G'J1CZ<%A+;^*,(3Q@T@FEOBVWFW'W^[;].:,K&:]DKEYR92WY.JU;*2 MK6]FG9^K L,8T*Q9?U,\;]%0\U];ASJ>I]_;MV27OL2GYSYG'6$J>_B0>5D= M_IS@()$R7*+4<)[V!A+Y)%$D]\F;7Y5?:.9!+,7OFW,4#8[;XQ(9&LDEE1;T M]\X^(MJ7V=5"1:VOME+12 H_'SB%/<0U:VC-QZI'5-Q+DV,ZPZG^U*#A[7T; M6U/?&O4B2^D'*$^^15V@(^[G:/7A\OS[M8F&]8M\6<("K,J\\V^OU^A0BJ;V"MCR+R"M^(Y,&Y^Q@-79)RI@ M]8DPD,V/F'M$PD\%:WA;/.$HEFLX">O&SK"TBDL)_+WU<_'QW<>K\] MQ=5Z\_^>7\=Q=%5U=EU08MZ7EM=-.QQA2PIBA;9;WD1WHC*T@N7,5?Z6 _M> MW6]Q/1HV]Y#M"%@,F2TH8NUH<>289)]O)!L1P?T7=K3RXS=<(+CU'=KZ!/L[ M7MRQ"1M'K^JQ20'':UJW1?B3K_A[+D7=#E6,;7()Q?%7ZH!#$RK9V[C8+4>G M9\:39Z,7(JG%1C#YL4C]'CN@;,\ WQ8WW4YOUBH9?%A_@6=&K/_),^=P2S$X MPB&R!@_L$*O!_B?'#:,,UN2SK5K:*E'0XU?%DR:T?D(PA_PQ4W\H+-[;]>8V M5C\'#3)H4XLHX)1L0B#'>7(G9MG_];_^%WHEFNUE3>VCO:=Y5YKG::*"V"NR M[U4@7(X[T,!'"2_Z>R>]><=4&DPR@S\;PJ:8C.PEE.YKJ<74Y>N3U7_[]O)Z MD:!7?U+PJ.I5P^)AFDIC'L,J57 L>M76S.N<-YL77E!;K=[&O_6C9G\_)9B2-U=W,K)OKE!TJ'C3UYB>Q916K?R2^'74'\;=-]ETL>A,_C05"$M_. MN^.FEN-B:)&QLSN)7QYWAZDO$R9G6T,ADC,FJ3>P?8TFHM_"0QHHQQLR(=]I R9(W-URJ0'4J: MDMK'Q#3 M@4-V9/+FUW++D:SU1W[*@5I.WI'TC!*QEI_']$R!+8YENO@9/G5JV;P T0J' MV>AQ.?3!F,[-G:ND=#SGB(@P,[6*!)$ *1/HL)4D]Y.$]'3L_NY[?Q_^5M2? MPG$U7NA_/P >K&$PIHUOG9=IZM@IVE&TSQ;NN6^>+;7Q?69+3;ULMCR*O7M; MKUS[/?8Z;O.[[7W<](MI(3'*IM5J*];[#0O6WNRWKEE[Z\,^IA@[TYM; P!P\(H?E=#]Z0G]FN1(]> MB%WIT,V+=BGBMWOBP(,%R#P5A<1EA[@_8NN<_3V9H%:2_<&AD"9H^J6QZ@>< MO;WK926%0]?TFT]0HM-O/H4O9%8PE._$YJYW-U7Q_^TH(N\+117_AK,-*Z0< M+>,<="4UWI87Z\<;$3$RFPA]B7,I[\KVY0_(AMFYB+8NX]X92 M*I$ M+>(2H*>ZZ&TL6S1CA4=&Z["V@71G7$@!G4L2K?'Q1]. #[PG8^#S\U/1XDJF M/!A:BIL\C,>!*PF8R'H#>O:2;+0)E2%=M>0%'A,YM;]5R'L3CVFJ-9*DE;C M2/VQUJ(ID2=S)&XL#9+' A2+_#EVC31D=DS=>[WD>_V9=+#OP::-_$;B3:E4 MS;7(EAQPZ0@Y"Z?SO-2RBF2'Y3/W()?2B BGN+02-NQ/,N.,7P-=0 M:>%!<:F.B%DWU>.(J%LK8C0-)+,96.\2O.U[TG:CW>QE>Q(E9[$@8FIAO,2. MMK=T1VO@SK[*,7_O-"UD9C90-Z)A:&FGA.ED1X^@52I:GB#[">8:JK^06.6ZB'E "+9=)R*;SNB M/$#48"I]>YCJ9)B*Y6LH,!")QJF@Q5XJ"K&7ZB51HJ#^"%8LZ/TQ6N-D*GQ# M&8/Z8^/4H*.R!G&/B07%L@>)T9W0;*.OF\LBU)_$*@F)G4KF[V,-A?C;@'P= MI;\H""\H$1#-R2/^QT,0WMMX\#SL??V11#& QE9\90CG(S%@Y4VOFQH!,9\- M ?_3^]B$]A\=I330?^N&Q4'LQ^^)V:\KH:/V[0)'V^6Y7VL8K(G]A-WK>DP\F>S%^2W+YR1 MI.-OM(QQ0,,XL(RECMK[_%FCGDQ!#)2!O1JO=DPJ"/HJ?!K?'4T M-J&P*ON;X"L=KVI:YBO<%??^@0\S#$TDX[ZZ_/SZ?$^+M8?2+:6[A3LMWRVC MC0Q;;'C(8V\8]K=^?"PYV_P39SHA6_A[\@KKMR!2U<=YL4N(XN$HDX]\ \>F MXW;0S9#D[9ANHJ* 1:QUI'GD6Z!3W:9?]/=T2,HM'7S#J7 A:J35YELU8[U9 M+1KV.:FK(L.X$+<_: !;3$YDSQGM]].-]1O [(8-(W^9!E5[2Z77Q"[5GO1BP=Z',>X+ MV5OS**)5K[%VLGHM#(N->5J"M^X9Q %$-D@;F?\W^=-#"](V*I\#UE&G:< 8QALB3*(>(=;N!P4Z M\+') ?!"Z4<8!$<"NM>^ZET*"B=58; %=(,B!["T@V\HT@O@QT>B5*DB@QM, MC#\XK*+8(N1 :>#@\-U4ZZG9K8?VRI4O[?C2ML*=O,*8+7:*-_"605)=-#!1 M:6+ 4Q$N>D2LWU[GTB^]$=#V[L)WZ-A(NWLZ;Z#]06I17TN!&\M,CR!>WMFK M@N/T?)FE] :E.]NW:0F>FJXQ^S*0( .+8QOCV ]8TL5ZN;Z/2'I/3=A8JDLX MY(*ZL?4?)Q)+V(2FIK\WX0?K[Y.&WUO*U,;R3PKF9)B$ Q\FX6+VU+V-5:-$ MRPDRJ)4.9.@!MYN6' Q6V@$D\=N6PQ77H[^PVI"G]M0=W?MXLI9L;/G5,E%1 MU5F]SF'RIK1=\WC-0[56#]C/5$G*IBC"XW8TA;+FR^_J?U\ MJ=> /7)?6^O)'ME65M_,ID'[0GQETQ5[<%<'M*6/^NJOW][M 6VE2,%"&AU+ M#&WOULCAH&X.)HA#.MYSN.*:ME8-^C[PDJG48-]V@U+Q72KVILOU'H0L9!>I M@6DV%L9-90"FRO#F85G<6#H(2?S=^BN,C2?QCM"A_V[V:-_;/S\]'?'V_MJ^ MD8!#XD8DVTK:!]E\.!/Z<;NX$BD$>U1S5#L_V/J5;;TY.]3R=A&2A]@KF)09QNCQ;;DY3_OL L!N/K/BI+_[<$T$-$;'+E-L\M MB;_=S#)ISYOA9P[?^.8V]E> ;D"^\;MZ1&\*K?AIL[XMB@45H?TB00;GF%.5 M+CO?TIX&8XDX3ICHS=J!#6.4<\3S>//K%@OYK0]PH.]]\YCAU]@P20,GL:U6 M2$'"H1Z%O1%@2^=)^?*AQ!!?CM*NLDW'Z5^GT%*#6GU7BB7P B3W #TVW6H; M<6IE]&;;F-(&<./82(6+8D$K'+=O>C]Y, MV+.2=O#G[G6W\Q.>IE5*96F?(OR%(5@J"33N6_ <108=5G/&8*+L*265QZ]$ M]K9)"KY@G 0!V#-MQ"\I5U0FN")=X.WKRPMV([Z$5P?ID['.D^QLR9VU+2.^ MF?'3Q'>*QKJ-39E Z19_7I6MS;TN2>C8?C-6VT4:[J96F<6@75F1L?Y6"AV- M[VJ2*AOZ(AS,@@E@4][LG#O]10GH;HJ]R<$=^63,\]5J1P94_P37TE/SIHN) MC+7\5*CC/!E5VC(0Z8?Q%38%"6H@&@1/UDGBSU6U_>?_'U!+ P04 " "[ MA$A,%\")C:0" !4$ #0 'AL+W-T>6QE-"KQA/3M0GY^'.90HQO]]_^+*4^>X/\<^_= MWEYX>W#6M>\[QP%&7N-+&N-H^!X'?RYZ&(;;A:VS(W[\1/''M#O2PZ=R/P[> ME1_MD+^$!; MZ]WV/;CF)SO$OQ)1$K7:(K_I?3#!Z8X$GR$!/@6U)4/'_5"* M4;@E1;6B1JU>W$Y@]'A@V [MOI;1P 8'U;&8C#,IFM-QA+W!J!,.:$%8C,\) MHU-%;51&.&4K;W8RB612(6V.IQ:0,K8&'&!OF(QSHC4H<6$Z;K S_N9"5?MFE1O"F2*K:'",FP#W,$FF4J6@ MUFDB7)LF8P:9Q5%T-K=/+?/ .K66W#122F92$,=01U0-(YL 8]?V<_8CV]!> M9LB/L:\DQ,A2U$TSZZK9O#6W4X*VFM=NRPZ?I8MRNI#Z4VFF(US?;E>X4I#1 MI>LOLS6 42=YSE8?&9T)#GXR.Q-&STPX&9,Z#YI+1>^,GMTJB3& PF@!2M.D M;?FE2'X#2UUOIV7V7.9!#YE?>IUG($ 1UH8V>_]_7N5_3'PT^GMD]U7I K\@ MHRU.>@!YW ?(81\@>[$G3_H >=H#R-$+?#5?&_*H%PL9]0%R\,J00553M@K7 MC;)U;473DC)-184[IVD*GL?>&V+\W5Y*V$;QV%2O1EZ3J;GB;^B;V!0R4C)] M9:?HG#%NVI<6W!2Y]:B;M42,F_8W2&G)W=TM:/Y'F-P#4$L#!!0 ( +N$ M2$P/U^?H_P8 *I$ / >&PO=V]R:V)O;VLN>&ULQ9Q=;^(X%(;_BL75 M[,4L(>1SU%;JE,X*J3M%I9I[$PRUF@\V'VWGWZ\=8'M2DE=[<\I5(4#RR(G] M'!_[].*U*)]71?$LWK(TKRY'3W6]^S8>5\F3RF3U9[%3N?ED4Y29K,W;JW>C]NW0B:U?E&/V/RQ?:DQ[][HF_E_V$J-AN=J%F1-)G*ZSU4J5)9ZR*OGO2N&HE<9NIR M-+N=BWF^*<1-\:)*L9!;)8X_&XGVNO/UY6AB7M>R-C]XT95>I6HDRF_:?%#. MUQ-+S4=X8]X7J5Z;JZ_%=YG*/%%BV38, 70!H'LV0/N60$X!Y/03(9<6POZ@ M$L7&W/ZD() >@/3. 6D9EW61/!-('T#Z9VO)&UD]$<@ 0 :\D#-5):7>V>,6 M['M3Z5Q5M,.$ "[DA5OJ;:[-=Z6YM]=)4C1YK?.M6)A63;2BD!& C+AO5&S:9KX\/7R4>5*+TBVQ)WC&14R;,4CGV6+%4VY/V M0QZ9,(OD.OFG,1=MCU,FI(T)LS<6I?EU6?]N;^JMX=M]#%^0+R;,PICGM??UDQI)YOE8;G>M:?;VCF,@9 M$V9I/*BJ+G5BI?L.NF]/BHB,,6%6QH$I2#:^R7'=:"4XQF'5P9TS:O6?( M 2ZS Y8JW7R=Y\;M[5S'=$U5OG3QD Y<]FE$ENEZ'Y7;6VDB=AM@JOQ#=.DB M*[C,5IB927]5Z]K$1QTFI *7?=9@1GVU;[!2KYHVU%R8"2T%1!)PSSES<".* MB43@\L\=AB-U-Z:82 5Q M$K$?V_$/2H@D,F66" W=>^%@?HK9*?TQ?"\F.@AZSB,5ME( \NOLQ4 M+37MN1Y<]V"V"HQK/9]B(JMXS%;!F-0J'K**QVP5C!E23&05[YR3&8].9CQD M%8_9*AB33F8\Y!>/V2\0TW?HVB$RCL]L'(Q))S,^LH[/;!V,Z5),9"&?VT(0 MG M\O&1?'QF^6!,*A\?R<=GEL]@BNHD?O.1?/PS9=+FN4WR9G1/"))/<,Y,6D#E M$R#Y!.=[]HIA(/ &S>#KY4_)&+)LLDR7%A%N_F W43?/V/9)(/ &S>(;RO =. MBHG$$S"+9P#S>KUN&Y9B(O$$["OZ ^GH$S^&2#PALWB&, _-23&1>$)F\0QA M_FCL,JV@F$@\(;-X8'(_I+.>$,DG9)8/QJ2SGA#))V26#UR#F%%'AD@^(;-\ MP!J$[>L4$\DG9)9/9PWB]LV]K8DD%'[BMK)#_YGI*DD+.Q&JZ+ 9(0E%G[#3K+?Q(N2< MB-DY+=4QK)!II^6ZPT^$G!,Q.Z?%/(Q!/; 4$SDG8E_O6?VGZT6I38_>&R(DG8A9 M.CV8))*[)I@QDD[\^3L,WC%CFG*+D87B3]_Y+&R&V$1O\L-T-T86BIDMU(,Y MMUM5\THG9FBBF,A",;.%>C"7S:K2:RW+W^*68B(+QB639_%82M-IDIIJ)T;:B9FU<\ \!$69F7UG M3292>U3LY&^*B;03A42SFX"I-9/!CT[PXH MK,=TV.O[$>A]!Q169#KL=?X(M%M_"RLT'?9:_V'0B>-U0&'9IL,L(%H#TZNA MB0,+-QWN&IVA>IB3G-O$@26<3JNB&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/%VSMNVT 4A>&M M&%J .>]'8+M*XS;)!@29E@3K!9)![-U'41,%L/FG,,XT% @*,Z?Z0 SON?O6 M[Y;3]G@8-]O3>/.ZWQW&^\5FFDY?NFY<;?K]\>7RZ7PR/3W9Q\V,YK/OI?M&][KI?Q^%EW/3] M-':7'WM[WN#\E[=3_S_;'Y^?MZO^ZW'U<]\?IG=2_-U@T;T?R,T'JTM M<&WU7EL V^K%MD"VU9MM 6VK5]L"VU;OM@6XK5YN"W1;O=T6\+9ZO1WH[?1Z M.]#;-7C7II=MO=X.]'9ZO1WH[?1Z.]#;Z?5VH+?3Z^U ;Z?7VX'>3J^W [V= M7F\/>GN]WA[T]GJ]/>CM&YR5T&&)7F\/>GN]WA[T]GJ]/>CM]7I[T-OK]?:@ MM]?K[4%OK]<[@-Y!KW< O8->[P!Z![W> ?0.#[P!Z![W> M ?0.>KT#Z!WT>@?0.^CUCJ!WU.L=0>^HUSN"WE&O=P2]HU[O"'K'!M\JZ6.E M7N\(>D>]WA'TCGJ](^@=]7I'T#OJ]4Z@=]+KG4#OI-<[@=Y)KW<"O9->[P1Z M)[W>"?1.#69-:-A$KW<"O9->[P1Z)[W>"?1.>KTSZ)WU>F?0.^OUSJ!WUNN= M0>^LUSN#WEFO=P:]LU[O#'KG!K."-"RHUSN#WEFO=P:]LU[O GH7O=X%]"YZ MO0OH7?1Z%]"[Z/4NH'?1ZUU [Z+7NX#>1:]W ;U+@UEO&O;6ZUU [Z+7NX+> M5:]W!;VK7N\*>E>]WA7TKGJ]*^A=]7I7T+OJ]:Z@=]7K74'OJM>[@MZU05>' MRCHMVCI8UVG0US%4V#$-&CN&*CNF06?'4&G'-&CM&*KMF :]'4/%'=.@N6.H MNF,:='?,%>;C9CGT3]^G87M8CY\=Y9_%/XYS!?DXO>WZS\]Q6?7C %=L3^=M M^NYR_72"+JO^2=%=QQ@??@-02P,$% @ NX1(3*4K%8MU @ ASP !, M !;0V]N=&5N=%]4>7!E&ULS=O?;ILP%,?Q5XFXG0+8@(&IZ. D*_V2[7?KV;'X^S<:OCT(]N$^V] MGS\FB6OV9M NGF8SALIVLH/VX=3NDEDW![TSB4Q3E333Z,WHU_[4([J]^6RV M^K[WJT]/UT^M-Y&>Y[YKM.^F,7D8VU=-U\\-8VOZ98W;=[/[$!9$JR_'T,6% M:YLH5%V4O&'"ZQM/Y^&^;P_&VJXU_Q5MVFZ[QK13]]8OET-"14GP5Z16! M78[QH+OQ7U%^3M/A97ZR_/_X]C=02P$"% ,4 " "[A$A,'R// \ 3 M @ "P @ $ 7W)E;',O+G)E;'-02P$"% ,4 " "[ MA$A,9O,+8(( "Q $ @ 'I 9&]C4')O<',O87!P M+GAM;%!+ 0(4 Q0 ( +N$2$Q=*4%L[P "L" 1 " M 9D! !D;V-0&UL4$L! M A0#% @ NX1(3*3#2$&< @ H@D !@ ( !^ @ 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ NX1(3"O> M<2Z)! TQ0 !@ ( !*Q, 'AL+W=OH7 !X;"]W;W)K&PO=V]R:W-H965T M&UL4$L! A0#% @ NX1(3%#MU&PO=V]R:W-H965T&UL4$L! M A0#% @ NX1(3#,%5NVW 0 T@, !D ( !@"P 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ NX1( M3!?S'\ZV 0 T@, !D ( !23( 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ NX1(3.D(G6"V 0 T@, M !D ( !$3@ 'AL+W=OV>K&PO=V]R:W-H965TP[ !X;"]W;W)K&UL4$L! A0#% @ NX1(3'V!?;RV 0 T@, !D M ( !V3T 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ NX1(3'G0X**X 0 T@, !D ( !HD, 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ NX1(3,.- MOO6W 0 T@, !D ( !;$D 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ NX1(3#9 [MZ. @ 1 H !D M ( !-D\ 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ NX1(3-GW$[?% 0 -P0 !D ( ! MX%4 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ NX1(3+R,]EBW 0 T@, !D ( !Q5L 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ NX1(3/>..TBW 0 T@, !D M ( !B&< 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ NX1(3!&U)!RV 0 T@, !D ( !FFT M 'AL+W=O&PO=V]R:W-H965T=Q !X;"]W;W)K&UL4$L! A0#% @ MNX1(3(1*4W,* @ #08 !D ( !YW, 'AL+W=O&UL4$L! A0#% @ NX1(3%*YB\P8 @ MU08 !D ( !=GH 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ NX1(3+H9;H6S 0 T@, !D M ( !A($ 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ NX1(3$Z^=D2_ 0 U0, !D ( !C8< 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ NX1( M3%#-Z,KM 0 VP0 !D ( !BX\ 'AL+W=O&PO=V]R:W-H965TP $ !4$ 9 " &UL4$L! A0#% @ NX1(3#BZ&PO=V]R:W-H965T&UL4$L! A0#% @ NX1(3+;Z2O0R" 6S4 !D M ( !YY\ 'AL+W=O&PO=V]R:W-H965T M 9 M " >6M !X;"]W;W)K&UL4$L! A0# M% @ NX1(3-L#=6QG P 50\ !D ( !+;, 'AL+W=O M&PO=V]R:W-H965TY M !X;"]W;W)K&UL4$L! A0#% @ NX1(3",D M.:O6 P 7Q( !D ( !K+L 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ NX1(3&2T(L9?! =18 !D M ( !'<4 'AL+W=O&PO M=V]R:W-H965TY*0( M (4& 9 " 4', !X;"]W;W)K&UL4$L! A0#% @ NX1(3+9N05R7 @ 40D !D ( ! MH&PO=V]R:W-H965T&UL4$L! A0#% M @ NX1(3-(;'W.T @ \ D !D ( !!M< 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ NX1(3!BYE/ # M! SQ0 !D ( !+M\ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ NX1(3-'Z&=!B P 6A !D M ( !&ND 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ NX1(3#9#++U5 P MPT !D ( !N_$ M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ MNX1(3*NP3B'M @ )0L !D ( !Y_T 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ NX1(3'AC0;9+ @ . @ !D M ( !V \! 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ NX1(3!OHF"O 0 U@, !H ( !D1@! 'AL M+W=O&UL4$L! A0#% @ NX1(3 M<8@:] M 0 T@, !H ( !B1H! 'AL+W=O&UL4$L! A0#% @ NX1(3'01YPZ^ 0 U@, !H M ( !?AP! 'AL+W=O&UL4$L! A0#% @ MNX1(3+>_D#&UL4$L! A0#% @ NX1(3#(Q6MC+ 0 E 0 !H M ( !RR ! 'AL+W=O&UL4$L! M A0#% @ NX1(3$QO]I0U @ D 8 !H ( !SB(! 'AL M+W=O&UL4$L! A0#% @ NX1(3*';*&84 M @ N04 !H ( !.R4! 'AL+W=O&UL4$L! A0#% @ NX1(3&LV?7REY0 $I8# !0 M ( !AR&UL4$L! A0#% @ NX1(3!? MB8VD @ 5! T ( !7@T" 'AL+W-T>6QE&PO M=V]R:V)O;VLN>&UL4$L! A0#% @ NX1(3)"%Q\\8 P U#X !H M ( !61<" 'AL+U]R96QS+W=O'P 3QT" end XML 124 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 125 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 127 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 425 455 1 true 124 0 false 13 false false R1.htm 0001000 - Document - DEI Info Cover Page Document Sheet http://www.ensigngroup.net/role/DeiInfoCoverPageDocument DEI Info Cover Page Document Cover 1 false false R2.htm 1001000 - Statement - Consolidated Balance Sheets Sheet http://www.ensigngroup.net/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 1001001 - Statement - Consolidated Balance Sheets Balance Sheet (Paranthetical) Sheet http://www.ensigngroup.net/role/ConsolidatedBalanceSheetsBalanceSheetParanthetical Consolidated Balance Sheets Balance Sheet (Paranthetical) Statements 3 false false R4.htm 1002000 - Statement - Consolidated Statements of Income Sheet http://www.ensigngroup.net/role/ConsolidatedStatementsOfIncome Consolidated Statements of Income Statements 4 false false R5.htm 1005000 - Statement - Consolidated Statement of Stockholders' Equity Statement Sheet http://www.ensigngroup.net/role/ConsolidatedStatementOfStockholdersEquityStatement Consolidated Statement of Stockholders' Equity Statement Statements 5 false false R6.htm 1006000 - Statement - Consolidated Statements of Cash Flows Sheet http://www.ensigngroup.net/role/ConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 6 false false R7.htm 2101100 - Disclosure - Description of Business Sheet http://www.ensigngroup.net/role/DescriptionOfBusiness Description of Business Notes 7 false false R8.htm 2104100 - Disclosure - Significant Accounting Policies Sheet http://www.ensigngroup.net/role/SignificantAccountingPolicies Significant Accounting Policies Notes 8 false false R9.htm 2106100 - Disclosure - Common Stock Sheet http://www.ensigngroup.net/role/CommonStock Common Stock Notes 9 false false R10.htm 2113100 - Disclosure - Computation of Net Income Per Common Share Sheet http://www.ensigngroup.net/role/ComputationOfNetIncomePerCommonShare Computation of Net Income Per Common Share Notes 10 false false R11.htm 2116100 - Disclosure - Fair Value Measurements Sheet http://www.ensigngroup.net/role/FairValueMeasurements Fair Value Measurements Notes 11 false false R12.htm 2119100 - Disclosure - Revenue and Accounts Receivable Sheet http://www.ensigngroup.net/role/RevenueAndAccountsReceivable Revenue and Accounts Receivable Notes 12 false false R13.htm 2125100 - Disclosure - Business Segments Sheet http://www.ensigngroup.net/role/BusinessSegments Business Segments Notes 13 false false R14.htm 2128100 - Disclosure - Acquisitions Sheet http://www.ensigngroup.net/role/Acquisitions Acquisitions Notes 14 false false R15.htm 2134100 - Disclosure - Property and Equipment Sheet http://www.ensigngroup.net/role/PropertyAndEquipment Property and Equipment Notes 15 false false R16.htm 2137100 - Disclosure - Intangible Assets - Net Sheet http://www.ensigngroup.net/role/IntangibleAssetsNet Intangible Assets - Net Notes 16 false false R17.htm 2140100 - Disclosure - Goodwill and Other Indefinite-Lived Intangible Assets Sheet http://www.ensigngroup.net/role/GoodwillAndOtherIndefiniteLivedIntangibleAssets Goodwill and Other Indefinite-Lived Intangible Assets Notes 17 false false R18.htm 2141100 - Disclosure - Restricted and Other Assets Sheet http://www.ensigngroup.net/role/RestrictedAndOtherAssets Restricted and Other Assets Notes 18 false false R19.htm 2142100 - Disclosure - Other Accrued Liabilities Sheet http://www.ensigngroup.net/role/OtherAccruedLiabilities Other Accrued Liabilities Notes 19 false false R20.htm 2145100 - Disclosure - Income Taxes Sheet http://www.ensigngroup.net/role/IncomeTaxes Income Taxes Notes 20 false false R21.htm 2146100 - Disclosure - Debt Sheet http://www.ensigngroup.net/role/Debt Debt Notes 21 false false R22.htm 2147100 - Disclosure - Options and Awards Sheet http://www.ensigngroup.net/role/OptionsAndAwards Options and Awards Notes 22 false false R23.htm 2148100 - Disclosure - Leases Sheet http://www.ensigngroup.net/role/Leases Leases Notes 23 false false R24.htm 2149100 - Disclosure - Self-Insurance Reserves Sheet http://www.ensigngroup.net/role/SelfInsuranceReserves Self-Insurance Reserves Notes 24 false false R25.htm 2150100 - Disclosure - Commitments and Contingencies Sheet http://www.ensigngroup.net/role/CommitmentsAndContingencies Commitments and Contingencies Notes 25 false false R26.htm 2151100 - Disclosure - Divestitures Sheet http://www.ensigngroup.net/role/Divestitures Divestitures Notes 26 false false R27.htm 2152100 - Disclosure - Defined Contribution Plan Sheet http://www.ensigngroup.net/role/DefinedContributionPlan Defined Contribution Plan Notes 27 false false R28.htm 2204201 - Disclosure - Significant Accounting Policies Level 2 (Policies) Sheet http://www.ensigngroup.net/role/SignificantAccountingPoliciesLevel2Policies Significant Accounting Policies Level 2 (Policies) Policies http://www.ensigngroup.net/role/SignificantAccountingPolicies 28 false false R29.htm 2313301 - Disclosure - Computation of Net Income Per Common Share (Tables) Sheet http://www.ensigngroup.net/role/ComputationOfNetIncomePerCommonShareTables Computation of Net Income Per Common Share (Tables) Tables http://www.ensigngroup.net/role/ComputationOfNetIncomePerCommonShare 29 false false R30.htm 2316301 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.ensigngroup.net/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.ensigngroup.net/role/FairValueMeasurements 30 false false R31.htm 2319301 - Disclosure - Revenue and Accounts Receivable (Tables) Sheet http://www.ensigngroup.net/role/RevenueAndAccountsReceivableTables Revenue and Accounts Receivable (Tables) Tables http://www.ensigngroup.net/role/RevenueAndAccountsReceivable 31 false false R32.htm 2325301 - Disclosure - Business Segments (Tables) Sheet http://www.ensigngroup.net/role/BusinessSegmentsTables Business Segments (Tables) Tables http://www.ensigngroup.net/role/BusinessSegments 32 false false R33.htm 2328301 - Disclosure - Acquisitions (Tables) Sheet http://www.ensigngroup.net/role/AcquisitionsTables Acquisitions (Tables) Tables http://www.ensigngroup.net/role/Acquisitions 33 false false R34.htm 2334301 - Disclosure - Property and Equipment (Tables) Sheet http://www.ensigngroup.net/role/PropertyAndEquipmentTables Property and Equipment (Tables) Tables http://www.ensigngroup.net/role/PropertyAndEquipment 34 false false R35.htm 2337301 - Disclosure - Intangible Assets - Net (Tables) Sheet http://www.ensigngroup.net/role/IntangibleAssetsNetTables Intangible Assets - Net (Tables) Tables http://www.ensigngroup.net/role/IntangibleAssetsNet 35 false false R36.htm 2340301 - Disclosure - Goodwill and Other Indefinite-Lived Intangible Assets (Tables) Sheet http://www.ensigngroup.net/role/GoodwillAndOtherIndefiniteLivedIntangibleAssetsTables Goodwill and Other Indefinite-Lived Intangible Assets (Tables) Tables http://www.ensigngroup.net/role/GoodwillAndOtherIndefiniteLivedIntangibleAssets 36 false false R37.htm 2341301 - Disclosure - Restricted and Other Assets (Tables) Sheet http://www.ensigngroup.net/role/RestrictedAndOtherAssetsTables Restricted and Other Assets (Tables) Tables http://www.ensigngroup.net/role/RestrictedAndOtherAssets 37 false false R38.htm 2342301 - Disclosure - Other Accrued Liabilities (Tables) Sheet http://www.ensigngroup.net/role/OtherAccruedLiabilitiesTables Other Accrued Liabilities (Tables) Tables http://www.ensigngroup.net/role/OtherAccruedLiabilities 38 false false R39.htm 2345301 - Disclosure - Income Taxes (Tables) Sheet http://www.ensigngroup.net/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.ensigngroup.net/role/IncomeTaxes 39 false false R40.htm 2346301 - Disclosure - Debt (Tables) Sheet http://www.ensigngroup.net/role/DebtTables Debt (Tables) Tables http://www.ensigngroup.net/role/Debt 40 false false R41.htm 2347301 - Disclosure - Options and Awards (Tables) Sheet http://www.ensigngroup.net/role/OptionsAndAwardsTables Options and Awards (Tables) Tables http://www.ensigngroup.net/role/OptionsAndAwards 41 false false R42.htm 2348301 - Disclosure - Leases (Tables) Sheet http://www.ensigngroup.net/role/LeasesTables Leases (Tables) Tables http://www.ensigngroup.net/role/Leases 42 false false R43.htm 2349301 - Disclosure - Self-Insurance Reserves (Tables) Sheet http://www.ensigngroup.net/role/SelfInsuranceReservesTables Self-Insurance Reserves (Tables) Tables http://www.ensigngroup.net/role/SelfInsuranceReserves 43 false false R44.htm 2401401 - Disclosure - Description of Business (Details) Sheet http://www.ensigngroup.net/role/DescriptionOfBusinessDetails Description of Business (Details) Details http://www.ensigngroup.net/role/DescriptionOfBusiness 44 false false R45.htm 2404402 - Disclosure - Significant Accounting Policies Divestiture (Details) Sheet http://www.ensigngroup.net/role/SignificantAccountingPoliciesDivestitureDetails Significant Accounting Policies Divestiture (Details) Details 45 false false R46.htm 2404403 - Disclosure - Significant Accounting Policies Revenue and Accounts Receivable (Details) Sheet http://www.ensigngroup.net/role/SignificantAccountingPoliciesRevenueAndAccountsReceivableDetails Significant Accounting Policies Revenue and Accounts Receivable (Details) Details 46 false false R47.htm 2404404 - Disclosure - Significant Accounting Policies Property and Equipment (Details) Sheet http://www.ensigngroup.net/role/SignificantAccountingPoliciesPropertyAndEquipmentDetails Significant Accounting Policies Property and Equipment (Details) Details 47 false false R48.htm 2404405 - Disclosure - Significant Accounting Policies Impairment (Details) Sheet http://www.ensigngroup.net/role/SignificantAccountingPoliciesImpairmentDetails Significant Accounting Policies Impairment (Details) Details 48 false false R49.htm 2404406 - Disclosure - Significant Accounting Policies Intangible Assets and Goodwill (Details) Sheet http://www.ensigngroup.net/role/SignificantAccountingPoliciesIntangibleAssetsAndGoodwillDetails Significant Accounting Policies Intangible Assets and Goodwill (Details) Details 49 false false R50.htm 2404408 - Disclosure - Significant Accounting Policies Self-Insurance General and Professional (Details) Sheet http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceGeneralAndProfessionalDetails Significant Accounting Policies Self-Insurance General and Professional (Details) Details 50 false false R51.htm 2404409 - Disclosure - Significant Accounting Policies Self-Insurance Workers' Compensation (Details) Sheet http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceWorkersCompensationDetails Significant Accounting Policies Self-Insurance Workers' Compensation (Details) Details 51 false false R52.htm 2404410 - Disclosure - Significant Accounting Policies Self Insurance Recoveries (Details) Sheet http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceRecoveriesDetails Significant Accounting Policies Self Insurance Recoveries (Details) Details 52 false false R53.htm 2404411 - Disclosure - Significant Accounting Policies Self-Insurance Health Insurance (Details) Sheet http://www.ensigngroup.net/role/SignificantAccountingPoliciesSelfInsuranceHealthInsuranceDetails Significant Accounting Policies Self-Insurance Health Insurance (Details) Details 53 false false R54.htm 2404413 - Disclosure - Significant Accounting Policies Income Taxes (Details) Sheet http://www.ensigngroup.net/role/SignificantAccountingPoliciesIncomeTaxesDetails Significant Accounting Policies Income Taxes (Details) Details 54 false false R55.htm 2404414 - Disclosure - Significant Accounting Policies Recent Accounting Standards Adopted (Details) Sheet http://www.ensigngroup.net/role/SignificantAccountingPoliciesRecentAccountingStandardsAdoptedDetails Significant Accounting Policies Recent Accounting Standards Adopted (Details) Details 55 false false R56.htm 2406401 - Disclosure - Common Stock (Details) Sheet http://www.ensigngroup.net/role/CommonStockDetails Common Stock (Details) Details http://www.ensigngroup.net/role/CommonStock 56 false false R57.htm 2413402 - Disclosure - Computation of Net Income Per Common Share (Details) Sheet http://www.ensigngroup.net/role/ComputationOfNetIncomePerCommonShareDetails Computation of Net Income Per Common Share (Details) Details http://www.ensigngroup.net/role/ComputationOfNetIncomePerCommonShareTables 57 false false R58.htm 2413403 - Disclosure - Computation of Net Income Per Common Share Antidilutive Shares (Details) Sheet http://www.ensigngroup.net/role/ComputationOfNetIncomePerCommonShareAntidilutiveSharesDetails Computation of Net Income Per Common Share Antidilutive Shares (Details) Details 58 false false R59.htm 2416402 - Disclosure - Fair Value Measurements (Details) Sheet http://www.ensigngroup.net/role/FairValueMeasurementsDetails Fair Value Measurements (Details) Details http://www.ensigngroup.net/role/FairValueMeasurementsTables 59 false false R60.htm 2416403 - Disclosure - Fair Value Measurements Investments (Details) Sheet http://www.ensigngroup.net/role/FairValueMeasurementsInvestmentsDetails Fair Value Measurements Investments (Details) Details 60 false false R61.htm 2419402 - Disclosure - Revenue and Accounts Receivable Revenue (Details) Sheet http://www.ensigngroup.net/role/RevenueAndAccountsReceivableRevenueDetails Revenue and Accounts Receivable Revenue (Details) Details 61 false false R62.htm 2419403 - Disclosure - Revenue and Accounts Receivable Accounts Receivable (Details) Sheet http://www.ensigngroup.net/role/RevenueAndAccountsReceivableAccountsReceivableDetails Revenue and Accounts Receivable Accounts Receivable (Details) Details 62 false false R63.htm 2425402 - Disclosure - Business Segments (Details) Sheet http://www.ensigngroup.net/role/BusinessSegmentsDetails Business Segments (Details) Details http://www.ensigngroup.net/role/BusinessSegmentsTables 63 false false R64.htm 2425403 - Disclosure - Business Segments Revenue by Segment (Details) Sheet http://www.ensigngroup.net/role/BusinessSegmentsRevenueBySegmentDetails Business Segments Revenue by Segment (Details) Details 64 false false R65.htm 2425404 - Disclosure - Business Segments Schedule of Segment Reporting Information, by Segment (Details) Sheet http://www.ensigngroup.net/role/BusinessSegmentsScheduleOfSegmentReportingInformationBySegmentDetails Business Segments Schedule of Segment Reporting Information, by Segment (Details) Details 65 false false R66.htm 2428402 - Disclosure - Acquisitions Acquisition Summary (Details) Sheet http://www.ensigngroup.net/role/AcquisitionsAcquisitionSummaryDetails Acquisitions Acquisition Summary (Details) Details 66 false false R67.htm 2428404 - Disclosure - Acquisitions (Details) Sheet http://www.ensigngroup.net/role/AcquisitionsDetails Acquisitions (Details) Details http://www.ensigngroup.net/role/AcquisitionsTables 67 false false R68.htm 2434402 - Disclosure - Property and Equipment (Details) Sheet http://www.ensigngroup.net/role/PropertyAndEquipmentDetails Property and Equipment (Details) Details http://www.ensigngroup.net/role/PropertyAndEquipmentTables 68 false false R69.htm 2434403 - Disclosure - Property and Equipment Additional Disclosures (Details) Sheet http://www.ensigngroup.net/role/PropertyAndEquipmentAdditionalDisclosuresDetails Property and Equipment Additional Disclosures (Details) Details 69 false false R70.htm 2437402 - Disclosure - Intangible Assets - Net (Details) Sheet http://www.ensigngroup.net/role/IntangibleAssetsNetDetails Intangible Assets - Net (Details) Details http://www.ensigngroup.net/role/IntangibleAssetsNetTables 70 false false R71.htm 2437403 - Disclosure - Intangible Assets - Net Additional Disclosures (Details) Sheet http://www.ensigngroup.net/role/IntangibleAssetsNetAdditionalDisclosuresDetails Intangible Assets - Net Additional Disclosures (Details) Details 71 false false R72.htm 2437404 - Disclosure - Intangible Assets - Net Future Amortization (Details) Sheet http://www.ensigngroup.net/role/IntangibleAssetsNetFutureAmortizationDetails Intangible Assets - Net Future Amortization (Details) Details 72 false false R73.htm 2440402 - Disclosure - Goodwill and Other Indefinite-Lived Intangible Assets Goodwill Rollforward (Details) Sheet http://www.ensigngroup.net/role/GoodwillAndOtherIndefiniteLivedIntangibleAssetsGoodwillRollforwardDetails Goodwill and Other Indefinite-Lived Intangible Assets Goodwill Rollforward (Details) Details 73 false false R74.htm 2440403 - Disclosure - Goodwill and Other Indefinite-Lived Intangible Assets Indefinite-lived intangble assets (Details) Sheet http://www.ensigngroup.net/role/GoodwillAndOtherIndefiniteLivedIntangibleAssetsIndefiniteLivedIntangbleAssetsDetails Goodwill and Other Indefinite-Lived Intangible Assets Indefinite-lived intangble assets (Details) Details 74 false false R75.htm 2441402 - Disclosure - Restricted and Other Assets (Details) Sheet http://www.ensigngroup.net/role/RestrictedAndOtherAssetsDetails Restricted and Other Assets (Details) Details http://www.ensigngroup.net/role/RestrictedAndOtherAssetsTables 75 false false R76.htm 2442402 - Disclosure - Other Accrued Liabilities (Details) Sheet http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails Other Accrued Liabilities (Details) Details http://www.ensigngroup.net/role/OtherAccruedLiabilitiesTables 76 false false R77.htm 2445402 - Disclosure - Income Taxes Expense (Details) Sheet http://www.ensigngroup.net/role/IncomeTaxesExpenseDetails Income Taxes Expense (Details) Details 77 false false R78.htm 2445403 - Disclosure - Income Taxes Rate Reconciliation (Details) Sheet http://www.ensigngroup.net/role/IncomeTaxesRateReconciliationDetails Income Taxes Rate Reconciliation (Details) Details 78 false false R79.htm 2445404 - Disclosure - Income Taxes Deferred (Details) Sheet http://www.ensigngroup.net/role/IncomeTaxesDeferredDetails Income Taxes Deferred (Details) Details 79 false false R80.htm 2445405 - Disclosure - Income Taxes Other Disclosures (Details) Sheet http://www.ensigngroup.net/role/IncomeTaxesOtherDisclosuresDetails Income Taxes Other Disclosures (Details) Details 80 false false R81.htm 2446402 - Disclosure - Debt (Details) Sheet http://www.ensigngroup.net/role/DebtDetails Debt (Details) Details http://www.ensigngroup.net/role/DebtTables 81 false false R82.htm 2446403 - Disclosure - Debt Additional Disclosures (Details) Sheet http://www.ensigngroup.net/role/DebtAdditionalDisclosuresDetails Debt Additional Disclosures (Details) Details 82 false false R83.htm 2446404 - Disclosure - Debt Other Additional Disclosures (Details) Sheet http://www.ensigngroup.net/role/DebtOtherAdditionalDisclosuresDetails Debt Other Additional Disclosures (Details) Details 83 false false R84.htm 2446405 - Disclosure - Debt Future Principal Obligations (Details) Sheet http://www.ensigngroup.net/role/DebtFuturePrincipalObligationsDetails Debt Future Principal Obligations (Details) Details 84 false false R85.htm 2447402 - Disclosure - Options and Awards Lead Paragraphs (Details) Sheet http://www.ensigngroup.net/role/OptionsAndAwardsLeadParagraphsDetails Options and Awards Lead Paragraphs (Details) Details 85 false false R86.htm 2447403 - Disclosure - Options and Awards Valuation Assumptions (Details) Sheet http://www.ensigngroup.net/role/OptionsAndAwardsValuationAssumptionsDetails Options and Awards Valuation Assumptions (Details) Details 86 false false R87.htm 2447404 - Disclosure - Options and Awards Exercise Price and Fair Value (Details) Sheet http://www.ensigngroup.net/role/OptionsAndAwardsExercisePriceAndFairValueDetails Options and Awards Exercise Price and Fair Value (Details) Details 87 false false R88.htm 2447405 - Disclosure - Options and Awards Options Outstanding Rollforward (Details) Sheet http://www.ensigngroup.net/role/OptionsAndAwardsOptionsOutstandingRollforwardDetails Options and Awards Options Outstanding Rollforward (Details) Details 88 false false R89.htm 2447406 - Disclosure - Options and Awards Options Outstanding by Exercise Price (Details) Sheet http://www.ensigngroup.net/role/OptionsAndAwardsOptionsOutstandingByExercisePriceDetails Options and Awards Options Outstanding by Exercise Price (Details) Details 89 false false R90.htm 2447407 - Disclosure - Options and Awards Restricted Awards Granted (Details) Sheet http://www.ensigngroup.net/role/OptionsAndAwardsRestrictedAwardsGrantedDetails Options and Awards Restricted Awards Granted (Details) Details 90 false false R91.htm 2447408 - Disclosure - Options and Awards Restricted Award Rollforward (Details) Sheet http://www.ensigngroup.net/role/OptionsAndAwardsRestrictedAwardRollforwardDetails Options and Awards Restricted Award Rollforward (Details) Details 91 false false R92.htm 2447409 - Disclosure - Options and Awards Compensation Expense (Details) Sheet http://www.ensigngroup.net/role/OptionsAndAwardsCompensationExpenseDetails Options and Awards Compensation Expense (Details) Details 92 false false R93.htm 2447410 - Disclosure - Options and Awards Intrinsic Values (Details) Sheet http://www.ensigngroup.net/role/OptionsAndAwardsIntrinsicValuesDetails Options and Awards Intrinsic Values (Details) Details 93 false false R94.htm 2447411 - Disclosure - Options and Awards Subsidiary Equity Plan (Details) Sheet http://www.ensigngroup.net/role/OptionsAndAwardsSubsidiaryEquityPlanDetails Options and Awards Subsidiary Equity Plan (Details) Details 94 false false R95.htm 2448402 - Disclosure - Leases (Details) Sheet http://www.ensigngroup.net/role/LeasesDetails Leases (Details) Details http://www.ensigngroup.net/role/LeasesTables 95 false false R96.htm 2448403 - Disclosure - Leases Additional Disclosures (Details) Sheet http://www.ensigngroup.net/role/LeasesAdditionalDisclosuresDetails Leases Additional Disclosures (Details) Details 96 false false R97.htm 2448404 - Disclosure - Leases Sale Leaseback Transactions (Details) Sheet http://www.ensigngroup.net/role/LeasesSaleLeasebackTransactionsDetails Leases Sale Leaseback Transactions (Details) Details 97 false false R98.htm 2448405 - Disclosure - Leases Future minimum lease payments (Details) Sheet http://www.ensigngroup.net/role/LeasesFutureMinimumLeasePaymentsDetails Leases Future minimum lease payments (Details) Details 98 false false R99.htm 2449402 - Disclosure - Self-Insurance Reserves (Details) Sheet http://www.ensigngroup.net/role/SelfInsuranceReservesDetails Self-Insurance Reserves (Details) Details http://www.ensigngroup.net/role/SelfInsuranceReservesTables 99 false false R100.htm 2450401 - Disclosure - Commitments and Contingencies Litigation (Details) Sheet http://www.ensigngroup.net/role/CommitmentsAndContingenciesLitigationDetails Commitments and Contingencies Litigation (Details) Details 100 false false R101.htm 2450403 - Disclosure - Commitments and Contingencies Medicare Revenue Recoupments (Details) Sheet http://www.ensigngroup.net/role/CommitmentsAndContingenciesMedicareRevenueRecoupmentsDetails Commitments and Contingencies Medicare Revenue Recoupments (Details) Details 101 false false R102.htm 2450404 - Disclosure - Commitments and Contingencies Other Matters (Details) Sheet http://www.ensigngroup.net/role/CommitmentsAndContingenciesOtherMattersDetails Commitments and Contingencies Other Matters (Details) Details 102 false false R103.htm 2450405 - Disclosure - Commitments and Contingencies Concentrations (Details) Sheet http://www.ensigngroup.net/role/CommitmentsAndContingenciesConcentrationsDetails Commitments and Contingencies Concentrations (Details) Details 103 false false R104.htm 2450406 - Disclosure - Commitments and Contingencies Cash in Excess of FDIC Limits (Details) Sheet http://www.ensigngroup.net/role/CommitmentsAndContingenciesCashInExcessOfFdicLimitsDetails Commitments and Contingencies Cash in Excess of FDIC Limits (Details) Details 104 false false R105.htm 2451402 - Disclosure - Divestitures (Details) Sheet http://www.ensigngroup.net/role/DivestituresDetails Divestitures (Details) Details http://www.ensigngroup.net/role/Divestitures 105 false false R106.htm 2452402 - Disclosure - Defined Contribution Plan (Details) Sheet http://www.ensigngroup.net/role/DefinedContributionPlanDetails Defined Contribution Plan (Details) Details http://www.ensigngroup.net/role/DefinedContributionPlan 106 false false All Reports Book All Reports ensg-20171231.xml ensg-20171231.xsd ensg-20171231_cal.xml ensg-20171231_def.xml ensg-20171231_lab.xml ensg-20171231_pre.xml http://xbrl.sec.gov/stpr/2011-01-31 http://fasb.org/us-gaap/2017-01-31 http://xbrl.sec.gov/sic/2011-01-31 http://xbrl.sec.gov/dei/2014-01-31 true true ZIP 129 0001125376-18-000028-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001125376-18-000028-xbrl.zip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
MV'-$9&8I'QIW>]"4TG:4 ,'_T>,#G[,/$C E+,?Y40BQS2M3*?-]$:$Y<@\) MW#$OSE/9TB2-9%S =>([AJ>\XT5*W 8B@.3+_!#A/,D72SRU5/@4;Y&9.DBF M$F%O,*T\ S.KA/.8RSF="2RWU/9L^!^9]9F[@7 ?4.'=9-W2ER36TS=6DQ)/HUCHI-<\"RX%!09P _!0Y5)^3>E>$*FA+^+W*$U@\U@ M>4E7E_/Y\]&4P7NA"]8< 9#KD?NM2X^7OKJ9]UU>]5BRXK./0VF;?)7=9IXZB+5J#>UBQ92LH !3 K\Z MW]<<<-_"V@%>;MMVM]7LMCI=V[X8]"^O1\/K3K-S?3[J7IQ7;NU45)%@O3_Y M[L/%Q]^NV-?1_WOUI;X!;A0C6' V F\$MR)YX AM#PH@9^I6RU*-9]C59*+V M=RK@89R%X#;/*3$[\ D99#F>57C/%LZ?. MXK0(7XG\YL\/9#0%#[T(3Y-G&[(PB!O'%Q;V8%MW&1KL M!NB#9P+ZAGK0MFUV0>A]-&7Z$RVBJQ5=ORTYB0/#S''DT' M.[W$(EX\#"]J*YNZ;^H1HYX6HZY&VZC_P;/Y]D)&PQX_);XKU^Z1A'LF6P45 MT4^#WRK&2>(XXCCBN$,13H/SW*P[NUW++;1#&M&FD$);1XOJYEQ!ZXFN97>T M-1(V92GQ/NKJ=SA=33!0,QAH-ZUFITTP0#! ,'#",- :@#6@K5N?*4OY4ABH M,B!7>P="E.+T!:].7CCKETQFP":"3L&LG?S9X"_JR\!Y MBCS&,,G1A95(I(P1J7;7:K5(I$BD2*2TB10>=FV22)D3]:R[ %ZJX\F4AWCH M+:8383C*"B..JP'AB.-V(1SE(>Z2A[BU/5L[>[5K=5H#77!ER@(?GX=7WPV" MVDG$:]MJMCNZ666Q[#7*2WI# D,"LT5*25-?$-$4UC M#O3%Y8]]+[E&7G1]U=+QB!88>"U]946>I,MI6WXD>R1[1=GK=[6Y5B37) MH*JQU%6P-ZVKCHQ^R>Q9'5N?:#Z5WEA!Y:+:F:6TAT.RN$%+MJQ6=V^YQCNI MRUI(<(WCER2J]1!5\"7[+5*;-8F$HJP4Z:%(CR8ZK>^?22)&(D8B1B)6%^NRQ!GM7MVMR*]AHJ\*8]EG M:8-;,@Y3;%JT'W_O&*HV;4W"/5.LDII/G4Y%Y6?6T*T6;$1AYLIM P(P C!- M(8,*ZV<1@!& $8 1@%5=\L$>5+1A<:H 5O I?Q(-6]==O[>!%8A6VW:[:WLG MHY =?-E-FL!(]' /7,_W2NW-LU;E<>(D:1)&<[DEE(2%GO'>/5]L%A7Z1D^B M<*JQ9[0%0XQG\GW^W!)-QL/I+/)BZB!=6O_"4TKJFCI(K\;J"&OOJD1WD$ M6N;<_PM5EB\94 :W';@Y)+TDO2>_I2&_]XF/5%-3*MO#$:; % M'<]8P!/<&LRV!6]XP"=>J M;$K1R:UI^R$,SL9\G+J)AUDW*D(9&^E.&2-C=J/Z8HRF,$C5RL@@.:N7ECI. MT6HVAB1:)G((B5;]18L*=%.$;FL27OV5>LE<)+^#22@RZLG!@OM>=QK:CE/6 M>M.YQK4*ZZ6.:BTN%91\,44 *$Y'?UU?7NZ51]Z M/FR0?&]=3$QA% IC'%AK';,\O6[JBY97TA;(%"FD:#J)FQ9QT[?)2^)6;3#2 MKKV-*>JR%TYQL%D4WGNQQJWBI^LUGMZ!K8Y=E9&Z"WWI1%>]0CI'5BKX!.6_ M/6A4U/>6Y)_DG^2_!O)?D9%/\K^C_->WH'9M"U:OCKZI>?1?[SB["*? A/._ MQ:7>I-V0WW MPX<&8_BFI=ZH7B!OC?C$YVY2*I.=E\&&E[7L1O-'BSW -#B\7KPEN\=9>P?6 M>_@17JIM$3;1O/",$A@;6R&Z\O+/ RWEG_N'+8'\PN+3ARW 7*NYUV\7T[ Z MNGVJWTSUFP_ =VVJ-DKUFRNG)#'J81AU:^>;$MDW\^WE&G?J=<&7>O.V$G[> M(W'K'WL[#4ZL&$&)X[0:ELVZL]O(=:,4<$]WJ9T]YJV8VQ:S3KDZ=L_J-JEX MW4&,^^--;R,8J!D,M&RKW];6W]:4I7PI#%3I.M7?A, 6I$[@RCZHN&&;3%*? M.:X+U:YM-8?5%SPWA5>JUL<&.8G&*>I3E*ZN->Q2 MG3%RB)^19N%\9V[$QUXUFJMV(M2VVFUM^9VF+#*YA>9HFQI*1*='72_(0WI. MT\4XC=!#(FOMT<)(EMW6=SSWV(TU(>X?>8E:)]NI M(E/QT;(MW;:A+7A-82EMY9'(22/)6Z$3%=?=E#!6XAJ>MC"2Z_@(<;\D6*5"E, @ MP_51EW%HZRL"2"XCN8SD,FXK>;;5;%6_L7<:LD<)D'@4>A9QUU,1TV#,G&D( MT_[?Y_9,6+7+Z3EEB6DVKU]&FI4Y#8L@S>X2*GR(^ M<[R=SJUKBZTU:G>;>T@-(5JOTBKNU M%^T//'EA%M SV'-->XZ=A-OT!#5M=:!>WMVD#A6D;+!>.A7%$IY#,U/8!^\[ MD7.>QEDM!J%9+;1P/:"N'GVQ6FVKV:\H+O,<@M:"\5X*DO7I>%7D;QO6L=BT MYS]IG'B3>;5]I!B3'9Y4+REVY\0LXBYRR9@Y8#ZZV+J)PW>^DZ 9&6YL-K4I M!H1]G58(M!,>V7UK.%PU)G::-XY8TZ@Z5G.P>D1JEV=90.=XQMW$N^?^W&(/ M7G('JQ" (>^,D1^FP 2E-2CT-U:;7_K(W;:&MB9J8RU([!(V!\%A/$#F6M.) M#/@("9#Z"4X"K\?Z6R,W:=17P,K"A;B.2:2RIAASG2B: VT>G&B\18+D>QA!X*Q1&U_&L8),&/B ;C-%<*A<,DE\KVIEX@T M)UB60'"C,YOYH(Q%+A2LQ15V])A%'CSZ_P-5P/ATYH=S%-&S'"X7]>,:[/? MYW$LGI1Q1!IS^<7RL]1-[(;#@#EP3C"VQ(7%20 ^^#Y<KC[_7'5G=B;L?2NJP0)9-Z^64U_>& M^QZ_QY:)"1)MBFOI>]^0WQ)84Q:$^#@'!H8HKD#OA@=\XN48F#U:+#;><(.K M"A#VOWRL"1A;6P!CJSI@_!MPR8Q'P [!+?-#D)$21\5"?8"Q>Y?WC$0F%&(* M9.% 4R3+%#Y&'FY&I1$^:(.^6;B.*P#;V+WOI!%ZYEI1!RF3)M+R6@-C"ZK# MI"4-6E9&A';1I$#RQ4RTDQP7R9K<>2#H?Z5.E$A@@1N[XD&]_$']%12^7#Q@ M$J81+&?A"=QQ[\3[+("&R O36.'PILDX?ARJH2FH$Q_BDJT1;S(VE@;;%;HY M")D'I'&354JE <+ ;8!")TBCA#36U*PTXY&#NU'/'&^E/+U!>UBJ7ZU:.JN$ MN&-O+-#@SKD'A8TJ=M/*6<*NEB#K18K;%C\*6'X(4Q^ ?S+)VMPN.(*++X&W M\P:VC9(GY?K@&WD33_3+!2;GH#E@R#\!=X*=[OC2-0J*XE9RFB)LE0L.O- I MB"[(]B#Y[ PZ5_VKBU?_ M6&+*(N\\T3)W7=CBV3RM4>W)CWCY6T QH)1\DJ0>NCIK\B5VLEH*A0, =;?I M#0V, OSIW/A>? >7"@@%O'Z"8 M2L$VC<#\BN(EV;P%*0=%"5:8O%18OY,4OTC!> 5R,K2XUD0Z?F9WX0,^TI(C M"0"Y,[,P M%L@:EQ=PZGR#R[,+03:\J6!$<00FCM/I3-S44*[EQ@L$/X((P.#"P,+%A%F! M).VW('SP^?A6#%;9P6(\X'1]XZB*[KPX"2,, [,$V'R<"8M@@DF: M "XS%WCA5KY?L29XJU$(+@H,2\XMG %1A1TX 85R[\5A%,L0TV((^&"4"9#F M6+B2&0E D?ECF.]E*O@W^QH\H&]"A$,\),3'\GF;1'TCF8 R;I(*),'P#U!> M*%XIV'N,_E3AY& ,ZR)5"/>O\";&B!9[70AOO<$5\P#2T-T$VT!@%Q WMWRD MU0,Z7@1CQTN6R!J+@-W,ZQD$E#BMZ")=WCP&+9SA,$+03WAQUN+S) JGK-UM M-']$_FS9^(<(C0@@ )L84OH80!< MM DZ:[!(@,R.]X05:8BM]8)]I,UF\))Y6S:!55'O-:;R%F;PZ++9;=D7S5[[ M\KS5A/^]NKKJCSJ]BZOV]>CRO+-/,UALYY6SE)L9=*J5.M/IZHF/*[V,OUR] MOV;O/GSY_?/HP\45^WSUY>KS'U=?=/#>OB=8N3.^O &[XUB?F5SQG,%5KF0G M(1J$PF3$#5_T2,"4X,(+1B_=2^:(R6&*KK(2530V>(316;GS@OIYJ^!1'C!\ MJR7V8_3R/=&WO/"4DD0M"Q1^+KXF"*.IXY<--+PF?[!<1I?[OKKFEU?-5^)S M/'/<[//ST5#N9,A!.FD29E_('"?QS8,W3N[@:B"$2I=P@;LPN/@V^V-E^1;C M+J:A+E(H>FL3D[?/9)5CZK9_?#I)8VT>B9K3RVX?'O3M_S][7];<.'*L^WS. MKT!TW+E61T :K"38XW&$5KO/:4^/6_)US"-$%$5X0( &0*DUO_Y65A4VDI)( MJD 6P R'IR4* M9^>56N1SV=GSWCBZ^4^_>D4D#K^D';S?UY6VIOEX>>5^^ MAGV XI0U=-T?_=9;TG_EP4YFM/R:)A.29?PDX8L(C#UO06ADQ,T9<=^TZ@)] MD'^0?Y!_D'\.0A^TKA!T>[,^#U$:K:#U^:\D_9VDV9_800N)LVT;!R+OHYNK6K+_C>L M6$_9"S]B.0@B*ZWB7)YC,-B%@?4=.]V+1T$EXNTA2*K5A!V3Q-'D/(;&NEZ?PNA#NLL6WKIB/-V%9E MQ]O6SZB&>PP)T](];XB00$@@)(I0J:>;KK19S0@)A$3G(3%T=!.UA!1O0Z%H M1ZMN2.2'LTQC$RA9(^0PA4Y%K0ZC[,_ .I.J(&^;X\[W$:;?$^DZA,CNJK0^ M@<_0K5'[1^4(/@0?@F\9?/90=U'S(?@0? < WV"@&X/5&0@(OEW AV=1/UVR M_IO08RI*X!U(.JMUFH*F]H2/$J#$8".)VH!G"PG*!T7IP)86B'F+-JKP$<8N M%5)W?<.33',3\81X.G8\U1KM(ZX05WC&MB$Y3-VRI&7Z]041>,2V0_GWY#EK" F$1.$$_'CB>L-D-<*8"KSN'&U*T1]CB5X40I%-90 MJ]JLI385-A7(0;*@#MR[M%:W4U?E3VO%D_.Q.T M$XS7MM'1?VFZNS6"0A*%Y,&2V8>Z,917SX5"$H4D"DD5B(Q"4J(EJ0_EM7!! M&8DR$F6D$D1&&2F/ED-+']HM=5Q$(?ER0//'G.4\K+E^;PNK$2T*8W(ZY2%% MTS)^^.D5*NY(Q"TE9!\6]^]%EH>39_Y1& F#[\\_?2[>Z"K,QI1&BY3WNZL/6AC0#_QQ?GIUXSH>9:O1N6FYULW0 MLZY<]_+Z8C2\N# OAMZ'ORRQ57WW[\(9I?8OY$G[ELS\EX_A=H2,_*.(S[_< MG?_RU\\77ZZU\]O;Z[M;K78L3%\DWQE<=;5K#EY!4NTA#?L(T%>'(_Q>_Y8X M26=^U/P>N*9\,!/;VIA$D;CFYP_&!_8[U4GCXO?M=_$I#/(I_9&^I%"%5,U% M_CPCGXH?5C:Q6E3]=*PZ)!VN/=+<_(!-K,G[X6T%O-9&$/>_[_;10;_]G;-QW='IE=XXS'%OH5H$R:954MW#I"\N8Z6&_/7F%JT)&W7MO\7 M^X Z:N?@33X0[4LX(=K);\1/,VFE:5CN'>!],5P]5[!!K4UD]*,=X M2!^DCQ3!99HHN&2FW2)O(6\M\=;&YW:H#%'8(WT.*+#LVFLLQ6F8H: M3U5$L**AAO1!^G2 /ALKPP/(^,-;8V]E3".O(1:1/BBK.B:K.G(HV68"YQ?B M9T3SQ_]9A%D(#C9=2X:6>W^E6;M-89PSK[NDZ3_K=*+&65IQ_8$(TD(;$4]V M$Q&U.0#NPT:V*%I0M+0N6DY&TGJXK2*D+VR#924*"QY5F&2?LD49\6%[.)87 M9<#!94 GM @:'^C7H&A!T8*B91]^S5!Z(!+]&A0\Z-<54%DM+\4\0>8J^> MIN;IKM,^]E2!$6HV1!?:C8@N1%IIK-T%U+WA3[ MOFLV+*_Z"?H@S.XC&"LU'B_H&L;/LM@'19!J]&E5]AAGV,?W ,JKN M-/-0%3':MH^%B.@Q(DXH)&Q3-JL2 M9GLC(A 1G4?$B51(H$6%@.DY8/YO-7T<%4GS/3&M_+6T\G$8A?FSEJ=^0+38 MGQ%9[*,0!9630UTA7,MG79A8KI32Z\\QZM"65_;=]S-4A!9":ZM8]ZA];*'# MALA#Y"U7##OMFTNJ8 B5&D(+[46$%D*KZ] ZL0:82X[V(B)O__;B0%KGS-XK M-4PD_^ERD=%%DE1+2<0&86;3<(YC.C"7?!<"F1XFDQ]$>[4PC^FP2DP?2?3- MWJ".*J*X;1<-$77$B#HQ==>6%TGB\5X6UF,EO=CY^?Y?D?B2-H_ H ML?.$:Q7)?29 M.L#.-%.%?=IVIE&:H31#:=9>M,+434M:PZ7W$^VX QDH[%#8H;!K+5)DZ5Y; MYX=HNJ$T0VF&TFROCJ@YL Y/,U78!Z492C.%V!&EV7:.J*<;GKQ!1.B'HJQ# M68>R3DE99[NZ,51 UJG"/N^UW&K)##_F,-E]W?5[6UB-:%$8D],I87+/M(P? M#D^UUQ97V^)_+[(\G#SSC\*8RMW\DVU0#,E\@?-90OGY#U8AJ9'OTT??D\831M$#^9:'/Z$Y5*VKW/-B'WXX<0E)Z?923/-#^G#QC3"^B+ M^>/_+$+8H@EOT1J23->>IN%XJH69EC_/0:?"=?PK8/X7U;2:K\WIZI( ODW* M*TV212J'-I0F4A[$A+^<)TY](FDG44D/='*TF^>[T9G2M$_\Q2<%0I&Q'Y*:GS\8']COU(D;%[^O MH?9=.*,,_PL5J]^2F;\23WD*@WQ*?Z3O*!Q+ZA=&_CPCGXH?5EZ^6E0]E;ST M)YVUY0&;)Z/S)7FC']YV6->ZS>*5WG?[?K]]M_3\%BH[E,R;9K\^<:#<)U' M'_0;Q?X6,95RY?8!"F;>(.OKI.3:M5UB4M]\$:^:AC@78A=7:YL1;4?87Q]E>CD-J&7S:&5!>18TC+W55E=P\"D*-11M8VI;)'J(Q, MW=W#5 95^ &5D0Q(;2."^ZN,3-W!T:NHC+9"SC;IJT>IC)RAO-HL5$:]5T9W M]$_$G^1DITA8[U229>L#4UJ*O"J;C#JI4]TX]IH1*KZ-G1."A? MQ[L[IPE(.;/[WV[,\L>FS-/(>,E?X9$F&0)655^5,BY^VD+6A*65$2!F0\94*!(.5!IRSO M/"4Q>:)"E8/FGCPG(DTWC*GD$7_0BV31 ]TV^G9C017Q.FD(H.:Z'+9C3D%"A>^,TWI=>%,4]QG*3!TY62'"!-=:K0.8UW.=,^3QJ9S00$=%:2HKGUC7MU MD6++F>Z)ZD4F1B83+N'A$7X4Z=K](F_9IF_KS0.=2H M GX%C1/X,_^!9,)^HARLC:=^"I]D"VH1^%F!T %L(H2DD)B)-UYV.["Z&.,$F<+*&/X-05) M_9FNZ[MVLBI*_B!I\A$,!)#Y4G2I=>;^(.5!9QI=M@;[SRC!)>H2#BC04B(* MG>@%E+&;BO,3HQ25EUI(Z,*(BN,3GD M,_$RHPX DT=,O !QP@EHATD(8@H\R 2J->D2CJEWT+Q?.]G M(3@93-^S>)8VI\X#54AAPFY/05T(;4RD$BZ?2$PK%(* 6D0>Z4O;LND L!#V+)'$'K:9$P2CPGZ"*47BHPJ5B M=6.M5YBN)E#M:"_(8>+!@5T;ML,B%EQL<"V$6HMO,F,?-BD +J)FJ,\\QX1> M#%8%1T&.V3^5!'QJ%R C 4562A66C11 M6OQ&6CS1,G@H4!9#UK=UZH. I[1DQA9=\8P"#,*_JX%>)H >?>HW+JB-2GL(K3J'!OY41O);6IX,I3WKF'M,"K M6BAI1CEY0%O(D&P++W0[GY.;ZIP[J=OKSVOWG]4=O*9N7A)_E/]8\(2JL#D+ M76PDVOB7UZ.W;4@QB5%Q66(,6$:B("N.1_XN% 7=J*SL(@!A)6Z"-/A*K^^= MZ#L2/R;1HXB94 LF%1'450=*&% 95V807_%!5Y^"WN87^@&HY5G938-_N'0( MNNJ 43L'(M_WU,S2)79=,FU+']ERSL9D.6"FY>K6FBS] WM@WDBW!I);+_7# M ^MPPXJ[)_K8YU-Y]ES2.%1IQ,-KEG"]M1'Y7GA<+ !8I0OD4Y]*AK30#O2V M%Z,SC2"\ONXF*6^7A=_E4"DC0>=XW2S'FEI!+'<.R M+$R84"P M/Q1G=FF8_7ZFW?AA!/'S/.$&Z3/?C+^3(&0F*P"/_Q(&XCB2M>BI7%K6XV3I M*#0CX$U'KW%3Z0.]D'(!7QR0^[P( E#^"IF)+,C;,& X1>8)'(:"Q5$ZT;6V M7GX,Z2TA?0$PJ6KA4$IQ?P%?7KX$<\7!9:#OV%Q@%5+@1\^P4WD:/CS0*\9I MDF6GQ3,8K3)FZ+V6,K/(J8'&&\BPMZWS4"U>'0F-_2\>?Q5ODH5E4R&JN'/8 MB2 $%Q06P,+VU0$):XZ5E+'XLC-6^4+0VX::%,DL' N+K7$:51S)\>>PD['R M N$GO?^PB24E.TM)R0<)"U#V^KN?4HAR)52WD*DMM:"65TH?0:GOY-\'OGCBF^H/ -.9_"D]BCA-B28C\DC=QWX 4 8P<:?:>=L.2"#J#?- M. XDC[_JL!0K!I07"^9GHOS@"AY/UKT&715+:N1_6S"4I(3^$XO$+29KBSUE M+=^JKET4:B)#M+F:1IP!,@8*B290REREM@T!32A@(8ZNHV1,W_AEP=@G MK795=8V=A&F6%^@3WZ&0!Y=)Q6E()0.IF%>4S#* MZI>ZG&I1571)4PSUD;0FY&IHBH'N2DI]+S3%H#U- 4[IJK\ 3,/](#O M+%5WCU3L*XYC0W('9,+.1QX;40^FTXN>%<-Y<5,R SYUKE[]^/KUG[-$\CT[256N(A/*:R=N>O!3!$"I:DC$A M@5@S-YBUDY=W'&DYNN?(2JKB!P@U.]D?1THQ5T]9-=[67 MP*[[#:*9FR_@/S2':W!_9$(:(>U>F1UO>/9+EDBM1H8Y=8QQZM4Z=)_EY$/( M&T("+!@*B<6.IBJ;H\IK+,\<1:U:5'AB 0S\2'@*BWH6RMJDLCB@# 3'?\O& MUI*IO>*>YC.6(U7=\_F M;W@XNT@S%@>(A;\,&@B"3=5(D(YD^S)XU89:[+Y#FS>9[]Q8S:< M'"*+.;><'-(5DJF+YR-J+&R[NN=@:^%6Q53OI)&T(3TH='K<=!EDBSU:C8MC MUV6T=%Z>!+#-6)JND*R[0J=?EH[IX'@YM'2VD4;2+&,4.KVV=!Q]Y.!\";1T MMI$MTOA%(9)U5^CTR=*Q=<=9S4-%2P8E,,@$JX5PN$HLY6DO+W1MO^CS$Q]Z+JZ*2_X@M/, M-M4Z+T\S>WVFUYM#NIH3O> B?LNOE*+CYVUF>0UMZ]HTASX_%.8TZ\<\R<5;6_C@-?"3I,HT#[/H#*8 M5ZNM[/PN;*6=%L-_PGA,YD6)0=7TLIFY/J<:+.&C7S0"M1Q^T:.^[ .B/4V) MZ$E<5-]F4];QXYZ\5AF10/'V'"CP4I$$M )M=+: )-Z5WH-IR18 M0/9VL_D>;U_<[*_'6AA7!0OU,2ZU!=6&0["!7+"&-7WZBB5"&;D?C1>\=K/L M:Q(435%JO8@?PD?"NKWG:1(UOAE:/Y%9R-_NC9$5+Z^2U;37-HVUVQ4]I3+> M_H51 *XE&/^<@-R!/GEQ2]8AHM-*MJZZCDV;#&LXU>*J*I M9IB(,A'>+7&Y=A=V_64"O]X>8IT,>U$L-:1744G^C3.': _?*'EP,7.?J8N2-O)O1Q:5UY5X[INVU+L .F7__@D2[)='D]',Q@4&. M^"K;>5D_+??VAEX.H1]%SU#3.SEEHQ\$%!Y(S!JD :-2YIQ0IN"5+;4. G/6 M>0$P0:">:4$7-X<&$Y$?SK037I]:>VQ*6/>S)/Y8UFGZ#P\I>:!< [.SR"G, MD*)8@L$*K'$8Z\;)41F%LS _T[[P(O!J E?YU1E+^R^^JQ("81J1UEOTC1Z.R>=81:3R$I%7_"A!-6&N/D *0%>Z]/8!\)F]V55=18HV&C:7#9 M" \Z[JW99WGM)5R)$QPN*2[IOW'HO])CW2];+58LK+?R;J;<^130(+GVAM5K MG6DWHO)G[5NS?IK4#*)LG$"K7\ )+TB_!'[S@X1S>!UY)=8*0+,FP1QW$EOM MRB-0C9'EK,V6N[9R._2BB[:<9;KREGD?^?'O)*])3;;A'#0-B<#;TXNA&N/: M#4]3WN9#C"&Z?^:7:I'_Q"= '8[C-I:M;3"EE/K0C=^@1=;EO;^SQE3?LN%- MPMNWTBMA[]=S4]'#=PY]8:%5*374X0D%8W2Y.O/N1?M)M)XM58P@Q89F&_SI M*4E_)VGV)]XE,\ZXJ5-4?#*49=J)$/34_/>YLON7S]R=7%R[]BD?F1W66'C= M([OTY]!2IAB1QYT^5E0K2FW%.D53&"%%WF2/C?[!G/_NQJ(5G079H_,2/-BL3X^ ME!,6S*;IP-QNJAL]<;8".H- M4E.9.R)$N)%!U2*5\D;.1SC$7/XQSA#,U?27(>8B'E (DK&83% PHW@"DQML MH,T](3&?B\F4C)B#R,L07\@; MEM#+J3=#=YZUV ,//0T):Y-1S*ZENT0WC7)&XRM :194HK_YT3,;)@6?BWB% M"% 4K\_% 5<7K-45_2[1#FO-6*H.LM\&QSHRF;D*HD&?X# (Z5:0;%76U>1B M[?ZFG 5;N;2\V9A $"TY""4JQ^G3J)KSH9?XTLXU[BOF6(0%T)IA2.@U.%^D MXZG/VT65?<5+.PND>Y;5Q%MI,_$>)>R%LOJM=>C W1(Z.1S&1Q6#KNE+LXYX M3,'I]29QR]O,! 6;WPQ=+JCG!'\=IR$,@F"R/-MHXP4!*6KUVC3G&W*?0JA MXQ$"<].-I(@[90RB],9)<\F7-^ZG#IS\4GSF/8/;K_K9!F.AMT9B"H_[B+R/D3Q43 M0F2,342H67XL.+^89;R3MI@"06;S*'FF>.%JC/]6]KZNL,)F]]Y3PW82BBC? MC&K A]KCQ1"INJF6)-2FTK[67()2/JJ M:=9!RZF\[\41:]-&-]18-#UB*&4;7E%-6G03:B0ES7Z2-Y'*T4U#UJ(DM2%O MO7<2GV,U:(Z@TE=[DL?YDIO#,$_Y8>9'\Q1:\0G4K(\UU,0[GTX%Z'D M:@(YD[=A<1K] -L"H]%NR5$^X6:S9IIO3],RW]=.9#[!@-J0F;VP5*_,DOA MG(4KWM]V7P6/G7LO$VK.P.3B@(F]DZJS-FPUM7.Y&12DBX?LHX@^L>;:M=&A MI8(6VF#F_YM*42XBV(#&2K\OG4+",-)G)E,B4L:@JLG*_*B<32YF#%GTQ,[* M[V16%YL6N)D?M:OG5!K<'?&9;)GG12S?I>@33M5B!J>4Q3'NFN.]*E*[1$*^ M&7)/R+;P1J10Y$R[( ]AS&)Y*V,I_E2&OJK! &(H-Q-UAR:69$IT5PPV!-$] MB4+R6$X%#,#2R4DU9H+)!6:$SN@?BRCT32FF;L& KCHGUN/8[(DPQHV:H]#& M=,$L7*KL0C;8W8PAU%_E<]PE+N&#?63OHJYO4=*6^ M&*VQYDM$I#UK]HA-BAD7R2*C&F26Q&$.ZJ,6%*T:ZXZ?QU'E93"I?*;]D[4K MA>]>6C'3#N*!<$EAIZP=.YEEBUDQ,IG%@BD?I&R4<$[]Z"!K2(=:@(&W?6=Z MA _TJY^#V1AB^<.TB9@&+@EU6CN3J*&?(9$1GT]/+0#R/TC]-PZ@(7+ > MOTUYTPS=TQ=DIJH5]T)L&=^6$S5A\!$@F8KKT?A!! IZQ.&LK_#GN MNY]I5XMR[B:3DFQZ2@)SO0O7KGXP4Y,(W)JJWH\/=BP7"IE6&9_\6+Y;@5D^ MV*[&;WQ.. O%5?&#^JB/<9$86X[-H6N&QO]T[Y,9Q*A>&0@+ZZ^[J]P"R[A! MNDQNG7TL9KP1/P6.A&'5?C;5H"B%R]O*,(71"WQ4Y5.Q1C^@]E$&PV6*@2U; M9U^^FE993\#\A3R=E_W6?TV3F/XXYAJ(7[Q#3OGP9G1!/Q]>6S?NI3/TG)$Q MN#:<<]=PO1OW^@ARRK\1: JI5935FJ2MIU/*,:ZO><@-C(9T$8E\]A :4U+G MBP65J8H7*=F7'(DB]R*>E*S8A 4L0 MR*IG1/Y3DLGQJ];HMKM(N$_J.= MW)S?7GQO&1:5DC M@W_-_5QH48.-#2HCCR&U4(KF6@RRNB#*G=L88IIH4DX6%N*V^JU@K M&[8<\!*!VEU/(76;6:C4?WO$6*DG*W%6#=Y-ZTF.0H''Q? 284X*LE:J(GXN MN6,IRX*U_&=]KC4@!;S!9&DYU2IJ&I)-9*LR- 3+5([; MNDSIM1>0*1!7VM>NRL,*O>=!PKA88*[0P =^CW:(?,@I72*\P&0:E>\+-@8% M)$$).#!K*=2IH_-->RDPFQI\NY3? MP1V:0)R; AF*)59^,]5/132_T)9E(=LF;R$H)C:ZW =V2@ >"=W+L/(SWG@Z M&ZQ7<$Q1IJ3+"VW9NF/)&=NCP_!-KN>9>\[.KRGF3T7:GEZREI2O8XP'_G^@ M%><\FM3C'("S$WM!$JA4AHD0P%J9TL^YJ%UO)(P4L83:U9. U'L(2R6F11F$F/;^O6\LO>9IUJ= M,392]@ESZ:W$M=R9 'HE#4GXS*]0 0XW>+97EE>;P5KVTM>X9 M=]WHOG_F/L/%(H=\">TWDLMVW5#^[.+>/=<*@AO.W8QKI6;0JQ0$>=F3H/H, M CS/ZR'*_4 M_+-Z$*_F&7*3Y_SV4AN:'C,APLI[@AA1TT$3LUS+Z&%& S<6+#,*YQ:E]L*"WT-//$V+[#FJ_B).,1P$OHA-?M2 MRC&0V*%-233/N"@5QEE,_3?JT*PR"C6.Y@LX0J#F5$U#%PFX# ]PXLI$V)0^ MHK@!?," \*J4H K;/T'0G8 I6\BKLZY+XD:(*\P:*NE>G$V(E)5&X$LDCL(C M^ L7-C:$3ADW>@P/FT_# M29Z)E;#68RR7MKJ2NW':C/I=@C599@:39"S;JIRXS5X0A#2]50R8A[/=XMLI M#<")+$?0BV0QY@?7'].\W1>GB-S6*T32F@<)(S%CD[9&<"CN%1XB9+ GHP\<0U6$D%CFK1;::F-(.KU4M6WQ0]!&< ME) ^),#7YJ?^J9&5*HQM:*QVLTAA^\&X%E%2GME7?/UDK0E'G;$'PE(7F2D' M74NXL=9@-U[<5O /9 &R;!:40/N40.>+!_"8=A= I=&VD4LM*MBJYAI+YU40 M1:O\#D@)'I-P+IQ ]DD9,MLT-:%F#^; EWGM6(N]9U9?Y$GXD;+M?0XK+;(R MP'>'C^A64%A3;V/*/A9ITB=$X ML9;&S58"1(;CCU)B,F<0K-.4Y_W2KZ3?R8]*'OA2:AE9%8E8P02W6&IN/F^! M**H;3L+'C]41!#_Y;+Q+K>1*U!&?K-PA_.3:7>,DG4,5$#E-GECF,E0"5(^" MW;SWX]_7_[7H%PE?!=L10BG@_8)'4AA'/!9G*2)18T8H@P9,/U'[4MQ);^7' M-$P"%C1DC%,D8?XA>@370SJP-KB;[2KO,$A%&:O:IKO$$AJ7,I-%3E[]$AR M3Y#,>#5^E2NX' !8KQMK.G#??G];BJFAXY6Q0;W=Y*?7)_E?]D#920,TSQU8 M^17Q7PID%L8J%WVL2H(P?W:E3W9EP:X3\FLR9_U:J0'ER9G_>]%GNI2%+.[) M/RNO_2BRK]D(@=-DS:UAI2L9!QDY9(NX!LUL*NW9] MP^MJ@27JZST5:T]:@KVG$:,L"R58.$%9H- M7N>>Y$\0IA7=1%CP6N1=?2RVB)4K+>\;:\JTN =Q4;0W#BD3^FGM+7DN'U]B ME8T#943L#>,$I O(?_I:G.8 DXRUGUY93M/TJ M+!6>EIY1+L]YL7%858+GA8]X3GN199N>_W5.^R;5U+<4] M*=Y,CA*Z#*:S,/4[ R?>5NIKM)'ZJE6XBTV&% QQEE/%Y4!+Y:OJF.DSR'S- M-W*F%H4VS/C#RD4M,:7?J-:K)VWD4_)B'\8URUAJLM@97=,'95F+=V^O*SF? M@V H'!'2'$ @C+^"RVK^PUIU*EBX<)=J6>>U3&"]"%+SI.$5]RLH)Z4T8\$- M-=M8R:VH(JX2IYKX.3$_EII>6.?<+.J#)%:^M;'ZB"AP+8()3=#P6N6 ]\(!;T4C4%8*[;D+3'*KP>'POY8.T]8 M"IZS$TU.2OXWX9 P\V*Y,K>>V59[PQ=WOT$M?P:Q^3]$72U/\S]Q*I(7+DMS MJQO;61,VU8=UL7/_7.<:#?J,/R2IL"-4.+T\TZZ;&D#X)4?JQZ!P?JMJ![1H MO6:G.D$2OKD?G4+T:I&=^BR@LA35K&PA8.XH@JK\9ID>.V-KL,>Z#("5FIZ: M?S=>%"0K MRS0KK:88^A3E29K5$V*J7#6P?ZHG:SPQ11"4V$IH2D*9^:U-1;SAAKQDV5] ML]?PB3B6+%" M5MS]+<)?N7 0%CR1OWK,^FR4NK7\IVPIW:F1$EU39X7EG!3GXV]8R-PS@F-A MIK/BRB0OF6 MB>Y)E#RA!#U 8JQ3DY^PXY]!F?-X\>L%YT+8TIM#;LI$U78R MH<:WF 5N&;;]<1D;IZ](K;E4!,:I2<:\?N8VQ0\1/^%,R13ZO3Y"LE= (EY. M64OM6G"':BDB57PM] !BG[WV];6\@W+IV0*Z;A$0UZSM2A$Y*!Y<+[RK(AI5 M*[>BBTO5@*>Z"N@KNH@4!Y:-(TI^W,A:@(EC1&'7T0M/H'_;THDF!^I'C;UW M\SDEW*I3SB(;JVE<5S+SM6/.0/0.+67$R0N'K&))O.,IZQI,>VLA'';/,Q#7,4O40 ,^,.@0IN"!AS!KA MP%D]>R(A 8P'+(TQ;]"0U=FL6.F/GV&Y=Y5V^$9$.X>_ILEBOJS"#J9$ MJYI@NDP^C2*NQ70B7O>Y=#/]PFHUC*,I'KA7ECZOT6"5X<42NQ;W/ $"U$^E ME6J-X8H._]R-+EB+>H=%R\SZ25&SM+!BH\\Q'_ &93SIVB&5[&7%-U%?*2FL MNI5C).KL3:A^3;C)!V+ SQI)N>#"!*%P06&$[+SJ;]:4<47LD_K7\"F5)E2K MC#.=156YV"TE-%AN8NACM01N6_#BN=)/ MB&E'52WI<4-FW"#!$HD"Z:@8GX M8[&@T_OGT^+G>FYH<_/+MF\\";#>6VI;&P3>IW!%*QXH3:2:!UF\%@LWPR;6 M,E7A*ZN 0G-?JS>%WQZA=Q,[**R?RU*0)VR0#&]AQ**Q+-;2Z-3%I-M+#V!, M7(LC5C6C0"0J,ME105CG/V"8,&^>PX=IH/%Q3=6I[5)[T*HOK%#);].04Z3> M?O2)]>:LAV&;M;+W?E" 7GU=91+E(SA838F;BI(!*S[%(UN1M M>"9TLY*4Z3/1M4KPMLY)FL%&5"H1XA55D[YZOO:2+<"2**N"P'C*VZU78;1, M6\IXH'\JFDP*8)TK5T,%B_**/@X\!:O^)Y?R^"AS(#HQXGXDF\Y;WM9;_.I LU,KYK/ M\ZIU4;4S+O 7@TN+FZNW.'YS<6Y>W-M7E^/;JP+X^;"W6<[ M,9G3QM?78%Y=WUY^^_SKW>>OOVA?;[2+?]Y^_N7Z]K8USTMV-]2]NX[MC].M M(;_JEWXJI\ ?GGW-DJ:X0:M3>VM\IIV,DRBJ&AR(*YJIIA]U'J(JNN"(SJCE MR3-/\:SI'QXJUZL>VEKE4#;-6+U,(X58X_I9'7H1(./3S$#>\>:RK!5MU4C6 M'[-VZ]P S.A6CA(\OC%K-&T1_0-I;(CBD!ZUBO*^+06*91ON05^TZ+B M)"22)@I8MJR.W/ZX/).7\D1G(&=A4\CRYNRDTU^R>3$&@/V!,0]$8L?%R?TR MS]0ZS]5&RYZGX1_4,=(;4URJZ9^? W\*_R1/]./_!=>(DN47\^_/3H M!_3?K[]']+H9_$0-(; 4;ZGY,J4/3:DVC(O!,+KVS]RGJZ]-.V2C8J@.!)NM M:5'\Z664L7!).<,0D@$R MI6FHVO#P2EE5:67+0Z#W)@\&D@;EU%ZJ,+FB!*89E$E[2RVZ0 ?Z@:@59'J@ MF#*ROYX5UKQ20MNO7),:;:$%]"KPQX>9I2P_Q9U#K53<"FVU(/8&AI M<18* 78>"[CE3H%V"<>_:>66E!F@9812A[H!ZEI%U,M8S'QVH%@=&%9!9W:, M237!P[/.)WWI6AIFOR_W N?>"?0T2REA_R"UF3,$[*?!41*L7K!\Y M[W!'';UY<3X%QU#U&Y<"R!!Y9QT#F_0<%P/FR_*Q\AG/O.A#C*#_R,\QRFXT M&7/%6$W;*3_<+4>*)2]NY0NO"(.Q8Y9QD]+;&.98C!F=055W8V_ MKF]S%/.5?N-->4HCRF)S\_>X 2,\E7,2U?@?#9DQ[/\?''!3\K@:B85 M& 5>B)\"M+:*?^H\N HYR7'9GJ4IT9:W;/U7;WD6(_L\I7%6 W*,3YG<[>1E M<#%PK:%WZ=J#H3N\=CWGVKVX.3\_=]S+"\OKV7M_M?OKRFDQB;]2J0%H:.RKB6#%#U!6L?NGR_^<[;WWM_IV_?[]>_P0_4 MVF(94X(%[Y,\3V8_-> %PJ2.G?KO_/K&1ZPZE7WRYC)K@ :S#UH'?)J& 06Q MW)/D,IK[NDYMT+Q<[O##Z[02R!:4,.??-:9[M2**M LMUX*\1JV:T!@SMZ?E M5():.&E3$B+?O9/O[ /PW1NT/#PGKCV*>9F8BC%;2U;H[NDRR'I;L=YJ&%VF M\(-T=DA5CH-3<0XQ'A,RF?2,4:]8%Z@L6XB!]:Q;5$SR0\+Z1=(+3F%(M!P; MD0\_5[='CBSXJ<(%;5L"J/![C A'-PU$!/K_6_C_K#^I2&^)_#B@[QID;8!) M*D4/K'=&7OMFGRHL@JYI!S15?\!EZZZU<6CWZ,&%;M-/E[SK<[U-*>22LKJX M);4F$KVA@4,K*JYS8+-TVY)VA*<*0Z 'I8Y>ZAPB!L/5TKPCQP/Z3R_3]I ;UA2!'8JWXUB]D0#0']NPK#FPY'D?NQ)/%0Y$ M]ZP#:O!X(#I9)'"6)($YV*"\7OY,!S9F)A ]Y5^L;/7[U'N,O1YOWL^:'I:- MK(-:[I=(^@I7^S57;0A$,X8_-5HPZ!OT>1!=):H9S_!M:5"T07]@W3TI6::L M>[S/QYGQ<8QKQN30OZ^=N?'/.9N%((9NW#^7 P#.-&VCT!F/FFE//LN!JQIS MUX9C%DT0&ITX1)\2TMW5A_ZO%]RME^E^J#AB[U>I?7@RN;ZZN MKVZN;=L=#(8CP[.NW9O1I32HS]K;O*D -@7 I@ J5/5WZN4[DL.AG$^, M30&P*0 V!5"-$[$I #8%.!SK85, "8SZCX7/0@0P%9R'(B9DMEWF-(F)YN M#SR$!+KBF]+VJABQ(1K:MP&C'B6?Z\8 :X?1\51(1_4'7 -])*_;4N_!A4[1 M3Y=^-M6F)&*I?7FZR'(V1VCNYR&,.4&+$)PD?6!(:X&JRL:CCZ2._ND@(FPL MP4<7::L*P9 -4@M$+S,TXUXWX]PAFG'H(RFDH_H$+F,/'>W[ B[TD7ZZ"F'0 M*QX=K=B %H;)T2M"KZA"A.E)BVSW!1'H%;U,VU]3&&J+^F5C!UV'8I;:2%#TU7&K3>H(XJ[($^E4):JF^( MS]M<@NQ>=2P:V[K5E*FQ#,U78!WU@ M17N;H#1#:?:VE>;IPX&T6@J49MUK\\\:S]"M>K.K/_"M3%*O;2&GI60.DWEC M:.<_@V[Q9=HK-'0_3\,_DMC7M4MZ[R1)XQ!^!D[R@T37/@?^%/Y)GNC'_^O' MF9_IVB_D/O6SWWWXZ=$/Z+__S/VIKOW+SZ:4 #DTLX\#[5]AQII8QS!&P(S_C'?!%D:(6^,^9EJ34(!V3&/YV3X+L3%OJ]Z*% M?(A!^4&C8S]H%OHY#":F*PX6<_HPZ(I??,96.$Y)$$*'_0BHE?%N^(]^&B8+ M]E2ZABQ9I/1/9]IR4P M&8\7T"5_2N+Z? #1]YXOBW\54"!X9!M"WQZ&)(?P M;3 Y.0Q( &^V5$U3O!M]&+PS>]WR;_3MBG+.,^V->D]X /3DS[19$O.A!FQU M 7M7':A,"7]/IGXTH8O3:T_^NQ_&.?T_W5&Z8_S1/I\WT/R*D._NPX(2/TF! M /]9A"F?"4VIK%,2AHG[VB0,%N/0 M9\_/YL!78J8"K(7>DE%N!_8X8R,)QD 6L:_-00YTM=4\AK"D-*,?GWW1G'' MZ$J?"*_.U@3T +X&=YD]MOB:;$K83(17C[HJKH6'9M,DS4]SDLZT.?V)WE/T M>X<;^3=E>6U@1,'[, !"+"RF(D4S+=C@?"I>GU)?[%R4@$2J?\':=ZXNJ_>@ MW_;57Y?IP=JY#J]/:Z@/=RBR*W^EWYF?Q\$U9;,Y<-F.4QX,^_)\=&$-SB]< M]W(T&+E7YF#HFLZ5-S+=P46_ICS\^NWKK]??[G[3SG^YTJ[_\<_/O_[]^I>[ M6GH+?9F\%=77_A"%,NT69#HIN$)GTU,V'Z.PZ;MNL-4-/P#',. 8A@[=CF,8 MNA"GP#$,.(;AH'R'O?![-X8!F:UKS(:#%R2PYA?J-1P2M-WN8XW=SS?O?C[2 M#4_>%/-.L\U[3P4Z)+N44ZLHP5""[2C!AKH[D)>IT6FV>:\$ZX@'VB8)+Q9A M!$OCAW'A# [$V+$1MBF%^VS'T@<.#G- QQGK3DM,&(YNR4NOZ0LFT+]_F;;E M,7$; .I1*9QGZB[V#$$/5"7]U"-XN;9N#A%>Z!YM3,*;11J'.62/@7LT";_# MS^@:P7VN;CG2^FFKLM_H&*FC>#J'B($^LC%4@&[1YL>>Q,_(-(G:#[SUQX@; M#77+:O\$3Q4601>I YJJ/^CR#-T+L:\KB6&BJH'ZB*U MH\7ZUT[$& M]]YT[!"\.JS>>@,O=^3HKHV>V?X\L^ZWEOM"W;!/T#E@,5OP[@L!]"$9AZPS M IJ3&Y#PQ'0O M^XKRE>8E[7 A]BV43;Y^]"VTA[KAR3/RC[YQ(3K9NUL@*,Y0G+VS5-%S=&8&=9)+EZ)ZS M&G??Y5FPJ(BU"[T79:%-BQB:R,[]M.SDE_D1H1+>SPA 3\M3:$[+,P&"10JW MPU52EO9,-U\C,33,K/>:DO-PZ!ETIMT2HOV2Y$0SA^]_+O\5+O\4YI37QK6, MO]7+UKRL M7_^2[O';ZT(_6&[4NDWGU8TZMOZ:T.UZWJ9;J^%>&,/1T!XYIN6.SJV+ZQOO M8F ,SX?7Y][HRFV]6VO=^-EW=^\7.+T1.BAIJ[TVLW@GL*\/4;!^Q&%,,>!' M$6M[#392H/FLI7.8:M,PRY,4;"G6Q1C:7,_],.75_M"?."9+"(M8JVYA0XICB3 D!/=GD^HR'J 9[->X%+HET]3LCI->Z>=R!,Y M2W)'&@@9.RD(O M;1^_O-;E&KY?@_[5TD3;DHC:2*QM(]#_RL (->S9CSV;LV=R9V[%G"FMBS&7LV'Y3OL(TN]FQ&9L.>S=U/ MC,>>S>\*V\LBW1%T/,6>S9@0H8!:10F&$FQ'"88]FQ4J[.B\Y84]F[%G,Y;- M8VNR;3"!/9O1O]^.MMBS&7LVHP?:3?W4(WAASV9TC[8C(?9LQI[-Z!BA8X0] MF]$MPI[-*H ,>S:CBZ2:INH/NK!G,WI(VY$0>S:_RX?"GLWH8V''+WGDPI[- MZ*-U"7^]L1RQ9S,Z9@@O[-FL"+RP9S/V;)9 0NS9O 6QL&G R((<]F[%G M\UZIB#V;E:_K.8HFI]BS&9UL92P0%&D)LTF=V2!Y:M=)? "3!8U!!AV*9CWF T-*^O!N9H M8%^Z5];5R/4\Y^;"]6[Y.YUX(^6LI)EFGWS]K,_W>2 M:G/_F?XW2Q;IF&A/!'*+,]$4+]N])=ZF?%M[1D-&*]XB;S0Z\PS7&'B6-:#O MZ[GR&N99KI2.>>:HTSWGC$ZO'E\>7[Z#+W_@)IO=WOE.,1YF"BK2**=G7GIE MQ2A^4+"/=GR_P:"%Z]5!"]@34A[/H2!#07;01J-R:+5Y?ZO#B[4[&+O#9M/X M$3NBNOT]C"(JY&Y)^AB.MZI'5HJTR*.]X='S#$8\P+P7RI^?J0J>$Q9'TKZ$ MC_2MD%61555AU;\E,Z+]C?A1/F7<^K MH!:O(COVMM/]79)3XU.<_R'7M1"_0:Y;Y3K!;]H/R'$'C-XHE"759ECG[R2@ M[QY*&T2A$-G48D+L?]]>8EGO^]\/#%LWC?8+X3K!-W ?YL>B"%. %5&$;=% M77<&(Y1@*,%0@BG$BBC!-N^D;>K6'OK4=X)M4(*A!%.$%5&";4UF5-]]E#6*RIKV^J4=--[BG+4?;5EE MD_9()!V0TLY7$7F8-O_Z^6J*V2,'R!YYM_S>M\QVS*'NR9O5I@H&VK9\$!,] MQD0+,0O$!>*B\[@8>;IAXBA"A 1" E4%X@)Q\4J'3=/5/7D=-A$31X.)=G%P MR/"H-907'D5 ' <@L([D[3J2TXRW:9#%@(401H@A1A"A"%"&*$$6((D35A6AO("C;ST1X(;SV M*[@[';UWS_8V*1.AB=!L*[NY^T-$;Q?W.33)D\5LQ\Y3;>_!H1A8@Z M1D29NC6P=7=@(9X03Y@ OE'[&>\,*R(0$)@ +BL!W(_]!T(UL,1F%PJ13BU& M/,Y#=\LSJ8V#'<,07@BOCKCE"#&$&$*LTF"F[EFHP!!=B"Y48 @QA%C7(&8; MMFY[\I(O$5X(K\,33IF@M#F0%Y1&;"&VVDI<[GRT^MF/=*'(T^: 'N#/JJ J6U!CI@Z9DP9 ]T<#A%3B"G$E"Q,F;IM[ZV" M$B&%D.H]I"Q7-URT_#H/J9>I-=R-6.5M)^;'-I#4/:1XEF[+JTQ#*!R-=CFL M1CEH7-@]DYW:C[KER '58C)S]_M:W$%3"RTECR1>8#JS6K+=IB(K2!;W$7F7 M<._VY')YLZ3?HNU[ADVW0:ULSHYQ$.8ER4D$Y M:0_T@=-2W!BE)$I)E)(H);LO)1U+=PQY11XH)5%*HI14@5=12G;CO!2%) I) M%)(H)#LO)$WHAZS;9DO9CR@G44XJ(B>E4K8CX#:,,P5.'%;9\$ 4EBX-?D#8 M'RB%H$I>+@&1% M,H$V29,9_5-47/5 8I+2^P-ZJ;C?C\=A%/GILY:1]#$F@&L;%84Q.9T2MK&F9?SP MTZ;RH?:,!DL9E#O8,T)*LIC_7O^2.$EG?M3@.A.N*1_,R*.-212):W[^8'Q@ MOU-^&Q>_KR'373BCV_8+>=*^)3-_!:E/89!/Z8_T'84PI:")_'E&/A4_K+S\ MA[?!M@8'FZ?\B#6-?GA;)*V5GN+^P]YN='KU^/+X\AU\>?N87_Z]MW>*\;!W M@"*-M/OD1S2L&,5+Q\;4C"2I+(*Q7Y^X+7J?1 %_T&]@Y%^O-?*E9=\<.\^A M($-!UJH@L_<2^I UDV0?8NTN]>,LS,,D]B,6+;G]/8PB*N1N191#+3:4%N1$ M'NT.CYYG69A!, [X\S-5P7/"(D?:E_"1OA6R*K*J*JSZMV1&M+\1/\JGC%O_ MEF1SRIK(HJJR:!N>2[=9^#R*M*_8?J_/[*@8Q_'"WF]R"WN1ZP[;^4=YKA/\ MIDE+23AVCL-);*],8B,!??US)U8P_# M[#K!-W ?)NZB"%. %5&$;5[#-=#MD;S:A$ZS#4HPE&"*L")*L"UJ,'1'XKR& M3K,-2C"48(JP(DHP)6=>=H)W4(P=@QA3A=N4D%3*""/7'>HCB5T]5-]]E#6* MRII^3@>U[;/VHRVK;-(>B;#DNW/(P[1Y<;Z:8O;( ;)'WBV_]RZS1P/=-7': M#6(",=%BS )Q@;CH/"X\0W<-:2VA$!((B$XA\JG%C#++Z-H[ =N[5SS4 MW;8ZH&]!-U50V;9&0'0B.@^BO8&@9#<3 MT87HVJ_<[G3LWCUK:6 R*CZ$9JN' 0VBF9T/^M\N[G-HD2>+V8Z=I]K.0I#5 M[;.-X:6&X>K&2%J2 I:?(IZ.&$^2N^T@F!!,QPNFD:&/)#9^03 AF(X73.U% MKQ%1B*AC1)2IFY:E.R,'\81X4CK[NQM=L@9#>:GA""6$$N:-OY8W[L?^ Z&Z M6V*/#(5(IQ8C'N=AO>4,=<^19QWAD2#""^'5JD./$$.((<0J#W^H#P:HP!!= MB"Y48 @QA%C7(&8-7-TUL-=F!_;0%+GD&(- M!M1%D@85A,+1:)?#:I0#1X51MR"@#A\#WBRBWOUV&'?0"T-+R2.)%YC,K)9L MMZG("I+%?43>)=R[/>YT5(KJFUHV@G>:ULS MHYQ$.8ER4D$Y:=GZP!X2D*2122*"112'9>2)KZP'5T3V*],,I)E),JRDFIE.T(N U#8JG7NPE< ML>&!*"Q=&OR L#]0"D&5O.:VD+WV!@6WXC)O-Z*5MYV8'[652C)M[C\G::;Y M499H83R.%@')BF0";9(F,_JGJ+CJ@<0DI?<']%)QOQ^/PRCRTV48^%3^LD.+# MVY)D#<@WSV?B*S1'/[PM;]>J!G'_86\W.KUZ?'E\^0Z^O'W,+__>VSO%>-@6 M09'NXGURDAI6C.)U<=RKD$4P]NL3MTSODRC@#_H-/)7KM9Z*BSS7KF.N&-%0 MD'6)J>J"S%8MKK,/R767^G$6YF$2^Q$+R-S^'D81E6.W(DJ#G(:<)H73SK,L MS" D"%SVF>K*.6$!'^U+^$@7C@R'#">7X?Z6S(CV-^)'^93QW-^2;$X9#!GM M@(S6AB^@/".>1Y'V%=OQ(0\EPG^$V3EJ1P[!R' MD]E>F.Q>EP-UNL39C%)71S,IIAV$XA\JG%C#+K[Z02^:"F MSM#41X8TP;XSW51!9=L: =&)Z#QPYAI"%"&*$$6((D01H@A1A"A"5%V(]@:" MDMU,1!>B:[]RN].Q>_>LI7%YJ/@0FJT>!C2(9G8^Z'^[N,^AMYXL9CMVGFH[ M"V'SLHQ]BW3/=O2A(7M:M-KU)VV+;D33L:))!!."Z7C!-+1TPY(]QA?! MA& Z1C"U%[M&1"&BCA%1(VN@VP/9 3%$TY&CZ8 (.F1H>3 Z,Q%*""7,&=]' MSK@?^P^$:FZ)_3$4(IU:C'BSD MO/Z^7]/PT<^)YL>!EN#\>C6K/#MG'8T&^DAB?/H-\JB"I;;E.$+JB"$U\'3' MDQ4KIM2!M+@(A"1!T]HFQJ][EH]W4>4B]3:[@;L^$<0=M,+24/))X M@;G,:LEVFXJL(%G<1^1=PKW;,]+E3:U^B[;O&6O=C2(A4S>AZ,[S#D_33O!> MVYH9Y23*2923ZLE)SZ."LJ6P,0I)%)(H)%%(=EY(C@S==@>')V@G& ^%) K) MKO J"LENG):BD$0AB4(2A63GA:2IVXZI>Q8:DR@G^RTGI5*V(^ VC#/936C? M0>"*#0]$8>G2X >$_8$2"*K4-;>%W+4W*+@5EWF[$:V\[<3\J*V4D6ES_SE) M,\V/LD0+XW&T"$A6I!)HDS29T3]%Q54/)"8IO3^@EXK[_7@<1I&?/FL921_# M,;T;'KY(Z;4Y:ZZFC>E/A-X]25*-WJ,]4Y6GD3B@C[DB8S*[IX^Q35VS#-,] MVV$_?\Q]*C[67K_FYS__N,A.'WQ__ND;&2>P^M#/PR3^.OG&W_J&OO0M>9C1 M56=WR642,Y$!;WU']^8B2L:__^6__^O/Q5-NQU,2+"+R=7(^'E/@Y=DO24ZR M+XD?9^=Q@J#?/II-#IS3-6._RA4+I4N$;^/".?BA]6 MV.G#ZT+96RLN-\\+XPL\U+Y'O-N0[^P!\]R[K?!^VM.-;5;:Y;66/.KW/ MD!CHMB,M5:DOD$"O_BVOOAV-TI]VZZZK#P8X+P0=3H644Z_0Y1HXRP!]H=W; MAHM,KE9PUK299^@NB9Y\N,Q8>4Q4 F73Q:1 MYHM*"+0J-Z#DB6/KH\'>/+6=RA!5X;IMVKHK!L8.Z[G>(Z#@NVW1Y%%:IVHP.*,JEJUL#5C8$"G9=5X1_TLA7-N$5QAN+L M;7'F.+IC*]#93A7^D1C5V+4IQ3O:2;S8E2)=D.!+Z-^'49B')+O;M@F%:PT' MY\.+2W,TO'"=T<6Y95A7EY?FC>E:MN,-#MN$ B EDPF^\KXFG&Q:5-$-*)6% M60[]*!H-'3ZM\$='.SF8AH&]&YJW=[OY0J=>OB,Q8>4,0>S=@+T;L)Q>-4[L M=N\&E:UL9#WLY+ 71OW'@CXX?];\+%ND_(R62)NOB &8=W%8%^(KCNX-,"4$ M8\$'C@5+E32=J*)70@QUH_N"HP^,]F54)[A&8O1793^R31)^(Q.Z^1E4&;'P M]PX6?>]JS2U3'\A+3E-EI]O6]JC4>PP)T]-M>6D4?8$$NN*OM6Z?D#0E03&: MH T8]:<:8:@; WF#F-#Q5 9BW=51_0'70!^-,*J#3M'&)+STLZDV)1&?!)(N MLIS5^LS]/"0ME?AT#E26/C"D%:>JLO'H(ZFC?SJ("'LH+36S+XA %^FUV%L6 M0E*A%I!YDH4MU8[VR(QSAVC&H8^DD([J$[B,$?8:01]I\_A>^ C*"X^.EFU M"\/DZ!6A5U0APO2P;S=Z15MT0$WF]/V?M=S_3M E>OU8UM -3UYU>]_-M@XA MK+L:JC_H&NFFO"DLO0<7^D0_?8['R8R XD*G:$7>>)9I29/4JNPXND;J*)[. MX<*DKI&%B$#7:%/:?J6.D9^'2>Q'E,!)MDA)V>[B&6VY5VTY$RTY=),4TE;] M@9:ICX;2U%COP85N$N_7U JF^M:U=Z@/35<:M(YD^(IZ8.JPENH;HES=]S_6+WP7:X##O#RB9?+SJ7#&S=:\M4.,;&L.@#[VY=H#1#:?9.*\W3 MAP-L<]V& 2>ES?6K_:E?ZFK]GT68DN!S')!)&(F!G&S3!KG/ :^]:%R7, M@-^4]VL/;8AY[+*-7;8[=#MVV>Z"&;IQR]D6:/6Z?;#/OMH5Z6Q3U[#',?8X M5HTAL?.Q!/:]2_V :+$_4[/=<2?:26(3TJU2U^0-$^TTUV"D4=%((PHP%&"O M"3"G_89[G> :B<%%E?W3-DGX=Q+05TR)YL>!QG\)X2R8VM592S6,?4O,L)SV M!O7V%WOJP4PY&^%X(65ZNN/(2WL_$DAAE*&_Z0"=L,>ZD2O0#3/?"=H+Q,)*!0K(KO(I"4J*=.-)=>3V:4$AN:E[*2,7:/:EJ?9K6Q2(+8Y)E M[,E9",7&]/;:;]LD97F>>75U,3(N[8L;US.-T="Z&MCVQ>C2L:^M"[/UI*Q& MPM"@F:A49&EM\-PNY2J-1F>695A#:V0XCF<[CKS,)=.2DKHTL Z;O6-T.O<( M7[XK+]^1N+ARIG"U7%/MB-T^LV8TV]1;C6 AXV'^UJNP;M3>6.&+UAVFB MZHFACAR-Z(;;_LRQ3G -"C 48(JP(@JPS068I7LF5NI@HKL<$EXLP@B6QA+= MP]D\I:)RAC.QB[8U-G5II#7A4F7/VU;\J-][# D++&AIYP8("81$YR$QM'77 MP+D?,HPKA7S&-FE[_9]%. ^_== AXW55;_8&8+7& #D(+H870JD$+A\EC3&YC$OXU28*G,(K0 MS8+ @ZV/,!:'D0>,/%3JQ-!M1YJQAI! 2'0>$J:A#^2UF^@+)# >]S)M;_S' M)&6=U2AUVVJZWQL/!N-O&"104E/U!V+V".-O""V$5CO6X@#N;_9D0>B6!O%>^>:(R"ZP$<;/ M6K=24("A )/D=3FZ:\D[,D8!A@(,!1@*L#T>09HC?22QT1I*L*8C^OYAW)N/ MSEX_>OLRF6=W[B.-[*'5][%^J9LF6F$OF^@U0>Y:K!9[+\#UL5U[0"Z7;[PTZN,O\U.;;#;#>VD^%1TTS D MSD%WI,Q!=]QWCJ,^\!SUP][>[=7CUN$8=L5=%VDG1"W0\G4S5B;&_+)@J3R:;ZMN]KN[K_.V#@H.MK;)L,/^Q3YX(Y_L M4(L[I]OD/Q EUW;]G:3C,"/:KVDX?GV)B%;4K$>D6;7_1[*W) I" A48*K"N M*+!#+3&9:"I;Z]O).2Q_6"L5UY/V?_QXX:?/&H\&MS] 1Y6SQ!:FKNJNW?Z, ME*,X#^L06)4S8:2;>-UF19S1OGERY9F+$]I1?JDLOX[0K+!T2V)!",(288EF M!9H5>Q1@SMFP_3;UG6":]\JOCJ00M-K#/O7C X>\E0'6P,;.Q'O8[YXI\O[V M K+L,PL1@8A0"A';'^HI1Q_DGPWYYZU#XV/D'SR,>V560)).2"C1G&VO"/C9P==VX0H[; M1ZHGF<\JSV%G*)U3'>'6]O[0S1AL>(3,]CW.Z9)>TP517.QQ!W MMP'1=9L&^0=#W!CBWE.]R7+_(34K3I0QGUW=<=K/_E2 6S "US<5J#RW*9'# MJ8RD,8TS6]Y,$-7W'B6-HI*FGVKV+**YO$^HH. J_;=G2/RBV<,P>CQ#W$FEHF Y9;=.'LJJ\AKZ^KFL'WZ'45CVP[!52WAAPF?K;)5%SQ^TSP; MM#]V2)6]1TFCJ*3IY]&XI0\-!\&E(H\<$[A0C?=>C7MG>YCRH\K6OU?0X+$8 MUFW4ZS8\:7/K5-G>ME4Q:MP>'U-9QIF-B$!$*(6([<\96N4F)6STOO*/&N=4 M:O$/GE-AH<:["S6&[?N(F-6E&/#4%?-'5)GAGGEXR(+@ZBNXNFY<((^(J69V,\HN:,/[='A::@ XV$PKV_:5'EN MPZ3.QK&!?69@5B=*FCY%OY4!EZ4/]U!_B>!"<*$:/W(U;IP9[7=(567OWRMI M:E& 'W.?^DIKKU_S\Y]_7&2G#[X__W0[GI)@$9&OD\MD-DOBVSP9__YUD6>Y M'P.7?$NBZ"9)G_PTN(-ON*/DN(CH-7_Y[__Z\]J'S.EKQ'GV=?(Y'B? RE?@PD_D8F/W^XN0*G_!_.;W=7'[0PH!_XX_ST9G!A M#YV;PA[\L;5F=_'?AC&3:+^1)^Y;,_).+?BRP/)\_\HS"F0C3_9!OT&IE\_;2R3KW#@_?"VV%ZK&_C] MYOMN/^RW'_9V?/=]?7OW,EU6)*:WFT#WWN4U5,LUWTJL:COO94MRM7#:\1M5 M]MKUBJ[?P:9$'MR%!]_,[6N!!5=IN7DSJ\-SK,R3.+4X4?6C<^3%-;PH+=*Y M;^HAHQX7HVX\?1:S15[FV\M%FH+3W@K78AI_)X]%E",<W&T)M*#\ZI!&M"BFDG>UVZ@C7U4T'>R(I'[?H?^Z'*KQSE&+ -G0#9]BC M&$ Q<-1BP/*H-2"M1D25K7RO&&@S(-=Y!^(V]W.RBZOZ9A^7-X+(_6FB9.FC MX<;1X?>V0.A]FF6'XDC*:7,$Y\I]U#_VI!G&"$X$)X)3)CB' VG!JZ,'9_>2 MR10X1) )S,[ASZ3^HL19F6^01QDFZ5U8"2&E#*1L5[D0E)4Q)@'N*ACYB.A.$P*PPYK@.$0X[;A7"8A[A+'F)_ M6SB[NF-)ZXZFR@;WS\/K[@%!YQ!Q8NJ&+6W>_.JV=R@O":< (& V22DQY 41 M56%]E2,:G3? VLOCZLUI\\C#MIH]]**[JY;Z RUJX%D2&_SC#%?$'F)O4^P- M76FNU9$CKR,95!U&70MGT[+ZR+0PRTUW3'G0?"N]L87.19TS2_$,!['X@I:T M=,O=6Z[Q3NJR$PCNOK[W[74SXDVGOKQ \987\_5U$>;=TK$*&MW(-AAG[,WX.)T\BS3:I_# M$&((,8080FPO45-[T'4K\B[)Y75A?',X<[O^7A^Z-FU,PCU3K)6>3X[34ON9 M=7/!N\!&&&9NW39 88"3%+(H,7^62C 4("A $,!UG;+!]-KZ<#B6 68[&'+ MV\U)7C]N^8K:8E$S8@F8\XIE!?+;^OO4)# MPBH[]%=,'C4,>3-\/2DC?(?682?!=GH0[7MOWR_M,6OQG>'MH=H==?8QX*[' MPVO5Y3LUYC JQHG=GD^+S-8U9MNX)K CXJ[54RZPZ:/$C[6G,)]JMXOX+EUD MN:Z%L%4DR[6Y_\PL[?\L_)1^%#T?$LJJD.TH9Y&8CJ$/+&EQ757VLG^16>54 MEG3Z=")BMD\AT8VXJNEXNBE/@G2""R3&33'3>^F^RY0$8:Y-_'$8A?ESTX;9 MQ:0^GK0XU] I2J0AL>\9<1T"G'+:_PC195H6PJMM)=@$ZN.&NL>)AS=L*6EN_0%$CURO* >-IP\=PA#4NFH M;F&\;0YTPY0VW_E%JAU%I*1#V.RNHYMN^_T/CP*8W?/NVE"87TB6 M?=+&BS2%SA0S/U_0*T.2H0E*[SL9Z2-;FAY$E_HK\-[+=_[W\RPC>78>!U]"_QZR=4.2 M-5LT;-!TX69H7P]OS@>.-QS<&.;%U=65X8R<:\MU1S?NE=>OI@MW4Z)!HPL_ M?OY3UNACK?F,FBP++*KH23^&C@SURE\-R,BN@\(XS4^)EBUF,S^E7Q5H]X3J MD3--@V]:ZI,=QOS6E$PB,LYYFP<^$KKJGTV_S#+/C!]T[8F^!J%?S[ZEN,=? M>X?MTCOHE[[*O]MLP@8;V5 RBK>>&(W./,,U!IYE#>C[>JYRC2A&!^W%X'6Z MD427WKU[+OU*A;&WFQ#VY 3BL U%G]M0J,MW:G0&D)7=12$AGU M,(S:;G\+A4[8VO2JK]:X4R+?4;9)[VLV@ZT.HOKUW;J'J:Z"[\DJ45=G*]T;+U7,S MNW7>AV*@8V+ ,O4A%G_NTW7JO@D!W;Y9>C!,4X4SU7RRB#1_/*;OCNG";ZA= M2$XP63X^F.]'&[ M_083>E^O$/?_^='"S\,DUOSBI I-Q=?;9-C8P 8;V'1&_?4'>9Q.GF5:[8]!U%7>7Y'ZTKB:X%;BU4(6AKC5JN[HKK[/BFUVCCL%:5<_UZ[#N M.RHPMN(:'C<8T75\A;BW.72I8"TPT'!]O6&W*>U('%U&=!G19=P8>:9N6.T? M[!T']C !$DJAYRD9AR)B&@>:/TOH:__!/F@#BQV$G*=;CB?;W>DWM-#I.V;$ M6(8^<*1IJ>- #'IFKU#QUY3,_7"GNG5LC+^*3UL?6/)2+[$U/CIXAW;PC@F[ M0WFJ%;';LH/8R\/&6J>L0X"Y7X<<)Y:E#SUI-7>;$F\KX';B:*3#OFEWHOJ"6K[F]SR)IMVH8.42:T7 MIZ58PC8T4X5]X+XCJ?-4SFI12)IU0@MW0]1U9'J5K1O#EN(RVQ"T$XSW7B$I M>:K5%G.JUH^ZNO;3F')M]BM);Z=^2B[\+!Q?/%\FLUD27T;4+-MFT-7 <<^' MMGU^>36\<@?&P+NYO/%N["O3&UU<73G.W@==;?",AO!4?,:2:1CRIBJ9EI2Q M2@,:.%/J-VHS:-=4L03:<8R74L.W*I>KQM0> MQ9A2O0E2"@V)>G]$!)GO#>:3UO06M2TRVUO,MG&T%T>0O7)VLYB1U,_I^[7" MFCCXJ9,A]0X+0^0XY+ACXCBU"/=^M];LODHEN1;&XV2V3<.O=BMO^G"XUZ5L M!,?0/7E];U792@D>-#I]* :.1PRXEN[)*Y)092M1#* 80#&PC1AP]9&\N+PJ M6_E>,=!B5*[[/L07DF6?M+CT)#0_S]/P?L$S4O)$H_2&#)XTB2+Z!O2JG*0D MP[F7;[55E-8_ S. ,7B$T*HEGNJ>BY->$%P(KE8ZD.*$LE;MR@9'=+]8_I>7 M#<>[*=&NXXQ^K?97R@9S7?LL" M&V%P[* M MW;L+3/<:P&!N.N/0=;H*O5 'G9+.XDF5.=T'>#GC91CJ#SP"+\%+1;S*9V>C'@2OX3KZ>+9J3-PK<\Y60V/$(&(%W-05DH^DQ DO,X MF12LO_.1)%'[].P\/(N"Z"P(/WQ(-[ MI:U_2G(FK-"+DY@6L9@_9P-2B,ER.LO22FC:)_UYK :9<-87\^[R+D&)WB1Y M>+!?&?O%F?D@2T3/PE\.^5!DD(5B'O4!.*8%Q[38\SB.:<$Q+68/SW%,"XYI M,0:#.+P Q[3LVW\#\*T!'XYI@=*9IW2V;YS$,2T'$6=O$.(L%D,@#H@[),29 M93@()&6B8#."8%L@ 9 R@&-:]NN5LW\.@6-: MM# 1Q[2HZZ;A/ *U%I[#,2T@%\BERY^$8UKVZ(+V(]N'CSBFQ=Z9[>%LTL$Q M+7"NF>9<@X!!P'!,"P0, @8!:[Z X9@60^:?!OM[S,FF;W%4GE%&-,9P0"*0 M:(;A@,1#1B(VX^*8%DL"N1HVE05^@)\&X<SE@Q!3:ZW=L&3WK,$?N#8M<^3DH!N\"NPV27RO-,FLXN6S9WJ[39G\F$ M?Y"Q=#D;L;2@R6R .,BS$:&<3T9,=QEB[9&XI/Q,X85=ONXE"YU M7DQG7#P1@6/O;?E:HL@MQ71S3:@WX9^&!-).U%6V96N==9HB$'!8@%$O,"KL MJ-M]!4:!46!4U&V!4>:$Y[BV.T5/^S+7OAC0WM7K'=WG<9OUSD!])_(U';2T MA=U,P=\!^7^TPDJ!'4'6563UU&7U EGM(6MS![V'<;W!"%C9F8UN0H=N"W)..)M_WH6X*,D_^C!O20+X@7ZKDJZMN41_R!?F" M?$&^]GEVM0OYTC4C??[LZKV]V(+1]G,,='?VV+'WEI"O8WF.\Z,U''(WC'M# M4LY*TR)^5Q[P'-^R\E#H0A3'!IGX+LT*,J"]0OPMCX86FU4&QQKRAFR3@[U,1S_' YZ'R7)G24O$\4+(YE?^VR_J+/Y9#GG?X/8<( (Y93T(YN5_C2NEO M?EK]BX?-/W->_6!0O<=OI3?HBO[X1@OV[=&9[%=2F;8ZM-YKG8477K?3[9Z? M?8[:YRWO4ZO;.F][X85_?N'5<6C]XGGK@:]X9^]SI]@/F.C#9&AF08N)D*=[ MD@OKDJE L9GM24%_5-](5$_]1Y>J9 S[&^#V\>8GX_:\%HN> M\X>15W?E(LKFOO?J!=NO/&Z]:_-1\WCYC1^W;R%G27.BW20Q>I4KX.%U([,C M$O=Q3N]B?[G#= VXVP5W=43"+MM2532 :<=)[P>).APS:BT)H-8#5&7.00 5 M0-4)U(WWK=N>,E.G[[MR&)6N"_9CS%(N(X>>>#I4"8*^4-TZUU."\$1=Y-\Z M"\T!I,]$&E-3O3$22@>U5%Q/0"X(:NT2.]@+]H*]!\1>^_QCRJUV6:P]<1390=3L""?0W!C?7V>Y7Q0UGF! M#^!# _B@S+W<%#[ ._G"0;-9^J[/^I->$)B_LR^%T,"DRP MQ'/'K1-E^?RM7G1^"W\$_!$;FB/R/5^9/4PA /QTX 5X8GJWO1=MWQ30\&; M#KH=+MTTI9X\5+II=$;NYS!=G5:\RN2!NO-='&2<9[?QRF-TM>4_/;P-6RU/ MUR!U%_MB1Y==+IW]6,X#_'O/+@__;S1*>3U"_ M<;KJK7--/Y.S>C1.LGO&+EE^&_=8F?KZC'+6_[00TWF:B +*O[X.Y$_L"K$5\R?Q6+B;)?I-"6;;D!)![)OK&YJ*?I?%U776IISU>26[I3;X+D MCLW9G5%W2^INR?*P<8[U^>MZR(S]E^A9R<52QZK5L8SIXOQU R-2NKX&E-W= M#-A]%I+F9<%NAMP!:A;DL0;4+$A4K0.'2%.]'T]&0N4I@44FBI;NH*PZA[!. M$7BV;:SP,ZH[6G4=1*UW>;><3B?0;BXK4".?P^X# Y>J(& 0L)<$K L!@X"9 M,LU8>QZ.MJU4^V>>UU87+H.-4T;,WTV9">6,%WGT;R_S9QH8T9: M1SS?"?SE(]X//+>%>52RMX^RD1$=9.\'(\"(V7.>TPW "!5C,(-F/:8,SAZY MJ&:_)FT4SOV#1@DO3CG/6*+-MB,V?FIFD0+8 MVX,>#CG;GK+)&:@):L(EN44^PD@=]9I.+3@DJUWV>K1ZQ88O4_;-&;Q:N:D) MK5^UC)Q W?1\_59#&U#4/'>7S=:"FD'--C99Q^ET]KAQV@84-4_-C)O?0+^@ M7XH\-DZ[HRZ1/?3K\>Q20=X&M?D65B=U^!RG<<%^CV]9_[>TH.F-/+?UE',F MGGR4$V*#= UGT>?3\+SC=R]:9V'4.8\^N^?!:11X_D44=8-/VM,U/-IXWQX_ MGYL!&_Q_/O([2C;X>U&M&[V[-N]2K]=T-3]N]]NCX5%W@-[@AH>CWY ]20V; M?S^\>LN(G=5;X&L?24S^M_R ]3W>,#(L@#^O:!OM->;S*:5)N_!/2$+?Y3+K,"@%H MN&];V6 ?X <"AN[S(-'WTCRS?FBA;T3?6*=]=LMHL/^DVO6L_:[F[#RZCU3A M?2 K!FJP#^QC@7T,RV9OF*?_#X9A/;@(^YAA'VB5(JVR9%%29P#G[XQR1FCO M_R8QC\NT9#VYI0=L;:J:Z4T7VCJ)[#5-\Z%CQ0Y)9?ML:S*(AH3PD;J#&&Q M@'P.>_PA+9 6[=)RW.VJMLF<(4V!#;:5&"P\IH!DG]IBC'P$D;*#:DQI1PP^ M[-, *WH1##XPKX&T0%H@+?N8UW24.R(QKX'P8%YS&/.:EAMB7O.XGCCCZ7G; M?J:W65[FY4OD>BHGRH:UYMC/+L4UR'!Z'3#!B=M FQD'M@,\\R4('6_S#?X' M?^P+V 5V;3-!;3MA6]D<=:U=MIJ\FD))9?-3< _<6PQ3BYRPI9][IM (/1O8 MA7$CV 5V-8!=QRTGC)3%;&'<".Z!>QOW;*X3^NK.,VIZSX;M51]E'H31=<+Z M).OU)N(=>O>JX ,),LT^6K7'/4$>WQHZ+^OZ*-]IA\J&AZ;(J.XY%AC18$8< M"TJH.Q,<$R,0IN&$\96YQDW!/?H/T&%GZ$%AN5*?7G&743J!NVW?3UU!!+5!K*U]W5S^W,&$#\\"\ISN&6_J'2Z9P M")T:J(7Q(J@%:ME.K6._C5ARC!?!O/V/%]O*,F1 F'\9C'-.!6/)=#.1%"":OI??2TX8J/,D;FB>PYZ9@7 '3+C :;GHPM"%@5$8%()18)2)C!*#0C_<&Z4P* 3A M#IQP@=..]C8),X4ZK^W"-$;R>];[[Z^R@B;*$(6E1.L-IY7)33:<98A[)/Z! M$/]^-I$'1;RF;S1^P5?9F3%KS;<6F%:<-A,X75]=.,#.-C,%/KHGTU SJ!G4 M3)^WPG,\7UG"I=<;[; =&1 [B!W$3INGR'N'&+I!S:!F4+.]3D2]ME^_ MS4R!#]0,:F80'*%FVTU$(\>-U!U$A'DHM Y:!ZTS4NN"T'$[!FB=*?!Y[]N*!U_N.P-67^2L*^#SW$:%^SW^);U?TL+FM[$ MHD!Y-$S!KV395\(09TG6^_[+?_WMIQ6/3XI)SOXA"AE-1M^8*"'YD]Z/Q!_\ MYY^MOZ[.CTC<%Q_07O&N M];G5_71V=M'QHRCLGH71^7GPR0NZ[5;GM.N=ND>_/&FVQ2:XBD>,DS_8'?F6 MC>CS2KKP>!*G[-V0E<+M^>Z;1S3S!-8^+N#BWQ->Q(/[ZJ,X%6)=? @D\51B MI;(O&54&)HFT(QE/+4P&64YHDE0?CK^(?EEU[$[TLMM- @/6$3EF_2SH]Z)7?6K-,VE->+/Y-F M^8@FCZ$@[WDHN.0@Z;$DF=[S\Y%[5%X+@>G-KK='Z(CF-W%:O22=%-GL@VI@ M47YR%_>+H;A;&&*JBT+6$CKF[,/LCX]/I6S^WHN14 ]R&*Z,;ML\EJIZI2AZ MLUYO5ZK^M$JU/M[=ZZ\?]A;R\O*NHMIUEO2K@OX2?:.J$0,&\?/7#6H(EUUC MRY>AMD;4E8#M="1&B\4.PR]DA7[RG!@@Z#^[''P^Q*0TGIA&1BUUH1L'-$L\ MP%'%3(V491"#Z#3X# RI+4$W5(454_!?BX08U&WKU18?9Q"8)#K-&NEX+?VY M+TVA$D8Z*M1(^2FR$)U&CG1:3K>E+(S*%/QCI*-56]2%W9EC,GM%ITDCG_5H8(&-$Z[YQJ#W'==T2K&,!/ MPSZ%;4D5.YFS<R9:8QKC3ME\&OA2AL M"3N[O-6] "1AHLI],@M])3+B54GA"&\U)[S5=Y7$MP;M>N-;79O#:U%Y5!Z5 M-[SREO@:C9N.SE^W:[8S;1^1U;,1L5:ODDD.[F@W$T9J((?H_A48O,IIRF-Y M+B%-RHG#Y7>!2#'0OV3Y;=QC.*D0^TSVM,^$\Y@7 GD2A;^)Z=B8E7,R\KN8 M\HK), !9'R ;";@OV8B1+XPFQ;#$W)>,CP7 #0 3;&R)0GY6@RQ*(^^=%^C MNFT.K;!]L7JO6Z__'TTG-+\G5;X'99MBL-"J;_7?_G74EN,K7$2U&C;R.21V M-#"6! H&!7LQ$D1_(+,5J(& 0< ,@2($;',!^YZOKS@YDTZ9YM#*N]SY<7GE.)])TOA88!48=(*-"Q^MH.G\3 MC *C#I!1@=/6=08D& 5&'2"C/-=IKSC4!Y12[[0PR&FZUX#"1QOJC0TI-,!\ M<*;6%1AH2N/K[NH-DB#CQ@"0FL.6FL ) _V'%YG2]E":0U :*X(5C) A.T)< MO+;CN?JS<5L!&R@8%,P0*$+!-C95QW%]90X NU$# 8. &0)%"-C&IFJY3A1A MIQ=B_]28\'?&^0=R'O-QQO4% 5JW+*4AR,^4%M?=[:-W!R_ "_ "O OP(L# MY\5QR_%<93&HR\VN;X%/.8_>@C @# BC@3"(AGO>B'].\MZ0^_K78PYC% M@7@@'HAGB_ND65Z2TSXR(&UN+;_MM-3MHCR4/;OF,L$+>3I0PHD%;8M+]>F0%+F.L-6 M-7U>QR9L56L'V*J&91DL@(U$# (F"%0A(!M[O_L.%T7 M!UM#P:!@)D$1"K;%(19(V 0!@X"9!44(V,:F:G<6KZXL.9*D9?#K@'J;MM-0= -&@!'6,\)W M_ X8 4: $0^K+('3573'7V;;Y;LY6Z+04YJ7?V:!6 $_W:,,@%35N& *1A$C6%T_8#=7%$T(C M&Z*1>K>6Z[8C)!.2J=';U'("7]V1D]#,AF@FQI668Q4BJO^+OG]Y/^+L;2L^__-???EJ^[8\LO66\8/UOXM\\[HF_+@MQ]_^D<<%/ M>T5\&Q?W5_)E'@H2%DZE&;^QP<]'G\_E=V^U-T M$007W8OST U.HPLOZOKM[JG_Z:SENY^/?GG2+(LFOHI'C),_V!WYEHWH\P*\ M\'@2I^S=L%H>\GSWS2,">@)H'Q?:71[F$0_NJX_B5&A\\2&0E%2)A5/")Z,1 MS>])-B#%D(GG:3'ALZM/V4A@]/[OG B8O*M:@.0/32#NEH:F=S3O\$\3IAHTSYYFKZC4R7Q*']?_+&\/6:GVL2W9WA? IJ>;WX(VF6CVCRF!ORGH>"2]$A/98DTWM^/G*/RFNAJ+W9 M]?:4O8O[Q5#\*>HX%7(!QH2..?LP^V.I\O.76EP&?Q#WSLK8A_UY2[8Q&#=]J#5J>XTM7QZ@]:2JY@N6Z.YFP.ZS M 21B]//N7U7G.Q__D-.RVU4UZ 4$YZ\; ()/(?B_Y0<2=<(D](:17W,J2CVG M!2.?:9R3?]%DPG:80B!\;%WXV,/39Y;Z31A.>QB_3HEQACR M!+ZRS,JF-*_NOAA=;H.W*OG^B;H#,9K""$PUG[=MY5,RMO5FH MV8<16L0Z>WNMYIP"ZG5.]I!AWA0686[T:A-^SO(!BU7V:+H3!-7:L05[2Q:$ M[@USKX;/O;SV283$*9A[*5KF>QH59N9"GS%]66L/::0- Z6Z[!T8;GN M42_?/>FH.R#5]+;'E!3+=2J7)[ X@2DCIHQS/K@GH;)A:U,8@2DCENM>Y=7T M]S! @S_3,-;9VVLU:+FN>Z(P_QGF1D8,![%<9TS'YFE* H/E.E/(9F\O9EUG M)>9>$>9>F'MI6J[3'[;4W'UY+5__! [[\LQBKG$]'Q;Z#GNA3XP/6NKRB9G> M]IC,8J%/I2>H@WUYF&QBLKG0F>"824PVL="GUA_:W5]0[&%[0@UBG;V]5J,6 M^A $B;E1C0M]=G=,'=J_MQ)7?X%4Z"/N9,I"W7[.X'Y %?R@DB9 M'Q!'%4G]7' WTM1(U/.6<%W_H0H$]M M]_0T\,ZCMAN%T9G;]2Y.NV>1WPW:G[N?O+-:#P$JVU_K"4 +!PK((VSWN).EQ^T^*\:J MREOB6C1NQ/?PNIT:SOEXS:D>&F;'BQ-BK>X'X*Y)Y\MH0*)*;TQC7%JJO . MWAKH;1RQ#]_K\T ]9]<%B3F?T+0G!MT9+[A#4E88Z8VQPC%HA*O&#F^S[W34 M)9BQ&S5P)Q^".]D**$+ -E\N<]J>LC!ANU&CT$MM\@Q5IPE_S^2;LWQ$XI1/ M\G)$EF2<,TYRUI.R67I&2T_O+A.)QD6:A$[01:2)\1-MXSK\YC*BY7@N&('Y M_Q;S_W'&XX*3N[@8DH2F?5'7K8XH/\!P^M#IJCLYH/'Q!Q8QS=Z>JCGD"IS0 MQQE2F#9M;,)/=!P7-"'Q:)P+ H^8*")GG.6W[&FW5L;+)"P5TVDM79QU9/.= MP%>VA&<*(#"#,J=?LHX1;63"P/QI<]O^D15,>N=8?%LZYP9Y-B*S)0>_T6VV=WQJ[>2/N-W;)TPBZS2=YC M_ NC23'\1'/V-;^A:?P?6L19NO4.V[.H>Q:>^9_.+H+3L.-?G)V>?7*#=N=3 M^Y-_<7[>U;[#]L4-M:[R#;6E"1B:4RU/X?J@6.P70,$-Y]! MUH_/QNR(5VLL55Y"X'!S'"J+H52#0V5^(.-Q(>EYXOR#]47=XUH/;K,[DQ7RGVV^6;+5-6":& M1Q_@.5ZM$_V)59_AT'F(?5@K^9!K6>:==1YWD&(@R%$ M<\UW>BCC(R'GQ>'TW-&'2=4EQ$+[ 0[T7&J[#C5;=T"-4%-=)S* M[-CQG*Z+&2?863\[#65DO1VGI@-4#I":..2N^'B5R0/,'QRX\E@0TP(-524: MU>"==?QVX(1M=2' -@3MZNX1T?'5R:%:DWI$RGLW4.G J=3B*FE*;YCHF33YXIJS9!6X@1-$^M-CF((,W1V8002SJV=KYIJ3 MUU;HE@.WP"UT7?.M-FVY_4Q_0DG0"_0ZS*[+!;=,A$C#N'6(79?;=CH=T OT M0M>EH^M2&>K7=&Y9DA]0IDJB-T02@0ZH [J7;;B91'O8-3X-0!=U)M=%(@%#HI MA>[)R&EWP2EP"IV4PIG4WC(#-(50&D,<[=]^_(W=LG2R37CC%I@*!*;ZV>0Z M8:]BG_'.)@O/ M=14&];S:P =\*AMH7Q?M,8[!.,9SVF'+B91OWL0XQ@9!LRREP'X',L88TN:Q MBBFDQG#$>/(J'8Y8,4:V8ZQBR83."5J>$_F:SE+8QJ968.^ 1CD-TTEX:^HV M\ %[:Q86HMX75%AMU?U[TZ,%ZRR%DB^8Z]\37L2#^X7?C78SV,-CQ]Y;\ESL M/*$)STB<]I))GW&25ZM39)!G(_%5,KOKAJ4L%\_WQ:W3YVG:BY.$YO>$L_PV M[HFG!UE.Q'?D7IB%$Y;VQ?WGK,=&U^+^P'.([WJ=\M]V^2+BC[#\8Y*+'RC* MO!^D)_YB^6:%S8LY,=/T.H%B2"\[_?NG]Q/^[H;2\8?+WI#U)PG[.IBN=5YF MDUS XPNC23'\)-KX:WY#T_@_M(BS]$KR\DK4ZBS)>M]_^:^__;1O-;*L Q*A\_NY]^^5"$$*946ND;&_Q\]/E<0NZ?K;^NSH](W!1N&G\T_>^:?S^92/Z? ==5RM>"1"GDL(T(7U: M4&FU4NU+DE_?D^L)%V_-N7B@M.\'%9"MN+V)R1X-#US1,Y6EQ$(%TNIZ\6=2 MB8;D4?_FR7L>"JZLT&-),KWGYR/WJ+P675AO=KU]8X]H?A.GU4O229'-/JCZ MW/*3N[A?#,7=PA#3SE5TG D=<_9A]L<2'.;OO1@^,0]L"U>&F6T>@5&]D]]^ ML[Y+7SE4F=:IWL==J]\>E=_Y\:[-+X^ZH^[&U]V2O<5:Q\)&Y !MF"MI/H() MS([-7S-.W=)@Y>5=-52]SI)^5=!?8I9%+E;/D7=P<("H(*IZHM;!TV5;JDHF MO@]:7^4TY;%T38B9M?1.77Z/DT20_'+J)5MJANW<2JM_]3AX:Q;\E3F2P8WF M<..4\YA+_Y+DQ6^BZQNSTJ%#?H]OI;/JL"@"%JAC@6% _Y*-&*G\W276OV1\ M+(#]/, !1 !1B^(F"?DJE^N ."!N+XB[2.)1G)9K<\ <,+>?.5=YI*]6IXE! M$6)[V)UIV/, MWAJC7N("Q_75.25&B %.80*C MP"A5YCIN*UW?V] \5B;CAI,#A,/0T#:?[8:K4:[M&W:JK4_/NG6QEF=8/FPL M]NFS[2&L!H:MR/$#3>YRG!L G81.0B?MUTG%FXB@DO4"$KG(H+'06,,T5O$N M)V@L1J)021.P"I549TL_W+H'HUH&=>!/^ /^ /^@+_Z30?\ 7_ M7_/P9YSAC#&6;8C;(JQ836*W9QO#E/FPID#W9>N])L[=&&_4L><[KJLID'T' MFS4[:Z4E@>QZW55E0/LU&V0Y(^,\NXUYG*5$7,Z"W0OZ@W%EZ?7026P^+,'H M%V@"FH FH EH IJ )J#))#099Q_@1]E4656. ANV@^\O%4%-%E/OIFEW';^S MQZ0M-L#HM1T@@HJ>M^TY&^>L%]-"NF9HVB=TE ES_*?\0!D,S;&E75T'_/:O M@I4-?GF_ZW1]=8)O>N/KGLQ :B UD)IGQI9.$+2@-% :* V41JO2=%OJ]KV8 MWO+0&>@,=*8>G>DX?AM* Z6!TD!I[$L98#H"H#?0&^A-/7K3:CDMA3EF36_\ MUTJ-)?'63V5FR,IB0E%,\Q2GN:8R/%S()%,!54 54 54V6 JH JH JJ *AM, M!50!58I-M3"'?E_0ZX2MNG]OD_L%BR5QRMY-S>3Y[IN/"YZ(?T]X$0_N%WXW MVLUR\V.SO+>D3+7'IR=SY>R6I1,F_C_.&1>?<,)9?AOW&*^V-?=9G]""%$-& M/F4CT?+W?^=R/:1Z+!XKLZ7WB,B?7$RXJR3F1=>4G+^^) MKL\T_ENR^KPR<95,^J)^_9?BB6>9"\LOV(_I(S2%-=\L> MW1\_27]8;B07-Z8\EF5/"^#?XR01[3%K(8=0SD6!LHG*0L0+,O&/J$$2WY;- M,VM+^?U0UFG(:%(,I]=\++Y\:!_9-K^N?]^8SRPB?[)L\:/3)"%?96,++:4% MN\GR>V/;.7A+KAZAM"?49")J/RG C32U /J4Q$.1! GMD_G>3"8C>/ MS?^^W/K_; NO%GTBP?T>11G^7)>QX*KJK28TDRO>?G(_>HO!:]56]VO0(I5_%(6/ /=D>^ M92.ZM#@RHOE-G%8O22=%-ON@ZA++3^[B?C'\T.V>1&[HMB/?;PNC1.&;V?X3 MT44G=,S9A]D?'Y\ZF^>UR%=U[7ZXLMO=W$-M?GE47?4W?BZ6[+ J'6-MH%^BMKM,Q_!K,TDJ2''WQ9I+=:,6KIBS7 KC1'&Z<+CJP M?EMP8/U>.;! $5#DP"GR1?KDO\Q]\E^F/OEGJ0$( \)F0?AA[0=8!58-Q^I% M$H_B5&G^)Z 5:-4UM\P*,:G4ZAPR:)N:3J_1;.U]D&HL M5S;*,LB:QNF @'6E#/2?HM)S(#;2;S KDR.>PLBYGN S-X"I.'P*Z?K=Y7)VQKK-$7(P"@P M:J]S'_!JC\%WX!UX!]ZA/P.OIB-$+U(W 0:CP*A#9]1QZ'@*(Q0V-,\<-MO: MIT8>PLD!PF%H:)O/=L/5*-?V#3O5UJ=GW;I8R]OO6MYC3@:"D_UL(C-NOD:X M[%ZR4;?8M\ZVA[ :&'0Z3B=0%YFULTVMP)YV;R!T$CH)G31/)Q5O(H)*U@M( MY(R QD)C#=-8Q;N &\E6'_JZ9+#-BUX\4E85;-$- MJ;?/ J%7Z( IC%;6F]1E$1TNVD@,K"/%78+A.-#M1(#"0&&@, \*XW1<#P)C MGL"HLR7DQPS<07Z6Y:?MA!W(CX'R X&!P#1 8([#EA.VE"U-O':!P6#PP(,# M_8'^V+-MT' L8)0#E8'*[$EENIX3M3H0F&T$!J<(KDDYR7A!V(\Q2SES2,H* MD@U(//NB6D-4ACASS&JM]YIX=6.\2L=MQ]U?8G^UFWI, M0=S&JVJ6Q*/K]3J5<>G7;)#EC(SS[#;F<982<3F+62_H#\:59_#3"2SR'&1X]MS]DX9[V8%M+%0M,^H:-,F.,_Y0=PSUO8M1Z0^[T)[G6_ M[?A==8)O>N._5LLA-9 :2,UNUF@Y7J@N/-STMH?20&F@-#7M1/'5); SO>6A M,] 9Z$P].M-Q E==PF'3VQY* Z6!TC1G![_I"(#>0&^@-_7H31 Y[4C=^;"F M-_YKI<:2N.FG,C-D93&A**9YBM-<4QD>+F22J8 JH JH JIL,!50!50!54"5 M#:8"JH JQ:9:F$._+^AUPE;=O[?)_8+%DCAE[Z9F\GSWS<<%3\2_)[R(!_<+ MOQOM9KGY*5;>6U)FON/3@[)R=LO2"1/_'^>,BT\XX2R_C7N,5]N3^ZQ/:$&* M(2.?LI%H^?N__;\QG%I$_6;;XT6F2D*^RL866 MTH+=9/G]"2&FMG3PEEP]PFE/Z,E$U']. S*@O3@1QI>P'E*9&7(@H#QK@722 M"YO=/&Z ]^4F_F?;X(1\FY*M0DAI3?F3"94%"/*\6/J+S3NDMS*K !.P3)*L M1V?/"+C*31 /#24J-V:]LCE%505XI122J1CH8F9-'M0-W[?')/>>_=F%4AYU MH:[HTLI2XK)%RNO%GTFS?$231[VL)^]Y*+@R?8\ER?2>GX_DDZ*;+9!U4G7GYR%_>+H;A;&&*Z1T8, M(Q(ZYNS#[(^/3QWB\_=>=$$_##_\<.708',O=O5.?OO-^J'9RL'BM$[U/NY: M_?:H_,Z/=VU^>=0==3>^[I8L@FI=1VZ@+Z5V^\Q',&N35FI()[C.G[+Y.'5+ M@Y67=]50]3I+^E5!?XGQ-;E(Y83AG/78Z%I,>0+/(;[KA3MX6D!4$'7_GDX= M/-W>$[IGYEX]]15=3GT)EU,7P9*EMW.L$%,FK=X-@_:"Z71[S):W!WDV(N)W6"XGH[T)%Z_.WW:"2'^V-BN0(Y_#]F"(F %0A(AMGF X M$BJF[C@GJV$#!8."&0)%*-CFR>5<)PC;4# H&!3,("A"P39/[M)VNJ'^O'56 MP 8*!@4S!(I0,"/3X5F!'<@89,P0*$+&MO#H!RW/B7S,)I6(F"5Q[2I-MC)3 MP)*]-B]Y,0U!G1+8L"YBOH7%[!TL&LZ7^K+%.4X0,C *C]CKW :_J MBJX#[\"[@^<=>'7 O(HB#WP"G\ G1>8Z#IS UW2$^_/FF<-F6_O4R$.X.$ X M# QM\]ANN!;EVKY9I]KV]*Q3%RMY^UW)>\S)0'"RGTUD@LC7")?="S;JEOK6 MV?80U@(]/W*B8.,L3OIL:@7VM/L"H9/02>BD<3JI> ,11+)>/+Y.194U B36 MO'$5E6P M13>DWCX+A%ZA Z8P6EEO4I=%-'0*0=OIM%1['PS'@6XG A0&"@.%F2F,Y[3: MZG)$60$#.P1&G2TA/V;@#O*S8H#CA!'&-P;*#P0& M, @3EN1T['519'^-H% M!H/! P\.] ?Z8\^F0<.Q@%$.5 8JLZ](WL!Q(Q\"LXW X/S ->DF&2\(^S%F M*6<.25E!L@&)9U]4:XC*$&>.68U3^8?777MFZ!Z-:!G7@3_@#_@#_H"_^DT' M_ %_P%_S\&>VP$BINAYVYZS<DRO?%U3V8@-9 :2,WJYP(G"* T4!HH#91&\RPV.NG,C-D93&A**9YBM-<4QD>+F22J8 JH JH JIL,!50!50!54"5#:8" MJH JQ:9:F$._+^AUPE;>O_#W0J62.&7OIC7Q?/?-QP5GP;\GO(@']PMO&>U6 MN?G!5MY;4B;#X].SLW)VR]()$_\?YXR+3SCA++^->XQ7.X_[K$]H08HA(Y^R MD6B<^[]SDHU93@O1>H1/KGGBP>*[.E]XC(GUQ,N*LDYD77E)R]O6Z[/ M-/Y;LOI$,7&53/JB?OV70GYGN07++]B/Z2,W+!6F2JJ[^Z,XC7DA37?+'MT? M/TE06.[U%C>F/)9E3PO@W^,D$>TQ:R&'4,Y%@;*)RD+$"S+QCZA!$M^6S3-K M2_G]4-9IR&A2#*?7?"R^?&@?V3:_KG_?F,\L(G^R;/&CTR0A7V5C"[FC!;O) M\GMCVSEX2ZX>H;0G"#\1M9^3@ QH+TZ$Z26HAU2FBAP((,_LGTYR8;&;Q^9_ M7^[.?[8%3LBW*=4J?)2VE#^94%F H,Z+I;_8N$-Z*],%, '*),EZ=/:, *O< MI?#03*)R8]8K&U-454!7:A692H&N]JK+Q3G]^Z?W$_[NAM+QA\O>D/4G"?LZ MF-+\6VD#8B3F?"F-]_^:^__;2BB"'-V1GEK"]Q)-JR M?+K\E)].BF&6BSKT_T>T5WY9B%*^CN7W?R:"T6?W%S]8WHLY^S,7S?>-IC?L MX==$GYM*=(!)W>BUQ<>KYWM$O3]IKTHXW1/EABV)G3,V8?9'TN5G[_4XI+'?*#>63D4W7S5I'JGH/MF M_51@Y>1D6J?7/=Y^W>-^K;_^RKI[;KT_7^OC'9M?WJOYY_<+'$M77VOW3, ^ ML _L _O /F;:Y^%U?2,]Q[7;!_C9$#]FKCS4;A_@!_:!??;3?SU48UU?MFDJ M\9>BJ%<89\%YU6-RG6BAFMW=K",?*Z_N*N?==9;TJW)*9S7Y.G6@_JOTF6YJ M-TLFLUJCL4%&C63T5#%P;RDM]TW8K_,5#P!0>7"'R:IFEM%@'TQQ@!\,477T M>'],Y ([NCKMJG10J#I+:._[N\O>,$L8)Y]IG)-_T62B[$A@8$L]GEYKRXWG MB?KA]XV-:)S*^*9/XON<]HH)3=,J(8I>3W^G]46E]R5P86_YE38%Q3>^^SI %U"L_!B4L87 W28DL(^ ML(_I]L%9$R_D--I'HOM#!Z!%AGMI.*$ ;2=A&T;;TFCO8+$M+=8Z<9L(LP,6 M-6-R 'K(;6PF0@Z)6KO8QWBT(=?HHY%2UX?.0&<:U(4K&S!JZ-0;:+ #1IHY MN,)@4:^3KG&^.&6G#$-P3+.//2Z/IME&F0.M:89I*73'0G#4V\>8@4S+5W9V MH"F=K>Y))_B@=ZO^%G$Q&L[2=)>3KH$/X(-5]M'KO[37+LW'C3$HP;A"C1_$ M(+^C7@>)I_\,:PB.-8;3/3ON*!OE'8S1$*RT/Y[<1#@(&M9K4:QGL3 H::+ #1IHQN,+X2+-?JG'N)V6= M/@3'-/OHG>6')UUEKLNFV0;Q.<\8IG/214"@P8)CSD F:*FR@RF=K>Y))_C0 MX/B<5@@^@ ^U]P\&NU24\0.XP;CBD'04\3DO.DCT[UJ&X%AC.+VSXS:2"2$^ M9R].F";"[(!%S9CA52O _G C$=(P:AU@?([GM%W]80,@%\AEB^&TTDU_/P:D M880$$5?NF6J< TI9IP_!,L$'QH,#W7-8D N!.@O/18[?P5%7(%>3>BZ#74I-S&AYP$@S!U>1,F=^XT4< M@3K2":7,*P#!,X&UF$LXT:!('9=Q-Z)OU9C];_KYW1C--(/G8["$'&()$3R ML(>-F.&9:#C=Q,7H>[EG$1V+NJUNZ%@V],&^+ZBPR\K[5_S]T_L)?W=#Z?C# M96_(^I.$?1U<#FG.SBAG_4_9:,Q23HLX2\M/^>FD&&:Y>/G^_Z3"K)=%UOO^ M=2R__S.A*3^[O_C!\E[,V9]YW&/?:'K#KH3=SA)QWR__];>?7OJU/^G]B*7% MZ1W-^PL%\W_19%*^PBGGDU'UV96LY$/)HN52V3S?V.#GH\_G,L+MGZV_KLZ/ M2-P7']!>\;+JK M>,0X^8/=D6_9B#[?&2X\GL0I>S=DI1)ZOOOFXP)\_CWA13RXKSZ*A1W3XD,@ MB:W4]3QD1+8?3>_)1%B7%.*#09:(/EW(":%S6XI/0FI\*@?=*? MY/)F^>@2%'=YJ7N!;TZ8J'*?G+,>&UVSG 2>0V23E?^V"4W[9&4BL5U^\,.+ M#-JPO5ZD^T(9C[3<%>VYV,#R>O%'TBP?T>21W'ORGH>"2QZ3'DN2Z3T_'[E' MY;40J=[L>GNTWL7]8BC^%'6<:J/0O82..?LP^V.I\O.76ESAF>NEOS).8O-% MHND[M=^L5^25G<;T^5<^'M3[\Z]\O%/OS[<.NO9;_OQN:Z8:%N"-'+*7EW>5 M3%YG2;\JZ%?9)Y&_1 ^B:E")6?46FQ[W#[Z7 :1LF=/O W?^6'X@Q\JDP$+UAY%O,O[_[G#/Q%RT8< @<[@6'%S_&K"=Q^'L\ M .J NIK4[U]90HLXB8M[8! 8K >#Y_%M+-JM3_Z*6;+Q2-#$V%@K'.(J-RD; MM,9EF0HJP5Z1 2AM(N9_>0<>F\A/WC246!12;#<7VB4_*=4U+ MS H\-AN/07CB0QN!11.PZ)Y$&T,1J;F4)H<'0=7;QYQI:E>9=\04[.N><((/ MIME'YTN M=D]"*!S@MK<)9GN7":;*S *[[_5?E44@&WR.T[A@O\>WK/];6M#T)A;/B#)8 MP3]/BDG.3D>9://_E&7+;0TI9UOG$/"]H'ON!9_:[3,_;+D7W?9GO]N-3L\_ MG7_J>NVV]AP"B[CS@O&/O2<5N!"_,:(R+IHNV).PRJ!E(@%&>T.2#73M 0L,9U27[@M+UM- 9]TH'W M23A.9P]&QG$Z"B,Y?"=RU4U8<>K!ALKYVM@$%1$$CR(3V(V,;_C&QO*A].8\ MYKTDXZ*8;0(.O.Z9=W[^N15^"L[#J'46M5SWXE/K-/3/6^W/KJ\]X$#KHM;9 M_US^]L?%Y26YO/CU'Q=_7%V^V.Z[+?]W=WOK[JL@NN&K[OT8B"%=CFGDB*G*8^E M.-"D/,."?X^3A(G_L_PV[C'ND+MAW!N2..TED[Z@IHR0F9:6I3)D9O9$.LFY M_($![V1'S,OA&%"\!,V8E:D@2WU8OM.DOK2MI\9?E+G_GBX\[U46/YNQ12=<346TF))>?$'+U MZ.E/PY@-R,4/UIL40J+)U\% /)'+W\QD$%%<<-(K[YFW3Y_U8BXK/*+?Y:U9 M3CY]/?^'0W)V&[,[3@9Q2M->+-HK3@-*5HSP=(YHQ/$E'" M(,]&)69&V74L2-V/Z4V:B3KU>(G(LCPBP9$D5)3R0)[JL!Q[S\,I2YOD-Q+/ M)?^JZ)5YM5YZH_F[G"S24PQD1N.$%=,SACB5*CDHS;OJE^)T7E;.>ME-*EY1 M*!$9YZR@/\@-C4N-4E+?_VY)/_BRSV&7LLI*<[8(!EFOE,4E6K@@1BQ429Y2 M(2@A\\5.!#;O22I,*ZI$;VYR=B-P6=9# G_%1'Y/%OJ; MJ?I,%3&?#2@?>I_R'6;*22:I-'L)^FPP$&_5C^7_9"/,=+K\>?F0&!32F[*# M&E-1(29>MTI+>M!Q7E4H]:Z''H[!9 M,>*93/2>\N'KC.;5&))GY3CJH6W%<#Z;W S56*6U'%ZDM&4W'PV;V](GY,OZ M ?9#\]R)+F'>GE+U1?.7O8G:AEO.9K;;H&6AK<2 HA?+^EHEAHNS<);T1=_[ M[RR7?>JH_&$^C,>R>Q7-PHMRB/3\"'0VSYI/4&:C6MG<#Z(JRI"_>O0P/#YZ M&!0+7JOL\M!%/S-I8;?E;B;!-]%4Y00S[56$%(V2]G0LM#>1;9A-\E(Z MLVH/S6S:>2WW2Q$Y,4T7VGR4]5DRG=UP,=65H\^*RB/Z(QZ)ERJ;___$$%3" M3#"E5(,'SLNW$!<#\>/5Z.Z$_,I247K56=/^*$Z%*.95MS#=X#,=\(K1ZJP" MY2_*NL[>5LXCQI-\G,F[Q:_VQ;P@EV4M3*2KWY7S\23C L^S >DFV)U]QUE2 M'4WS\,,/D_D^+6AEF>F^HFJV0GL]&40O7V2<);$4D=D^I6=&U=5L1@@IY=-A MK[!S+X^OJU?\(Q-C]5=/+:I+>?L'"82X-].,R\EH5#)_0"X7IA:G\VK\.:W& MBB'X*Z$K/2Y?S_\AYB;"2+*]*Y>)["F9,,[UO+V%'88Q?X#O#!BE(^71-&?Y MT1F6^I5O7!CUFHGF4N)A*=W 6HFN1ZETO>UT/4*V(TLGK&R'L@\2/?^]//ZW M:KUR7( ->6LWY'6[)Y$;NNW(]]NBOE&H;GN>'ZHY2[?>_7FO?=RU^NU1>53> MPLK7?/ZUW2UO%? 0F]F(/)3&Y5>9CV+J.$_:L$W;<@<\N5B]M@?,J<$UJZ<+>Y?39:7+Z>J"63!4%@D+C-J#T=/%%;W?%E;T M?J]6] !50-40J);+ME_F895?IFNU@*BA$-U/ BJ;('R:).1K&8%I%%8!Q\;F M0[O*Y)KYMVHQ"ZC3X+\!ZI91-\4;PVM!O,"MS(YW!2$"3, "A"PC9/6>$ZK;;^A+]6 MP 8*!@4S!(I0L,VW_GF.'VR32!<*!@6#@D'!C%&P6>H*S]=/5"NP QD[!!DS M!6U&*)4Q8M1NM90F,32]]:$UAFI-,\^.#UHG^KTMRS#19R+EA,11N$8NO#9Q M?35']$@-T2.OUN]]:W;+ZSA11YF+R10.Z![Y@!,-YH0&GP5X 5Y8SXMNY+B> MLH@04 *4L)X2Z"K "_!B^;G0"YTH0E\!3M2^1F.,>]3OJ'./@A"'00CL(UF_ MC^3=-/NW*LP99#ZSP*AR&UV#SLYU?2?J+!]BHN1DO"T,9PHM=7<)H"?H67, M&B@*BH*BH"@H"HJ"HJ H*&HN11M#0=7S3- +]-JO<%OMO0]/EH]\0\\':IJ_ M'/#(:)[U;O_+R74AD^2I MNA8TIW'(*J?)\:1E2.YP=.U%*W:04;4,&GP^63 MXGP[(!/(=+AD\MRNX[?4Y=\#F\"FPV63/O\U& 5&'2*C/,=O!T[87CXF''P" MGQ ON*Y=G2"'1$@! + 506 TY3>,-$#*TQV89#IS +B82ZZ^Y$GQCC(& 9Z M@5Z63,M!,5 ,%)OW8)X3^>C P"ZP"QT8* :*V4:QP V<(%(7? EZ@5[U&\X8 MI[375N>4!K? +5V!R]9[J__,XUM:,$+3/LEPIKR9.S:M&QUY0=?I="-E K;& M/J:02;>0@U.'S"FW[7B=#C@%3H%3JCCE.4&PMQV4H!0HU7A*^:'CAACY64^I MYZW5VV]U,,D^ID2^$ZC;F08J'$SO4F^/4JM?.#Q1'=J/ON7 ":4Q MF-G^O!97,JD%R=DM2R<(9S9+VP,A6?UL7JSM+>IUM7W/8M Y3 MZM@]%[9"Q_>4';RXNTVMP)[NGADZ"9V$3AJHDT';:;NE$$F()$02(FF]2'HR'[(3>)JB'Z&3T$E# M=%*I92TAM^N>&+#BL S#FBRL7 W>@/8UA1#,@]="#=%K:RRX%\U!P:1[28TDRO>?G(_>HO!9XZ\VN5YCI*AZ)9ON#W9%OV8@N,?4N M[A=#\:>HXU1,!6D2.N;LP^R/I2[$/6KG*:\KB(LY0F MI;?D\GN<)$+D+J=>#K-@J,S)"8S:@]%3SF,NG7$2G[^)+GC,2L\1^3V^%;4" M5 %54Z#Z)1LQ\H71I!B6:/V2\;& )B!J*D1US%SLAO!IDI"O2+_79#@:AKAJ M8^\WM1M[@;IZ,_\8C[HIWHBRD(1#1QQ.8GOA)#;6%W6/^ZJP9I#9S *A#I+: M'8"I+OBW\;&]H>\Y[AX.L[,"-_(Y!.Y"P@R (B1L\SU<;2?HJMN;8#5LH&!0 M,$.@" 7;8@^&TU)X7H/5L(&"0<$,@2(4S,@S+ZW #F3L$&3,%+09H53&B%$8 M=IRNPJP>IK<^M,90K6GFZ:!!<*+?V[(,$WTFPI9OZYB'L/GI^FJ.Z)$:HD=> MK=][U^QNVPD]G'8#3H 3>6X 5X83TO(M<)764IH4 )4,)Z2J"K "_ B^7G M6IV.XV): 4[4OT9CC'O4CTZ4+3V $(=!".PC6;^/Y!VOTC2HPIQ!YC,+C"JW MT>E; =O[K+CCA+HRH&]A-U-8J;M' #O!SIKCST!14!04!45!45 4% 5%05%S M*=H8"BJ>9H)=8-=^==MJWWUXHNG 9'1\H*;6Q8!'1O.L=_I?3JX+F2)/%=@. M'5.ZHQ!49?O4<7BIZX:.VU46I(#MI^#3 ?-)<;8=D ED.EPR=5VGJS#Q"\@$ M,ATNF?1YK\$H,.H0&>4YGN\[K6X+? *?C([^MB-+5KNC+C0<5 *5$#?^4MPX M3>D-$WVWPAP9!IG.+" >YF*]W^HX44O=Z A+@J 7Z*5U0@^*@6*@V'R&WW': M;71@8!?8A0X,% /%;*.8WPZ=T$6N9]"K[H#I1@9$>^T399G@P"UP2U?$L_7> MZC_S^)86C-"T3S(<16_F3D_K1D>>[SE16YV"K[&/*632+>3@U %SJMMQ_$#U M;@)0"I0Z7$IU'"_TP"@P"HQ29*Z6Z[0]'Y2RG5+/6ZNSF[$>'COVWNI@DG5, M\=MM,4521A50X6!ZEWI[E)J]PNA;0*CZ?<";>=3M3X=Q)7-AD)S=LG2"8&:S MM#T0DM7/)M<)>Y6XVWWM%TG/:8K#3R'84T6 M5JX&;T#[FD((YL%KH8;HM346W IET6Y&>WCLV'M+EG:2D3&]SW).:,(S$J>] M9-)G?!9,0 9Y-A)?);.[;EC*<0W_7:)SNTY_N""OE8 M=?_>.N:%!DSBE+T;LK+!/=]]HPOWF_ZUZVMO*G<+93QBB"O 7I81BY9.J^O% M'TFS?$231R3RY#T/!9>M*L"3)--[?CYRC\IK09_>['J% :_BD4#A'^R.?,M& M=$EX[N)^,?S0[9Y$;NBV(]\7DWLW"M_,>@JA" D=<_9A]L>2*8[6*\D*DF\> MSU2]H==]LUYO5W8-T^?K?=RU^NU1>53>PLH'AUSYUSYN%?"0%L&0[.)-FB0] M&L48OB^NFE6H,EAY>5>-3*^SI%\5])>B;EA1H.0V02J12$+ M3//K[$.YKG*:\KB(LY0FI4/F\GN<)$+'+J=>&B -2%."M%/.8RY=@A)EOXF^ ME+L.)U:B!@$' #($B!,S((S"MP YD M[!!DS!2T&:%4QHA1*Q3CJ5#_>,J4UH?6&*HU![B_/&@IS!F/W>-F0*])G$60 M^G1A-D?820UA)[O8JM:#& [C$3.-%@3FCP=H 7X(7UO&@' MCMM1EC8.E EK*<$N@KP KQ8,:WHADZH[NPC<.)@.*&7!W7Z3OWNB;)<%"#$ M81 "&U#6;T!YQZN,":HP9Y#YS *CROUW2HUD-$SVWPOP8!IG.+" >YD*] MUVTYG9:RK6]8#@2]0"^]TWE0#!0#Q>8]F'0_=\ NL OL0@<&BH%BEE',=]M. MIZ-N 17T KWJ-YPQ'FM/930TN 5N(9/SZN?^S.-;6C!"TS[)<'Z]F;L\K1L= M==M.5Z%_>HUY3.&2;AT'I0Z84NW(:47J/&:@%"AU\)1R E?9L01@%!AU$P* MQ+@OQ+C/>DH];ZW.;L9Z>.S8>ZN#2=8QQ7'J5FI_#> MDJ""4(=!*(V1S/9GPKB2:3!(SFY9.D$LLUG:'@C)ZF>3ZX2]2MSM/B-=W:G5 MZVS[FF.M[=@DY#F>W'071?7;U KLZ>Z9H9/02>BD>3H914(H-;F-(9(028@D M1-)ZD>RZ3A"VZS>H%<"#2$(D;<$J1-*.U5*()$02(@F1M%XD/2=H>4[D8S ) MG6RV3BJUK"7D=MT3U4EH7V'@.0QKLK!R-7@#VM<40# /70LUQ*ZML>!6*(MV M,]K#8\?>6[*TC8R,Z7V6$9?AOWQ-.R\$DN[BW*Y&JD)_YBXNE!EA/Q#+D771YA:5\4 M<\YZ;'0MB@D\A_BN%Y[LT)[O"RKD8]7]>^N8%QHPB5/V;LC*!O=\]\U'XT81 M=;WLE6C[098(21"4(&6C"= 4)3"*H?@S83V)K4&<2E31A/1I005#TU*T2]Q= MWY/K"1=OS;EXX&8DH/5!164KC#Y;W852'LF *QA=EA(+.*?5]>+/I%D^HLDC MI?#D/0\%5U;HL229WO/SD7M47@N-Z,VN5QCZ*AX)JOW![LBW;$27U'5$\YLX MK5Z23HIL]D$E1.4G=W&_&(J[A2&F?:30PH2..?LP^V,)#D?K-72%O&T>QU6] MD]]^L[ZG6=DI3NM4[^.NU6^/RN_\>-?FET?=47?CZXY,$(8D5&_2U/#1""8P M>R_@FG'JE@8K+^^JH>IUEO2K@OZ2\[.+E?.SC3>V@Z@@JE:BUL'395NJ.IEE M'[2^RFG*XR+.4C&SECZ:R^]QD@B27TX=-TO-L)V3:?6O'@?;;"3= _R5^8/! MC>9PXY3SF$O_DN3%;Z+K&[/2H4-^CV^EL^JP* (6J&.!84#_DHT8^<)H4@Q+ MK'_)^%@ ^WF X@ HA;%31+R%8D,@;B](>XBB4=Q2N4 &)@#YO8SYRIWYFMU MFA@4\:'3F_)M,21!_ [+Y32V-^'BU5FN;-QBD#6-H[IR*;0[@E-=]/ !! >' MK=#Q/?WG,%B!'/D<8G\A8@9 $2*VN8@%;:?=4K>_P6K<0,(@889 $1*VN82U M?*?EZC^0V K<0,(@889 $1*V>4+FT'%#=;GOK(8-% P*9@@4H6!&GOIK!78@ M8Y Q0Z (&=O"IQ^UNDZP>4@X1.PEZU@2,*_29+^5V\*K3;P/6\Z7[+5YR8L[ MW>N4P(9U$?.],69OC=&0^,UQ?9R2A9-,P"B3YS[@55WQ=> =>'?PO .O#IA7 M8H08X*P[, J,4F6NX[;2];T-S;-51DE3> @G!PB'H:%M/ML-5Z-C!&LLOI'K(X[W+H'HUH&=>!/^ / M^ /^@+_Z30?\ 7_ 7_/P9YSAC#&6;8C;(JQ836*W9QO#E/FPID#W9>N])L[= M&&_4L><[KJLID'T'FS4[:Z4E@>QZW55E0/LU&V0Y(^,\NXUYG*5$7,Z"W0OZ M@W%EZ?7026P^+,'H%V@"FH FH EH IJ )J#))#099Q_@1]E4656. ANV@^\O M%4%-%E/OIFEW';^SQZ0M-L#HM1T@@HJ>M^TY&^>L%]-"NF9HVB=TE ES_*?\ M0!D,S;&E75T'_/:O@I4-?GF_ZW1]=8)O>N/KGLQ :B UD)IGQI9.$+2@-% : M* V41JO2=%OJ]KV8WO+0&>@,=*8>G>DX?AM* Z6!TD!I[$L98#H"H#?0&^A- M/7K3:CDMA3EF36_\UTJ-)?'63V5FR,IB0E%,\Q2GN:8R/%S()%,!54 54 54 MV6 JH JH JJ *AM,!50!58I-M3"'?E_0ZX2MNG]OD_L%BR5QRMY-S>3Y[IN/ M"YZ(?T]X$0_N%WXWVLUR\V.SO+>D3+7'IR=SY>R6I1,F_C_.&1>?<,)9?AOW M&*^V-?=9G]""%$-&/F4CT?+W?^=R/:1Z+!XKLZ7WB,B?7 M$RXJR3F1=>4G+^^)KL\T_ENR^KPR<95,^J)^_9?BB6>9"\LOV(_I(S2%-=\L>W1\_27]8;B07-Z8\EF5/"^#?XR01[3%K(8=0SD6!LHG* M0L0+,O&/J$$2WY;-,VM+^?U0UFG(:%(,I]=\++Y\:!_9-K^N?]^8SRPB?[)L M\:/3)"%?96,++:4%N\GR>V/;.7A+KAZAM"?49")J/RG C32U /J4Q$ M.1! GMD_G>3"8C>/S?^^W/K_; NO%GTBP?T>11G^7)>QX*KJK28TDRO>?G(_>HO!:]56]V MO0(I5_%(6/ /=D>^92.ZM#@RHOE-G%8O22=%-ON@ZA++3^[B?C'\T.V>1&[H MMB/?;PNC1.&;V?X3T44G=,S9A]D?'Y\ZF^>UR%=U[7ZXLMO=W$-M?GE47?4W?BZ6[+ J'6-MH%^BMKM,Q_!K,TD MJ2''WQ9I+=:,6K MIBS7 KC1'&Z<+CJP?EMP8/U>.;! $5#DP"GR1?KDO\Q]\E^F/OEGJ0$( \)F M0?AA[0=8!58-Q^I%$H_B5&G^)Z 5:-4UM\P*,:G4ZAPR:)N:3J_1;.U]D&HL5S;*,LB:QNF @'6E#/2?HM)S(#;2; MS KDR.>PLBYGN S-X"I.'P*Z?K M=Y7)VQKK-$7(P"@P:J]S'_!JC\%WX!UX!]ZA/P.OIB-$+U(W 0:CP*A#9]1Q MZ'@*(Q0V-,\<-MO:IT8>PLD!PF%H:)O/=L/5*-?V#3O5UJ=GW;I8R]OO6MYC M3@:"D_UL(C-NOD:X[%ZR4;?8M\ZVA[ :&'0Z3B=0%YFULTVMP)YV;R!T$CH) MG31/)Q5O(H)*U@M(Y(R QD)C#=-8Q;N &\E6'_JZ M9+#-BUX\4E85;-$-J;?/ J%7Z( IC%;6F]1E$1TNVD@,K"/%78+A.-#M1(#" M0&&@, \*XW1<#P)CGL"HLR7DQPS<07Z6Y:?MA!W(CX'R X&!P#1 8([#EA.V ME"U-O':!P6#PP(,#_8'^V+-MT' L8)0#E8'*[$EENIX3M3H0F&T$!J<(KDDY MR7A!V(\Q2SES2,H*D@U(//NB6D-4ACASS&JM]YIX=6.\ M2L=MQ]U?8G^UFWI,0=S&JVJ6Q*/K]3J5<>G7;)#EC(SS[#;F<982<3F+62_H M#\:59_#3"2SR'&1X]MS]DX9[V8%M+%0M,^H:-,F.,_Y0=P MSUO8M1Z0^[T)[G6_[?A==8)O>N._5LLA-9 :2,UNUF@Y7J@N/-STMH?20&F@ M-#7M1/'5); SO>6A,] 9Z$P].M-Q E==PF'3VQY* Z6!TC1G![_I"(#>0&^@ M-_7H31 Y[4C=^;"F-_YKI<:2N.FG,C-D93&A**9YBM-<4QD>+F22J8 JH JH M JIL,!50!50!54"5#:8"JH JQ:9:F$._+^AUPE;=O[?)_8+%DCAE[Z9F\GSW MS<<%3\2_)[R(!_<+OQOM9KGY*5;>6U)FON/3@[)R=LO2"1/_'^>,BT\XX2R_ MC7N,5]N3^ZQ/:$&*(2.?LI%H^?N__;\QG%I$_ M6;;XT6F2D*^RL866TH+=9/G]"2&FMG3PEEP]PFE/Z,E$U']. S*@O3@1QI>P M'E*9&7(@H#QK@722"YO=/&Z ]^4F_F?;X(1\FY*M0DAI3?F3"94%"/*\6/J+ MS3NDMS*K !.P3)*L1V?/"+C*31 /#24J-V:]LCE%505XI122J1CH8F9-'M0- MW[?')/>>_=F%4AYUH:[HTLI2XK)%RNO%GTFS?$231[VL)^]Y*+@R?8\ER?2> MGX_DDZ*;+9!U4G7GYR M%_>+H;A;&&*Z1T8,(Q(ZYNS#[(^/3QWB\_=>=$$_##_\<.708',O=O5.?OO- M^J'9RL'BM$[U/NY:_?:H_,Z/=VU^>=0==3>^[I8L@FI=1VZ@+Z5V^\Q',&N3 M5FI()[C.G[+Y.'5+@Y67=]50]3I+^E5!?XGQ-;E(Y83AG/78Z%I,>0+/(;[K MA3MX6D!4$'7_GDX=/-W>$[IGYEX]]15=3GT)EU,7P9*EMW.L$%,FK=X-@_:"Z71[S):W!WDV(N)W6"XG MH[T)%Z_.WW:"2'^V-BN0(Y_# M]F"(F %0A(AMGF X$BJF[C@GJV$#!8."&0)%*-CFR>5<)PC;4# H&!3,("A" MP39/[M)VNJ'^O'56P 8*!@4S!(I0,"/3X5F!'<@89,P0*$+&MO#H!RW/B7S, M)I6(F"5Q[2I-MC)3P)*]-B]Y,0U!G1+8L"YBOH7%[!TL&LZ7^K+%. M4X0,C *C]CKW :_JBJX#[\"[@^<=>'7 O(HB#WP"G\ G1>8Z#IS UW2$^_/F MF<-F6_O4R$.X.$ X# QM\]ANN!;EVKY9I]KV]*Q3%RMY^UW)>\S)0'"RGTUD M@LC7")?="S;JEOK6V?80U@(]/W*B8.,L3OIL:@7VM/L"H9/02>BD<3JI> ,1 M1+)>/+Y.194U B36O'$5E6P13>DWCX+A%ZA Z8P6EEO4I=%-'0*0=OIM%1['PS'@6XG M A0&"@.%F2F,Y[3:ZG)$60$#.P1&G2TA/V;@#O*S8H#CA!'&-P;*#P0& M, M@3EN1T['519'^-H%!H/! P\.] ?Z8\^F0<.Q@%$.5 8JLZ](WL!Q(Q\"LXW MX/S ->DF&2\(^S%F*6<.25E!L@&)9U]4:XC*$&>.68U3^8?777MFZ!Z-:!G7 M@3_@#_@#_H"_^DT'_ %_P%_S\&>VP$BINAYVYZS<DRO?%U3V8@-9 :2,WJYP(G"* T M4!HH#91&\RPV.NG,C-D93&A**9YBM-<4QD>+F22J8 JH JH JIL M,!50!50!54"5#:8"JH JQ:9:F$._+^AUPE;>O_#W0J62.&7OIC7Q?/?-QP5G MP;\GO(@']PMO&>U6N?G!5MY;4B;#X].SLW)VR]()$_\?YXR+3SCA++^->XQ7 M.X_[K$]H08HA(Y^RD6B<^[]SDHU93@O1>H1/KGGBP>*[.E]XC(GUQ,N M*LDYD77E)R]O6Z[/-/Y;LOI$,7&53/JB?OV70GYGN07++]B/Z2,W+!6F2JJ[ M^Z,XC7DA37?+'MT?/TE06.[U%C>F/)9E3PO@W^,D$>TQ:R&'4,Y%@;*)RD+$ M"S+QCZA!$M^6S3-K2_G]4-9IR&A2#*?7?"R^?&@?V3:_KG_?F,\L(G^R;/&C MTR0A7V5C"[FC!;O)\GMCVSEX2ZX>H;0G"#\1M9^3@ QH+TZ$Z26HAU2FBAP( M(,_LGTYR8;&;Q^9_7^[.?[8%3LBW*=4J?)2VE#^94%F H,Z+I;_8N$-Z*],% M, '*),EZ=/:, *OY5X8D1,)I#XY9STVNA; #CR'^*[7 M*5]'_+%\:./2D?D\QXH%20X*$A96/--/*6)D+-A(4'DV*2R^9+"X'H M,;T?E>,(\0T=BS'$CW@D&B>Y5U1IW^EX:BJML"7:3N@MYZO>^:623 ZF15OT M92? 9 L(]8CS4A6487K5,EG-=O0"122S53.?$K'B8:5T=V*(2-*L[!2Y> M9E9+^8+/O%\HR'S)&/DC*QCQ.LZK+5)=RML_Q(+O<:]Z\=^E/'-UC3>8Y.7D MH<\*&B,BIK&%7V4U)X24X8EYU<&(B40['Q!3V7B&#'3]2U%7X2?3I9<]_FHLAU V3!9W= MSV_YL^IY3N]HWO\Z+H<-OXH;"_Y;^J>H>-;_WW(,R/JGHA7H#2N_/!>U_BRD M]5^R-[N2 ^*'%RF'+>+B&QO\?/3Y7+;G/UM_79T?D;@O/J"]XIWKGW5;GT]/ MHY8?A<'9>=3]%)X%YT$[_-QMGW:[1[\\&8LNML=5/!)#E#_8'?F6C>CSH3.O M&RG_>FJ^6_[9FZJAKFR'#_D%^\'R7LQ+?/>JB=I M0&,ZTNG'?)S0^\H?CKF[,/LCX]/8V/F+[48C3+WH?HKO82;![14[]3N_/_M76UOXD@2 M_GZ_PLKI=%]( !N_S>Z-Y-?52G?:Z';WI/NT,K8)K;$QU[;#Y-]O574;FX09 M((&)N;$TB@9PMZOKY:GJ-O7PM\.GM'O/C>6:WC;[O^]PZYJ%OZJUOXZ] MX0)\N+TD<:"7&X&0\R)+Q$14$RC_A<1TPG.2GC]2.NM9W)N>(ZF'*+^_O?-] MW>'B% _FOX'+IP=_'#PP_?Q0]R& M*_]I3I7E#OY8=?>1JNHJ.,+4?0\VAKZD*_[YCMZTXLRLH0^GEQ[R/87665O^ MK@+1>]$/>!VDH>KD3KL\1EV%UPP -@!83UQQ +"C567>32Y/&'453O-6_+J2 M1N@+;P5??IM@./[I#:KW!G5F]MF.#/KB^YN28,F-IWL[/] M*&9?+#F@P( " PJ\T_ZC+X9\EYU$CXY'+KS%N#SMZ("RW^/3)F-/[\CPM*D' M'O(]A=99#VO[XFV].(_M#^9[?AX;9'<1=GE?R\PN]GLL?T/HM6Y7V1L?CIB&9%S_-MW=.=T'5TW;8M M1S11DF*C;IJOL^(IE1,G M#*:N"M[0-1 1AKQ"Z38HEHJ8%6\*5LBI[[=M="Q'"H\P@IX4S(B2.>9_-2M9 ME38D)UU5C6CI"IH^?*M M3K\E\D>@'G8D%QHL*\YBE%I\*-7"RK).$]'C*9@K<([-DL5+[,,6)"0/J,=Z M78A&YE5-/:L2DX<$Q'' MO],X98\HSM%!KPEXMZDS97OZUG[)X#4:T,_-6$# ITCYA M#W(.OI<174!#Q)) 7"QXD2O_2A/(\5S(+5ZP!!G;P(%SB&#AO \8P"N"CO8C M,"2DHT2AX9(.;(U.2'/!;1^QJQD@!_N:BYH3>56P!0IBA2LI&%%+2:.EJ%E+ MQ-.6>4I2PH%]B="HPD"$&>:T5&(7B!2B D ($,"'RX7;8Q%39Q%O)E8V##Y$ M^HLY*BG+4D2 KT?E6?WRW*WT/P/\(M()(CW4DEQ5-!?D"ZB(EPXRZG+L"6]) M4H[@V@&SB!+!J),)"!0?TBU@RXE'2KS$Z@:31G-_M,4ZJBIPG7(D!JA0"&PA;ZNX&8;!DY7+1E/;M'2 M%F]3AJN"YXN<+(F'>&J.O-C3N:PU'BK-ZEWY"-1Z%M1.$F2"EJJ5*@6 M28\@C/".R"[ D6Z-0JHCK92A'$*_V[JA(]06%,T?=N3JZ(X< E*) MDK&H&#^-QG8.245NG%@M'9?MN>?![ MF?ZR"+9+/*(.L&>Z';J:ZTP"?>;8KJJ%IF,9INEZCJI>OOC?P5OUV^+M%^J M5G^4_:%\S&69>?9,_YL@3@.PBQH4#=D*?(5!J/R*D2E(TPB%5^"@.68 ^/3ZB2ASW$B)N*+=#Z.;1I[3C\H1TG?6(3+M8M%"'23=-MH4%YAK!-$;\ M8TSD(+;=6C0L/7AAIY#^TAAQ%Z)'D=&W=[5-IM@G#M]'EYG4O$EFO*$0DA @ M<2$OH'8JP:G8 D !1&R5PKZ,6WNE$Y1((DN0+*-#&(()%P#@@5%%V>KFH2@2 M+%]&SWC<7O"\C78(8P%I%H T@BFRT2_ YJ;@GR#E_WUW TF4KE3.46479Q'+ M=ZE:04Q>$]%DMH P WO24CJ6&TFN4=K"5=%G+/V\4#[36[S F%M6U?K#>+S9;.X^ MSWEV5_"'L3J9:&/\>(P7WLCKL1KYQPW5GJ"!&YA:SIT5L;QDR1$R_TH0J;G! M+/!"S3:LJ:X;CF7;03#U[(D;V(X]G3339M$\S22L'AKS1S;/=L4A@M:"WRCC M0_(8P(D\8V+/0=BW'L70]M&';K>N!'1J!&1J&;NO[Y#DTYCAYFEAQ>"RJ4CK+ M%:,B'A^(&WG%&'<-M\U4S7",\-?X>@&#Y%2W$\>R/,L,)X&AZ:IM._I4U[P@ M]-R9Z;F^_W*1(-([+/"DX+G&!9X4C=T%VKXS^,;7<4/="L+CK@O$-3W,< M6S>"OBSPI/"^1@N>A!>7L> S%'N-!H])Y,^5((2"*H2.I.#=/ ,9D)LN7=W^ M_NO-1_QM _D@1BGJ"G=B=/(AMMKBK*QBMPG+:J) E\4G '@A>57%L0G52G(W MO&DX*B+)40&%40ZU%AW.E\TI.Q M5,^RB#^UE.FO43+]I^:TD1$E,[&>'#=9.\T>ZSQ[!TO8CW_Y<8P:91_P[\<_ M 5!+ P04 " "[A$A,[55ET#P> #JB $ $0 &5N'-D[5UM<]LXDOZ^OX+G+SM7=8XMVTDFJ-YX3N/F >$T4][HS>' M>PZF+O,(G7W:^S;>/QV?7U_O_>/WO_WV7_O[_SR[OW$NF!LM, V=_'A1SYXSGP/@;N'"^0@\*0DTD4XBO&%Q=X MBB(__+07T;\BY),IP9X0P<=018F@\#I$?(;#KVB!@R5R\:>]>1@N/QXS3@5\0G^4"CQ/N/^&\9F@ M/#P^@-<3%."4G#)*HX6Z@!?R@W"UQ >":%]084[C@GU]NQA+RO=__ MYCBR"Y#%DO'0H37HIBB8R))1L#]#:"EAV#\<[0,0<<>Y82X*93(#] M,$B?[.>LW@@9]IR#;N)PYN-@0_)(7NL*!+UA4P))7GT$TO6B!G'J1>"O_;3< M/CS:'QVM)T4^'KM)D9;;A!0?#A!W 6H!FQONX^>ECR@*&5]=B;_;2>9S7N)R MF3,!$3^ B*-W:X@H.5,\ QO>7J1BJ8W*T:%9TA)KUZ^VQVW$*);\&A? MTA0+9G^M+8^'"7 \Z2)*6@9^[.>%^PF G]UYY\;("LE?:S<"H8\XD+[9<1(9=VI^U=$ @EVL.? JV_WU]JULZR_5"QEGU:0]Y_?CT9'OXX.#YU] MYX($KL^"B&/Q1['X;P?50A5V48"]6_J[_%W5.RF(I_. EGYY>$]W\/%+SU MH&H-S(D6F*&#<,<)XW=B/<2\S6%C8&J$[%@+F>3NQ.QW8!8;X %-?-P7M*2P M#ISCHU^/#T?Z\12S&1("9U% * Z",9Y!++Y+^]>*ZKV MPHO(&7AI#P&W/+= MK583![V)>JN8[FLX#-(:5=OS'C]B&N&S5?)@?82:.!H1JTTJ=<02WLYDE3[; M@2C:!?:FO,C'M]/DR3V&P >ALVLZ97PAQ=T@Q/WJ,W: FB-8[P!IS0Z;9CT@ MJ]PIU/X_NSY2QJRSZ]' 0.]^O%6X'PK#.SP?Y)PM%B24ZI]2[YQ1Z+"8NJ03 M)CHN6L_D[:'",REP1J&NLS7B6_.6]/CF->P@+;?]%RSF3<1QLD2\QZY K6?08:UJ MC)#7UKEZR-,:L\5OHU0,MZW"22@:+ M+*/CD+D_.L*6EM(N@@[?-2R"8,\/B@^SJ?L-E$IA[6 X?-OHQB MX6^G7W%X35VVP'>8)\T[%T:_&RAF=MKQ,3I6CX^4+:P4!6,GY@P;?!F(P'P' M7:FM3X5M]X@?A>01RP?]9J0UZM&.R=&QVA-I";93K#9^--@YRPC1RP#?&F;5 M&K(MS#M(U8W?.9S>@:DVQ#XZ5H38NP ZQ-@[#9A//+CI<89\N*$SGF/7$S':@A$'QCSO$$17+HE"L@/U-H-7, MW CCJ#V,Y3^=7THU#77D96UW.P5SQ?$[@FFYF]LT9Z8$ZZ@34X";9"SSI8@DEN3:B=Z**>$.Q@37JJ>=)=LC/6Z)' M.,[(2AN*.7FGB+@!2R?G67@YS' :M$<_8%IC4 N'20R&VMA742A:X8X3ZI(E M\F\G?G+ H.?X,/,S E0[X"0!BAD[&6>GP'JPZ,D]XPU:-S,_(WJU76^)7KRY MO3-T)?0Z!Y$+A;1!XI-WBB!Q;.:&%_Z] &98GN>0V=H$USL?T4[-KN:@];W> M'BE]+\G)*;)R@-<.CSX&2\M(?S[G2.D(-* S4 NE;-X>1DO'1VO'WAXI[5@C M2D,T;@1N/9VS1\SOT RG.2T[X=/ 0@/-8;:SE271%#\OK^45+$>R]_-0)#U5Y[5QS.%+.-1D?B*:DG(:.1)]Y1L-&.\L8<0R"5&8&572=$BL7T7IAR9!2*#[2Q>XP"16F]BS52N5@%+H/O\=U=J7IA MO?\T4OE/)0B&YS)=(<+_1'Z$OV $3=(U)XBZO-8*C51Q>.#C2$9.D=/0D>AN MF;1LM"9JI H'-^ R2&NE;-IKF7]TDV I.!IQJVVE-.%68+[#,&V5SE./CHMV M#AJI8I&-8VQXT]%GQKPGXONGU)-!\FN:L,251DDTAKD;;8XQ)]7LB]K';9-"*3D]\SWIXP_(>YU-[";JU._ MU:.ZG-ZK/^2E"C(,TE)WA$[Y.GO[XCVG7?7&3E2;Q_MUH@*)+TE(*H^#8HI= MCS)"VMDKZ,=?OW=YJ/ 7^O6) 7H3\9FY!_3<"<9B*;T7H,IPF9QVEL6'V=07 M>(HYQSUF:PT3O>54YOF\%"W?XPYF,P\C,C7'J(1,PFWH MP$@SOM:)I1;,C%#5#IN5H(JGFJ&?52JT\ST*9=(;ZA*?],R@U(J=$;B:WU@" M#A@[9\!?<9>C&:K26O_L^+W2/ZLZQOMP M17S8*&SHT&Q7SEJS=OQ>:=:4Z.W.TFKAW0B2K4%3^'MJT';HR(:-S_*?+B!O M]W]Z>Q$=V!H15*REU @FUQ"*E>Q0C9N_AX/1Q$/K:!R_5SH:#2-N>#['#49! M)QR2 OK(C^H+9W'!P37MAGR'%LSTJR#5EYABICOOH(I97WA:(U'S 1(DAMOD M\53Y1;!=1 OYZ ZM>AX;:A(7<(8V9#+CI(1V3:&@I5>\-H Y,]39+ MK"\_F.%RBOP'O4E4;?C+9\Q=$D!6 1>+I]E9Q/4Q-;(V(EN;C13(IK4XLAKY MIG "<@>Q%US#74X!F"N;I(=ST9*A"]@T\T2O+W;10&H6@J0F=GJY)Q7!_1UE480:Y] M\$P!QR(R82]]#NHW3ZS MW<1!'Y15Y7M+TA[&K)P"KQT>/<:4GI%^&*GRO36BLQLW>5MTGY^T?/33E"K? MFP:EX;LKC6K!V?*,Q:RD9.0!FC@<.PH5-!G5EK M[=[QB<)]4,.W.S.DQW4B:&K2[23-QTCOAJHR &H0&:=N: M6KBS?3,PTCOBJL2!6J2&:.@>,8W@T(A8F["(AL$]=C%YA(;H!).&C=;@C3XH M#9YD%X>&$H9.SG&'CVR&^I,^IK /?ZV!''U0>.L&1)7/AFDXF_%(WFT6Y I3 M([**J4^/;/I^AV:YX7M,A49FVNEP]$$Y'>K1&^"4.,;^])J*]H&O'PMW ?/' M3CBIR^N]?M4D"'SV,T9.RFGH2'0W?UHV>E]?9? :KY:$W;H2KT7N#GY R=E.,.H;@= MQ)-H 2+B>.FK^$!X#VNXH1JUAO/PY&14-YQZU)U"YCK:[%:XS0EE*B[<"M0E#."2/6[&GRWXV#;:S).*YK%U',X%?3U$#X M($MOO.L.%9!N\"/VCS;M=U>XZF ^.CPY4BR4###+"IPCYY?TR0[0I"$V<[*B M=Q7&$5V[SFN">G8JS*:BGW&W8-YZP%:;+XS_@/S4@JOE^P*FNJ,9J&6*JSC!)'4_?=R/K'_ MY]WCMX/GP/N(EDM"IPP>)0\H9;'T\AD\PK[\UJB#)D'(D1M^V@MYA/=D?Q*M M-?OWZ='AX7NXGOX%+R:8[SD4+?"GO?ICXOO@NJ<,@F@B]V*@ML_0<3[M/4^X M3SZ2$"_VG%#(^FF/,DJCQ4>/+1"AU^(%J+#GQ(1+,9*9]R )/8$F<-IS#CJ) M/BK(6%- ^7)K:N1BU]9A9ZL[M&+\-+C#'%;3M],'@:.O.FB;*+<6BUY-(/1? MQJQU#4 HI*()N\$XFW$\0Z%P*KW(#2%:7(%20V !G*ET8LW+_$=AJX0E6A#Y M">8$##3#-5U,U+:!Y/MRI[V"3/6IA4;"]\?")L)7S5R\#,^9SSCRV(6LK:"' MELA"M8) M+DO9@K7C99B)ER=NG]%A&.O@I"9SDKE2!#"?6H8(%<(/FH5KFJ* MZ6AL5PI1#S[I*3P63Y12*:%3MT-I"PQD(KI&:+G955;42-U'L>0)#?$,\XV; M2(WD8\P?B0MN\PR8J+'M4M "6,5*3$Q5#Y@OV/0KH^?@CL=29?M"Z;*?)B521=L0]M:U$S+_ MP&'FH)3[:.-;^PSM6100BH- 3G2!7%T!M]-GDO5$/4D[E;SPHT<6L'*.N]K/ M 4DM>-F;,1'9!]DYXOB!1T%X?WG]4.YXZE?;-W_G*)C_@7UAL:5T5XS?XX" MX0YRT74D_0W @E$<(KZJZC")SX=R3U ;V./7$9QE/QV^A6'B?CR"@MT0QCB*GT[E+%09RI?P-*+4%D>P=<_XHC! MN<^$PSBK^%V=BFS?'[O $P&+T#^"YZ)W)E\SFV+,X["Q4$CHDNK7@7Y[2]&" M=L*2"+GNX91?DM_DAH%EX8M2UL]4N;;DMGFA2HWEWM^J9FGU)-LTM#4M'M!S MH=UEK%G>B*BJHJ&S#:E&8W.! Y>396PLL[5HQ:*:B*PSH87+9S5=E*]LUJ . MA_K=UM<"EV?7#Q>G]T!X+F3S4GD5S_O+NA0<>OKT*D'%6$:1'RI$S=]8(^P7 M] Q? %4(F[^Q1UA"FX3-WFQ96.'Q"][TNH^ XR0XO'IYABJ7VPWLQ=)G*XR3_0WI09^A 'O%8SQ? M&06SA+,O3":MT:^L;.+.%E^Q2CK"+9OF<7\S9XN\%(L!,+@ MFVC]!W8544\1?,Z!ZU;F!3T>#T_4#D^OF;7T6:][1&?XDLSFE5T^$Y%]4?FZ MQ%?"!)FT*M&\"J58Q(U*%6E>@U)?Q8 R*56B>0U*W9IUNGUE*HWAHI1)J3+1 MJU"+/!N5*I"\!I4>S#@]O#*4'N8<&T=4F>A5J/7$C$H52+8?N\S/-0EG"/,O M2/BM7)Z$.>4DLBY4I)2XM&>GI=C^CEVS9K!+)805BXW">:#:4XN/ M .6RED_]*)[;9ZSCZYQ9K\FN\93MM9'*0L78 L-1I=,9IF[EJ'+#.SN5B-O^ ME'I_L&!)H,UC6WPC?M.@"E2' C:KFXB.0 D]CBWIM^]3Z(2]%=Q0*3+3FMJZ M4]>YY"CK@A(,2%)9,/$MZ"PV^CKIR]- *TJ;QV(NMO*P?!M"&]7+@:A9%=6K M[1N0:^IR6%5PI7%R#>OB@>@%V/A6WAW\:6(;2P?2_S MW#4U@))R*QO[ZRN:N6>ME"U2VZ\PH3[@6'1>3!26>PZ M-,M>=AQ:T-DP*76>@NR><-H$TC0ZH)(.#>?DUBAOQ2&Z:SB(&<0^'H\3R^6J MJ5Y9-\%H!B<,^H"X\$%[?#M-SFG(6 YD 9$_+E!8.W/6I^#6SPQBR M(!0SIYN?E"=RSA!-2U&2L6*)5L5X8[^BUG6$K"ENL)@K,83M1<,6 O=!LMJF ML_@F[-<(%@1L>H\I?D(^'.#-;-N:/+863L\;(74*A>,0+> @[S2B7IR9,K9/ MF:IM*&USP IZ4IPZBND)>FFYA.&%@USYIZB_(#[+I^0>Y;:3-J2UIC?79[?W M;=5+B2U+A7(CVGR6YGHJ[_2H7VW=[N9BQ7?B9+(91+R0?7LS?O,9_#U:W&+L M0&_;(KT%:J5]K/ICBS>O;I@;HP+W HKK$]4+BYNEM&KA& ME)OA/)%=4+<-74I8MTXV2E\>56VIMS_8E!I^Q>'M]#SB'*+**(RX/)L@%HSP M$M0 /U.E;-N"MKDJ&MR#8 SF 4Z?RTOO@ -L]JNR%+6FWGXD 43% S;SY!5$TPQYL!):Q5KW8/JS% MXU SCG$I&-3TTKI-S7@/G51RN=6>VC?VBMX M\>1<-71DH+'.]9"9PGPR99P25/86U:^V;X6$7"[^#RV2K&D;PK-MB:V( MQ<:QI-OI/4;^90!.>O)%(/F=*;B$E:G5AG+KAU3-4GXGX3R.KCZPNXB[<_&P MO8X-I:W6.PX?MD.R0&N)3BR[3HX#2%-1U4/Y?ONQT+IP3Z+KR$Y42,$1-.O2 M1&Z/:EE8.MN'*J2L,!%9YZ/E L=.OVS[R^=2E@PB27B)FFUEHGU M$F-_QM&B!EPSV=8-PVV^-"OGT?U&"WL,1BI[]5!ECFVGFZZD=4.NH$6RAO@: M<;GY5=+I5*'3&?9JCO#FV&T]PM^H"@AJU#_,ATRX M^SA)8'!!.'9#QH.R,D;:E\QDT&N)EL@MC$F<;:$^TAK?6[?C_8INOXO>Q:G/@@>6?!P@7KO$Q_E2Y4Q$]IZU M2"5G4WF[\(D+$;B7!.,!%#A-0N0G!VO:MBSS:L*Y\5=B"EN'Q0<6;QE*,;J3U>H7E@I/GPSA./:]3SE&PNL6);#\0X+AR!1^S!49*+ M"'KE%1'66=YG_Q=&^:S;I^"6S]F81193$20M"><@<7M-J\4LUE-,K" MF8;S M<"YDFDL>S8Y>Y62HI*3N7 M6L/LR52":X^BMA*7LUEV+K4M/1MM8JY!' MFOB_F6%"F=ABN':EUL8%FL1\J M0]- MOUS;RUT1+(?SN)@E ;"1CJ+\2O)W ">DL9JY.0%*.$]U3_[6G5)6M)N MW2/1R5D[2=&6V(J3%(FP#1_NO2_?VKB9&.W;E81_N0 M.[OXE7LQ,6#^J#C9WX'>NAG1('MI9FQ):_$,.8:,Z=[I K9RO?+%LW(LH@VA M?4$))2PU\V,@VK[I:>QDVI_NV6(6"6+ 0\_IY?EVB07S$H/G_<#^%)-(?+(H:X27X;VEKP*\4)/=1B%4 M"?Y4]JG>RM[[L3O6999$O>ZD^> M,3[%TGV\+^QT_)2:MKSCH]:Q&A8LY;+6-X^IJ&T.N:$E4O?S=BHMBS L6$(: MG*UBE,\%C#/&5PV^PH:96A%$:%!*CN[3*)PS3OZ#O6]PA*7P'2#8APH4'[E( M!XFAR=;G;O5,,#&;F4F#F3F'CPYQ.!@3LGBG.6FL1T3\2KJ\GU17_Z8V?0^K M?0?MI25L $.2SY_:M/TJ?:UMG$01T4PLZ?-K^M7QO7:KMJYFV]'+KJ? \\\6 M9&VT#@?KSE_WUZ86=-@$)_N"9QJMBAFUXSS:>6;M;WPF^-:OU&^0GX7!*8UR MJELH>1=HWT@M^;SFQO&KXZ-PEG=M+A8? .ZO6_G4\ ;X6-A]P/N.%WF5P:)X M8:GXBY@V4D"TA[\T%.,,AY'RN];>F]U9V.REL M%EJ7&8\;0O#M:"U4LG"-6O8YI#(3!B*+U5K!8=KX:&W-Z=33V& [DP+WEXM?'MRT676_7/JE@7>(HB/VP4.W]OF>"5>R6:][8)7KXHHGF_ M9<'A+&L2W1=&)XFTC#%_)"ZNQ\K;DUL7&&\I>C$VUZV(Q8$XK2+3AJA;UT+V M+3BU&@3*3Q5V*V+!_*25%Y*WR&AI?(>U%F<_1XME%+09\VO MMV]X:[)5,[#J"+:6W[,1B3^18! %-Z(K^2P+(Y?A,-!L'Y/OF,SF<'0R_ACB MA1@(8D!X_R+8SV QT&SI.$LC+M\9_R'Z3O'T3AD4'<'/0^2W ] F<.=X@7[_ MV_\!4$L#!!0 ( +N$2$SZU0'-M2L /;L 0 5 96YS9RTR,#$W,3(S M,5]C86PN>&UL[7U9DQPY^O7KR*-8QU_(?2?O[U]_>3% MS"]OXG3QY'D3[2*&)Y_KQ<3U,QNGOQCUOQ9?[((K0L]6?UE4D__ M_&O^P]EY?/)E7O]U[C_&&_MZYNUBU?;'Q>+VKT^??O[\^2]?7#/YRZSY\)1B MS)[>E=K[1?X7VGZ&\H\0H8B1OWR9AU^>0 ^G\U7;+1K9?O[ET?>?V>IK8HQY MNOKMW:?S>M>'4"UY^I]_O'ZWZB>JI_.%G?KXR[_\TY,G:SB:V22^C>E)_N^_ MOWWUH)(XG=)J_>?K,_]>RGM<9KSFTOJKD8Q/3K[_ YQ^@ MXT01NN[V/^_Z=O'U-O[ZR[R^N9U 1Y_V),F]O[];WMS8YNN+N+#UY"01CU8R MC.QG2%I$KC=-/6O>1/@S=!2W74W#].*]=9-XDK0/2_0GU6_+>3V-\_F[^"&O M74=EVO?]\UE>CD#?66Z:.PI>\^Y M]17IT>]Q&AL[>5U;5T_JQ=?G$UO?=.]8FVJ+].\U[*(?5O!V[]3>NHKTY(\( MU+=-W.P7;Z.'DJ=LE'W47:2GUXN/L?G#+A9@A'7OVX':^NT-Z.F+F?^SC:C? M?3J('"<@M[M$KU+=+A>KF7.=_AX7K\">OHF@@F\:_PC4:R%GZSK*2OX,R!;J MR7)1?XJK'YQ VNZ5E^UKCST;M1_M]+_3:^JS%]/Y;%*'[%#ZS4ZRH^3=QQB/ M&VI'"Q:0\?X_WMC&3F$-7L .,SE;^*,U#M.K=S#Z,6\KURF3H8D?K'C1V>/63\M#8[":KO[.)L$T E>_M<2%-2[7Y[9VQ8U#MPK,(ZR MJ70UF7T^:8TX6,'P,G>828]*]R?MB^B.,N'^-_VV_"R$E?//3E[4G7U&Z9N_\&5(;C(ATL-KA\K8>V3>G!I6T[S"T*]REK MG7W)SV>?8O/&?HC;X]CC8AXNUZ>$<]_4MVL[8NM4/B[>@4(#R]::ETOT)]65K9O_L)-E_"/:O!.U.FX\ M6&A@V5H.:9NR TOZ:IJ'K[/0^ZL96/YV)&U1M#\Y?Y_-PN=Z,GDV#2M=ZM4T MY.VL7L37,%?"J^G"3C_4T/:S^;R%-^;,ZD;KS_;SM[/)),V:S[8)+9G5>T.C M8;#SUW>_'0:.D]H<#9EV\[53I?WU;>T;>&^_')=XQZ>#R &:<6R:V'9*'2\Y MB)0OO]S")VU]_4<+#B+CBEBGF\CM:QA$ZK=VL3I/;O)46;_?=H<.[VN M07O2=LX=*=B?C*]!_SXNT,.O^FZ]RZ1J7T/?4I\DX,"RK$G]!RAD-\N;U8_> MV*^GV) G5M.W_._L)*[^YJS_\WUCIW/K3W'QGU9+W]*WF]2[ONU/DNO;]0V# M:7B6[:ZCTNS[?CB)\DDQ?+A:O/P2&U_/\U&2C_#3.T?&F7UI M6]]P/7J57?KPH5\UVW;&G5;+<-+#K HYX.!#8V\_GBO\P4J&DWWS[^OE(M^: MRK?1?OOZ@ ]G=N?4>DOV\'0G5)[=:5UBL3_/?;4-UYMW2S>O0VV;K^O@G1..9L^H:KA^M-,N#I<:3KJ\W*\V8K!4EC>W MIRAM9U358S]6017>-\L8ME<:6MS-.5)L)=G\VV;N()#98:5K(MM?&Y]P_:H@_!%Y6Q'WN,E^Y/RWHZZ.89I=V!Y MK-SP$K8<\Y;%AY>WW=BW*]VGM*NK7'G#]'ZV7%TT]K'^E)L[+NOQLF4D??R3 MUNSH4&F9OFU^UT.'=M=4IA=MV=^VAOZD?A[,8-Q<#8?S.;U&UNT;W=S:NCE!F3VOME*]N1^2TD-W M]E97K#\/3T]AA]J&+_73O[;5%^KO:]B()[27=7%W587ZT<%8[%IOH1YF!>G^ MS]]E!W9V?3T+L]OVGM8^VRC6\_W*8C^];EU_H1X_T)0VN5- /"!CBO/YV@/3 M0\=/;V:,_O];M)/%Q[M_]M[QP_6/T>/3?;9]U#U&3W/@XJ?8#-'1O56/T<^< M\3,V#X(/>N_P\3;V]MS;B<^Z/Q1Y#?_>?)[[>%[*S75#\ M_DFU :&>^LDR1VG4TYRN:]U8L_[=MK&)=7'RZR]0<=6V:,6X\=QIAA@3$6FF M,8HQ$L2,EQ8+$HW1#SLSR5F89\T&[WV]V:"\2IR<[-RMTAPOY^B#M;=/YG_>_+A:*R3/;1.OFP]VNHDT?@-_0A?>Q>93[; D2E%;)'RBBG)J-8EM\+C'P&>-?S)K0FQ^_87\\N1S MK#]\7*S^NJ[%-OX1,1_FF]Y\\72>5_=<(ZH7\69;/N?1'G+09R7!A*X>(=:> M:?*J_;38\6GE54Q>>8($3P8) ]A8J?T:$>*E3S&=/^STQQWV'A'[-K9_>[IK ME1YF^2ZR/;?.-5NRY9/2PQ85['ANUY+BM,_(6E*J(RE52XIR8@[4DJ(=36$Z MB# [DY0.V5*QKIV82'04$5HF_AQ%MO/5_WX4YCNQ7L^^I<39H1(_^*Z2G#CB MK4.6.H9HQ"OMP"#"A4B))2TT&<\(^";H%>@\Z^F_A!7@^C9NMI!76ZWG33;, M0/5:K-,KK6(H9G^'[28G7)I-)BNC#=:*.%\< &>8!BO&L)+<,,2UI@@P9TB$ MR)!R3@MG0F).7:IIT0-O9A<*\G&38X"IV9&A)]=5.6N=2]@")-PAA<$*\XQ@ M1"@AR5BPQY3HQ7S&;(7SY=->( 0NSZO@@!>.ZN1%QXC8+E$@1H+36D M2W/^@/,?;, [0E-XH#?9.QY>GSJ^$[0H75%J>)26@@$-JQQG,:" J4KU*IP)_ Z1]YLZH]N'/N* M5!PS:EW"*$HED/,F(&=H1!SC3'9*+>G@=2BI1'1:#7K$IQP+UEET0>-92WTO M.OKP]G"D9.68)!8SAICR*?MJ/9*1)(2I4OY8JQ]EK#O@46I4CZ2D?_EE MQWS2,E*2"XTH="B@&8]5;!S!IZ0X3HQ;!1WD9_/%?.C<*5_F$I1XY[^ M [;2XU="#W#C6-&*"!.\PWFK5!$1%?*)O=$(.@N_4L9PT4KG'+SG[3I9!>V< MIJ -!B($,H'G3C&-%)..N\2](QUTZ#('=_T.VJQ/L$:@_''O[../JR0BY1+, M@Z@Q= ]CA[R. 7%EI+4T).XZK'G%:7#:2.T?\?/A*7U4^\9^S:>([0]I'Q:H ME%74"= 8%1,>$1LX\0<#HYH3QS'E^Z/[YDA0X!6["A_ M1Z*PXS0Y4*H21H FB#5*,E D4W3(4+ \.6R^/('%D%('5:*,V[YG@O0+5U'3 MZJ358T^)RO$HO;<,# Y)$8LYR%5IB@3!#BR$1(BY^*/_GBG1'U3%=,O9]$.. M4,DOB;=0+A]_725)7#*@>GMF!7*P@2(E#$$YQB4JYZ3E';3+,H[ZGFG0#TQC M4*"5CV5W@4I3ZJ1,"7%NH5\Y5D)$[!$V3$BCL*6L@Y997(?H9F;T!=&8&D,K M,APN6+F(L0W066%!,S+)>9A+4B,=-$]:)1Q=AQORQ?6&3J3H':JSXSVVIXIO MXRKL9+UM;2A[V,UT2O'*\(0#%PHYK /2(H(U!5K1YK(_P_#GCZ0AG#7X P-6 M;'W8\[K;MF>_VWIZ^%BW90V5BBDDI1@*PN48.P(84*\!",65PHD8WB$TK+@^ MT6W%& RS8KQYY+#M^=9M/PU4&'/.N*%@IH6 5/(YSLY)I Q-+!+)HF(_D/+2 MOZM\-)S'8^I)K*NX(T(G)9%(F(-:QP.*-L"4U#B2!-BR+B&M99RL8PSR49Z= M@6RQ^W??59] E+"V**AHD20"K4(*5"9L"%B9)[:C\\?ARVF!] M?[6N.T;%CF;N7G)Z8^OP:OKF;'(*B5XLO;G.%E&L-+VTQAJ;S_6@0H<[6O#^DXQPM7 M6 KOJ.9YM;7(>^.04((BFJ)-B@>,28>HR#)V=L]\&02U4GQYWX#:OVR^MMI; M'G]<<2R5SENPYY0@FR38E!1P3%*RE&- 4[L$G4=-[R$3=_1,B%Y@*D6 /^KI MK%DI8$=-H.\_K;P30&R A@E/ 1HJ$)>*HD0D,5$03]@/N'D45T5[P+54,I<] M.53N_R,_L3U=?(R+&IIZ*.6@25W>+>#/?)OI.NUX$NEB!-GQHPM [/$LN/OE M& +- 3H[_W@UF7T>+S_/[@0# M@M(6.0MZ@R.:2DVYL+K5BCH,(CF]!'3C33/[5,,8_/;UW^VN18"JIR*W3OL/^4L9T'6[X'^<,&P[7 M@G? 4[TXDAWRVT>5#=8G+")2D8#-'B1&+ J&M.(,S#(1/+WXR..A!N[Q'?#S M42MXV[>)OMXD%KZ=Q-6(3,.SFZR+K9.Y'V!&F^(54PY[1@(203N$A5(HI&"0 MM4):91CC\>*UUD*<&0C/8LZS>V)>IZMZ"DHJ@/-\-E]=@,]OHZ^"C %'0<1<,U3#CLD;9@,EHI!$W),U C+M[Q4HAP9? M MMJKE2W3?GI-]_M$V'PYJW+L+5(92%Y,/R.7#?$4(131X"_,LN1 ES+W4(4-* MF0"(4BM67PB6XL@_&L#M.J7KM WAR!&"K^;S9?;3Y)7V %^.%P9#Q>?05.BY MM#$[-14RWB64B.,F&*I8%[=OF>0(A;@S")JE\Z[\R2WV6YS&=/ LZ4C) M*BD1,'&@*U)%<@!1@(Y;A0 !B2EHC;A+%&^9E O%M/"^H2QHSG^J\_NT5[/F MQ6SI%FDYV=Z(.VS@[RU6,>((M8N4N((<1WB7\ID82AG M\O>)8S'E.B>%_PW4M7#_B=1#^O/. E5D,?JD\U&;P8@+J4"%$P8)AZV.5'DM M.C"E3 Z&4AIR7P@6NZ:Z>C<,UL+-(IA?Z=C=B=.\TYWJK0P/2N:5V&FP6IFS M#!GL-"*<,\\HHZY+="?!/Y555AKJ@IN>CS&L'H[YEH$Q+A:3]6';27P\O;(* M1XJYBS ]F!D__[U-#L\KM.# MK*]W*5\/D*U=!95P+' K.=*21V1S4B<2!IRY/!_U33::VC72$1\Y(CA_%::93[Y+CN8^,DYU!'+T=FS M=:CM?"CA'%8=K+#R!J!Q@<*VSACR-,+>;AA%D;D40_3.FPY'PT3^SV!;WQB? M?:G]L80]/&MP=I65\MIX+AFRRF!D)$Q""HK!)G6_2& -=UG+?@I/^@@@GTVO MK/+%>;/.!K:8S;8/SL+P3&8@;YS&Q2RE^DL,-G._OCN6W,>N\VNLI"'>)\&0 M4SX@"4Q'E^=WZ0S/$N7WY2MK'8R1280U]@@ M%T)"8-9($(*#)0P3CL@.;_Z2G\H_/P2:X[%H?\K#DPBUOYJ*!,<,S_DUB5:@ M#GB+C"4$22+RV05W075(Z$_QS\VM7H$==;%JEO>.S>.YR];N6BH:,<$X/Z6& M 7GK8 DWA+,)%(CH\=$I_JFCU87$=CV.[\KF=1*]=%51@LZB0 @$U M@1O$\K.AQD:!@B-!8(5QN#03KRPK7UJ6QGQJ%41&VKJ$B"V:1Q M1"Y"WT5^1I#DF]%:^DB\U%Z)+ODYRZ3C&W?)Z@/44M3:@]3:>]+Q4NB.2BJ% M&3'Y->NH7,AJJ,FOY-*]SMH<":5I74J48"76P>$O'*9* ,**1)I029M@9S1CU'1P3H[KK.X_\]P$T M0\(Z&L&V1^VKMR_7N0@VOSETC>N4:BH3F/"&4"0<#4B;I%",CB%-J,6"@)TM M.MR^&3>&9G"2]0OLV:[Z1W*M+IF%O>>(QPM5,H@4\_/+@H/9RY*4R'/O-IEY MC;!2]'.-] >FQ2 PEEYKKF;-_>##[;G3]?1MM).7\YP)9=6Q^2H7W<$0T?-J MK!(.P3@K08>D,3M7 A(DSZZ6T[!=*X^PZ>0Z*EA?.:RTH(A:F^_]9Y,'A\V;\23PI%V'@^=1[X_V MNE(-#&JYJX!;$_7;>YX9NP,KT[XBE1+8RQ \+,_*H0B3 1D7,0!*%,9@[I#0 MP7,^ZO71OE>>'C$Y<_/KM+8R3F/>*=54#/-H8LIO M-[$\(ZU 0;O\0K8!E/(++5T"E$<-C1ER@1L UY%/:+Z]VW1&=/+.&BKC,>%> M1Q23%$AB 1@POGHND(/NP )776+ZQKVDVC>[A@-UY/.9N[1;7=-7IOK]"["#%DGNVFY M*^XL6RG"A5.<(VE ,= J>@13RH"*($!)\ Y[W.7VQ)A;8>=A/G2;N2><=JT)VURB=AH\R%7/YX?\WZ?4424MHQ5*(I\SD"0&%JNR6FSN M;6BA59?E:=03D;[I5AKH\F&ZVQ?S5KW: M/%O6*C!W5\$J"4*(B]G)D22"#E-DE#=(!QZXUB08W.6%Y'$/1(9:RWK#LOR6 M]_#%D5;[WL,BE7+:8F4X4D$K6,&]1Y9BB;CP0DA!J>IR!X6,>T5@N-VO,XK? MN%+JF?$GRYWT;;;#S;@ S"YJW)X!\44^70(WK;>:4^6\QS9IX[W[X MRR^+QL(< 18U7U_!L,QW/\9Z^(Q\J%8K*U@2U *=K<@JOV8H*<:1$5(SKV1T MZ>(/JLZES^-3\PN"N=0.5T89';02LL/ 'Q]0BDS!#6 /\ M3C'%NH14EZ'0Q8S]; B\2P8^SM_&3W&ZC.]B\ZGVJ[M.1R(;=Y2 >2R]EM0C MSQ0 A\'&S%Y2)!*1V@F17ZV^=$YU'KL=,8K]8%6*#]O'\3;9#P\M+-]_6N%@ M4E(!HZ@50<*%A&QP 32NH$!O$PJTK8L_#N^; CV@5'+L8=\*GU(AO4W]O$G"]G[T& M,^S#"J]OCQ,<($*K\CD8B,I(#6),140-B2B9P& B84:LP#[(#MI&H76A5X(, MA5LIWFSO=+S\4B]6P) #)'G\<>6ELXQ$CQS8^\@*(9#A7"&7L-*P QH?.^3G M+Q2[V2L&HF/V1(Y-;;Q8[OJZT#K#HL80H2QXI[CW*K^P@2P6EP3"+:8? MN3(A+;V.?S\@%=LVXA24I$E^H#OX@>+0AG&X9 5&/R&12^3S M$P&6I 1H.K"^>'Y\4$NG10=BE E1Z7>GZ!VP5\D888W/@'\P=3+,C1U&,)$O1IR2M_ $2 M=_4Y;H_<\EWQ*L>![=L+Z]ZW.MK97:2BB@MC#46<:HLB7YUF.(((S)] I:21 M= CH+[/(#$J*WG K>%?VQ-?(]SV=K;1308N(-),2I2@#\HXDE*SUPF).G.K@ M(BOD NGUT*X/C,H!9"O7[)XT4]WSSF,7\1%[:>S LT M7ZZEJV5.#/*FJ:>^OK63:S?9N+X*]G;]I-.XB+_/2>B';RC5TQR,!TI?[9:Y MCIPQOIFGV?/8I-F_LA_ABYI?W?>B#-3OW3;VZ7_#XX=22 M;18:X6_YA4HV5;YS13A[9>OF/^QD&?]8W7"*#UZ0*]EF&7QW-GWO#;81I2@R MW+_/9N%S/9EL'S9\!;7#@@FJWVM@7@"UW$X_U"#(PT0PER'-]O.WL\DDS9K/ MM@EEQNM$.7?^^NZW%RER$?+=FH)1))."L-EJHGE]N ]G.OH_C(\=\+:.4.A[X3]_?F& Y^59$2=(HN2+ M=+.3^>9AMW9OH?751$5)8"EX@; 7*K]ZJ1 -1B.I/*6":$EDETM.1L4,B) M8)$*RO 8 @FXGS"\_Q',[1?IT3B\NG?V0!]O0\9OI2HE?&#"B1S*[I#ESL(@ M1(IT?E):2&6CZ_"Z0YE0OA*LZ@3992]Q#]XH['U->U![%:)*P1H/B!F*,/,6 M248<2D980G1DE'6P \I$#E[,(M85VM%HF3UGZ[';+L.GT.YQZ8I+0XW6.6$< M:-K2.(Q$B %QKS%.,3JA.MRI+'0^.[PAT0MRI5ESYPDZS5+85:QR+ID4L$2. M2Y+?>Q)(:TW!3F"_:26NQ/,K3+B0+W\4VZ_[ ,V&@VV$C>6>V.<\^WEB354( M4<0(6RQUBB")0?VS6,#>ZVBB22C,;#\;SH]$I7)@CDVP>&OK-G=L6Y6O3')2 M2BJ1D1PCSBULOQSDX1CCP)F25'>P[,O:8,7(U!7",L%G#Z*Y5[*.?8IU>4&1 M ]V&7K^[<7IW#Q>L J4"9Y)Y;!UB3@'=H*>(,!F,Y=8&]8/DWN@XHM]?FNX; MMF+7YM>"7\60;VJ=P91])2LFG:64680YP&GR4VDT,((2Y3E#!"H2O,&56^C%H,J]AU,XASN'R%<&8ZN0)BC$RA%D22":*44HB3U+FL>N0 MD:6,CCD\?7H'L;1NN>'_V60ZJ9XJ@C9$ O8H>B>0\]RAE&]K:&\%I@9+&>VE MDVJ([6MH%$=BU>GJ3[L**B*$41MS"3;9(\G[A%E 14S+271/;S/--/ M1;&!H!WYSMZN^]+/PO]=KH.^K]/W/O&MJ^#KZ7;MV4U5H*9ZAQD ZIU!RCJ, MG'4:5!HE/;'2<=XAMJB,'V>(O?4"@"[N[5F%;!>_EW9/@+>P#+R-?C;U@-DF MH41A$0J%I#^,@[\7G%RNQ1&O(NZ09FP7X]7^6PJ'0\OE+YS0/1GWB]OEJL,@RV3+IU>6>59#-H*B: VC"0G M&GG!\\/G3G(5)".Z'W_ D!$1XU"K/TA+:2>/H%G?Y;\O_?_?.RYL[[@_.!O] M^>\P'N\_Q\FG^ >HT!_/W%E:5%QY0"UP[Q HU!0I&BPBQ&C$#,$*=&^A28=X MJ9]YWQD&W4O8E1YW[/]$V[S_/.N-AIOZJLBY)1)+1") 0Y4&?#PS*-+D73(2 MQN?B;SQ<#/O.!_5R27,BH[ MQ*B7<>-<%.W.1/5R>?<>FC\4LGYFC96T6G$!=DGDSB"2DZI1RQUL#=;9! AI MVN%0IK'VV? M]!S;J73W*-0.0>]D7!Y,4-ZNABHJ&W$^MQ<\8$0"$8ADWQ])3C!J@A*XE>TP M*@Z;R+KN<&PJJ@3FTDGF$.$ZHN@(12&(K(61J!.)TOB+3_,R" /VO3TX%*S% M'@)HUY%7T_>?9WF?:O4 9MNZ*JZ9%X%BI(T%2"PSR F9$(U6Y?LF"O.+#YR] M(+IU0O;R&)=-POXX=U<;:/N6,2%S$)40,!�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Ǳ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�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end